Tricuspid	B-Entity
valve	I-Entity
regurgitation	I-Entity
and	O
lithium	B-Entity
carbonate	I-Entity
toxicity	I-Entity
in	O
a	O
newborn	O
infant	O
.	O

A	O
newborn	O
with	O
massive	O
tricuspid	B-Entity
regurgitation	I-Entity
,	O
atrial	B-Entity
flutter	I-Entity
,	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
,	O
and	O
a	O
high	O
serum	O
lithium	I-Entity
level	O
is	O
described	O
.	O

This	O
is	O
the	O
first	O
patient	O
to	O
initially	O
manifest	O
tricuspid	B-Entity
regurgitation	I-Entity
and	O
atrial	B-Entity
flutter	I-Entity
,	O
and	O
the	O
11th	O
described	O
patient	O
with	O
cardiac	B-Entity
disease	I-Entity
among	O
infants	O
exposed	O
to	O
lithium	I-Entity
compounds	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
.	O

Lithium	B-Entity
carbonate	I-Entity
may	O
be	O
a	O
factor	O
in	O
the	O
increasing	O
incidence	O
of	O
congenital	B-Entity
heart	I-Entity
disease	I-Entity
when	O
taken	O
during	O
early	O
pregnancy	O
.	O

It	O
also	O
causes	O
neurologic	B-Entity
depression	I-Entity
,	O
cyanosis	I-Entity
,	O
and	O
cardiac	B-Entity
arrhythmia	I-Entity
when	O
consumed	O
prior	O
to	O
delivery	O
.	O



Phenobarbital	I-Entity
-	O
induced	O
dyskinesia	I-Entity
in	O
a	O
neurologically	B-Entity
-	I-Entity
impaired	I-Entity
child	O
.	O

A	O
2-year	O
-	O
old	O
child	O
with	O
known	O
neurologic	B-Entity
impairment	I-Entity
developed	O
a	O
dyskinesia	I-Entity
soon	O
after	O
starting	O
phenobarbital	I-Entity
therapy	O
for	O
seizures	I-Entity
.	O

Known	O
causes	O
of	O
movement	B-Entity
disorders	I-Entity
were	O
eliminated	O
after	O
evaluation	O
.	O

On	O
repeat	O
challenge	O
with	O
phenobarbital	I-Entity
,	O
the	O
dyskinesia	I-Entity
recurred	O
.	O

Phenobarbital	I-Entity
should	O
be	O
added	O
to	O
the	O
list	O
of	O
anticonvulsant	O
drugs	O
that	O
can	O
cause	O
movement	B-Entity
disorders	I-Entity
.	O



Acute	O
changes	O
of	O
blood	O
ammonia	I-Entity
may	O
predict	O
short	O
-	O
term	O
adverse	O
effects	O
of	O
valproic	B-Entity
acid	I-Entity
.	O

Valproic	B-Entity
acid	I-Entity
(	O
VPA	I-Entity
)	O
was	O
given	O
to	O
24	O
epileptic	I-Entity
patients	O
who	O
were	O
already	O
being	O
treated	O
with	O
other	O
antiepileptic	O
drugs	O
.	O

A	O
standardized	O
loading	O
dose	O
of	O
VPA	I-Entity
was	O
administered	O
,	O
and	O
venous	O
blood	O
was	O
sampled	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
hours	O
.	O

Ammonia	I-Entity
(	O
NH3	I-Entity
)	O
was	O
higher	O
in	O
patients	O
who	O
,	O
during	O
continuous	O
therapy	O
,	O
complained	O
of	O
drowsiness	I-Entity
(	O
7	O
patients	O
)	O
than	O
in	O
those	O
who	O
were	O
symptom	O
-	O
free	O
(	O
17	O
patients	O
)	O
,	O
although	O
VPA	I-Entity
plasma	O
levels	O
were	O
similar	O
in	O
both	O
groups	O
.	O

By	O
measuring	O
VPA	I-Entity
-	O
induced	O
changes	O
of	O
blood	O
NH3	I-Entity
content	O
,	O
it	O
may	O
be	O
possible	O
to	O
identify	O
patients	O
at	O
higher	O
risk	O
of	O
obtundation	O
when	O
VPA	I-Entity
is	O
given	O
chronically	O
.	O



Calcitonin	O
injection	O
resulted	O
in	O
a	O
potentiation	O
of	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
and	O
a	O
partial	O
prevention	O
of	O
apomorphine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
.	O

Moreover	O
calcitonin	O
induced	O
a	O
significant	O
decrease	O
in	O
nigral	O
GAD	O
activity	O
but	O
no	O
change	O
in	O
striatal	O
DA	I-Entity
and	O
DOPAC	I-Entity
concentration	O
or	O
GAD	O
activity	O
.	O

The	O
results	O
are	O
discussed	O
in	O
view	O
of	O
a	O
primary	O
action	O
of	O
calcitonin	O
on	O
the	O
striatonigral	O
GABAergic	O
pathway	O
mediating	O
the	O
DA	I-Entity
-	O
related	O
behavioral	O
messages	O
of	O
striatal	O
origin	O
.	O



Development	O
of	O
isoproterenol	I-Entity
-	O
induced	O
cardiac	B-Entity
hypertrophy	I-Entity
.	O

The	O
development	O
of	O
cardiac	B-Entity
hypertrophy	I-Entity
was	O
studied	O
in	O
adult	O
female	O
Wistar	O
rats	O
following	O
daily	O
subcutaneous	O
injections	O
of	O
isoproterenol	I-Entity
(	O
ISO	I-Entity
)	O
(	O
0.3	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

A	O
time	O
course	O
was	O
established	O
for	O
the	O
change	O
in	O
tissue	O
mass	O
,	O
RNA	O
and	O
DNA	O
content	O
,	O
as	O
well	O
as	O
hydroxyproline	I-Entity
content	O
.	O

The	O
total	O
content	O
of	O
hydroxyproline	I-Entity
remained	O
stable	O
during	O
the	O
first	O
2	O
days	O
of	O
treatment	O
but	O
increased	O
46%	O
after	O
4	O
days	O
of	O
therapy	O
.	O

Ventricular	O
DNA	O
content	O
was	O
unchanged	O
during	O
the	O
early	O
stage	O
(	O
1	O
-	O
4	O
days	O
)	O
of	O
hypertrophic	I-Entity
growth	O
but	O
increased	O
to	O
a	O
new	O
steady	O
-	O
state	O
level	O
19%	O
above	O
the	O
controls	O
after	O
8	O
days	O
of	O
treatment	O
.	O

Intraventricular	O
pressures	O
and	O
coronary	O
flow	O
measures	O
were	O
similar	O
for	O
control	O
and	O
experimental	O
animals	O
following	O
4	O
days	O
of	O
developed	O
hypertrophy	I-Entity
.	O

However	O
,	O
dP	O
/	O
dt	O
in	O
the	O
ISO	I-Entity
-	O
treated	O
hearts	O
was	O
slightly	O
but	O
significantly	O
(	O
P	O
less	O
than	O
0.05	O
)	O
elevated	O
.	O

These	O
data	O
indicate	O
that	O
the	O
adaptive	O
response	O
to	O
ISO	I-Entity
shows	O
an	O
early	O
hypertrophic	I-Entity
phase	O
(	O
1	O
-	O
4	O
days	O
)	O
characterized	O
by	O
a	O
substantial	O
increase	O
in	O
RNA	O
content	O
and	O
cardiac	O
mass	O
in	O
the	O
absence	O
of	O
changes	O
in	O
DNA	O
.	O

However	O
,	O
prolonged	O
stimulation	O
(	O
8	O
-	O
12	O
days	O
)	O
appears	O
to	O
represent	O
a	O
complex	O
integration	O
of	O
both	O
cellular	O
hypertrophy	I-Entity
and	O
hyperplasia	I-Entity
within	O
the	O
heart	O
.	O



Co	O
-	O
carcinogenic	I-Entity
effect	O
of	O
retinyl	B-Entity
acetate	I-Entity
on	O
forestomach	B-Entity
carcinogenesis	I-Entity
of	O
male	O
F344	O
rats	O
induced	O
with	O
butylated	B-Entity
hydroxyanisole	I-Entity
.	O

The	O
potential	O
modifying	O
effect	O
of	O
retinyl	B-Entity
acetate	I-Entity
(	O
RA	I-Entity
)	O
on	O
butylated	B-Entity
hydroxyanisole	I-Entity
(	O
BHA)-induced	I-Entity
rat	O
forestomach	B-Entity
tumorigenesis	I-Entity
was	O
examined	O
.	O

Male	O
F344	O
rats	O
,	O
5	O
weeks	O
of	O
age	O
,	O
were	O
maintained	O
on	O
diet	O
containing	O
1%	O
or	O
2%	O
BHA	I-Entity
by	O
weight	O
and	O
simultaneously	O
on	O
drinking	O
water	O
supplemented	O
with	O
RA	I-Entity
at	O
various	O
concentrations	O
(	O
w	O
/	O
v	O
)	O
for	O
52	O
weeks	O
.	O

In	O
groups	O
given	O
2%	O
BHA	I-Entity
,	O
although	O
marked	O
hyperplastic	O
changes	O
of	O
the	O
forestomach	O
epithelium	O
were	O
observed	O
in	O
all	O
animals	O
,	O
co	O
-	O
administration	O
of	O
0.25%	O
RA	I-Entity
significantly	O
(	O
P	O
less	O
than	O
0.05	O
)	O
increased	O
the	O
incidence	O
of	O
forestomach	B-Entity
tumors	I-Entity
(	O
squamous	B-Entity
cell	I-Entity
papilloma	I-Entity
and	O
carcinoma	I-Entity
)	O
to	O
60%	O
(	O
9/15	O
,	O
2	O
rats	O
with	O
carcinoma	I-Entity
)	O
from	O
15%	O
(	O
3/20	O
,	O
one	O
rat	O
with	O
carcinoma	I-Entity
)	O
in	O
the	O
group	O
given	O
RA	I-Entity
-	O
free	O
water	O
.	O

In	O
rats	O
given	O
1%	O
BHA	I-Entity
,	O
RA	I-Entity
co	O
-	O
administered	O
at	O
a	O
dose	O
of	O
0.05	O
,	O
0.1	O
,	O
0.2	O
or	O
0.25%	O
showed	O
a	O
dose	O
-	O
dependent	O
enhancing	O
effect	O
on	O
the	O
development	O
of	O
the	O
BHA	I-Entity
-	O
induced	O
epithelial	B-Entity
hyperplasia	I-Entity
.	O

Tumors	I-Entity
,	O
all	O
papillomas	I-Entity
,	O
were	O
induced	O
in	O
3	O
rats	O
(	O
17%	O
)	O
with	O
0.25%	O
RA	I-Entity
and	O
in	O
one	O
rat	O
(	O
10%	O
)	O
with	O
0.05%	O
RA	I-Entity
co	O
-	O
administration	O
.	O

RA	I-Entity
alone	O
did	O
not	O
induce	O
hyperplastic	O
changes	O
in	O
the	O
forestomach	O
.	O

These	O
findings	O
indicate	O
that	O
RA	I-Entity
acted	O
as	O
a	O
co	O
-	O
carcinogen	O
in	O
the	O
BHA	I-Entity
forestomach	B-Entity
carcinogenesis	I-Entity
of	O
the	O
rat	O
.	O



Ketanserin	I-Entity
pretreatment	O
reverses	O
alfentanil	I-Entity
-	O
induced	O
muscle	B-Entity
rigidity	I-Entity
.	O

Systemic	O
pretreatment	O
with	O
ketanserin	I-Entity
,	O
a	O
relatively	O
specific	O
type-2	O
serotonin	I-Entity
receptor	O
antagonist	O
,	O
significantly	O
attenuated	O
the	O
muscle	B-Entity
rigidity	I-Entity
produced	O
in	O
rats	O
by	O
the	O
potent	O
short	O
-	O
acting	O
opiate	O
agonist	O
alfentanil	I-Entity
.	O

Following	O
placement	O
of	O
subcutaneous	O
electrodes	O
in	O
each	O
animal	O
's	O
left	O
gastrocnemius	O
muscle	O
,	O
rigidity	I-Entity
was	O
assessed	O
by	O
analyzing	O
root	O
-	O
mean	O
-	O
square	O
electromyographic	O
activity	O
.	O

Intraperitoneal	O
ketanserin	I-Entity
administration	O
at	O
doses	O
of	O
0.63	O
and	O
2.5	O
mg	O
/	O
kg	O
prevented	O
the	O
alfentanil	I-Entity
-	O
induced	O
increase	O
in	O
electromyographic	O
activity	O
compared	O
with	O
animals	O
pretreated	O
with	O
saline	O
.	O

Chlordiazepoxide	I-Entity
at	O
doses	O
up	O
to	O
10	O
mg	O
/	O
kg	O
failed	O
to	O
significantly	O
influence	O
the	O
rigidity	I-Entity
produced	O
by	O
alfentanil	I-Entity
.	O

Despite	O
the	O
absence	O
of	O
rigidity	I-Entity
,	O
animals	O
that	O
received	O
ketanserin	I-Entity
(	O
greater	O
than	O
0.31	O

followed	O
by	O
alfentanil	I-Entity
were	O
motionless	O
,	O
flaccid	O
,	O
and	O
less	O
responsive	O
to	O
external	O
stimuli	O
than	O
were	O
animals	O
receiving	O
alfentanil	I-Entity
alone	O
.	O

Rats	O
that	O
received	O
ketanserin	I-Entity
and	O
alfentanil	I-Entity
exhibited	O
less	O
rearing	O
and	O
exploratory	O
behavior	O
at	O
the	O
end	O
of	O
the	O
60-min	O
recording	O
period	O
than	O
did	O
animals	O
that	O
received	O
ketanserin	I-Entity
alone	O
.	O

These	O
results	O
,	O
in	O
combination	O
with	O
previous	O
work	O
,	O
suggest	O
that	O
muscle	B-Entity
rigidity	I-Entity
,	O
a	O
clinically	O
relevant	O
side	O
-	O
effect	O
of	O
parenteral	O
narcotic	O
administration	O
,	O
may	O
be	O
partly	O
mediated	O
via	O
serotonergic	O
pathways	O
.	O

Pretreatment	O
with	O
type-2	O
serotonin	I-Entity
antagonists	O
may	O
be	O
clinically	O
useful	O
in	O
attenuating	O
opiate	O
-	O
induced	O
rigidity	I-Entity
,	O
although	O
further	O
studies	O
will	O
be	O
necessary	O
to	O
assess	O
the	O
interaction	O
of	O
possibly	O
enhanced	O
CNS	O
,	O
cardiovascular	B-Entity
,	I-Entity
and	I-Entity
respiratory	I-Entity
depression	I-Entity
.	O



Glycopyrronium	I-Entity
requirements	O
for	O
antagonism	O
of	O
the	O
muscarinic	O
side	O
effects	O
of	O
edrophonium	I-Entity
.	O

We	O
have	O
compared	O
,	O
in	O
60	O
adult	O
patients	O
,	O
the	O
cardiovascular	O
effects	O
of	O
glycopyrronium	I-Entity
5	O
micrograms	O
kg-1	O
and	O
10	O
micrograms	O
kg-1	O
given	O
either	O
simultaneously	O
or	O
1	O
min	O
before	O
edrophonium	I-Entity
1	O
mg	O
kg-1	O
.	O

Use	O
of	O
glycopyrronium	I-Entity
5	O
micrograms	O
kg-1	O
provided	O
greater	O
cardiovascular	O
stability	O
and	O
,	O
given	O
1	O
min	O
before	O
the	O
edrophonium	I-Entity
,	O
was	O
sufficient	O
to	O
minimize	O
early	O
,	O
edrophonium	I-Entity
-	O
induced	O
bradycardias	I-Entity
.	O

This	O
low	O
dose	O
of	O
glycopyrronium	I-Entity
provided	O
good	O
control	O
of	O
oropharyngeal	O
secretions	O
.	O



Involvement	O
of	O
locus	O
coeruleus	O
and	O
noradrenergic	O
neurotransmission	O
in	O
fentanyl	I-Entity
-	O
induced	O
muscular	B-Entity
rigidity	I-Entity
in	O
the	O
rat	O
.	O

Whereas	O
muscular	B-Entity
rigidity	I-Entity
is	O
a	O
well	O
-	O
known	O
side	O
effect	O
that	O
is	O
associated	O
with	O
high	O
-	O
dose	O
fentanyl	I-Entity
anesthesia	O
,	O
a	O
paucity	O
of	O
information	O
exists	O
with	O
regard	O
to	O
its	O
underlying	O
mechanism(s	O
)	O
.	O

We	O
investigated	O
in	O
this	O
study	O
the	O
possible	O
engagement	O
of	O
locus	O
coeruleus	O
of	O
the	O
pons	O
in	O
this	O
phenomenon	O
,	O
using	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
anesthetized	O
with	O
ketamine	I-Entity
.	O

Under	O
proper	O
control	O
of	O
respiration	O
,	O
body	O
temperature	O
and	O
end	O
-	O
tidal	O
CO2	I-Entity
,	O
intravenous	O
administration	O
of	O
fentanyl	I-Entity
(	O
50	O
or	O
100	O
micrograms	O
/	O
kg	O
)	O
consistently	O
promoted	O
an	O
increase	O
in	O
electromyographic	O
activity	O
recorded	O
from	O
the	O
gastrocnemius	O
and	O
abdominal	O
rectus	O
muscles	O
.	O

Such	O
an	O
induced	O
muscular	B-Entity
rigidity	I-Entity
by	O
the	O
narcotic	O
agent	O
was	O
significantly	O
antagonized	O
or	O
even	O
reduced	O
by	O
prior	O
electrolytic	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
or	O
pretreatment	O
with	O
the	O
alpha	O
-	O
adrenoceptor	O
blocker	O
,	O
prazosin	I-Entity
.	O

Microinjection	O
of	O
fentanyl	I-Entity
(	O
2.5	O
micrograms/50	O
nl	O
)	O
directly	O
into	O
this	O
pontine	O
nucleus	O
,	O
on	O
the	O
other	O
hand	O
,	O
elicited	O
discernible	O
electromyographic	O
excitation	O
.	O

It	O
is	O
speculated	O
that	O
the	O
induction	O
of	O
muscular	B-Entity
rigidity	I-Entity
by	O
fentanyl	I-Entity
may	O
involve	O
the	O
coerulospinal	O
noradrenergic	O
fibers	O
to	O
the	O
spinal	O
motoneurons	O
.	O



Cerebral	B-Entity
sinus	I-Entity
thrombosis	I-Entity
as	O
a	O
potential	O
hazard	O
of	O
antifibrinolytic	O
treatment	O
in	O
menorrhagia	I-Entity
.	O

We	O
describe	O
a	O
42-year	O
-	O
old	O
woman	O
who	O
developed	O
superior	O
sagittal	B-Entity
and	I-Entity
left	I-Entity
transverse	I-Entity
sinus	I-Entity
thrombosis	I-Entity
associated	O
with	O
prolonged	O
epsilon	B-Entity
-	I-Entity
aminocaproic	I-Entity
acid	I-Entity
therapy	O
for	O
menorrhagia	I-Entity
.	O

This	O
antifibrinolytic	O
agent	O
has	O
been	O
used	O
in	O
women	O
with	O
menorrhagia	I-Entity
to	O
promote	O
clotting	O
and	O
reduce	O
blood	B-Entity
loss	I-Entity
.	O

Although	O
increased	O
risk	O
of	O
thromboembolic	B-Entity
disease	I-Entity
has	O
been	O
reported	O
during	O
treatment	O
with	O
epsilon	B-Entity
-	I-Entity
aminocaproic	I-Entity
acid	I-Entity
,	O
cerebral	B-Entity
sinus	I-Entity
thrombosis	I-Entity
has	O
not	O
been	O
previously	O
described	O
.	O

Careful	O
use	O
of	O
epsilon	B-Entity
-	I-Entity
aminocaproic	I-Entity
acid	I-Entity
therapy	O
is	O
recommended	O
.	O



Hemorrhagic	B-Entity
cystitis	I-Entity
complicating	O
bone	O
marrow	O
transplantation	O
.	O

Hemorrhagic	B-Entity
cystitis	I-Entity
is	O
a	O
potentially	O
serious	O
complication	O
of	O
high	O
-	O
dose	O
cyclophosphamide	I-Entity
therapy	O
administered	O
before	O
bone	O
marrow	O
transplantation	O
.	O

In	O
an	O
attempt	O
to	O
obviate	O
the	O
inconvenience	O
of	O
bladder	O
irrigation	O
,	O
we	O
conducted	O
a	O
feasibility	O
trial	O
of	O
uroprophylaxis	O
with	O
mesna	I-Entity
,	O
which	O
neutralizes	O
the	O
hepatic	O
metabolite	O
of	O
cyclophosphamide	I-Entity
that	O
causes	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

Of	O
97	O
patients	O
who	O
received	O
standard	O
prophylaxis	O
,	O
4	O
had	O
symptomatic	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

In	O
contrast	O
,	O
two	O
of	O
four	O
consecutive	O
patients	O
who	O
received	O
mesna	I-Entity
uroprophylaxis	O
before	O
allogeneic	O
bone	O
marrow	O
transplantation	O
had	O
severe	O
hemorrhagic	B-Entity
cystitis	I-Entity
for	O
at	O
least	O
2	O
weeks	O
.	O

Because	O
of	O
this	O
suboptimal	O
result	O
,	O
we	O
resumed	O
the	O
use	O
of	O
bladder	O
irrigation	O
and	O
forced	O
hydration	O
to	O
minimize	O
the	O
risk	O
of	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O



Reversal	O
of	O
central	O
benzodiazepine	I-Entity
effects	O
by	O
flumazenil	I-Entity
after	O
intravenous	O
conscious	O
sedation	O
with	O
diazepam	I-Entity
and	O
opioids	O
:	O
report	O
of	O
a	O
double	O
-	O
blind	O
multicenter	O
study	O
.	O

The	O
Flumazenil	I-Entity
in	O
Intravenous	O
Conscious	O
Sedation	O
with	O
Diazepam	I-Entity
Multicenter	O
Study	O
Group	O
II	O
.	O

The	O
efficacy	O
and	O
safety	O
of	O
a	O
new	O
benzodiazepine	I-Entity
antagonist	O
,	O
flumazenil	I-Entity
,	O
were	O
assessed	O
in	O
a	O
double	O
-	O
blind	O
multicenter	O
study	O
.	O

Flumazenil	I-Entity
(	O
mean	O
dose	O
,	O
0.76	O
mg	O
)	O
or	O
placebo	O
(	O
mean	O
dose	O
,	O
8.9	O
ml	O
)	O
was	O
administered	O
intravenously	O
to	O
130	O
and	O
67	O
patients	O
,	O
respectively	O
,	O
who	O
had	O
been	O
given	O
diazepam	I-Entity
in	O
conjunction	O
with	O
an	O
opioid	O
(	O
fentanyl	I-Entity
,	O
meperidine	I-Entity
,	O
or	O
morphine	I-Entity
)	O
for	O
the	O
induction	O
and	O
maintenance	O
of	O
intravenous	O
conscious	O
sedation	O
for	O
diagnostic	O
or	O
therapeutic	O
surgical	O
procedures	O
.	O

The	O
group	O
assessable	O
for	O
efficacy	O
comprised	O
122	O
patients	O
treated	O
with	O
flumazenil	I-Entity
and	O
64	O
patients	O
given	O
placebo	O
.	O

After	O
5	O
minutes	O
,	O
80/115	O
(	O
70%	O
)	O
flumazenil	I-Entity
-	O
treated	O
patients	O
,	O
compared	O
with	O
21/63	O
(	O
33%	O
)	O
placebo	O
-	O
treated	O
patients	O
,	O
were	O
completely	O
awake	O
and	O
alert	O
,	O
as	O
indicated	O
by	O
a	O
score	O
of	O
5	O
on	O
the	O
Observer	O
's	O
Assessment	O
of	O
Alertness	O
/	O
Sedation	O
Scale	O
.	O

Flumazenil	I-Entity
-	O
treated	O
patients	O
also	O
performed	O
significantly	O
better	O
on	O
the	O
Finger	O
-	O
to	O
-	O
Nose	O
Test	O
and	O
the	O
recall	O
of	O
pictures	O
shown	O
at	O
the	O
5-minute	O
assessment	O
.	O

Flumazenil	I-Entity
was	O
well	O
tolerated	O
,	O
with	O
no	O
serious	O
adverse	O
effects	O
reported	O
.	O

Thirty	O
-	O
nine	O
(	O
30%	O
)	O
of	O
flumazenil	I-Entity
-	O
treated	O
patients	O
,	O
compared	O
with	O
17	O
(	O
25%	O
)	O
of	O
placebo	O
-	O
treated	O
patients	O
had	O
one	O
or	O
more	O
drug	O
-	O
related	O
adverse	O
experiences	O
.	O

The	O
most	O
common	O
adverse	O
effects	O
were	O
nausea	I-Entity
and	O
vomiting	I-Entity
in	O
the	O
flumazenil	I-Entity
group	O
and	O
nausea	I-Entity
and	O
injection	O
-	O
site	O
pain	I-Entity
in	O
the	O
placebo	O
group	O
.	O

Flumazenil	I-Entity
was	O
found	O
to	O
promptly	O
reverse	O
sedation	O
induced	O
by	O
diazepam	I-Entity
in	O
the	O
presence	O
of	O
opioids	O
.	O



Hepatic	O
adenomas	I-Entity
and	O
focal	B-Entity
nodular	I-Entity
hyperplasia	I-Entity
of	O
the	O
liver	O
in	O
young	O
women	O
on	O
oral	B-Entity
contraceptives	I-Entity
:	O
case	O
reports	O
.	O

Two	O
cases	O
of	O
hepatic	O
adenoma	I-Entity
and	O
one	O
of	O
focal	B-Entity
nodular	I-Entity
hyperplasia	I-Entity
presumably	O
associated	O
with	O
the	O
use	O
of	O
oral	B-Entity
contraceptives	I-Entity
,	O
are	O
reported	O
.	O

Histologic	O
differences	O
and	O
clinical	O
similarities	O
between	O
hepatic	O
adenoma	I-Entity
and	O
focal	B-Entity
nodular	I-Entity
hyperplasia	I-Entity
of	O
the	O
liver	O
are	O
discussed	O
.	O



Arterial	O
thromboembolism	I-Entity
in	O
patients	O
receiving	O
systemic	O
heparin	I-Entity
therapy	O
:	O
a	O
complication	O
associated	O
with	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
.	O

Arterial	O
thromboembolism	I-Entity
is	O
a	O
recognized	O
complication	O
of	O
systemic	O
heparin	I-Entity
therapy	O
.	O

Characteristic	O
of	O
the	O
entity	O
is	O
arterial	B-Entity
occlusion	I-Entity
by	O
platelet	O
-	O
fibrin	O
thrombi	I-Entity
with	O
distal	O
ischemia	I-Entity
occurring	O
four	O
to	O
twenty	O
days	O
after	O
the	O
initiation	O
of	O
heparin	I-Entity
therapy	O
,	O
preceded	O
by	O
profound	O
thrombocytopenia	I-Entity
with	O
platelet	O
counts	O
in	O
the	O
range	O
of	O
30,000	O
to	O
40,000	O
per	O
cubic	O
millimeter	O
.	O

The	O
clinically	O
apparent	O
occlusion	O
may	O
be	O
preceded	O
by	O
gastrointestinal	B-Entity
and	I-Entity
musculoskeletal	I-Entity
symptoms	I-Entity
that	O
appear	O
to	O
be	O
ischemic	I-Entity
in	O
origin	O
,	O
and	O
might	O
serve	O
to	O
warn	O
the	O
clinician	O
of	O
these	O
complications	O
.	O

Previous	O
reports	O
of	O
these	O
phenomena	O
as	O
well	O
as	O
recent	O
studies	O
of	O
the	O
effect	O
of	O
heparin	I-Entity
are	O
reviewed	O
.	O

The	O
common	O
factor	O
relating	O
thromboembolism	I-Entity
and	O
thrombocytopenia	I-Entity
is	O
heparin	I-Entity
-	O
induced	O
platelet	B-Entity
aggregation	I-Entity
.	O

Appropriate	O
treatment	O
consists	O
of	O
discontinuation	O
of	O
heparin	I-Entity
,	O
and	O
anticoagulation	O
with	O
sodium	B-Entity
warfarin	I-Entity
if	O
necessary	O
.	O



Long	O
-	O
term	O
prognosis	O
for	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	I-Entity
-	O
induced	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
.	O

BACKGROUND	O
:	O
The	O
prognosis	O
for	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	I-Entity
-	O
induced	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
remains	O
unknown	O
.	O

AIM	O
:	O
To	O
examine	O
whether	O
paracetamol	I-Entity
-	O
induced	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
increases	O
long	O
-	O
term	O
mortality	O
.	O

We	O
followed	O
up	O
all	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	I-Entity
-	O
induced	O
acute	B-Entity
liver	I-Entity
injury	I-Entity
,	O
hospitalized	O
in	O
a	O
Danish	O
national	O
referral	O
centre	O
during	O
1984	O
-	O
2004	O
.	O

We	O
compared	O
age	O
-	O
specific	O
mortality	O
rates	O
from	O
1	O
year	O
post	O
-	O
discharge	O
through	O
2008	O
between	O
those	O
in	O
whom	O
the	O
liver	B-Entity
injury	I-Entity
led	O
to	O
an	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
and	O
those	O
in	O
whom	O
it	O
did	O
not	O
.	O

On	O
average	O
,	O
age	O
-	O
specific	O
mortality	O
rates	O
were	O
slightly	O
higher	O
for	O
the	O
101	O
patients	O
whose	O
paracetamol	I-Entity
-	O
induced	O
liver	B-Entity
injury	I-Entity
had	O
caused	O
an	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
(	O
adjusted	O
mortality	O
rate	O
ratio	O
=	O
1.70	O
,	O
95%	O
CI	O
1.02	O
-	O
2.85	O
)	O
,	O
but	O
the	O
association	O
was	O
age	O
-	O
dependent	O
,	O
and	O
no	O
survivors	O
of	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
died	O
of	O
liver	B-Entity
disease	I-Entity
,	O
whereas	O
suicides	O
were	O
frequent	O
in	O
both	O
groups	O
.	O

These	O
observations	O
speak	O
against	O
long	O
-	O
term	O
effects	O
of	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
.	O

More	O
likely	O
,	O
the	O
elevated	O
mortality	O
rate	O
ratio	O
resulted	O
from	O
incomplete	O
adjustment	O
for	O
the	O
greater	O
prevalence	O
of	O
substance	B-Entity
abuse	I-Entity
among	O
survivors	O
of	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
.	O

CONCLUSIONS	O
:	O
Paracetamol	I-Entity
-	O
induced	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
did	O
not	O
affect	O
long	O
-	O
term	O
mortality	O
.	O

Clinical	O
follow	O
-	O
up	O
may	O
be	O
justified	O
by	O
the	O
cause	O
of	O
the	O
liver	B-Entity
failure	I-Entity
,	O
but	O
not	O
by	O
the	O
liver	B-Entity
failure	I-Entity
itself	O
.	O



Serotonin	I-Entity
6	O
receptor	O
gene	O
is	O
associated	O
with	O
methamphetamine	I-Entity
-	O
induced	O
psychosis	I-Entity
in	O
a	O
Japanese	O
population	O
.	O

Altered	O
serotonergic	O
neural	O
transmission	O
is	O
hypothesized	O
to	O
be	O
a	O
susceptibility	O
factor	O
for	O
psychotic	B-Entity
disorders	I-Entity
such	O
as	O
schizophrenia	I-Entity
.	O

The	O
serotonin	I-Entity
6	O
(	O
5-HT6	I-Entity
)	O
receptor	O
is	O
therapeutically	O
targeted	O
by	O
several	O
second	O
generation	O
antipsychotics	O
,	O
such	O
as	O
clozapine	I-Entity
and	O
olanzapine	I-Entity
,	O
and	O
d	B-Entity
-	I-Entity
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
in	O
rats	O
is	O
corrected	O
with	O
the	O
use	O
of	O
a	O
selective	O
5-HT6	I-Entity
receptor	O
antagonist	O
.	O

In	O
addition	O
,	O
the	O
disrupted	O
prepulse	O
inhibition	O
induced	O
by	O
d	B-Entity
-	I-Entity
amphetamine	I-Entity
or	O
phencyclidine	I-Entity
was	O
restored	O
by	O
5-HT6	I-Entity
receptor	O
antagonist	O
in	O
an	O
animal	O
study	O
using	O
rats	O
.	O

These	O
animal	O
models	O
were	O
considered	O
to	O
reflect	O
the	O
positive	O
symptoms	O
of	O
schizophrenia	I-Entity
,	O
and	O
the	O
above	O
evidence	O
suggests	O
that	O
altered	O
5-HT6	I-Entity
receptors	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
psychotic	B-Entity
disorders	I-Entity
.	O

The	O
symptoms	O
of	O
methamphetamine	I-Entity
(	O
METH)-induced	I-Entity
psychosis	I-Entity
are	O
similar	O
to	O
those	O
of	O
paranoid	B-Entity
type	I-Entity
schizophrenia	I-Entity
.	O

Therefore	O
,	O
we	O
conducted	O
an	O
analysis	O
of	O
the	O
association	O
of	O
the	O
5-HT6	I-Entity
gene	O
(	O
HTR6	O
)	O
with	O
METH	I-Entity
-	O
induced	O
psychosis	I-Entity
.	O

Using	O
five	O
tagging	O
SNPs	O
(	O
rs6693503	O
,	O
rs1805054	O
,	O
rs4912138	O
,	O
rs3790757	O
and	O
rs9659997	O
)	O
,	O
we	O
conducted	O
a	O
genetic	O
association	O
analysis	O
of	O
case	O
-	O
control	O
samples	O
(	O
197	O
METH	I-Entity
-	O
induced	O
psychosis	I-Entity
patients	O
and	O
337	O
controls	O
)	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
age	O
and	O
sex	O
of	O
the	O
control	O
subjects	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
methamphetamine	I-Entity
dependence	O
patients	O
.	O

rs6693503	O
was	O
associated	O
with	O
METH	I-Entity
-	O
induced	O
psychosis	I-Entity
patients	O
in	O
the	O
allele	O
/	O
genotype	O
-	O
wise	O
analysis	O
.	O

In	O
the	O
haplotype	O
-	O
wise	O
analysis	O
,	O
we	O
detected	O
an	O
association	O
between	O
two	O
markers	O
(	O
rs6693503	O
and	O
rs1805054	O
)	O
and	O
three	O
markers	O
(	O
rs6693503	O
,	O
rs1805054	O
and	O
rs4912138	O
)	O
in	O
HTR6	O
and	O
METH	I-Entity
-	O
induced	O
psychosis	I-Entity
patients	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
HTR6	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
METH	I-Entity
-	O
induced	O
psychosis	I-Entity
in	O
the	O
Japanese	O
population	O
.	O



Effect	O
of	O
increasing	O
intraperitoneal	O
infusion	O
rates	O
on	O
bupropion	B-Entity
hydrochloride	I-Entity
-	O
induced	O
seizures	I-Entity
in	O
mice	O
.	O

BACKGROUND	O
:	O
It	O
is	O
not	O
known	O
if	O
there	O
is	O
a	O
relationship	O
between	O
input	O
rate	O
and	O
incidence	O
of	O
bupropion	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

This	O
is	O
important	O
,	O
since	O
different	O
controlled	O
release	O
formulations	O
of	O
bupropion	I-Entity
release	O
the	O
active	O
drug	O
at	O
different	O
rates	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
varying	O
the	O
intraperitoneal	O
infusion	O
rates	O
of	O
bupropion	B-Entity
HCl	I-Entity
120	O

mg	O
/	O
kg	O
,	O
a	O
known	O
convulsive	I-Entity
dose	O
50	O
(	O
CD50	O
)	O
,	O
on	O
the	O
incidence	O
and	O
severity	O
of	O
bupropion	I-Entity
-	O
induced	O
convulsions	I-Entity
in	O
the	O
Swiss	O
albino	O
mice	O
.	O

A	O
total	O
of	O
69	O
mice	O
,	O
approximately	O
7	O
weeks	O
of	O
age	O
,	O
and	O
weighing	O
21.0	O
to	O
29.1	O
g	O
were	O
randomly	O
assigned	O
to	O
bupropion	B-Entity
HCl	I-Entity
120	O
mg	O
/	O
kg	O
treatment	O
by	O
intraperitoneal	O
(	O
IP	O
)	O
administration	O
in	O
7	O
groups	O
(	O
9	O
to	O
10	O
animals	O
per	O
group	O
)	O
.	O

Bupropion	B-Entity
HCl	I-Entity
was	O
infused	O
through	O
a	O
surgically	O
implanted	O
IP	O
dosing	O
catheter	O
with	O
infusions	O
in	O
each	O
group	O
of	O
0	O
min	O
,	O
15	O
min	O
,	O
30	O
min	O
,	O
60	O
min	O
,	O
90	O
min	O
,	O
120	O
min	O
,	O
and	O
240	O
min	O
.	O

The	O
number	O
,	O
time	O
of	O
onset	O
,	O
duration	O
and	O
the	O
intensity	O
of	O
the	O
convulsions	I-Entity
or	O
absence	O
of	O
convulsions	I-Entity
were	O
recorded	O
.	O

The	O
results	O
showed	O
that	O
IP	O
administration	O
of	O
bupropion	B-Entity
HCl	I-Entity
120	O
mg	O
/	O
kg	O
by	O
bolus	O
injection	O
induced	O
convulsions	I-Entity
in	O
6	O
out	O
of	O
10	O
mice	O
(	O
60%	O
of	O
convulsing	O
mice	O
)	O
in	O
group	O
1	O
.	O

Logistic	O
regression	O
analysis	O
revealed	O
that	O
infusion	O
time	O
was	O
significant	O
(	O
p	O
=	O
0.0004	O
;	O
odds	O
ratio	O
=	O
0.974	O
)	O
and	O
increasing	O
the	O
IP	O
infusion	O
time	O
of	O
bupropion	B-Entity
HCl	I-Entity
120	O
mg	O
/	O
kg	O
was	O
associated	O
with	O
a	O
91%	O
reduced	O
odds	O
of	O
convulsions	I-Entity
at	O
infusion	O
times	O
of	O
15	O
to	O
90	O
min	O
compared	O
to	O
bolus	O
injection	O
.	O

Further	O
increase	O
in	O
infusion	O
time	O
resulted	O
in	O
further	O
reduction	O
in	O
the	O
odds	O
of	O
convulsions	I-Entity
to	O
99.8%	O
reduction	O
at	O
240	O
min	O
.	O

In	O
conclusion	O
,	O
the	O
demonstration	O
of	O
an	O
inverse	O
relationship	O
between	O
infusion	O
time	O
of	O
a	O
fixed	O
and	O
convulsive	I-Entity
dose	O
of	O
bupropion	I-Entity
and	O
the	O
risk	O
of	O
convulsions	I-Entity
in	O
a	O
prospective	O
study	O
is	O
novel	O
.	O



Detailed	O
spectral	O
profile	O
analysis	O
of	O
penicillin	I-Entity
-	O
induced	O
epileptiform	B-Entity
activity	I-Entity
in	O
anesthetized	O
rats	O
.	O

Penicillin	I-Entity
model	O
is	O
a	O
widely	O
used	O
experimental	O
model	O
for	O
epilepsy	I-Entity
research	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
portray	O
a	O
detailed	O
spectral	O
analysis	O
of	O
penicillin	I-Entity
-	O
induced	O
epileptiform	B-Entity
activity	I-Entity
in	O
comparison	O
with	O
basal	O
brain	O
activity	O
in	O
anesthetized	O
Wistar	O
rats	O
.	O

urethane	I-Entity
and	O
connected	O
to	O
an	O
electrocorticogram	O
setup	O
.	O

After	O
a	O
short	O
period	O
of	O
basal	O
activity	O
recording	O
,	O
epileptic	I-Entity
focus	O
was	O
induced	O
by	O
injecting	O
400IU/2	O
microl	O
penicillin	B-Entity
-	I-Entity
G	I-Entity
potassium	I-Entity
into	O
the	O
left	O
lateral	O
ventricle	O
while	O
the	O
cortical	O
activity	O
was	O
continuously	O
recorded	O
.	O

Basal	O
activity	O
,	O
latent	O
period	O
and	O
the	O
penicillin	I-Entity
-	O
induced	O
epileptiform	B-Entity
activity	I-Entity
periods	O
were	O
then	O
analyzed	O
using	O
both	O
conventional	O
methods	O
and	O
spectral	O
analysis	O
.	O

Our	O
results	O
show	O
that	O
the	O
most	O
affected	O
frequency	O
bands	O
were	O
delta	O
,	O
theta	O
,	O
beta-2	O
and	O
gamma-2	O
bands	O
during	O
the	O
epileptiform	B-Entity
activity	I-Entity
and	O
there	O
were	O
marked	O
differences	O
in	O
terms	O
of	O
spectral	O
densities	O
between	O
three	O
investigated	O
episodes	O
(	O
basal	O
activity	O
,	O
latent	O
period	O
and	O
epileptiform	B-Entity
activity	I-Entity
)	O
.	O

Our	O
results	O
may	O
help	O
to	O
analyze	O
novel	O
data	O
obtained	O
using	O
similar	O
experimental	O
models	O
and	O
the	O
simple	O
analysis	O
method	O
described	O
here	O
can	O
be	O
used	O
in	O
similar	O
studies	O
to	O
investigate	O
the	O
basic	O
neuronal	O
mechanism	O
of	O
this	O
or	O
other	O
types	O
of	O
experimental	O
epilepsies	I-Entity
.	O



High	O
dose	O
dexmedetomidine	I-Entity
as	O
the	O
sole	O
sedative	O
for	O
pediatric	O
MRI	O
.	O

This	O
large	O
-	O
scale	O
retrospective	O
review	O
evaluates	O
the	O
sedation	O
profile	O
of	O
dexmedetomidine	I-Entity
.	O

AIM	O
:	O
To	O
determine	O
the	O
hemodynamic	O
responses	O
,	O
efficacy	O
and	O
adverse	O
events	O
associated	O
with	O
the	O
use	O
of	O
high	O
dose	O
dexmedetomidine	I-Entity
as	O
the	O
sole	O
sedative	O
for	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
studies	O
.	O

Dexmedetomidine	I-Entity
has	O
been	O
used	O
at	O
our	O
institution	O
since	O
2005	O
to	O
provide	O
sedation	O
for	O
pediatric	O
radiological	O
imaging	O
studies	O
.	O

Over	O
time	O
,	O
an	O
effective	O
protocol	O
utilizing	O
high	O
dose	O
dexmedetomidine	I-Entity
as	O
the	O
sole	O
sedative	O
agent	O
has	O
evolved	O
.	O

Data	O
were	O
analyzed	O
from	O
all	O
747	O
consecutive	O
patients	O
who	O
received	O
dexmedetomidine	I-Entity
for	O
MRI	O
sedation	O
from	O
April	O
2005	O
to	O
April	O
2007	O
.	O

Since	O
2005	O
,	O
the	O
10-min	O
loading	O
dose	O
of	O
our	O
dexmedetomidine	I-Entity
protocol	O
increased	O
from	O
2	O
to	O
3	O
microg.kg(-1	O
)	O
,	O
and	O
the	O
infusion	O
rate	O
increased	O
from	O
1	O
to	O
1.5	O
to	O
2	O
microg.kg(-1).h(-1	O
)	O
.	O

The	O
current	O
sedation	O
protocol	O
progressively	O
increased	O
the	O
rate	O
of	O
successful	O
sedation	O
(	O
able	O
to	O
complete	O
the	O
imaging	O
study	O
)	O
when	O
using	O
dexmedetomidine	I-Entity
alone	O
from	O
91.8%	O
to	O
97.6%	O
(	O
P	O
=	O
0.009	O
)	O
,	O
reducing	O
the	O
requirement	O
for	O
adjuvant	O
pentobarbital	I-Entity
in	O
the	O
event	O
of	O
sedation	O
failure	O
with	O
dexmedetomidine	I-Entity
alone	O
and	O
decreased	O
the	O
mean	O
recovery	O
time	O
by	O
10	O
min	O
(	O
P	O

Although	O
dexmedetomidine	I-Entity
sedation	O
was	O
associated	O
with	O
a	O
16%	O
incidence	O
of	O
bradycardia	I-Entity
,	O
all	O
concomitant	O
mean	O
arterial	O
blood	O
pressures	O
were	O
within	O
20%	O
of	O
age	O
-	O
adjusted	O
normal	O
range	O
and	O

oxygen	I-Entity
saturations	O
were	O
95%	O
or	O
higher	O
.	O

CONCLUSION	O
:	O
Dexmedetomidine	I-Entity
in	O
high	O
doses	O
provides	O
adequate	O
sedation	O
for	O
pediatric	O
MRI	O
studies	O
.	O

While	O
use	O
of	O
high	O
dose	O
dexmedetomidine	I-Entity
is	O
associated	O
with	O
decreases	O
in	O
heart	O
rate	O
and	O
blood	O
pressure	O
outside	O
the	O
established	O
'	O
awake	O
'	O
norms	O
,	O
this	O
deviation	O
is	O
generally	O
within	O
20%	O
of	O
norms	O
,	O
and	O
is	O
not	O
associated	O
with	O
adverse	O
sequelae	O
.	O

Dexmedetomidine	I-Entity
is	O
useful	O
as	O
the	O
sole	O
sedative	O
for	O
pediatric	O
MRI	O
.	O



Methamphetamine	I-Entity
causes	O
alterations	O
in	O
the	O
MAP	O
kinase	O
-	O
related	O
pathways	O
in	O
the	O
brains	O
of	O
mice	O
that	O
display	O
increased	O
aggressiveness	I-Entity
.	O

Aggressive	B-Entity
behaviors	I-Entity
have	O
been	O
reported	O
in	O
patients	O
who	O
suffer	O
from	O
some	O
psychiatric	B-Entity
disorders	I-Entity
,	O
and	O
are	O
common	O
in	O
methamphetamine	I-Entity
(	O
METH	I-Entity
)	O
abusers	O
.	O

Herein	O
,	O
we	O
report	O
that	O
multiple	O
(	O
but	O
not	O
single	O
)	O
injections	O
of	O
METH	I-Entity
significantly	O
increased	O
aggressiveness	I-Entity
in	O
male	O
CD-1	O
mice	O
.	O

This	O
increase	O
in	O
aggressiveness	I-Entity
was	O
not	O
secondary	O
to	O
METH	I-Entity
-	O
induced	O
hyperactivity	I-Entity
.	O

Analysis	O
of	O
protein	O
expression	O
using	O
antibody	O
microarrays	O
and	O
Western	O
blotting	O
revealed	O
differential	O
changes	O
in	O
MAP	O
kinase	O
-	O
related	O
pathways	O
after	O
multiple	O
and	O
single	O
METH	I-Entity
injections	O
.	O

There	O
were	O
statistically	O
significant	O
(	O
p<0.05	O
)	O
decreases	O
in	O
MEK1	O
,	O
Erk2p	O
,	O
GSK3alpha	O
,	O
14	O
-	O
3	O
-	O
3e	O
,	O
and	O
MEK7	O
in	O
the	O
striata	O
of	O
mice	O
after	O
multiple	O
injections	O
of	O
METH	I-Entity
.	O

MEK1	O
was	O
significantly	O
decreased	O
also	O
after	O
a	O
single	O
injection	O
of	O
METH	I-Entity
,	O
but	O
to	O
a	O
much	O
lesser	O
degree	O
than	O
after	O
multiple	O
injections	O
of	O
METH	I-Entity
.	O

In	O
the	O
frontal	O
cortex	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
GSK3alpha	O
after	O
multiple	O
(	O
but	O
not	O
single	O
)	O
injections	O
of	O
METH	I-Entity
.	O

These	O
findings	O
suggest	O
that	O
alterations	O
in	O
MAP	O
kinase	O
-	O
related	O
pathways	O
in	O
the	O
prefronto	O
-	O
striatal	O
circuitries	O
might	O
be	O
involved	O
in	O
the	O
manifestation	O
of	O
aggressive	B-Entity
behaviors	I-Entity
in	O
mice	O
.	O



Lamotrigine	I-Entity
associated	O
with	O
exacerbation	O
or	O
de	O
novo	O
myoclonus	I-Entity
in	O
idiopathic	B-Entity
generalized	I-Entity
epilepsies	I-Entity
.	O

Five	O
patients	O
with	O
idiopathic	B-Entity
generalized	I-Entity
epilepsies	I-Entity
(	O
IGE	I-Entity
)	O
treated	O
with	O
lamotrigine	I-Entity
(	O
LTG	I-Entity
)	O
experienced	O
exacerbation	O
or	O
de	O
novo	O
appearance	O
of	O
myoclonic	B-Entity
jerks	I-Entity
(	O
MJ	I-Entity
)	O
.	O

In	O
three	O
patients	O
,	O
LTG	I-Entity
exacerbated	O
MJ	I-Entity
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
early	O
aggravation	O
during	O
titration	O
.	O

MJ	I-Entity
disappeared	O
when	O
LTG	I-Entity
dose	O
was	O
decreased	O
by	O
25	O
to	O
50%	O
.	O

In	O
two	O
patients	O
,	O
LTG	I-Entity
exacerbated	O
MJ	I-Entity
in	O
a	O
delayed	O
but	O
more	O
severe	O
manner	O
,	O
with	O
myoclonic	B-Entity
status	I-Entity
that	O
only	O
ceased	O
after	O
LTG	I-Entity
withdrawal	O
.	O



rTMS	O
of	O
supplementary	O
motor	O
area	O
modulates	O
therapy	O
-	O
induced	O
dyskinesias	I-Entity
in	O
Parkinson	B-Entity
disease	I-Entity
.	O

The	O
neural	O
mechanisms	O
and	O
circuitry	O
involved	O
in	O
levodopa	I-Entity
-	O
induced	O
dyskinesia	I-Entity
are	O
unclear	O
.	O

Using	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
over	O
the	O
supplementary	O
motor	O
area	O
(	O
SMA	O
)	O
in	O
a	O
group	O
of	O
patients	O
with	O
advanced	O
Parkinson	B-Entity
disease	I-Entity
,	O
the	O
authors	O
investigated	O
whether	O
modulation	O
of	O
SMA	O
excitability	O
may	O
result	O
in	O
a	O
modification	O
of	O
a	O
dyskinetic	I-Entity
state	O
induced	O
by	O
continuous	O
apomorphine	I-Entity
infusion	O
.	O

rTMS	O
at	O
1	O
Hz	O
was	O
observed	O
to	O
markedly	O
reduce	O
drug	B-Entity
-	I-Entity
induced	I-Entity
dyskinesias	I-Entity
,	O
whereas	O
5-Hz	O
rTMS	O
induced	O
a	O
slight	O
but	O
not	O
significant	O
increase	O
.	O



Assessment	O
of	O
the	O
onset	O
and	O
persistence	O
of	O
amnesia	I-Entity
during	O
procedural	O
sedation	O
with	O
propofol	I-Entity
.	O

To	O
assess	O
patients	O
'	O
ability	O
to	O
repeat	O
and	O
recall	O
words	O
presented	O
to	O
them	O
while	O
undergoing	O
procedural	O
sedation	O
with	O
propofol	I-Entity
,	O
and	O
correlate	O
their	O
recall	O
with	O
their	O
level	O
of	O
awareness	O
as	O
measured	O
by	O
bispectral	O
index	O
(	O
BIS	O
)	O
monitoring	O
.	O

This	O
was	O
a	O
prospective	O
,	O
single	O
-	O
intervention	O
study	O
of	O
consenting	O
adult	O
patients	O
undergoing	O
procedural	O
sedation	O
with	O
propofol	I-Entity
between	O
December	O
28	O
,	O
2002	O
,	O
and	O
October	O
31	O
,	O
2003	O
.	O

The	O
mean	O
highest	O
BIS	O
score	O
corresponding	O
to	O
the	O
inability	B-Entity
to	I-Entity
repeat	I-Entity
words	I-Entity
was	O
81.5	O
(	O
95%	O
CI	O
=	O
78.1	O
to	O
84.8	O
)	O
.	O

Furthermore	O
,	O
patients	O
had	O
no	O
recall	O
of	O
words	O
repeated	O
prior	O
to	O
procedural	O
sedation	O
in	O
BIS	O
ranges	O
associated	O
with	O
recall	O
after	O
procedural	O
sedation	O
,	O
suggestive	O
of	O
retrograde	B-Entity
amnesia	I-Entity
.	O



Assessment	O
of	O
perinatal	O
hepatitis	B-Entity
B	I-Entity
and	O
rubella	I-Entity
prevention	O
in	O
New	O
Hampshire	O
delivery	O
hospitals	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
current	O
performance	O
on	O
recommended	O
perinatal	O
hepatitis	B-Entity
B	I-Entity
and	O
rubella	I-Entity
prevention	O
practices	O
in	O
New	O
Hampshire	O
.	O

Assessment	O
was	O
done	O
on	O
the	O
following	O
:	O
prenatal	O
screening	O
for	O
hepatitis	B-Entity
B	I-Entity
and	O
rubella	I-Entity
,	O
administration	O
of	O
the	O
hepatitis	B-Entity
B	I-Entity
vaccine	O
birth	O
dose	O
to	O
all	O
infants	O
,	O
administration	O
of	O
hepatitis	B-Entity
B	I-Entity
immune	O
globulin	O
to	O
infants	O
who	O
were	O
born	O
to	O
hepatitis	B-Entity
B	I-Entity
surface	I-Entity
antigen	I-Entity
-	O
positive	O
mothers	O
,	O
rubella	I-Entity
immunity	O
,	O
and	O
administration	O
of	O
in	O
-	O
hospital	O
postpartum	O
rubella	I-Entity
vaccine	O
to	O
rubella	I-Entity
nonimmune	O
women	O
.	O

RESULTS	O
:	O
Prenatal	O
screening	O
rates	O
for	O
hepatitis	B-Entity
B	I-Entity
(	O
98.8%	O
)	O
and	O
rubella	I-Entity
(	O
99.4%	O
)	O
were	O
high	O
.	O

Hepatitis	B-Entity
B	I-Entity
vaccine	O
birth	O
dose	O
was	O
administered	O
to	O
76.2%	O
of	O
all	O
infants	O
.	O

All	O
infants	O
who	O
were	O
born	O
to	O
hepatitis	B-Entity
B	I-Entity
surface	I-Entity
antigen	I-Entity
-	O
positive	O
mothers	O
also	O
received	O
hepatitis	B-Entity
B	I-Entity
immune	O
globulin	O
.	O

Multivariate	O
logistic	O
regression	O
showed	O
that	O
the	O
month	O
of	O
delivery	O
and	O
infant	O
birth	O
weight	O
were	O
independent	O
predictors	O
of	O
hepatitis	B-Entity
B	I-Entity
vaccination	O
.	O

Women	O
who	O
were	O
born	O
between	O
1971	O
and	O
1975	O
had	O
the	O
highest	O
rate	O
of	O
rubella	I-Entity
nonimmunity	O
(	O
9.5%	O
)	O
.	O

In	O
-	O
hospital	O
postpartum	O
rubella	I-Entity
vaccine	O
administration	O
was	O
documented	O
for	O
75.6%	O
of	O
nonimmune	O
women	O
.	O

This	O
study	O
documents	O
good	O
compliance	O
in	O
New	O
Hampshire	O
's	O
birthing	O
hospitals	O
with	O
national	O
guidelines	O
for	O
perinatal	O
hepatitis	B-Entity
B	I-Entity
and	O
rubella	I-Entity
prevention	O
and	O
highlights	O
potential	O
areas	O
for	O
improvement	O
.	O



Doxorubicin	I-Entity
is	O
an	O
anti	O
-	O
tumor	I-Entity
agent	O
that	O
represses	O
cardiac	O
-	O
specific	O
gene	O
expression	O
and	O
induces	O
myocardial	O
cell	O
apoptosis	O
.	O

Doxorubicin	I-Entity
depletes	O
cardiac	O
p300	O
,	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
required	O
for	O
the	O
maintenance	O
of	O
the	O
differentiated	O
phenotype	O
of	O
cardiac	O
myocytes	O
.	O

However	O
,	O
the	O
role	O
of	O
p300	O
in	O
protection	O
against	O
doxorubicin	I-Entity
-	O
induced	O
apoptosis	O
is	O
unknown	O
.	O

Transgenic	O
mice	O
overexpressing	O
p300	O
in	O
the	O
heart	O
and	O
wild	O
-	O
type	O
mice	O
were	O
subjected	O
to	O
doxorubicin	I-Entity
treatment	O
.	O

Doxorubicin	I-Entity
induced	O
myocardial	O
cell	O
apoptosis	O
in	O
wild	O
-	O
type	O
mice	O
but	O
not	O
in	O
transgenic	O
mice	O
.	O

These	O
findings	O
demonstrate	O
that	O
overexpression	O
of	O
p300	O
protects	O
cardiac	O
myocytes	O
from	O
doxorubicin	I-Entity
-	O
induced	O
apoptosis	O
and	O
reduces	O
the	O
extent	O
of	O
acute	O
heart	B-Entity
failure	I-Entity
in	O
adult	O
mice	O
in	O
vivo	O
.	O



Mitochondrial	O
DNA	O
and	O
its	O
respiratory	O
chain	O
products	O
are	O
defective	O
in	O
doxorubicin	I-Entity
nephrosis	I-Entity
.	O

Doxorubicin	I-Entity
induces	O
a	O
self	O
-	O
perpetuating	O
nephropathy	I-Entity
characterized	O
by	O
early	O
glomerular	B-Entity
and	I-Entity
late	I-Entity
-	I-Entity
onset	I-Entity
tubular	I-Entity
lesions	I-Entity
in	O
rats	O
.	O

We	O
investigated	O
the	O
potential	O
role	O
of	O
mitochondrial	B-Entity
injury	I-Entity
in	O
the	O
onset	O
of	O
these	O
lesions	O
.	O

Rats	O
were	O
treated	O
with	O
intravenous	O
doxorubicin	I-Entity
(	O
1	O
mg	O
kg(-1	O
)	O

Glomerular	B-Entity
and	I-Entity
tubular	I-Entity
injury	I-Entity
was	O
monitored	O
and	O
correlated	O
to	O
the	O
activity	O
or	O
expression	O
of	O
respiratory	O
chain	O
components	O
.	O

Finally	O
,	O
we	O
quantified	O
both	O
nuclear	O
and	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
as	O
well	O
as	O
superoxide	I-Entity
production	O
and	O
the	O
4834	O
base	O
pair	O
'	O
common	O
'	O
mtDNA	O
deletion	O
.	O

The	O
'	O
long	O
-	O
term	O
'	O
group	O
had	O
significant	O
glomerular	B-Entity
and	I-Entity
tubular	I-Entity
lesions	I-Entity
,	O
depressed	O
activities	O
of	O
mtDNA	O
-	O
encoded	O
NADH	O
dehydrogenase	O
and	O
cytochrome	O
-	O
c	O
oxidase	O
(	O
COX	O
)	O
and	O
increased	O
citrate	I-Entity
synthase	O
activity	O
.	O

In	O
'	O
short	O
-	O
term	O
'	O
rats	O
,	O
there	O
were	O
fewer	O
tubular	B-Entity
lesions	I-Entity
,	O
but	O
similar	O
numbers	O
of	O
glomerular	B-Entity
lesions	I-Entity
activity	O
.	O

Among	O
all	O
animals	O
,	O
glomerular	B-Entity
and	I-Entity
tubular	I-Entity
injury	I-Entity
were	O
inversely	O
correlated	O
with	O
mtDNA	O
levels	O
,	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
activities	O
and	O
with	O
the	O
expression	O
of	O
the	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
subunit	O
COX	O
-	O
I.	O
Injury	O
was	O
positively	O
correlated	O
with	O
superoxide	I-Entity
production	O
and	O
the	O
activities	O
of	O
nucleus	O
-	O
encoded	O
mitochondrial	O
or	O
cytoplasmic	O
enzymes	O
.	O

These	O
results	O
suggest	O
an	O
important	O
role	O
for	O
quantitative	O
and	O
qualitative	O
mtDNA	O
alterations	O
through	O
the	O
reduction	O
of	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
function	O
and	O
induction	O
of	O
superoxide	I-Entity
in	O
doxorubicin	I-Entity
-	O
induced	O
renal	B-Entity
lesions	I-Entity
.	O



Amphotericin	B-Entity
B	I-Entity
-	O
induced	O
seizures	I-Entity
in	O
a	O
patient	O
with	O
AIDS	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
multiple	O
episodes	O
of	O
seizure	I-Entity
activity	O
in	O
an	O
AIDS	I-Entity
patent	O
following	O
amphotericin	B-Entity
B	I-Entity
infusion	O
.	O

A	O
46-year	O
-	O
old	O
African	O
-	O
American	O
man	O
experienced	O
recurrent	O
grand	B-Entity
mal	I-Entity
seizures	I-Entity
during	O
intravenous	O
infusion	O
of	O
amphotericin	B-Entity
B	I-Entity
,	O
then	O
petit	O
mal	O
seizures	I-Entity
as	O
the	O
infusion	O
was	O
stopped	O
and	O
the	O
drug	O
concentrations	O
decreased	O
with	O
time	O
.	O

The	O
patients	O
concurrent	O
medications	O
included	O
didanosine	I-Entity
,	O
hydroxyzine	I-Entity
,	O
promethazine	I-Entity
,	O
hydrocortisone	I-Entity
,	O
and	O
prochlorperazine	I-Entity
.	O

Despite	O
administration	O
of	O
phenytoin	I-Entity
and	O
lorazepam	I-Entity
,	O
the	O
seizures	I-Entity
persisted	O
and	O
occurred	O
only	O
during	O
amphotercin	B-Entity
B	I-Entity
administration	O
.	O

DISCUSSION	O
:	O
AIDS	I-Entity
and	O
cryptococcal	B-Entity
meningitis	I-Entity
,	O
both	O
of	O
which	O
the	O
patient	O
had	O
,	O
can	O
potentially	O
cause	O
seizures	I-Entity
.	O

The	O
patient	O
had	O
a	O
history	O
of	O
alcohol	B-Entity
abuse	I-Entity
;	O
alcohol	I-Entity
intake	O
as	O
well	O
as	O
withdrawal	O
can	O
also	O
cause	O
seizures	I-Entity
.	O

Didanosine	I-Entity
also	O
has	O
a	O
potential	O
for	O
inducing	O
seizures	I-Entity
.	O

However	O
,	O
these	O
other	O
potential	O
causes	O
of	O
seizure	I-Entity
were	O
ruled	O
out	O
.	O

The	O
time	O
course	O
of	O
events	O
suggested	O
that	O
amphotericin	B-Entity
B	I-Entity
was	O
the	O
cause	O
of	O
the	O
seizures	I-Entity
in	O
this	O
AIDS	I-Entity
patient	O
.	O

CONCLUSIONS	O
:	O
Amphotericin	B-Entity
B	I-Entity
seems	O
to	O
be	O
the	O
probable	O
cause	O
of	O
the	O
seizures	I-Entity
.	O

To	O
date	O
,	O
only	O
three	O
cases	O
of	O
seizures	I-Entity
associated	O
with	O
amphotericin	B-Entity
B	I-Entity
have	O
been	O
reported	O
in	O
the	O
literature	O
,	O
but	O
healthcare	O
providers	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
this	O
rare	O
adverse	O
effect	O
.	O



Therapeutic	O
drug	O
monitoring	O
of	O
tobramycin	I-Entity
:	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
dosage	O
regimen	O
(	O
once	O
-	O
daily	O
vs.	O
twice	O
-	O
daily	O
)	O
of	O
tobramicyn	I-Entity
on	O
steady	O
-	O
state	O
serum	O
concentrations	O
and	O
toxicity	I-Entity
.	O

tobramycin	I-Entity
(	O
4	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
randomised	O
to	O
two	O
groups	O
.	O

Group	O
OD	O
(	O
n	O
=	O
22	O
)	O
received	O
a	O
once	O
-	O
daily	O
dose	O
of	O
tobramycin	I-Entity
and	O
group	O
TD	O
(	O
n	O
=	O
21	O
)	O
received	O
the	O
same	O
dose	O
divided	O
into	O
two	O
doses	O
daily	O
.	O

Tobramycin	I-Entity
serum	O
concentrations	O
(	O
peak	O
and	O
trough	O
)	O
were	O
measured	O
by	O
enzyme	O
multiplied	O
immunoassay	O
.	O

Increased	O
serum	O
creatinine	I-Entity
was	O
observed	O
in	O
73%	O
of	O
patients	O
in	O
OD	O
versus	O
57%	O
of	O
patients	O
in	O
TD	O
,	O
without	O
evidence	O
of	O
nephrotoxicity	I-Entity
.	O

In	O
TD	O
group	O
,	O
three	O
patients	O
developed	O
decreased	B-Entity
auditory	I-Entity
function	I-Entity
,	O
of	O
which	O
one	O
presented	O
with	O
an	O
auditory	B-Entity
loss	I-Entity
of	O
-30	O
dB	O
,	O
whereas	O
in	O
the	O
OD	O
group	O
only	O
one	O
patient	O
presented	O
decreased	B-Entity
auditory	I-Entity
function	I-Entity
.	O

This	O
small	O
study	O
suggests	O
that	O
a	O
once	O
-	O
daily	O
dosing	O
regimen	O
of	O
tobramycin	I-Entity
is	O
at	O
least	O
as	O
effective	O
as	O
and	O
is	O
no	O
more	O
and	O
possibly	O
less	O
toxic	O
than	O
the	O
twice	O
-	O
daily	O
regimen	O
.	O



Chronic	O
effects	O
of	O
a	O
novel	O
synthetic	O
anthracycline	I-Entity
derivative	O
(	O
SM-5887	I-Entity
)	O
on	O
normal	O
heart	O
and	O
doxorubicin	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
in	O
beagle	O
dogs	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
chronic	O
cardiotoxic	I-Entity
potential	O
of	O
SM-5887	I-Entity
and	O
a	O
possible	O
deteriorating	O
effect	O
of	O
SM-5887	I-Entity
on	O
low	O
-	O
grade	O
cardiotoxicity	I-Entity

pre	O
-	O
induced	O
by	O
doxorubicin	I-Entity
in	O
beagle	O
dogs	O
.	O

In	O
the	O
chronic	O
treatment	O
,	O
beagle	O
dogs	O
of	O
each	O
sex	O
were	O
given	O
intravenously	O
once	O
every	O
3	O
weeks	O
,	O
either	O
a	O
sublethal	O
dose	O
of	O
doxorubicin	I-Entity
(	O
1.5	O
mg	O
/	O
kg	O
)	O
or	O
SM-5887	I-Entity
(	O
2.5	O
mg	O
/	O
kg	O
)	O
.	O

Animals	O
which	O
received	O
over	O
six	O
courses	O
of	O
doxorubicin	I-Entity
demonstrated	O
the	O
electrocardiogram	O
(	O
ECG	O
)	O
changes	O
,	O
decrease	O
of	O
blood	O
pressure	O
and	O
high	O
-	O
grade	O
histopathological	O
cardiomyopathy	I-Entity
,	O
while	O
animals	O
which	O
were	O
terminally	O
sacrificed	O
after	O
the	O
SM-5887	I-Entity
administration	O
did	O
not	O
show	O
any	O
changes	O
in	O
ECG	O
,	O
blood	O
pressure	O
and	O
histopathological	O
examinations	O
.	O

To	O
examine	O
a	O
possibly	O
deteriorating	O
cardiotoxic	I-Entity
effect	O
of	O
SM-5887	I-Entity
,	O
low	O
-	O
grade	O
cardiomyopathy	I-Entity
was	O
induced	O
in	O
dogs	O
by	O
four	O
courses	O
of	O
doxorubicin	I-Entity
(	O
1.5	O
mg	O
/	O
kg	O
)	O
.	O

Nine	O
weeks	O
after	O
pre	O
-	O
treatment	O
,	O
dogs	O
were	O
given	O
four	O
courses	O
of	O
either	O
doxorubicin	I-Entity
(	O
1.5	O
mg	O
/	O
kg	O
)	O
or	O
SM-5887	I-Entity
(	O
2.5	O
mg	O
/	O
kg	O
)	O
once	O
every	O
3	O
weeks	O
.	O

The	O
low	O
-	O
grade	O
cardiotoxic	I-Entity
changes	O
were	O
enhanced	O
by	O
the	O
additional	O
doxorubicin	I-Entity
treatment	O
.	O

On	O
the	O
contrary	O
,	O
the	O
SM-5887	I-Entity
treatment	O
did	O
not	O
progress	O
the	O
grade	O
of	O
cardiomyopathy	I-Entity
.	O

In	O
conclusion	O
,	O
SM-5887	I-Entity
does	O
not	O
have	O
any	O
potential	O
of	O
chronic	O
cardiotoxicity	I-Entity
and	O
deteriorating	O
effect	O
on	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
in	O
dogs	O
.	O



Posteroventral	O
medial	O
pallidotomy	O
in	O
advanced	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

medial	O
pallidotomy	O
sometimes	O
produces	O
striking	O
improvement	O
in	O
patients	O
with	O
advanced	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
,	O
but	O
the	O
studies	O
to	O
date	O
have	O
involved	O
small	O
numbers	O
of	O
patients	O
and	O
short	O
-	O
term	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
underwent	O
serial	O
,	O
detailed	O
assessments	O
both	O
after	O
drug	O
withdrawal	O
(	O
""""	O
off	O
""""	O
period	O
)	O
and	O
while	O
taking	O
their	O
optimal	O
medical	O
regimens	O
(	O
""""	O
on	O
""""	O
period	O
)	O
.	O

The	O
percent	O
improvements	O
at	O
six	O
months	O
were	O
as	O
follows	O
:	O
off	O
-	O
period	O
score	O
for	O
overall	O
motor	O
function	O
,	O
28	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
19	O
to	O
38	O
percent	O
)	O
,	O
with	O
most	O
of	O
the	O
improvement	O
in	O
the	O
contralateral	O
limbs	O
;	O
off	O
-	O
period	O
score	O
for	O
activities	O
of	O
daily	O
living	O
,	O
29	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
19	O
to	O
39	O
percent	O
)	O
;	O
on	O
-	O
period	O
score	O
for	O
contralateral	O
dyskinesias	I-Entity
,	O
82	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
72	O
to	O
91	O
percent	O
)	O
;	O
and	O
on	O
-	O
period	O
score	O
for	O
ipsilateral	O
dyskinesias	I-Entity
,	O
44	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
29	O
to	O
59	O
percent	O
)	O
.	O

The	O
improvements	O
in	O
dyskinesias	I-Entity
and	O
the	O
total	O
scores	O
for	O
off	O
-	O
period	O
parkinsonism	I-Entity
,	O
contralateral	O
bradykinesia	I-Entity
,	O
and	O
rigidity	I-Entity
were	O
sustained	O
in	O
the	O
11	O
patients	O
examined	O
at	O
two	O
years	O
.	O

The	O
improvement	O
in	O
ipsilateral	O
dyskinesias	I-Entity
was	O
lost	O
after	O
one	O
year	O
,	O
and	O
the	O
improvements	O
in	O
postural	O
stability	O
and	O
gait	O
lasted	O
only	O
three	O
to	O
six	O
months	O
.	O

In	O
late	O
-	O
stage	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
,	O
pallidotomy	O
significantly	O
reduces	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
and	O
off	O
-	O
period	O
disability	O
.	O



Neuropeptide	O
-	O
Y	O
immunoreactivity	O
in	O
the	O
pilocarpine	I-Entity
model	O
of	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
.	O

Neuropeptide	O
-	O
Y	O
(	O
NPY	O
)	O
is	O
expressed	O
by	O
granule	O
cells	O
and	O
mossy	O
fibres	O
of	O
the	O
hippocampal	O
dentate	O
gyrus	O
during	O
experimental	O
temporal	B-Entity
lobe	I-Entity
epilepsy	I-Entity
(	O
TLE	I-Entity
)	O
.	O

This	O
expression	O
may	O
represent	O
an	O
endogenous	O
damping	O
mechanism	O
since	O
NPY	O
has	O
been	O
shown	O
to	O
block	O
seizure	I-Entity
-	O
like	O
events	O
following	O
high	O
-	O
frequency	O
stimulation	O
in	O
hippocampal	O
slices	O
.	O

The	O
pilocarpine	I-Entity
(	O
PILO	I-Entity
)	O
model	O
of	O
epilepsy	I-Entity
is	O
characterized	O
by	O
an	O
acute	O
period	O
of	O
status	B-Entity
epilepticus	I-Entity
followed	O
by	O
spontaneous	O
recurrent	O
seizures	I-Entity
and	O
related	O
brain	B-Entity
damage	I-Entity
.	O

PILO	I-Entity
-	O
injected	O
animals	O
exhibited	O
NPY	O
immunoreactivity	O
in	O
the	O
region	O
of	O
the	O
mossy	O
fibre	O
terminals	O
,	O
in	O
the	O
dentate	O
gyrus	O
inner	O
molecular	O
layer	O
and	O
,	O
in	O
a	O
few	O
cases	O
,	O
within	O
presumed	O
granule	O
cells	O
.	O

In	O
addition	O
,	O
PILO	I-Entity
injected	O
animals	O
exhibited	O
a	O
reduction	O
in	O
the	O
number	O
of	O
NPY	O
-	O
immunoreactive	O
interneurons	O
compared	O
with	O
controls	O
.	O

The	O
results	O
demonstrate	O
that	O
changes	O
in	O
NPY	O
expression	O
,	O
including	O
expression	O
in	O
the	O
granule	O
cells	O
and	O
mossy	O
fibres	O
and	O
the	O
loss	O
of	O
vulnerable	O
NPY	O
neurons	O
,	O
are	O
present	O
in	O
the	O
PILO	I-Entity
model	O
of	O
TLE	I-Entity
.	O



During	O
the	O
follow	O
-	O
up	O
,	O
3	O
patients	O
(	O
12%	O
)	O
developed	O
steroid	I-Entity
-	O
induced	O
elevated	B-Entity
intraocular	I-Entity
pressure	I-Entity
(	O
IOP	O
)	O
that	O
resolved	O
after	O
corticosteroid	I-Entity
therapy	O
was	O
discontinued	O
.	O

The	O
transient	O
steroid	I-Entity
-	O
induced	O
IOP	B-Entity
rise	I-Entity
did	O
not	O
seem	O
to	O
cause	O
functional	O
impairment	O
.	O



Liposomal	O
daunorubicin	I-Entity
in	O
advanced	O
Kaposi	B-Entity
's	I-Entity
sarcoma	I-Entity
:	O
a	O
phase	O
II	O
study	O
.	O

We	O
report	O
a	O
non	O
-	O
randomized	O
Phase	O
II	O
clinical	O
trial	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
liposomal	O
daunorubicin	I-Entity
(	O
DaunoXome	O
)	O
in	O
the	O
treatment	O
of	O
AIDS	I-Entity
related	O
Kaposi	B-Entity
's	I-Entity
sarcoma	I-Entity
.	O

Eleven	O
homosexual	O
men	O
with	O
advanced	O
Kaposi	B-Entity
's	I-Entity
sarcoma	I-Entity
were	O
entered	O
in	O
the	O
trial	O
.	O

Changes	O
in	O
size	O
,	O
colour	O
and	O
associated	O
oedema	I-Entity
of	O
selected	O
'	O
target	O
'	O
lesions	O
were	O
measured	O
.	O

Clinical	O
,	O
biochemical	O
and	O
haematological	O
toxicities	I-Entity
were	O
assessed	O
.	O

Stabilization	O
of	O
Kaposi	B-Entity
's	I-Entity
sarcoma	I-Entity
occurred	O
in	O
the	O
remaining	O
six	O
,	O
maintained	O
until	O
the	O
end	O
of	O
the	O
trial	O
period	O
in	O
four	O
.	O

The	O
drug	O
was	O
generally	O
well	O
tolerated	O
,	O
with	O
few	O
mild	O
symptoms	O
of	O
toxicity	I-Entity
.	O

The	O
main	O
problem	O
encountered	O
was	O
haematological	O
toxicity	I-Entity
,	O
with	O
three	O
subjects	O
experiencing	O
severe	O
neutropenia	I-Entity
(	O
neutrophil	O
count	O
<	O
0.5	O
x	O
10(9)/l	O
)	O
.	O

There	O
was	O
no	O
evidence	O
of	O
cardiotoxicity	I-Entity
.	O

In	O
this	O
small	O
patient	O
sample	O
,	O
liposomal	O
daunorubicin	I-Entity
was	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	O
in	O
the	O
treatment	O
of	O
Kaposi	B-Entity
's	I-Entity
sarcoma	I-Entity
.	O



Failure	O
of	O
ancrod	O
in	O
the	O
treatment	O
of	O
heparin	I-Entity
-	O
induced	O
arterial	O
thrombosis	I-Entity
.	O

The	O
morbidity	O
and	O
mortality	O
associated	O
with	O
heparin	I-Entity
-	O
induced	O
thrombosis	I-Entity
remain	O
high	O
despite	O
numerous	O
empirical	O
therapies	O
.	O

Ancrod	O
has	O
been	O
used	O
successfully	O
for	O
prophylaxis	O
against	O
development	O
of	O
thrombosis	I-Entity
in	O
patients	O
with	O
heparin	I-Entity
induced	O
platelet	B-Entity
aggregation	I-Entity
who	O
require	O
brief	O
reexposure	O
to	O
heparin	I-Entity
,	O
but	O
its	O
success	O
in	O
patients	O
who	O
have	O
developed	O
the	O
thrombosis	I-Entity
syndrome	O
is	O
not	O
well	O
defined	O
.	O

The	O
authors	O
present	O
a	O
case	O
of	O
failure	O
of	O
ancrod	O
treatment	O
in	O
a	O
patient	O
with	O
heparin	I-Entity
-	O
induced	O
thrombosis	I-Entity
.	O



Seizure	I-Entity
after	O
flumazenil	I-Entity
administration	O
in	O
a	O
pediatric	O
patient	O
.	O

Flumazenil	I-Entity
is	O
a	O
benzodiazepine	I-Entity
receptor	O
antagonist	O
used	O
to	O
reverse	O
sedation	O
and	O
respiratory	B-Entity
depression	I-Entity
induced	O
by	O
benzodiazepines	I-Entity
.	O

Seizures	I-Entity
and	O
cardiac	B-Entity
arrhythmias	I-Entity
have	O
complicated	O
its	O
use	O
in	O
adult	O
patients	O
.	O

Overdose	I-Entity
patients	O
who	O
have	O
coingested	O
tricyclic	O
antidepressants	O
have	O
a	O
higher	O
risk	O
of	O
these	O
complications	O
.	O

Little	O
information	O
exists	O
concerning	O
adverse	O
effects	O
of	O
flumazenil	I-Entity
in	O
children	O
.	O

We	O
report	O
the	O
occurrence	O
of	O
a	O
generalized	O
tonic	B-Entity
-	I-Entity
clonic	I-Entity
seizure	I-Entity
in	O
a	O
pediatric	O
patient	O
following	O
the	O
administration	O
of	O
flumazenil	I-Entity
.	O



Remodelling	O
of	O
nerve	O
structure	O
in	O
experimental	O
isoniazid	I-Entity
neuropathy	I-Entity
in	O
the	O
rat	O
.	O

The	O
neuropathy	I-Entity
caused	O
by	O
a	O
single	O
dose	O
of	O
isoniazid	I-Entity
in	O
rats	O
was	O
studied	O
with	O
a	O
computer	O
-	O
assisted	O
morphometric	O
method	O
.	O



Selective	O
injection	O
of	O
iopentol	I-Entity
,	O
iohexol	I-Entity
and	O
metrizoate	I-Entity
into	O
the	O
left	O
coronary	O
artery	O
of	O
the	O
dog	O
.	O

Induction	O
of	O
ventricular	B-Entity
fibrillation	I-Entity
and	O
decrease	O
of	O
aortic	O
pressure	O
.	O

In	O
twenty	O
beagle	O
dogs	O
selective	O
injections	O
were	O
made	O
into	O
the	O
left	O
coronary	O
artery	O
with	O
iopentol	I-Entity
,	O
iohexol	I-Entity
and	O
metrizoate	I-Entity
in	O
doses	O
of	O
4	O
ml	O
,	O
8	O
ml	O
and	O
16	O
ml	O
.	O

Thirty	O
-	O
six	O
iopentol	I-Entity
injections	O
,	O
35	O
iohexol	I-Entity
injections	O
and	O
37	O
metrizoate	I-Entity
injections	O
were	O
made	O
.	O

Frequencies	O
of	O
ventricular	B-Entity
fibrillation	I-Entity
were	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0.05	O
)	O
after	O
iopentol	I-Entity
(	O
0%	O
)	O
and	O
iohexol	I-Entity
(	O
3%	O
)	O
than	O
after	O
metrizoate	I-Entity
(	O
22%	O
)	O
.	O

Iopentol	I-Entity
and	O
iohexol	I-Entity
also	O
produced	O
significantly	O
less	O
decrease	O
in	O
aortic	O
blood	O
pressure	O
than	O
metrizoate	I-Entity
at	O
the	O
different	O
doses	O
.	O



Magnetic	O
resonance	O
imaging	O
of	O
cerebral	O
venous	B-Entity
thrombosis	I-Entity
secondary	O
to	O
""""	O
low	O
-	O
dose	O
""""	O
birth	O
control	O
pills	O
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
cerebral	O
deep	B-Entity
venous	I-Entity
thrombosis	I-Entity
in	O
a	O
21-year	O
-	O
old	O
white	O
woman	O
are	O
presented	O
.	O

The	O
only	O
known	O
risk	O
factor	O
was	O
""""	O
low	O
-	O
dose	O
""""	O
oral	B-Entity
contraceptive	I-Entity
pills	O
.	O



Relation	O
of	O
perfusion	O
defects	O
observed	O
with	O
myocardial	O
contrast	O
echocardiography	O
to	O
the	O
severity	O
of	O
coronary	B-Entity
stenosis	I-Entity
:	O
correlation	O
with	O
thallium-201	I-Entity
single	O
-	O
photon	O
emission	O
tomography	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
myocardial	O
contrast	O
echocardiography	O
is	O
a	O
valuable	O
technique	O
for	O
delineating	O
regions	O
of	O
myocardial	O
underperfusion	O
secondary	O
to	O
coronary	B-Entity
occlusion	I-Entity
and	O
to	O
critical	O
coronary	B-Entity
stenoses	I-Entity
in	O
the	O
presence	O
of	O
hyperemic	I-Entity
stimulation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
myocardial	O
contrast	O
echocardiography	O
performed	O
with	O
a	O
stable	O
solution	O
of	O
sonicated	O
albumin	O
could	O
detect	O
regions	O
of	O
myocardial	O
underperfusion	O
resulting	O
from	O
various	O
degrees	O
of	O
coronary	B-Entity
stenosis	I-Entity
.	O

The	O
perfusion	O
defect	O
produced	O
in	O
16	O
open	O
chest	O
dogs	O
was	O
compared	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
measured	O
by	O
the	O
postmortem	O
dual	O
-	O
perfusion	O
technique	O
and	O
with	O
thallium-201	I-Entity
single	O
-	O
photon	O
emission	O
tomography	O
(	O
SPECT	O
)	O
.	O

During	O
a	O
transient	O
(	O
20-s	O
)	O
coronary	B-Entity
occlusion	I-Entity
,	O
a	O
perfusion	O
defect	O
was	O
observed	O
with	O
contrast	O
echocardiography	O
in	O
14	O
of	O
the	O
15	O
dogs	O
in	O
which	O
the	O
occlusion	O
was	O
produced	O
.	O

During	O
dipyridamole	I-Entity
-	O
induced	O
hyperemia	I-Entity
,	O
12	O
of	O
the	O
16	O
dogs	O
with	O
a	O
partial	O
coronary	B-Entity
stenosis	I-Entity
had	O
a	O
visible	O
area	O
of	O
hypoperfusion	O
by	O
contrast	O
echocardiography	O
.	O

The	O
four	O
dogs	O
without	O
a	O
perfusion	O
defect	O
had	O
a	O
stenosis	O
that	O
resulted	O
in	O
a	O
mild	O
(	O
0%	O
to	O
50%	O
)	O
reduction	O
in	O
dipyridamole	I-Entity
-	O
induced	O
hyperemia	I-Entity
.	O

Thallium-201	I-Entity

SPECT	O
demonstrated	O
a	O
perfusion	O
defect	O
in	O
all	O
14	O
dogs	O
analyzed	O
during	O
dipyridamole	I-Entity
-	O
induced	O
hyperemia	I-Entity
;	O
the	O
size	O
of	O
the	O
perfusion	O
defect	O
correlated	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
(	O
r	O
=	O
0.58	O
;	O
p	O
less	O
than	O
0.03	O
)	O
and	O
with	O
the	O
perfusion	O
defect	O
by	O
contrast	O
echocardiography	O
(	O
r	O
=	O
0.58	O
;	O
p	O
less	O
than	O
0.03	O
)	O
.	O

Thus	O
,	O
myocardial	O
contrast	O
echocardiography	O
can	O
be	O
used	O
to	O
visualize	O
and	O
quantitate	O
the	O
amount	O
of	O
jeopardized	O
myocardium	O
during	O
moderate	O
to	O
severe	O
degrees	O
of	O
coronary	B-Entity
stenosis	I-Entity
.	O

The	O
results	O
obtained	O
show	O
a	O
correlation	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
similar	O
to	O
that	O
obtained	O
with	O
thallium-201	I-Entity
SPECT	O
.	O



Potential	O
deleterious	O
effect	O
of	O
furosemide	I-Entity
in	O
radiocontrast	O
nephropathy	I-Entity
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
furosemide	I-Entity
in	O
addition	O
to	O
intravenous	O
fluids	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	I-Entity
.	O

18	O
patients	O
,	O
referred	O
to	O
a	O
radiocontrast	O
study	O
,	O
considered	O
at	O
risk	O
because	O
of	O
preexisting	O
renal	B-Entity
insufficiency	I-Entity
,	O
were	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
,	O
performed	O
at	O
the	O
secondary	O
care	O
center	O
of	O
a	O
1,100-bed	O
private	O
university	O
hospital	O
.	O

In	O
addition	O
to	O
fluids	O
,	O
the	O
treatment	O
group	O
received	O
furosemide	I-Entity
(	O
mean	O
dose	O
110	O
mg	O
)	O
intravenously	O
30	O
min	O
prior	O
to	O
the	O
injection	O
of	O
contrast	O
material	O
.	O

Renal	B-Entity
function	I-Entity
significantly	I-Entity
deteriorated	I-Entity
in	O
the	O
group	O
pretreated	O
with	O
furosemide	I-Entity
(	O
p	O

<	O
0.005	O
by	O
ANOVA	O
)	O
,	O
with	O
a	O
rise	O
in	O
serum	O
creatinine	I-Entity
from	O
145	O
+	O
/-	O

Renal	B-Entity
failure	I-Entity
was	O
associated	O
with	O
weight	B-Entity
loss	I-Entity
in	O
the	O
furosemide	I-Entity
-	O
treated	O
group	O
.	O

Furosemide	I-Entity
may	O
be	O
deleterious	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	I-Entity
.	O



The	O
renal	O
pathology	O
in	O
a	O
case	O
of	O
lithium	I-Entity
-	O
induced	O
diabetes	B-Entity
insipidus	I-Entity
.	O

A	O
case	O
of	O
lithium	I-Entity
-	O
induced	O
diabetes	B-Entity
insipidus	I-Entity
is	O
reported	O
.	O

It	O
is	O
suggested	O
that	O
these	O
changes	O
represent	O
a	O
specific	O
toxic	O
effect	O
of	O
lithium	I-Entity
,	O
reported	O
here	O
for	O
the	O
first	O
time	O
in	O
man	O
.	O



Etiologic	O
factors	O
in	O
the	O
pathogenesis	O
of	O
liver	B-Entity
tumors	I-Entity
associated	O
with	O
oral	B-Entity
contraceptives	I-Entity
.	O

Within	O
the	O
last	O
several	O
years	O
,	O
previously	O
rare	O
liver	B-Entity
tumors	I-Entity
have	O
been	O
seen	O
in	O
young	O
women	O
using	O
oral	B-Entity
contraceptive	I-Entity
steroids	I-Entity
.	O

The	O
Registry	O
for	O
Liver	B-Entity
Tumors	I-Entity
Associated	O
with	O
Oral	B-Entity
Contraceptives	I-Entity
at	O
the	O
University	O
of	O
California	O
,	O
Irvine	O
,	O
has	O
clearly	O
identified	O
27	O
cases	O
.	O

Common	O
to	O
these	O
71	O
cases	O
has	O
been	O
a	O
histopathologic	O
diagnosis	O
of	O
focal	B-Entity
nodular	I-Entity
hyperplasia	I-Entity
,	O
adenoma	I-Entity
,	O
hamartoma	I-Entity
,	O
and	O
hepatoma	I-Entity
.	O

Significant	O
statistical	O
etiologic	O
factors	O
include	O
prolonged	O
uninterrupted	O
usage	O
of	O
oral	B-Entity
contraceptive	I-Entity
steroids	I-Entity
.	O

Eight	O
deaths	O
and	O
liver	O
rupture	I-Entity
in	O
18	O
patients	O
attest	O
to	O
the	O
seriousness	O
of	O
this	O
new	O
potentially	O
lethal	O
adverse	O
phenomenon	O
.	O



Graft	B-Entity
-	I-Entity
versus	I-Entity
-	I-Entity
host	I-Entity
disease	I-Entity
prophylaxis	O
with	O
everolimus	I-Entity
and	O
tacrolimus	I-Entity
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
sinusoidal	B-Entity
obstruction	I-Entity
syndrome	I-Entity
and	O
microangiopathy	I-Entity
:	O
results	O
of	O
the	O
EVTAC	O
trial	O
.	O

A	O
calcineurin	O
inhibitor	O
combined	O
with	O
methotrexate	I-Entity
is	O
the	O
standard	O
prophylaxis	O
for	O
graft	B-Entity
-	I-Entity
versus	I-Entity
-	I-Entity
host	I-Entity
disease	I-Entity
(	O
GVHD	I-Entity
)	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
.	O

Everolimus	I-Entity
,	O
a	O
derivative	O
of	O
sirolimus	I-Entity
,	O
seems	O
to	O
mediate	O
antileukemia	O
effects	O
.	O

We	O
report	O
on	O
a	O
combination	O
of	O
everolimus	I-Entity
and	O
tacrolimus	I-Entity
in	O
24	O
patients	O
(	O
median	O
age	O
,	O
62	O
years	O
)	O
with	O
either	O
myelodysplastic	B-Entity
syndrome	I-Entity
(	O
MDS	I-Entity
;	O
n	O
=	O
17	O
)	O
or	O
acute	B-Entity
myeloid	I-Entity
leukemia	I-Entity
(	O
AML	I-Entity
;	O
n	O
=	O
7	O
)	O
undergoing	O
intensive	O
conditioning	O
followed	O
by	O
HSCT	O
from	O
related	O
(	O
n	O
=	O
4	O
)	O
or	O
unrelated	O
(	O
n	O
=	O
20	O
)	O
donors	O
.	O

All	O
patients	O
engrafted	O
,	O
and	O
only	O
1	O
patient	O
experienced	O
grade	O
IV	O
mucositis	I-Entity
.	O

Nine	O
patients	O
(	O
37%	O
)	O
developed	O
acute	O
grade	O
II	O
-	O
IV	O
GVHD	I-Entity
,	O
and	O
11	O
of	O
17	O
evaluable	O
patients	O
(	O
64%	O
)	O
developed	O
chronic	O
extensive	O
GVHD	I-Entity
.	O

Transplantation	B-Entity
-	I-Entity
associated	I-Entity
microangiopathy	I-Entity
(	O
TMA	I-Entity
)	O
occurred	O
in	O
7	O
patients	O
(	O
29%	O
)	O
,	O
with	O
2	O
cases	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O

The	O
study	O
was	O
terminated	O
prematurely	O
because	O
an	O
additional	O
6	O
patients	O
(	O
25%	O
)	O
developed	O
sinusoidal	B-Entity
obstruction	I-Entity
syndrome	I-Entity
(	O
SOS	I-Entity
)	O
,	O
which	O
was	O
fatal	O
in	O
2	O
cases	O
.	O

Although	O
this	O
new	O
combination	O
appears	O
to	O
be	O
effective	O
as	O
a	O
prophylactic	O
regimen	O
for	O
acute	O
GVHD	I-Entity
,	O
the	O
incidence	O
of	O
TMA	I-Entity
and	O
SOS	I-Entity
is	O
considerably	O
higher	O
than	O
seen	O
with	O
other	O
regimens	O
.	O



Effect	O
of	O
some	O
convulsants	O
on	O
the	O
protective	O
activity	O
of	O
loreclezole	I-Entity
and	O
its	O
combinations	O
with	O
valproate	I-Entity
or	O
clonazepam	I-Entity
in	O
amygdala	O
-	O
kindled	O
rats	O
.	O

Loreclezole	I-Entity
(	O
5	O
mg	O
/	O
kg	O
)	O
exerted	O
a	O
significant	O
protective	O
action	O
in	O
amygdala	O
-	O
kindled	O
rats	O
,	O
reducing	O
both	O
seizure	I-Entity
and	O
afterdischarge	O
durations	O
.	O

The	O
combinations	O
of	O
loreclezole	I-Entity
(	O
2.5	O
mg	O
/	O
kg	O
)	O
with	O
valproate	I-Entity
,	O
clonazepam	I-Entity
,	O
or	O
carbamazepine	I-Entity
(	O
applied	O
at	O
their	O
subprotective	O
doses	O
)	O
also	O
exhibited	O
antiseizure	O
effect	O
in	O
this	O
test	O
.	O

Among	O
several	O
chemoconvulsants	O
,	O
bicuculline	I-Entity
,	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartic	I-Entity
acid	I-Entity
and	O
BAY	B-Entity
k-8644	I-Entity
(	O
the	O
opener	O
of	O
L	O
-	O
type	O
calcium	I-Entity
channels	O
)	O
reversed	O
the	O
protective	O
activity	O
of	O
loreclezole	I-Entity
alone	O
and	O
its	O
combination	O
with	O
valproate	I-Entity
.	O

On	O
the	O
other	O
hand	O
,	O
bicuculline	I-Entity
,	O
aminophylline	I-Entity
and	O
BAY	B-Entity
k-8644	I-Entity
inhibited	O
the	O
anticonvulsive	O
action	O
of	O
loreclezole	I-Entity
combined	O
with	O
clonazepam	I-Entity
.	O

The	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
protective	O
activity	O
of	O
loreclezole	I-Entity
and	O
its	O
combinations	O
with	O
other	O
antiepileptics	O
may	O
involve	O
potentiation	O
of	O
GABAergic	O
neurotransmission	O
and	O
blockade	O
of	O
L	O
-	O
type	O
of	O
calcium	I-Entity
channels	O
.	O



Acute	B-Entity
liver	I-Entity
failure	I-Entity
with	O
concurrent	O
bupropion	I-Entity
and	O
carbimazole	I-Entity
therapy	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
fatal	O
liver	B-Entity
failure	I-Entity
possibly	O
associated	O
with	O
concurrent	O
use	O
of	O
bupropion	I-Entity
and	O
carbimazole	I-Entity
.	O

A	O
41-year	O
-	O
old	O
Chinese	O
man	O
with	O
a	O
history	O
of	O
hyperthyroidism	I-Entity
had	O
been	O
treated	O
with	O
carbimazole	I-Entity
and	O
propranolol	I-Entity
for	O
the	O
past	O
5	O
years	O
.	O

He	O
received	O
a	O
10-day	O
course	O
of	O
bupropion	I-Entity
as	O
an	O
aid	O
for	O
smoking	O
cessation	O
10	O
weeks	O
prior	O
to	O
presentation	O
.	O

He	O
developed	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
with	O
rapid	O
deterioration	O
of	O
renal	O
function	O
.	O

Liver	O
biopsy	O
showed	O
evidence	O
of	O
nonspecific	O
drug	B-Entity
-	I-Entity
induced	I-Entity
acute	I-Entity
liver	I-Entity
injury	I-Entity
.	O

His	O
condition	O
was	O
further	O
complicated	O
by	O
sepsis	I-Entity
and	O
coagulopathy	I-Entity
.	O

The	O
likelihood	O
that	O
bupropion	I-Entity
induced	O
hepatotoxicity	I-Entity
in	O
our	O
patient	O
was	O
possible	O
,	O
based	O
on	O
the	O
Naranjo	O
probability	O
scale	O
.	O

DISCUSSION	O
:	O
Although	O
there	O
is	O
increasing	O
evidence	O
of	O
hepatotoxicity	I-Entity
induced	O
by	O
bupropion	I-Entity
,	O
this	O
is	O
the	O
first	O
case	O
of	O
fatality	O
that	O
could	O
have	O
resulted	O
from	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
in	O
a	O
patient	O
receiving	O
bupropion	I-Entity
while	O
on	O
concomitant	O
treatment	O
with	O
carbimazole	I-Entity
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
acute	B-Entity
liver	I-Entity
insult	I-Entity
induced	O
by	O
bupropion	I-Entity
given	O
concurrently	O
with	O
other	O
hepatotoxic	I-Entity
drugs	O
.	O



Hormone	O
therapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	O
symptoms	O
and	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	B-Entity
disease	I-Entity
,	O
osteoporosis	I-Entity
and	O
dementia	I-Entity
in	O
older	O
women	O
.	O

To	O
assess	O
the	O
effect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortality	O
,	O
cardiovascular	O
outcomes	O
,	O
cancer	I-Entity
,	O
gallbladder	B-Entity
disease	I-Entity
,	O
cognition	O
,	O
fractures	I-Entity
and	O
quality	O
of	O
life	O
.	O

We	O
searched	O
the	O
following	O
databases	O
to	O
November	O
2007	O
:	O
Trials	O
Register	O
of	O
the	O
Cochrane	O
Menstrual	B-Entity
Disorders	I-Entity
and	O
Subfertility	O
Group	O
,	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biological	O
Abstracts	O
.	O

HT	O
included	O
oestrogens	I-Entity
,	O
with	O
or	O
without	O
progestogens	I-Entity
,	O
via	O
oral	O
,	O
transdermal	O
,	O
subcutaneous	O
or	O
transnasal	O
routes	O
.	O

In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Entity
thrombo	I-Entity
-	I-Entity
embolism	I-Entity
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
's	O
use	O
)	O
,	O
stroke	I-Entity
(	O
after	O
three	O
years	O
)	O
,	O
breast	B-Entity
cancer	I-Entity
and	O
gallbladder	B-Entity
disease	I-Entity
.	O

Long	O
-	O
term	O
oestrogen	I-Entity
-	O
only	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Entity
thrombo	I-Entity
-	I-Entity
embolism	I-Entity
,	O
stroke	I-Entity
and	O
gallbladder	B-Entity
disease	I-Entity
(	O
after	O
one	O
to	O
two	O
years	O
,	O
three	O
years	O
and	O
seven	O
years	O
'	O
use	O
respectively	O
)	O
,	O
but	O
did	O
not	O
significantly	O
increase	O
the	O
risk	O
of	O
breast	B-Entity
cancer	I-Entity
.	O

The	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	I-Entity
and	O
(	O
for	O
combined	O
HT	O
)	O
colon	B-Entity
cancer	I-Entity
,	O
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
women	O
aged	O
over	O
65	O
who	O
were	O
relatively	O
healthy	O
(	O
i.e.	O
generally	O
fit	O
,	O
without	O
overt	O
disease	O
)	O
and	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	I-Entity
.	O

Among	O
women	O
with	O
cardiovascular	B-Entity
disease	I-Entity
,	O
long	O
-	O
term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Entity
thrombo	I-Entity
-	I-Entity
embolism	I-Entity
.	O

One	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year	O
old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen	I-Entity
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
sized	O
placebo	O
groups	O
.	O

The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	B-Entity
thrombo	I-Entity
-	I-Entity
embolism	I-Entity
in	O
women	O
taking	O
combined	O
continuous	O
HT	O
:	O
their	O
absolute	O
risk	O
remained	O
low	O
,	O
at	O
less	O
than	O
1/500	O
.	O



Passage	O
of	O
mannitol	I-Entity
into	O
the	O
brain	O
around	O
gliomas	I-Entity
:	O
a	O
potential	O
cause	O
of	O
rebound	O
phenomenon	O
.	O

Widespread	O
use	O
of	O
mannitol	I-Entity
to	O
reduce	O
brain	B-Entity
edema	I-Entity
and	O
lower	O
elevated	B-Entity
ICP	I-Entity
in	O
brain	B-Entity
tumor	I-Entity
patients	O
continues	O
to	O
be	O
afflicted	O
by	O
the	O
so	O
-	O
called	O
rebound	O
phenomenon	O
.	O

Leakage	O
of	O
mannitol	I-Entity
into	O
the	O
brain	O
parenchyma	O
through	O
an	O
altered	O
BBB	O
and	O
secondary	O
reversal	O
of	O
osmotic	O
gradient	O
is	O
considered	O
the	O
major	O
cause	O
of	O
rebound	O
.	O

As	O
a	O
contribution	O
to	O
this	O
issue	O
we	O
decided	O
to	O
research	O
the	O
possible	O
passage	O
of	O
mannitol	I-Entity
into	O
the	O
brain	O
after	O
administration	O
to	O
21	O
brain	B-Entity
tumor	I-Entity
patients	O
.	O

METHODS	O
:	O
Mannitol	I-Entity
(	O
18%	O
solution	O
;	O
1	O
g	O
/	O
kg	O
)	O
was	O
administered	O
as	O
a	O
bolus	O
to	O
patients	O
(	O
ten	O
had	O
malignant	B-Entity
glioma	I-Entity
,	O

seven	O
brain	O
metastases	I-Entity
and	O
four	O
meningioma	I-Entity
)	O
about	O
30	O
minutes	O
before	O
craniotomy	O
.	O

During	O
resection	O
,	O
a	O
sample	O
of	O
the	O
surrounding	O
edematous	I-Entity
white	O
matter	O
was	O
taken	O
at	O
the	O
same	O
time	O
as	O
a	O
10	O
ml	O
venous	O
blood	O
sample	O
.	O

Mannitol	I-Entity
concentrations	O
were	O
measured	O
in	O
plasma	O
and	O
white	O
matter	O
by	O
a	O
modified	O
version	O
of	O
the	O
enzyme	O
assay	O
of	O
Blonquist	O
et	O
al	O
.	O

In	O
most	O
glioma	I-Entity
patients	O
,	O
mannitol	I-Entity
concentrations	O
in	O
white	O
matter	O
were	O
2	O
to	O
6	O
times	O
higher	O
than	O
in	O
plasma	O
(	O
mean	O
3.5	O
times	O
)	O
.	O

In	O
meningioma	I-Entity
and	O
metastases	I-Entity
patients	O
plasma	O
concentrations	O
of	O
mannitol	I-Entity
were	O
higher	O
than	O
white	O
matter	O
concentrations	O
except	O
in	O
three	O
cases	O
with	O
infiltration	O
by	O
neoplastic	O
cells	O
.	O

The	O
results	O
of	O
our	O
study	O
show	O
that	O
even	O
after	O
a	O
single	O
bolus	O
,	O
mannitol	I-Entity
may	O
leak	O
through	O
the	O
altered	O
BBB	O
near	O
gliomas	I-Entity
,	O
reversing	O
the	O
initial	O
plasma	O
-	O
to	O
-	O
blood	O
osmotic	O
gradient	O
,	O
aggravating	O
peritumoral	O
edema	I-Entity
and	O
promoting	O
rebound	O
of	O
ICP	O
.	O



Can	O
lidocaine	I-Entity
reduce	O
succinylcholine	I-Entity
induced	O
postoperative	B-Entity
myalgia	I-Entity
?	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	O
of	O
lidocaine	I-Entity
pretreatment	O
on	O
reduction	O
of	O
succinylcholine	I-Entity
-	O
induced	O
myalgia	I-Entity
in	O
patients	O
undergoing	O
general	O
anesthesia	O
for	O
gynecological	O
surgery	O
.	O

Group	O
PS	O
,	O
the	O
control	O
group	O
,	O
received	O
normal	O
saline	O
and	O
succinylcholine	I-Entity
1.5	O
mg	O
x	O
kg(-1	O
)	O
;	O
Group	O
LS	O
,	O
lidocaine	I-Entity
1.5	O
mg	O
x	O
kg(-1	O
)	O
and	O
succinylcholine	I-Entity
1.5	O
mg	O
x	O
kg(-1	O
)	O
;	O
Group	O
PR	O
,	O
normal	O
saline	O
and	O
rocuronium	I-Entity
0.6	O
mg	O
x	O
kg(-1	O
)	O
.	O

Morphine	I-Entity
0.1	O
mg	O
x	O
kg(-1	O
)	O

thiopental	I-Entity
iv	O
.	O

followed	O
by	O
succinylcholine	I-Entity
(	O
Group	O
PS	O
,	O
LS	O
)	O
or	O
rocuronium	I-Entity
(	O
Group	O
PR	O
)	O
for	O
tracheal	O
intubation	O
.	O

Following	O
administration	O
of	O
these	O
agents	O
,	O
the	O
presence	O
,	O
and	O
degree	O
of	O
fasciculation	I-Entity
were	O
assessed	O
visually	O
on	O
a	O
four	O
point	O
scale	O
by	O
one	O
investigator	O
who	O
was	O
blinded	O
to	O
the	O
drug	O
administered	O
.	O

Twenty	O
-	O
four	O
hours	O
later	O
,	O
any	O
myalgia	I-Entity
experienced	O
was	O
assessed	O
according	O
to	O
a	O
structured	O
questionaire	O
and	O
graded	O
by	O
a	O
four	O
point	O
scale	O
by	O
one	O
investigator	O
blinded	O
to	O
the	O
intraoperative	O
management	O
.	O

The	O
results	O
indicate	O
that	O
muscle	B-Entity
fasciculation	I-Entity
was	O
not	O
found	O
in	O
Group	O
PR	O
while	O
the	O
patients	O
in	O
Group	O
LS	O
had	O
a	O
lower	O
incidence	O
of	O
muscle	B-Entity
fasciculation	I-Entity
than	O
those	O
in	O
Group	O
PS	O
(	O
p	O

At	O
24	O
h	O
,	O
the	O
incidence	O
of	O
myalgia	I-Entity
was	O
higher	O
in	O
Group	O
PS	O
than	O
in	O
Group	O
LS	O
and	O
PR	O
(	O

A	O
correlation	O
was	O
not	O
found	O
between	O
the	O
incidence	O
of	O
myalgia	I-Entity
and	O
the	O
occurrence	O
of	O
muscle	B-Entity
fasciculation	I-Entity
.	O

In	O
conclusion	O
,	O
where	O
succinylcholine	I-Entity
is	O
used	O
,	O
lidocaine	I-Entity
is	O
proven	O
to	O
be	O
the	O
useful	O
pretreatment	O
agent	O
for	O
the	O
reduction	O
of	O
postoperative	B-Entity
myalgia	I-Entity
.	O



Open	O
-	O
label	O
assessment	O
of	O
levofloxacin	I-Entity
for	O
the	O
treatment	O
of	O
acute	O
bacterial	O
sinusitis	I-Entity
in	O
adults	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
levofloxacin	I-Entity
(	O
500	O
mg	O
orally	O
once	O
daily	O
for	O
10	O
to	O
14	O
days	O
)	O
in	O
treating	O
adult	O
outpatients	O
with	O
acute	O
bacterial	O
sinusitis	I-Entity
.	O

Adverse	O
events	O
considered	O
to	O
be	O
related	O
to	O
levofloxacin	I-Entity
administration	O
were	O
reported	O
by	O
29	O
patients	O
(	O
9%	O
)	O
.	O

The	O
most	O
common	O
drug	O
-	O
related	O
adverse	O
events	O
were	O
diarrhea	I-Entity
,	O
flatulence	I-Entity
,	O
and	O
nausea	I-Entity
;	O
most	O
adverse	O
events	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
levofloxacin	I-Entity
500	O
mg	O
once	O
daily	O
is	O
an	O
effective	O
and	O
safe	O
treatment	O
for	O
acute	O
bacterial	O
sinusitis	I-Entity
.	O



Clinical	O
evaluation	O
on	O
combined	O
administration	O
of	O
oral	O
prostacyclin	I-Entity
analogue	O
beraprost	I-Entity
and	O
phosphodiesterase	O
inhibitor	O
cilostazol	I-Entity
.	O

Among	O
various	O
oral	O
antiplatelets	O
,	O
a	O
combination	O
of	O
a	O
novel	O
prostacyclin	I-Entity
analogue	O
beraprost	I-Entity
(	O
BPT	I-Entity
)	O
and	O
a	O
potent	O
phosphodiesterase	O
inhibitor	O
cilostazol	I-Entity
(	O
CLZ	I-Entity
)	O
may	O
result	O
in	O
untoward	O
clinical	O
effects	O
due	O
to	O
possible	O
synergistic	O
elevation	O
of	O
intracellular	O
cAMP	I-Entity
(	O
cyclic	B-Entity
adenosine	I-Entity
3',5'-monophosphate	I-Entity
)	O
.	O

Twelve	O
healthy	O
volunteers	O
were	O
assigned	O
to	O
take	O
BPT	I-Entity
/	O
CLZ	I-Entity
in	O
the	O
following	O
schedule	O
;	O
BPT	I-Entity
:	O
40	O
micrograms	O
at	O
day	O
1	O
and	O
120	O
micrograms	O
t.i.d	O
.	O

from	O
day	O
7	O
to	O
14	O
,	O
CLZ	I-Entity
:	O
200	O
mg	O
t.i.d	O
.	O

At	O
various	O
time	O
intervals	O
,	O
physical	O
examination	O
and	O
blood	O
collection	O
for	O
ex	O
vivo	O
platelet	B-Entity
aggregation	I-Entity
and	O
determination	O
of	O
intraplatelet	O
cAMP	I-Entity
were	O
performed	O
.	O

Seven	O
out	O
of	O
12	O
subjects	O
experienced	O
headache	I-Entity
of	O
a	O
short	O
duration	O
accompanying	O
facial	B-Entity
flush	I-Entity
in	O
one	O
and	O
nausea	I-Entity
in	O
one	O
,	O
especially	O
after	O
ingestion	O
of	O
CLZ	I-Entity
.	O

Intraplatelet	O
cAMP	I-Entity
content	O
was	O
gradually	O
but	O
significantly	O
increased	O
to	O
9.84	O
+	O
/-	O

In	O
conclusion	O
,	O
the	O
combined	O
administration	O
of	O
BPT	I-Entity
/	O
CLZ	I-Entity
is	O
safe	O
at	O
doses	O
used	O
in	O
the	O
study	O
,	O
though	O
the	O
beneficial	O
clinical	O
effect	O
of	O
the	O
combined	O
administration	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O



Gastrointestinal	O
tolerability	O
of	O
etoricoxib	I-Entity
in	O
rheumatoid	B-Entity
arthritis	I-Entity
patients	O
:	O
results	O
of	O
the	O
etoricoxib	I-Entity
vs	O
diclofenac	B-Entity
sodium	I-Entity
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE	O
-	O
II	O
)	O
.	O

OBJECTIVE	O
:	O
A	O
randomised	O
,	O
double	O
-	O
blind	O
study	O
to	O
compare	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tolerability	O
,	O
safety	O
and	O
efficacy	O
of	O
etoricoxib	I-Entity
and	O
diclofenac	I-Entity
in	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
(	O
RA	I-Entity
)	O
.	O

A	O
total	O
of	O
4086	O
patients	O
(	O
mean	O
age	O
60.8	O
years	O
)	O
diagnosed	O
with	O
RA	I-Entity
were	O
enrolled	O
and	O
received	O
etoricoxib	I-Entity
90	O
mg	O
daily	O
(	O
n	O
=	O
2032	O
)	O
or	O
diclofenac	I-Entity
75	O
mg	O
twice	O
daily	O
(	O
n	O
=	O
2054	O
)	O
.	O

Use	O
of	O
gastroprotective	O
agents	O
and	O
low	O
-	O
dose	O
aspirin	I-Entity
was	O
allowed	O
.	O

General	O
safety	O
was	O
also	O
assessed	O
,	O
including	O
adjudicated	O
thrombotic	B-Entity
cardiovascular	I-Entity
event	O
data	O
.	O

;	O
maximum	O
)	O
duration	O
of	O
treatment	O
was	O
19.3	O
(	O
10.3	O
;	O
32.9	O
)	O
and	O
19.1	O
(	O
10.4	O
;	O
33.1	O
)	O
months	O
in	O
the	O
etoricoxib	I-Entity
and	O
diclofenac	I-Entity
groups	O
,	O
respectively	O
.	O

The	O
cumulative	O
discontinuation	O
rate	O
due	O
to	O
GI	B-Entity
AEs	I-Entity
was	O
significantly	O
lower	O
with	O
etoricoxib	I-Entity
than	O
diclofenac	I-Entity
(	O
5.2	O
vs	O
8.5	O
events	O
per	O
100	O
patient	O
-	O
years	O
,	O
respectively	O
;	O
hazard	O
ratio	O
0.62	O
(	O
95%	O
CI	O
:	O
0.47	O
,	O
0.81	O
;	O
p	O
<	O

The	O
incidence	O
of	O
discontinuations	O
for	O
hypertension	I-Entity
-	O
related	O
and	O
oedema	I-Entity
-	O
related	O
AEs	O
were	O
significantly	O
higher	O
with	O
etoricoxib	I-Entity
(	O
2.5%	O
and	O
1.1%	O
respectively	O
)	O
compared	O
with	O
diclofenac	I-Entity
(	O
1.5%	O
and	O
0.4%	O
respectively	O
;	O
p<0.001	O
for	O
hypertension	I-Entity
and	O
p<0.01	O
for	O
oedema	I-Entity
)	O
.	O

Etoricoxib	I-Entity
and	O
diclofenac	I-Entity
treatment	O
resulted	O
in	O
similar	O
efficacy	O
(	O
PGADS	O
mean	O
changes	O
from	O
baseline	O
-0.62	O
vs	O
-0.58	O
,	O
respectively	O
)	O
.	O

Etoricoxib	I-Entity
90	O
mg	O
demonstrated	O
a	O
significantly	O
lower	O
risk	O
for	O
discontinuing	O
treatment	O
due	O
to	O
GI	B-Entity
AEs	I-Entity
compared	O
with	O
diclofenac	I-Entity
150	O
mg	O
.	O

Discontinuations	O
from	O
renovascular	O
AEs	O
,	O
although	O
less	O
common	O
than	O
discontinuations	O
from	O
GI	B-Entity
AEs	I-Entity
,	O
were	O
significantly	O
higher	O
with	O
etoricoxib	I-Entity
.	O



Placebo	O
-	O
level	O
incidence	O
of	O
extrapyramidal	B-Entity
symptoms	I-Entity
(	O
EPS	I-Entity
)	O
with	O
quetiapine	I-Entity
in	O
controlled	O
studies	O
of	O
patients	O
with	O
bipolar	B-Entity
mania	I-Entity
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
extrapyramidal	B-Entity
symptoms	I-Entity
(	O
EPS	I-Entity
)	O
,	O
including	O
akathisia	I-Entity
,	O
with	O
quetiapine	I-Entity
in	O
patients	O
with	O
bipolar	B-Entity
mania	I-Entity
.	O

Two	O
studies	O
evaluated	O
quetiapine	I-Entity
monotherapy	O
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
(	O
n	O
=	O
209	O
)	O
versus	O
placebo	O
(	O
n	O
=	O
198	O
)	O
,	O
with	O
lithium	I-Entity
or	O
haloperidol	I-Entity
monotherapy	O
as	O
respective	O
active	O
controls	O
.	O

Two	O
studies	O
evaluated	O
quetiapine	I-Entity
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
in	O
combination	O
with	O
a	O
mood	O
stabilizer	O
(	O
lithium	I-Entity
or	O
divalproex	I-Entity
,	O
QTP	I-Entity

+	O
Li	I-Entity
/	O
DVP	I-Entity
)	O
(	O
n	O
=	O
196	O
)	O
compared	O
to	O
placebo	O
and	O
mood	O
stabilizer	O
(	O
PBO	O

+	O
Li	I-Entity
/	O
DVP	I-Entity
)	O
(	O
n	O
=	O
203	O
)	O
.	O

Extrapyramidal	B-Entity
symptoms	I-Entity
were	O
evaluated	O
using	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
(	O
SAS	O
)	O
,	O
the	O
Barnes	O
Akathisia	O
Rating	O
Scale	O
(	O
BARS	O
)	O
,	O
adverse	O
event	O
reports	O
and	O
anticholinergic	O
drug	O
usage	O
.	O

The	O
incidence	O
of	O
EPS	I-Entity
-	O
related	O
adverse	O
events	O
,	O
including	O
akathisia	I-Entity
,	O
was	O
no	O
different	O
with	O
quetiapine	I-Entity
monotherapy	O
(	O
12.9%	O
)	O
than	O
with	O
placebo	O
(	O
13.1%	O
)	O
.	O

Similarly	O
,	O
EPS	I-Entity
-	O
related	O
adverse	O
events	O
with	O
QTP	I-Entity
+	O
Li	I-Entity
/	O
DVP	I-Entity
(	O
21.4%	O
)	O
were	O
no	O
different	O
than	O
with	O
PBO	O
+	O
Li	I-Entity
/	O
DVP	I-Entity
(	O
19.2%	O
)	O
.	O

Adverse	O
events	O
related	O
to	O
EPS	I-Entity
occurred	O
in	O
59.6%	O
of	O
patients	O
treated	O
with	O
haloperidol	I-Entity
(	O

n	O
=	O
99	O
)	O
monotherapy	O
,	O
whereas	O
26.5%	O
of	O
patients	O
treated	O
with	O
lithium	I-Entity
(	O

n	O
=	O
98	O
)	O
monotherapy	O
experienced	O
adverse	O
events	O
related	O
to	O
EPS	I-Entity
.	O

The	O
incidence	O
of	O
akathisia	I-Entity
was	O
low	O
and	O
similar	O
with	O
quetiapine	I-Entity
monotherapy	O
(	O
3.3%	O
)	O
and	O
placebo	O
(	O
6.1%	O
)	O
,	O
and	O
with	O
QTP	I-Entity
+	O
Li	I-Entity
/	O
DVP	I-Entity
(	O
3.6%	O
)	O
and	O
PBO	O
+	O
Li	I-Entity
/	O
DVP	I-Entity
(	O
4.9%	O
)	O
.	O

Lithium	I-Entity
was	O
associated	O
with	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0.05	O
)	O
of	O
tremor	I-Entity
(	O
18.4%	O
)	O
than	O
quetiapine	I-Entity
(	O
5.6%	O
)	O
;	O
cerebellar	O
tremor	I-Entity
,	O
which	O
is	O
a	O
known	O
adverse	O
effect	O
of	O
lithium	I-Entity
,	O
may	O
have	O
contributed	O
to	O
the	O
elevated	O
rate	O
of	O
tremor	I-Entity
in	O
patients	O
receiving	O
lithium	I-Entity
therapy	O
.	O

Haloperidol	I-Entity
induced	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O

<	O
0.001	O
)	O
of	O
akathisia	I-Entity
(	O
33.3%	O
versus	O
5.9%	O
)	O
,	O
tremor	I-Entity
(	O
30.3%	O
versus	O
7.8%	O
)	O
,	O
and	O
extrapyramidal	B-Entity
syndrome	I-Entity
(	O
35.4%	O
versus	O
5.9%	O
)	O
than	O
quetiapine	I-Entity
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
quetiapine	I-Entity
and	O
placebo	O
on	O
SAS	O
and	O
BARS	O
scores	O
.	O

Anticholinergic	O
use	O
was	O
low	O
and	O
similar	O
with	O
quetiapine	I-Entity
or	O
placebo	O
.	O

In	O
bipolar	B-Entity
mania	I-Entity
,	O
the	O
incidence	O
of	O
EPS	I-Entity
,	O
including	O
akathisia	I-Entity
,	O
with	O
quetiapine	I-Entity
therapy	O
is	O
similar	O
to	O
that	O
with	O
placebo	O
.	O



Contribution	O
of	O
the	O
sympathetic	O
nervous	O
system	O
to	O
salt	O
-	O
sensitivity	O
in	O
lifetime	O
captopril	I-Entity
-	O
treated	O
spontaneously	O
hypertensive	I-Entity
rats	O
.	O

OBJECTIVE	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
,	O
in	O
lifetime	O
captopril	I-Entity
-	O
treated	O
spontaneously	O
hypertensive	I-Entity
rats	O
(	O
SHR	O
)	O
,	O
the	O
sympathetic	O
nervous	O
system	O
contributes	O
importantly	O
to	O
the	O
hypertensive	I-Entity
effect	O
of	O
dietary	B-Entity
sodium	I-Entity
chloride	I-Entity
supplementation	O
.	O

Male	O
SHR	O
(	O
aged	O
6	O
weeks	O
)	O
that	O
had	O
been	O
treated	O
from	O
conception	O
onward	O
with	O
either	O
captopril	I-Entity
or	O
vehicle	O
remained	O
on	O
a	O
basal	O
sodium	B-Entity
chloride	I-Entity
diet	O
or	O
were	O
fed	O
a	O
high	O
sodium	B-Entity
chloride	I-Entity
diet	O
.	O

After	O
2	O
weeks	O
,	O
the	O
rats	O
were	O
subjected	O
to	O
ganglionic	O
blockade	O
and	O
2	O
days	O
later	O
,	O
an	O
infusion	O
of	O
clonidine	I-Entity
.	O

Lifetime	O
captopril	I-Entity
treatment	O
significantly	O
lowered	O
mean	O
arterial	O
pressure	O
in	O
both	O
groups	O
.	O

Intravenous	O
infusion	O
of	O
the	O
ganglionic	O
blocker	O
hexamethonium	I-Entity
resulted	O
in	O
a	O
rapid	O
decline	O
in	O
MAP	O
that	O
eliminated	O
the	O
dietary	B-Entity
sodium	I-Entity
chloride	I-Entity
-	O
induced	O
increase	B-Entity
in	I-Entity
MAP	I-Entity
in	O
both	O
groups	O
.	O

Infusion	O
of	O
the	O
central	O
nervous	O
system	O
alpha2-adrenergic	B-Entity
receptor	I-Entity
agonist	I-Entity
clonidine	I-Entity
also	O
resulted	O
in	O
a	O
greater	O
reduction	O
in	O
MAP	O
in	O
both	O
groups	O
of	O
SHR	O
that	O
were	O
fed	O
the	O
high	O
(	O
compared	O
with	O
the	O
basal	O
)	O
sodium	B-Entity
chloride	I-Entity
diet	O
.	O

In	O
both	O
lifetime	O
captopril	I-Entity
-	O
treated	O
and	O
control	O

SHR	O
,	O
the	O
sympathetic	O
nervous	O
system	O
contributes	O
to	O
the	O
pressor	O
effects	O
of	O
a	O
high	O
sodium	B-Entity
chloride	I-Entity
diet	O
.	O



Dose	O
-	O
related	O
beneficial	O
and	O
adverse	O
effects	O
of	O
dietary	O
corticosterone	I-Entity
on	O
organophosphorus	I-Entity
-	O
induced	O
delayed	O
neuropathy	I-Entity
in	O
chickens	O
.	O

Tri	B-Entity
-	I-Entity
ortho	I-Entity
-	I-Entity
tolyl	I-Entity
phosphate	I-Entity
(	O
TOTP	I-Entity
)	O
,	O
360	O
mg	O
/	O
kg	O
,	O
po	O
,	O
and	O
0,0'-diisopropyl	B-Entity
phosphorofluoridate	I-Entity
(	O
DFP	I-Entity
)	O
,	O
1	O
mg	O
/	O
kg	O
sc	O
,	O
were	O
administered	O
to	O
adult	O
White	O
Leghorn	O
chickens	O
24	O
hr	O
after	O
they	O
were	O
placed	O
on	O
diets	O
containing	O
0	O
to	O
300	O
ppm	O
corticosterone	I-Entity
.	O

Supplemented	O
diets	O
were	O
continued	O
until	O
clinical	O
signs	O
and	O
lesions	O
of	O
delayed	O
neuropathy	I-Entity
appeared	O
.	O

Although	O
low	O
concentrations	O
(	O
less	O
than	O
or	O
equal	O
to	O
50	O
ppm	O
)	O
of	O
corticosterone	I-Entity
had	O
beneficial	O
effects	O
on	O
TOTP	I-Entity
-	O
induced	O
neuropathy	I-Entity
,	O
greater	O
than	O
or	O
equal	O
to	O
200	O
ppm	O
exacerbated	O
clinical	O
signs	O
in	O
chickens	O
given	O
either	O
TOTP	I-Entity
or	O
DFP	I-Entity
.	O

Neurotoxic	I-Entity
esterase	O
activities	O
24	O
hr	O
after	O
TOTP	I-Entity
or	O
DFP	I-Entity
were	O
less	O
than	O
20%	O
of	O
values	O
measured	O
in	O
chickens	O
not	O
given	O
organophosphorous	I-Entity
compounds	O
.	O

corticosterone	I-Entity
without	O
TOTP	I-Entity
or	O
DFP	I-Entity
had	O
significantly	O
elevated	O
activity	O
of	O
plasma	O
cholinesterase	O
and	O
significantly	O
inhibited	O
activity	O
of	O
liver	O
carboxylesterase	O
.	O

Degenerating	B-Entity
myelinated	I-Entity
fibers	I-Entity
were	O
also	O
evident	O
in	O
distal	O
levels	O
of	O
the	O
peripheral	O
nerves	O
of	O
chickens	O
given	O
TOTP	I-Entity
or	O
DFP	I-Entity
.	O



In	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-Entity
A2A	I-Entity
/	I-Entity
A1	I-Entity
receptor	I-Entity
antagonist	I-Entity
in	O
animal	O
models	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

The	O
in	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-Entity
A(2A)/A(1	I-Entity
)	I-Entity
receptor	I-Entity
antagonist	I-Entity
in	O
several	O
animal	O
models	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
is	O
described	O
.	O

nM	O
)	O
that	O
has	O
excellent	O
activity	O
,	O
after	O
oral	O
administration	O
,	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
including	O
mouse	O
and	O
rat	O
models	O
of	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
,	O
mouse	O
model	O
of	O
reserpine	I-Entity
-	O
induced	O
akinesia	I-Entity
,	O
rat	O
6-hydroxydopamine	I-Entity
(	O
6-OHDA	I-Entity
)	O
lesion	O
model	O
of	O
drug	O
-	O
induced	O
rotation	O
,	O
and	O
MPTP	I-Entity
-	O
treated	O
non	O
-	O
human	O
primate	O
model	O
.	O



An	O
extremely	O
rare	O
case	O
of	O
delusional	B-Entity
parasitosis	I-Entity
in	O
a	O
chronic	B-Entity
hepatitis	I-Entity
C	I-Entity
patient	O
during	O
pegylated	B-Entity
interferon	I-Entity
alpha-2b	I-Entity
and	O
ribavirin	I-Entity
treatment	O
.	O

During	O
treatment	O
of	O
chronic	B-Entity
hepatitis	I-Entity
C	I-Entity
patients	O
with	O
interferon	O
and	O
ribavirin	I-Entity
,	O
a	O
lot	O
of	O
side	O
effects	O
are	O
described	O
.	O

Twenty	O
-	O
three	O
percent	O
to	O
44%	O
of	O
patients	O
develop	O
depression	I-Entity
.	O

A	O
minority	O
of	O
patients	O
evolve	O
to	O
psychosis	I-Entity
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
cases	O
of	O
psychogenic	B-Entity
parasitosis	I-Entity
occurring	O
during	O
interferon	O
therapy	O
have	O
been	O
described	O
in	O
the	O
literature	O
.	O

We	O
present	O
a	O
49-year	O
-	O
old	O
woman	O
who	O
developed	O
a	O
delusional	B-Entity
parasitosis	I-Entity
during	O
treatment	O
with	O
pegylated	B-Entity
interferon	I-Entity
alpha-2b	I-Entity
weekly	O
and	O
ribavirin	I-Entity
.	O

All	O
the	O
complaints	O
disappeared	O
after	O
stopping	O
pegylated	B-Entity
interferon	I-Entity
alpha-2b	I-Entity
and	O
reappeared	O
after	O
restarting	O
it	O
.	O



Possible	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
related	O
to	O
concomitant	O
treatment	O
with	O
paroxetine	I-Entity
and	O
alprazolam	I-Entity
.	O

A	O
74-year	O
-	O
old	O
man	O
with	O
depressive	B-Entity
symptoms	I-Entity
was	O
admitted	O
to	O
a	O
psychiatric	I-Entity
hospital	O
due	O
to	O
insomnia	I-Entity
,	O
loss	B-Entity
of	I-Entity
appetite	I-Entity
,	O
exhaustion	O
,	O
and	O
agitation	I-Entity
.	O

Medical	O
treatment	O
was	O
initiated	O
at	O
a	O
daily	O
dose	O
of	O
20	O
mg	O
paroxetine	I-Entity
and	O
1.2	O
mg	O
alprazolam	I-Entity
.	O

On	O
the	O
10th	O
day	O
of	O
paroxetine	I-Entity
and	O
alprazolam	I-Entity
treatment	O
,	O
the	O
patient	O
exhibited	O
marked	O
psychomotor	B-Entity
retardation	I-Entity
,	O
disorientation	O
,	O
and	O
severe	O
muscle	B-Entity
rigidity	I-Entity
with	O
tremors	I-Entity
.	O

The	O
patient	O
had	O
a	O
fever	I-Entity
(	O
38.2	O
degrees	O
C	O
)	O
,	O
fluctuating	O
blood	O
pressure	O
(	O
between	O
165/90	O
and	O
130/70	O
mg	O
mm	O
Hg	O
)	O
,	O
and	O
severe	O
extrapyramidal	B-Entity
symptoms	I-Entity
.	O

Laboratory	O
tests	O
showed	O
an	O
elevation	O
of	O
creatine	I-Entity
phosphokinase	O
(	O
2218	O
IU	O
/	O
L	O
)	O
,	O
aspartate	I-Entity
aminotransferase	O
(	O
134	O
IU	O
/	O
L	O
)	O
,	O
alanine	I-Entity
aminotransferase	O
(	O
78	O
IU	O
/	O
L	O
)	O
,	O
and	O
BUN	O
(	O
27.9	O
mg	O
/	O
ml	O
)	O
levels	O
.	O

The	O
patient	O
received	O
bromocriptine	I-Entity
and	O
diazepam	I-Entity
to	O
treat	O
his	O
symptoms	O
.	O

7	O
days	O
later	O
,	O
the	O
fever	I-Entity
disappeared	O
and	O
the	O
patient	O
's	O
serum	O
CPK	O
levels	O
were	O
normalized	O
(	O
175	O
IU	O
/	O
L	O
)	O
.	O

This	O
patient	O
presented	O
with	O
symptoms	O
of	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
(	O
NMS	I-Entity
)	O
,	O
thus	O
demonstrating	O
that	O
NMS	I-Entity
-	O
like	O
symptoms	O
can	O
occur	O
after	O
combined	O
paroxetine	I-Entity
and	O
alprazolam	I-Entity
treatment	O
.	O

The	O
adverse	O
drug	O
reaction	O
score	O
obtained	O
by	O
the	O
Naranjo	O
algorithm	O
was	O
6	O
in	O
our	O
case	O
,	O
indicating	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
's	O
NMS	I-Entity
-	O
like	O
adverse	O
symptoms	O
and	O
the	O
combined	O
treatment	O
used	O
in	O
this	O
case	O
.	O

Several	O
risk	O
factors	O
for	O
NMS	I-Entity
should	O
be	O
noted	O
in	O
elderly	O
depressive	I-Entity
patients	O
whose	O
symptoms	O
often	O
include	O
dehydration	I-Entity
,	O
agitation	I-Entity
,	O
malnutrition	I-Entity
,	O
and	O
exhaustion	O
.	O

Careful	O
therapeutic	O
intervention	O
is	O
necessary	O
in	O
cases	O
involving	O
elderly	O
patients	O
who	O
suffer	O
from	O
depression	I-Entity
.	O



Pilocarpine	I-Entity
seizures	I-Entity
cause	O
age	O
-	O
dependent	O
impairment	B-Entity
in	I-Entity
auditory	I-Entity
location	I-Entity
discrimination	I-Entity
.	O

Children	O
who	O
have	O
status	B-Entity
epilepticus	I-Entity
have	O
continuous	O
or	O
rapidly	O
repeating	O
seizures	I-Entity
that	O
may	O
be	O
life	O
-	O
threatening	O
and	O
may	O
cause	O
life	O
-	O
long	O
changes	O
in	O
brain	O
and	O
behavior	O
.	O

The	O
extent	O
to	O
which	O
status	B-Entity
epilepticus	I-Entity
causes	O
deficits	B-Entity
in	I-Entity
auditory	I-Entity
discrimination	I-Entity
is	O
unknown	O
.	O

A	O
naturalistic	O
auditory	O
location	O
discrimination	O
method	O
was	O
used	O
to	O
evaluate	O
this	O
question	O
using	O
an	O
animal	O
model	O
of	O
status	B-Entity
epilepticus	I-Entity
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
injected	O
with	O
saline	O
on	O
postnatal	O
day	O
(	O
P	O
)	O
20	O
,	O
or	O
a	O
convulsant	O
dose	O
of	O
pilocarpine	I-Entity
on	O
P20	O
or	O
P45	O
.	O

Pilocarpine	I-Entity
on	O
either	O
day	O
induced	O
status	B-Entity
epilepticus	I-Entity
;	O
status	B-Entity
epilepticus	I-Entity
at	O
P45	O
resulted	O
in	O
CA3	O
cell	O
loss	O
and	O
spontaneous	O
seizures	I-Entity
,	O
whereas	O
P20	O
rats	O
had	O
no	O
cell	O
loss	O
or	O
spontaneous	O
seizures	I-Entity
.	O

In	O
status	B-Entity
epilepticus	I-Entity
(	O
P20	O
)	O
rats	O
,	O
acquisition	O
of	O
the	O
sound	O
-	O
source	O
location	O
discrimination	O
was	O
moderately	O
impaired	O
.	O

Status	B-Entity
epilepticus	I-Entity
(	O
P45	O
)	O
rats	O
failed	O
to	O
acquire	O
either	O
sound	O
-	O
source	O
location	O
or	O
sound	O
-	O
silence	O
discriminations	O
.	O

Status	B-Entity
epilepticus	I-Entity
in	O
rat	O
causes	O
an	O
age	O
-	O
dependent	O
,	O
long	O
-	O
term	O
impairment	B-Entity
in	I-Entity
auditory	I-Entity
discrimination	I-Entity
.	O

This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	B-Entity
auditory	I-Entity
location	I-Entity
discrimination	I-Entity
in	O
humans	O
.	O



Cardiovascular	O
risk	O
with	O
cyclooxygenase	B-Entity
inhibitors	I-Entity
:	O
general	O
problem	O
with	O
substance	O
specific	O
differences	O
?	O

Randomised	O
clinical	O
trials	O
and	O
observational	O
studies	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
myocardial	B-Entity
infarction	I-Entity
,	O
stroke	I-Entity
,	O
hypertension	I-Entity
and	O
heart	B-Entity
failure	I-Entity
during	O
treatment	O
with	O
cyclooxygenase	B-Entity
inhibitors	I-Entity
.	O

Cyclooxygenase	B-Entity
inhibitors	I-Entity
cause	O
complex	O
changes	O
in	O
renal	O
,	O
vascular	O
and	O
cardiac	O
prostanoid	O
profiles	O
thereby	O
increasing	O
vascular	O
resistance	O
and	O
fluid	O
retention	O
.	O

A	O
comparison	O
of	O
individual	O
selective	O
and	O
unselective	O
cyclooxygenase	B-Entity
inhibitors	I-Entity
suggests	O
substance	O
-	O
specific	O
differences	O
,	O
which	O
may	O
depend	O
on	O
differences	O
in	O
pharmacokinetic	O
parameters	O
or	O
inhibitory	O
potency	O
and	O
may	O
be	O
contributed	O
by	O
prostaglandin	I-Entity
-	O
independent	O
effects	O
.	O

Diagnostic	O
markers	O
such	O
as	O
N	B-Entity
-	I-Entity
terminal	I-Entity
pro	I-Entity
brain	I-Entity
natriuretic	I-Entity
peptide	I-Entity
(	O
NT	B-Entity
-	I-Entity
proBNP	I-Entity
)	O
or	O
high	O
-	O
sensitive	O
C	O
-	O
reactive	O
protein	O
might	O
help	O
in	O
the	O
early	O
identification	O
of	O
patients	O
at	O
risk	O
,	O
thus	O
avoiding	O
the	O
occurrence	O
of	O
serious	O
cardiovascular	B-Entity
toxicity	I-Entity
.	O



Predictors	O
of	O
decreased	B-Entity
renal	I-Entity
function	I-Entity
in	O
patients	O
with	O
heart	B-Entity
failure	I-Entity
during	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
:	O
results	O
from	O
the	O
studies	O
of	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
(	O
SOLVD	O
)	O
BACKGROUND	O
:	O

Although	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
reduces	O
mortality	O
rates	O
in	O
patients	O
with	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
(	O
CHF	I-Entity
)	O
,	O
it	O
may	O
also	O
cause	O
decreased	B-Entity
renal	I-Entity
function	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
quantify	O
specific	O
clinical	O
predictors	O
of	O
reduction	B-Entity
in	I-Entity
renal	I-Entity
function	I-Entity
in	O
patients	O
with	O
CHF	I-Entity
who	O
are	O
prescribed	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
.	O

We	O
analyzed	O
data	O
from	O
the	O
Studies	O
of	O
Left	B-Entity
Ventricular	I-Entity
Dysfunction	I-Entity
(	O
SOLVD	O
)	O
,	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
enalapril	I-Entity
for	O
the	O
treatment	O
of	O
CHF	I-Entity
.	O

There	O
were	O
3379	O
patients	O
randomly	O
assigned	O
to	O
enalapril	I-Entity
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
974	O
days	O
and	O
3379	O
patients	O
randomly	O
assigned	O
to	O
placebo	O
with	O
a	O
mean	O
follow	O
-	O
up	O
of	O
967	O
days	O
.	O

Decreased	B-Entity
renal	I-Entity
function	I-Entity
was	O
defined	O
as	O
a	O
rise	O
in	O
serum	O
creatinine	I-Entity
>	O
/=0.5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
from	O
baseline	O
.	O

We	O
used	O
time	O
-	O
to	O
-	O
event	O
analysis	O
to	O
identify	O
potential	O
predictors	O
of	O
decrease	O
in	O
renal	O
function	O
including	O
age	O
,	O
baseline	O
ejection	O
fraction	O
,	O
baseline	O
creatinine	I-Entity
,	O
low	O
systolic	O
blood	O
pressure	O
(	O
<	O
100	O
mm	O
Hg	O
)	O
,	O
history	O
of	O
hypertension	I-Entity
,	O
diabetes	I-Entity
,	O
and	O
use	O
of	O
antiplatelet	O
,	O
diuretic	I-Entity
,	O
and	O
beta	O
-	O
blocker	O
therapy	O
.	O

Patients	O
randomly	O
assigned	O
to	O
enalapril	I-Entity
had	O
a	O
33%	O
greater	O
likelihood	O
of	O
decreased	B-Entity
renal	I-Entity
function	I-Entity
than	O
controls	O
(	O
P	O
=	O
.003	O
)	O
.	O

By	O
multivariate	O
analysis	O
,	O
in	O
both	O
the	O
placebo	O
and	O
enalapril	I-Entity
groups	O
older	O
age	O
,	O
diuretic	I-Entity
therapy	O
,	O
and	O
diabetes	I-Entity
were	O
associated	O
with	O
decreased	B-Entity
renal	I-Entity
function	I-Entity
,	O
whereas	O
beta	O
-	O
blocker	O
therapy	O
and	O
higher	O
ejection	O
fraction	O
were	O
renoprotective	O
.	O

Older	O
age	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
developing	O
decreased	B-Entity
renal	I-Entity
function	I-Entity
in	O
both	O
groups	O
,	O
but	O
significantly	O
more	O
so	O
in	O
the	O
enalapril	I-Entity
group	O
(	O
enalapril	I-Entity
:	O
risk	O
ratio	O
[	O
RR	O
]	O
1.42	O
per	O
10	O
years	O
,	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.32	O
-	O
1.52	O
with	O
enalapril	I-Entity
;	O
placebo	O
:	O
RR	O
1.18	O
,	O
95%	O
CI	O
1.12	O
-	O
1.25	O
)	O
.	O

Diuretic	I-Entity
therapy	O
was	O
likewise	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
decreased	B-Entity
renal	I-Entity
function	I-Entity
in	O
the	O
enalapril	I-Entity
group	O
(	O
RR	O
1.89	O
,	O
95%	O
CI	O
1.70	O
-	O
2.08	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
RR	O
1.35	O
,	O
95%	O
CI	O
1.09	O
-	O
1.66	O
)	O
.	O

Conversely	O
,	O
enalapril	I-Entity
had	O
a	O
relative	O
renoprotective	O
effect	O
(	O
RR	O
1.33	O
,	O
95%	O
CI	O
1.13	O
-	O
1.53	O
)	O
compared	O
with	O
placebo	O
(	O
RR	O
1.96	O
,	O
95%	O
CI	O
1.57	O
-	O
2.44	O
)	O
in	O
patients	O
with	O
diabetes	I-Entity
.	O

A	O
lower	O
risk	O
of	O
renal	B-Entity
impairment	I-Entity
was	O
seen	O
in	O
both	O
groups	O
with	O
beta	O
-	O
blocker	O
therapy	O
(	O
RR	O
0.70	O
,	O
95%	O
CI	O
0.57	O
-	O
0.85	O
)	O
and	O
higher	O
baseline	O
ejection	O
fraction	O
(	O
RR	O
0.93	O
per	O
5%	O
increment	O
,	O
95%	O
CI	O
0.91	O
-	O
0	O
.	O

Enalapril	I-Entity
use	O
caused	O
a	O
33%	O
increase	O
in	O
the	O
risk	O
of	O
decreased	B-Entity
renal	I-Entity
function	I-Entity
in	O
patients	O
with	O
CHF	I-Entity
.	O

Diuretic	I-Entity
use	O
and	O
advanced	O
age	O
increased	O
this	O
risk	O
.	O

Diabetes	I-Entity
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
renal	B-Entity
impairment	I-Entity
in	O
all	O
patients	O
with	O
CHF	I-Entity
,	O
but	O
this	O
risk	O
was	O
reduced	O
in	O
the	O
enalapril	I-Entity
group	O
compared	O
with	O
the	O
placebo	O
group	O
.	O



Pemoline	I-Entity
induced	O
acute	O
choreoathetosis	I-Entity
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Pemoline	I-Entity
is	O
an	O
oxazolidine	I-Entity
derivative	O
that	O
is	O
structurally	O
different	O
from	O
amphetamines	I-Entity
and	O
used	O
in	O
the	O
treatment	O
of	O
attention	B-Entity
deficit	I-Entity
disorder	I-Entity
.	O

Pemoline	I-Entity
has	O
not	O
been	O
commonly	O
associated	O
in	O
the	O
literature	O
as	O
a	O
cause	O
of	O
acute	O
movement	B-Entity
disorders	I-Entity
.	O

The	O
following	O
case	O
describes	O
two	O
children	O
acutely	O
poisoned	O
with	O
pemoline	I-Entity
who	O
experienced	O
profound	O
choreoathetosis	I-Entity
.	O

Two	O
,	O
3-year	O
-	O
old	O
male	O
,	O
identical	O
twin	O
siblings	O
presented	O
to	O
the	O
emergency	O
department	O
after	O
found	O
playing	O
with	O
a	O
an	O
empty	O
bottle	O
of	O
pemoline	I-Entity
originally	O
containing	O
59	O
tablets	O
.	O

The	O
children	O
had	O
a	O
medical	O
history	O
significant	O
for	O
attention	B-Entity
deficit	I-Entity
disorder	I-Entity
previously	O
treated	O
with	O
methylphenidate	I-Entity
without	O
success	O
.	O

This	O
was	O
their	O
first	O
day	O
of	O
pemoline	I-Entity
therapy	O
.	O

The	O
choreoathetoid	I-Entity
movements	O
began	O
45	O
min	O
to	O
1	O
h	O
after	O
ingestion	O
.	O

The	O
children	O
gave	O
no	O
history	O
of	O
prior	O
movement	B-Entity
disorders	I-Entity
and	O
there	O
was	O
no	O
family	O
history	O
of	O
movement	B-Entity
disorders	I-Entity
.	O

The	O
children	O
received	O
gastrointestinal	O
decontamination	O
and	O
high	O
doses	O
of	O
intravenous	O
benzodiazepines	I-Entity
in	O
an	O
attempt	O
to	O
control	O
the	O
choreoathetoid	I-Entity
movements	O
.	O

Despite	O
treatment	O
,	O
the	O
children	O
continued	O
to	O
have	O
choreoathetosis	I-Entity
for	O
approximately	O
24	O
hours	O
.	O

Pemoline	I-Entity
associated	O
movement	B-Entity
disorder	I-Entity
has	O
been	O
rarely	O
reported	O
in	O
the	O
acute	O
toxicology	O
literature	O
.	O

The	O
possibility	O
of	O
choreoathetoid	I-Entity
movements	O
should	O
be	O
considered	O
in	O
patients	O
presenting	O
after	O
pemoline	I-Entity
overdose	I-Entity
.	O



Continuous	O
subcutaneous	O
administration	O
of	O
mesna	I-Entity
to	O
prevent	O
ifosfamide	I-Entity
-	O
induced	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

Hemorrhagic	B-Entity
cystitis	I-Entity
is	O
a	O
major	O
potential	O
toxicity	I-Entity
of	O
ifosfamide	I-Entity
that	O
can	O
be	O
prevented	O
by	O
administering	O
mesna	I-Entity
along	O
with	O
the	O
cytotoxic	O
agent	O
.	O

Mesna	I-Entity
is	O
generally	O
administered	O
by	O
the	O
intravenous	O
route	O
,	O
although	O
experience	O
with	O
oral	O
delivery	O
of	O
the	O
drug	O
has	O
increased	O
.	O

The	O
continuous	O
subcutaneous	O
administration	O
of	O
mesna	I-Entity
has	O
the	O
advantage	O
of	O
not	O
requiring	O
intravenous	O
access	O
.	O

In	O
addition	O
,	O
subcutaneous	O
delivery	O
of	O
the	O
neutralizing	O
agent	O
will	O
not	O
be	O
associated	O
with	O
the	O
risk	O
of	O
inadequate	O
urinary	O
mesna	I-Entity
concentrations	O
,	O
such	O
as	O
in	O
a	O
patient	O
taking	O
oral	O
mesna	I-Entity
who	O
experiences	O
severe	O
ifosfamide	I-Entity
-	O
induced	O
emesis	I-Entity
and	O
is	O
unable	O
to	O
absorb	O
the	O
drug	O
.	O

Limited	O
clinical	O
experience	O
with	O
continuous	O
subcutaneous	O
mesna	I-Entity
administration	O
suggests	O
it	O
is	O
a	O
safe	O
,	O
practical	O
,	O
and	O
economic	O
method	O
of	O
drug	O
delivery	O
that	O
permits	O
ifosfamide	I-Entity
to	O
be	O
administered	O
successfully	O
in	O
the	O
outpatient	O
setting	O
.	O



Modification	O
of	O
drug	O
action	O
by	O
hyperammonemia	I-Entity
.	O

Pretreatment	O
with	O
ammonium	B-Entity
acetate	I-Entity
(	O
NH4Ac	I-Entity
)	O
(	O
6	O
mmol	O
/	O
kg	O
s.c	O
.	O
)	O

approximately	O
doubled	O
the	O
time	O
morphine	I-Entity
-	O
treated	O
mice	O
remained	O
on	O
a	O
hot	O
surface	O
and	O
similarly	O
increased	O
muscular	O
incoordination	I-Entity
by	O
diazepam	I-Entity
,	O
but	O
NH4Ac	I-Entity
treatment	O
alone	O
had	O
no	O
effect	O
.	O

Thus	O
,	O
hyperammonemia	I-Entity
is	O
capable	O
of	O
altering	O
drug	O
action	O
and	O
must	O
be	O
considered	O
along	O
with	O
impaired	O
drug	O
metabolism	O
in	O
enhanced	O
drug	O
responses	O
associated	O
with	O
liver	B-Entity
disease	I-Entity
.	O

Experiments	O
in	O
vitro	O
showed	O
that	O
acetylcholine	I-Entity
-	O
induced	O
catecholamine	I-Entity
release	O
from	O
bovine	O
adrenal	O
medulla	O
is	O
depressed	O
as	O
much	O
as	O
50%	O
by	O
0.3	O
mM	O
NH4Ac	I-Entity
and	O
KCl	I-Entity
-	O
induced	O
contractions	O
of	O
guinea	O
-	O
pig	O
ileum	O
were	O
inhibited	O
20%	O
by	O
5	O
mM	O
NH4Ac	I-Entity
.	O

Addition	O
of	O
excess	O
calcium	I-Entity
reversed	O
the	O
depression	I-Entity
in	O
both	O
tissues	O
,	O
but	O
calcium	I-Entity
-	O
independent	O
catecholamine	I-Entity
release	O
by	O
acetaldehyde	I-Entity
was	O
not	O
blocked	O
by	O
NH4Ac	I-Entity
.	O

These	O
results	O
suggested	O
that	O
ammonia	I-Entity
blocks	O
calcium	I-Entity
channels	O
.	O

Parallels	O
in	O
the	O
actions	O
of	O
NH4Ac	I-Entity
and	O
the	O
calcium	I-Entity
channel	O
blocker	O
verapamil	I-Entity
support	O
this	O
concept	O
.	O

Both	O
verapamil	I-Entity
(	O
10	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O

and	O
NH4Ac	I-Entity
pretreatment	O
enhanced	O
morphine	I-Entity
analgesia-	I-Entity
and	O
diazepam	I-Entity
-	O
induced	O
muscular	O
incoordination	I-Entity
and	O
antagonized	O
amphetamine	I-Entity
-	O
induced	O
motor	O
activity	O
,	O
and	O
neither	O
verapamil	I-Entity
nor	O
NH4Ac	I-Entity
affected	O
the	O
convulsant	O
action	O
of	O
metrazol	I-Entity
.	O

The	O
data	O
suggest	O
that	O
hyperammonemia	I-Entity
exerts	O
a	O
calcium	I-Entity
channel	O
blocking	O
action	O
which	O
enhances	O
the	O
effects	O
of	O
central	O
nervous	O
system	O
depressants	O
and	O
certain	O
opioid	O
analgesics	O
.	O



Risk	O
of	O
nephropathy	I-Entity
after	O
consumption	O
of	O
nonionic	O
contrast	B-Entity
media	I-Entity
by	O
children	O
undergoing	O
cardiac	O
angiography	O
:	O
a	O
prospective	O
study	O
.	O

Despite	O
increasing	O
reports	O
on	O
nonionic	O
contrast	B-Entity
media	I-Entity
-	O
induced	O
nephropathy	I-Entity
(	O
CIN	I-Entity
)	O
in	O
hospitalized	O
adult	O
patients	O
during	O
cardiac	O
procedures	O
,	O
the	O
studies	O
in	O
pediatrics	O
are	O
limited	O
,	O
with	O
even	O
less	O
focus	O
on	O
possible	O
predisposing	O
factors	O
and	O
preventive	O
measures	O
for	O
patients	O
undergoing	O
cardiac	O
angiography	O
.	O

This	O
prospective	O
study	O
determined	O
the	O
incidence	O
of	O
CIN	I-Entity
for	O
two	O
nonionic	O
contrast	B-Entity
media	I-Entity
(	O
CM	I-Entity
)	O
,	O
iopromide	I-Entity
and	O
iohexol	I-Entity
,	O
among	O
80	O
patients	O
younger	O
than	O
18	O
years	O
and	O
compared	O
the	O
rates	O
for	O
this	O
complication	O
in	O
relation	O
to	O
the	O
type	O
and	O
dosage	O
of	O
CM	I-Entity
and	O
the	O
presence	O
of	O
cyanosis	I-Entity
.	O

The	O
80	O
patients	O
in	O
the	O
study	O
consecutively	O
received	O
either	O
iopromide	I-Entity
(	O
group	O
A	O
,	O
n	O
=	O
40	O
)	O
or	O
iohexol	I-Entity

Serum	O
sodium	I-Entity
(	O
Na	I-Entity
)	O
,	O
potassium	I-Entity
(	O
K	I-Entity
)	O
,	O
and	O
creatinine	I-Entity
(	O
Cr	I-Entity
)	O
were	O
measured	O
24	O
h	O
before	O
angiography	O
as	O
baseline	O
values	O
,	O
then	O
measured	O
again	O
at	O
12-	O
,	O
24-	O
,	O
and	O
48-h	O
intervals	O
after	O
CM	I-Entity
use	O
.	O

Urine	O
samples	O
for	O
Na	I-Entity
and	O
Cr	I-Entity
also	O
were	O
checked	O
at	O
the	O
same	O
intervals	O
.	O

Risk	O
of	O
renal	B-Entity
failure	I-Entity
,	O
Injury	B-Entity
to	I-Entity
the	I-Entity
kidney	I-Entity
,	O
Failure	B-Entity
of	I-Entity
kidney	I-Entity
function	I-Entity
,	O
Loss	B-Entity
of	I-Entity
kidney	I-Entity
function	I-Entity
,	O
and	O
End	O
-	O
stage	O
renal	B-Entity
damage	I-Entity
(	O
RIFLE	O
criteria	O
)	O
were	O
used	O
to	O
define	O
CIN	I-Entity
and	O
its	O
incidence	O
in	O
the	O
study	O
population	O
.	O

Accordingly	O
,	O
among	O
the	O
15	O
CIN	I-Entity
patients	O
(	O
18.75%	O
)	O
,	O
7.5%	O
of	O
the	O
patients	O
in	O
group	O
A	O
had	O
increased	O
risk	O
and	O
3.75%	O
had	O
renal	B-Entity
injury	I-Entity
,	O
whereas	O
5%	O
of	O
group	O
B	O
had	O
increased	O
risk	O
and	O
2.5%	O
had	O
renal	B-Entity
injury	I-Entity
.	O

Whereas	O
33.3%	O
of	O
the	O
patients	O
with	O
CIN	I-Entity
were	O
among	O
those	O
who	O
received	O
the	O
proper	O
dosage	O
of	O
CM	I-Entity
,	O
the	O
percentage	O
increased	O
to	O
66.6%	O
among	O
those	O
who	O
received	O
larger	O
doses	O
,	O
with	O
a	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
CIN	I-Entity
related	O
to	O
the	O
different	O
dosages	O
of	O
CM	I-Entity
(	O
p	O
=	O
0.014	O
)	O
.	O

Among	O
the	O
15	O
patients	O
with	O
CIN	I-Entity
,	O
6	O
had	O
cyanotic	O
congenital	B-Entity
heart	I-Entity
diseases	I-Entity
,	O
but	O
the	O
incidence	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
for	O
the	O
noncyanotic	O
patients	O
(	O
p	O
=	O
0.243	O
)	O
.	O

Although	O
clinically	O
silent	O
,	O
CIN	I-Entity
is	O
not	O
rare	O
in	O
pediatrics	O
.	O

The	O
incidence	O
depends	O
on	O
dosage	O
but	O
not	O
on	O
the	O
type	O
of	O
consumed	O
nonionic	O
CM	I-Entity
,	O
nor	O
on	O
the	O
presence	O
of	O
cyanosis	I-Entity
,	O
and	O
although	O
CIN	I-Entity
usually	O
is	O
reversible	O
,	O
more	O
concern	O
is	O
needed	O
for	O
the	O
prevention	O
of	O
such	O
a	O
complication	O
in	O
children	O
.	O



A	O
case	O
of	O
ventricular	B-Entity
tachycardia	I-Entity
related	O
to	O
caffeine	I-Entity
pretreatment	O
.	O

Suboptimal	O
seizure	I-Entity
duration	O
is	O
commonly	O
encountered	O
in	O
electroconvulsive	O
therapy	O
practice	O
,	O
especially	O
in	O
older	O
patients	O
with	O
higher	O
seizure	I-Entity
thresholds	O
.	O

Intravenous	O
caffeine	I-Entity
is	O
commonly	O
used	O
to	O
improve	O
seizure	I-Entity
duration	O
and	O
quality	O
in	O
such	O
patients	O
and	O
is	O
generally	O
well	O
tolerated	O
aside	O
from	O
occasional	O
reports	O
of	O
relatively	O
benign	O
ventricular	B-Entity
ectopy	I-Entity
.	O

We	O
describe	O
a	O
patient	O
with	O
no	O
previous	O
history	O
of	O
cardiac	B-Entity
disease	I-Entity
or	O
arrhythmia	I-Entity
who	O
developed	O
sustained	O
bigeminy	O
and	O
2	O
brief	O
runs	O
of	O
ventricular	B-Entity
tachycardia	I-Entity
after	O
caffeine	I-Entity
administration	O
.	O

Although	O
intravenous	O
caffeine	I-Entity
is	O
generally	O
well	O
tolerated	O
,	O
the	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
unpredictable	O
and	O
serious	O
ventricular	B-Entity
arrhythmias	I-Entity
.	O



Optical	O
coherence	O
tomography	O
can	O
measure	O
axonal	O
loss	O
in	O
patients	O
with	O
ethambutol	I-Entity
-	O
induced	O
optic	B-Entity
neuropathy	I-Entity
.	O

PURPOSE	O
:	O
To	O
map	O
and	O
identify	O
the	O
pattern	O
,	O
in	O
vivo	O
,	O
of	O
axonal	B-Entity
degeneration	I-Entity
in	O
ethambutol	I-Entity
-	O
induced	O
optic	B-Entity
neuropathy	I-Entity
using	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
.	O

Ethambutol	I-Entity
is	O
an	O
antimycobacterial	O
agent	O
often	O
used	O
to	O
treat	O
tuberculosis	I-Entity
.	O

A	O
serious	O
complication	O
of	O
ethambutol	I-Entity
is	O
an	O
optic	B-Entity
neuropathy	I-Entity
that	O
impairs	O
visual	O
acuity	O
,	O
contrast	O
sensitivity	O
,	O
and	O
color	O
vision	O
.	O

However	O
,	O
early	O
on	O
,	O
when	O
the	O
toxic	O
optic	B-Entity
neuropathy	I-Entity
is	O
mild	O
and	O
partly	O
reversible	O
,	O
the	O
funduscopic	O
findings	O
are	O
often	O
subtle	O
and	O
easy	O
to	O
miss	O
.	O

METHODS	O
:	O
Three	O
subjects	O
with	O
a	O
history	O
of	O
ethambutol	I-Entity
(	O
EMB)-induced	I-Entity
optic	B-Entity
neuropathy	I-Entity
of	O
short-	O
,	O
intermediate-	O
,	O
and	O
long	O
-	O
term	O
visual	B-Entity
deficits	I-Entity
were	O
administered	O
a	O
full	O
neuro	O
-	O
ophthalmologic	O
examination	O
including	O
visual	O
acuity	O
,	O
color	O
vision	O
,	O
contrast	O
sensitivity	O
,	O
and	O
fundus	O
examination	O
.	O

In	O
all	O
subjects	O
with	O
history	O
of	O
EMB	I-Entity
-	O
induced	O
optic	B-Entity
neuropathy	I-Entity
,	O
there	O
was	O
a	O
mean	O
loss	O
of	O
72%	O
nerve	O
fiber	O
layer	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
(	O
patient	O
A	O
,	O
with	O
eventual	O
recovery	O
of	O
visual	O
acuity	O
and	O
fields	O
,	O
58%	O
loss	O
;	O
patient	O
B	O
,	O
with	O
intermediate	O
visual	B-Entity
deficits	I-Entity
,	O
68%	O
loss	O
;	O
patient	O
C	O
,	O
with	O
chronic	O
visual	B-Entity
deficits	I-Entity
,	O
90%	O
loss	O
)	O
,	O
with	O
an	O
average	O
mean	O
optic	O
nerve	O
thickness	O
of	O
26+/-16	O
microm	O
.	O

In	O
both	O
sets	O
(	O
four	O
)	O
of	O
eyes	O
of	O
the	O
subjects	O
with	O
persistent	O
visual	B-Entity
deficits	I-Entity
(	O
patients	O
B	O
and	O
C	O
)	O
,	O
there	O
was	O
an	O
average	O
loss	O
of	O
79%	O
of	O
nerve	O
fiber	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
.	O

The	O
OCT	O
results	O
in	O
these	O
patients	O
with	O
EMB	I-Entity
-	O
induced	O
optic	B-Entity
neuropathy	I-Entity
show	O
considerable	O
loss	O
especially	O
of	O
the	O
temporal	O
fibers	O
.	O

This	O
is	O
consistent	O
with	O
prior	O
histopathological	O
studies	O
that	O
show	O
predominant	O
loss	O
of	O
parvo	O
-	O
cellular	O
axons	O
(	O
or	O
small	O
-	O
caliber	O
axons	O
)	O
within	O
the	O
papillo	O
-	O
macular	O
bundle	O
in	O
toxic	O
or	O
hereditary	O
optic	B-Entity
neuropathies	I-Entity
.	O

OCT	O
can	O
be	O
a	O
valuable	O
tool	O
in	O
the	O
quantitative	O
analysis	O
of	O
optic	B-Entity
neuropathies	I-Entity
.	O

Additionally	O
,	O
in	O
terms	O
of	O
management	O
of	O
EMB	I-Entity
-	O
induced	O
optic	B-Entity
neuropathy	I-Entity
,	O
it	O
is	O
important	O
to	O
properly	O
manage	O
ethambutol	I-Entity
dosing	O
in	O
patients	O
with	O
renal	B-Entity
impairment	I-Entity
and	O
to	O
achieve	O
proper	O
transition	O
to	O
a	O
maintenance	O
dose	O
once	O
an	O
appropriate	O
loading	O
dose	O
has	O
been	O
reached	O
.	O



Effects	O
of	O
the	O
cyclooxygenase-2	O
specific	O
inhibitor	O
valdecoxib	I-Entity
versus	O
nonsteroidal	O
antiinflammatory	O
agents	O
and	O
placebo	O
on	O
cardiovascular	O
thrombotic	I-Entity
events	O
in	O
patients	O
with	O
arthritis	I-Entity
.	O

There	O
have	O
been	O
concerns	O
that	O
the	O
risk	O
of	O
cardiovascular	O
thrombotic	I-Entity
events	O
may	O
be	O
higher	O
with	O
cyclooxygenase	O
(	O
COX)-2-specific	O
inhibitors	O
than	O
nonselective	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

We	O
evaluated	O
cardiovascular	O
event	O
data	O
for	O
valdecoxib	I-Entity
,	O
a	O
new	O
COX-2-specific	O
inhibitor	O
in	O
approximately	O
8000	O
patients	O
with	O
osteoarthritis	I-Entity
and	O
rheumatoid	B-Entity
arthritis	I-Entity
treated	O
with	O
this	O
agent	O
in	O
randomized	O
clinical	O
trials	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
thrombotic	I-Entity
events	O
(	O
cardiac	O
,	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
,	O
or	O
arterial	O
thrombotic	I-Entity
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	I-Entity
(	O
10	O
-	O
80	O
mg	O
daily	O
)	O
,	O
nonselective	O
NSAID	O
(	O
diclofenac	I-Entity
75	O
mg	O
bid	O
,	O
ibuprofen	I-Entity
800	O
mg	O
tid	O
,	O
or	O
naproxen	I-Entity
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	I-Entity
and	O
rheumatoid	B-Entity
arthritis	I-Entity
trials	O
that	O
were	O
6	O
-	O
52	O
weeks	O
in	O
duration	O
.	O

in	O
users	O
of	O
low	O
-	O
dose	O
(	O
<	O
or	O
=	O
325	O
mg	O
daily	O
)	O
aspirin	I-Entity
(	O
n	O
=	O
1051	O
)	O
and	O
nonusers	O
of	O
aspirin	I-Entity
(	O
n	O
=	O
6883	O
)	O
.	O

Crude	O
and	O
exposure	O
-	O
adjusted	O
incidences	O
of	O
thrombotic	I-Entity
events	O
were	O
similar	O
for	O
valdecoxib	I-Entity
,	O
NSAIDs	O
,	O
and	O
placebo	O
.	O

The	O
risk	O
of	O
serious	O
thrombotic	I-Entity
events	O
was	O
also	O
similar	O
for	O
each	O
valdecoxib	I-Entity
dose	O
.	O

Thrombotic	I-Entity
risk	O
was	O
consistently	O
higher	O
for	O
users	O
of	O
aspirin	I-Entity
users	O
than	O
nonusers	O
of	O
aspirin	I-Entity
(	O
placebo	O
,	O
1.4%	O
vs.	O
0%	O
;	O
valdecoxib	I-Entity
,	O
1.7%	O
vs.	O
0.2%	O
;	O
NSAIDs	O
,	O
1.9%	O
vs.	O
0.5%	O
)	O
.	O

The	O
rates	O
of	O
events	O
in	O
users	O
of	O
aspirin	I-Entity
were	O
similar	O
for	O
all	O
3	O
treatment	O
groups	O
and	O
across	O
valdecoxib	I-Entity
doses	O
.	O

valdecoxib	I-Entity
doses	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
thrombotic	I-Entity
events	O
relative	O
to	O
nonselective	O
NSAIDs	O
or	O
placebo	O
in	O
osteoarthritis	I-Entity
and	O
rheumatoid	B-Entity
arthritis	I-Entity
patients	O
in	O
controlled	O
clinical	O
trials	O
.	O



A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
of	O
ephedrine	I-Entity
for	O
SSRI	O
-	O
induced	O
female	O
sexual	B-Entity
dysfunction	I-Entity
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
ephedrine	I-Entity
,	O
an	O
alpha-	O
and	O
beta	O
-	O
adrenergic	O
agonist	O
previously	O
shown	O
to	O
enhance	O
genital	O
blood	O
flow	O
in	O
women	O
,	O
has	O
beneficial	O
effects	O
in	O
reversing	O
antidepressant	O
-	O
induced	O
sexual	B-Entity
dysfunction	I-Entity
.	O

Nineteen	O
sexually	B-Entity
dysfunctional	I-Entity
women	O
receiving	O
either	O
fluoxetine	I-Entity
,	O
sertraline	I-Entity
,	O
or	O
paroxetine	I-Entity
participated	O
in	O
an	O
eight	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
cross	O
-	O
over	O
study	O
of	O
the	O
effects	O
of	O
ephedrine	I-Entity
(	O
50	O
mg	O
)	O
on	O
self	O
-	O
report	O
measures	O
of	O
sexual	O
desire	O
,	O
arousal	O
,	O
orgasm	O
,	O
and	O
sexual	O
satisfaction	O
.	O

Although	O
there	O
were	O
significant	O
improvements	O
relative	O
to	O
baseline	O
in	O
sexual	O
desire	O
and	O
orgasm	O
intensity	O
/	O
pleasure	O
on	O
50	O
mg	O
ephedrine	I-Entity
1-hr	O
prior	O
to	O
sexual	O
activity	O
,	O
significant	O
improvements	O
in	O
these	O
measures	O
,	O
as	O
well	O
as	O
in	O
sexual	O
arousal	O
and	O
orgasmic	O
ability	O
also	O
were	O
noted	O
with	O
placebo	O
.	O



Erectile	B-Entity
dysfunction	I-Entity
occurs	O
following	O
substantia	O
nigra	O
lesions	O
in	O
the	O
rat	O
.	O

Erectile	O
function	O
was	O
assessed	O
6	O
weeks	O
following	O
uni-	O
and	O
bilateral	O
injections	O
of	O
6-hydroxydopamine	I-Entity
in	O
the	O
substantia	O
nigra	O
nucleus	O
of	O
the	O
brain	O
.	O

Behavioral	O
apomorphine	I-Entity
-	O
induced	O
penile	O
erections	O
were	O
reduced	O
(	O
5/8	O
)	O
and	O
increased	O
(	O
3/8	O
)	O
in	O
uni-	O
and	O
bilateral	O
lesioned	O
animals	O
.	O

Concentration	O
of	O
dopamine	I-Entity
and	O
its	O
metabolites	O
were	O
decreased	O
in	O
the	O
striatum	O
of	O
substantia	O
nigra	O
lesioned	O
rats	O
.	O

Lesions	O
of	O
the	O
substantia	O
nigra	O
are	O
therefore	O
associated	O
with	O
erectile	B-Entity
dysfunction	I-Entity
in	O
rats	O
and	O
may	O
serve	O
as	O
a	O
model	O
to	O
study	O
erectile	B-Entity
dysfunction	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O



Potential	O
therapeutic	O
use	O
of	O
the	O
selective	O
dopamine	I-Entity
D1	O
receptor	O
agonist	O
,	O
A-86929	I-Entity
:	O
an	O
acute	O
study	O
in	O
parkinsonian	I-Entity
levodopa	I-Entity
-	O
primed	O
monkeys	O
.	O

The	O
clinical	O
utility	O
of	O
dopamine	I-Entity
(	O
DA	I-Entity
)	O

D1	O
receptor	O
agonists	O
in	O
the	O
treatment	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
is	O
still	O
unclear	O
.	O

The	O
therapeutic	O
use	O
of	O
selective	O
DA	I-Entity
D1	O
receptor	O
agonists	O
such	O
as	O
SKF-82958	I-Entity
(	O
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze	B-Entity
pine	I-Entity
hydrobromide	I-Entity
)	O
and	O
A-77636	I-Entity
(	O
[	B-Entity
1R	I-Entity
,	I-Entity
3S	I-Entity
]	I-Entity
3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo	I-Entity
pyran	I-Entity
hydrochloride	I-Entity
)	O
seems	O
limited	O
because	O
of	O
their	O
duration	O
of	O
action	O
,	O
which	O
is	O
too	O
short	O
for	O
SKF-82958	I-Entity
(	O
<	O
1	O
hr	O
)	O
and	O
too	O
long	O
for	O
A-77636	I-Entity
(	O
>	O
20	O

We	O
therefore	O
conducted	O
the	O
present	O
acute	O
dose	O
-	O
response	O
study	O
in	O
four	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	I-Entity
(	O
MPTP)-exposed	I-Entity
cynomolgus	O
monkeys	O
primed	O
to	O
exhibit	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
to	O
evaluate	O
the	O
locomotor	O
and	O
dyskinetic	I-Entity
effects	O
on	O
challenge	O
with	O
four	O
doses	O
(	O
from	O
0.03	O
to	O
1.0	O
mg	O
/	O
kg	O
)	O
of	O
A-86929	I-Entity
(	O
[	B-Entity
-]-[5aR,11bS]-4,5,5a,6,7,11b	I-Entity
-	I-Entity
hexahydro-2-propyl-3-thia-5-+	I-Entity
+	I-Entity
+	I-Entity
azacyclopent-1-	I-Entity
ena[c]phenathrene-9	I-Entity
-	I-Entity
10-diol	I-Entity
)	O
,	O
a	O
selective	O
and	O
full	O
DA	I-Entity
D1-like	O
receptor	O
agonist	O
with	O
an	O
intermediate	O
duration	O
of	O
action	O
.	O

Levodopa	I-Entity
and	O
the	O
DA	I-Entity

D2-like	O
receptor	O
agonist	O
,	O
LY-171555	I-Entity
(	O
[	B-Entity
4aR	I-Entity
-	I-Entity
trans]-4,4a,5,6,7,8,8a,9-o	I-Entity
-	I-Entity
dihydro-5n	I-Entity
-	I-Entity
propyl-2H	I-Entity
-	I-Entity
pyrazo	I-Entity
lo-3	I-Entity
-	I-Entity
4-quinoline	I-Entity
hydrochloride	I-Entity
)	O
were	O
also	O
used	O
for	O
comparison	O
.	O

Acute	O
administration	O
of	O
A-86929	I-Entity
was	O
as	O
efficacious	O
in	O
alleviating	O
MPTP	I-Entity
-	O
induced	O
parkinsonism	I-Entity
as	O
levodopa	I-Entity
and	O
LY-171555	I-Entity
,	O
but	O
was	O
less	O
likely	O
to	O
reproduce	O
the	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
in	O
these	O
animals	O
than	O
with	O
either	O
LY-171555	I-Entity
or	O
subsequent	O
challenge	O
of	O
levodopa	I-Entity
.	O

Selective	O
stimulation	O
of	O
the	O
DA	I-Entity
D1	O
receptor	O
may	O
provide	O
better	O
integration	O
of	O
neural	O
inputs	O
transmitted	O
to	O
the	O
internal	O
segment	O
of	O
the	O
globus	O
pallidus	O
(	O
referred	O
to	O
as	O
the	O
basal	O
ganglia	O
output	O
)	O
compared	O
with	O
levodopa	I-Entity
and	O
selective	O
DA	I-Entity
D2	O
receptor	O
agonist	O
.	O

Potent	O
DA	I-Entity
D1	O
receptor	O
agents	O
with	O
an	O
intermediate	O
duration	O
of	O
efficacy	O
such	O
as	O
A-86929	I-Entity
(	O
approximately	O
4	O
hr	O
at	O
higher	O
doses	O
tested	O
)	O
are	O
potential	O
therapeutic	O
tools	O
in	O
PD	I-Entity
and	O
merit	O
further	O
attention	O
.	O



Deaths	O
from	O
local	O
anesthetic	O
-	O
induced	O
convulsions	I-Entity
in	O
mice	O
.	O

Median	O
convulsant	O
(	O
CD50	O
)	O
and	O
median	O
lethal	O
(	O
LD50	O
)	O
doses	O
of	O
three	O
representative	O
local	O
anesthetics	O
were	O
determined	O
in	O
adult	O
mice	O
to	O
evaluate	O
the	O
threat	O
to	O
life	O
of	O
local	O
anesthetic	O
-	O
induced	O
convulsions	I-Entity
.	O

The	O
CD50	O
and	O
LD50	O
,	O
respectively	O
,	O
were	O
57.7	O
and	O
58.7	O
mg	O
/	O
kg	O
for	O
bupivacaine	I-Entity
,	O
111.0	O
and	O
133.1	O
mg	O
/	O
kg	O
for	O
lidocaine	I-Entity
,	O
and	O
243.4	O
and	O
266.5	O
mg	O
/	O
kg	O
for	O
chloroprocaine	I-Entity
.	O

When	O
given	O
intraperitoneally	O
,	O
bupivacaine	I-Entity
thus	O
was	O
only	O
about	O
twice	O
as	O
toxic	O
as	O
lidocaine	I-Entity
and	O
four	O
times	O
as	O
toxic	O
as	O
chloroprocaine	I-Entity
.	O

Convulsions	I-Entity
always	O
preceded	O
death	O
,	O
except	O
after	O
precipitous	O
cardiopulmonary	B-Entity
arrest	I-Entity
from	O
extreme	O
doses	O
.	O

A	O
CD50	O
dose	O
of	O
local	O
anesthetic	O
(	O
causing	O
convulsions	I-Entity
in	O
50%	O
of	O
mice	O
)	O
was	O
fatal	O
in	O
90%	O
of	O
bupivacaine	I-Entity
-	O
induced	O
seizures	I-Entity
,	O
in	O
57%	O
of	O
the	O
chloroprocaine	I-Entity
group	O
,	O
and	O
in	O
6%	O
of	O
the	O
lidocaine	I-Entity
group	O
.	O

The	O
narrow	O
gap	O
between	O
convulsant	O
and	O
lethal	O
doses	O
of	O
local	O
anesthetics	O
indicates	O
that	O
untreated	O
convulsions	I-Entity
present	O
much	O
more	O
of	O
a	O
threat	O
to	O
life	O
than	O
heretofore	O
appreciated	O
.	O



Myoclonic	B-Entity
,	I-Entity
atonic	I-Entity
,	I-Entity
and	I-Entity
absence	I-Entity
seizures	I-Entity
following	O
institution	O
of	O
carbamazepine	I-Entity
therapy	O
in	O
children	O
.	O

Five	O
children	O
,	O
aged	O
3	O
to	O
11	O
years	O
,	O
treated	O
with	O
carbamazepine	I-Entity
for	O
epilepsy	I-Entity
,	O
had	O
an	O
acute	O
aberrant	O
reaction	O
characterized	O
by	O
the	O
onset	O
of	O
myoclonic	B-Entity
,	I-Entity
atypical	I-Entity
absence	I-Entity
and/or	I-Entity
atonic	I-Entity
(	I-Entity
minor	I-Entity
motor	I-Entity
)	I-Entity
seizures	I-Entity
within	O
a	O
few	O
days	O
.	O

When	O
the	O
carbamazepine	I-Entity
was	O
discontinued	O
,	O
two	O
of	O
the	O
children	O
returned	O
to	O
their	O
former	O
state	O
very	O
quickly	O
,	O
two	O
had	O
the	O
minor	O
motor	O
seizures	I-Entity
resolve	O
in	O
3	O
and	O
6	O
months	O
,	O
and	O
one	O
had	O
the	O
seizures	I-Entity
persist	O
.	O

The	O
child	O
in	O
whom	O
the	O
seizures	I-Entity
persisted	O
was	O
later	O
found	O
to	O
have	O
ceroid	B-Entity
lipofuscinosis	I-Entity
.	O



Naloxone	I-Entity
reversal	O
of	O
hypotension	I-Entity
due	O
to	O
captopril	I-Entity
overdose	I-Entity
.	O

The	O
hemodynamic	O
effects	O
of	O
captopril	I-Entity
and	O
other	O
angiotensin	B-Entity
-	I-Entity
converting	I-Entity
enzyme	I-Entity
inhibitors	I-Entity
may	O
be	O
mediated	O
by	O
the	O
endogenous	O
opioid	O
system	O
.	O

The	O
opioid	O
antagonist	O
naloxone	I-Entity
has	O
been	O
shown	O
to	O
block	O
or	O
reverse	O
the	O
hypotensive	I-Entity
actions	O
of	O
captopril	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
an	O
intentional	O
captopril	I-Entity
overdose	I-Entity
,	O
manifested	O
by	O
marked	O
hypotension	I-Entity
,	O
that	O
resolved	O
promptly	O
with	O
the	O
administration	O
of	O
naloxone	I-Entity
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
captopril	I-Entity
-	O
induced	O
hypotension	I-Entity
treated	O
with	O
naloxone	I-Entity
.	O

Our	O
experience	O
demonstrates	O
a	O
possible	O
role	O
of	O
naloxone	I-Entity
in	O
the	O
reversal	O
of	O
hypotension	I-Entity
resulting	O
from	O
captopril	I-Entity
.	O



Carbamazepine	I-Entity
-	O
induced	O
cardiac	B-Entity
dysfunction	I-Entity
.	O

A	O
patient	O
with	O
sinus	O
bradycardia	I-Entity
and	O
atrioventricular	B-Entity
block	I-Entity
,	O
induced	O
by	O
carbamazepine	I-Entity
,	O
prompted	O
an	O
extensive	O
literature	O
review	O
of	O
all	O
previously	O
reported	O
cases	O
.	O

From	O
the	O
analysis	O
of	O
these	O
cases	O
,	O
two	O
distinct	O
forms	O
of	O
carbamazepine	I-Entity
-	O
associated	O
cardiac	B-Entity
dysfunction	I-Entity
emerged	O
.	O

One	O
patient	O
group	O
developed	O
sinus	B-Entity
tachycardias	I-Entity
in	O
the	O
setting	O
of	O
a	O
massive	O
carbamazepine	I-Entity
overdose	I-Entity
.	O

The	O
second	O
group	O
consisted	O
almost	O
exclusively	O
of	O
elderly	O
women	O
who	O
developed	O
potentially	O
life	O
-	O
threatening	O
bradyarrhythmias	I-Entity
or	O
atrioventricular	B-Entity
conduction	I-Entity
delay	I-Entity
,	O
associated	O
with	O
either	O
therapeutic	O
or	O
modestly	O
elevated	O
carbamazepine	I-Entity
serum	O
levels	O
.	O

Because	O
carbamazepine	I-Entity
is	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
many	O
neurologic	O
and	O
psychiatric	I-Entity
conditions	O
,	O
the	O
recognition	O
of	O
the	O
latter	O
syndrome	O
has	O
important	O
implications	O
for	O
the	O
use	O
of	O
this	O
drug	O
in	O
elderly	O
patients	O
.	O



Glutamatergic	O
neurotransmission	O
mediated	O
by	O
NMDA	I-Entity
receptors	O
in	O
the	O
inferior	O
colliculus	O
can	O
modulate	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
.	O

Functional	O
evidence	O
relating	O
the	O
IC	O
to	O
motor	O
behavior	O
derives	O
from	O
experiments	O
showing	O
that	O
activation	O
of	O
the	O
IC	O
by	O
electrical	O
stimulation	O
or	O
excitatory	O
amino	B-Entity
acid	I-Entity
microinjection	O
causes	O
freezing	O
,	O
escape	O
-	O
like	O
behavior	O
,	O
and	O
immobility	O
.	O

The	O
present	O
study	O
examined	O
the	O
influence	O
of	O
excitatory	O
amino	B-Entity
acid	I-Entity
-	O
mediated	O
mechanisms	O
in	O
the	O
IC	O
on	O
the	O
catalepsy	I-Entity
induced	O
by	O
the	O
dopamine	I-Entity
receptor	O
blocker	O
haloperidol	I-Entity
administered	O

Haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
was	O
challenged	O
with	O
prior	O
intracollicular	O
microinjections	O
of	O
glutamate	I-Entity
NMDA	I-Entity
receptor	O
antagonists	O
,	O
MK-801	I-Entity
(	O
15	O
or	O
30	O
mmol/0.5	O
microl	O
)	O
and	O
AP7	I-Entity
(	O
10	O
or	O
20	O
nmol/0.5	O
microl	O
)	O
,	O
or	O
of	O
the	O
NMDA	I-Entity
receptor	O
agonist	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
d	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
,	O
20	O
or	O
30	O
nmol/0.5	O
microl	O
)	O
.	O

The	O
results	O
showed	O
that	O
intracollicular	O
microinjection	O
of	O
MK-801	I-Entity
and	O
AP7	I-Entity
previous	O
to	O
systemic	O
injections	O
of	O
haloperidol	I-Entity
significantly	O
attenuated	O
the	O
catalepsy	I-Entity
,	O
as	O
indicated	O
by	O
a	O
reduced	O
latency	O
to	O
step	O
down	O
from	O
a	O
horizontal	O
bar	O
.	O

Accordingly	O
,	O
intracollicular	O
microinjection	O
of	O
NMDA	I-Entity
increased	O
the	O
latency	O
to	O
step	O
down	O
the	O
bar	O
.	O

These	O
findings	O
suggest	O
that	O
glutamate	I-Entity
-	O
mediated	O
mechanisms	O
in	O
the	O
neural	O
circuits	O
at	O
the	O
IC	O
level	O
influence	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
and	O
participate	O
in	O
the	O
regulation	O
of	O
motor	O
activity	O
.	O



Metabotropic	O
glutamate	I-Entity
7	O
receptor	O
subtype	O
modulates	O
motor	O
symptoms	O
in	O
rodent	O
models	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Metabotropic	O
glutamate	I-Entity
(	O
mGlu	O
)	O

receptors	O
modulate	O
synaptic	O
transmission	O
in	O
the	O
central	O
nervous	O
system	O
and	O
represent	O
promising	O
therapeutic	O
targets	O
for	O
symptomatic	O
treatment	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
.	O

Among	O
the	O
eight	O
mGlu	O
receptor	O
subtypes	O
,	O
mGlu7	O
receptor	O
is	O
prominently	O
expressed	O
in	O
the	O
basal	O
ganglia	O
,	O
but	O
its	O
role	O
in	O
restoring	O
motor	O
function	O
in	O
animal	O
models	O
of	O
PD	I-Entity
is	O
not	O
known	O
.	O

The	O
effects	O
of	O
N	B-Entity
,	I-Entity
N'-dibenzhydrylethane-1,2-diamine	I-Entity
dihydrochloride	I-Entity
(	O
AMN082	I-Entity
)	O
,	O
the	O
first	O
selective	O
allosteric	O
activator	O
of	O
mGlu7	O
receptors	O
,	O
were	O
thus	O
tested	O
in	O
different	O
rodent	O
models	O
of	O
PD	I-Entity
.	O

Here	O
,	O
we	O
show	O
that	O
oral	O
(	O
5	O
mg	O
/	O
kg	O
)	O
or	O
intrastriatal	O
administration	O
(	O
0.1	O
and	O
0.5	O
nmol	O
)	O
of	O
AMN082	I-Entity
reverses	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
in	O
rats	O
.	O

AMN082	I-Entity
(	O
2.5	O
and	O
5	O
mg	O
/	O
kg	O
)	O
reduces	O
apomorphine	I-Entity
-	O
induced	O
rotations	O
in	O
unilateral	O
6-hydroxydopamine	I-Entity
(	O
6-OHDA)-lesioned	I-Entity
rats	O
.	O

In	O
a	O
more	O
complex	O
task	O
commonly	O
used	O
to	O
evaluate	O
major	O
akinetic	I-Entity
symptoms	O
of	O
PD	I-Entity
patients	O
,	O
5	O
mg	O
/	O
kg	O
AMN082	I-Entity
reverses	O
the	O
increased	O
reaction	O
time	O
to	O
respond	O
to	O
a	O
cue	O
of	O
bilateral	O
6-OHDA	I-Entity
-	O
lesioned	O
rats	O
.	O

In	O
addition	O
,	O
AMN082	I-Entity
reduces	O
the	O
duration	O
of	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
in	O
a	O
mGlu7	O
receptor	O
-	O
dependent	O
manner	O
in	O
wild	O
-	O
type	O
but	O
not	O
mGlu7	O
receptor	O
knockout	O
mice	O
.	O

Higher	O
doses	O
of	O
AMN082	I-Entity
(	O
10	O
and	O
20	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O

have	O
no	O
effect	O
on	O
the	O
same	O
models	O
of	O
PD	I-Entity
.	O

Overall	O
these	O
findings	O
suggest	O
that	O
mGlu7	O
receptor	O
activation	O
can	O
reverse	O
motor	O
dysfunction	O
associated	O
with	O
reduced	O
dopamine	I-Entity
activity	O
.	O



Nimodipine	I-Entity
prevents	O
memory	B-Entity
impairment	I-Entity
caused	O
by	O
nitroglycerin	I-Entity
-	O
induced	O
hypotension	I-Entity
in	O
adult	O
mice	O
.	O

Hypotension	I-Entity
and	O
a	O
resultant	O
decrease	O
in	O
cerebral	O
blood	O
flow	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
cognitive	B-Entity
dysfunction	I-Entity
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
nimodipine	I-Entity
(	O
NIMO	I-Entity
)	O
administered	O
at	O
the	O
onset	O
of	O
nitroglycerin	I-Entity
(	O
NTG)-induced	I-Entity
hypotension	I-Entity
would	O
preserve	O
long	O
-	O
term	O
associative	O
memory	O
.	O

Ninety	O
-	O
six	O
Swiss	O
-	O
Webster	O
mice	O
(	O
30	O
-	O
35	O
g	O
,	O
6	O
-	O
8	O
wk	O
)	O
,	O
were	O
randomized	O
into	O
6	O
groups	O
1	O
)	O
saline	O
(	O
control	O
)	O
,	O
2	O
)	O
NTG	I-Entity
immediately	O
after	O
learning	O
,	O
3	O
)	O
NTG	I-Entity
3	O
h	O
after	O
learning	O
,	O
4	O
)	O
NTG	I-Entity
and	O
NIMO	I-Entity
,	O
5	O
)	O
vehicle	O
,	O
and	O
6	O
)	O

NIMO	I-Entity
alone	O
.	O

The	O
extent	O
of	O
hypotension	I-Entity
and	O
changes	O
in	O
brain	O
tissue	O
oxygenation	O
(	O
PbtO(2	O
)	O
)	O
and	O
in	O
cerebral	O
blood	O
flow	O
were	O
studied	O
in	O
a	O
separate	O
group	O
of	O
animals	O
.	O

Mice	O
subjected	O
to	O
hypotensive	I-Entity
episodes	O
showed	O
a	O
significant	O
decrease	O
in	O
latency	O
time	O
(	O
178	O
+	O
/-	O

156	O
s	O
)	O
compared	O
with	O
those	O
injected	O
with	O
saline	O
,	O
NTG	I-Entity
+	O
NIMO	I-Entity
,	O
or	O
delayed	O
NTG	I-Entity
(	O
580	O
+	O
/-	O

In	O
a	O
separate	O
group	O
of	O
mice	O
not	O
subjected	O
to	O
behavioral	O
studies	O
,	O
the	O
same	O
dose	O
of	O
NTG	I-Entity
(	O
n	O
=	O
3	O
)	O
and	O
NTG	I-Entity
+	O
NIMO	I-Entity
(	O
n	O
=	O
3	O
)	O
caused	O
mean	O
arterial	O
blood	O
pressure	O
to	O
decrease	O
from	O
85.9	O
+	O
/-	O

Mean	O
arterial	O
blood	O
pressure	O
in	O
mice	O
treated	O
with	O
NIMO	I-Entity
alone	O
decreased	O
from	O
88.1	O
+	O
/-	O

5.2	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	I-Entity
group	O
and	O
from	O
38.6	O
+	O
/-	O

2.0	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	I-Entity
+	O
NIMO	I-Entity
groups	O
,	O
respectively	O
.	O

In	O
a	O
PA	O
retention	O
paradigm	O
,	O
the	O
injection	O
of	O
NTG	I-Entity
immediately	O
after	O
learning	O
produced	O
a	O
significant	O
impairment	O
of	O
long	O
-	O
term	O
associative	O
memory	O
in	O
mice	O
,	O
whereas	O
delayed	O
induced	O
hypotension	I-Entity
had	O
no	O
effect	O
.	O

NIMO	I-Entity
attenuated	O
the	O
disruption	O
in	O
consolidation	O
of	O
long	O
-	O
term	O
memory	O
caused	O
by	O
NTG	I-Entity
but	O
did	O
not	O
improve	O
latency	O
in	O
the	O
absence	O
of	O
hypotension	I-Entity
.	O

The	O
observed	O
effect	O
of	O
NIMO	I-Entity
may	O
have	O
been	O
attributable	O
to	O
the	O
preservation	O
of	O
calcium	I-Entity
homeostasis	O
during	O
hypotension	I-Entity
,	O
because	O
there	O
were	O
no	O
differences	O
in	O
the	O
PbtO(2	O
)	O
indices	O
among	O
groups	O
.	O



Fatal	O
haemopericardium	I-Entity
and	O
gastrointestinal	B-Entity
haemorrhage	I-Entity
due	O
to	O
possible	O
interaction	O
of	O
cranberry	O
juice	O
with	O
warfarin	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
fatal	O
internal	O
haemorrhage	I-Entity
in	O
an	O
elderly	O
man	O
who	O
consumed	O
only	O
cranberry	O
juice	O
for	O
two	O
weeks	O
while	O
maintaining	O
his	O
usual	O
dosage	O
of	O
warfarin	I-Entity
.	O

We	O
propose	O
that	O
naturally	O
occurring	O
compounds	O
such	O
as	O
flavonoids	I-Entity
,	O
which	O
are	O
present	O
in	O
fruit	O
juices	O
,	O
may	O
increase	O
the	O
potency	O
of	O
warfarin	I-Entity
by	O
competing	O
for	O
the	O
enzymes	O
that	O
normally	O
inactivate	O
warfarin	I-Entity
.	O



Isoproterenol	I-Entity
induces	O
primary	O
loss	O
of	O
dystrophin	O
in	O
rat	O
hearts	O
:	O
correlation	O
with	O
myocardial	B-Entity
injury	I-Entity
.	O

The	O
mechanism	O
of	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
damage	I-Entity
is	O
unknown	O
,	O
but	O
a	O
mismatch	O
of	O
oxygen	I-Entity
supply	O
vs.	O
demand	O
following	O
coronary	O
hypotension	I-Entity
and	O
myocardial	B-Entity
hyperactivity	I-Entity
is	O
the	O
best	O
explanation	O
for	O
the	O
complex	O
morphological	O
alterations	O
observed	O
.	O

Severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
have	O
been	O
demonstrated	O
to	O
be	O
caused	O
by	O
isoproterenol	I-Entity
.	O

Taking	O
into	O
account	O
that	O
the	O
sarcolemmal	O
integrity	O
is	O
stabilized	O
by	O
the	O
dystrophin	O
-	O
glycoprotein	O
complex	O
(	O
DGC	O
)	O
that	O
connects	O
actin	O
and	O
laminin	O
in	O
contractile	O
machinery	O
and	O
extracellular	O
matrix	O
and	O
by	O
integrins	O
,	O
this	O
study	O
tests	O
the	O
hypothesis	O
that	O
isoproterenol	I-Entity
affects	O
sarcolemmal	O
stability	O
through	O
changes	O
in	O
the	O
DGC	O
and	O
integrins	O
.	O

We	O
found	O
different	O
sensitivity	O
of	O
the	O
DGC	O
and	O
integrin	O
to	O
isoproterenol	I-Entity
subcutaneous	O
administration	O
.	O

In	O
conclusion	O
,	O
administration	O
of	O
isoproterenol	I-Entity
to	O
rats	O
results	O
in	O
primary	O
loss	O
of	O
dystrophin	O
,	O
the	O
most	O
sensitive	O
among	O
the	O
structural	O
proteins	O
that	O
form	O
the	O
DGC	O
that	O
connects	O
the	O
extracellular	O
matrix	O
and	O
the	O
cytoskeleton	O
in	O
cardiomyocyte	O
.	O

These	O
changes	O
,	O
related	O
to	O
ischaemic	B-Entity
injury	I-Entity
,	O
explain	O
the	O
severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	O
and	O
irreversible	O
injury	O
induced	O
by	O
isoproterenol	I-Entity
.	O



High	O
fat	I-Entity
diet	O
-	O
fed	O
obese	I-Entity
rats	O
are	O
highly	O
sensitive	O
to	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

Often	O
,	O
chemotherapy	O
by	O
doxorubicin	I-Entity
(	O
Adriamycin	I-Entity
)	O
is	O
limited	O
due	O
to	O
life	O
threatening	O
cardiotoxicity	I-Entity
in	O
patients	O
during	O
and	O
posttherapy	O
.	O

Recently	O
,	O
we	O
have	O
shown	O
that	O
moderate	O
diet	O
restriction	O
remarkably	O
protects	O
against	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

This	O
cardioprotection	O
is	O
accompanied	O
by	O
decreased	O
cardiac	O
oxidative	O
stress	O
and	O
triglycerides	I-Entity
and	O
increased	O
cardiac	O
fatty	O
-	O
acid	O
oxidation	O
,	O
ATP	I-Entity
synthesis	O
,	O
and	O
upregulated	O
JAK	O
/	O
STAT3	O
pathway	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40%	O
high	O
fat	I-Entity
diet	O
(	O
HFD	O
)	O
,	O
which	O
induces	O
obesity	I-Entity
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
(	O
250	O
-	O
275	O
g	O
)	O
,	O
sensitizes	O
to	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

A	O
LD(10	O
)	O
dose	O
(	O
8	O
mg	O
doxorubicin	I-Entity
/	O
kg	O
,	O
ip	O
)	O
administered	O
on	O
day	O
43	O
of	O
the	O
HFD	O
feeding	O
regimen	O
led	O
to	O
higher	O
cardiotoxicity	I-Entity
,	O
cardiac	B-Entity
dysfunction	I-Entity
,	O
lipid	O
peroxidation	O
,	O
and	O
80%	O
mortality	O
in	O
the	O
obese	I-Entity
(	O
OB	I-Entity
)	O
rats	O
in	O
the	O
absence	O
of	O
any	O
significant	O
renal	B-Entity
or	I-Entity
hepatic	I-Entity
toxicity	I-Entity
.	O

Doxorubicin	I-Entity
toxicokinetics	O
studies	O
revealed	O
no	O
change	O
in	O
accumulation	O
of	O
doxorubicin	I-Entity
and	O
doxorubicinol	I-Entity
(	O
toxic	O
metabolite	O
)	O
in	O
the	O
normal	O
diet	O
-	O
fed	O
(	O
ND	O
)	O
and	O
OB	I-Entity
hearts	O
.	O

Mechanistic	O
studies	O
revealed	O
that	O
OB	I-Entity
rats	O
are	O
sensitized	O
due	O
to	O
:	O
(	O
1	O
)	O
higher	O
oxyradical	O
stress	O
leading	O
to	O
upregulation	O
of	O
uncoupling	O
proteins	O
2	O
and	O
3	O
,	O
(	O
2	O
)	O
downregulation	O
of	O
cardiac	O
peroxisome	O
proliferators	O
activated	O
receptor	O
-	O
alpha	O
,	O
(	O
3	O
)	O
decreased	O
plasma	O
adiponectin	O
levels	O
,	O
(	O
4	O
)	O
decreased	O
cardiac	O
fatty	O
-	O
acid	O
oxidation	O
(	O
666.9+/-14.0	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
ND	O
versus	O
400.2+/-11.8	O
nmol	O

/	O
min	O
/	O
g	O
heart	O
in	O
OB	I-Entity
)	O
,	O
(	O
5	O
)	O
decreased	O
mitochondrial	O
AMP	I-Entity
-	O
alpha2	O
protein	O
kinase	O
,	O
and	O
(	O
6	O
)	O
86%	O
drop	O
in	O
cardiac	O
ATP	I-Entity
levels	O
accompanied	O
by	O
decreased	O
ATP	I-Entity
/	O
ADP	I-Entity
ratio	O
after	O
doxorubicin	I-Entity
administration	O
.	O

In	O
conclusion	O
,	O
HFD	O
-	O
induced	O
obese	I-Entity
rats	O
are	O
highly	O
sensitized	O
to	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
by	O
substantially	O
downregulating	O
cardiac	O
mitochondrial	O
ATP	I-Entity
generation	O
,	O
increasing	O
oxidative	O
stress	O
and	O
downregulating	O
the	O
JAK	O
/	O
STAT3	O
pathway	O
.	O



Complete	O
atrioventricular	B-Entity
block	I-Entity
secondary	O
to	O
lithium	I-Entity
therapy	O
.	O

Sinus	B-Entity
node	I-Entity
dysfunction	I-Entity
has	O
been	O
reported	O
most	O
frequently	O
among	O
the	O
adverse	O
cardiovascular	O
effects	O
of	O
lithium	I-Entity
.	O

In	O
the	O
present	O
case	O
,	O
complete	O
atrioventricular	B-Entity
(	I-Entity
AV	I-Entity
)	I-Entity
block	I-Entity
with	O
syncopal	B-Entity
attacks	I-Entity
developed	O
secondary	O
to	O
lithium	I-Entity
therapy	O
,	O
necessitating	O
permanent	O
pacemaker	O
implantation	O
.	O

Serum	O
lithium	I-Entity
levels	O
remained	O
under	O
or	O
within	O
the	O
therapeutic	O
range	O
during	O
the	O
syncopal	B-Entity
attacks	I-Entity
.	O

Lithium	I-Entity
should	O
be	O
used	O
with	O
extreme	O
caution	O
,	O
especially	O
in	O
patients	O
with	O
mild	O
disturbance	O
of	O
AV	O
conduction	O
.	O



Neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
induced	O
by	O
ziprasidone	I-Entity
on	O
the	O
second	O
day	O
of	O
treatment	O
.	O

Neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
(	O
NMS	I-Entity
)	O
is	O
the	O
rarest	O
and	O
most	O
serious	O
of	O
the	O
neuroleptic	O
-	O
induced	O
movement	B-Entity
disorders	I-Entity
.	O

We	O
describe	O
a	O
case	O
of	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
(	O
NMS	I-Entity
)	O
associated	O
with	O
the	O
use	O
of	O
ziprasidone	I-Entity
.	O

Although	O
conventional	O
neuroleptics	O
are	O
more	O
frequently	O
associated	O
with	O
NMS	I-Entity
,	O
atypical	O
antipsychotic	O
drugs	O
like	O
ziprasidone	I-Entity
may	O
also	O
be	O
a	O
cause	O
.	O

The	O
patient	O
is	O
a	O
24-year	O
-	O
old	O
male	O
with	O
a	O
history	O
of	O
schizophrenia	I-Entity
who	O
developed	O
signs	O
and	O
symptoms	O
of	O
NMS	I-Entity
after	O
2	O
days	O
of	O
treatment	O
with	O
an	O
80-mg	O
/	O
day	O
dose	O
of	O
orally	O
administrated	O
ziprasidone	I-Entity
.	O

NMS	I-Entity
due	O
to	O
ziprasidone	I-Entity
reported	O
in	O
the	O
literature	O
.	O



Role	O
of	O
mangiferin	I-Entity
on	O
biochemical	O
alterations	O
and	O
antioxidant	O
status	O
in	O
isoproterenol	I-Entity
-	O
induced	O
myocardial	B-Entity
infarction	I-Entity
in	O
rats	O
.	O

The	O
current	O
study	O
dealt	O
with	O
the	O
protective	O
role	O
of	O
mangiferin	I-Entity
,	O
a	O
polyphenol	I-Entity
from	O
Mangifera	O
indica	O
Linn	O
.	O

(	O
Anacardiaceae	O
)	O
,	O
on	O
isoproterenol	I-Entity
(	O
ISPH)-induced	I-Entity
myocardial	B-Entity
infarction	I-Entity
(	O
MI	I-Entity
)	O
in	O
rats	O
through	O
its	O
antioxidative	O
mechanism	O
.	O

Subcutaneous	O
injection	O
of	O
ISPH	I-Entity
(	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
in	O
1	O
ml	O
saline	O
)	O
to	O
rats	O
for	O
2	O
consecutive	O
days	O
caused	O
myocardial	B-Entity
damage	I-Entity
in	O
rat	O
heart	O
,	O
which	O
was	O
determined	O
by	O
the	O
increased	O
activity	O
of	O
serum	O
lactate	I-Entity
dehydrogenase	O
(	O
LDH	O
)	O
and	O
creatine	I-Entity
phosphokinase	O
isoenzymes	O
(	O
CK	O
-	O
MB	O
)	O
,	O
increased	O
uric	B-Entity
acid	I-Entity
level	O
and	O
reduced	O
plasma	O
iron	I-Entity
binding	O
capacity	O
.	O

The	O
protective	O
role	O
of	O
mangiferin	I-Entity
was	O
analyzed	O
by	O
triphenyl	B-Entity
tetrazolium	I-Entity
chloride	I-Entity
(	O
TTC	I-Entity
)	O
test	O
used	O
for	O
macroscopic	O
enzyme	O
mapping	O
assay	O
of	O
the	O
ischemic	B-Entity
myocardium	I-Entity
.	O

The	O
heart	O
tissue	O
antioxidant	O
enzymes	O
such	O
as	O
superoxide	I-Entity
dismutase	O
,	O
catalase	O
,	O
glutathione	I-Entity
peroxidase	O
,	O
glutathione	I-Entity
transferase	O
and	O
glutathione	I-Entity
reductase	O
activities	O
,	O
non	O
-	O
enzymic	O
antioxidants	O
such	O
as	O
cerruloplasmin	O
,	O
Vitamin	B-Entity
C	I-Entity
,	O
Vitamin	B-Entity
E	I-Entity
and	O

glutathione	I-Entity
levels	O
were	O
altered	O
in	O
MI	I-Entity
rats	O
.	O

Upon	O
pretreatment	O
with	O
mangiferin	I-Entity
(	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
suspended	O
in	O
2	O
ml	O
of	O
dimethyl	B-Entity
sulphoxide	I-Entity
)	O
given	O
intraperitoneally	O
for	O
28	O
days	O
to	O
MI	I-Entity
rats	O
protected	O
the	O
above	O
-	O
mentioned	O
parameters	O
to	O
fall	O
from	O
the	O
normal	O
levels	O
.	O

Activities	O
of	O
heart	O
tissue	O
enzymic	O
antioxidants	O
and	O
serum	O
non	O
-	O
enzymic	O
antioxidants	O
levels	O
rose	O
significantly	O
upon	O
mangiferin	I-Entity
administration	O
as	O
compared	O
to	O
ISPH	I-Entity
-	O
induced	O
MI	I-Entity
rats	O
.	O

From	O
the	O
present	O
study	O
it	O
is	O
concluded	O
that	O
mangiferin	I-Entity
exerts	O
a	O
beneficial	O
effect	O
against	O
ISPH	I-Entity
-	O
induced	O
MI	I-Entity
due	O
to	O
its	O
antioxidant	O
potential	O
,	O
which	O
regulated	O
the	O
tissues	O
defense	O
system	O
against	O
cardiac	B-Entity
damage	I-Entity
.	O



Remifentanil	I-Entity
pretreatment	O
reduces	O
myoclonus	I-Entity
after	O
etomidate	I-Entity
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
pretreatment	O
with	O
remifentanil	I-Entity
1	O
microg	O
/	O
kg	O
and	O
the	O
effect	O
of	O
gender	O
on	O
the	O
incidence	O
of	O
myoclonus	I-Entity
after	O
anesthesia	O
induction	O
with	O
etomidate	I-Entity
.	O

Sixty	O
patients	O
were	O
pretreated	O
in	O
a	O
randomized	O
double	O
-	O
blinded	O
fashion	O
with	O
remifentanil	I-Entity
1	O
microg	O
/	O
kg	O
or	O
placebo	O
.	O

Two	O
minutes	O
after	O
remifentanil	I-Entity
or	O
placebo	O
injection	O
,	O
etomidate	I-Entity
0.3	O
mg	O
/	O
kg	O
was	O
given	O
.	O

Myoclonus	I-Entity
was	O
recorded	O
with	O
a	O
scale	O
of	O
0	O
to	O
3	O
.	O

The	O
grade	O
of	O
sedation	O
(	O
none	O
,	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
,	O
nausea	I-Entity
,	O
pruritus	I-Entity
,	O
and	O
apnea	I-Entity
were	O
recorded	O
after	O
injection	O
of	O
both	O
drugs	O
.	O

The	O
incidence	O
of	O
myoclonus	I-Entity
was	O
significantly	O
lower	O
in	O
the	O
remifentanil	I-Entity
group	O
(	O
6.7%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
70%	O
)	O

None	O
of	O
the	O
patients	O
experienced	O
sedation	O
,	O
apnea	I-Entity
,	O
nausea	I-Entity
,	O
or	O
pruritus	I-Entity
after	O
injection	O
of	O
both	O
drugs	O
.	O

In	O
the	O
placebo	O
group	O
,	O
male	O
patients	O
were	O
associated	O
with	O
significantly	O
increased	O
incidence	O
of	O
myoclonus	I-Entity
after	O
etomidate	I-Entity
administration	O
.	O

CONCLUSION	O
:	O
Pretreatment	O
with	O
remifentanil	I-Entity
1	O
microg	O
/	O

kg	O
reduced	O
myoclonus	I-Entity
after	O
etomidate	I-Entity
induction	O
without	O
side	O
effects	O
such	O
as	O
sedation	O
,	O
apnea	I-Entity
,	O
nausea	I-Entity
,	O
or	O
pruritus	I-Entity
.	O

Men	O
experience	O
increased	O
incidence	O
of	O
myoclonus	I-Entity
than	O
women	O
after	O
etomidate	I-Entity
administration	O
.	O



Daidzein	I-Entity
activates	O
choline	I-Entity
acetyltransferase	O
from	O
MC	O
-	O
IXC	O
cells	O
and	O
improves	O
drug	O
-	O
induced	O
amnesia	I-Entity
.	O

The	O
choline	I-Entity
acetyltransferase	O
(	O
ChAT	O
)	O
activator	O
,	O
which	O
enhances	O
cholinergic	O
transmission	O
via	O
an	O
augmentation	O
of	O
the	O
enzymatic	O
production	O
of	O
acetylcholine	I-Entity
(	O
ACh	I-Entity
)	O
,	O
is	O
an	O
important	O
factor	O
in	O
the	O
treatment	O
of	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
(	O
AD	I-Entity
)	O
.	O

Via	O
the	O
sequential	O
isolation	O
of	O
Pueraria	O
thunbergiana	O
,	O
the	O
active	O
component	O
was	O
ultimately	O
identified	O
as	O
daidzein	I-Entity
(	O
4',7-dihydroxy	B-Entity
-	I-Entity
isoflavone	I-Entity
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
effects	O
of	O
daidzein	I-Entity
from	O
Pueraria	O
thunbergiana	O
on	O
scopolamine	I-Entity
-	O
induced	O
impairments	B-Entity
of	I-Entity
learning	I-Entity
and	I-Entity
memory	I-Entity
,	O
we	O
conducted	O
a	O
series	O
of	O
in	O
vivo	O
tests	O
.	O

Administration	O
of	O
daidzein	I-Entity
(	O
4.5	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
to	O
mice	O
was	O
shown	O
significantly	O
to	O
reverse	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
,	O
according	O
to	O
the	O
results	O
of	O
a	O
Y	O
-	O
maze	O
test	O
.	O

Injections	O
of	O
scopolamine	I-Entity
into	O
mice	O
resulted	O
in	O
impaired	O
performance	O
on	O
Y	O
-	O
maze	O
tests	O
(	O
a	O
37%	O
decreases	O
in	O
alternation	O
behavior	O
)	O
.	O

By	O
way	O
of	O
contrast	O
,	O
mice	O
treated	O
with	O
daidzein	I-Entity
prior	O
to	O
the	O
scopolamine	I-Entity
injections	O
were	O
noticeably	O
protected	O
from	O
this	O
performance	O
impairment	O
(	O
an	O
approximately	O
12%-21%	O
decrease	O
in	O
alternation	O
behavior	O
)	O
.	O

These	O
results	O
indicate	O
that	O
daidzein	I-Entity
might	O
play	O
a	O
role	O
in	O
acetylcholine	I-Entity
biosynthesis	O
as	O
a	O
ChAT	O
activator	O
,	O
and	O
that	O
it	O
also	O
ameliorates	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
.	O



Possible	O
azithromycin	I-Entity
-	O
associated	O
hiccups	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
persistent	O
hiccups	I-Entity
associated	O
by	O
azithromycin	I-Entity
therapy	O
.	O

A	O
76-year	O
-	O
old	O
man	O
presented	O
with	O
persistent	O
hiccups	I-Entity
after	O
beginning	O
azithromycin	I-Entity
for	O
the	O
treatment	O
of	O
pharyngitis	I-Entity
.	O

Hiccups	I-Entity
were	O
persistent	O
and	O
exhausting	O
.	O

Discontinuation	O
of	O
azithromycin	I-Entity
and	O
therapy	O
with	O
baclofen	I-Entity
finally	O
resolved	O
hiccups	I-Entity
.	O

No	O
organic	O
cause	O
of	O
hiccups	I-Entity
was	O
identified	O
despite	O
extensive	O
investigation	O
.	O

DISCUSSION	O
:	O
Pharmacotherapeutic	O
agents	O
have	O
been	O
uncommonly	O
associated	O
with	O
hiccups	I-Entity
.	O

Corticosteroids	O
(	O
dexamethasone	I-Entity
and	O
methylprednisolone	I-Entity
)	O
,	O
benzodiazepines	I-Entity
(	O
midazolam	I-Entity
)	O
and	O
general	O
anaesthesia	O
have	O
been	O
the	O
specific	O
agents	O
mentioned	O
most	O
frequently	O
in	O
the	O
literature	O
as	O
being	O
associated	O
with	O
the	O
development	O
of	O
hiccups	I-Entity
.	O

Few	O
cases	O
of	O
drug	O
-	O
induced	O
hiccups	I-Entity
have	O
been	O
reported	O
related	O
to	O
macrolide	I-Entity
antimicrobials	O
.	O

Using	O
the	O
Naranjo	O
adverse	O
effect	O
reaction	O
probability	O
scale	O
this	O
event	O
could	O
be	O
classified	O
as	O
possible	O
(	O
score	O
5	O
points	O
)	O
,	O
mostly	O
because	O
of	O
the	O
close	O
temporal	O
sequence	O
,	O
previous	O
reports	O
on	O
this	O
reaction	O
with	O
other	O
macrolides	I-Entity
and	O
the	O
absence	O
of	O
any	O
alternative	O
explanation	O
for	O
hiccups	I-Entity
.	O

Our	O
hypothesis	O
is	O
that	O
a	O
vagal	O
mechanism	O
mediated	O
by	O
azithromycin	I-Entity
could	O
be	O
the	O
pathogenesis	O
of	O
hiccups	I-Entity
in	O
our	O
patient	O
.	O

Diagnosis	O
of	O
drug	O
-	O
induced	O
hiccups	I-Entity
is	O
difficult	O
and	O
often	O
achieved	O
only	O
by	O
a	O
process	O
of	O
elimination	O
.	O

However	O
,	O
macrolide	I-Entity
antimicrobials	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
hiccups	I-Entity
and	O
vagal	O
mechanism	O
could	O
explain	O
the	O
development	O
of	O
this	O
side	O
-	O
effect	O
.	O



Time	O
trends	O
in	O
warfarin	I-Entity
-	O
associated	O
hemorrhage	I-Entity
.	O

The	O
annual	O
incidence	O
of	O
warfarin	I-Entity
-	O
related	O
bleeding	I-Entity
at	O
Brigham	O
and	O
Women	O
's	O
Hospital	O
increased	O
from	O
0.97/1,000	O
patient	O
admissions	O
in	O
the	O
first	O
time	O
period	O
(	O
January	O
1995	O
to	O
October	O
1998	O
)	O
to	O
1.19/1,000	O
patient	O
admissions	O
in	O
the	O
second	O
time	O
period	O
(	O
November	O
1998	O
to	O
August	O
2002	O
)	O
of	O
this	O
study	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
major	O
and	O
intracranial	B-Entity
bleeding	I-Entity
increased	O
from	O
20.2%	O
and	O
1.9%	O
,	O
respectively	O
,	O
in	O
the	O
first	O
time	O
period	O
,	O
to	O
33.3%	O
and	O
7.8%	O
,	O
respectively	O
,	O
in	O
the	O
second	O
.	O



Fatal	O
haemorrhagic	B-Entity
myocarditis	I-Entity
secondary	O
to	O
cyclophosphamide	I-Entity
therapy	O
.	O

Haemorrhagic	B-Entity
myocarditis	I-Entity
is	O
a	O
rare	O
but	O
important	O
complication	O
of	O
cyclophosphamide	I-Entity
therapy	O
.	O



Glyceryl	B-Entity
trinitrate	I-Entity
induces	O
attacks	O
of	O
migraine	B-Entity
without	I-Entity
aura	I-Entity
in	O
sufferers	O
of	O
migraine	B-Entity
with	I-Entity
aura	I-Entity
.	O

Migraine	B-Entity
with	I-Entity
aura	I-Entity
and	O
migraine	B-Entity
without	I-Entity
aura	I-Entity
have	O
the	O
same	O
pain	I-Entity
phase	O
,	O
thus	O
indicating	O
that	O
migraine	B-Entity
with	I-Entity
aura	I-Entity
and	O
migraine	B-Entity
without	I-Entity
aura	I-Entity
share	O
a	O
common	O
pathway	O
of	O
nociception	O
.	O

In	O
recent	O
years	O
,	O
increasing	O
evidence	O
has	O
suggested	O
that	O
the	O
messenger	O
molecule	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
is	O
involved	O
in	O
pain	I-Entity
mechanisms	O
of	O
migraine	B-Entity
without	I-Entity
aura	I-Entity
.	O

In	O
order	O
to	O
clarify	O
whether	O
the	O
same	O
is	O
true	O
for	O
migraine	B-Entity
with	I-Entity
aura	I-Entity
,	O
in	O
the	O
present	O
study	O
we	O
examined	O
the	O
headache	I-Entity
response	O
to	O
intravenous	O
infusion	O
of	O
glyceryl	B-Entity
trinitrate	I-Entity
(	O
GTN	I-Entity
)	O

(	O
0.5	O
microg	O
/	O
kg	O
/	O
min	O
for	O
20	O
min	O
)	O
in	O
12	O
sufferers	O
of	O
migraine	B-Entity
with	I-Entity
aura	I-Entity
.	O

The	O
specific	O
aim	O
was	O
to	O
elucidate	O
whether	O
an	O
aura	O
and/or	O
an	O
attack	O
of	O
migraine	B-Entity
without	I-Entity
aura	I-Entity
could	O
be	O
induced	O
.	O

Headache	I-Entity
was	O
more	O
severe	O
in	O
migraineurs	I-Entity
than	O
in	O
the	O
controls	O
during	O
and	O
immediately	O
after	O
GTN	I-Entity
infusion	O
(	O
p=0.037	O
)	O
as	O
well	O
as	O
during	O
the	O
following	O
11	O
h	O
(	O
p	O
=	O
0.008	O
)	O
.	O

In	O
the	O
controls	O
,	O
the	O
GTN	I-Entity
-	O
induced	O
headache	I-Entity
gradually	O
disappeared	O
,	O
whereas	O
in	O
migraineurs	I-Entity
peak	O
headache	I-Entity
intensity	O
occurred	O
at	O
a	O
mean	O
time	O
of	O
240	O
min	O
post	O
-	O
infusion	O
.	O

At	O
this	O
time	O
the	O
induced	O
headache	I-Entity
in	O
6	O
of	O
12	O
migraineurs	I-Entity
fulfilled	O
the	O
diagnostic	O
criteria	O
for	O
migraine	B-Entity
without	I-Entity
aura	I-Entity
of	O
the	O
International	O
Headache	I-Entity
Society	O
.	O

The	O
results	O
therefore	O
suggest	O
that	O
NO	I-Entity
is	O
involved	O
in	O
the	O
pain	I-Entity
mechanisms	O
of	O
migraine	B-Entity
with	I-Entity
aura	I-Entity
.	O

Since	O
cortical	O
spreading	O
depression	I-Entity
has	O
been	O
shown	O
to	O
liberate	O
NO	I-Entity
in	O
animals	O
,	O
this	O
finding	O
may	O
help	O
our	O
understanding	O
of	O
the	O
coupling	O
between	O
cortical	O
spreading	O
depression	I-Entity
and	O
headache	I-Entity
in	O
migraine	B-Entity
with	I-Entity
aura	I-Entity
.	O



Stroke	I-Entity
and	O
cocaine	I-Entity
or	O
amphetamine	I-Entity
use	O
.	O

The	O
association	O
of	O
cocaine	I-Entity
and	O
amphetamine	I-Entity
use	O
with	O
hemorrhagic	O
and	O
ischemic	I-Entity
stroke	I-Entity
is	O
based	O
almost	O
solely	O
on	O
data	O
from	O
case	O
series	O
.	O

The	O
limited	O
number	O
of	O
epidemiologic	O
studies	O
of	O
stroke	I-Entity
and	O
use	O
of	O
cocaine	I-Entity
and/or	O
amphetamine	I-Entity
have	O
been	O
done	O
in	O
settings	O
that	O
serve	O
mostly	O
the	O
poor	O
and/or	O
minorities	O
.	O

We	O
attempted	O
to	O
identify	O
all	O
incident	O
strokes	I-Entity
in	O
women	O
ages	O
15	O
-	O
44	O
years	O
during	O
a	O
3-year	O
period	O
using	O
hospital	O
admission	O
and	O
discharge	O
records	O
,	O
emergency	O
department	O
logs	O
,	O
and	O
payment	O
requests	O
for	O
out	O
-	O
of	O
-	O
plan	O
hospitalizations	O
.	O

There	O
were	O
347	O
confirmed	O
stroke	I-Entity
cases	O
and	O
1,021	O
controls	O
.	O

The	O
univariate	O
matched	O
odds	O
ratio	O
for	O
stroke	I-Entity
in	O
women	O
who	O
admitted	O
to	O
using	O
cocaine	I-Entity
and/or	O
amphetamine	I-Entity
was	O
8.5	O
(	O
95%	O
confidence	O
interval	O
=	O
3.6	O
-	O
20.0	O
)	O
.	O

After	O
further	O
adjustment	O
for	O
potential	O
confounders	O
,	O
the	O
odds	O
ratio	O
in	O
women	O
who	O
reported	O
using	O
cocaine	I-Entity
and/or	O
amphetamine	I-Entity
was	O
7.0	O
(	O
95%	O
confidence	O
interval	O
=	O
2.8	O
-	O
17.9	O
)	O
.	O

The	O
use	O
of	O
cocaine	I-Entity
and/or	O
amphetamine	I-Entity
is	O
a	O
strong	O
risk	O
factor	O
for	O
stroke	I-Entity
in	O
this	O
socioeconomically	O
heterogeneous	O
,	O
insured	O
urban	O
population	O
.	O



Prevention	O
of	O
breast	B-Entity
cancer	I-Entity
with	O
tamoxifen	I-Entity
:	O
preliminary	O
findings	O
from	O
the	O
Italian	O
randomised	O
trial	O
among	O
hysterectomised	O
women	O
.	O

Italian	O
Tamoxifen	I-Entity
Prevention	O
Study	O
.	O

Tamoxifen	I-Entity
is	O
a	O
candidate	O
chemopreventive	O
agent	O
in	O
breast	B-Entity
cancer	I-Entity
,	O
although	O
the	O
drug	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
endometrial	B-Entity
cancer	I-Entity
.	O

Therefore	O
we	O
did	O
a	O
trial	O
in	O
hysterectomised	O
women	O
of	O
tamoxifen	I-Entity
as	O
a	O
chemopreventive	O
.	O

In	O
October	O
,	O
1992	O
,	O
we	O
started	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
,	O
randomised	O
trial	O
of	O
tamoxifen	I-Entity
in	O
women	O
(	O
mainly	O
in	O
Italy	O
)	O
who	O
did	O
not	O
have	O
breast	B-Entity
cancer	I-Entity
and	O
who	O
had	O
had	O
a	O
hysterectomy	O
.	O

Women	O
were	O
randomised	O
to	O
receive	O
tamoxifen	I-Entity
20	O
mg	O
per	O
day	O
or	O
placebo	O
,	O
both	O
orally	O
for	O
5	O
years	O
.	O

The	O
primary	O
endpoints	O
are	O
the	O
occurrence	O
of	O
and	O
deaths	O
from	O
breast	B-Entity
cancer	I-Entity
.	O

41	O
cases	O
of	O
breast	B-Entity
cancer	I-Entity
occurred	O
so	O
far	O
;	O
there	O
have	O
been	O
no	O
deaths	O
from	O
breast	B-Entity
cancer	I-Entity
.	O

There	O
is	O
no	O
difference	O
in	O
breast	B-Entity
-	I-Entity
cancer	I-Entity
frequency	O
between	O
the	O
placebo	O
(	O
22	O
cases	O
)	O
and	O
tamoxifen	I-Entity
(	O
19	O
)	O
arms	O
.	O

There	O
is	O
a	O
statistically	O
significant	O
reduction	O
of	O
breast	B-Entity
cancer	I-Entity
among	O
women	O
receiving	O
tamoxifen	I-Entity
who	O
also	O
used	O
hormone	O
-	O
replacement	O
therapy	O
during	O
the	O
trial	O
:	O
among	O
390	O
women	O
on	O
such	O
therapy	O
and	O
allocated	O
to	O
placebo	O
,	O
we	O
found	O
eight	O
cases	O
of	O
breast	B-Entity
cancer	I-Entity
compared	O
with	O
one	O
case	O
among	O
362	O
women	O
allocated	O
to	O
tamoxifen	I-Entity
.	O

Compared	O
with	O
the	O
placebo	O
group	O
,	O
there	O
was	O
a	O
significantly	O
increased	O
risk	O
of	O
vascular	B-Entity
events	I-Entity
and	O
hypertriglyceridaemia	I-Entity
among	O
women	O
on	O
tamoxifen	I-Entity
.	O

Although	O
this	O
preliminary	O
analysis	O
has	O
low	O
power	O
,	O
in	O
this	O
cohort	O
of	O
women	O
at	O
low	O
-	O
to	O
-	O
normal	O
risk	O
of	O
breast	B-Entity
cancer	I-Entity
,	O
the	O
postulated	O
protective	O
effects	O
of	O
tamoxifen	I-Entity
are	O
not	O
yet	O
apparent	O
.	O

Women	O
using	O
hormone	O
-	O
replacement	O
therapy	O
appear	O
to	O
have	O
benefited	O
from	O
use	O
of	O
tamoxifen	I-Entity
.	O

There	O
were	O
no	O
deaths	O
from	O
breast	B-Entity
cancer	I-Entity
recorded	O
in	O
women	O
in	O
the	O
study	O
.	O

It	O
is	O
essential	O
to	O
continue	O
follow	O
-	O
up	O
to	O
quantify	O
the	O
long	O
-	O
term	O
risks	O
and	O
benefits	O
of	O
tamoxifen	I-Entity
therapy	O
.	O



A	O
measure	O
of	O
pupillary	B-Entity
oscillation	I-Entity
as	O
a	O
marker	O
of	O
cocaine	I-Entity
-	O
induced	O
paranoia	I-Entity
.	O

Cocaine	I-Entity
-	O
induced	O
paranoia	I-Entity
(	O
CIP	I-Entity
)	O
remains	O
an	O
important	O
drug	O
-	O
induced	O
model	O
of	O
idiopathic	O
paranoia	I-Entity
for	O
which	O
no	O
psychophysiologic	O
marker	O
has	O
yet	O
emerged	O
.	O

Measures	O
of	O
pupillary	B-Entity
oscillation	I-Entity
were	O
able	O
to	O
significantly	O
distinguish	O
a	O
group	O
of	O
abstinent	O
crack	B-Entity
cocaine	I-Entity
abusers	O
endorsing	O
past	O
CIP	I-Entity
(	O
n	O
=	O
32	O
)	O
from	O
another	O
group	O
of	O
crack	I-Entity
addicts	O
who	O
denied	O
past	O
CIP	I-Entity
(	O
n	O
=	O
29	O
)	O
.	O



Seizures	I-Entity
induced	O
by	O
combined	O
levomepromazine	I-Entity
-	O
fluvoxamine	I-Entity
treatment	O
.	O

We	O
report	O
a	O
case	O
of	O
combined	O
levomepromazine	I-Entity
-	O
fluvoxamine	I-Entity
treatment	O
-	O
induced	O
seizures	I-Entity
.	O

It	O
seems	O
that	O
combined	O
treatment	O
of	O
fluvoxamine	I-Entity
with	O
phenothiazines	I-Entity
may	O
possess	O
proconvulsive	O
activity	O
.	O



Why	O
may	O
epsilon	B-Entity
-	I-Entity
aminocaproic	I-Entity
acid	I-Entity
(	O
EACA	I-Entity
)	O
induce	O
myopathy	I-Entity
in	O
man	O
?	O

A	O
case	O
of	O
necrotizing	B-Entity
myopathy	I-Entity
due	O
to	O
a	O
short	O
epsilon	B-Entity
-	I-Entity
aminocaproic	I-Entity
acid	I-Entity
(	O
EACA	I-Entity
)	O
treatment	O
in	O
a	O
72	O
year	O
-	O
old	O
patient	O
with	O
subarachnoid	B-Entity
haemorrhage	I-Entity
(	O
SAH	I-Entity
)	O
is	O
described	O
.	O



Comparison	O
of	O
the	O
effectiveness	O
of	O
ranitidine	I-Entity
and	O
cimetidine	I-Entity
in	O
inhibiting	O
acid	O
secretion	O
in	O
patients	O
with	O
gastric	O
hypersecretory	O
states	O
.	O

The	O
H2-histamine	I-Entity
receptor	O
antagonists	O
ranitidine	I-Entity
and	O
cimetidine	I-Entity
were	O
compared	O
for	O
their	O
abilities	O
to	O
control	O
gastric	O
acid	O
hypersecretion	O
on	O
a	O
short-	O
and	O
long	O
-	O
term	O
basis	O
in	O
22	O
patients	O
with	O
gastric	O
acid	O
hypersecretory	O
states	O
.	O

Nineteen	O
patients	O
had	O
Zollinger	B-Entity
-	I-Entity
Ellison	I-Entity
syndrome	I-Entity
,	O
one	O
patient	O
had	O
systemic	B-Entity
mastocytosis	I-Entity
,	O
and	O
two	O
patients	O
had	O
idiopathic	O
hypersecretion	O
.	O

The	O
rates	O
of	O
onset	O
of	O
the	O
action	O
of	O
cimetidine	I-Entity
and	O
ranitidine	I-Entity
were	O
the	O
same	O
.	O

However	O
,	O
ranitidine	I-Entity
was	O
threefold	O
more	O
potent	O
than	O
cimetidine	I-Entity
both	O
in	O
acute	O
inhibition	O
studies	O
and	O
in	O
the	O
median	O
maintenance	O
dose	O
needed	O
(	O
1.2	O
g	O
per	O
day	O
for	O
ranitidine	I-Entity
and	O
3.6	O
g	O
per	O
day	O
for	O
cimetidine	I-Entity
)	O
.	O

Sixty	O
percent	O
of	O
the	O
males	O
developed	O
breast	O
changes	O
or	O
impotence	I-Entity
while	O
taking	O
cimetidine	I-Entity
and	O
in	O
all	O
cases	O
these	O
changes	O
disappeared	O
when	O
cimetidine	I-Entity
was	O
replaced	O
by	O
ranitidine	I-Entity
.	O

Treatment	O
with	O
high	O
doses	O
of	O
cimetidine	I-Entity
(	O
one	O
to	O
60	O
months	O
;	O
median	O
,	O
11	O
months	O
)	O
or	O
ranitidine	I-Entity
(	O
two	O
to	O
31	O
months	O
;	O
median	O
,	O
14	O
months	O
)	O
was	O
not	O
associated	O
with	O
hepatic	B-Entity
or	I-Entity
hematologic	I-Entity
toxicity	I-Entity
or	O
alterations	O
of	O
serum	O
gastrin	O
concentrations	O
,	O
but	O
ranitidine	I-Entity
therapy	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
serum	O
creatinine	I-Entity
level	O
than	O
seen	O
with	O
cimetidine	I-Entity
therapy	O
.	O

Both	O
are	O
safe	O
at	O
high	O
doses	O
,	O
but	O
ranitidine	I-Entity
is	O
threefold	O
more	O
potent	O
and	O
does	O
not	O
cause	O
the	O
antiandrogen	O
side	O
effects	O
frequently	O
seen	O
with	O
high	O
doses	O
of	O
cimetidine	I-Entity
.	O



A	O
catch	O
in	O
the	O
Reye	I-Entity
.	O

Twenty	O
-	O
six	O
cases	O
of	O
Reye	B-Entity
syndrome	I-Entity
from	O
The	O
Children	O
's	O
Hospital	O
,	O
Camperdown	O
,	O
Australia	O
,	O
occurring	O
between	O
1973	O
and	O
1982	O
were	O
reviewed	O
.	O

Of	O
these	O
,	O
20	O
cases	O
met	O
the	O
US	O
Public	O
Health	O
Service	O
Centers	O
for	O
Disease	O
Control	O
criteria	O
for	O
the	O
diagnosis	O
of	O
Reye	B-Entity
syndrome	I-Entity
.	O

Aspirin	I-Entity
or	O
salicylate	I-Entity

ingestion	O
had	O
occurred	O
in	O
only	O
one	O
of	O
the	O
20	O
cases	O
(	O
5%	O
)	O
,	O
and	O
paracetamol	I-Entity
(	O
acetaminophen	I-Entity
)	O
had	O
been	O
administered	O
in	O
only	O
six	O
of	O
the	O
cases	O
(	O
30%	O
)	O
.	O

Pathologic	O
confirmation	O
of	O
the	O
diagnosis	O
of	O
Reye	B-Entity
syndrome	I-Entity
was	O
accomplished	O
in	O
90%	O
of	O
the	O
cases	O
.	O

The	O
incidence	O
of	O
Reye	B-Entity
syndrome	I-Entity
in	O
New	O
South	O
Wales	O
,	O
Australia	O
,	O
is	O
estimated	O
from	O
this	O
study	O
to	O
be	O
approximately	O
nine	O
cases	O
per	O
1	O
million	O
children	O
compared	O
with	O
recent	O
US	O
data	O
of	O
ten	O
to	O
20	O
cases	O
per	O
1	O
million	O
children	O
and	O
three	O
to	O
seven	O
cases	O
per	O
1	O
million	O
children	O
in	O
Great	O
Britain	O
.	O

The	O
mortality	O
for	O
these	O
Reye	B-Entity
syndrome	I-Entity
cases	O
in	O
Australia	O
was	O
45%	O
as	O
compared	O
with	O
a	O
32%	O
case	O
-	O
fatality	O
rate	O
in	O
the	O
United	O
States	O
.	O

In	O
Australia	O
,	O
the	O
pediatric	O
usage	O
of	O
aspirin	I-Entity
has	O
been	O
extremely	O
low	O
for	O
the	O
past	O
25	O
years	O
(	O
less	O
than	O
1%	O
of	O
total	O
dosage	O
units	O
sold	O
)	O
,	O
with	O
paracetamol	I-Entity
(	O
acetaminophen	I-Entity
)	O
dominating	O
the	O
pediatric	O
analgesic	O
and	O
antipyretic	O
market	O
.	O

Reye	B-Entity
syndrome	I-Entity
may	O
be	O
disappearing	O
from	O
Australia	O
despite	O
a	O
total	O
lack	O
of	O
association	O
with	O
salicylates	I-Entity
or	O
aspirin	I-Entity
ingestion	O
,	O
since	O
there	O
were	O
no	O
cases	O
found	O
at	O
The	O
Children	O
's	O
Hospital	O
in	O
1983	O
,	O
1984	O
,	O
or	O
1985	O
.	O



St.	B-Entity
Anthony	I-Entity
's	I-Entity
fire	I-Entity
,	O
then	O
and	O
now	O
:	O
a	O
case	O
report	O
and	O
historical	O
review	O
.	O

A	O
rare	O
case	O
of	O
morbid	O
vasospasm	I-Entity
,	O
together	O
with	O
striking	O
angiographic	O
findings	O
,	O
is	O
described	O
secondary	O
to	O
the	O
ingestion	O
of	O
methysergide	I-Entity
by	O
a	O
48-year	O
-	O
old	O
woman	O
.	O

A	O
discussion	O
of	O
the	O
history	O
of	O
ergot	I-Entity
includes	O
its	O
original	O
discovery	O
,	O
the	O
epidemics	O
of	O
gangrene	I-Entity
that	O
it	O
has	O
caused	O
through	O
the	O
ages	O
and	O
its	O
past	O
and	O
present	O
role	O
in	O
the	O
management	O
of	O
migraine	B-Entity
headache	I-Entity
.	O

Despite	O
the	O
advent	O
of	O
calcium	I-Entity
channel	O
blockers	O
and	O
beta	O
-	O
adrenergic	O
antagonists	O
,	O
ergot	I-Entity
preparations	O
continue	O
to	O
play	O
a	O
major	O
role	O
in	O
migraine	I-Entity
therapy	O
,	O
so	O
that	O
the	O
danger	O
of	O
St.	B-Entity
Anthony	I-Entity
's	I-Entity
fire	I-Entity
persists	O
.	O



Beta-2-adrenoceptor	O
-	O
mediated	O
hypokalemia	I-Entity
and	O
its	O
abolishment	O
by	O
oxprenolol	I-Entity
.	O

The	O
time	O
course	O
and	O
concentration	O
-	O
effect	O
relationship	O
of	O
terbutaline	I-Entity
-	O
induced	O
hypokalemia	I-Entity
was	O
studied	O
,	O
using	O
computer	O
-	O
aided	O
pharmacokinetic	O
-	O
dynamic	O
modeling	O
.	O

Subsequently	O
we	O
investigated	O
the	O
efficacy	O
of	O
oxprenolol	I-Entity
in	O
antagonizing	O
such	O
hypokalemia	I-Entity
,	O
together	O
with	O
the	O
pharmacokinetic	O
interaction	O
between	O
both	O
drugs	O
.	O

Six	O
healthy	O
subjects	O
were	O
given	O
a	O
0.5	O
mg	O
subcutaneous	O
dose	O
of	O
terbutaline	I-Entity
on	O
two	O
occasions	O
:	O
1	O
hour	O
after	O
oral	O
administration	O
of	O
a	O
placebo	O
and	O
1	O
hour	O
after	O
80	O
mg	O
oxprenolol	I-Entity
orally	O
.	O

In	O
the	O
7-hour	O
period	O
after	O
terbutaline	I-Entity
administration	O
,	O
plasma	O
samples	O
were	O
taken	O
for	O
determination	O
of	O
plasma	O
potassium	I-Entity
levels	O
and	O
drug	O
concentrations	O
.	O

The	O
sigmoid	O
Emax	O
model	O
offered	O
a	O
good	O
description	O
of	O
the	O
relation	O
between	O
terbutaline	I-Entity
concentrations	O
and	O
potassium	I-Entity
effects	O
.	O

Oxprenolol	I-Entity
caused	O
decreases	O
of	O
65%	O
and	O
56%	O
of	O
terbutaline	I-Entity
volume	O
of	O
distribution	O
and	O
clearance	O
,	O
respectively	O
,	O
and	O
an	O
increase	O
of	O
130%	O
of	O
its	O
AUC	O
.	O

In	O
spite	O
of	O
higher	O
terbutaline	I-Entity
concentrations	O
after	O
oxprenolol	I-Entity
pretreatment	O
,	O
the	O
hypokalemia	I-Entity
was	O
almost	O
completely	O
antagonized	O
by	O
the	O
beta	O
2-blocking	O
action	O
.	O



Midline	O
B3	O
serotonin	I-Entity
nerves	O
in	O
rat	O
medulla	O
are	O
involved	O
in	O
hypotensive	I-Entity
effect	O
of	O
methyldopa	I-Entity
.	O

Previous	O
experiments	O
in	O
this	O
laboratory	O
have	O
shown	O
that	O
microinjection	O
of	O
methyldopa	I-Entity
onto	O
the	O
ventrolateral	O
cells	O
of	O
the	O
B3	O
serotonin	I-Entity
neurons	O
in	O
the	O
medulla	O
elicits	O
a	O
hypotensive	I-Entity
response	O
mediated	O
by	O
a	O
projection	O
descending	O
into	O
the	O
spinal	O
cord	O
.	O

The	O
present	O
experiments	O
were	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
midline	O
cells	O
of	O
the	O
B3	O
serotonin	I-Entity
neurons	O
in	O
the	O
medulla	O
,	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O

In	O
spontaneously	O
hypertensive	I-Entity
,	O
stroke	I-Entity
-	O
prone	O
rats	O
,	O
microinjection	O
of	O
methyldopa	I-Entity
into	O
the	O
area	O
of	O
the	O
midline	O
B3	O
serotonin	I-Entity
cell	O
group	O
in	O
the	O
ventral	O
medulla	O
caused	O
a	O
potent	O
hypotension	I-Entity
of	O
30	O
-	O
40	O
mm	O
Hg	O
,	O
which	O
was	O
maximal	O
2	O
-	O
3	O
h	O
after	O
administration	O
and	O
was	O
abolished	O
by	O
the	O
serotonin	I-Entity
neurotoxin	O
5,7-dihydroxytryptamine	I-Entity
(	O
5,7-DHT	I-Entity
)	O
injected	O
intracerebroventricularly	O
.	O

However	O
,	O
intraspinal	O
injection	O
of	O
5,7-DHT	I-Entity
to	O
produce	O
a	O
more	O
selective	O
lesion	O
of	O
only	O
descending	O
serotonin	I-Entity
projections	O
in	O
the	O
spinal	O
cord	O
did	O
not	O
affect	O
this	O
hypotension	I-Entity
.	O

Further	O
,	O
5,7-DHT	I-Entity
lesion	O
of	O
serotonin	I-Entity
nerves	O
travelling	O
in	O
the	O
median	O
forebrain	O
bundle	O
,	O
one	O
of	O
the	O
main	O
ascending	O
pathways	O
from	O
the	O
B3	O
serotonin	I-Entity
cells	O
,	O
did	O
not	O
affect	O
the	O
fall	O
in	O
blood	O
pressure	O
associated	O
with	O
a	O
midline	O
B3	O
serotonin	I-Entity
methyldopa	I-Entity
injection	O
.	O

It	O
is	O
concluded	O
therefore	O
that	O
,	O
unlike	O
the	O
ventrolateral	O
B3	O
cells	O
which	O
mediate	O
a	O
methyldopa	I-Entity
-	O
induced	O
hypotension	I-Entity
via	O
descending	O
projections	O
,	O
the	O
midline	O
serotonin	I-Entity
B3	O
cells	O
in	O
the	O
medulla	O
contribute	O
to	O
the	O
hypotensive	I-Entity
action	O
of	O
methyldopa	I-Entity
,	O
either	O
by	O
way	O
of	O
an	O
ascending	O
projection	O
which	O
does	O
not	O
pass	O
through	O
the	O
median	O
forebrain	O
bundle	O
,	O
or	O
through	O
a	O
projection	O
restricted	O
to	O
the	O
caudal	O
brainstem	O
.	O



Yohimbine	I-Entity
treatment	O
of	O
sexual	B-Entity
side	I-Entity
effects	I-Entity
induced	O
by	O
serotonin	I-Entity
reuptake	O
blockers	O
.	O

:	O
Preclinical	O
and	O
clinical	O
studies	O
suggest	O
that	O
yohimbine	I-Entity
facilitates	O
sexual	O
behavior	O
and	O
may	O
be	O
helpful	O
in	O
the	O
treatment	O
of	O
male	B-Entity
impotence	I-Entity
.	O

A	O
single	O
case	O
report	O
suggests	O
that	O
yohimbine	I-Entity
may	O
be	O
used	O
to	O
treat	O
the	O
sexual	B-Entity
side	I-Entity
effects	I-Entity
of	O
clomipramine	I-Entity
.	O

This	O
study	O
evaluated	O
yohimbine	I-Entity
as	O
a	O
treatment	O
for	O
the	O
sexual	B-Entity
side	I-Entity
effects	I-Entity
caused	O
by	O
serotonin	I-Entity
reuptake	O
blockers	O
.	O

METHOD	O
:	O
Six	O
patients	O
with	O
either	O
obsessive	B-Entity
compulsive	I-Entity
disorder	I-Entity
,	O
trichotillomania	I-Entity
,	O
anxiety	I-Entity
,	O
or	O
affective	B-Entity
disorders	I-Entity
who	O
suffered	O
sexual	B-Entity
side	I-Entity
effects	I-Entity
after	O
treatment	O
with	O
serotonin	I-Entity
reuptake	O
blockers	O
were	O
given	O
yohimbine	I-Entity
on	O
a	O
p.r.n	O
.	O

Various	O
doses	O
of	O
yohimbine	I-Entity
were	O
used	O
to	O
determine	O
the	O
ideal	O
dose	O
for	O
each	O
patient	O
.	O

Five	O
of	O
the	O
six	O
patients	O
experienced	O
improved	O
sexual	O
functioning	O
after	O
taking	O
yohimbine	I-Entity
.	O

One	O
patient	O
who	O
failed	O
to	O
comply	O
with	O
yohimbine	I-Entity
treatment	O
had	O
no	O
therapeutic	O
effects	O
.	O

Side	O
effects	O
of	O
yohimbine	I-Entity
included	O
excessive	O
sweating	O
,	O
increased	O
anxiety	I-Entity
,	O
and	O
a	O
wound	O
-	O
up	O
feeling	O
in	O
some	O
patients	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
yohimbine	I-Entity
may	O
be	O
an	O
effective	O
treatment	O
for	O
the	O
sexual	B-Entity
side	I-Entity
effects	I-Entity
caused	O
by	O
serotonin	I-Entity
reuptake	O
blockers	O
.	O

Future	O
controlled	O
studies	O
are	O
needed	O
to	O
further	O
investigate	O
the	O
effectiveness	O
and	O
safety	O
of	O
yohimbine	I-Entity
for	O
this	O
indication	O
.	O



Hypersensitivity	I-Entity
immune	O
reaction	O
as	O
a	O
mechanism	O
for	O
dilevalol	I-Entity
-	O
associated	O
hepatitis	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
assess	O
lymphocyte	O
reactivity	O
to	O
dilevalol	I-Entity
and	O
to	O
serum	O
containing	O
putative	O
ex	O
vivo	O
dilevalol	I-Entity
antigens	O
or	O
metabolites	O
in	O
a	O
case	O
of	O
dilevalol	I-Entity
-	O
induced	O
liver	B-Entity
injury	I-Entity
.	O

A	O
58-year	O
-	O
old	O
woman	O
with	O
a	O
clinical	O
diagnosis	O
of	O
dilevalol	I-Entity
-	O
induced	O
liver	B-Entity
injury	I-Entity
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
collected	O
from	O
the	O
patient	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
a	O
solution	O
of	O
dilevalol	I-Entity
and	O
also	O
with	O
sera	O
collected	O
from	O
a	O
volunteer	O
before	O
and	O
after	O
dilevalol	I-Entity
intake	O
.	O

No	O
lymphocyte	O
proliferation	O
was	O
observed	O
either	O
in	O
the	O
patient	O
or	O
in	O
the	O
healthy	O
volunteer	O
in	O
the	O
presence	O
of	O
dilevalol	I-Entity
solutions	O
.	O

A	O
significant	O
proliferative	O
response	O
to	O
serum	O
collected	O
after	O
dilevalol	I-Entity
intake	O
was	O
observed	O
in	O
the	O
case	O
of	O
the	O
patient	O
compared	O
with	O
the	O
proliferative	O
response	O
to	O
the	O
serum	O
collected	O
before	O
the	O
drug	O
intake	O
.	O

The	O
methodology	O
used	O
allowed	O
the	O
detection	O
of	O
lymphocyte	O
sensitization	O
to	O
sera	O
containing	O
ex	O
vivo	O
-	O
prepared	O
dilevalol	I-Entity
antigens	O
,	O
suggesting	O
the	O
involvement	O
of	O
an	O
immunologic	O
mechanism	O
in	O
dilevalol	I-Entity
-	O
induced	O
liver	B-Entity
injury	I-Entity
.	O



Reversible	O
myocardial	B-Entity
hypertrophy	I-Entity
induced	O
by	O
tacrolimus	I-Entity
in	O
a	O
pediatric	O
heart	O
transplant	O
recipient	O
:	O
case	O
report	O
.	O

Tacrolimus	I-Entity
is	O
a	O
potent	O
immunosuppressant	O
that	O
is	O
frequently	O
used	O
in	O
organ	O
transplantation	O
.	O

However	O
,	O
adverse	O
effects	O
include	O
cardiac	B-Entity
toxicity	I-Entity
.	O

Herein	O
we	O
describe	O
transient	O
myocardial	B-Entity
hypertrophy	I-Entity
induced	O
by	O
tacrolimus	I-Entity
after	O
heart	O
transplantation	O
.	O

The	O
hypertrophy	I-Entity
caused	O
no	O
clinical	O
symptoms	O
but	O
was	O
noted	O
because	O
of	O
elevation	O
of	O
plasma	O
brain	O
natriuretic	O
peptide	O
concentration	O
and	O
confirmed	O
at	O
echocardiography	O
.	O

Initially	O
,	O
allograft	O
rejection	O
was	O
feared	O
;	O
however	O
,	O
myocardial	O
biopsy	O
samples	O
revealed	O
only	O
interstitial	O
edema	I-Entity
and	O
mild	O
myocardial	B-Entity
hypertrophy	I-Entity
;	O
neither	O
cellular	O
nor	O
humoral	O
rejection	O
was	O
detected	O
.	O

The	O
blood	O
tacrolimus	I-Entity
concentration	O
was	O
higher	O
than	O
usual	O
at	O
that	O
time	O
;	O
thus	O
,	O
tacrolimus	I-Entity
dosage	O
was	O
reduced	O
.	O

Myocardial	B-Entity
hypertrophy	I-Entity
completely	O
resolved	O
upon	O
reducing	O
the	O
target	O
concentration	O
of	O
tacrolimus	I-Entity
and	O
did	O
not	O
recur	O
,	O
as	O
confirmed	O
at	O
echocardiography	O
and	O
myocardial	O
biopsy	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
tacrolimus	I-Entity
induces	O
reversible	O
myocardial	B-Entity
hypertrophy	I-Entity
.	O

In	O
patients	O
receiving	O
tacrolimus	I-Entity
therapy	O
,	O
blood	O
concentration	O
should	O
be	O
carefully	O
controlled	O
and	O
extreme	O
attention	O
paid	O
to	O
cardiac	O
involvement	O
.	O



Comparison	O
of	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
findings	O
in	O
advanced	O
idiopathic	B-Entity
Parkinson	I-Entity
's	I-Entity
disease	I-Entity
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
pilot	O
study	O
to	O
compare	O
the	O
results	O
of	O
stereotactic	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
in	O
advanced	O
idiopathic	B-Entity
Parkinson	I-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
refractory	O
to	O
medical	O
treatment	O
was	O
designed	O
.	O

3.5	O
years	O
)	O
,	O
disabling	O
motor	O
fluctuations	O
(	O
Hoehn	O
_	O
Yahr	O
stage	O
3	O
-	O
5	O
in	O
off	O
-	O
drug	O
phases	O
)	O
and	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
were	O
selected	O
.	O

All	O
patients	O
had	O
bilateral	O
symptoms	O
and	O
their	O
levodopa	I-Entity
equivalent	O
dosing	O
were	O
analysed	O
.	O

Clinical	O
evaluation	O
included	O
the	O
use	O
of	O
the	O
Unified	O
Parkinson	B-Entity
's	I-Entity
Disease	I-Entity
Rating	O
Scale	O
(	O
UPDRS	O
)	O
,	O
Hoehn_Yahr	O
score	O
and	O
Schwab	O
England	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
score	O
in	O
'	O
on'-	O
and	O
'	O
off'-drug	O
conditions	O
before	O
surgery	O
and	O
6	O
months	O
after	O
surgery	O
.	O

There	O
was	O
statistically	O
significant	O
improvement	O
in	O
all	O
contralateral	O
major	O
parkinsonian	I-Entity
motor	O
signs	O
in	O
all	O
patients	O
followed	O
for	O
6	O
months	O
.	O

Levodopa	I-Entity
equivalent	O
daily	O
intake	O
was	O
significantly	O
reduced	O
in	O
the	O
STN	O
group	O
.	O

Complications	O
were	O
observed	O
in	O
two	O
patients	O
:	O
one	O
had	O
a	O
left	O
homonymous	B-Entity
hemianopsia	I-Entity
after	O
pallidotomy	O
and	O
another	O
one	O
developed	O
left	O
hemiballistic	O
movements	O
3	O
days	O
after	O
subthalamotomy	O
which	O
partly	O
improved	O
within	O
1	O
month	O
with	O
Valproate	I-Entity
1000	O
mg	O
/	O
day	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
lesions	O
of	O
the	O
unilateral	O
STN	O
and	O
GPi	O
are	O
equally	O
effective	O
treatment	O
for	O
patients	O
with	O
advanced	O
PD	I-Entity
refractory	O
to	O
medical	O
treatment	O
.	O



Protective	O
effects	O
of	O
antithrombin	O
on	O
puromycin	B-Entity
aminonucleoside	I-Entity
nephrosis	I-Entity
in	O
rats	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
antithrombin	O
,	O
a	O
plasma	O
inhibitor	O
of	O
coagulation	O
factors	O
,	O
in	O
rats	O
with	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
nephrosis	I-Entity
,	O
which	O
is	O
an	O
experimental	O
model	O
of	O
human	O
nephrotic	B-Entity
syndrome	I-Entity
.	O

Antithrombin	O
(	O
50	O
or	O
500	O
IU	O
/	O
kg	O
/	O
i.v	O
.	O
)	O
was	O
administered	O
to	O
rats	O
once	O
a	O
day	O
for	O
10	O
days	O
immediately	O
after	O
the	O
injection	O
of	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
50	O
mg	O
/	O
kg	O
/	O
i.v	O
.	O
)	O
.	O

Treatment	O
with	O
antithrombin	O
attenuated	O
the	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
hematological	B-Entity
abnormalities	I-Entity
.	O

Puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
renal	B-Entity
dysfunction	I-Entity
and	O
hyperlipidemia	I-Entity
were	O
also	O
suppressed	O
.	O

Histopathological	O
examination	O
revealed	O
severe	O
renal	B-Entity
damage	I-Entity
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	O
expansion	O
in	O
the	O
kidney	O
of	O
control	O
rats	O
,	O
while	O
an	O
improvement	O
of	O
the	O
damage	O
was	O
seen	O
in	O
antithrombin	O
-	O
treated	O
rats	O
.	O

In	O
addition	O
,	O
antithrombin	O
treatment	O
markedly	O
suppressed	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
apoptosis	O
of	O
renal	O
tubular	O
epithelial	O
cells	O
.	O

Furthermore	O
,	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
increases	O
in	O
renal	O
cytokine	O
content	O
were	O
also	O
decreased	O
.	O

These	O
findings	O
suggest	O
that	O
thrombin	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
nephrotic	B-Entity
syndrome	I-Entity
.	O

Treatment	O
with	O
antithrombin	O
may	O
be	O
clinically	O
effective	O
in	O
patients	O
with	O
nephrotic	B-Entity
syndrome	I-Entity
.	O



Reverse	O
or	O
inverted	O
left	B-Entity
ventricular	I-Entity
apical	I-Entity
ballooning	I-Entity
syndrome	I-Entity
(	O
reverse	O
Takotsubo	B-Entity
cardiomyopathy	I-Entity
)	O
in	O
a	O
young	O
woman	O
in	O
the	O
setting	O
of	O
amphetamine	I-Entity
use	O
.	O

Transient	O
left	B-Entity
ventricular	I-Entity
apical	I-Entity
ballooning	I-Entity
syndrome	I-Entity
was	O
first	O
described	O
in	O
Japan	O
as	O
""""	O
Takotsubo	B-Entity
cardiomyopathy	I-Entity
.	O

One	O
of	O
the	O
rarest	O
is	O
the	O
reverse	O
type	O
of	O
this	O
syndrome	O
,	O
with	O
hyperdynamic	O
apex	O
and	O
complete	O
akinesia	I-Entity
of	O
the	O
base	O
(	O
as	O
opposed	O
to	O
the	O
classic	O
apical	B-Entity
ballooning	I-Entity
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
an	O
interesting	O
case	O
of	O
a	O
young	O
woman	O
who	O
presented	O
with	O
this	O
rare	O
type	O
of	O
reverse	O
apical	B-Entity
ballooning	I-Entity
syndrome	I-Entity
occurring	O
after	O
amphetamine	I-Entity
use	O
.	O



Attenuated	O
disruption	O
of	O
prepulse	O
inhibition	O
by	O
dopaminergic	O
stimulation	O
after	O
maternal	O
deprivation	O
and	O
adolescent	O
corticosterone	I-Entity
treatment	O
in	O
rats	O
.	O

The	O
development	O
of	O
schizophrenia	I-Entity
may	O
include	O
an	O
early	O
neurodevelopmental	O
stress	O
component	O
which	O
increases	O
vulnerability	O
to	O
later	O
stressful	O
life	O
events	O
,	O
in	O
combination	O
leading	O
to	O
overt	O
disease	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
an	O
early	O
stress	O
,	O
in	O
the	O
form	O
of	O
maternal	O
deprivation	O
,	O
combined	O
with	O
a	O
later	O
stress	O
,	O
simulated	O
by	O
chronic	O
periadolescent	O
corticosterone	I-Entity
treatment	O
,	O
on	O
behaviour	O
in	O
rats	O
.	O

Acute	O
treatment	O
with	O
apomorphine	I-Entity
caused	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
controls	O
and	O
in	O
rats	O
that	O
had	O
undergone	O
either	O
maternal	O
deprivation	O
or	O
corticosterone	I-Entity
treatment	O
,	O
but	O
was	O
surprisingly	O
absent	O
in	O
rats	O
that	O
had	O
undergone	O
the	O
combined	O
early	O
and	O
late	O
stress	O
.	O

Amphetamine	I-Entity
treatment	O
significantly	O
disrupted	O
PPI	O
in	O
both	O
non	O
-	O
deprived	O
groups	O
,	O
but	O
was	O
absent	O
in	O
both	O
maternally	O
deprived	O
groups	O
.	O

The	O
serotonin-1A	I-Entity
receptor	O
agonist	O
,	O
8-OH	B-Entity
-	I-Entity
DPAT	I-Entity
,	O
induced	O
a	O
significant	O
disruption	O
of	O
PPI	O
in	O
all	O
groups	O
.	O

Amphetamine	I-Entity
-	O
induced	O
locomotor	B-Entity
hyperactivity	I-Entity
was	O
similar	O
in	O
all	O
groups	O
.	O

These	O
results	O
show	O
an	O
inhibitory	O
interaction	O
of	O
early	O
stress	O
,	O
caused	O
by	O
maternal	O
deprivation	O
,	O
combined	O
with	O
'	O
adolescent	O
'	O
stress	O
,	O
simulated	O
by	O
corticosterone	I-Entity
treatment	O
,	O
on	O
dopaminergic	O
regulation	O
of	O
PPI	O
.	O

The	O
altered	O
effects	O
of	O
apomorphine	I-Entity
and	O
amphetamine	I-Entity
could	O
indicate	O
differential	O
changes	O
in	O
dopamine	I-Entity
receptor	O
signalling	O
leading	O
to	O
functional	O
desensitisation	O
,	O
or	O
altered	O
modulation	O
of	O
sensory	O
gating	O
in	O
the	O
nucleus	O
accumbens	O
by	O
limbic	O
structures	O
such	O
as	O
the	O
hippocampus	O
.	O



Peripheral	O
iron	B-Entity
dextran	I-Entity
induced	O
degeneration	B-Entity
of	I-Entity
dopaminergic	I-Entity
neurons	I-Entity
in	O
rat	O
substantia	O
nigra	O
.	O

Iron	I-Entity
accumulation	O
is	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

To	O
demonstrate	O
the	O
relationship	O
between	O
peripheral	O
iron	I-Entity
overload	O
and	O
dopaminergic	O
neuron	O
loss	O
in	O
rat	O
substantia	O
nigra	O
(	O
SN	O
)	O
,	O
in	O
the	O
present	O
study	O
we	O
used	O
fast	O
cyclic	O
voltammetry	O
,	O
tyrosine	I-Entity
hydroxylase	O
(	O
TH	O
)	O

immunohistochemistry	O
,	O
Perls	O
'	O
iron	I-Entity
staining	O
,	O
and	O
high	O
performance	O
liquid	O
chromatography	O
-	O
electrochemical	O
detection	O
to	O
study	O
the	O
degeneration	B-Entity
of	I-Entity
dopaminergic	I-Entity
neurons	I-Entity
and	O
increased	O
iron	I-Entity
content	O
in	O
the	O
SN	O
of	O
iron	B-Entity
dextran	I-Entity
overloaded	O
animals	O
.	O

The	O
findings	O
showed	O
that	O
peripheral	O
iron	B-Entity
dextran	I-Entity
overload	O
increased	O
the	O
iron	I-Entity
staining	O
positive	O
cells	O
and	O
reduced	O
the	O
number	O
of	O
TH	O
-	O
immunoreactive	O
neurons	O
in	O
the	O
SN	O
.	O

As	O
a	O
result	O
,	O
dopamine	I-Entity
release	O
and	O
content	O
,	O
as	O
well	O
as	O
its	O
metabolites	O
contents	O
were	O
decreased	O
in	O
caudate	O
putamen	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
iron	B-Entity
dextran	I-Entity
can	O
increase	O
the	O
iron	I-Entity
level	O
in	O
the	O
SN	O
,	O
where	O
excessive	O
iron	I-Entity
causes	O
the	O
degeneration	B-Entity
of	I-Entity
dopaminergic	I-Entity
neurons	I-Entity
.	O

The	O
chronic	O
iron	I-Entity
overload	O
may	O
be	O
more	O
destructive	O
to	O
dopaminergic	O
neurons	O
than	O
the	O
acute	O
iron	I-Entity
overload	O
.	O



Warfarin	I-Entity
-	O
induced	O
leukocytoclastic	B-Entity
vasculitis	I-Entity
.	O

Skin	O
reactions	O
associated	O
with	O
oral	O
coumarin	I-Entity
-	O
derived	O
anticoagulants	O
are	O
an	O
uncommon	O
occurrence	O
.	O

Leukocytoclastic	B-Entity
vasculitis	I-Entity
(	O
LV	I-Entity
)	O
is	O
primarily	O
a	O
cutaneous	B-Entity
small	I-Entity
vessel	I-Entity
vasculitis	I-Entity
,	O
though	O
systemic	O
involvement	O
may	O
be	O
encountered	O
.	O

We	O
report	O
4	O
patients	O
with	O
late	O
-	O
onset	O
LV	I-Entity
probably	O
due	O
to	O
warfarin	I-Entity
.	O

All	O
4	O
patients	O
presented	O
with	O
skin	B-Entity
eruptions	I-Entity
that	O
developed	O
after	O
receiving	O
warfarin	I-Entity
for	O
several	O
years	O
.	O

The	O
results	O
of	O
skin	B-Entity
lesion	I-Entity
biopsies	O
were	O
available	O
in	O
3	O
patients	O
,	O
confirming	O
LV	B-Entity
Cutaneous	I-Entity
lesions	I-Entity
resolved	O
in	O
all	O
patients	O
after	O
warfarin	I-Entity
was	O
discontinued	O
.	O

In	O
2	O
of	O
the	O
4	O
patients	O
,	O
rechallenge	O
with	O
warfarin	I-Entity
led	O
to	O
recurrence	O
of	O
the	O
lesions	O
.	O

LV	I-Entity
may	O
be	O
a	O
late	O
-	O
onset	O
adverse	O
reaction	O
associated	O
with	O
warfarin	I-Entity
therapy	O
.	O



The	O
activation	O
of	O
spinal	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
receptors	O
may	O
contribute	O
to	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
induced	O
by	O
neuraxial	O
morphine	I-Entity
after	O
a	O
noninjurious	O
interval	O
of	O
spinal	B-Entity
cord	I-Entity
ischemia	I-Entity
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
and	O
activation	O
of	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
d	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O
receptors	O
after	O
neuraxial	O
morphine	I-Entity
following	O
a	O
noninjurious	O
interval	O
of	O
aortic	B-Entity
occlusion	I-Entity
in	O
rats	O
.	O

Spinal	B-Entity
cord	I-Entity
ischemia	I-Entity
was	O
induced	O
by	O
aortic	B-Entity
occlusion	I-Entity
for	O
6	O
min	O
with	O
a	O
balloon	O
catheter	O
.	O

In	O
a	O
microdialysis	O
study	O
,	O
10	O
muL	O
of	O
saline	O
(	O
group	O
C	O
;	O
n	O
=	O
8)	O
or	O
30	O
mug	O
of	O
morphine	I-Entity
(	O
group	O
M	O
;	O
n	O

=	O
8)	O
was	O
injected	O
intrathecally	O
(	O
IT	O
)	O
0.5	O
h	O
after	O
reflow	O
,	O
and	O
30	O
mug	O
of	O
morphine	I-Entity
(	O
group	O
SM	O
;	O

Second	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
IT	O
MK-801	I-Entity
(	O
30	O
mug	O
)	O
on	O
the	O
histopathologic	O
changes	O
in	O
the	O
spinal	O
cord	O
after	O
morphine	I-Entity
-	O
induced	O
spastic	B-Entity
paraparesis	I-Entity
.	O

After	O
IT	O
morphine	I-Entity
,	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
glutamate	I-Entity
concentration	O
was	O
increased	O
in	O
group	O
M	O
relative	O
to	O
both	O
baseline	O
and	O
group	O
C	O
(	O
P	O
<	O
0.05	O
)	O
.	O

IT	O
MK-801	I-Entity
significantly	O
reduced	O
the	O
number	O
of	O
dark	O
-	O
stained	O
alpha	O
-	O
motoneurons	O
after	O
morphine	I-Entity
-	O
induced	O
spastic	B-Entity
paraparesis	I-Entity
compared	O
with	O
the	O
saline	O
group	O
.	O

These	O
data	O
indicate	O
that	O
IT	O
morphine	I-Entity
induces	O
spastic	B-Entity
paraparesis	I-Entity
with	O
a	O
concomitant	O
increase	O
in	O
CSF	O
glutamate	I-Entity
,	O
which	O
is	O
involved	O
in	O
NMDA	I-Entity
receptor	O
activation	O
.	O

We	O
suggest	O
that	O
opioids	O
may	O
be	O
neurotoxic	I-Entity
in	O
the	O
setting	O
of	O
spinal	B-Entity
cord	I-Entity
ischemia	I-Entity
via	O
NMDA	I-Entity
receptor	O
activation	O
.	O



Reduced	O
sodium	I-Entity
channel	O
density	O
,	O
altered	O
voltage	O
dependence	O
of	O
inactivation	O
,	O
and	O
increased	O
susceptibility	O
to	O
seizures	I-Entity
in	O
mice	O
lacking	O
sodium	I-Entity
channel	O
beta	O
2-subunits	O
.	O

Sodium	I-Entity
channel	O
beta	O
-	O
subunits	O
modulate	O
channel	O
gating	O
,	O
assembly	O
,	O
and	O
cell	O
surface	O
expression	O
in	O
heterologous	O
cell	O
systems	O
.	O

We	O
generated	O
beta2(-/-	O
)	O
mice	O
to	O
investigate	O
the	O
role	O
of	O
beta2	O
in	O
control	O
of	O
sodium	I-Entity
channel	O
density	O
,	O
localization	O
,	O
and	O
function	O
in	O
neurons	O
in	O
vivo	O
.	O

Measurements	O
of	O
[	O
(	O
3)H]saxitoxin	I-Entity
(	O
STX	I-Entity
)	O
binding	O
showed	O
a	O
significant	O
reduction	O
in	O
the	O
level	O
of	O
plasma	O
membrane	O
sodium	I-Entity
channels	O
in	O
beta2(-/-	O
)	O
neurons	O
.	O

The	O
loss	O
of	O
beta2	O
resulted	O
in	O
negative	O
shifts	O
in	O
the	O
voltage	O
dependence	O
of	O
inactivation	O
as	O
well	O
as	O
significant	O
decreases	O
in	O
sodium	I-Entity
current	O
density	O
in	O
acutely	O
dissociated	O
hippocampal	O
neurons	O
.	O

The	O
integral	O
of	O
the	O
compound	O
action	O
potential	O
in	O
optic	O
nerve	O
was	O
significantly	O
reduced	O
,	O
and	O
the	O
threshold	O
for	O
action	O
potential	O
generation	O
was	O
increased	O
,	O
indicating	O
a	O
reduction	O
in	O
the	O
level	O
of	O
functional	O
plasma	O
membrane	O
sodium	I-Entity
channels	O
.	O

In	O
contrast	O
,	O
the	O
conduction	O
velocity	O
,	O
the	O
number	O
and	O
size	O
of	O
axons	O
in	O
the	O
optic	O
nerve	O
,	O
and	O
the	O
specific	O
localization	O
of	O
Na(v)1.6	I-Entity
channels	O
in	O
the	O
nodes	O
of	O
Ranvier	O
were	O
unchanged	O
.	O

beta2(-/-	O
)	O
mice	O
displayed	O
increased	O
susceptibility	O
to	O
seizures	I-Entity
,	O
as	O
indicated	O
by	O
reduced	O
latency	O
and	O
threshold	O
for	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
,	O
but	O
seemed	O
normal	O
in	O
other	O
neurological	O
tests	O
.	O

Our	O
observations	O
show	O
that	O
beta2-subunits	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
sodium	I-Entity
channel	O
density	O
and	O
function	O
in	O
neurons	O
in	O
vivo	O
and	O
are	O
required	O
for	O
normal	O
action	O
potential	O
generation	O
and	O
control	O
of	O
excitability	O
.	O



Screening	O
for	O
stimulant	O
use	O
in	O
adult	O
emergency	O
department	O
seizure	I-Entity
patients	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
positive	O
plasma	O
drug	O
screening	O
for	O
cocaine	I-Entity
or	O
amphetamine	I-Entity
in	O
adult	O
emergency	O
department	O
seizure	I-Entity
patients	O
.	O

This	O
prospective	O
study	O
evaluated	O
consecutive	O
eligible	O
seizure	I-Entity
patients	O
who	O
had	O
a	O
plasma	O
sample	O
collected	O
as	O
part	O
of	O
their	O
clinical	O
evaluation	O
.	O

Plasma	O
was	O
tested	O
for	O
amphetamine	I-Entity
and	O
the	O
cocaine	I-Entity
metabolite	O
benzoylecgonine	I-Entity

Plasma	O
samples	O
with	O
benzoylecgonine	I-Entity
greater	O
than	O
150	O
ng	O
/	O
mL	O
or	O
an	O
amphetamine	I-Entity
greater	O
than	O
500	O
ng	O
/	O
mL	O
were	O
defined	O
as	O
positive	O
.	O

Patient	O
demographics	O
,	O
history	O
of	O
underlying	O
drug	O
or	O
alcohol	I-Entity
-	O
related	O
seizure	I-Entity
disorder	O
,	O
estimated	O
time	O
from	O
seizure	I-Entity
to	O
sample	O
collection	O
,	O
history	O
or	O
suspicion	O
of	O
cocaine	B-Entity
or	I-Entity
amphetamine	I-Entity
abuse	I-Entity
,	O
results	O
of	O
clinical	O
urine	O
testing	O
for	O
drugs	O
of	O
abuse	O
,	O
and	O
assay	O
results	O
were	O
recorded	O
without	O
patient	O
identifiers	O
.	O

Fourteen	O
of	O
248	O
(	O
5.6%	O
,	O
95%	O
CI	O
2.7%-8.5%	O
)	O
plasma	O
samples	O
were	O
positive	O
by	O
immunoassay	O
testing	O
for	O
benzoylecgonine	I-Entity
and	O
no	O
samples	O
(	O
0%	O
,	O
95%	O
CI	O
0	O
-	O
1.2%	O
)	O
were	O
positive	O
for	O
amphetamine	I-Entity
.	O

Positive	O
test	O
results	O
were	O
more	O
common	O
in	O
patient	O
visits	O
where	O
there	O
was	O
a	O
history	O
or	O
suspicion	O
of	O
cocaine	B-Entity
or	I-Entity
amphetamine	I-Entity
abuse	I-Entity
(	O
p	O

During	O
this	O
study	O
period	O
,	O
routine	O
plasma	O
screening	O
for	O
cocaine	I-Entity
and	O
amphetamines	I-Entity
in	O
adult	O
seizure	I-Entity
patients	O
had	O
a	O
low	O
yield	O
.	O

As	O
a	O
result	O
,	O
routine	O
plasma	O
screening	O
would	O
yield	O
few	O
cases	O
of	O
stimulant	O
drug	O
in	O
which	O
there	O
was	O
neither	O
a	O
history	O
nor	O
suspicion	O
of	O
drug	B-Entity
abuse	I-Entity
in	O
this	O
population	O
.	O



The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
functional	O
anatomy	O
of	O
the	O
globus	O
pallidus	O
internus	O
(	O
GPi	O
)	O
by	O
studying	O
the	O
effects	O
of	O
unilateral	O
pallidotomy	O
on	O
parkinsonian	I-Entity
'	O
off	O
'	O
signs	O
and	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
(	O
LID	I-Entity
)	O
.	O

We	O
found	O
significant	O
positive	O
correlations	O
between	O
the	O
preoperative	O
levodopa	I-Entity
responsiveness	O
of	O
motor	O
signs	O
and	O
the	O
levodopa	I-Entity
responsiveness	O
of	O
scores	O
in	O
timed	O
tests	O
(	O
Core	O
Assessment	O
Program	O
for	O
Intracerebral	O
Transplantations	O
)	O
in	O
the	O
contralateral	O
limbs	O
and	O
the	O
improvement	O
in	O
these	O
scores	O
after	O
surgery	O
,	O
whereas	O
there	O
was	O
no	O
correlation	O
with	O
the	O
improvement	O
in	O
LID	I-Entity
.	O

0.0001	O
,	O
r	O
=	O
0.8	O
)	O
between	O
the	O
volume	O
of	O
the	O
ventral	O
lesion	O
in	O
the	O
GPi	O
and	O
the	O
improvement	O
in	O
LID	I-Entity
in	O
the	O
contralateral	O
limbs	O
,	O
whereas	O
there	O
was	O
no	O
correlation	O
between	O
the	O
ventral	O
volume	O
and	O
the	O
improvement	O
in	O
parkinsonian	I-Entity
'	O
off	O
'	O
signs	O
.	O

The	O
volumes	O
of	O
the	O
total	O
lesion	O
cylinder	O
and	O
the	O
dorsal	O
lesion	O
did	O
not	O
correlate	O
with	O
the	O
outcome	O
of	O
either	O
dyskinesias	I-Entity
or	O
parkinsonian	I-Entity
'	O
off	O
'	O
signs	O
.	O

The	O
differential	O
predictive	O
value	O
of	O
levodopa	I-Entity
responsiveness	O
for	O
the	O
outcome	O
of	O
parkinsonian	I-Entity
'	O
off	O
'	O
signs	O
and	O
LID	I-Entity
and	O
the	O
different	O
correlations	O
of	O
ventral	O
lesion	O
volume	O
with	O
dyskinesias	I-Entity
and	O
parkinsonian	I-Entity
'	O
off	O
'	O
signs	O
indicate	O
that	O
different	O
anatomical	O
or	O
pathophysiological	O
substrates	O
may	O
be	O
responsible	O
for	O
the	O
generation	O
of	O
parkinsonian	I-Entity
'	O
off	O
'	O
signs	O
and	O
dyskinesias	I-Entity
.	O

Whereas	O
cells	O
in	O
a	O
wider	O
area	O
of	O
the	O
GPi	O
may	O
be	O
implicated	O
in	O
parkinsonism	I-Entity
,	O
the	O
ventral	O
GPi	O
seems	O
to	O
be	O
crucial	O
for	O
the	O
manifestation	O
of	O
LID	I-Entity
.	O

We	O
suggest	O
that	O
our	O
observations	O
are	O
additional	O
proof	O
of	O
the	O
functional	O
somatotopy	O
of	O
the	O
systems	O
within	O
the	O
GPi	O
that	O
mediate	O
parkinsonism	I-Entity
and	O
dyskinesias	I-Entity
,	O
especially	O
along	O
the	O
dorsoventral	O
trajectory	O
used	O
in	O
pallidotomy	O
.	O



Pain	I-Entity
responses	O
in	O
methadone	I-Entity
-	O
maintained	O
opioid	O
abusers	O
.	O

Providing	O
pain	I-Entity
management	O
for	O
known	O
opioid	O
abusers	O
is	O
a	O
challenging	O
clinical	O
task	O
,	O
in	O
part	O
because	O
little	O
is	O
known	O
about	O
their	O
pain	I-Entity
experience	O
and	O
analgesic	O
requirements	O
.	O

This	O
study	O
was	O
designed	O
to	O
describe	O
pain	I-Entity
tolerance	O
and	O
analgesic	O
response	O
in	O
a	O
sample	O
of	O
opioid	B-Entity
addicts	I-Entity
stabilized	O
in	O
methadone	I-Entity
-	O
maintenance	O
(	O
MM	O
)	O
treatment	O
(	O
n	O
=	O
60	O
)	O
in	O
comparison	O
to	O
matched	O
nondependent	O
control	O
subjects	O
(	O
n	O
=	O
60	O
)	O
.	O

By	O
using	O
a	O
placebo	O
-	O
controlled	O
,	O
two	O
-	O
way	O
factorial	O
design	O
,	O
tolerance	O
to	O
cold	O
-	O
pressor	O
(	O
CP	O
)	O
pain	I-Entity
was	O
examined	O
,	O
both	O
before	O
and	O
after	O
oral	O
administration	O
of	O
therapeutic	O
doses	O
of	O
common	O
opioid	O
(	O
hydromorphone	I-Entity
2	O
mg	O
)	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
(	O
ketorolac	I-Entity
10	O
mg	O
)	O
analgesic	O
agents	O
.	O

Results	O
showed	O
that	O
MM	O
individuals	O
were	O
significantly	O
less	O
tolerant	O
of	O
CP	O
pain	I-Entity
than	O
control	O
subjects	O
,	O
replicating	O
previous	O
work	O
.	O

These	O
data	O
indicate	O
that	O
MM	O
opioid	O
abusers	O
represent	O
a	O
pain	B-Entity
-	I-Entity
intolerant	I-Entity
subset	O
of	O
clinical	O
patients	O
.	O

Their	O
complaints	O
of	O
pain	I-Entity
should	O
be	O
evaluated	O
seriously	O
and	O
managed	O
aggressively	O
.	O



Although	O
an	O
indicator	O
of	O
renal	B-Entity
tubular	I-Entity
dysfunction	I-Entity
,	O
an	O
increased	O
urinary	O
N	O
-	O
acetyl	O
-	O
beta	O

Puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN	I-Entity
)	O
was	O
administered	O
to	O
Sprague	O
Dawley	O
rats	O
to	O
induce	O
proteinuria	I-Entity
.	O

Following	O
intravenous	O
PAN	I-Entity
urine	O
volume	O
and	O
urine	O
NAG	O
activity	O
increased	O
significantly	O
by	O
day	O
two	O
,	O
but	O
returned	O
to	O
normal	O
by	O
day	O
four	O
.	O

Peak	O
urine	O
NAG	O
activity	O
and	O
a	O
change	O
in	O
NAG	O
isoenzyme	O
pattern	O
coincided	O
with	O
both	O
the	O
peak	O
proteinuria	I-Entity
and	O
the	O
reduction	O
in	O
intracellular	O
protein	O
and	O
NAG	O
droplets	O
(	O
day	O
six	O
onwards	O
)	O
.	O



Over	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
its	O
receptor	O
during	O
the	O
development	O
of	O
estrogen	I-Entity
-	O
induced	O
rat	O
pituitary	B-Entity
tumors	I-Entity
may	O
mediate	O
estrogen	I-Entity
-	O
initiated	O
tumor	I-Entity
angiogenesis	O
.	O

Estrogens	I-Entity
,	O
which	O
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
human	O
and	O
animal	O
cancers	I-Entity
,	O
can	O
induce	O
tumor	I-Entity
angiogenesis	O
in	O
the	O
pituitary	O
of	O
Fischer	O
344	O
rats	O
.	O

The	O
mechanistic	O
details	O
of	O
tumor	I-Entity
angiogenesis	O
induction	O
,	O
during	O
estrogen	I-Entity
carcinogenesis	I-Entity
,	O
are	O
still	O
unknown	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
estrogen	I-Entity
in	O
the	O
regulation	O
of	O
tumor	I-Entity
angiogenesis	O
in	O
the	O
pituitary	O
of	O
female	O
rats	O
,	O
the	O
density	O
of	O
blood	O
vessels	O
was	O
analysed	O
using	O
factor	O
VIII	O
related	O
antigen	O
(	O
FVIIIRAg	O
)	O
immunohistochemistry	O
and	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
/	O
vascular	O
permeability	O
factor	O
(	O
VEGF	O
/	O
VPF	O
)	O
was	O
examined	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
analysis	O
.	O

The	O
results	O
demonstrated	O
that	O
17beta	B-Entity
-	I-Entity
estradiol	I-Entity
(	O
E2	I-Entity
)	O
induces	O
neovascularization	O
,	O
as	O
well	O
as	O
the	O
growth	O
and	O
enlargement	O
of	O
blood	O
vessels	O
after	O
7	O
days	O
of	O
exposure	O
.	O

The	O
high	O
tumor	I-Entity
angiogenic	O
potential	O
was	O
associated	O
with	O
an	O
elevated	O
VEGF	O
/	O
VPF	O
protein	O
expression	O
in	O
the	O
E2	I-Entity
exposed	O
pituitary	O
of	O
ovariectomized	O
(	O
OVEX	O
)	O
rats	O
.	O

After	O
15	O
days	O
of	O
E2	I-Entity
exposure	O
,	O
VEGF	O
/	O
VPF	O
protein	O
expression	O
,	O
in	O
the	O
non	O
-	O
endothelial	O
cell	O
population	O
,	O
sharply	O
declined	O
and	O
was	O
restricted	O
to	O
the	O
blood	O
vessels	O
.	O

Furthermore	O
,	O
immunohistochemical	O
studies	O
demonstrated	O
that	O
VEGFR-2	O
(	O
flk-1/KDR	O
)	O
,	O
expression	O
was	O
elevated	O
significantly	O
in	O
the	O
endothelial	O
cells	O
of	O
microblood	O
vessels	O
after	O
7	O
days	O
of	O
E2	I-Entity
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
over	O
expression	O
of	O
VEGF	O
and	O
its	O
receptor	O
(	O
VEGFR-2	O
)	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
initial	O
step	O
of	O
the	O
regulation	O
of	O
estrogen	I-Entity
induced	O
tumor	I-Entity
angiogenesis	O
in	O
the	O
rat	O
pituitary	O
.	O



Pravastatin	I-Entity
-	O
associated	O
myopathy	I-Entity
.	O

A	O
case	O
of	O
acute	O
inflammatory	B-Entity
myopathy	I-Entity
associated	O
with	O
the	O
use	O
of	O
pravastatin	I-Entity
,	O
a	O
new	O
hydrophilic	O
3-hydroxy-3	O

The	O
patient	O
,	O
a	O
69-year	O
-	O
old	O
man	O
was	O
affected	O
by	O
non	B-Entity
-	I-Entity
insulin	I-Entity
-	I-Entity
dependent	I-Entity
diabetes	I-Entity
mellitus	I-Entity
and	O
hypertension	I-Entity
.	O

He	O
assumed	O
pravastatin	I-Entity
(	O
20	O
mg	O
/	O
day	O
)	O
because	O
of	O
hypercholesterolemia	I-Entity
.	O

He	O
was	O
admitted	O
with	O
acute	O
myopathy	I-Entity
of	O
the	O
lower	O
limbs	O
which	O
resolved	O
in	O
a	O
few	O
days	O
after	O
pravastatin	I-Entity
discontinuation	O
.	O

A	O
previously	O
unknown	O
hypothyroidism	I-Entity
,	O
probably	O
due	O
to	O
chronic	O
autoimmune	B-Entity
thyroiditis	I-Entity
,	O
was	O
evidenced	O
.	O

While	O
lovastatin	I-Entity
and	O
simvastatin	I-Entity
have	O
been	O
associated	O
with	O
toxic	O
myopathy	I-Entity
,	O
pravastatin	I-Entity
-	O
associated	O
myopathy	I-Entity
could	O
represent	O
a	O
distinct	O
,	O
inflammatory	O
entity	O
.	O



Dose	O
-	O
effect	O
and	O
structure	O
-	O
function	O
relationships	O
in	O
doxorubicin	I-Entity
cardiomyopathy	I-Entity
.	O

The	O
cardiomyopathy	I-Entity
(	O
CM	I-Entity
)	O
produced	O
by	O
the	O
anticancer	O
drug	O
doxorubicin	I-Entity
(	O
DXR	I-Entity
)	O
(	O
Adriamycin	I-Entity
)	O
provides	O
a	O
unique	O
opportunity	O
to	O
analyze	O
dose	O
-	O
effect	O
and	O
structure	O
-	O
function	O
relationships	O
during	O
development	O
of	O
myocardial	B-Entity
disease	I-Entity
.	O

We	O
measured	O
the	O
degree	O
of	O
morphologic	O
damage	O
by	O
ultrastructural	O
examination	O
of	O
endomyocardial	O
biopsy	O
and	O
the	O
degree	O
of	O
performance	O
abnormally	O
by	O
right	O
heart	O
catheterization	O
in	O
patients	O
receiving	O
DXR	I-Entity
.	O

Morphologic	O
damage	O
was	O
variable	O
but	O
was	O
proportional	O
to	O
the	O
total	O
cumulative	O
DXR	I-Entity
dose	O
between	O
100	O
and	O
600	O
mg	O
/	O
m2	O
.	O

In	O
DXR	I-Entity
-	O
CM	I-Entity
myocardial	B-Entity
damage	I-Entity
is	O
proportional	O
to	O
the	O
degree	O
of	O
cytotoxic	O
insult	O
(	O
DXR	I-Entity
dose	O
)	O
while	O
myocardial	O
function	O
is	O
preserved	O
until	O
a	O
critical	O
dose	O
or	O
degree	O
of	O
damage	O
is	O
reached	O
,	O
after	O
which	O
myocardial	O
performance	O
deteriorates	O
rapidly	O
.	O



Fatal	O
aplastic	B-Entity
anemia	I-Entity
following	O
topical	O
administration	O
of	O
ophthalmic	O
chloramphenicol	I-Entity
.	O

A	O
73-year	O
-	O
old	O
woman	O
died	O
of	O
aplastic	B-Entity
anemia	I-Entity
less	O
than	O
two	O
months	O
after	O
undergoing	O
cataract	I-Entity
extraction	O
and	O
beginning	O
topical	O
therapy	O
with	O
chloramphenicol	I-Entity
.	O

The	O
first	O
signs	O
of	O
pancytopenia	I-Entity
began	O
within	O
one	O
month	O
of	O
the	O
surgery	O
.	O

The	O
pattern	O
of	O
the	O
aplastic	B-Entity
anemia	I-Entity
was	O
associated	O
with	O
an	O
idiosyncratic	O
response	O
to	O
chloramphenicol	I-Entity
.	O

This	O
was	O
the	O
second	O
report	O
of	O
fatal	O
aplastic	B-Entity
anemia	I-Entity
after	O
topical	O
treatment	O
with	O
chloramphenicol	I-Entity
for	O
ocular	O
conditions	O
,	O
although	O
two	O
cases	O
of	O
reversible	O
bone	B-Entity
marrow	I-Entity
hypoplasia	I-Entity
have	O
also	O
been	O
reported	O
.	O

Any	O
other	O
suspected	O
cases	O
of	O
ocular	B-Entity
toxicity	I-Entity
associated	O
with	O
topically	O
applied	O
chloramphenicol	I-Entity
should	O
be	O
reported	O
to	O
the	O
National	O
Registry	O
of	O
Drug	O
-	O
Induced	O
Ocular	O
Side	O
Effects	O
,	O
Oregon	O
Health	O
Sciences	O
University	O
,	O
Portland	O
,	O
OR	O
97201	O
.	O



Bradycardia	I-Entity
due	O
to	O
trihexyphenidyl	B-Entity
hydrochloride	I-Entity
.	O

A	O
chronic	O
schizophrenic	I-Entity
patient	O
was	O
treated	O
with	O
an	O
anticholinergic	O
drug	O
,	O
trihexyphenidyl	B-Entity
hydrochloride	I-Entity
.	O

The	O
patient	O
developed	O
,	O
paradoxically	O
,	O
sinus	O
bradycardia	I-Entity
.	O

The	O
reaction	O
was	O
specific	O
to	O
trihexyphenidyl	I-Entity
and	O
not	O
to	O
other	O
anticholinergic	O
drugs	O
.	O

This	O
antidyskinetic	O
drug	O
is	O
widely	O
used	O
in	O
clinical	O
psychiatric	I-Entity
practice	O
and	O
physicians	O
should	O
be	O
aware	O
of	O
this	O
side	O
effect	O
.	O



Experimental	O
cyclosporine	I-Entity
nephrotoxicity	I-Entity
:	O
risk	O
of	O
concomitant	O
chemotherapy	O
.	O

The	O
role	O
of	O
cyclosporine	I-Entity
(	O
CSA	I-Entity
)	O
alone	O
or	O
in	O
combination	O
with	O
various	O
chemotherapeutics	O
in	O
the	O
development	O
of	O
renal	B-Entity
toxicity	I-Entity
was	O
evaluated	O
in	O
rats	O
.	O

Administration	O
of	O
20	O
mg	O
/	O
kg	O
/	O
day	O
CSA	I-Entity
for	O
4	O
weeks	O
caused	O
renal	O
functional	O
and	O
structural	O
changes	O
similar	O
to	O
those	O
reported	O
in	O
man	O
.	O

The	O
combined	O
administration	O
of	O
CSA	I-Entity
and	O
various	O
chemotherapeutic	O
drugs	O
with	O
a	O
nephrotoxic	I-Entity
potential	O
,	O
such	O
as	O
gentamicin	I-Entity
(	O
at	O
therapeutic	O
doses	O
)	O
,	O
amphothericin	B-Entity
B	I-Entity
and	O
ketoconazole	I-Entity
,	O
which	O
are	O
frequently	O
used	O
in	O
immunosuppressed	O
patients	O
,	O
did	O
not	O
aggravate	O
the	O
CSA	I-Entity
induced	O
toxicity	I-Entity
in	O
the	O
rat	O
model	O
.	O

Gentamicin	I-Entity
at	O
toxic	O
doses	O
,	O
however	O
,	O
increased	O
CSA	I-Entity
nephrotoxicity	I-Entity
.	O

Thus	O
,	O
the	O
nephrotoxicity	I-Entity
induced	O
by	O
CSA	I-Entity
has	O
a	O
different	O
pathogenetic	O
mechanism	O
.	O



Receptor	O
mechanisms	O
of	O
nicotine	I-Entity
-	O
induced	O
locomotor	B-Entity
hyperactivity	I-Entity
in	O
chronic	O
nicotine	I-Entity
-	O
treated	O
rats	O
.	O

Rats	O
were	O
pretreated	O
with	O
saline	O
or	O
nicotine	I-Entity
(	O
1.5	O
mg	O
/	O
kg	O
per	O
day	O
)	O
by	O
subcutaneously	O
implanting	O
each	O
animal	O
with	O
an	O
Alzet	O
osmotic	O
mini	O
-	O
pump	O
which	O
continuously	O
released	O
saline	O
or	O
nicotine	I-Entity
for	O
1	O
,	O
5	O
and	O
14	O
days	O
.	O

At	O
the	O
end	O
of	O
each	O
pretreatment	O
period	O
,	O
animals	O
were	O
used	O
for	O
(	O
i	O
)	O
determining	O
their	O
locomotor	O
response	O
to	O
acutely	O
injected	O
nicotine	I-Entity
(	O
0.2	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
and	O
(	O
ii	O
)	O
measuring	O
the	O
density	O
of	O
L-[3H]nicotine	I-Entity
and	O
[	O
3H]spiperone	I-Entity
binding	O
sites	O
in	O
the	O
striatum	O
.	O

We	O
observed	O
no	O
changes	O
in	O
nicotine	I-Entity
-	O
induced	O
locomotor	O
response	O
,	O
striatal	O
L-[3H]nicotine	I-Entity
and	O
[	O
3H]spiperone	I-Entity
binding	O
in	O
the	O
animals	O
pretreated	O
with	O
nicotine	I-Entity
for	O
1	O
day	O
.	O

In	O
rats	O
which	O
were	O
pretreated	O
with	O
nicotine	I-Entity
for	O
5	O
days	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
nicotine	I-Entity
-	O
stimulated	O
locomotor	O
response	O
which	O
was	O
associated	O
with	O
an	O
increase	O
in	O
the	O
number	O
of	O
L-[3H]nicotine	I-Entity
binding	O
sites	O
and	O
also	O
with	O
an	O
elevated	O
dopamine	I-Entity
(	O
DA	I-Entity
)	O
level	O
in	O
the	O
striatum	O
.	O

The	O
number	O
of	O
striatal	O
[	O
3H]spiperone	I-Entity
binding	O
sites	O
was	O
not	O
affected	O
.	O

In	O
animals	O
pretreated	O
with	O
nicotine	I-Entity
for	O
14	O
days	O
,	O
the	O
nicotine	I-Entity
-	O
induced	O
locomotor	O
response	O
remained	O
to	O
be	O
potentiated	O
.	O

However	O
,	O
this	O
response	O
was	O
correlated	O
with	O
an	O
elevated	O
number	O
of	O
striatal	O
[	O
3H]spiperone	I-Entity
binding	O
sites	O
,	O
whereas	O
the	O
number	O
of	O
striatal	O
L-[3H]nicotine	I-Entity
binding	O
sites	O
and	O
the	O
striatal	O
DA	I-Entity
level	O
were	O
normal	O
.	O

These	O
results	O
suggest	O
that	O
chronic	O
nicotine	I-Entity
-	O
treated	O
rats	O
develop	O
locomotor	B-Entity
hyperactivity	I-Entity
in	O
response	O
to	O
nicotine	I-Entity
initially	O
due	O
to	O
increases	O
of	O
both	O
the	O
density	O
of	O
nicotinic	O
receptors	O
and	O
DA	I-Entity
concentration	O
,	O
followed	O
by	O
inducing	O
DA	I-Entity
receptor	O
supersensitivity	O
in	O
the	O
striatum	O
.	O



Hydrocortisone	I-Entity
-	O
induced	O
hypertension	I-Entity
in	O
humans	O
:	O
pressor	O
responsiveness	O
and	O
sympathetic	O
function	O
.	O

Oral	O
hydrocortisone	I-Entity
increases	O
blood	O
pressure	O
and	O
enhances	O
pressor	O
responsiveness	O
in	O
normal	O
human	O
subjects	O
.	O

We	O
studied	O
the	O
effects	O
of	O
1	O
week	O
of	O
oral	O
hydrocortisone	I-Entity
(	O
200	O
mg	O
/	O
day	O
)	O
on	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
total	O
peripheral	O
resistance	O
,	O
forearm	O
vascular	O
resistance	O
,	O
and	O
norepinephrine	I-Entity
spillover	O
to	O
plasma	O
in	O
eight	O
healthy	O
male	O
volunteers	O
.	O

3.4	O
,	O
p	O
less	O
than	O
0.01	O
)	O
,	O
associated	O
with	O
an	O
increased	B-Entity
cardiac	I-Entity
output	I-Entity
(	O
5.85	O
-	O
7.73	O
l	O
/	O
min	O
,	O
SED	O
+	O
/-	O

The	O
rise	O
in	O
forearm	O
vascular	O
resistance	O
accompanying	O
intra	O
-	O
arterial	O
norepinephrine	I-Entity
(	O
25	O
,	O
50	O
,	O
and	O
100	O
ng	O
/	O
min	O
)	O
was	O
also	O
significantly	O
greater	O
after	O
hydrocortisone	I-Entity
,	O
increasing	O
from	O
an	O
average	O
of	O
14.9	O
+	O
/-	O

5.5	O
R	O
units	O
after	O
hydrocortisone	I-Entity

A	O
shift	O
to	O
the	O
left	O
in	O
the	O
dose	O
-	O
response	O
relation	O
and	O
fall	O
in	O
threshold	O
suggested	O
increased	O
sensitivity	O
to	O
norepinephrine	I-Entity
after	O
treatment	O
.	O

Measurement	O
of	O
resting	O
norepinephrine	I-Entity
spillover	O
rate	O
to	O
plasma	O
and	O
norepinephrine	I-Entity
uptake	O
indicated	O
that	O
overall	O
resting	O
sympathetic	O
nervous	O
system	O
activity	O
was	O
not	O
increased	O
.	O

The	O
rise	B-Entity
in	I-Entity
resting	I-Entity
blood	I-Entity
pressure	I-Entity
with	O
hydrocortisone	I-Entity
is	O
associated	O
with	O
an	O
increased	B-Entity
cardiac	I-Entity
output	I-Entity
(	O
presumably	O
due	O
to	O
increased	O
blood	O
volume).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Effects	O
of	O
suprofen	I-Entity
on	O
the	O
isolated	O
perfused	O
rat	O
kidney	O
.	O

Although	O
suprofen	I-Entity
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
in	O
greater	O
than	O
100	O
subjects	O
,	O
the	O
mechanism	O
of	O
damage	O
remains	O
unclear	O
.	O

The	O
direct	O
nephrotoxic	I-Entity
effects	O
of	O
a	O
single	O
dose	O
of	O
15	O
mg	O
of	O
suprofen	I-Entity
were	O
compared	O
in	O
the	O
recirculating	O
isolated	O
rat	O
kidney	O
perfused	O
with	O
cell	O
-	O
free	O
buffer	O
with	O
or	O
without	O
the	O
addition	O
of	O
5	O
mg	O
/	O
dL	O
of	O
uric	B-Entity
acid	I-Entity
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
renal	O
sodium	I-Entity
excretion	O
,	O
oxygen	I-Entity
consumption	O
,	O
or	O
urinary	O
flow	O
rates	O
in	O
kidneys	O
perfused	O
with	O
suprofen	I-Entity
compared	O
with	O
the	O
drug	O
-	O
free	O
control	O
groups	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
decline	O
in	O
glomerular	O
filtration	O
rate	O
was	O
found	O
after	O
the	O
introduction	O
of	O
suprofen	I-Entity
to	O
the	O
kidney	O
perfused	O
with	O
uric	B-Entity
acid	I-Entity
;	O
no	O
changes	O
were	O
found	O
with	O
suprofen	I-Entity
in	O
the	O
absence	O
of	O
uric	B-Entity
acid	I-Entity
.	O

A	O
significant	O
decrease	O
in	O
the	O
baseline	O
excretion	O
rate	O
of	O
uric	B-Entity
acid	I-Entity
was	O
found	O
in	O
rats	O
given	O
suprofen	I-Entity
,	O
compared	O
with	O
drug	O
-	O
free	O
controls	O
.	O

However	O
,	O
the	O
fractional	O
excretion	O
of	O
uric	B-Entity
acid	I-Entity
was	O
unchanged	O
between	O
the	O
groups	O
over	O
the	O
experimental	O
period	O
.	O

In	O
summary	O
,	O
suprofen	I-Entity
causes	O
acute	B-Entity
declines	I-Entity
in	I-Entity
renal	I-Entity
function	I-Entity
,	O
most	O
likely	O
by	O
directly	O
altering	O
the	O
intrarenal	O
distribution	O
of	O
uric	B-Entity
acid	I-Entity
.	O



Cocaine	I-Entity
-	O
induced	O
brainstem	O
seizures	I-Entity
and	O
behavior	O
.	O

electrical	O
current	O
stimulations	O
and	O
by	O
acute	O
and	O
chronic	O
administration	O
of	O
cocaine	I-Entity
.	O

Cocaine	I-Entity
(	O
40	O
mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
for	O
an	O
acute	O
experiment	O
and	O
subsequent	O
20	O
mg	O
/	O
kg	O
doses	O
twice	O
daily	O
for	O
3	O
days	O
in	O
a	O
chronic	O
study	O
.	O

Cocaine	I-Entity
generated	O
more	O
abnormal	O
behaviors	O
in	O
the	O
brainstem	O
perturbation	O
group	O
,	O
especially	O
the	O
electrically	O
perturbated	O
subjects	O
.	O

The	O
abnormal	O
behaviors	O
were	O
yawning	O
,	O
retrocollis	O
,	O
hyperactivity	I-Entity
,	O
hypersensitivity	I-Entity
,	O
""""	O
beating	O
drum	O
""""	O
behavior	O
,	O
squealing	O
,	O
head	O
bobbing	O
,	O
circling	O
,	O
sniffing	O
,	O
abnormal	O
posturing	O
,	O
and	O
facial	O
twitching	O
.	O

Hypersensitivity	I-Entity
to	O
various	O
auditory	O
,	O
tactile	O
,	O
and	O
visual	O
stimulation	O
was	O
present	O
and	O
shifts	O
in	O
the	O
brainstem	O
ambient	O
power	O
spectral	O
frequency	O
occurred	O
in	O
response	O
to	O
tactile	O
stimulation	O
.	O

Cocaine	I-Entity
was	O
found	O
to	O
activate	O
the	O
discharge	O
system	O
and	O
thus	O
induce	O
abnormal	O
behaviors	O
that	O
are	O
generated	O
at	O
the	O
discharge	O
site	O
and	O
at	O
distant	O
sites	O
to	O
which	O
the	O
discharge	O
propagates	O
.	O



Increased	O
sulfation	O
and	O
decreased	O
7alpha	O
-	O
hydroxylation	O
of	O
deoxycholic	B-Entity
acid	I-Entity
in	O
ethinyl	B-Entity
estradiol	I-Entity
-	O
induced	O
cholestasis	I-Entity
in	O
rats	O
.	O

Deoxycholic	B-Entity
acid	I-Entity
conjugation	O
,	O
transport	O
capacity	O
,	O
and	O
metabolism	O
were	O
compared	O
in	O
control	O
and	O
ethinyl	B-Entity
estradiol	I-Entity
-	O
treated	O
rats	O
.	O

Control	O
rats	O
were	O
found	O
to	O
have	O
a	O
lower	O
capacity	O
to	O
transport	O
deoxycholic	B-Entity
acid	I-Entity
than	O
taurodeoxycholic	B-Entity
acid	I-Entity
,	O
and	O
both	O
were	O
decreased	O
by	O
ethinyl	B-Entity
estradiol	I-Entity
treatment	O
.	O

During	O
[	O
24	O
-	O
14C]sodium	B-Entity
deoxycholate	I-Entity
infusion	O
,	O
[	O
14C]biliary	O
bile	B-Entity
acid	I-Entity
secretion	O
increased	O
,	O
but	O
bile	O
flow	O
did	O
not	O
change	O
significantly	O
in	O
either	O
control	O
or	O
ethinyl	B-Entity
estradiol	I-Entity
-	O
treated	O
rats	O
.	O

Ethinyl	B-Entity
estradiol	I-Entity
-	O
treated	O
animals	O
excreted	O
significantly	O
less	O
14C	O
as	O
taurocholic	B-Entity
acid	I-Entity
than	O
did	O
control	O
animals	O
,	O
consistent	O
with	O
an	O
impairment	O
of	O
7alpha	O
-	O
hydroxylation	O
of	O
taurodeoxycholic	B-Entity
acid	I-Entity
.	O

Ethinyl	B-Entity
estradiol	I-Entity
treatment	O
did	O
not	O
impair	O
conjugation	O
of	O
deoxycholic	B-Entity
acid	I-Entity
,	O
but	O
did	O
result	O
in	O
an	O
increase	O
in	O
sulfation	O
of	O
taurodeoxycholic	B-Entity
acid	I-Entity
from	O
1.5%	O
in	O
controls	O
to	O
nearly	O
4.0%	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
rat	O
has	O
a	O
poorer	O
tolerance	O
for	O
deoxycholic	B-Entity
acid	I-Entity
than	O
do	O
certain	O
other	O
species	O
.	O

Furthermore	O
,	O
the	O
rat	O
converts	O
deoxycholic	B-Entity
acid	I-Entity
,	O
a	O
poor	O
choleretic	O
,	O
to	O
taurocholic	B-Entity
acid	I-Entity
,	O
a	O
good	O
choleretic	O
.	O

When	O
this	O
conversion	O
is	O
impaired	O
with	O
ethinyl	B-Entity
estradiol	I-Entity
treatment	O
,	O
sulfation	O
may	O
be	O
an	O
important	O
alternate	O
pathway	O
for	O
excretion	O
of	O
this	O
potentially	O
harmful	O
bile	B-Entity
acid	I-Entity
.	O



Effects	O
of	O
ouabain	I-Entity
on	O
myocardial	O
oxygen	I-Entity
supply	O
and	O
demand	O
in	O
patients	O
with	O
chronic	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
.	O

A	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
study	O
in	O
patients	O
without	O
heart	B-Entity
failure	I-Entity
.	O

The	O
effects	O
of	O
digitalis	B-Entity
glycosides	I-Entity
on	O
myocardial	O
oxygen	I-Entity
supply	O
and	O
demand	O
are	O
of	O
particular	O
interest	O
in	O
the	O
presence	O
of	O
obstructive	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
,	O
but	O
have	O
not	O
been	O
measured	O
previously	O
in	O
man	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
ouabain	I-Entity
(	O
0.015	O
mg	O

/	O
kg	O
body	O
weight	O
)	O
on	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
parameters	O
in	O
11	O
patients	O
with	O
severe	O
chronic	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
without	O
clinical	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
.	O

Because	O
the	O
protocol	O
was	O
long	O
and	O
involved	O
interventions	O
which	O
might	O
affect	O
the	O
determinations	O
,	O
we	O
also	O
studied	O
in	O
nine	O
patients	O
using	O
an	O
identical	O
protocol	O
except	O
that	O
ouabain	I-Entity
administration	O
was	O
omitted	O
.	O

Left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
volume	O
fell	O
in	O
each	O
patient	O
given	O
ouabain	I-Entity
,	O
even	O
though	O
they	O
were	O
initially	O
elevated	O
in	O
only	O
two	O
patients	O
.	O

Left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
fell	O
from	O
11.5+/-1.4	O
(	O
mean+/-SE	O
)	O
to	O
5.6+/-0.9	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
volume	O
fell	O
from	O
100+/-17	O
to	O
82+/-12	O
ml	O
/	O
m2	O
(	O
P	O
less	O
than	O
0.01	O
)	O
1	O
h	O
after	O
ouabain	I-Entity
infusion	O
was	O
completed	O
.	O

No	O
significant	O
change	O
in	O
myocardial	O
oxygen	I-Entity
consumption	O
occurred	O
after	O
ouabain	I-Entity
administration	O
but	O
this	O
may	O
be	O
related	O
to	O
a	O
greater	O
decrease	O
in	O
mean	O
arterial	O
pressure	O
in	O
the	O
ouabain	I-Entity
patients	O
than	O
in	O
the	O
control	O
patients	O
.	O

We	O
conclude	O
that	O
in	O
patients	O
with	O
chronic	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
who	O
are	O
not	O
in	O
clinical	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
left	B-Entity
ventricular	I-Entity
end	I-Entity
-	I-Entity
diastolic	I-Entity
volume	I-Entity
falls	I-Entity
after	O
ouabain	I-Entity
administration	O
even	O
when	O
it	O
is	O
initially	O
normal	O
.	O

Though	O
this	O
fall	O
would	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
wall	O
tension	O
,	O
and	O
,	O
therefore	O
,	O
of	O
myocardial	O
oxygen	I-Entity
consumption	O
,	O
it	O
may	O
not	O
be	O
of	O
sufficient	O
magnitude	O
to	O
prevent	O
a	O
net	O
increase	O
in	O
myocardial	O
oxygen	I-Entity
consumption	O
.	O



Prolongation	B-Entity
of	I-Entity
the	I-Entity
QT	I-Entity
interval	I-Entity
related	O
to	O
cisapride	I-Entity
-	O
diltiazem	I-Entity
interaction	O
.	O

Cisapride	I-Entity
,	O
a	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
substrate	O
,	O
is	O
widely	O
prescribed	O
for	O
the	O
treatment	O
of	O
gastrointestinal	B-Entity
motility	I-Entity
disorders	I-Entity
.	O

Prolongation	B-Entity
of	I-Entity
QT	I-Entity
interval	I-Entity
,	O
torsades	B-Entity
de	I-Entity
pointes	I-Entity
,	O
and	O
sudden	B-Entity
cardiac	I-Entity
death	I-Entity
have	O
been	O
reported	O
after	O
concomitant	O
administration	O
with	O
erythromycin	I-Entity
or	O
azole	I-Entity
antifungal	O
agents	O
,	O
but	O
not	O
with	O
other	O
CYP3A4	O
inhibitors	O
.	O

A	O
possible	O
drug	O
interaction	O
occurred	O
in	O
a	O
45-year	O
-	O
old	O
woman	O
who	O
was	O
taking	O
cisapride	I-Entity
for	O
gastroesophageal	B-Entity
reflux	I-Entity
disorder	I-Entity
and	O
diltiazem	I-Entity
,	O
an	O
agent	O
that	O
has	O
inhibitory	O
effect	O
on	O
CYP3A4	O
,	O
for	O
hypertension	I-Entity
.	O

The	O
patient	O
was	O
in	O
near	O
syncope	I-Entity
and	O
had	O
QT	B-Entity
-	I-Entity
interval	I-Entity
prolongation	I-Entity
.	O

After	O
discontinuing	O
cisapride	I-Entity
,	O
the	O
QT	O
interval	O
returned	O
to	O
normal	O
and	O
symptoms	O
did	O
not	O
recur	O
.	O

We	O
suggest	O
that	O
caution	O
be	O
taken	O
when	O
cisapride	I-Entity
is	O
prescribed	O
with	O
any	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
including	O
diltiazem	I-Entity
.	O



Paclitaxel	I-Entity
combined	O
with	O
carboplatin	I-Entity
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
ovarian	B-Entity
cancer	I-Entity
.	O

In	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
paclitaxel	I-Entity
(	O
Taxol	I-Entity
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O

given	O
as	O
a	O
3-hour	O
infusion	O
in	O
combination	O
with	O
carboplatin	I-Entity
administered	O
every	O
21	O
days	O
to	O
women	O
with	O
advanced	O
ovarian	B-Entity
cancer	I-Entity
,	O
paclitaxel	I-Entity
doses	O
were	O
escalated	O
as	O
follows	O
:	O
level	O
1	O
,	O
135	O
mg	O
/	O
m2	O
;	O
level	O
2	O
,	O
160	O
mg	O
/	O
m2	O
;	O
level	O
3	O
,	O
185	O
mg	O
/	O
m2	O
;	O
and	O
level	O
4,210	O
mg	O
/	O
m2	O
.	O

The	O
fixed	O
dose	O
of	O
carboplatin	I-Entity
at	O
levels	O
1	O
through	O
4	O
was	O
given	O
to	O
achieve	O
an	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
of	O
5	O
using	O
the	O
Calvert	O
formula	O
.	O

In	O
levels	O
5	O
and	O
6	O
the	O
carboplatin	I-Entity
dose	O
was	O
targeted	O
at	O
AUCs	O
of	O
6	O
and	O
7.5	O
,	O
respectively	O
,	O
combined	O
with	O
a	O
fixed	O
paclitaxel	I-Entity
dose	O
of	O
185	O
mg	O
/	O
m2	O
.	O

The	O
dose	O
-	O
limiting	O
toxicity	I-Entity
of	O
the	O
combination	O
was	O
myelosuppression	I-Entity
(	O
leukopenia	I-Entity
,	O
granulocytopenia	I-Entity
,	O
and	O
thrombocytopenia	I-Entity
)	O
.	O

Neurotoxicity	I-Entity
was	O
largely	O
moderate	O
.	O

We	O
conclude	O
that	O
the	O
combination	O
of	O
paclitaxel	I-Entity
185	O
mg	O
/	O
m2	O
administered	O
as	O
a	O
3-hour	O
infusion	O
followed	O
immediately	O
by	O
a	O
1-hour	O
infusion	O
of	O
carboplatin	I-Entity
at	O
an	O
AUC	O
of	O
6	O
can	O
be	O
administered	O
safely	O
in	O
a	O
21-day	O
schedule	O
in	O
the	O
outpatient	O
setting	O
.	O

The	O
recommended	O
dose	O
for	O
phase	O
III	O
studies	O
is	O
paclitaxel	I-Entity
185	O
mg	O
/	O
m2	O
and	O
carboplatin	I-Entity
AUC	O
6	O
.	O



Treatment	O
of	O
tacrolimus	I-Entity
-	O
related	O
adverse	O
effects	O
by	O
conversion	O
to	O
cyclosporine	I-Entity
in	O
liver	O
transplant	O
recipients	O
.	O

When	O
tacrolimus	I-Entity
side	O
effects	O
persist	O
despite	O
dose	O
reduction	O
,	O
conversion	O
to	O
cyclosporine	I-Entity
-	O
based	O
immunosuppression	O
(	O
CyA	O
)	O
is	O
necessary	O
.	O

We	O
characterized	O
tacrolimus	I-Entity
side	O
effects	O
that	O
warranted	O
discontinuation	O
of	O
the	O
drug	O
,	O
and	O
outcomes	O
after	O
conversion	O
.	O

Of	O
388	O
liver	O
recipients	O
who	O
received	O
tacrolimus	I-Entity
as	O
primary	O
immunosuppression	O
,	O
70	O
required	O
conversion	O
to	O
CyA.	O
We	O
recorded	O
indication	O
for	O
conversion	O
,	O
whether	O
conversion	O
was	O
early	O
or	O
late	O
after	O
transplantation	O
,	O
tacrolimus	I-Entity
dose	O
and	O
trough	O
blood	O
level	O
at	O
conversion	O
,	O
and	O
incidence	O
of	O
rejection	O
after	O
conversion	O
.	O

Indications	O
for	O
early	O
conversion	O
were	O
neurotoxicity	I-Entity
(	O
20	O
)	O
,	O
(	B-Entity
insulin	I-Entity
-	I-Entity
dependent	I-Entity
)	I-Entity
diabetes	I-Entity
mellitus	I-Entity
(	O
IDDM	I-Entity
)	O
(	O
5	O
)	O
,	O
nephrotoxicity	I-Entity
(	O
3	O
)	O
,	O
gastrointestinal	B-Entity
(	I-Entity
GI	I-Entity
)	I-Entity
toxicity	I-Entity
(	O
6	O
)	O
,	O
and	O
cardiomyopathy	I-Entity
(	O
1	O
)	O
,	O
and	O
for	O
late	O
conversion	O
were	O
neurotoxicity	I-Entity
(	O
15	O
)	O
,	O
IDDM	I-Entity
(	O
12	O
)	O
,	O
nephrotoxicity	I-Entity
(	O
3	O
)	O
,	O
GI	B-Entity
toxicity	I-Entity
(	O
5	O
)	O
,	O
hepatotoxicity	I-Entity
(	O
6	O
)	O
,	O
post	B-Entity
-	I-Entity
transplant	I-Entity
lmphoproliferate	I-Entity
disease	I-Entity
(	O
PTLD	I-Entity
)	O
(	O
2	O
)	O
,	O
cardiomyopathy	I-Entity
(	O
1	O
)	O
,	O
hemolytic	B-Entity
anemia	I-Entity
(	O
1	O
)	O
,	O
and	O
pruritus	I-Entity
(	O
1	O
)	O
.	O

When	O
tacrolimus	I-Entity
side	O
effects	O
are	O
unresponsive	O
to	O
dose	O
reduction	O
,	O
conversion	O
to	O
CyA	O
can	O
be	O
accomplished	O
safely	O
,	O
with	O
no	O
increased	O
risk	O
of	O
rejection	O
and	O
excellent	O
long	O
-	O
term	O
outcome	O
.	O



Relative	O
efficacy	O
and	O
toxicity	I-Entity
of	O
netilmicin	I-Entity
and	O
tobramycin	I-Entity
in	O
oncology	O
patients	O
.	O

We	O
prospectively	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
netilmicin	B-Entity
sulfate	I-Entity
or	O
tobramycin	B-Entity
sulfate	I-Entity
in	O
conjunction	O
with	O
piperacillin	B-Entity
sodium	I-Entity
in	O
118	O
immunocompromised	O
patients	O
with	O
presumed	O
severe	O
infections	I-Entity
.	O

Nephrotoxicity	I-Entity
occurred	O
in	O
a	O
similar	O
proportion	O
in	O
patients	O
treated	O
with	O
netilmicin	I-Entity
and	O
tobramycin	I-Entity
(	O
17%	O
vs	O
11%	O
)	O
.	O

Ototoxicity	I-Entity
occurred	O
in	O
four	O
(	O
9.5%	O
)	O
of	O
42	O
netilmicin	I-Entity
and	O
piperacillin	I-Entity
and	O
in	O
12	O
(	O
22%	O
)	O

of	O
54	O
tobramycin	I-Entity
and	O
piperacillin	I-Entity
-	O
treated	O
patients	O
.	O

Of	O
those	O
evaluated	O
with	O
posttherapy	O
audiograms	O
,	O
three	O
of	O
four	O
netilmicin	I-Entity
and	O
piperacillin	I-Entity
-	O
treated	O
patients	O
had	O
auditory	O
thresholds	O
return	O
to	O
baseline	O
compared	O
with	O
one	O
of	O
nine	O
tobramycin	I-Entity
and	O
piperacillin	I-Entity
-	O
treated	O
patients	O
.	O

The	O
number	O
of	O
greater	O
than	O
or	O
equal	O
to	O
15-dB	O
increases	O
in	O
auditory	O
threshold	O
as	O
a	O
proportion	O
of	O
total	O
greater	O
than	O
or	O
equal	O
to	O
15-dB	O
changes	O
(	O
increases	O
and	O
decreases	O
)	O
was	O
significantly	O
lower	O
in	O
netilmicin	I-Entity
and	O
piperacillin-	I-Entity
vs	O
tobramycin	I-Entity
and	O
piperacillin	I-Entity
-	O
treated	O
patients	O
(	O
18	O
of	O
78	O
vs	O
67	O
of	O
115	O
)	O
.	O

We	O
conclude	O
that	O
aminoglycoside	I-Entity
-	O
associated	O
ototoxicity	I-Entity
was	O
less	O
severe	O
and	O
more	O
often	O
reversible	O
with	O
netilmicin	I-Entity
than	O
with	O
tobramycin	I-Entity
.	O



Effect	O
of	O
prostaglandin	I-Entity
synthetase	O
inhibitors	O
on	O
experimentally	O
induced	O
convulsions	I-Entity
in	O
rats	O
.	O

To	O
investigate	O
the	O
relationship	O
of	O
prostaglandins	I-Entity
(	O
PGs	I-Entity
)	O
to	O
seizure	I-Entity
induction	O
,	O
the	O
effects	O
of	O
six	O
PG	O
synthetase	O
inhibitors	O
on	O
convulsions	I-Entity
induced	O
by	O
flurothyl	I-Entity
,	O
picrotoxin	I-Entity
,	O
pentetrazol	I-Entity
(	O
PTZ	I-Entity
)	O
,	O
electroshock	O
or	O
bicuculline	I-Entity
were	O
evaluated	O
.	O

Ibuprofen	I-Entity
,	O
sulindac	I-Entity
,	O
mefenamic	B-Entity
acid	I-Entity
,	O
and	O
low	O
dose	O
meclofenamic	B-Entity
acid	I-Entity
increased	O
the	O
latency	O
-	O
to	O
-	O
onset	O
in	O
the	O
flurothyl	I-Entity
and/or	O
PTZ	I-Entity
models	O
;	O
the	O
electroshock	O
,	O
picrotoxin	I-Entity
and	O
bicuculline	I-Entity
models	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
pretreatment	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
PGs	I-Entity
are	O
involved	O
in	O
the	O
mechanism(s	O
)	O
underlying	O
fluorthyl-	I-Entity
and	O
PTZ	I-Entity
-	O
induced	O
convulsions	I-Entity
,	O
but	O
not	O
picrotoxin-	I-Entity
,	O
electroshock-	O
,	O
or	O
bicuculline	I-Entity
-	O
induced	O
convulsions	I-Entity
.	O



Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
-	O
associated	O
angioedema	I-Entity
of	O
the	O
stomach	O
and	O
small	O
intestine	O
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
on	O
a	O
45-year	O
old	O
African	O
-	O
American	O
female	O
with	O
newly	O
diagnosed	O
hypertension	I-Entity
,	O
who	O
was	O
started	O
on	O
a	O
combination	O
pill	O
of	O
amlodipine	I-Entity
/	O
benazapril	I-Entity
10/5	O
mg	O
.	O

The	O
very	O
next	O
day	O
,	O
she	O
presented	O
at	O
the	O
emergency	O
room	O
(	O
ER	O
)	O
with	O
abdominal	B-Entity
pain	I-Entity
,	O
nausea	I-Entity
and	O
vomiting	I-Entity
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
(	O
ACEI)-induced	O
angioedema	I-Entity
was	O
suspected	O
,	O
and	O
anti	O
-	O
hypertensive	I-Entity
medications	O
were	O
discontinued	O
.	O

Her	O
symptoms	O
improved	O
within	O
the	O
next	O
24	O
hours	O
,	O
and	O
repeat	O
CT	O
after	O
72	O
hours	O
revealed	O
marked	O
improvement	O
in	O
stomach	O
and	O
small	O
bowel	O
thickening	O
and	O
resolution	O
of	O
ascites	I-Entity
.	O

The	O
recognition	O
of	O
angiotensin	I-Entity
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
and	O
angiotensin	I-Entity
receptor	O
blocker	O
(	O
ARB	O
)	O

intestinal	B-Entity
angioedema	I-Entity
constitutes	O
a	O
challenge	O
to	O
primary	O
care	O
physicians	O
,	O
internists	O
,	O
emergency	O
room	O
personal	O
and	O
surgeons	O
.	O



Valproic	B-Entity
acid	I-Entity

I	O
:	O
time	O
course	O
of	O
lipid	O
peroxidation	O
biomarkers	O
,	O
liver	B-Entity
toxicity	I-Entity
,	O
and	O
valproic	B-Entity
acid	I-Entity
metabolite	O
levels	O
in	O
rats	O
.	O

A	O
single	O
dose	O
of	O
valproic	B-Entity
acid	I-Entity
(	O
VPA	I-Entity
)	O
,	O
which	O
is	O
a	O
widely	O
used	O
antiepileptic	O
drug	O
,	O
is	O
associated	O
with	O
oxidative	O
stress	O
in	O
rats	O
,	O
as	O
recently	O
demonstrated	O
by	O
elevated	O
levels	O
of	O
15-F(2t)-isoprostane	I-Entity
(	O
15-F(2t)-IsoP	I-Entity
)	O
.	O

To	O
determine	O
whether	O
there	O
was	O
a	O
temporal	O
relationship	O
between	O
VPA	I-Entity
-	O
associated	O
oxidative	O
stress	O
and	O
hepatotoxicity	I-Entity
,	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
ip	O
with	O
VPA	I-Entity
(	O
500	O
mg	O
/	O
kg	O
)	O
or	O
0.9%	O
saline	O
(	O
vehicle	O
)	O
once	O
daily	O
for	O
2	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
or	O
14	O
days	O
.	O

Oxidative	O
stress	O
was	O
assessed	O
by	O
determining	O
plasma	O
and	O
liver	O
levels	O
of	O
15-F(2t)-IsoP	I-Entity
,	O
lipid	B-Entity
hydroperoxides	I-Entity
(	O
LPO	I-Entity
)	O
,	O
and	O
thiobarbituric	B-Entity
acid	I-Entity
reactive	I-Entity
substances	I-Entity
(	O
TBARs	I-Entity
)	O
.	O

Plasma	O
and	O
liver	O
15-F(2t)-IsoP	I-Entity
were	O
elevated	O
and	O
reached	O
a	O
plateau	O
after	O
day	O
2	O
of	O
VPA	I-Entity
treatment	O
compared	O
to	O
control	O
.	O

Liver	O
LPO	I-Entity
levels	O
were	O
not	O
elevated	O
until	O
day	O
7	O
of	O
treatment	O
(	O
1.8-fold	O
versus	O
control	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Liver	O
and	O
plasma	O
TBARs	I-Entity
were	O
not	O
increased	O
until	O
14	O
days	O
(	O
2-fold	O
vs.	O
control	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Liver	B-Entity
toxicity	I-Entity
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha	O
-	O
glutathione	I-Entity
S	O
-	O
transferase	O
(	O
alpha	O
-	O
GST	O
)	O
and	O
by	O
histology	O
.	O

Serum	O
alpha	O
-	O
GST	O
levels	O
were	O
significantly	O
elevated	O
by	O
day	O
4	O
,	O
which	O
corresponded	O
to	O
hepatotoxicity	I-Entity
as	O
shown	O
by	O
the	O
increasing	O
incidence	O
of	O
inflammation	I-Entity
of	O
the	O
liver	O
capsule	O
,	O
necrosis	I-Entity
,	O
and	O
steatosis	I-Entity
throughout	O
the	O
study	O
.	O

The	O
liver	O
levels	O
of	O
beta	O
-	O
oxidation	O
metabolites	O
of	O
VPA	I-Entity
were	O
decreased	O
by	O
day	O
14	O
,	O
while	O
the	O
levels	O
of	O
4-ene	B-Entity
-	I-Entity
VPA	I-Entity
and	O
(	O
E)-2,4-diene	B-Entity
-	I-Entity
VPA	I-Entity
were	O
not	O
elevated	O
throughout	O
the	O
study	O
.	O

Overall	O
,	O
these	O
findings	O
indicate	O
that	O
VPA	I-Entity
treatment	O
results	O
in	O
oxidative	O
stress	O
,	O
as	O
measured	O
by	O
levels	O
of	O
15-F(2t)-IsoP	I-Entity
,	O
which	O
precedes	O
the	O
onset	O
of	O
necrosis	I-Entity
,	O
steatosis	I-Entity
,	O
and	O
elevated	O
levels	O
of	O
serum	O
alpha	O
-	O
GST	O
.	O



Pheochromocytoma	I-Entity
unmasked	O
by	O
amisulpride	I-Entity
and	O
tiapride	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
unmasking	O
of	O
pheochromocytoma	I-Entity
in	O
a	O
patient	O
treated	O
with	O
amisulpride	I-Entity
and	O
tiapride	I-Entity
.	O

A	O
42-year	O
-	O
old	O
white	O
man	O
developed	O
acute	O
hypertension	I-Entity
with	O
severe	O
headache	I-Entity
and	O
vomiting	I-Entity
2	O
hours	O
after	O
the	O
first	O
doses	O
of	O
amisulpride	I-Entity
100	O
mg	O
and	O
tiapride	I-Entity
100	O
mg	O
.	O

Both	O
drugs	O
were	O
immediately	O
discontinued	O
,	O
and	O
the	O
patient	O
recovered	O
after	O
subsequent	O
nicardipine	I-Entity
and	O
verapamil	I-Entity
treatment	O
.	O

Abdominal	O
ultrasound	O
showed	O
an	O
adrenal	O
mass	O
,	O
and	O
postoperative	O
histologic	O
examination	O
confirmed	O
the	O
diagnosis	O
of	O
pheochromocytoma	I-Entity
.	O

DISCUSSION	O
:	O
Drug	O
-	O
induced	O
symptoms	O
of	O
pheochromocytoma	I-Entity
are	O
often	O
associated	O
with	O
the	O
use	O
of	O
substituted	O
benzamide	I-Entity
drugs	O
,	O
but	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O

In	O
our	O
case	O
,	O
use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicated	O
a	O
possible	O
relationship	O
between	O
the	O
hypertensive	I-Entity
crisis	O
and	O
amisulpride	I-Entity
and	O
tiapride	I-Entity
therapy	O
.	O

As	O
of	O
March	O
24	O
,	O
2005	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
amisulpride-	I-Entity
and	O
tiapride	I-Entity
-	O
induced	O
hypertensive	I-Entity
crisis	O
in	O
a	O
patient	O
with	O
pheochromocytoma	I-Entity
.	O

Physicians	O
and	O
other	O
healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
this	O
potential	O
adverse	O
effect	O
of	O
tiapride	I-Entity
and	O
amisulpride	I-Entity
.	O



Quantitative	O
drug	O
levels	O
in	O
stimulant	O
psychosis	I-Entity
:	O
relationship	O
to	O
symptom	O
severity	O
,	O
catecholamines	I-Entity
and	O
hyperkinesia	I-Entity
.	O

To	O
examine	O
the	O
relationship	O
between	O
quantitative	O
stimulant	O
drug	O
levels	O
,	O
catecholamines	I-Entity
,	O
and	O
psychotic	B-Entity
symptoms	I-Entity
,	O
nineteen	O
patients	O
in	O
a	O
psychiatric	I-Entity
emergency	O
service	O
with	O
a	O
diagnosis	O
of	O
amphetamine-	I-Entity
or	O
cocaine	I-Entity
-	O
induced	O
psychosis	I-Entity
were	O
interviewed	O
,	O
and	O
plasma	O
and	O
urine	O
were	O
collected	O
for	O
quantitative	O
assays	O
of	O
stimulant	O
drug	O
and	O
catecholamine	I-Entity
metabolite	O
levels	O
.	O

Methamphetamine	I-Entity
or	O
amphetamine	I-Entity
levels	O
were	O
related	O
to	O
several	O
psychopathology	O
scores	O
and	O
the	O
global	O
hyperkinesia	I-Entity
rating	O
.	O

HVA	O
levels	O
were	O
related	O
to	O
global	O
hyperkinesia	I-Entity
but	O
not	O
to	O
psychopathology	O
ratings	O
.	O

Although	O
many	O
other	O
factors	O
such	O
as	O
sensitization	O
may	O
play	O
a	O
role	O
,	O
intensity	O
of	O
stimulant	O
-	O
induced	O
psychotic	B-Entity
symptoms	I-Entity
and	O
stereotypies	I-Entity
appears	O
to	O
be	O
at	O
least	O
in	O
part	O
dose	O
-	O
related	O
.	O



Delayed	O
asystolic	I-Entity
cardiac	B-Entity
arrest	I-Entity
after	O
diltiazem	I-Entity
overdose	I-Entity
;	O
resuscitation	O
with	O
high	O
dose	O
intravenous	O
calcium	I-Entity
.	O

A	O
51	O
year	O
old	O
man	O
took	O
a	O
mixed	O
overdose	I-Entity
including	O
1.8	O
-	O
3.6	O
g	O
of	O
diltiazem	I-Entity
,	O
paracetamol	I-Entity
,	O
aspirin	I-Entity
,	O
isosorbide	I-Entity
nitrate	I-Entity
,	O
and	O
alcohol	I-Entity
.	O

He	O
initially	O
presented	O
to	O
hospital	O
after	O
six	O
hours	O
with	O
mild	O
hypotension	I-Entity
and	O
was	O
treated	O
with	O
activated	O
charcoal	O
and	O
intravenous	O
fluids	O
.	O

Eighteen	O
hours	O
after	O
the	O
overdose	I-Entity
he	O
had	O
two	O
generalised	O
tonic	B-Entity
-	I-Entity
clonic	I-Entity
seizures	I-Entity
.	O

The	O
patient	O
remained	O
unresponsive	O
with	O
junctional	O
bradycardia	I-Entity
,	O
unrecordable	O
blood	O
pressure	O
,	O
and	O
then	O
became	O
asystolic	I-Entity
.	O

He	O
was	O
resuscitated	O
with	O
high	O
dose	O
(	O
13.5	O
g	O
)	O
intravenous	O
calcium	I-Entity
and	O
adrenaline	I-Entity
(	O
epinephrine	I-Entity
)	O
.	O

This	O
case	O
suggests	O
there	O
is	O
a	O
role	O
for	O
aggressive	O
high	O
dose	O
intravenous	O
calcium	I-Entity
therapy	O
in	O
severe	O
diltiazem	I-Entity
overdose	I-Entity
,	O
particularly	O
with	O
the	O
onset	O
of	O
asystole	I-Entity
.	O

It	O
should	O
be	O
considered	O
early	O
in	O
cases	O
of	O
cardiac	B-Entity
arrest	I-Entity
after	O
diltiazem	I-Entity
overdose	I-Entity
.	O

The	O
case	O
also	O
highlights	O
the	O
problems	O
with	O
delayed	O
toxicity	I-Entity
when	O
whole	O
bowel	O
irrigation	O
is	O
not	O
administered	O
.	O



Renal	B-Entity
papillary	I-Entity
necrosis	I-Entity
due	O
to	O
naproxen	I-Entity
.	O

A	O
31-year	O
-	O
old	O
man	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
,	O
who	O
had	O
previously	O
been	O
treated	O
with	O
sulindac	I-Entity
,	O
fenoprofen	B-Entity
calcium	I-Entity
,	O
high	O
dose	O
salicylates	I-Entity
and	O
gold	I-Entity
salts	O
,	O
developed	O
renal	B-Entity
papillary	I-Entity
necrosis	I-Entity
(	O
RPN	I-Entity
)	O
4	O
months	O
after	O
institution	O
of	O
naproxen	I-Entity
therapy	O
.	O

No	O
other	O
factor	O
predisposing	O
to	O
RPN	I-Entity
could	O
be	O
discovered	O
.	O

Sulindac	I-Entity
was	O
substituted	O
for	O
naproxen	I-Entity
and	O
no	O
further	O
adverse	O
renal	O
effects	O
occurred	O
over	O
the	O
next	O
12	O
months	O
.	O

We	O
review	O
previous	O
reports	O
linking	O
RPN	I-Entity
to	O
antiinflammatory	O
drug	O
use	O
and	O
discuss	O
possible	O
advantages	O
of	O
sulindac	I-Entity
in	O
patients	O
who	O
have	O
experienced	O
renal	B-Entity
toxicity	I-Entity
from	O
other	O
antiinflammatory	O
agents	O
.	O



Adverse	O
interaction	O
between	O
beta	B-Entity
-	I-Entity
adrenergic	I-Entity
blocking	I-Entity
drugs	I-Entity
and	O
verapamil	I-Entity
--	O
report	O
of	O
three	O
cases	O
.	O

Three	O
patients	O
with	O
ischaemic	B-Entity
heart	I-Entity
disease	I-Entity
developed	O
profound	O
cardiac	B-Entity
failure	I-Entity
,	O
hypotension	I-Entity
and	O
bradycardia	I-Entity
during	O
combined	O
therapy	O
with	O
verapamil	I-Entity
and	O
beta	B-Entity
-	I-Entity
adrenergic	I-Entity
blocking	I-Entity
drugs	I-Entity
.	O

Simultaneously	O
administration	O
of	O
beta	B-Entity
-	I-Entity
adrenergic	I-Entity
blocking	I-Entity
drugs	I-Entity
and	O
verapamil	I-Entity
may	O
result	O
in	O
profound	O
adverse	O
interactions	O
and	O
should	O
only	O
be	O
administered	O
with	O
great	O
caution	O
.	O



Adverse	O
reactions	O
to	O
bendrofluazide	I-Entity
and	O
propranolol	I-Entity
for	O
the	O
treatment	O
of	O
mild	O
hypertension	I-Entity
.	O

Report	O
of	O
Medical	O
Research	O
Council	O
Working	O
Party	O
on	O
Mild	O
to	O
Moderate	O
Hypertension	I-Entity
.	O

Participants	O
in	O
the	O
Medical	O
Research	O
Council	O
treatment	O
trial	O
for	O
mild	O
hypertension	I-Entity
are	O
randomly	O
allocated	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
:	O

bendrofluazide	I-Entity
,	O
propranolol	I-Entity
,	O
or	O
a	O
placebo	O
for	O
either	O
of	O
these	O
drugs	O
.	O

The	O
results	O
show	O
an	O
association	O
between	O
bendrofluazide	I-Entity
treatment	O
and	O
impotence	I-Entity
,	O
and	O
impotence	I-Entity
also	O
occurred	O
more	O
frequently	O
in	O
patients	O
taking	O
propranolol	I-Entity
than	O
in	O
those	O
taking	O
placebos	O
.	O

Other	O
adverse	O
reactions	O
significantly	O
linked	O
with	O
active	O
drugs	O
include	O
impaired	B-Entity
glucose	I-Entity
tolerance	I-Entity
in	O
men	O
and	O
women	O
and	O
gout	I-Entity
in	O
men	O
,	O
associated	O
with	O
bendrofluazide	I-Entity
treatment	O
,	O
and	O
Raynaud	B-Entity
's	I-Entity
phenomenon	I-Entity
and	O
dyspnoea	I-Entity
in	O
men	O
and	O
women	O
taking	O
propranolol	I-Entity
.	O

No	O
corneal	B-Entity
disease	I-Entity
is	O
known	O
to	O
have	O
occurred	O
in	O
the	O
propranolol	I-Entity
group	O
.	O

Mean	O
serum	O
potassium	I-Entity
level	O
fell	O
,	O
and	O
urea	I-Entity
and	O
uric	B-Entity
acid	I-Entity
levels	O
rose	O
,	O
in	O
men	O
and	O
women	O
taking	O
bendrofluazide	I-Entity
.	O

In	O
the	O
propranolol	I-Entity
group	O
,	O
serum	O
potassium	I-Entity
and	O
uric	B-Entity
acid	I-Entity
levels	O
rose	O
in	O
both	O
sexes	O
,	O
but	O
the	O
urea	I-Entity
level	O
rose	O
significantly	O
in	O
women	O
only	O
.	O



Dexmedetomidine	I-Entity
and	O
cardiac	O
protection	O
for	O
non	O
-	O
cardiac	O
surgery	O
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomised	O
controlled	O
trials	O
.	O

We	O
conducted	O
a	O
systematic	O
review	O
of	O
the	O
effects	O
of	O
dexmedetomidine	I-Entity
on	O
cardiac	O
outcomes	O
following	O
non	O
-	O
cardiac	O
surgery	O
.	O

We	O
included	O
prospective	O
,	O
randomised	O
peri	O
-	O
operative	O
studies	O
of	O
dexmedetomidine	I-Entity
that	O
reported	O
mortality	O
,	O
cardiac	O
morbidity	O
or	O
adverse	O
drug	O
events	O
.	O

Dexmedetomidine	I-Entity
was	O
associated	O
with	O
a	O
trend	O
towards	O
improved	O
cardiac	O
outcomes	O
;	O
all	O
-	O
cause	O
mortality	O
(	O
OR	O
0.27	O
,	O
95%	O
CI	O
0.01	O
-	O
7.13	O
,	O

p	O
=	O
0.44	O
)	O
,	O
non	O
-	O
fatal	O
myocardial	B-Entity
infarction	I-Entity
(	O
OR	O
0.26	O
,	O
95%	O
CI	O
0.04	O
-	O
1.60	O
,	O
p	O
=	O
0.14	O
)	O
,	O
and	O
myocardial	B-Entity
ischaemia	I-Entity
(	O
OR	O
0.65	O
,	O
95%	O
CI	O
0.26	O
-	O
1.63	O
,	O

Peri	O
-	O
operative	O
hypotension	I-Entity
(	O
26%	O
,	O
OR	O
3.80	O
,	O
95%	O

CI	O
1.91	O
-	O
7.54	O
,	O
p	O
=	O
0.0001	O
)	O
and	O
bradycardia	I-Entity
(	O
17%	O
,	O
OR	O
5.45	O
,	O
95%	O
CI	O
2.98	O
-	O
9.95	O
,	O
p	O

An	O
anticholinergic	O
did	O
not	O
reduce	O
the	O
incidence	O
of	O
bradycardia	I-Entity
(	O
p	O
=	O
0.43	O
)	O
.	O

A	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
of	O
dexmedetomidine	I-Entity
is	O
warranted	O
.	O



Differential	O
diagnosis	O
of	O
high	O
serum	O
creatine	I-Entity
kinase	O
levels	O
in	O
systemic	B-Entity
lupus	I-Entity
erythematosus	I-Entity
.	O

We	O
report	O
the	O
clinical	O
and	O
bioptic	O
findings	O
for	O
a	O
57-year	O
-	O
old	O
woman	O
with	O
severe	O
chloroquine	I-Entity
-	O
induced	O
myopathy	I-Entity
.	O

Since	O
1989	O
,	O
she	O
had	O
been	O
suffering	O
from	O
systemic	B-Entity
lupus	I-Entity
erythematosus	I-Entity
(	O
SLE	I-Entity
)	O
with	O
renal	B-Entity
involvement	I-Entity
and	O
undergone	O
periods	O
of	O
treatment	O
with	O
azathioprine	I-Entity
and	O
cyclophosphamide	I-Entity
.	O

Additional	O
therapy	O
with	O
chloroquine	I-Entity
(	O
CQ	I-Entity
)	O
was	O
started	O
because	O
of	O
arthralgia	I-Entity
.	O

At	O
the	O
same	O
time	O
,	O
slightly	O
increased	O
creatine	I-Entity
kinase	O
(	O
CK	O
)	O

Myositis	I-Entity
was	O
suspected	O
,	O
and	O
the	O
patient	O
was	O
treated	O
with	O
steroids	I-Entity
.	O

The	O
CK	O
increase	O
persisted	O
,	O
however	O
,	O
and	O
she	O
developed	O
progressive	O
muscular	B-Entity
weakness	I-Entity
and	O
muscular	B-Entity
atrophy	I-Entity
.	O

The	O
neurological	O
and	O
electrophysiological	O
findings	O
were	O
not	O
typical	O
of	O
myositis	I-Entity
.	O

Thus	O
,	O
muscle	O
biopsy	O
of	O
the	O
deltoid	O
muscle	O
was	O
performed	O
in	O
order	O
to	O
exclude	O
polymyositis	I-Entity
or	O
toxic	O
myopathy	I-Entity
.	O

As	O
it	O
revealed	O
chloroquine	I-Entity
-	O
induced	O
myopathy	I-Entity
,	O
medication	O
was	O
stopped	O
.	O

Discriminating	O
between	O
primary	O
SLE	I-Entity
-	O
induced	O
affection	B-Entity
of	I-Entity
the	I-Entity
musculoskeletal	I-Entity
system	I-Entity
and	O
drug	O
-	O
induced	O
side	O
effects	O
is	O
important	O
for	O
appropriate	O
treatment	O
of	O
SLE	I-Entity
patients	O
.	O



Intravenous	O
ribavirin	I-Entity
treatment	O
for	O
severe	O
adenovirus	B-Entity
disease	I-Entity
in	O
immunocompromised	O
children	O
.	O

The	O
incidence	O
of	O
severe	O
adenovirus	B-Entity
disease	I-Entity
in	O
pediatrics	O
is	O
increasing	O
in	O
association	O
with	O
growing	O
numbers	O
of	O
immunocompromised	O
children	O
,	O
where	O
case	O
fatality	O
rates	O
as	O
high	O
as	O
50%	O
to	O
80%	O
have	O
been	O
reported	O
.	O

There	O
are	O
no	O
approved	O
antiviral	O
agents	O
with	O
proven	O
efficacy	O
for	O
the	O
treatment	O
of	O
severe	O
adenovirus	B-Entity
disease	I-Entity
,	O
nor	O
are	O
there	O
any	O
prospective	O
randomized	O
,	O
controlled	O
trials	O
of	O
potentially	O
useful	O
anti	O
-	O
adenovirus	O
therapies	O
.	O

Apparent	O
clinical	O
success	O
in	O
the	O
treatment	O
of	O
severe	O
adenovirus	B-Entity
disease	I-Entity
is	O
limited	O
to	O
a	O
few	O
case	O
reports	O
and	O
small	O
series	O
.	O

Experience	O
is	O
greatest	O
with	O
intravenous	O
ribavirin	I-Entity
and	O
cidofovir	I-Entity
.	O

Ribavirin	I-Entity
,	O
a	O
guanosine	I-Entity
analogue	O
,	O
has	O
broad	O
antiviral	O
activity	O
against	O
both	O
RNA	O
and	O
DNA	O
viruses	O
,	O
including	O
documented	O
activity	O
against	O
adenovirus	O
in	O
vitro	O
.	O

Ribavirin	I-Entity
is	O
licensed	O
in	O
aerosol	O
form	O
for	O
the	O
treatment	O
of	O
respiratory	B-Entity
syncytial	I-Entity
virus	I-Entity
infection	I-Entity
,	O
and	O
orally	O
in	O
combination	O
with	O
interferon	O
to	O
treat	O
hepatitis	B-Entity
C.	I-Entity
Intravenous	O

ribavirin	I-Entity
is	O
the	O
treatment	O
of	O
choice	O
for	O
infection	B-Entity
with	I-Entity
hemorrhagic	I-Entity
fever	I-Entity
viruses	I-Entity
.	O

The	O
most	O
common	O
adverse	O
effect	O
of	O
intravenous	O
ribavirin	I-Entity
is	O
reversible	O
mild	O
anemia	I-Entity
.	O

The	O
use	O
of	O
cidofovir	I-Entity
in	O
severe	O
adenovirus	B-Entity
infection	I-Entity
has	O
been	O
limited	O
by	O
adverse	O
effects	O
,	O
the	O
most	O
significant	O
of	O
which	O
is	O
nephrotoxicity	I-Entity
.	O

OBJECTIVE	O
:	O
We	O
report	O
our	O
experience	O
with	O
intravenous	O
ribavirin	I-Entity
therapy	O
for	O
severe	O
adenovirus	B-Entity
disease	I-Entity
in	O
a	O
series	O
of	O
immunocompromised	O
children	O
and	O
review	O
the	O
literature	O
.	O

:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
of	O
5	O
children	O
treated	O
with	O
intravenous	O
ribavirin	I-Entity
for	O
documented	O
severe	O
adenovirus	B-Entity
disease	I-Entity
.	O

Two	O
patients	O
developed	O
adenovirus	O
hemorrhagic	B-Entity
cystitis	I-Entity
after	O
cardiac	O
and	O
bone	O
marrow	O
transplants	O
,	O
respectively	O
.	O

The	O
bone	O
marrow	O
transplant	O
patient	O
also	O
received	O
intravenous	O
cidofovir	I-Entity
for	O
progressive	O
disseminated	O
disease	O
.	O

An	O
additional	O
3	O
children	O
developed	O
adenovirus	B-Entity
pneumonia	I-Entity
;	O
2	O
were	O
neonates	O
,	O
1	O
of	O
whom	O
had	O
partial	O
DiGeorge	B-Entity
syndrome	I-Entity
.	O

Intravenous	O
ribavirin	I-Entity
was	O
administered	O
on	O
a	O
compassionate	O
-	O
use	O
protocol	O
.	O

RESULTS	O
:	O
Complete	O
clinical	O
recovery	O
followed	O
later	O
by	O
viral	O
clearance	O
was	O
observed	O
in	O
2	O
children	O
:	O
the	O
cardiac	O
transplant	O
recipient	O
with	O
adenovirus	O
hemorrhagic	B-Entity
cystitis	I-Entity
and	O
the	O
immunocompetent	O
neonate	O
with	O
adenovirus	B-Entity
pneumonia	I-Entity
.	O

The	O
remaining	O
3	O
children	O
died	O
of	O
adenovirus	B-Entity
disease	I-Entity
.	O

Intravenous	O
ribavirin	I-Entity
therapy	O
was	O
well	O
tolerated	O
.	O

Use	O
of	O
cidofovir	I-Entity
in	O
1	O
child	O
was	O
associated	O
with	O
progressive	B-Entity
renal	I-Entity
failure	I-Entity
and	O
neutropenia	I-Entity
.	O

Our	O
series	O
of	O
patients	O
is	O
representative	O
of	O
the	O
spectrum	O
of	O
immunocompromised	O
children	O
at	O
greatest	O
risk	O
for	O
severe	O
adenovirus	B-Entity
disease	I-Entity
,	O
namely	O
solid	O
-	O
organ	O
and	O
bone	O
marrow	O
transplant	O
recipients	O
,	O
neonates	O
,	O
and	O
children	O
with	O
immunodeficiency	I-Entity
.	O

Although	O
intravenous	O
ribavirin	I-Entity
was	O
not	O
effective	O
for	O
all	O
children	O
with	O
severe	O
adenovirus	B-Entity
disease	I-Entity
in	O
this	O
series	O
or	O
in	O
the	O
literature	O
,	O
therapy	O
is	O
unlikely	O
to	O
be	O
of	O
benefit	O
if	O
begun	O
late	O
in	O
the	O
course	O
of	O
the	O
infection	I-Entity
.	O

Early	O
identification	O
,	O
eg	O
by	O
polymerase	O
chain	O
reaction	O
of	O
those	O
patients	O
at	O
risk	O
of	O
disseminated	O
adenovirus	B-Entity
disease	I-Entity
may	O
permit	O
earlier	O
antiviral	O
treatment	O
and	O
better	O
evaluation	O
of	O
therapeutic	O
response	O
.	O

Two	O
of	O
5	O
children	O
with	O
severe	O
adenovirus	B-Entity
disease	I-Entity
treated	O
with	O
intravenous	O
ribavirin	I-Entity
recovered	O
.	O

The	O
availability	O
of	O
newer	O
rapid	O
diagnostic	O
techniques	O
,	O
such	O
as	O
polymerase	O
chain	O
reaction	O
,	O
may	O
make	O
earlier	O
,	O
more	O
effective	O
treatment	O
of	O
adenovirus	B-Entity
infection	I-Entity
possible	O
.	O

Given	O
the	O
seriousness	O
and	O
increasing	O
prevalence	O
of	O
adenovirus	B-Entity
disease	I-Entity
in	O
certain	O
hosts	O
,	O
especially	O
children	O
,	O
a	O
large	O
,	O
multicenter	O
clinical	O
trial	O
of	O
potentially	O
useful	O
anti	O
-	O
adenoviral	O
therapies	O
,	O
such	O
as	O
intravenous	O
ribavirin	I-Entity
,	O
is	O
clearly	O
required	O
to	O
demonstrate	O
the	O
most	O
effective	O
and	O
least	O
toxic	O
therapy	O
.	O



Hepatotoxicity	I-Entity
of	O
amiodarone	I-Entity
.	O

Amiodarone	I-Entity
has	O
proved	O
very	O
effective	O
in	O
the	O
treatment	O
of	O
otherwise	O
resistant	O
cardiac	O
tachyarrhythmias	I-Entity
.	O

The	O
use	O
of	O
amiodarone	I-Entity
has	O
,	O
however	O
,	O
been	O
limited	O
due	O
to	O
its	O
serious	O
side	O
-	O
effects	O
.	O

A	O
patient	O
with	O
cholestatic	B-Entity
hepatitis	I-Entity
due	O
to	O
amiodarone	I-Entity
treatment	O
is	O
presented	O
below	O
and	O
a	O
review	O
of	O
the	O
hepatotoxicity	I-Entity
of	O
amiodarone	I-Entity
is	O
given	O
.	O

It	O
is	O
concluded	O
that	O
solid	O
evidence	O
exists	O
of	O
hepatic	B-Entity
injury	I-Entity
due	O
to	O
amiodarone	I-Entity
treatment	O
,	O
including	O
steatosis	I-Entity
,	O
alterations	O
resembling	O
alcoholic	B-Entity
hepatitis	I-Entity
,	O
cholestatic	B-Entity
hepatitis	I-Entity
and	O
micronodular	O
cirrhosis	B-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
.	O

Patients	O
receiving	O
amiodarone	I-Entity
should	O
be	O
regularly	O
screened	O
with	O
respect	O
to	O
hepatic	O
enzyme	O
levels	O
.	O

Therapy	O
should	O
be	O
discontinued	O
on	O
the	O
suspicion	O
of	O
cholestatic	B-Entity
injury	I-Entity
or	O
hepatomegaly	I-Entity
.	O



Catalepsy	I-Entity
induced	O
by	O
combinations	O
of	O
ketamine	I-Entity
and	O
morphine	I-Entity
:	O
potentiation	O
,	O
antagonism	O
,	O
tolerance	O
and	O
cross	O
-	O
tolerance	O
in	O
the	O
rat	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
both	O
ketamine	I-Entity
and	O
morphine	I-Entity
induced	O
analgesia	I-Entity
and	O
catalepsy	I-Entity
in	O
the	O
rat	O
.	O

Pre	O
-	O
treatment	O
with	O
ketamine	I-Entity
produced	O
cross	O
-	O
tolerance	O
to	O
morphine	I-Entity
,	O
whereas	O
pretreatment	O
with	O
morphine	I-Entity
did	O
not	O
induce	O
cross	O
-	O
tolerance	O
to	O
ketamine	I-Entity
but	O
rather	O
augmented	O
the	O
cataleptic	I-Entity
response	O
;	O
this	O
augmentation	O
was	O
attributed	O
to	O
residual	O
morphine	I-Entity
in	O
the	O
brain	O
.	O

The	O
present	O
studies	O
explored	O
the	O
duration	O
of	O
the	O
loss	O
of	O
righting	O
reflex	O
induced	O
by	O
sub	O
-	O
effective	O
doses	O
of	O
ketamine	I-Entity
and	O
morphine	I-Entity
,	O
administered	O
simultaneously	O
.	O

There	O
was	O
mutual	O
potentiation	O
between	O
sub	O
-	O
effective	O
doses	O
of	O
ketamine	I-Entity
and	O
morphine	I-Entity
,	O
but	O
sub	O
-	O
effective	O
doses	O
of	O
ketamine	I-Entity
partly	O
antagonized	O
fully	O
-	O
effective	O
doses	O
of	O
morphine	I-Entity
.	O

Latency	O
to	O
the	O
loss	O
of	O
righting	O
reflex	O
,	O
rigidity	I-Entity
and	O
behavior	O
on	O
recovery	O
,	O
reflected	O
the	O
relative	O
predominance	O
of	O
ketamine	I-Entity
or	O
morphine	I-Entity
in	O
each	O
combination	O
.	O

Naloxone	I-Entity
inhibited	O
the	O
induced	O
cataleptic	I-Entity
effects	O
.	O

The	O
degree	O
and	O
time	O
course	O
of	O
development	O
of	O
tolerance	O
to	O
daily	O
administration	O
of	O
sub	O
-	O
effective	O
dose	O
combinations	O
of	O
ketamine	I-Entity
and	O
morphine	I-Entity
were	O
similar	O
.	O

Rats	O
,	O
tolerant	O
to	O
ketamine	I-Entity
-	O
dominant	O
combinations	O
,	O
were	O
cross	O
-	O
tolerant	O
to	O
both	O
drugs	O
,	O
while	O
those	O
tolerant	O
to	O
morphine	I-Entity
-	O
dominant	O
combinations	O
were	O
cross	O
-	O
tolerant	O
to	O
morphine	I-Entity
but	O
showed	O
either	O
no	O
cross	O
-	O
tolerance	O
or	O
an	O
augmented	O
response	O
to	O
ketamine	I-Entity
.	O

While	O
the	O
mutual	O
potentiation	O
,	O
antagonism	O
and	O
tolerance	O
suggest	O
common	O
mechanisms	O
for	O
the	O
induced	O
catalepsy	I-Entity
,	O
differences	O
in	O
latency	O
,	O
rigidity	I-Entity
and	O
behavior	O
,	O
asymmetry	O
of	O
cross	O
-	O
tolerance	O
and	O
a	O
widely	O
-	O
different	O
ID50	O
for	O
naloxone	I-Entity
would	O
argue	O
against	O
an	O
action	O
at	O
a	O
single	O
opioid	O
site	O
.	O



Acute	B-Entity
renal	I-Entity
failure	I-Entity
in	O
patients	O
with	O
AIDS	I-Entity
on	O
tenofovir	I-Entity
while	O
receiving	O
prolonged	O
vancomycin	I-Entity
course	O
for	O
osteomyelitis	I-Entity
.	O

Renal	B-Entity
failure	I-Entity
developed	O
after	O
a	O
prolonged	O
course	O
of	O
vancomycin	I-Entity
therapy	O
in	O
2	O
patients	O
who	O
were	O
receiving	O
tenofovir	B-Entity
disoproxil	I-Entity
fumarate	I-Entity
as	O
part	O
of	O
an	O
antiretroviral	O
regimen	O
.	O

Tenofovir	I-Entity
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
Fanconi	B-Entity
syndrome	I-Entity
and	O
renal	B-Entity
insufficiency	I-Entity
because	O
of	O
its	O
effects	O
on	O
the	O
proximal	O
renal	O
tubule	O
.	O

Vancomycin	I-Entity
nephrotoxicity	I-Entity
is	O
infrequent	O
but	O
may	O
result	O
from	O
coadministration	O
with	O
a	O
nephrotoxic	I-Entity
agent	O
.	O

Clinicians	O
should	O
be	O
aware	O
that	O
tenofovir	I-Entity
may	O
raise	O
the	O
risk	O
of	O
renal	B-Entity
failure	I-Entity
during	O
prolonged	O
administration	O
of	O
vancomycin	I-Entity
.	O



Delayed	O
leukoencephalopathy	I-Entity
with	O
stroke	I-Entity
-	O
like	O
presentation	O
in	O
chemotherapy	O
recipients	O
.	O

A	O
transient	O
leukoencephalopathy	I-Entity
mimicking	O
cerebrovascular	B-Entity
accident	I-Entity
has	O
been	O
described	O
as	O
a	O
complication	O
of	O
chemotherapy	O
,	O
most	O
commonly	O
in	O
recipients	O
of	O
intrathecal	O
methotrexate	I-Entity
for	O
childhood	O
leukaemia	I-Entity
.	O

METHODS	O
:	O
We	O
reviewed	O
the	O
medical	O
literature	O
for	O
single	O
reports	O
and	O
case	O
series	O
of	O
patients	O
presenting	O
with	O
stroke	I-Entity
-	O
like	O
episodes	O
while	O
receiving	O
systemic	O
or	O
intrathecal	O
chemotherapy	O
.	O

Patients	O
with	O
cerebrovascular	B-Entity
accidents	I-Entity
were	O
excluded	O
.	O

We	O
identified	O
27	O
reports	O
of	O
toxic	O
leukoencephalopathy	I-Entity
in	O
patients	O
treated	O
with	O
methotrexate	I-Entity
(	O
intrathecal	O
,	O
systemic	O
)	O
,	O
5-fluorouracil	I-Entity
and	O
its	O
derivative	O
carmofur	I-Entity
,	O
and	O
capecitabine	I-Entity
.	O

Diffusion	O
weighted	O
imaging	O
(	O
DWI	O
)	O
of	O
all	O
patients	O
revealed	O
well	O
demarcated	O
hyperintense	O
lesions	B-Entity
within	I-Entity
the	I-Entity
subcortical	I-Entity
white	I-Entity
matter	I-Entity
of	O
the	O
cerebral	O
hemispheres	O
and	O
the	O
corpus	O
callosum	O
,	O
corresponding	O
to	O
areas	O
of	O
decreased	O
proton	O
diffusion	O
on	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
maps	O
(	O
available	O
in	O
21/27	O
patients	O
)	O
.	O

However	O
,	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
sequences	O
frequently	O
revealed	O
persistent	O
white	B-Entity
matter	I-Entity
abnormalities	I-Entity
.	O

CONCLUSIONS	O
:	O
Several	O
pathophysiological	O
models	O
of	O
delayed	O
leukoencephalopathy	I-Entity
after	O
exposure	O
to	O
intrathecal	O
or	O
systemic	O
chemotherapy	O
have	O
been	O
proposed	O
.	O

DWI	O
findings	O
in	O
this	O
cohort	O
are	O
indicative	O
of	O
cytotoxic	B-Entity
oedema	I-Entity
within	I-Entity
cerebral	I-Entity
white	I-Entity
matter	I-Entity
and	O
lend	O
support	O
to	O
an	O
at	O
least	O
partially	O
reversible	O
metabolic	O
derangement	O
as	O
the	O
basis	O
for	O
this	O
syndrome	O
.	O



Down	O
-	O
regulation	O
of	O
norepinephrine	I-Entity
transporter	O
function	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	I-Entity
linking	O
to	O
the	O
alteration	O
of	O
sensitivity	O
of	O
local	O
-	O
anesthetics	O
-	O
induced	O
convulsions	I-Entity
and	O
the	O
counteraction	O
by	O
co	O
-	O
administration	O
with	O
local	O
anesthetics	O
.	O

Alterations	O
of	O
norepinephrine	I-Entity
transporter	O
(	O
NET	O
)	O
function	O
by	O
chronic	O
inhibition	O
of	O
NET	O
in	O
relation	O
to	O
sensitization	O
to	O
seizures	I-Entity
induce	O
by	O
cocaine	I-Entity
and	O
local	O
anesthetics	O
were	O
studied	O
in	O
mice	O
.	O

Daily	O
administration	O
of	O
desipramine	I-Entity
,	O
an	O
inhibitor	O
of	O
the	O
NET	O
,	O
for	O
5	O
days	O
decreased	O
[	O
(	O
3)H]norepinephrine	I-Entity
uptake	O
in	O
the	O
P2	O
fractions	O
of	O
hippocampus	O
but	O
not	O
cortex	O
,	O
striatum	O
or	O
amygdalae	O
.	O

Co	O
-	O
administration	O
of	O
lidocaine	I-Entity
,	O
bupivacaine	I-Entity
or	O
tricaine	I-Entity
with	O
desipramine	I-Entity
reversed	O
this	O
effect	O
.	O

Daily	O
treatment	O
of	O
cocaine	I-Entity
increased	O
[	O
(	O
3)H]norepinephrine	I-Entity
uptake	O
into	O
the	O
hippocampus	O
.	O

Daily	O
administration	O
of	O
desipramine	I-Entity
increased	O
the	O
incidence	O
of	O
appearance	O
of	O
lidocaine	I-Entity
-	O
induced	O
convulsions	I-Entity
and	O
decreased	O
that	O
of	O
cocaine	I-Entity
-	O
induced	O
convulsions	I-Entity
.	O

Co	O
-	O
administration	O
of	O
lidocaine	I-Entity
with	O
desipramine	I-Entity
reversed	O
the	O
changes	O
of	O
convulsive	I-Entity
activity	O
of	O
lidocaine	I-Entity
and	O
cocaine	I-Entity
induced	O
by	O
repeated	O
administration	O
of	O
desipramine	I-Entity
.	O

These	O
results	O
suggest	O
that	O
down	O
-	O
regulation	O
of	O
hippocampal	O
NET	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	I-Entity
may	O
be	O
relevant	O
to	O
desipramine	I-Entity
-	O
induced	O
sensitization	O
of	O
lidocaine	I-Entity
convulsions	I-Entity
.	O

Inhibition	O
of	O
Na(+	I-Entity
)	O
channels	O
by	O
local	O
anesthetics	O
may	O
regulate	O
desipramine	I-Entity
-	O
induced	O
down	O
-	O
regulation	O
of	O
NET	O
function	O
.	O

Repeated	O
administration	O
of	O
cocaine	I-Entity
induces	O
up	O
-	O
regulation	O
of	O
hippocampal	O
NET	O
function	O
.	O

Desipramine	I-Entity
-	O
induced	O
sensitization	O
of	O
lidocaine	I-Entity
seizures	I-Entity
may	O
have	O
a	O
mechanism	O
distinct	O
from	O
kindling	O
resulting	O
from	O
repeated	O
administration	O
of	O
cocaine	I-Entity
.	O



Definition	O
and	O
management	O
of	O
anemia	I-Entity
in	O
patients	O
infected	B-Entity
with	I-Entity
hepatitis	I-Entity
C	I-Entity
virus	I-Entity
.	O

Chronic	B-Entity
infection	I-Entity
with	I-Entity
hepatitis	I-Entity
C	I-Entity
virus	I-Entity
(	O
HCV	O
)	O
can	O
progress	O
to	O
cirrhosis	I-Entity
,	O
hepatocellular	B-Entity
carcinoma	I-Entity
,	O
and	O
end	B-Entity
-	I-Entity
stage	I-Entity
liver	I-Entity
disease	I-Entity
.	O

The	O
current	O
best	O
treatment	O
for	O
HCV	B-Entity
infection	I-Entity
is	O
combination	O
therapy	O
with	O
pegylated	O
interferon	I-Entity
and	O
ribavirin	I-Entity
.	O

Although	O
this	O
regimen	O
produces	O
sustained	O
virologic	O
responses	O
(	O
SVRs	O
)	O
in	O
approximately	O
50%	O
of	O
patients	O
,	O
it	O
can	O
be	O
associated	O
with	O
a	O
potentially	O
dose	O
-	O
limiting	O
hemolytic	B-Entity
anemia	I-Entity
.	O

Hemoglobin	O
concentrations	O
decrease	O
mainly	O
as	O
a	O
result	O
of	O
ribavirin	I-Entity
-	O
induced	O
hemolysis	I-Entity
,	O
and	O
this	O
anemia	I-Entity
can	O
be	O
problematic	O
in	O
patients	O
with	O
HCV	B-Entity
infection	I-Entity
,	O
especially	O
those	O
who	O
have	O
comorbid	O
renal	B-Entity
or	I-Entity
cardiovascular	I-Entity
disorders	I-Entity
.	O

In	O
general	O
,	O
anemia	I-Entity
can	O
increase	O
the	O
risk	O
of	O
morbidity	O
and	O
mortality	O
,	O
and	O
may	O
have	O
negative	O
effects	O
on	O
cerebral	O
function	O
and	O
quality	O
of	O
life	O
.	O

Although	O
ribavirin	I-Entity
-	O
associated	O
anemia	I-Entity
can	O
be	O
reversed	O
by	O
dose	O
reduction	O
or	O
discontinuation	O
,	O
this	O
approach	O
compromises	O
outcomes	O
by	O
significantly	O
decreasing	O
SVR	O
rates	O
.	O

Recombinant	O
human	O
erythropoietin	O
has	O
been	O
used	O
to	O
manage	O
ribavirin	I-Entity
-	O
associated	O
anemia	I-Entity
but	O
has	O
other	O
potential	O
disadvantages	O
.	O

Viramidine	I-Entity
,	O
a	O
liver	O
-	O
targeting	O
prodrug	O
of	O
ribavirin	I-Entity
,	O
has	O
the	O
potential	O
to	O
maintain	O
the	O
virologic	O
efficacy	O
of	O
ribavirin	I-Entity
while	O
decreasing	O
the	O
risk	O
of	O
hemolytic	B-Entity
anemia	I-Entity
in	O
patients	O
with	O
chronic	B-Entity
hepatitis	I-Entity
C.	I-Entity



Calcium	B-Entity
carbonate	I-Entity
toxicity	I-Entity
:	O
the	O
updated	O
milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
;	O
report	O
of	O
3	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
3	O
patients	O
with	O
calcium	B-Entity
carbonate	I-Entity
-	O
induced	O
hypercalcemia	I-Entity
and	O
gain	O
insights	O
into	O
the	O
cause	O
and	O
management	O
of	O
the	O
milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
.	O

METHODS	O
:	O
We	O
report	O
the	O
clinical	O
and	O
laboratory	O
data	O
in	O
3	O
patients	O
who	O
presented	O
with	O
severe	O
hypercalcemia	I-Entity
(	O
corrected	O
serum	O
calcium	I-Entity
>	O
or	O
=	O
14	O
mg	O
/	O
dL	O
)	O
and	O
review	O
the	O
pertinent	O
literature	O
on	O
milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
.	O

The	O
3	O
patients	O
had	O
acute	B-Entity
renal	I-Entity
insufficiency	I-Entity
,	O
relative	O
metabolic	B-Entity
alkalosis	I-Entity
,	O
and	O
low	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
,	O
PTH	O
-	O
related	O
peptide	O
,	O
and	O
1,25-dihydroxyvitamin	B-Entity
D	I-Entity
concentrations	O
.	O

Treatment	O
included	O
aggressive	O
hydration	O
and	O
varied	O
amounts	O
of	O
furosemide	I-Entity
.	O

The	O
2	O
patients	O
with	O
the	O
higher	O
serum	O
calcium	I-Entity
concentrations	O
received	O
pamidronate	I-Entity
intravenously	O
(	O
60	O
and	O
30	O
mg	O
,	O
respectively	O
)	O
,	O
which	O
caused	O
severe	O
hypocalcemia	I-Entity
.	O

Of	O
the	O
3	O
patients	O
,	O
2	O
were	O
ingesting	O
acceptable	O
doses	O
of	O
elemental	O
calcium	I-Entity
(	O
1	O
g	O
and	O
2	O
g	O
daily	O
,	O
respectively	O
)	O
in	O
the	O
form	O
of	O
calcium	B-Entity
carbonate	I-Entity
.	O

In	O
addition	O
to	O
our	O
highlighted	O
cases	O
,	O
we	O
review	O
the	O
history	O
,	O
classification	O
,	O
pathophysiologic	O
features	O
,	O
and	O
treatment	O
of	O
milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
and	O
summarize	O
the	O
cases	O
reported	O
from	O
early	O
1995	O
to	O
November	O
2003	O
.	O

Milk	B-Entity
-	I-Entity
alkali	I-Entity
syndrome	I-Entity
may	O
be	O
a	O
common	O
cause	O
of	O
unexplained	O
hypercalcemia	I-Entity
and	O
can	O
be	O
precipitated	O
by	O
small	O
amounts	O
of	O
orally	O
ingested	O
calcium	B-Entity
carbonate	I-Entity
in	O
susceptible	O
persons	O
.	O

Treatment	O
with	O
hydration	O
,	O
furosemide	I-Entity
,	O
and	O
discontinuation	O
of	O
the	O
calcium	I-Entity
and	O
vitamin	B-Entity
D	I-Entity
source	O
is	O
adequate	O
.	O

Pamidronate	I-Entity
treatment	O
is	O
associated	O
with	O
considerable	O
risk	O
for	O
hypocalcemia	I-Entity
,	O
even	O
in	O
cases	O
of	O
initially	O
severe	O
hypercalcemia	I-Entity
.	O



Management	O
strategies	O
for	O
ribavirin	I-Entity
-	O
induced	O
hemolytic	B-Entity
anemia	I-Entity
in	O
the	O
treatment	O
of	O
hepatitis	B-Entity
C	I-Entity
:	O
clinical	O
and	O
economic	O
implications	O
.	O

Recently	O
published	O
studies	O
have	O
demonstrated	O
increased	O
efficacy	O
and	O
cost	O
-	O
effectiveness	O
of	O
combination	O
therapy	O
with	O
interferon	O
and	O
alpha-2b	O
/	O
ribavirin	I-Entity
compared	O
with	O
interferon	B-Entity
-	I-Entity
alpha	I-Entity
monotherapy	O
in	O
the	O
treatment	O
of	O
chronic	B-Entity
hepatitis	I-Entity
C	I-Entity
(	O
CHC	I-Entity
)	O
.	O

Combination	O
therapy	O
is	O
associated	O
with	O
a	O
clinically	O
important	O
adverse	O
effect	O
:	O
ribavirin	I-Entity
-	O
induced	O
hemolytic	B-Entity
anemia	I-Entity
(	O
RIHA	I-Entity
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
direct	O
health	O
-	O
care	O
costs	O
and	O
management	O
of	O
RIHA	I-Entity
during	O
treatment	O
of	O
CHC	I-Entity
in	O
a	O
clinical	O
trial	O
setting	O
.	O

A	O
systematic	O
literature	O
review	O
was	O
conducted	O
to	O
synthesize	O
information	O
on	O
the	O
incidence	O
and	O
management	O
of	O
RIHA	I-Entity
.	O

Decision	O
-	O
analytic	O
techniques	O
were	O
used	O
to	O
estimate	O
the	O
cost	O
of	O
treating	O
RIHA	I-Entity
.	O

RESULTS	O
:	O
RIHA	I-Entity
,	O
defined	O
as	O
a	O
reduction	O
in	O
hemoglobin	O
to	O
less	O
than	O
100	O
g	O
/	O
L	O
,	O
occurs	O
in	O
approximately	O
7%	O
to	O
9%	O
of	O
patients	O
treated	O
with	O
combination	O
therapy	O
.	O

The	O
standard	O
of	O
care	O
for	O
management	O
of	O
RIHA	I-Entity
is	O
reduction	O
or	O
discontinuation	O
of	O
the	O
ribavirin	I-Entity
dosage	O
.	O

We	O
estimated	O
the	O
direct	O
cost	O
of	O
treating	O
clinically	O
significant	O
RIHA	I-Entity
to	O
be	O
170	O
per	O
patient	O
receiving	O
combination	O
therapy	O
per	O
48-week	O
treatment	O
course	O
(	O
range	O
68-	O
692	O
)	O
.	O

The	O
direct	O
cost	O
of	O
treating	O
clinically	O
significant	O
RIHA	I-Entity
is	O
1%	O
(	O
170/	O
16,459	O
)	O
of	O
drug	O
treatment	O
costs	O
.	O

Questions	O
remain	O
about	O
the	O
optimal	O
dose	O
of	O
ribavirin	I-Entity
and	O
the	O
incidence	O
of	O
RIHA	I-Entity
in	O
a	O
real	O
-	O
world	O
population	O
.	O

Despite	O
these	O
uncertainties	O
,	O
this	O
initial	O
evaluation	O
of	O
the	O
direct	O
cost	O
of	O
treating	O
RIHA	I-Entity
provides	O
an	O
estimate	O
of	O
the	O
cost	O
and	O
management	O
implications	O
of	O
this	O
clinically	O
important	O
adverse	O
effect	O
.	O



Effects	O
of	O
amine	I-Entity
pretreatment	O
on	O
ketamine	I-Entity
catatonia	I-Entity
in	O
pinealectomized	O
or	O
hypophysectomized	O
animals	O
.	O

The	O
present	O
studies	O
were	O
designed	O
to	O
clarify	O
the	O
role	O
of	O
catecholamines	I-Entity
and	O
pineal	O
idolamines	O
on	O
ketamine	I-Entity
-	O
induced	O
catatonia	I-Entity
in	O
the	O
intact	O
,	O
pinealectomized	O
or	O
hypophysectomized	O
chick	O
and	O
rat	O
.	O

In	O
the	O
pinealectomized	O
chick	O
,	O
pretreatment	O
with	O
dopamine	I-Entity
increased	O
the	O
duration	O
of	O
catatonia	I-Entity
(	O
DOC	O
)	O
after	O
ketamine	I-Entity
,	O
but	O
pretreatment	O
with	O
norepinephrine	I-Entity
did	O
not	O
.	O

Serotonin	I-Entity
and	O
N	B-Entity
-	I-Entity
acetyl	I-Entity
serotonin	I-Entity
which	O
augmented	O
ketamine	I-Entity
DOC	O
,	O
did	O
not	O
do	O
so	O
in	O
the	O
absence	O
of	O
the	O
pineal	O
gland	O
,	O
whereas	O
melatonin	I-Entity
potentiated	O
the	O
ketamine	I-Entity
DOC	O
in	O
both	O
the	O
intact	O
and	O
pinealectomized	O
chick	O
.	O

Ketamine	I-Entity
was	O
more	O
potent	O
in	O
the	O
hypophysectomized	O
chick	O
and	O
the	O
circadian	O
rhythm	O
noted	O
in	O
the	O
intact	O
chick	O
was	O
absent	O
;	O
furthermore	O
,	O
melatonin	I-Entity
did	O
not	O
augment	O
the	O
ketamine	I-Entity
DOC	O
whereas	O
dopamine	I-Entity
continued	O
to	O
do	O
so	O
.	O

This	O
study	O
did	O
not	O
demonstrate	O
a	O
species	O
difference	O
regarding	O
the	O
role	O
of	O
the	O
amines	I-Entity
on	O
the	O
pineal	O
in	O
spite	O
of	O
the	O
immature	O
blood	O
-	O
brain	O
barrier	O
in	O
the	O
young	O
chick	O
and	O
the	O
intact	O
barrier	O
in	O
the	O
rat	O
.	O

In	O
addition	O
,	O
these	O
data	O
indicate	O
a	O
direct	O
role	O
of	O
the	O
pituitary	O
in	O
the	O
augmentation	O
of	O
ketamine	I-Entity
DOC	O
induced	O
by	O
melatonin	I-Entity
.	O

Furthermore	O
,	O
dopamine	I-Entity
appeared	O
to	O
act	O
on	O
systems	O
more	O
closely	O
involved	O
with	O
the	O
induction	O
of	O
ketamine	I-Entity
catatonia	I-Entity
rather	O
than	O
directly	O
on	O
the	O
pituitary	O
.	O



Multicenter	O
,	O
double	O
-	O
blind	O
,	O
multiple	O
-	O
dose	O
,	O
parallel	O
-	O
groups	O
efficacy	O
and	O
safety	O
trial	O
of	O
azelastine	I-Entity
,	O
chlorpheniramine	I-Entity
,	O
and	O
placebo	O
in	O
the	O
treatment	O
of	O
spring	B-Entity
allergic	I-Entity
rhinitis	I-Entity
.	O

Azelastine	I-Entity
,	O
a	O
novel	O
antiallergic	O
medication	O
,	O
was	O
compared	O
with	O
chlorpheniramine	B-Entity
maleate	I-Entity
and	O
placebo	O
for	O
efficacy	O
and	O
safety	O
in	O
the	O
treatment	O
of	O
spring	B-Entity
allergic	I-Entity
rhinitis	I-Entity
in	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
multiple	O
-	O
dose	O
,	O
parallel	O
-	O
groups	O
study	O
.	O

Subjects	O
ranged	O
in	O
age	O
from	O
18	O
to	O
60	O
years	O
of	O
age	O
and	O
had	O
at	O
least	O
a	O
2-year	O
history	O
of	O
spring	B-Entity
allergic	I-Entity
rhinitis	I-Entity
,	O
confirmed	O
by	O
positive	O
skin	O
test	O
to	O
spring	O
aeroallergens	O
.	O

Medications	O
were	O
given	O
four	O
times	O
daily	O
;	O
the	O
azelastine	I-Entity
groups	O
received	O
0.5	O
,	O
1.0	O
,	O
or	O
2.0	O
mg	O
in	O
the	O
morning	O
and	O
evening	O
with	O
placebo	O
in	O
the	O
early	O
and	O
late	O
afternoon	O
;	O
the	O
chlorpheniramine	I-Entity
group	O
received	O
4.0	O
mg	O
four	O
times	O
daily	O
.	O

Symptoms	O
relief	O
in	O
the	O
group	O
receiving	O
the	O
highest	O
concentration	O
of	O
azelastine	I-Entity
(	O
2.0	O
mg	O
twice	O
daily	O
)	O
was	O
statistically	O
greater	O
than	O
in	O
the	O
placebo	O
group	O
during	O
all	O
weeks	O
of	O
the	O
study	O
.	O

Lower	O
doses	O
of	O
azelastine	I-Entity
were	O
statistically	O
more	O
effective	O
than	O
placebo	O
only	O
during	O
portions	O
of	O
the	O
first	O
3	O
weeks	O
of	O
the	O
study	O
.	O

In	O
contrast	O
,	O
although	O
the	O
chlorpheniramine	I-Entity
group	O
did	O
have	O
fewer	O
symptoms	O
than	O
the	O
placebo	O
group	O
during	O
the	O
study	O
,	O
the	O
difference	O
never	O
reached	O
statistical	O
significance	O
during	O
any	O
week	O
of	O
the	O
study	O
.	O

Drowsiness	I-Entity
and	O
altered	B-Entity
taste	I-Entity
perception	I-Entity
were	O
increased	O
significantly	O
over	O
placebo	O
only	O
in	O
the	O
high	O
-	O
dose	O
azelastine	I-Entity
group	O
.	O

Azelastine	I-Entity
appears	O
to	O
be	O
a	O
safe	O
,	O
efficacious	O
medication	O
for	O
seasonal	B-Entity
allergic	I-Entity
rhinitis	I-Entity
.	O



One	O
case	O
of	O
acute	O
hypercalcaemia	I-Entity
and	O
two	O
of	O
recurrent	O
nephrolithiasis	I-Entity
are	O
reported	O
in	O
patients	O
who	O
had	O
regularly	O
consumed	O
large	O
amounts	O
of	O
calcium	B-Entity
carbon	I-Entity
-	I-Entity
ate	I-Entity
-	O
sodium	B-Entity
bicarbonate	I-Entity
powders	O
for	O
more	O
than	O
20	O
years	O
.	O



Prolonged	O
paralysis	I-Entity
due	O
to	O
nondepolarizing	B-Entity
neuromuscular	I-Entity
blocking	I-Entity
agents	I-Entity
and	O
corticosteroids	I-Entity
.	O

The	O
long	O
-	O
term	O
use	O
of	O
nondepolarizing	B-Entity
neuromuscular	I-Entity
blocking	I-Entity
agents	I-Entity
(	O
ND	B-Entity
-	I-Entity
NMBA	I-Entity
)	O
has	O
recently	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
prolonged	O
muscle	B-Entity
weakness	I-Entity
,	O
although	O
the	O
site	O
of	O
the	O
lesion	O
and	O
the	O
predisposing	O
factors	O
have	O
been	O
unclear	O
.	O

We	O
report	O
3	O
patients	O
(	O
age	O
37	O
-	O
52	O
years	O
)	O
with	O
acute	O
respiratory	B-Entity
insufficiency	I-Entity
who	O
developed	O
prolonged	O
weakness	I-Entity
following	O
the	O
discontinuation	O
of	O
ND	B-Entity
-	I-Entity
NMBAs	I-Entity
.	O

Two	O
patients	O
also	O
received	O
intravenous	O
corticosteroids	I-Entity
.	O

Renal	O
function	O
was	O
normal	O
but	O
hepatic	O
function	O
was	O
impaired	O
in	O
all	O
patients	O
,	O
and	O
all	O
had	O
acidosis	I-Entity
.	O

The	O
serum	O
vecuronium	I-Entity
level	O
measured	O
in	O
1	O
patient	O
14	O
days	O
after	O
the	O
drug	O
had	O
been	O
discontinued	O
was	O
172	O
ng	O
/	O
mL.	O

A	O
muscle	O
biopsy	O
in	O
this	O
patient	O
showed	O
loss	B-Entity
of	I-Entity
thick	I-Entity
,	I-Entity
myosin	I-Entity
filaments	I-Entity
.	O

The	O
weakness	I-Entity
in	O
these	O
patients	O
is	O
due	O
to	O
pathology	B-Entity
at	I-Entity
both	I-Entity
the	I-Entity
neuromuscular	I-Entity
junction	I-Entity
(	O
most	O
likely	O
due	O
to	O
ND	B-Entity
-	I-Entity
NMBA	I-Entity
)	O
and	O
muscle	O
(	O
most	O
likely	O
due	O
to	O
corticosteroids	I-Entity
)	O
.	O

Hepatic	B-Entity
dysfunction	I-Entity
and	O
acidosis	I-Entity
are	O
contributing	O
risk	O
factors	O
.	O



Prostaglandin	B-Entity
E2-induced	I-Entity
bladder	B-Entity
hyperactivity	I-Entity
in	O
normal	O
,	O
conscious	O
rats	O
:	O
involvement	O
of	O
tachykinins	I-Entity
?	O

In	O
normal	O
conscious	O
rats	O
investigated	O
by	O
continuous	O
cystometry	O
,	O
intravesically	O
instilled	O
prostaglandin	B-Entity
(	I-Entity
PG	I-Entity
)	I-Entity
E2	I-Entity
facilitated	O
micturition	O
and	O
increased	O
basal	O
intravesical	O
pressure	O
.	O

The	O
effect	O
was	O
attenuated	O
by	O
both	O
the	O
NK1	O
receptor	O
selective	O
antagonist	O
RP	B-Entity
67,580	I-Entity
and	O
the	O
NK2	O
receptor	O
selective	O
antagonist	O
SR	B-Entity
48,968	I-Entity
,	O
given	O
intra	O
-	O
arterially	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
stimulation	O
of	O
both	O
NK1	O
and	O
NK2	O
receptors	O
.	O

Intra	O
-	O
arterially	O
given	O
PGE2	I-Entity
produced	O
a	O
distinct	O
increase	O
in	O
bladder	O
pressure	O
before	O
initiating	O
a	O
micturition	O
reflex	O
,	O
indicating	O
that	O
the	O
PG	I-Entity
had	O
a	O
direct	O
contractant	O
effect	O
on	O
the	O
detrusor	O
smooth	O
muscle	O
.	O

The	O
effect	O
of	O
intra	O
-	O
arterial	O
PGE2	I-Entity
could	O
not	O
be	O
blocked	O
by	O
intra	O
-	O
arterial	O
RP	B-Entity
67,580	I-Entity
or	O
SR	B-Entity
48,968	I-Entity
,	O
which	O
opens	O
the	O
possibility	O
that	O
the	O
micturition	O
reflex	O
elicited	O
by	O
intra	O
-	O
arterial	O
PGE2	I-Entity
was	O
mediated	O
by	O
pathways	O
other	O
than	O
the	O
reflex	O
initiated	O
when	O
the	O
PG	I-Entity
was	O
given	O
intravesically	O
.	O

The	O
present	O
results	O
thus	O
suggest	O
that	O
intra	O
-	O
arterial	O
PGE2	I-Entity
,	O
given	O
near	O
the	O
bladder	O
,	O
may	O
initiate	O
micturition	O
in	O
the	O
normal	O
rat	O
chiefly	O
by	O
directly	O
contracting	O
the	O
smooth	O
muscle	O
of	O
the	O
detrusor	O
.	O

However	O
,	O
when	O
given	O
intravesically	O
,	O
PGE2	I-Entity
may	O
stimulate	O
micturition	O
by	O
releasing	O
tachykinins	I-Entity
from	O
nerves	O
in	O
and/or	O
immediately	O
below	O
the	O
urothelium	O
.	O

These	O
tachykinins	I-Entity
,	O
in	O
turn	O
,	O
initiate	O
a	O
micturition	O
reflex	O
by	O
stimulating	O
NK1	O
and	O
NK2	O
receptors	O
.	O

Prostanoids	I-Entity
may	O
,	O
via	O
release	O
of	O
tachykinins	I-Entity
,	O
contribute	O
to	O
both	O
urge	O
and	O
bladder	B-Entity
hyperactivity	I-Entity
seen	O
in	O
inflammatory	O
conditions	O
of	O
the	O
lower	O
urinary	O
tract	O
.	O



Thiazide	I-Entity
diuretics	O
,	O
hypokalemia	I-Entity
and	O
cardiac	B-Entity
arrhythmias	I-Entity
.	O

Thiazide	I-Entity
diuretics	O
are	O
widely	O
accepted	O
as	O
the	O
cornerstone	O
of	O
antihypertensive	O
treatment	O
programs	O
.	O

Hypokalemia	I-Entity
is	O
a	O
commonly	O
encountered	O
metabolic	O
consequence	O
of	O
chronic	O
thiazide	I-Entity
therapy	O
.	O

We	O
treated	O
38	O
patients	O
(	O
22	O
low	O
renin	O
,	O
16	O
normal	O
renin	O
)	O
with	O
moderate	O
diastolic	B-Entity
hypertension	I-Entity
with	O
hydrochlorothiazide	I-Entity
(	O
HCTC	I-Entity
)	O
administered	O
on	O
a	O
twice	O
daily	O
schedule	O
.	O

The	O
serum	O
K	I-Entity
during	O
the	O
control	O
period	O
was	O
4.5	O
+	O
/-	O

/	O
l	O
an	O
on	O
50	O
,	O
100	O
,	O
150	O
and	O
200	O
mg	O
HCTZ	I-Entity
daily	O
3.9	O

Corresponding	O
figures	O
for	O
whole	O
body	O
K	I-Entity
were	O
4107	O
+	O
/-	O

In	O
13	O
patients	O
we	O
observed	O
the	O
effects	O
of	O
HCTZ	I-Entity
therapy	O
(	O
100	O
mg	O
daily	O
)	O
on	O
the	O
occurrence	O
of	O
PVC	O
's	O
during	O
rest	O
as	O
well	O
as	O
during	O
static	O
and	O
dynamic	O
exercise	O
.	O

Corresponding	O
figures	O
during	O
HCTZ	I-Entity
therapy	O
100	O
mg	O
daily	O
were	O
1.4	O
+	O
/-	O

K+	I-Entity
observed	O
r	O
=	O
0.72	O
,	O
p	O
less	O
than	O
0.001	O
.	O

In	O
conclusion	O
we	O
found	O
that	O
thiazide	I-Entity
diuretics	O
cause	O
hypokalemia	I-Entity
and	O
depletion	O
of	O
body	O
potassium	I-Entity
.	O

The	O
more	O
profound	O
hypokalemia	I-Entity
,	O
the	O
greater	O
the	O
propensity	O
for	O
the	O
occurrence	O
of	O
PVC	O
's	O
.	O



Diuretics	O
,	O
potassium	I-Entity
and	O
arrhythmias	I-Entity
in	O
hypertensive	I-Entity
coronary	B-Entity
disease	I-Entity
.	O

It	O
has	O
been	O
proposed	O
that	O
modest	O
changes	O
in	O
plasma	O
potassium	I-Entity
can	O
alter	O
the	O
tendency	O
towards	O
cardiac	B-Entity
arrhythmias	I-Entity
.	O

If	O
this	O
were	O
so	O
,	O
patients	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
might	O
be	O
especially	O
susceptible	O
.	O

Thus	O
,	O
myocardial	O
electrical	O
excitability	O
was	O
measured	O
in	O
patients	O
with	O
mild	O
essential	O
hypertension	I-Entity
and	O
known	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
after	O
8	O
weeks	O
of	O
treatment	O
with	O
a	O
potassium	I-Entity
-	O
conserving	O
diuretic	O
(	O
amiloride	I-Entity
)	O
and	O
a	O
similar	O
period	O
on	O
a	O
potassium	I-Entity
-	O
losing	O
diuretic	O
(	O
chlorthalidone	I-Entity
)	O
in	O
a	O
randomised	O
study	O
.	O

Plasma	O
potassium	I-Entity
concentrations	O
were	O
on	O
average	O
1	O
mmol	O
/	O
L	O
lower	O
during	O
the	O
chlorthalidone	I-Entity
phase	O
compared	O
to	O
amiloride	I-Entity
therapy	O
.	O

Blood	O
pressure	O
and	O
volume	O
states	O
as	O
assessed	O
by	O
bodyweight	O
,	O
plasma	O
renin	O
and	O
noradrenaline	I-Entity
(	O
norepinephrine	I-Entity
)	O

Compared	O
to	O
amiloride	I-Entity
treatment	O
,	O
the	O
chlorthalidone	I-Entity
phase	O
was	O
associated	O
with	O
an	O
increased	O
frequency	O
of	O
ventricular	B-Entity
ectopic	I-Entity
beats	I-Entity
(	O
24-hour	O
Holter	O
monitoring	O
)	O
and	O
a	O
higher	O
Lown	O
grading	O
,	O
increased	O
upslope	O
and	O
duration	O
of	O
the	O
monophasic	O
action	O
potential	O
,	O
prolonged	O
ventricular	O
effective	O
refractory	O
period	O
,	O
and	O
increased	O
electrical	O
instability	O
during	O
programmed	O
ventricular	O
stimulation	O
.	O

The	O
above	O
results	O
indicate	O
that	O
because	O
potassium	I-Entity
-	O
losing	O
diuretic	O
therapy	O
can	O
increase	O
myocardial	O
electrical	O
excitability	O
in	O
patients	O
with	O
ischaemic	B-Entity
heart	I-Entity
disease	I-Entity
,	O
even	O
minor	O
falls	O
in	O
plasma	O
potassium	I-Entity
concentrations	O
are	O
probably	O
best	O
avoided	O
in	O
such	O
patients	O
.	O



GABA	I-Entity
involvement	O
in	O
naloxone	I-Entity
induced	O
reversal	O
of	O
respiratory	B-Entity
paralysis	I-Entity
produced	O
by	O
thiopental	I-Entity
.	O

No	O
agent	O
is	O
yet	O
available	O
to	O
reverse	O
respiratory	B-Entity
paralysis	I-Entity
produced	O
by	O
CNS	O
depressants	O
,	O
such	O
as	O
general	O
anesthetics	O
.	O

In	O
this	O
study	O
naloxone	I-Entity
reversed	O
respiratory	B-Entity
paralysis	I-Entity
induced	O
by	O
thiopental	I-Entity
in	O
rats	O
.	O

thiopental	I-Entity
produced	O
anesthesia	O
without	O
altering	O
respiratory	O
rate	O
,	O
increased	O
GABA	I-Entity
,	O
decreased	O
glutamate	I-Entity
,	O
and	O
had	O
no	O
effect	O
on	O
aspartate	I-Entity
or	O
glycine	I-Entity
levels	O
compared	O
to	O
controls	O
in	O
rat	O
cortex	O
and	O
brain	O
stem	O
.	O

Pretreatment	O
of	O
rats	O
with	O
thiosemicarbazide	I-Entity
for	O
30	O
minutes	O
abolished	O
the	O
anesthetic	O
action	O
as	O
well	O
as	O
the	O
respiratory	O
depressant	O
action	O
of	O
thiopental	I-Entity
.	O

thiopental	I-Entity
produced	O
respiratory	B-Entity
arrest	I-Entity
with	O
further	O
increase	O
in	O
GABA	I-Entity
and	O
decrease	O
in	O
glutamate	I-Entity
again	O
in	O
cortex	O
and	O
brain	O
stem	O
without	O
affecting	O
any	O
of	O
the	O
amino	B-Entity
acids	I-Entity
studied	O
in	O
four	O
regions	O
of	O
rat	O
brain	O
.	O

Naloxone	I-Entity
(	O
2.5	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O

reversed	O
respiratory	B-Entity
paralysis	I-Entity
,	O
glutamate	I-Entity
and	O
GABA	I-Entity
levels	O
to	O
control	O
values	O
in	O
brain	O
stem	O
and	O
cortex	O
with	O
no	O
changes	O
in	O
caudate	O
or	O
cerebellum	O
.	O

These	O
data	O
suggest	O
naloxone	I-Entity
reverses	O
respiratory	B-Entity
paralysis	I-Entity
produced	O
by	O
thiopental	I-Entity
and	O
involves	O
GABA	I-Entity
in	O
its	O
action	O
.	O



National	O
project	O
on	O
the	O
prevention	O
of	O
mother	O
-	O
to	O
-	O
infant	O
infection	B-Entity
by	I-Entity
hepatitis	I-Entity
B	I-Entity
virus	I-Entity
in	O
Japan	O
.	O

In	O
Japan	O
,	O
a	O
nationwide	O
prevention	O
program	O
against	O
mother	O
-	O
to	O
-	O
infant	O
infection	B-Entity
by	I-Entity
hepatitis	I-Entity
B	I-Entity
virus	I-Entity
(	O
HBV	O
)	O
started	O
in	O
1985	O
.	O

This	O
program	O
consists	O
of	O
double	O
screenings	O
of	O
pregnant	O
women	O
and	O
prophylactic	O
treatment	O
to	O
the	O
infants	O
born	O
to	O
both	O
hepatitis	B-Entity
B	I-Entity
surface	I-Entity
antigen	I-Entity
(	O
HBsAg	I-Entity
)	O
and	O
hepatitis	B-Entity
B	I-Entity
e	I-Entity
antigen	I-Entity
(	O
HBeAg	I-Entity
)	O
positive	O
mothers	O
.	O

These	O
infants	O
are	O
treated	O
with	O
two	O
injections	O
of	O
hepatitis	B-Entity
B	I-Entity
immune	O
globulin	O
(	O
HBIG	O
)	O
and	O
at	O
least	O
three	O
injections	O
of	O
plasma	O
derived	O
hepatitis	B-Entity
B	I-Entity
vaccine	I-Entity
.	O

93.4%	O
pregnant	O
women	O
had	O
the	O
chance	O
to	O
be	O
examined	O
for	O
HBsAg	I-Entity
,	O
and	O
the	O
positive	O
rate	O
was	O
1.4	O
to	O
1.5%	O
.	O

The	O
HBeAg	I-Entity
positive	O
rate	O
in	O
HBsAg	I-Entity
positive	O
was	O
23	O
to	O
26%	O
.	O

The	O
HBsAg	I-Entity
positive	O
rate	O
in	O
neonates	O
and	O
in	O
infants	O
before	O
two	O
months	O
were	O
3%	O
and	O
2%	O
respectively	O
.	O



Nociceptive	O
effects	O
induced	O
by	O
intrathecal	O
administration	O
of	O
prostaglandin	B-Entity
D2	I-Entity
,	I-Entity
E2	I-Entity
,	I-Entity
or	I-Entity
F2	I-Entity
alpha	I-Entity
to	O
conscious	O
mice	O
.	O

The	O
effects	O
of	O
intrathecal	O
administration	O
of	O
prostaglandins	I-Entity
on	O
pain	I-Entity
responses	O
in	O
conscious	O
mice	O
were	O
evaluated	O
by	O
using	O
hot	O
plate	O
and	O
acetic	B-Entity
acid	I-Entity
writhing	O
tests	O
.	O

Prostaglandin	B-Entity
D2	I-Entity
(	O
0.5	O
-	O
3	O
ng	O
/	O
mouse	O
)	O
had	O
a	O
hyperalgesic	I-Entity
action	O
on	O
the	O
response	O
to	O
a	O
hot	O
plate	O
during	O
a	O
3	O
-	O
60	O
min	O
period	O
after	O
injection	O
.	O

Prostaglandin	B-Entity
E2	I-Entity
showed	O
a	O
hyperalgesic	I-Entity
effect	O
at	O
doses	O
of	O
1	O
pg	I-Entity
to	O
10	O
ng	O
/	O
mouse	O
,	O
but	O
the	O
effect	O
lasted	O
shorter	O
(	O
3	O
-	O
30	O
min	O
)	O
than	O
that	O
of	O
prostaglandin	B-Entity
D2	I-Entity
.	O

Similar	O
results	O
were	O
obtained	O
by	O
acetic	B-Entity
acid	I-Entity
writhing	O
tests	O
.	O

The	O
hyperalgesic	I-Entity
effect	O
of	O
prostaglandin	B-Entity
D2	I-Entity
was	O
blocked	O
by	O
simultaneous	O
injection	O
of	O
a	O
substance	O
P	O
antagonist	O
(	O
greater	O
than	O
or	O
equal	O
to	O
100	O
ng	O
)	O
but	O
not	O
by	O
AH6809	I-Entity
,	O
a	O
prostanoid	O
EP1-receptor	O
antagonist	O
.	O

Conversely	O
,	O
prostaglandin	B-Entity
E2-induced	I-Entity
hyperalgesia	I-Entity
was	O
blocked	O
by	O
AH6809	I-Entity
(	O
greater	O
than	O
or	O
equal	O
to	O
500	O
ng	O
)	O
but	O
not	O
by	O
the	O
substance	O
P	O
antagonist	O
.	O

Prostaglandin	B-Entity
F2	I-Entity
alpha	I-Entity
had	O
little	O
effect	O
on	O
pain	I-Entity
responses	O
.	O

These	O
results	O
demonstrate	O
that	O
both	O
prostaglandin	B-Entity
D2	I-Entity
and	O
prostaglandin	B-Entity
E2	I-Entity
exert	O
hyperalgesia	I-Entity
in	O
the	O
spinal	O
cord	O
,	O
but	O
in	O
different	O
ways	O
.	O



Swallowing	O
-	O
induced	O
atrial	B-Entity
tachyarrhythmia	I-Entity
triggered	O
by	O
salbutamol	I-Entity
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

On	O
electrocardiogram	O
,	O
episodes	O
of	O
atrial	B-Entity
tachyarrhythmia	I-Entity
were	O
recorded	O
immediately	O
after	O
swallowing	O
;	O
24-hour	O
Holter	O
monitoring	O
recorded	O
several	O
events	O
.	O

The	O
arrhythmia	I-Entity
resolved	O
after	O
therapy	O
with	O
atenolol	I-Entity
,	O
but	O
recurred	O
a	O
year	O
later	O
.	O

The	O
patient	O
noticed	O
that	O
before	O
these	O
episodes	O
he	O
had	O
been	O
using	O
an	O
inhalator	O
of	O
salbutamol	I-Entity
.	O

After	O
stopping	O
the	O
beta	O
-	O
agonist	O
,	O
and	O
after	O
a	O
week	O
with	O
the	O
atenolol	I-Entity
,	O
the	O
arrhythmia	I-Entity
disappeared	O
.	O

DISCUSSION	O
:	O
Swallowing	O
-	O
induced	O
atrial	B-Entity
tachyarrhythmia	I-Entity
(	O
SIAT	I-Entity
)	O
is	O
a	O
rare	O
phenomenon	O
.	O

Fewer	O
than	O
50	O
cases	O
of	O
SIAT	I-Entity
have	O
been	O
described	O
in	O
the	O
literature	O
.	O

This	O
article	O
summarizes	O
all	O
the	O
cases	O
published	O
,	O
creating	O
a	O
comprehensive	O
review	O
of	O
the	O
current	O
knowledge	O
and	O
approach	O
to	O
SIAT	I-Entity
.	O

It	O
discusses	O
demographics	O
,	O
clinical	O
characteristics	O
and	O
types	O
of	O
arrhythmia	I-Entity
,	O
postulated	O
mechanisms	O
of	O
SIAT	I-Entity
,	O
and	O
different	O
treatment	O
possibilities	O
such	O
as	O
medications	O
,	O
surgery	O
,	O
and	O
radiofrequency	O
catheter	O
ablation	O
(	O
RFCA	O
)	O
.	O

CONCLUSION	O
:	O
Salbutamol	I-Entity
is	O
presented	O
here	O
as	O
a	O
possible	O
trigger	O
for	O
SIAT	I-Entity
.	O

Although	O
it	O
is	O
difficult	O
to	O
define	O
causality	O
in	O
a	O
case	O
report	O
,	O
it	O
is	O
logical	O
to	O
think	O
that	O
a	O
beta	O
-	O
agonist	O
like	O
salbutamol	I-Entity
(	O
known	O
to	O
induce	O
tachycardia	I-Entity
)	O
may	O
be	O
the	O
trigger	O
of	O
adrenergic	O
reflexes	O
originating	O
in	O
the	O
esophagus	O
while	O
swallowing	O
and	O
that	O
a	O
beta	O
-	O
blocker	O
such	O
as	O
atenolol	I-Entity
(	O
that	O
blocks	O
the	O
adrenergic	O
activity	O
)	O
may	O
relieve	O
it	O
.	O



Coenzyme	B-Entity
Q10	I-Entity
treatment	O
ameliorates	O
acute	O
cisplatin	I-Entity
nephrotoxicity	I-Entity
in	O
mice	O
.	O

The	O
nephroprotective	O
effect	O
of	O
coenzyme	B-Entity
Q10	I-Entity
was	O
investigated	O
in	O
mice	O
with	O
acute	B-Entity
renal	I-Entity
injury	I-Entity
induced	O
by	O
a	O
single	O
i.p	O
.	O

injection	O
of	O
cisplatin	I-Entity
(	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Coenzyme	B-Entity
Q10	I-Entity
treatment	O

(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
,	O
i.p	O
.	O
)	O
was	O
applied	O
for	O
6	O
consecutive	O
days	O
,	O
starting	O
1	O
day	O
before	O
cisplatin	I-Entity
administration	O
.	O

Coenzyme	B-Entity
Q10	I-Entity
significantly	O
reduced	O
blood	B-Entity
urea	I-Entity
nitrogen	I-Entity
and	O
serum	O
creatinine	I-Entity
levels	O
which	O
were	O
increased	O
by	O
cisplatin	I-Entity
.	O

Coenzyme	B-Entity
Q10	I-Entity
significantly	O
compensated	O
deficits	O
in	O
the	O
antioxidant	O
defense	O
mechanisms	O
(	O
reduced	B-Entity
glutathione	I-Entity
level	O
and	O
superoxide	I-Entity
dismutase	O
activity	O
)	O
,	O
suppressed	O
lipid	O
peroxidation	O
,	O
decreased	O
the	O
elevations	O
of	O
tumor	I-Entity
necrosis	I-Entity
factor	O
-	O
alpha	O
,	O
nitric	B-Entity
oxide	I-Entity
and	O
platinum	I-Entity
ion	O
concentration	O
,	O
and	O
attenuated	O
the	O
reductions	O
of	O
selenium	I-Entity
and	O
zinc	I-Entity
ions	O
in	O
renal	O
tissue	O
resulted	O
from	O
cisplatin	I-Entity
administration	O
.	O

Also	O
,	O
histopathological	O
renal	B-Entity
tissue	I-Entity
damage	I-Entity
mediated	O
by	O
cisplatin	I-Entity
was	O
ameliorated	O
by	O
coenzyme	B-Entity
Q10	I-Entity
treatment	O
.	O

Immunohistochemical	O
analysis	O
revealed	O
that	O
coenzyme	B-Entity
Q10	I-Entity
significantly	O
decreased	O
the	O
cisplatin	I-Entity
-	O
induced	O
overexpression	O
of	O
inducible	O
nitric	B-Entity
oxide	I-Entity
synthase	O
,	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
caspase-3	O
and	O
p53	O
in	O
renal	O
tissue	O
.	O

It	O
was	O
concluded	O
that	O
coenzyme	B-Entity
Q10	I-Entity
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	I-Entity
nephrotoxicity	I-Entity
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O



Metformin	I-Entity
prevents	O
experimental	O
gentamicin	I-Entity
-	O
induced	O
nephropathy	I-Entity
by	O
a	O
mitochondria	O
-	O
dependent	O
pathway	O
.	O

The	O
antidiabetic	O
drug	O
metformin	I-Entity
can	O
diminish	O
apoptosis	O
induced	O
by	O
oxidative	O
stress	O
in	O
endothelial	O
cells	O
and	O
prevent	O
vascular	B-Entity
dysfunction	I-Entity
even	O
in	O
nondiabetic	O
patients	O
.	O

Here	O
we	O
tested	O
whether	O
it	O
has	O
a	O
beneficial	O
effect	O
in	O
a	O
rat	O
model	O
of	O
gentamicin	I-Entity
toxicity	I-Entity
.	O

Mitochondrial	O
analysis	O
,	O
respiration	O
intensity	O
,	O
levels	O
of	O
reactive	O
oxygen	I-Entity
species	O
,	O
permeability	O
transition	O
,	O
and	O
cytochrome	O
c	O
release	O
were	O
assessed	O
3	O
and	O
6	O
days	O
after	O
gentamicin	I-Entity
administration	O
.	O

Metformin	I-Entity
treatment	O
fully	O
blocked	O
gentamicin	I-Entity
-	O
mediated	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O

Metformin	I-Entity
also	O
protected	O
the	O
kidney	O
from	O
histological	O
damage	O
6	O
days	O
after	O
gentamicin	I-Entity
administration	O
.	O

These	O
in	O
vivo	O
markers	O
of	O
kidney	B-Entity
dysfunction	I-Entity
and	O
their	O
correction	O
by	O
metformin	I-Entity
were	O
complemented	O
by	O
in	O
vitro	O
studies	O
of	O
mitochondrial	O
function	O
.	O

We	O
found	O
that	O
gentamicin	I-Entity
treatment	O
depleted	O
respiratory	O
components	O
(	O
cytochrome	O
c	O
,	O
NADH	O
)	O
,	O
probably	O
due	O
to	O
the	O
opening	O
of	O
mitochondrial	O
transition	O
pores	O
.	O

These	O
injuries	O
,	O
partly	O
mediated	O
by	O
a	O
rise	O
in	O
reactive	O
oxygen	I-Entity
species	O
from	O
the	O
electron	O
transfer	O
chain	O
,	O
were	O
significantly	O
decreased	O
by	O
metformin	I-Entity
.	O

Thus	O
,	O
our	O
study	O
suggests	O
that	O
pleiotropic	O
effects	O
of	O
metformin	I-Entity
can	O
lessen	O
gentamicin	I-Entity
nephrotoxicity	I-Entity
and	O
improve	O
mitochondrial	O
homeostasis	O
.	O



Sedation	O
depth	O
during	O
spinal	O
anesthesia	O
and	O
the	O
development	O
of	O
postoperative	B-Entity
delirium	I-Entity
in	O
elderly	O
patients	O
undergoing	O
hip	B-Entity
fracture	I-Entity
repair	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
limiting	O
intraoperative	O
sedation	O
depth	O
during	O
spinal	O
anesthesia	O
for	O
hip	B-Entity
fracture	I-Entity
repair	O
in	O
elderly	O
patients	O
can	O
decrease	O
the	O
prevalence	O
of	O
postoperative	B-Entity
delirium	I-Entity
.	O

:	O
We	O
performed	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
controlled	O
trial	O
at	O
an	O
academic	O
medical	O
center	O
of	O
elderly	O
patients	O
(	O
>	O
or=65	O
years	O
)	O
without	O
preoperative	O
delirium	I-Entity
or	O
severe	O
dementia	I-Entity
who	O
underwent	O
hip	B-Entity
fracture	I-Entity
repair	O
under	O
spinal	O
anesthesia	O
with	O
propofol	I-Entity
sedation	O
.	O

Postoperative	B-Entity
delirium	I-Entity
was	O
assessed	O
as	O
defined	O
by	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B-Entity
Disorders	I-Entity
(	O
Third	O
Edition	O
Revised	O
)	O
criteria	O
using	O
the	O
Confusion	O
Assessment	O
Method	O
beginning	O
at	O
any	O
time	O
from	O
the	O
second	O
day	O
after	O
surgery	O
.	O

The	O
prevalence	O
of	O
postoperative	B-Entity
delirium	I-Entity
was	O
significantly	O
lower	O
in	O
the	O
light	O
sedation	O
group	O
(	O
11/57	O
[	O
19%	O
]	O
vs	O
23/57	O
[	O
40%	O
]	O
in	O
the	O
deep	O
sedation	O
group	O
;	O
P=.02	O
)	O
,	O
indicating	O
that	O
1	O
incident	O
of	O
delirium	I-Entity
will	O
be	O
prevented	O
for	O
every	O
4.7	O
patients	O
treated	O
with	O
light	O
sedation	O
.	O

SD	O
number	O
of	O
days	O
of	O
delirium	I-Entity
during	O
hospitalization	O
was	O
lower	O
in	O
the	O
light	O
sedation	O
group	O
than	O
in	O
the	O
deep	O
sedation	O
group	O
(	O
0.5+/-1.5	O
days	O
vs	O
1.4+/-4.0	O
days	O
;	O
P=.01	O
)	O
.	O

The	O
use	O
of	O
light	O
propofol	I-Entity
sedation	O
decreased	O
the	O
prevalence	O
of	O
postoperative	B-Entity
delirium	I-Entity
by	O
50%	O
compared	O
with	O
deep	O
sedation	O
.	O

Limiting	O
depth	O
of	O
sedation	O
during	O
spinal	O
anesthesia	O
is	O
a	O
simple	O
,	O
safe	O
,	O
and	O
cost	O
-	O
effective	O
intervention	O
for	O
preventing	O
postoperative	B-Entity
delirium	I-Entity
in	O
elderly	O
patients	O
that	O
could	O
be	O
widely	O
and	O
readily	O
adopted	O
.	O



Sorafenib	I-Entity
-	O
induced	O
acute	O
myocardial	B-Entity
infarction	I-Entity
due	O
to	O
coronary	B-Entity
artery	I-Entity
spasm	I-Entity
.	O

A	O
65-year	O
-	O
old	O
man	O
with	O
advanced	O
renal	B-Entity
cell	I-Entity
carcinoma	I-Entity
was	O
admitted	O
due	O
to	O
continuing	O
chest	B-Entity
pain	I-Entity
at	O
rest	O
.	O

Two	O
weeks	O
before	O
his	O
admission	O
,	O
sorafenib	I-Entity
had	O
been	O
started	O
.	O

He	O
was	O
diagnosed	O
with	O
non	O
-	O
ST	O
-	O
elevation	O
myocardial	B-Entity
infarction	I-Entity
by	O
laboratory	O
data	O
and	O
electrocardiogram	O
.	O

Enhanced	O
heart	O
magnetic	O
resonance	O
imaging	O
also	O
showed	O
subendocardial	B-Entity
infarction	I-Entity
.	O

Coronary	B-Entity
artery	I-Entity
spasm	I-Entity
was	O
induced	O
by	O
a	O
provocative	O
test	O
.	O

Cessation	O
of	O
sorafenib	I-Entity
and	O
administration	O
of	O
Ca	I-Entity
-	O
channel	O
blocker	O
and	O
nitrates	I-Entity
ameliorated	O
his	O
symptoms	O
,	O
but	O
relapse	O
occurred	O
after	O
resumption	O
of	O
sorafenib	I-Entity
.	O

Addition	O
of	O
oral	O
nicorandil	I-Entity
reduced	O
his	O
symptoms	O
and	O
maintained	O
stable	B-Entity
angina	I-Entity
status	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
sorafenib	I-Entity
-	O
induced	O
coronary	B-Entity
artery	I-Entity
spasm	I-Entity
.	O

Sorafenib	I-Entity
is	O
a	O
multikinase	O
inhibitor	O
that	O
targets	O
signaling	O
pathways	O
necessary	O
for	O
cellular	O
proliferation	O
and	O
survival	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
Rho	O
/	O
ROCK	O
pathway	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
coronary	B-Entity
artery	I-Entity
spasm	I-Entity
.	O

Our	O
report	O
may	O
show	O
an	O
adverse	O
effect	O
on	O
the	O
Rho	O
/	O
ROCK	O
pathway	O
by	O
sorafenib	I-Entity
use	O
.	O



Anxiogenic	O
potential	O
of	O
ciprofloxacin	I-Entity
and	O
norfloxacin	I-Entity
in	O
rats	O
.	O

The	O
possible	O
anxiogenic	O
effects	O
of	O
fluoroquinolones	I-Entity
,	O
namely	O
ciprofloxacin	I-Entity
and	O
norfloxacin	I-Entity
,	O
were	O
investigated	O
in	O
adult	O
Charles	O
Foster	O
albino	O
rats	O
of	O
either	O
sex	O
,	O
weighing	O
150	O
-	O
200	O
g.	O
METHODS	O
:	O

The	O
results	O
indicate	O
that	O
ciprofloxacin-	I-Entity
and	O
norfloxacin	I-Entity
-	O
treated	O
rats	O
showed	O
anxious	B-Entity
behaviour	I-Entity
in	O
comparison	O
to	O
control	O
rats	O
in	O
all	O
the	O
parameters	O
studied	O
.	O

However	O
,	O
ciprofloxacin-	I-Entity
and	O
norfloxacin	I-Entity
-	O
treated	O
rats	O
did	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
in	O
various	O
behavioural	O
parameters	O
.	O

CONCLUSION	O
:	O
The	O
present	O
experimental	O
findings	O
substantiate	O
the	O
clinically	O
observed	O
anxiogenic	O
potential	O
of	O
ciprofloxacin	I-Entity
and	O
norfloxacin	I-Entity
.	O



Myocardial	O
Fas	O
ligand	O
expression	O
increases	O
susceptibility	O
to	O
AZT	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
.	O

BACKGROUND	O
:	O
Dilated	B-Entity
cardiomyopathy	I-Entity
(	O
DCM	I-Entity
)	O
and	O
myocarditis	I-Entity
occur	O
in	O
many	O
HIV	B-Entity
-	I-Entity
infected	I-Entity
individuals	O
,	O
resulting	O
in	O
symptomatic	O
heart	B-Entity
failure	I-Entity
in	O
up	O
to	O
5%	O
of	O
patients	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
significantly	O
reduced	O
morbidity	O
and	O
mortality	O
of	O
acquired	B-Entity
immunodeficiency	I-Entity
syndrome	I-Entity
(	O
AIDS	I-Entity
)	O
,	O
but	O
has	O
resulted	O
in	O
an	O
increase	O
in	O
cardiac	B-Entity
and	I-Entity
skeletal	I-Entity
myopathies	I-Entity
.	O

In	O
order	O
to	O
investigate	O
whether	O
the	O
HAART	O
component	O
zidovudine	I-Entity
(	O
3'-azido-2',3'-deoxythymidine	I-Entity
;	O
AZT	I-Entity
)	O
triggers	O
the	O
Fas	O
-	O
dependent	O
cell	O
-	O
death	O
pathway	O
and	O
cause	O
cytoskeletal	O
disruption	O
in	O
a	O
murine	O
model	O
of	O
DCM	I-Entity
,	O
8-week	O
-	O
old	O
transgenic	O
(	O
expressing	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
:	O
FasL	O
Tg	O
)	O
and	O
non	O
-	O
transgenic	O
(	O
NTg	O
)	O
mice	O
received	O
water	O
ad	O
libitum	O
containing	O
different	O
concentrations	O
of	O
AZT	I-Entity
(	O
0	O
,	O
0.07	O
,	O
0.2	O
,	O
and	O
0.7	O
mg	O
/	O
ml	O
)	O
.	O

In	O
contrast	O
,	O
AZT	I-Entity
-	O
treated	O
FasL	O
Tg	O
mice	O
developed	O
cardiac	B-Entity
dilation	I-Entity
and	O
depressed	O
cardiac	O
function	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
concomitant	O
inflammatory	O
infiltration	O
of	O
both	O
ventricles	O
.	O

The	O
expression	O
of	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
,	O
as	O
identified	O
in	O
HIV	O
-	O
positive	O
patients	O
,	O
might	O
increase	O
the	O
susceptibility	O
to	O
HAART	O
-	O
induced	O
cardiomyopathy	I-Entity
due	O
to	O
activation	O
of	O
apoptotic	O
pathways	O
,	O
resulting	O
in	O
cardiac	B-Entity
dilation	I-Entity
and	I-Entity
dysfunction	I-Entity
.	O



Valproate	I-Entity
-	O
induced	O
chorea	I-Entity
and	O
encephalopathy	I-Entity
in	O
atypical	O
nonketotic	B-Entity
hyperglycinemia	I-Entity
.	O

Nonketotic	B-Entity
hyperglycinemia	I-Entity
is	O
a	O
disorder	B-Entity
of	I-Entity
amino	I-Entity
acid	I-Entity
metabolism	I-Entity
in	O
which	O
a	O
defect	O
in	O
the	O
glycine	I-Entity
cleavage	O
system	O
leads	O
to	O
an	O
accumulation	O
of	O
glycine	I-Entity
in	O
the	O
brain	O
and	O
other	O
body	O
compartments	O
.	O

In	O
the	O
classical	O
form	O
it	O
presents	O
as	O
neonatal	O
apnea	I-Entity
,	O
intractable	O
seizures	I-Entity
,	O
and	O
hypotonia	I-Entity
,	O
followed	O
by	O
significant	O
psychomotor	B-Entity
retardation	I-Entity
.	O

An	O
important	O
subset	O
of	O
children	O
with	O
nonketotic	B-Entity
hyperglycinemia	I-Entity
are	O
atypical	O
variants	O
who	O
present	O
in	O
a	O
heterogeneous	O
manner	O
.	O

This	O
report	O
describes	O
a	O
patient	O
with	O
mild	O
language	B-Entity
delay	I-Entity
and	O
mental	B-Entity
retardation	I-Entity
,	O
who	O
was	O
found	O
to	O
have	O
nonketotic	B-Entity
hyperglycinemia	I-Entity
following	O
her	O
presentation	O
with	O
acute	O
encephalopathy	I-Entity
and	O
chorea	I-Entity
shortly	O
after	O
initiation	O
of	O
valproate	I-Entity
therapy	O
.	O



Microinjection	O
of	O
ritanserin	I-Entity
into	O
the	O
CA1	O
region	O
of	O
hippocampus	O
improves	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
in	O
adult	O
male	O
rats	O
.	O

The	O
effect	O
of	O
ritanserin	I-Entity
(	O
5-HT2	O
antagonist	O
)	O
on	O
scopolamine	I-Entity
(	O
muscarinic	O
cholinergic	O
antagonist)-induced	O
amnesia	I-Entity
in	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
was	O
investigated	O
.	O

One	O
week	O
later	O
,	O
they	O
received	O
repeatedly	O
vehicles	O
(	O
saline	O
,	O
DMSO	I-Entity
,	O
saline+DMSO	I-Entity
)	O
,	O
scopolamine	I-Entity
(	O
2	O
microg/0.5	O
microl	O
saline	O
/	O
side	O
;	O
30	O
min	O
before	O
training	O
)	O
,	O
ritanserin	I-Entity
(	O
2	O
,	O
4	O
and	O
8	O
microg/0.5	O
microl	O
DMSO	I-Entity
/	O
side	O
;	O
20	O
min	O
before	O
training	O
)	O
and	O
scopolamine	I-Entity
(	O
2	O
microg/0.5	O
microl	O
;	O

30	O
min	O
before	O
ritanserin	I-Entity
injection)+ritanserin	I-Entity
(	O
4	O
microg/0.5	O
microl	O
DMSO	I-Entity
)	O
through	O
cannulae	O
each	O
day	O
.	O

The	O
results	O
showed	O
a	O
significant	O
increase	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
to	O
find	O
platform	O
in	O
scopolamine	I-Entity
-	O
treated	O
group	O
as	O
compared	O
to	O
saline	O
group	O
.	O

Ritanserin	I-Entity
-	O
treated	O
rats	O
(	O
4	O
microg/0.5	O
microl	O
/	O
side	O
)	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
mentioned	O
parameters	O
as	O
compared	O
to	O
DMSO	I-Entity
-	O
treated	O
group	O
.	O

However	O
,	O
scopolamine	I-Entity
and	O
ritanserin	I-Entity
co	O
-	O
administration	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
as	O
compared	O
to	O
the	O
scopolamine	I-Entity
-	O
treated	O
rats	O
.	O

Our	O
findings	O
show	O
that	O
microinjection	O
of	O
ritanserin	I-Entity
into	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
improves	O
the	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
.	O



Hypoxia	I-Entity
in	O
renal	B-Entity
disease	I-Entity
with	O
proteinuria	I-Entity
and/or	O
glomerular	O
hypertension	I-Entity
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
new	O
hypoxia	I-Entity
-	O
responsive	O
reporter	O
vector	O
using	O
a	O
hypoxia	I-Entity
-	O
responsive	O
element	O
of	O
the	O
5	O
'	O
vascular	O
endothelial	O
growth	O
factor	O
untranslated	O
region	O
and	O
generated	O
a	O
novel	O
hypoxia	I-Entity
-	O
sensing	O
transgenic	O
rat	O
.	O

We	O
then	O
applied	O
this	O
animal	O
model	O
to	O
the	O
detection	O
of	O
tubulointerstitial	O
hypoxia	I-Entity
in	O
the	O
diseased	B-Entity
kidney	I-Entity
.	O

With	O
this	O
model	O
,	O
we	O
were	O
able	O
to	O
identify	O
diffuse	O
cortical	O
hypoxia	I-Entity
in	O
the	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
nephrotic	B-Entity
syndrome	I-Entity
and	O
focal	O
and	O
segmental	O
hypoxia	I-Entity
in	O
the	O
remnant	O
kidney	O
model	O
.	O

Expression	O
of	O
the	O
hypoxia	I-Entity
-	O
responsive	O
transgene	O
increased	O
throughout	O
the	O
observation	O
period	O
,	O
reaching	O
2.2-fold	O
at	O
2	O
weeks	O
in	O
the	O
puromycin	B-Entity
aminonucleoside	I-Entity
model	O
and	O
2.6-fold	O
at	O
4	O
weeks	O
in	O
the	O
remnant	O
kidney	O
model	O
,	O
whereas	O
that	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
showed	O
a	O
mild	O
decrease	O
,	O
reflecting	O
distinct	O
behaviors	O
of	O
the	O
two	O
genes	O
.	O

The	O
degree	O
of	O
hypoxia	I-Entity
showed	O
a	O
positive	O
correlation	O
with	O
microscopic	O
tubulointerstitial	B-Entity
injury	I-Entity
in	O
both	O
models	O
.	O

Finally	O
,	O
we	O
identified	O
the	O
localization	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
,	O
ED-1-positive	O
,	O
and	O
terminal	O
dUTP	O
nick	O
-	O
end	O
labeled	O
-	O
positive	O
cells	O
in	O
the	O
hypoxic	I-Entity
cortical	O
area	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O

We	O
propose	O
here	O
a	O
possible	O
pathological	O
tie	O
between	O
chronic	O
tubulointerstitial	O
hypoxia	I-Entity
and	O
progressive	O
glomerular	B-Entity
diseases	I-Entity
.	O



Consensus	O
statement	O
concerning	O
cardiotoxicity	I-Entity
occurring	O
during	O
haematopoietic	O
stem	O
cell	O
transplantation	O
in	O
the	O
treatment	O
of	O
autoimmune	B-Entity
diseases	I-Entity
,	O
with	O
special	O
reference	O
to	O
systemic	B-Entity
sclerosis	I-Entity
and	O
multiple	B-Entity
sclerosis	I-Entity
.	O

Autologous	O
haematopoietic	O
stem	O
cell	O
transplantation	O
is	O
now	O
a	O
feasible	O
and	O
effective	O
treatment	O
for	O
selected	O
patients	O
with	O
severe	O
autoimmune	B-Entity
diseases	I-Entity
.	O

This	O
is	O
primarily	O
due	O
to	O
complications	O
related	O
to	O
either	O
the	O
stage	O
of	O
the	O
disease	O
at	O
transplant	O
or	O
due	O
to	O
infections	I-Entity
.	O

The	O
number	O
of	O
deaths	O
related	O
to	O
cardiac	B-Entity
toxicity	I-Entity
is	O
low	O
.	O

However	O
,	O
caution	O
is	O
required	O
when	O
cyclophosphamide	I-Entity
or	O
anthracyclines	I-Entity
such	O
as	O
mitoxantrone	I-Entity
are	O
used	O
in	O
patients	O
with	O
a	O
possible	O
underlying	O
heart	B-Entity
damage	I-Entity
,	O
for	O
example	O
,	O
systemic	B-Entity
sclerosis	I-Entity
patients	O
.	O

The	O
object	O
of	O
the	O
meeting	O
was	O
to	O
analyse	O
existing	O
data	O
,	O
both	O
published	O
or	O
available	O
,	O
in	O
the	O
European	O
Group	O
for	O
Blood	O
and	O
Marrow	O
Transplantation	O
autoimmune	B-Entity
disease	I-Entity
database	O
,	O
and	O
to	O
propose	O
a	O
safe	O
approach	O
to	O
such	O
patients	O
.	O



Immunohistochemical	O
study	O
on	O
inducible	O
type	O
of	O
nitric	B-Entity
oxide	I-Entity
(	O
iNOS	O
)	O
,	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
tumor	I-Entity
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
arteritis	I-Entity
induced	O
in	O
rats	O
by	O
fenoldopam	I-Entity
and	O
theophylline	I-Entity
,	O
vasodilators	O
.	O

Arteritis	I-Entity
induced	O
in	O
rats	O
by	O
vasodilators	O
,	O
fenoldopam	I-Entity
and	O
theophylline	I-Entity
,	O
was	O
examined	O
immunohistochemically	O
for	O
expressions	O
of	O
inducible	O
type	O
of	O
nitric	B-Entity
oxide	I-Entity
synthase	O
(	O
iNOS	O
)	O
,	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
tumor	I-Entity
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
.	O

Rats	O
were	O
administered	O
fenoldopam	I-Entity
for	O
24	O
hours	O
by	O
intravenous	O
infusion	O
with	O
or	O
without	O
following	O
repeated	O
daily	O
oral	O
administrations	O
of	O
theophylline	I-Entity
.	O

Irrespective	O
of	O
theophylline	I-Entity
administration	O
,	O
iNOS	O
antigens	O
were	O
remarkably	O
abundant	O
in	O
ED-1-positive	O
cells	O
on	O
day	O
5	O
and	O
8	O
post	O
-	O
fenoldopam	I-Entity
-	O
infusion	O
(	O
DPI	O
)	O
;	O
bFGF	O
antigens	O
were	O
remarkably	O
abundant	O
in	O
ED-1-positive	O
cells	O
on	O
1	O
and	O
3	O
DPI	O
;	O
TGF	O
-	O
beta1	O
antigens	O
were	O
observed	O
in	O
ED-1-positive	O
cells	O
on	O
and	O
after	O
5	O
DPI	O
.	O

These	O
results	O
suggest	O
that	O
the	O
peak	O
expression	O
of	O
iNOS	O
antigen	O
was	O
followed	O
by	O
that	O
of	O
bFGF	O
antigen	O
,	O
and	O
bFGF	O
may	O
have	O
a	O
suppressive	O
effect	O
on	O
iNOS	O
expression	O
in	O
these	O
rat	O
arteritis	I-Entity
models	O
.	O



Low	B-Entity
-	I-Entity
molecular	I-Entity
-	I-Entity
weight	I-Entity
heparin	I-Entity
for	O
the	O
treatment	O
of	O
patients	O
with	O
mechanical	O
heart	O
valves	O
.	O

Unfractionated	B-Entity
heparin	I-Entity
(	O
UH	I-Entity
)	O
is	O
currently	O
the	O
substitute	O
for	O
selected	O
patients	O
.	O

Low	B-Entity
-	I-Entity
molecular	I-Entity
-	I-Entity
weight	I-Entity
heparin	I-Entity
(	O
LMWH	I-Entity
)	O
offers	O
theoretical	O
advantages	O
over	O
UH	I-Entity
,	O
but	O
is	O
not	O
currently	O
considered	O
in	O
clinical	O
guidelines	O
as	O
an	O
alternative	O
to	O
UH	I-Entity
in	O
patients	O
with	O
prosthetic	O
valves	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
review	O
the	O
data	O
accumulated	O
so	O
far	O
on	O
the	O
use	O
of	O
LMWH	I-Entity
in	O
this	O
patient	O
population	O
and	O
to	O
discuss	O
its	O
applicability	O
in	O
common	O
practice	O
.	O

METHODS	O
:	O
For	O
this	O
paper	O
,	O
the	O
current	O
medical	O
literature	O
on	O
LMWH	I-Entity
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
was	O
extensively	O
reviewed	O
.	O

Data	O
to	O
establish	O
the	O
thromboembolic	I-Entity
risk	O
were	O
incomplete	O
.	O

The	O
incidence	O
rate	O
of	O
thromboembolism	I-Entity
was	O
0.9%	O
for	O
all	O
the	O
studies	O
and	O
0.5	O
,	O
0	O
,	O
20	O
,	O
and	O
0%	O
in	O
groups	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
,	O
respectively	O
;	O
for	O
hemorrhage	I-Entity
,	O
the	O
overall	O
rate	O
was	O
3.4%	O
(	O
3.8	O
,	O
2.6	O
,	O
10	O
,	O
and	O
0%	O
for	O
the	O
respective	O
groups	O
)	O
.	O

In	O
patients	O
with	O
mechanical	O
heart	O
valves	O
,	O
short	O
-	O
term	O
LMWH	I-Entity
therapy	O
compares	O
favorably	O
with	O
UH	I-Entity
.	O

Data	O
on	O
mid-	O
and	O
long	O
-	O
term	O
LMWH	I-Entity
administration	O
in	O
these	O
patients	O
are	O
sparse	O
.	O

Further	O
randomized	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
safety	O
and	O
precise	O
indications	O
for	O
the	O
use	O
of	O
LMWH	I-Entity
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
.	O



Topiramate	I-Entity
-	O
induced	O
nephrolithiasis	I-Entity
.	O

Topiramate	I-Entity
is	O
a	O
recently	O
developed	O
antiepileptic	O
medication	O
that	O
is	O
becoming	O
more	O
widely	O
prescribed	O
because	O
of	O
its	O
efficacy	O
in	O
treating	O
refractory	B-Entity
seizures	I-Entity
.	O

Urologists	O
should	O
be	O
aware	O
that	O
this	O
medication	O
can	O
cause	O
metabolic	B-Entity
acidosis	I-Entity
in	O
patients	O
secondary	O
to	O
inhibition	O
of	O
carbonic	O
anhydrase	O
.	O

These	O
factors	O
can	O
lead	O
to	O
the	O
development	O
of	O
calcium	B-Entity
phosphate	I-Entity
nephrolithiasis	I-Entity
.	O

We	O
report	O
the	O
first	O
two	O
cases	O
of	O
topiramate	I-Entity
-	O
induced	O
nephrolithiasis	I-Entity
in	O
the	O
urologic	O
literature	O
.	O



Spironolactone	I-Entity
:	O
is	O
it	O
a	O
novel	O
drug	O
for	O
the	O
prevention	O
of	O
amphotericin	B-Entity
B	I-Entity
-	O
related	O
hypokalemia	I-Entity
in	O
cancer	I-Entity
patients	O
?	O

OBJECTIVE	O
:	O
Nephrotoxicity	I-Entity
is	O
the	O
major	O
adverse	O
effect	O
of	O
amphotericin	B-Entity
B	I-Entity
(	O
AmB	I-Entity
)	O
,	O
often	O
limiting	O
administration	O
of	O
full	O
dosage	O
.	O

Selective	O
distal	O
tubular	O
epithelial	O
toxicity	I-Entity
seems	O
to	O
be	O
responsible	O
for	O
the	O
profound	O
potassium	I-Entity
wasting	O
that	O
is	O
a	O
major	O
clinical	O
side	O
effect	O
of	O
treatment	O
with	O
AmB.	I-Entity
Potassium	I-Entity
depletion	O
also	O
potentiates	O
the	O
tubular	O
toxicity	I-Entity
of	O
AmB.	I-Entity

This	O
study	O
was	O
designed	O
to	O
assess	O
the	O
ability	O
of	O
spironolactone	I-Entity
to	O
reduce	O
potassium	I-Entity
requirements	O
and	O
to	O
prevent	O
hypokalemia	I-Entity
in	O
neutropenic	I-Entity
patients	O
on	O
AmB	I-Entity
treatment	O
.	O

In	O
this	O
study	O
26	O
patients	O
with	O
various	O
hematological	B-Entity
disorders	I-Entity
were	O
randomized	O
to	O
receive	O
either	O
intravenous	O
AmB	I-Entity
alone	O
or	O
AmB	I-Entity
and	O
oral	O
spironolactone	I-Entity
100	O
mg	O
twice	O
daily	O
when	O
developing	O
a	O
proven	O
or	O
suspected	O
fungal	B-Entity
infection	I-Entity
.	O

Patients	O
receiving	O
concomitant	O
AmB	I-Entity
and	O
spironolactone	I-Entity
had	O
significantly	O
higher	O
plasma	O
potassium	I-Entity
levels	O
than	O
those	O
receiving	O
AmB	I-Entity
alone	O
(	O
P	O
=	O
0.0027	O
)	O
.	O

Those	O
patients	O
receiving	O
AmB	I-Entity
and	O
spironolactone	I-Entity
required	O
significantly	O
less	O
potassium	I-Entity
supplementation	O
to	O
maintain	O
their	O
plasma	O
potassium	I-Entity
within	O
the	O
normal	O
range	O
(	O
P	O
=	O
0.022	O
)	O
.	O

Moreover	O
,	O
urinary	O
potassium	I-Entity
losses	O
were	O
significantly	O
less	O
in	O
patients	O
receiving	O
AmB	I-Entity
and	O
spironolactone	I-Entity
than	O
those	O
receiving	O
AmB	I-Entity
alone	O
(	O
P	O
=	O
0.040	O
)	O
.	O

This	O
study	O
showed	O
that	O
spironolactone	I-Entity
can	O
reduce	O
potassium	I-Entity
requirements	O
and	O
prevent	O
hypokalemia	I-Entity
by	O
reducing	O
urinary	O
potassium	I-Entity
loss	O
in	O
neutropenic	I-Entity
patients	O
on	O
AmB	I-Entity
treatment	O
.	O



Dopamine	I-Entity
D2	O
receptor	O
signaling	O
controls	O
neuronal	O
cell	O
death	O
induced	O
by	O
muscarinic	O
and	O
glutamatergic	O
drugs	O
.	O

Dopamine	I-Entity
(	O
DA	I-Entity
)	O
,	O
through	O
D1/D2	O
receptor	O
-	O
mediated	O
signaling	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
control	O
of	O
epileptic	B-Entity
seizures	I-Entity
arising	O
in	O
the	O
limbic	O
system	O
.	O

Excitotoxicity	I-Entity
leading	O
to	O
neuronal	O
cell	O
death	O
in	O
the	O
affected	O
areas	O
is	O
a	O
major	O
consequence	O
of	O
seizures	I-Entity
at	O
the	O
cellular	O
level	O
.	O

In	O
this	O
respect	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
DA	I-Entity
receptors	O
in	O
the	O
occurrence	O
of	O
epilepsy	I-Entity
-	O
induced	O
neuronal	O
cell	O
death	O
.	O

Here	O
we	O
analyze	O
the	O
occurrence	O
of	O
seizures	I-Entity
and	O
neurotoxicity	I-Entity
in	O
D2R	O
-/-	O
mice	O
treated	O
with	O
the	O
cholinergic	O
agonist	O
pilocarpine	I-Entity
.	O

We	O
compared	O
these	O
results	O
with	O
those	O
previously	O
obtained	O
with	O
kainic	B-Entity
acid	I-Entity
(	O
KA	I-Entity
)	O
,	O
a	O
potent	O
glutamate	I-Entity
agonist	O
.	O

Importantly	O
,	O
D2R	O
-/-	O
mice	O
develop	O
seizures	I-Entity
at	O
doses	O
of	O
both	O
drugs	O
that	O
are	O
not	O
epileptogenic	O
for	O
WT	O
littermates	O
and	O
show	O
greater	O
neurotoxicity	I-Entity
.	O

However	O
,	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
result	O
in	O
a	O
more	O
widespread	O
neuronal	O
death	O
in	O
both	O
WT	O
and	O
D2R	O
-/-	O
brains	O
in	O
comparison	O
to	O
KA	I-Entity
.	O

Thus	O
,	O
the	O
absence	O
of	O
D2R	O
lowers	O
the	O
threshold	O
for	O
seizures	I-Entity
induced	O
by	O
both	O
glutamate	I-Entity
and	O
acetylcholine	I-Entity
.	O

Moreover	O
,	O
the	O
dopaminergic	O
control	O
of	O
epilepsy	I-Entity
-	O
induced	O
neurodegeneration	I-Entity
seems	O
to	O
be	O
mediated	O
by	O
distinct	O
interactions	O
of	O
D2R	O
signaling	O
with	O
these	O
two	O
neurotransmitters	O
.	O



Treatment	O
of	O
risperidone	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
with	O
a	O
dopamine	I-Entity
agonist	O
in	O
children	O
.	O

Risperidone	I-Entity
,	O
a	O
potent	O
antagonist	O
of	O
both	O
serotonergic	O
(	O
5HT2A	O
)	O
and	O
dopaminergic	O
D2	O
receptors	O
is	O
associated	O
with	O
hyperprolactinemia	I-Entity
in	O
adults	O
and	O
children	O
.	O

Chronically	O
elevated	O
prolactin	O
levels	O
in	O
children	O
with	O
prolactinomas	I-Entity
may	O
be	O
associated	O
with	O
arrested	O
growth	O
and	O
development	O
resulting	O
in	O
either	O
delayed	B-Entity
puberty	I-Entity
or	O
short	O
stature	O
.	O

These	O
possibilities	O
stress	O
the	O
importance	O
of	O
developing	O
a	O
safe	O
and	O
effective	O
approach	O
to	O
drug	O
-	O
induced	O
hyperprolactinemia	I-Entity
in	O
youth	O
.	O

We	O
report	O
the	O
successful	O
treatment	O
of	O
risperidone	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
with	O
cabergoline	I-Entity
in	O
youth	O
.	O

:	O
We	O
undertook	O
a	O
retrospective	O
case	O
review	O
of	O
four	O
children	O
with	O
risperidone	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
treated	O
with	O
cabergoline	I-Entity
.	O

Four	O
males	O
(	O
age	O
6	O
-	O
11	O
years	O
)	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B-Entity
Disorders	I-Entity
(	O
fourth	O
edition	O
)	O
bipolar	B-Entity
disorder	I-Entity
or	O
psychoses	I-Entity
,	O
with	O
risperidone	I-Entity
-	O
induced	O
elevations	O
in	O
serum	O
prolactin	O
levels	O
(	O
57.5	O
-	O
129	O
ng	O
/	O
mL	O
,	O
normal	O
5	O
-	O
15	O
ng	O
/	O
mL	O
)	O
,	O
were	O
treated	O
with	O
cabergoline	I-Entity

10.9	O
ng	O
/	O
mL	O
)	O
,	O
the	O
cabergoline	I-Entity
dose	O
was	O
reduced	O
to	O
1	O
mg	O
/	O
week	O
in	O
three	O
of	O
four	O
subjects	O
.	O

The	O
mean	O
duration	O
of	O
therapy	O
with	O
cabergoline	I-Entity
was	O
523.5	O
+	O
/-	O

129.7	O
days	O
,	O
and	O
the	O
mean	O
duration	O
of	O
therapy	O
with	O
risperidone	I-Entity
was	O
788.5	O
+	O
/-	O

Cabergoline	I-Entity
was	O
well	O
tolerated	O
without	O
adverse	O
effects	O
.	O

Cabergoline	I-Entity
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
risperidone	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
in	O
youth	O
;	O
however	O
,	O
further	O
research	O
is	O
needed	O
.	O



Cholestatic	B-Entity
jaundice	I-Entity
associated	O
with	O
the	O
use	O
of	O
metformin	I-Entity
.	O

We	O
report	O
a	O
patient	O
who	O
developed	O
cholestatic	B-Entity
jaundice	I-Entity
shortly	O
after	O
initiation	O
of	O
treatment	O
with	O
metformin	B-Entity
hydrochloride	I-Entity
.	O

A	O
percutaneous	O
liver	O
biopsy	O
was	O
obtained	O
showing	O
marked	O
cholestasis	I-Entity
,	O
with	O
portal	O
edema	I-Entity
,	O
ductular	O
proliferation	O
,	O
and	O
acute	O
inflammation	I-Entity
.	O

Metformin	B-Entity
hydrochloride	I-Entity
was	O
discontinued	O
,	O
and	O
the	O
patient	O
's	O
jaundice	I-Entity
resolved	O
slowly	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O

Given	O
the	O
onset	O
of	O
his	O
jaundice	I-Entity
2	O
wk	O
after	O
the	O
initiation	O
of	O
metformin	I-Entity
,	O
we	O
believe	O
that	O
this	O
case	O
represents	O
an	O
example	O
of	O
metformin	I-Entity
-	O
associated	O
hepatotoxicity	I-Entity
,	O
the	O
first	O
such	O
case	O
reported	O
.	O



Electro	O
-	O
oculography	O
,	O
electroretinography	O
,	O
visual	O
evoked	O
potentials	O
,	O
and	O
multifocal	O
electroretinography	O
in	O
patients	O
with	O
vigabatrin	I-Entity
-	O
attributed	O
visual	B-Entity
field	I-Entity
constriction	I-Entity
.	O

Symptomatic	O
visual	B-Entity
field	I-Entity
constriction	I-Entity
thought	O
to	O
be	O
associated	O
with	O
vigabatrin	I-Entity
has	O
been	O
reported	O
.	O

The	O
current	O
study	O
investigated	O
the	O
visual	O
fields	O
and	O
visual	O
electrophysiology	O
of	O
eight	O
patients	O
with	O
known	O
vigabatrin	I-Entity
-	O
attributed	O
visual	B-Entity
field	I-Entity
loss	I-Entity
,	O
three	O
of	O
whom	O
were	O
reported	O
previously	O
.	O

Six	O
of	O
the	O
patients	O
were	O
no	O
longer	O
receiving	O
vigabatrin	I-Entity
.	O

Seven	O
patients	O
showed	O
marked	O
visual	B-Entity
field	I-Entity
constriction	I-Entity
with	O
some	O
sparing	O
of	O
the	O
temporal	O
visual	O
field	O
.	O

Marked	O
visual	B-Entity
field	I-Entity
constriction	I-Entity
appears	O
to	O
be	O
associated	O
with	O
vigabatrin	I-Entity
therapy	O
.	O

The	O
field	O
defects	O
and	O
some	O
electrophysiological	O
abnormalities	O
persist	O
when	O
vigabatrin	I-Entity
therapy	O
is	O
withdrawn	O
.	O



Conversion	O
to	O
rapamycin	I-Entity
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
:	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
effects	O
of	O
RAPA	I-Entity
conversion	O
in	O
patients	O
undergoing	O
cyclosporine	I-Entity
(	O
CsA	I-Entity
)	O
or	O
tacrolimus	I-Entity
(	O
Tac	I-Entity
)	O
toxicity	I-Entity
.	O

Twenty	O
renal	O
transplant	O
recipients	O
were	O
switched	O
to	O
fixed	O
dose	O
rapamycin	I-Entity
(	O
RAPA	I-Entity
)	O
(	O
5	O
mg	O
/	O
day	O
)	O
0	O
to	O
204	O
months	O
posttransplant	O
.	O

The	O
indications	O
for	O
switch	O
were	O
chronic	O
CsA	I-Entity
or	O
Tac	I-Entity
nephrotoxicity	I-Entity
(	O
12	O
)	O
,	O
acute	O
CsA	I-Entity
or	O
Tac	I-Entity
toxicity	I-Entity
(	O
3	O
)	O
,	O
severe	O
facial	B-Entity
dysmorphism	I-Entity
(	O
2	O
)	O
,	O
posttransplant	B-Entity
lymphoproliferative	I-Entity
disorder	I-Entity
(	O
PTLD	I-Entity
)	O
in	O
remission	O
(	O
2	O
)	O
,	O
and	O
hepatotoxicity	I-Entity
in	O
1	O
.	O

In	O
the	O
12	O
patients	O
switched	O
because	O
of	O
chronic	O
nephrotoxicity	I-Entity
there	O
was	O
a	O
significant	O
decrease	O
in	O
serum	O
creatinine	I-Entity
[	O
233+/-34	O
to	O
210+/-56	O
micromol	O
/	O
liter	O
(	O
P<0.05	O
)	O
at	O
6	O
months	O
]	O
.	O

Facial	B-Entity
dysmorphism	I-Entity
improved	O
in	O
two	O
patients	O
.	O

No	O
relapse	O
of	O
PTLD	I-Entity
was	O
observed	O
.	O

Five	O
patients	O
developed	O
pneumonia	I-Entity
(	O
two	O
Pneumocystis	B-Entity
carinii	I-Entity
pneumonia	I-Entity
,	O
one	O
infectious	B-Entity
mononucleosis	I-Entity
with	O
polyclonal	O
PTLD	I-Entity
lung	O
infiltrate	O
)	O
and	O
two	O
had	O
bronchiolitis	B-Entity
obliterans	I-Entity
.	O

RAPA	I-Entity
was	O
discontinued	O
in	O
four	O
patients	O
,	O
because	O
of	O
pneumonia	I-Entity
in	O
two	O
,	O
PTLD	I-Entity
in	O
one	O
,	O
and	O
oral	O
aphtous	B-Entity
ulcers	I-Entity
in	O
one	O
.	O

RAPA	I-Entity
levels	O
were	O
high	O
(	O
>	O
15	O
ng	O
/	O
ml	O
)	O
in	O
7	O
of	O
13	O
(	O
54%	O
)	O
patients	O
.	O

RAPA	I-Entity
conversion	O
provides	O
adequate	O
immunosuppression	O
to	O
enable	O
CsA	I-Entity
withdrawal	O
.	O

However	O
,	O
when	O
converting	O
patients	O
to	O
RAPA	I-Entity
drug	O
levels	O
should	O
be	O
monitored	O
to	O
avoid	O
over	O
-	O
immunosuppression	O
and	O
adequate	O
antiviral	O
and	O
Pneumocystis	B-Entity
carinii	I-Entity
pneumonia	I-Entity
prophylaxis	O
should	O
be	O
given	O
.	O



Worsening	O
of	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
by	O
motor	O
and	O
mental	O
tasks	O
.	O

Ten	O
patients	O
who	O
had	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
with	O
disabling	O
dyskinesia	I-Entity
were	O
included	O
in	O
this	O
study	O
to	O
evaluate	O
the	O
role	O
of	O
mental	O
(	O
mental	O
calculation	O
)	O
and	O
motor	O
(	O
flexion	O
/	O
extension	O
of	O
right	O
fingers	O
,	O
flexion	O
/	O
extension	O
of	O
left	O
fingers	O
,	O
flexion	O
/	O
extension	O
of	O
the	O
neck	O
,	O
speaking	O
aloud	O
)	O
tasks	O
on	O
the	O
worsening	O
of	O
peak	O
-	O
dose	O
dyskinesia	I-Entity
following	O
administration	O
of	O
an	O
effective	O
single	O
dose	O
of	O
apomorphine	I-Entity
.	O

Compared	O
with	O
the	O
score	O
at	O
rest	O
(	O
1.3+/-0.3	O
)	O
,	O
a	O
significant	O
aggravation	O
of	O
the	O
dyskinesia	I-Entity
score	O
was	O
observed	O
during	O
speaking	O
aloud	O
(	O
5.2+/-1.1	O
,	O
p<0.05	O
)	O
,	O
movements	O
of	O
right	O
(	O
4.5+/-1.0	O
,	O
p<0.05	O
)	O
and	O
left	O
(	O
3.7+/-0.8	O
,	O
p<0.05	O
)	O
fingers	O
,	O
movements	O
of	O
the	O
neck	O
(	O
5.1+/-1.0	O
,	O
p<0.05	O
)	O
,	O
and	O
mental	O
calculation	O
(	O
3.1+/-1.0	O
,	O
p<0.05	O
)	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
tasks	O
such	O
as	O
""""	O
speaking	O
aloud	O
""""	O
could	O
be	O
used	O
for	O
objective	O
assessment	O
of	O
dyskinesia	I-Entity
severity	O
.	O



Structural	B-Entity
and	I-Entity
functional	I-Entity
impairment	I-Entity
of	I-Entity
mitochondria	I-Entity
in	O
adriamycin	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
in	O
mice	O
:	O
suppression	O
of	O
cytochrome	O
c	O
oxidase	O
II	O
gene	O
expression	O
.	O

The	O
use	O
of	O
adriamycin	I-Entity
(	O
ADR	I-Entity
)	O
in	O
cancer	I-Entity
chemotherapy	O
has	O
been	O
limited	O
due	O
to	O
its	O
cumulative	O
cardiovascular	B-Entity
toxicity	I-Entity
.	O

Earlier	O
observations	O
that	O
ADR	I-Entity
interacts	O
with	O
mitochondrial	O
cytochrome	O
c	O
oxidase	O
(	O
COX	O
)	O
and	O
suppresses	O
its	O
enzyme	O
activity	O
led	O
us	O
to	O
investigate	O
ADR	I-Entity
's	O
action	O
on	O
the	O
cardiovascular	O
functions	O
and	O
heart	O
mitochondrial	O
morphology	O
in	O
Balb	O
-	O
c	O
mice	O
i.p	O
.	O

treated	O
with	O
ADR	I-Entity
for	O
several	O
weeks	O
.	O

Our	O
results	O
indicated	O
that	O
1	O
)	O
treatment	O
of	O
mice	O
with	O
ADR	I-Entity
caused	O
cardiovascular	B-Entity
arrhythmias	I-Entity
characterized	O
by	O
bradycardia	I-Entity
,	O
extension	O
of	O
ventricular	O
depolarization	O
time	O
(	O
tQRS	O
)	O
,	O
and	O
failure	O
of	O
QRS	O
at	O
high	O
concentrations	O
(	O
10	O
-	O
14	O
mg	O
/	O
kg	O
body	O
weight	O
cumulative	O
dose	O
)	O
;	O
2	O
)	O
the	O
heart	O
mitochondria	O
underwent	O
swelling	I-Entity
,	O
fusion	O
,	O
dissolution	O
,	O
and/or	O
disruption	O
of	O
mitochondrial	O
cristae	O
after	O
several	O
weeks	O
of	O
treatment	O
.	O

Such	O
abnormalities	O
were	O
not	O
observed	O
in	O
the	O
mitochondria	O
of	O
liver	O
tissue	O
;	O
and	O
3	O
)	O
among	O
the	O
three	O
genes	O
of	O
COX	O
enzyme	O
examined	O
,	O
only	O
COXII	O
gene	O
expression	O
was	O
suppressed	O
by	O
ADR	I-Entity
treatment	O
,	O
mainly	O
after	O
8	O
weeks	O
in	O
both	O
heart	O
and	O
liver	O
.	O

Knowing	O
that	O
heart	O
mitochondria	O
represent	O
almost	O
40%	O
of	O
heart	O
muscle	O
by	O
weight	O
,	O
we	O
conclude	O
that	O
the	O
deteriorating	O
effects	O
of	O
ADR	I-Entity
on	O
cardiovascular	O
function	O
involve	O
mitochondrial	B-Entity
structural	I-Entity
and	I-Entity
functional	I-Entity
impairment	I-Entity
.	O



Enhanced	O
bradycardia	I-Entity
induced	O
by	O
beta	O
-	O
adrenoceptor	O
antagonists	O
in	O
rats	O
pretreated	O
with	O
isoniazid	I-Entity
.	O

High	O
doses	O
of	O
isoniazid	I-Entity
increase	O
hypotension	I-Entity
induced	O
by	O
vasodilators	O
and	O
change	O
the	O
accompanying	O
reflex	O
tachycardia	I-Entity
to	O
bradycardia	I-Entity
,	O
an	O
interaction	O
attributed	O
to	O
decreased	O
synthesis	O
of	O
brain	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid	I-Entity
(	O
GABA	I-Entity
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
possible	O
enhancement	O
by	O
isoniazid	I-Entity
of	O
bradycardia	I-Entity
induced	O
by	O
beta	O
-	O
adrenoceptor	O
antagonists	O
was	O
determined	O
in	O
rats	O
anaesthetised	O
with	O
chloralose	I-Entity
-	O
urethane	I-Entity
.	O

Isoniazid	I-Entity
significantly	O
increased	O
bradycardia	I-Entity
after	O
propranolol	I-Entity
,	O
pindolol	I-Entity
,	O
labetalol	I-Entity
and	O
atenolol	I-Entity
,	O
as	O
well	O
as	O
after	O
clonidine	I-Entity
,	O
but	O
not	O
after	O
hexamethonium	I-Entity
or	O
carbachol	I-Entity
.	O

Enhancement	O
was	O
not	O
observed	O
in	O
rats	O
pretreated	O
with	O
methylatropine	I-Entity
or	O
previously	O
vagotomised	O
.	O

These	O
results	O
are	O
compatible	O
with	O
interference	O
by	O
isoniazid	I-Entity
with	O
GABAergic	O
inhibition	O
of	O
cardiac	O
parasympathetic	O
tone	O
.	O



Epileptogenic	O
activity	O
of	O
folic	B-Entity
acid	I-Entity
after	O
drug	O
induces	O
SLE	I-Entity
(	O
folic	B-Entity
acid	I-Entity
and	O
epilepsy	I-Entity
)	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
effect	O
of	O
folic	B-Entity
acid	I-Entity
-	O
containing	O
multivitamin	O
supplementation	O
in	O
epileptic	I-Entity
women	O
before	O
and	O
during	O
pregnancy	O
in	O
order	O
to	O
determine	O
the	O
rate	O
of	O
structural	O
birth	B-Entity
defects	I-Entity
and	O
epilepsy	I-Entity
-	O
related	O
side	O
effects	O
.	O

Of	O
60	O
epileptic	I-Entity
women	O
with	O
periconceptional	O
folic	B-Entity
acid	I-Entity
(	O
0.8	O
mg)-containing	O
multivitamin	O
supplementation	O
,	O
no	O
one	O
developed	O
epilepsy	I-Entity
-	O
related	O
side	O
effects	O
during	O
the	O
periconception	O
period	O
.	O

One	O
epileptic	I-Entity
woman	O
delivered	O
a	O
newborn	O
with	O
cleft	B-Entity
lip	I-Entity
and	I-Entity
palate	I-Entity
.	O

Another	O
patient	O
exhibited	O
with	O
a	O
cluster	O
of	O
seizures	I-Entity
after	O
the	O
periconception	O
period	O
using	O
another	O
multivitamin	O
.	O

This	O
22-year	O
-	O
old	O
epileptic	I-Entity
woman	O
was	O
treated	O
continuously	O
by	O
carbamazepine	I-Entity
and	O
a	O
folic	B-Entity
acid	I-Entity
(	O
1	O
mg)-containing	O
multivitamin	O
from	O
the	O
20th	O
week	O
of	O
gestation	O
.	O

She	O
developed	O
status	B-Entity
epilepticus	I-Entity
and	O
later	O
symptoms	O
of	O
systemic	B-Entity
lupus	I-Entity
erythematodes	I-Entity
.	O

Her	O
pregnancy	O
ended	O
with	O
stillbirth	I-Entity
.	O

The	O
epileptic	I-Entity
pregnant	O
patient	O
's	O
autoimmune	B-Entity
disease	I-Entity
(	O
probably	O
drug	O
-	O
induced	O
lupus	I-Entity
)	O
could	O
damage	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
therefore	O
the	O
therapeutic	O
dose	O
(	O
>	O
or	O
=	O
1	O
mg	O
)	O
of	O
folic	B-Entity
acid	I-Entity
triggered	O
a	O
cluster	O
of	O
seizures	I-Entity
.	O

Physiological	O
dose	O
(	O
<	O
1	O
mg	O
)	O
of	O
folic	B-Entity
acid	I-Entity
both	O
in	O
healthy	O
and	O
60	O
epileptic	I-Entity
women	O
,	O
all	O
without	O
any	O
autoimmune	B-Entity
disease	I-Entity
,	O
did	O
not	O
increase	O
the	O
risk	O
for	O
epileptic	B-Entity
seizures	I-Entity
.	O



Effects	O
of	O
cisapride	I-Entity
on	O
symptoms	O
and	O
postcibal	O
small	O
-	O
bowel	O
motor	O
function	O
in	O
patients	O
with	O
irritable	B-Entity
bowel	I-Entity
syndrome	I-Entity
.	O

BACKGROUND	O
:	O
Irritable	B-Entity
bowel	I-Entity
syndrome	I-Entity
is	O
a	O
common	O
cause	O
of	O
abdominal	B-Entity
pain	I-Entity
and	O
discomfort	O
and	O
may	O
be	O
related	O
to	O
disordered	B-Entity
gastrointestinal	I-Entity
motility	I-Entity
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
effects	O
of	O
long	O
-	O
term	O
treatment	O
with	O
a	O
prokinetic	O
agent	O
,	O
cisapride	I-Entity
,	O
on	O
postprandial	O
jejunal	O
motility	O
and	O
symptoms	O
in	O
the	O
irritable	B-Entity
bowel	I-Entity
syndrome	I-Entity
(	O
IBS	I-Entity
)	O
.	O

METHODS	O
:	O
Thirty	O
-	O
eight	O
patients	O
with	O
IBS	I-Entity
(	O
constipation	I-Entity
-	O
predominant	O
,	O
n	O
=	O
17	O
;	O

diarrhoea	I-Entity
-	O
predominant	O
,	O
n	O
=	O
21	O
)	O
underwent	O
24-h	O
ambulatory	O
jejunal	O
manometry	O
before	O
and	O
after	O
12	O
week	O
's	O
treatment	O
[	O
cisapride	I-Entity
,	O
5	O
mg	O
three	O
times	O
daily	O
(	O
n	O
=	O
19	O
)	O
or	O
placebo	O

In	O
diarrhoea	I-Entity
-	O
predominant	O
patients	O
significant	O
differences	O
in	O
contraction	O
characteristics	O
were	O
observed	O
between	O
the	O
cisapride	I-Entity
and	O
placebo	O
groups	O
.	O

In	O
cisapride	I-Entity
-	O
treated	O
diarrhoea	I-Entity
-	O
predominant	O
patients	O
the	O
mean	O
contraction	O
amplitude	O
was	O
higher	O
(	O
29.3	O
+	O
/-	O

2.6	O
mm	O
Hg	O
,	O
cisapride	I-Entity
versus	O
placebo	O
(	O
P	O
<	O
0.001	O
)	O
;	O
pretreatment	O
,	O
25.7	O
+	O
/-	O

0.2	O
sec	O
,	O
cisapride	I-Entity
versus	O
placebo	O
(	O
P	O
<	O
0.001	O
)	O
;	O
pretreatment	O
,	O
3.1	O
+	O
/-	O

0.4	O
cont./min	O
,	O
cisapride	I-Entity
versus	O
placebo	O
(	O
P	O

No	O
significant	O
differences	O
in	O
jejunal	O
motility	O
were	O
found	O
in	O
the	O
constipation	I-Entity
-	O
predominant	O
IBS	I-Entity
group	O
.	O

Symptom	O
scores	O
relating	O
to	O
the	O
severity	O
of	O
constipation	I-Entity
were	O
lower	O
in	O
cisapride	I-Entity
-	O
treated	O
constipation	I-Entity
-	O
predominant	O
IBS	I-Entity
patients	O
[	O
score	O
,	O
54	O
+	O
/-	O

14	O
mm	O
,	O
cisapride	I-Entity
versus	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
;	O
pretreatment	O
,	O
62	O
+	O
/-	O

Diarrhoea	I-Entity
-	O
predominant	O
IBS	I-Entity
patients	O
had	O
a	O
higher	O
pain	I-Entity
score	O
after	O
cisapride	I-Entity
therapy	O
[	O
score	O
,	O
55	O
+	O
/-	O

12	O
mm	O
,	O
cisapride	I-Entity
versus	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
;	O
pretreatment	O
,	O
67	O
+	O
/-	O

CONCLUSION	O
:	O
Cisapride	I-Entity
affects	O
jejunal	O
contraction	O
characteristics	O
and	O
some	O
symptoms	O
in	O
IBS	I-Entity
.	O



Clarithromycin	I-Entity
-	O
induced	O
ventricular	B-Entity
tachycardia	I-Entity
.	O

Clarithromycin	I-Entity
is	O
a	O
relatively	O
new	O
macrolide	I-Entity
antibiotic	O
that	O
offers	O
twice	O
-	O
daily	O
dosing	O
.	O

It	O
differs	O
from	O
erythromycin	I-Entity
only	O
in	O
the	O
methylation	O
of	O
the	O
hydroxyl	O
group	O
at	O
position	O
6	O
.	O

Although	O
the	O
side	O
-	O
effect	O
profile	O
of	O
erythromycin	I-Entity
is	O
established	O
,	O
including	O
gastroenteritis	I-Entity
and	O
interactions	O
with	O
other	O
drugs	O
subject	O
to	O
hepatic	O
mixed	O
-	O
function	O
oxidase	O
metabolism	O
,	O
experience	O
with	O
the	O
newer	O
macrolides	I-Entity
is	O
still	O
being	O
recorded	O
.	O

Cardiotoxicity	I-Entity
has	O
been	O
demonstrated	O
after	O
both	O
intravenous	O
and	O
oral	O
administration	O
of	O
erythromycin	I-Entity
but	O
has	O
never	O
been	O
reported	O
with	O
the	O
newer	O
macrolides	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
ventricular	B-Entity
dysrhythmias	I-Entity
that	O
occurred	O
after	O
six	O
therapeutic	O
doses	O
of	O
clarithromycin	I-Entity
.	O

The	O
dysrhythmias	I-Entity
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O



Persistent	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
following	O
lithium	I-Entity
therapy	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
severe	O
hypernatraemic	O
dehydration	I-Entity
following	O
a	O
head	B-Entity
injury	I-Entity
.	O

Ten	O
years	O
previously	O
he	O
had	O
been	O
diagnosed	O
to	O
have	O
lithium	I-Entity
-	O
induced	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
,	O
and	O
lithium	I-Entity
therapy	O
had	O
been	O
discontinued	O
.	O

He	O
remained	O
thirsty	O
and	O
polyuric	I-Entity
despite	O
cessation	O
of	O
lithium	I-Entity
and	O
investigations	O
on	O
admission	O
showed	O
him	O
to	O
have	O
normal	O
osmoregulated	O
thirst	O
and	O
vasopressin	I-Entity
secretion	O
,	O
with	O
clear	O
evidence	O
of	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
.	O

Lithium	I-Entity
induced	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
is	O
considered	O
to	O
be	O
reversible	O
on	O
cessation	O
of	O
therapy	O
but	O
polyuria	I-Entity
persisted	O
in	O
this	O
patient	O
for	O
ten	O
years	O
after	O
lithium	I-Entity
was	O
stopped	O
.	O

We	O
discuss	O
the	O
possible	O
renal	O
mechanisms	O
and	O
the	O
implications	O
for	O
management	O
of	O
patients	O
with	O
lithium	I-Entity
-	O
induced	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
.	O



Late	O
cardiotoxicity	I-Entity
after	O
treatment	O
for	O
a	O
malignant	O
bone	B-Entity
tumor	I-Entity
.	O

Cardiac	O
function	O
was	O
assessed	O
in	O
long	O
-	O
term	O
survivors	O
of	O
malignant	O
bone	B-Entity
tumors	I-Entity
who	O
were	O
treated	O
according	O
to	O
Rosen	B-Entity
's	I-Entity
T5	I-Entity
or	I-Entity
T10	I-Entity
protocol	I-Entity
,	O
both	O
including	O
doxorubicin	I-Entity
.	O

Cumulative	O
doses	O
of	O
doxorubicin	I-Entity
were	O
225	O
-	O
550	O
mg	O
/	O
m2	O
(	O
median	O
dose	O
360	O
)	O
.	O

Eighteen	O
of	O
31	O
(	O
58%	O
)	O
patients	O
showed	O
cardiac	B-Entity
toxicity	I-Entity
,	O
defined	O
as	O
having	O
one	O
or	O
more	O
of	O
the	O
following	O
abnormalities	O
:	O
late	O
potentials	O
,	O
complex	O
ventricular	B-Entity
arrhythmias	I-Entity
,	O
left	O
ventricular	B-Entity
dilation	I-Entity
,	O
decreased	O
shortening	O
fraction	O
,	O
or	O
decreased	O
ejection	O
fraction	O
.	O

The	O
incidence	O
of	O
cardiac	B-Entity
abnormalities	I-Entity
increased	O
with	O
length	O
of	O
follow	O
-	O
up	O
(	O
P	O
<	O
or	O
=	O
.05	O
)	O
.	O

No	O
correlation	O
could	O
be	O
demonstrated	O
between	O
cumulative	O
dose	O
of	O
doxorubicin	I-Entity
and	O
cardiac	O
status	O
,	O
except	O
for	O
heart	O
rate	O
variability	O
.	O

The	O
incidence	O
of	O
doxorubicin	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
is	O
high	O
and	O
increases	O
with	O
follow	O
-	O
up	O
,	O
irrespective	O
of	O
cumulative	O
dose	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
heart	O
rate	O
variability	O
and	O
LVPW	O
index	O
could	O
be	O
sensitive	O
indicators	O
for	O
cardiotoxicity	I-Entity
.	O



Venous	B-Entity
complications	I-Entity
of	O
midazolam	I-Entity
versus	O
diazepam	I-Entity
.	O

Although	O
some	O
studies	O
have	O
suggested	O
fewer	O
venous	B-Entity
complications	I-Entity
are	O
associated	O
with	O
midazolam	I-Entity
than	O
with	O
diazepam	I-Entity
for	O
endoscopic	O
procedures	O
,	O
this	O
variable	O
has	O
not	O
been	O
well	O
documented	O
.	O

We	O
prospectively	O
evaluated	O
the	O
incidence	O
of	O
venous	B-Entity
complications	I-Entity
after	O
intravenous	O
injection	O
of	O
diazepam	I-Entity
or	O
midazolam	I-Entity
in	O
122	O
consecutive	O
patients	O
undergoing	O
colonoscopy	O
and	O
esophagogastroduodenoscopy	O
.	O

Overall	O
,	O
venous	B-Entity
complications	I-Entity
were	O
more	O
frequent	O
with	O
diazepam	I-Entity
(	O
22	O
of	O
62	O
patients	O
)	O
than	O
with	O
midazolam	I-Entity
(	O
4	O
of	O
60	O
patients	O
)	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
palpable	O
venous	O
cord	O
was	O
present	O
in	O
23%	O
(	O
14	O
of	O
62	O
)	O
of	O
patients	O
in	O
the	O
diazepam	I-Entity
group	O
,	O
compared	O
with	O
2%	O
(	O
1	O
of	O
60	O
patients	O
)	O
in	O
the	O
midazolam	I-Entity
group	O
(	O
p	O

Pain	I-Entity
at	O
the	O
injection	O
site	O
occurred	O
in	O
35%	O
(	O
22	O
of	O
62	O
)	O
of	O
patients	O
in	O
the	O
diazepam	I-Entity
group	O
compared	O
with	O
7%	O
(	O
4	O
of	O
60	O
patients	O
)	O
in	O
the	O
midazolam	I-Entity
group	O

Swelling	I-Entity
and	O
warmth	O
at	O
the	O
injection	O
site	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Smoking	O
,	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
use	O
,	O
intravenous	O
catheter	O
site	O
,	O
dwell	O
time	O
of	O
the	O
needle	O
,	O
alcohol	I-Entity
use	O
,	O
and	O
pain	I-Entity
during	O
the	O
injection	O
had	O
no	O
effect	O
on	O
the	O
incidence	O
of	O
venous	B-Entity
complications	I-Entity
.	O



Tetany	I-Entity
and	O
rhabdomyolysis	I-Entity
due	O
to	O
surreptitious	O
furosemide	I-Entity
--	O
importance	O
of	O
magnesium	I-Entity
supplementation	O
.	O

Diuretics	O
may	O
induce	O
hypokalemia	I-Entity
,	O
hypocalcemia	I-Entity
and	O
hypomagnesemia	I-Entity
.	O

While	O
severe	O
hypokalemia	I-Entity
may	O
cause	O
muscle	B-Entity
weakness	I-Entity
,	O
severe	O
hypomagnesemia	I-Entity
is	O
associated	O
with	O
muscle	B-Entity
spasms	I-Entity
and	O
tetany	I-Entity
which	O
can	O
not	O
be	O
corrected	O
by	O
potassium	I-Entity
and	O
calcium	I-Entity
supplementation	O
alone	O
(	O
1,2	O
)	O
.	O

Surreptitious	O
diuretic	O
ingestion	O
has	O
been	O
described	O
,	O
mainly	O
in	O
women	O
who	O
are	O
concerned	O
that	O
they	O
are	O
obese	I-Entity
or	O
edematous	I-Entity
.	O

Symptomatic	O
hypokalemia	I-Entity
has	O
been	O
reported	O
in	O
such	O
patients	O
(	O
3	O
-	O
7	O
)	O
and	O
in	O
one	O
case	O
hypocalcemia	I-Entity
was	O
observed	O
(	O
8)	O
,	O
but	O
the	O
effects	O
of	O
magnesium	I-Entity
depletion	O
were	O
not	O
noted	O
in	O
these	O
patients	O
.	O



Loss	O
of	O
glutamate	I-Entity
decarboxylase	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
rat	O
dentate	O
gyrus	O
following	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

In	O
situ	O
hybridization	O
methods	O
were	O
used	O
to	O
determine	O
if	O
glutamic	B-Entity
acid	I-Entity
decarboxylase	O
(	O
GAD	O
)	O

mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
are	O
vulnerable	O
to	O
seizure	I-Entity
-	O
induced	O
damage	O
in	O
a	O
model	O
of	O
chronic	O
seizures	I-Entity
.	O

Sprague	O
-	O
Dawley	O
rats	O
were	O
injected	O
intraperitoneally	O
with	O
pilocarpine	I-Entity
,	O
and	O
the	O
hippocampal	O
formation	O
was	O
studied	O
histologically	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
8	O
week	O
intervals	O
after	O
pilocarpine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

In	O
situ	O
hybridization	O
histochemistry	O
,	O
using	O
a	O
digoxigenin	I-Entity
-	O
labeled	O
GAD	O
cRNA	O
probe	O
,	O
demonstrated	O
a	O
substantial	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
in	O
the	O
pilocarpine	I-Entity
-	O
treated	O
rats	O
as	O
compared	O
to	O
controls	O
at	O
all	O
time	O
intervals	O
.	O

Additional	O
neuronanatomical	O
studies	O
,	O
including	O
cresyl	B-Entity
violet	I-Entity
staining	O
,	O
neuronal	B-Entity
degeneration	I-Entity
methods	O
,	O
and	O
histochemical	O
localization	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
suggested	O
that	O
the	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
was	O
related	O
to	O
neuronal	B-Entity
loss	I-Entity
rather	O
than	O
to	O
a	O
decrease	O
in	O
GAD	O
mRNA	O
levels	O
.	O

The	O
results	O
indicate	O
that	O
,	O
in	O
this	O
model	O
,	O
a	O
subpopulation	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
dentate	O
gyrus	O
is	O
selectively	O
vulnerable	O
to	O
seizure	I-Entity
-	O
induced	O
damage	O
.	O

Such	O
differential	O
vulnerability	O
appears	O
to	O
be	O
another	O
indication	O
of	O
the	O
heterogeneity	O
of	O
GABA	I-Entity
neurons	O
.	O



Protective	O
effect	O
of	O
misoprostol	I-Entity
on	O
indomethacin	I-Entity
induced	O
renal	B-Entity
dysfunction	I-Entity
in	O
elderly	O
patients	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
possible	O
protective	O
effects	O
of	O
misoprostol	I-Entity
on	O
renal	O
function	O
in	O
hospitalized	O
elderly	O
patients	O
treated	O
with	O
indomethacin	I-Entity
.	O

Forty	O
-	O
five	O
hospitalized	O
elderly	O
patients	O
(	O
>	O
65	O
years	O
old	O
)	O
who	O
required	O
therapy	O
with	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAID	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
indomethacin	I-Entity
,	O
150	O
mg	O
/	O
day	O
(	O
Group	O
A	O
)	O
,	O
or	O
indomethacin	I-Entity
150	O
mg	O
/	O
day	O
plus	O
misoprostol	I-Entity
at	O
0.6	O
mg	O
/	O
day	O
(	O
Group	O
B	O
)	O
.	O

Laboratory	O
variables	O
of	O
renal	O
function	O
[	O
serum	O
creatinine	I-Entity
,	O
blood	B-Entity
urea	I-Entity
nitrogen	I-Entity
(	O
BUN	I-Entity
)	O
and	O
electrolytes	O
]	O
were	O
evaluated	O
before	O
initiation	O
of	O
therapy	O
and	O
every	O
2	O
days	O
,	O
until	O
termination	O
of	O
the	O
study	O
(	O
a	O
period	O
of	O
at	O
least	O
6	O
days	O
)	O
.	O

Response	O
to	O
treatment	O
was	O
estimated	O
by	O
the	O
visual	O
analog	O
scale	O
for	O
severity	O
of	O
pain	I-Entity
.	O

Forty	O
-	O
two	O
patients	O
completed	O
the	O
study	O
,	O
22	O
in	O
Group	O
A	O
and	O
20	O
in	O
Group	O
B.	O
BUN	I-Entity
and	O
creatinine	I-Entity
increased	O
by	O
>	O
50%	O
of	O
baseline	O
levels	O
in	O
54	O
and	O
45%	O
of	O
Group	O
A	O
patients	O
,	O
respectively	O
,	O
compared	O
to	O
only	O
20	O
and	O
10%	O
of	O
Group	O
B	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Potassium	I-Entity
(	O
K	I-Entity
)	O
increment	O
of	O
0.6	O

The	O
mean	O
increments	O
in	O
BUN	I-Entity
,	O
creatinine	I-Entity
,	O
and	O
K	I-Entity
were	O
reduced	O
by	O
63	O
,	O
80	O
,	O
and	O
42%	O
,	O
respectively	O
,	O
in	O
Group	O
B	O
patients	O
compared	O
to	O
Group	O
A.	O
Response	O
to	O
treatment	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSION	O
:	O
Hospitalized	O
elderly	O
patients	O
are	O
at	O
risk	O
for	O
developing	O
indomethacin	I-Entity
related	O
renal	B-Entity
dysfunction	I-Entity
.	O

Addition	O
of	O
misoprostol	I-Entity
can	O
minimize	O
this	O
renal	B-Entity
impairment	I-Entity
without	O
affecting	O
pain	I-Entity
control	O
.	O



Nephrotoxic	I-Entity
effects	O
of	O
aminoglycoside	I-Entity
treatment	O
on	O
renal	O
protein	O
reabsorption	O
and	O
accumulation	O
.	O

To	O
quantify	O
the	O
effects	O
of	O
gentamicin	I-Entity
,	O
kanamycin	I-Entity
and	O
netilmicin	I-Entity
on	O
renal	O
protein	O
reabsorption	O
and	O
accumulation	O
,	O
these	O
drugs	O
were	O
administered	O
to	O
rats	O
intraperitoneally	O
(	O
30	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
7	O
,	O
14	O
or	O
21	O
days	O
.	O

Scanning	O
electron	O
microscopy	O
of	O
the	O
glomerular	O
endothelia	O
,	O
urinary	O
measurements	O
of	O
sodium	I-Entity
,	O
potassium	I-Entity
,	O
endogenous	O
lysozyme	O
,	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
)	O
as	O
well	O
as	O
clearance	O
and	O
accumulation	O
experiments	O
after	O
i.v	O
.	O

Gentamicin	I-Entity
administration	O
decreased	O
diameter	O
,	O
density	O
and	O
shape	O
of	O
endothelial	O
fenestrae	O
.	O

Kanamycin	I-Entity
and	O
netilmicin	I-Entity
appeared	O
to	O
have	O
no	O
effect	O
at	O
the	O
dose	O
used	O
.	O

All	O
three	O
aminoglycosides	I-Entity
decreased	O
GFR	O
and	O
increased	O
urinary	O
excretion	O
of	O
sodium	I-Entity
and	O
potassium	I-Entity
.	O

While	O
gentamicin	I-Entity
and	O
kanamycin	I-Entity
decreased	O
the	O
percentage	O
reabsorption	O
and	O
accumulation	O
of	O
lysozyme	O
after	O
i.v	O
.	O

administration	O
of	O
egg	O
-	O
white	O
lysozyme	O
netilmicin	I-Entity
had	O
no	O
effect	O
.	O

Daily	O
excretion	O
of	O
total	O
protein	O
,	O
endogenous	O
lysozyme	O
and	O
NAG	O
increased	O
only	O
after	O
treatment	O
with	O
kanamycin	I-Entity
and	O
gentamicin	I-Entity
.	O

Thus	O
,	O
aminoglycosides	I-Entity
may	O
act	O
as	O
nephrotoxicants	O
at	O
glomerular	O
and/or	O
tubular	O
level	O
inducing	O
impairment	B-Entity
of	I-Entity
renal	I-Entity
reabsorption	I-Entity
and	O
accumulation	O
of	O
proteins	O
.	O



Pharmacology	O
of	O
GYKI-41	B-Entity
099	I-Entity
(	O
chlorpropanol	I-Entity
,	O
Tobanum	I-Entity
)	O
a	O
new	O
potent	O
beta	O
-	O
adrenergic	O
antagonist	O
.	O

The	O
compound	O
GYKI-41	B-Entity
099	I-Entity
,	O
as	O
a	O
beta	O
-	O
adrenergic	O
antagonist	O
,	O
is	O
3	O
-	O
8	O
times	O
more	O
potent	O
than	O
propranolol	I-Entity
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Its	O
antiarrhythmic	O
effectiveness	O
surpasses	O
that	O
of	O
propranolol	I-Entity
and	O
pindolol	I-Entity
inhibiting	O
the	O
ouabain	I-Entity
arrhythmia	I-Entity
in	O
dogs	O
and	O
cats	O
.	O

GYKI-41	B-Entity
900	I-Entity
has	O
a	O
negligible	O
cardiodepressant	O
activity	O
;	O
it	O
is	O
not	O
cardioselective	O
.	O

There	O
was	O
a	O
prolonged	O
elimination	O
of	O
the	O
radioactivity	O
after	O
the	O
injection	O
of	O
14C-41	B-Entity
099	I-Entity
to	O
rats	O
and	O
dogs	O
.	O



Chorea	I-Entity
associated	O
with	O
oral	B-Entity
contraception	I-Entity
.	O

Three	O
patients	O
developed	O
chorea	I-Entity
while	O
receiving	O
oral	B-Entity
contraceptives	I-Entity
.	O

Two	O
were	O
young	O
patients	O
whose	O
chorea	I-Entity
developed	O
long	O
after	O
treatment	O
had	O
been	O
started	O
and	O
disappeared	O
soon	O
after	O
it	O
had	O
been	O
discontinued	O
.	O

The	O
third	O
patient	O
had	O
acute	O
amphetamine	I-Entity
-	O
induced	O
chorea	I-Entity
after	O
prolonged	O
oral	B-Entity
contraception	I-Entity
.	O

Prolonged	O
administration	O
of	O
female	O
sex	O
hormones	O
is	O
a	O
possible	O
cause	O
of	O
chorea	I-Entity
in	O
women	O
who	O
have	O
not	O
previously	O
had	O
chorea	I-Entity
or	O
rheumatic	B-Entity
fever	I-Entity
.	O



Reversal	O
of	O
ammonia	I-Entity
coma	I-Entity
in	O
rats	O
by	O
L	B-Entity
-	I-Entity
dopa	I-Entity
:	O
a	O
peripheral	O
effect	O
.	O

Ammonia	I-Entity
coma	I-Entity
was	O
produced	O
in	O
rats	O
within	O
10	O
to	O
15	O
minutes	O
of	O
an	O
intraperitonealinjection	O
of	O
1.7	O
mmol	O
NH4CL	I-Entity
.	O

This	O
coma	I-Entity
was	O
prevented	O
with	O
1.68	O
mmol	O
L	B-Entity
-	I-Entity
dopa	I-Entity
given	O
by	O
gastric	O
intubation	O
15	O
minutes	O
before	O
the	O
ammonium	B-Entity
salt	I-Entity
injection	O
.	O

The	O
effect	O
of	O
L	B-Entity
-	I-Entity
dopa	I-Entity
was	O
correlated	O
with	O
a	O
decrease	O
in	O
blood	O
and	O
brain	O
ammonia	I-Entity
,	O
an	O
increase	O
in	O
brain	O
dopamine	I-Entity
,	O
and	O
an	O
increase	O
in	O
renal	O
excretion	O
of	O
ammonia	I-Entity
and	O
urea	I-Entity
.	O

Intraventricular	O
infusion	O
of	O
dopamine	I-Entity
sufficient	O
to	O
raise	O
the	O
brain	O
dopamine	I-Entity
to	O
the	O
same	O
extent	O
did	O
not	O
prevent	O
the	O
ammonia	I-Entity
coma	I-Entity
nor	O
affect	O
the	O
blood	O
and	O
brain	O
ammonia	I-Entity
concentrations	O
.	O

Bilateral	O
nephrectomy	O
eliminated	O
the	O
beneficial	O
effect	O
of	O
L	B-Entity
-	I-Entity
dopa	I-Entity
on	O
blood	O
and	O
brain	O
ammonia	I-Entity
and	O
the	O
ammonia	I-Entity
coma	I-Entity
was	O
not	O
prevented	O
.	O

Thus	O
,	O
the	O
reduction	O
in	O
blood	O
and	O
brain	O
ammonia	I-Entity
and	O
the	O
prevention	O
of	O
ammonia	I-Entity
coma	I-Entity
after	O
L	B-Entity
-	I-Entity
dopa	I-Entity
,	O
can	O
be	O
accounted	O
for	O
by	O
the	O
peripheral	O
effect	O
of	O
dopamine	I-Entity
on	O
renal	O
function	O
rather	O
than	O
its	O
central	O
action	O
.	O

These	O
results	O
provide	O
a	O
reasonable	O
explanation	O
for	O
the	O
beneficial	O
effects	O
observed	O
in	O
some	O
encephalopathic	I-Entity
patients	O
receiving	O
L	B-Entity
-	I-Entity
dopa	I-Entity
.	O



Heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
after	O
liver	O
transplantation	O
.	O

Unfractionated	B-Entity
heparin	I-Entity
sodium	I-Entity
(	O
UFH	I-Entity
)	O
or	O
low	B-Entity
-	I-Entity
molecular	I-Entity
weight	I-Entity
heparin	I-Entity
(	O
LMWH	O
)	O
is	O
used	O
in	O
anticoagulant	O
protocols	O
at	O
several	O
institutions	O
to	O
prevent	O
thrombosis	I-Entity
after	O
liver	O
transplantation	O
.	O

Heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
(	O
HIT	I-Entity
)	O
is	O
an	O
adverse	O
immune	O
-	O
mediated	O
reaction	O
to	O
heparin	I-Entity
,	O
resulting	O
in	O
platelet	O
count	O
decreases	O
of	O
more	O
than	O
50%	O
.	O

The	O
frequencies	O
of	O
HIT	I-Entity
after	O
liver	O
transplantation	O
and	O
platelet	O
factor	O
4/heparin	I-Entity
-	O
reactive	O
antibody	O
(	O
HIT	I-Entity
antibody	O
)	O
positivity	O
in	O
liver	O
transplantation	O
patients	O
,	O
however	O
,	O
are	O
unknown	O
.	O

We	O
started	O
LMWH	O
(	O
25	O
IU	O
/	O
kg	O
/	O
h	O
)	O
on	O
postoperative	O
day	O
(	O
POD	O
)	O
1	O
,	O
switching	O
to	O
UFH	I-Entity
(	O
5000	O
U	O
/	O
d	O
)	O
on	O
POD	O
2	O
or	O
3	O
.	O

The	O
dose	O
of	O
UFH	I-Entity
was	O
changed	O
according	O
to	O
the	O
activated	O
clotting	O
time	O
level	O
.	O

HIT	I-Entity
antibody	O
levels	O
were	O
measured	O
the	O
day	O
before	O
surgery	O
and	O
on	O
POD	O
7	O
and	O
14	O
.	O

Two	O
patients	O
developed	O
hepatic	O
artery	O
thrombosis	I-Entity
on	O
POD	O
11	O
and	O
19	O
,	O
respectively	O
,	O
although	O
they	O
were	O
HIT	I-Entity
antibody	O
-	O
negative	O
and	O
their	O
platelet	O
counts	O
were	O
stable	O
.	O

The	O
heparin	I-Entity
-	O
induced	O
platelet	B-Entity
aggregation	I-Entity
test	O
was	O
negative	O
in	O
these	O
patients	O
.	O

The	O
percentage	O
of	O
HIT	I-Entity
antibody	O
-	O
positive	O
patients	O
was	O
0.5%	O
preoperatively	O
,	O
5.6%	O
on	O
POD	O
7	O
,	O
and	O
5.6%	O
on	O
POD	O
14	O
.	O

None	O
of	O
the	O
subjects	O
/	O
patients	O
developed	O
UFH	I-Entity
-	O
related	O
HIT	I-Entity
.	O

In	O
our	O
series	O
,	O
the	O
occurrence	O
of	O
HIT	I-Entity
after	O
liver	O
transplantation	O
was	O
uncommon	O
.	O



PTU	I-Entity
-	O
associated	O
vasculitis	I-Entity
in	O
a	O
girl	O
with	O
Turner	B-Entity
Syndrome	I-Entity
and	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
.	O

Palpable	O
purpura	I-Entity
is	O
a	O
concerning	O
clinical	O
finding	O
in	O
pediatric	O
patients	O
and	O
can	O
have	O
many	O
causes	O
,	O
including	O
infectious	O
and	O
autoimmune	O
processes	O
.	O

A	O
rare	O
cause	O
,	O
drug	O
-	O
induced	O
vasculitis	I-Entity
,	O
may	O
result	O
from	O
the	O
production	O
of	O
antineutrophil	O
cytoplasmic	O
antibodies	O
(	O
ANCAs	O
)	O
in	O
response	O
to	O
a	O
medication	O
.	O

We	O
report	O
a	O
girl	O
with	O
Turner	B-Entity
syndrome	I-Entity
and	O
Graves	B-Entity
'	I-Entity
disease	I-Entity
who	O
presented	O
with	O
palpable	O
purpuric	B-Entity
lesions	I-Entity
.	O

The	O
diagnosis	O
of	O
propylthiouracil	I-Entity
(	O
PTU)-associated	I-Entity
vasculitis	I-Entity
was	O
made	O
by	O
observation	O
of	O
consistent	O
clinical	O
features	O
,	O
the	O
detection	O
of	O
elevated	O
ANA	O
and	O
ANCA	O
in	O
the	O
blood	O
,	O
and	O
the	O
observed	O
clinical	O
resolution	O
of	O
symptoms	O
following	O
withdrawal	O
of	O
PTU	I-Entity
.	O

Subsequent	O
treatment	O
of	O
persistent	O
hyperthyroidism	I-Entity
with	O
radioablation	O
did	O
not	O
result	O
in	O
an	O
exacerbation	O
of	O
the	O
vasculitis	I-Entity
,	O
a	O
complication	O
described	O
in	O
prior	O
case	O
reports	O
.	O



Succinylcholine	I-Entity
-	O
induced	O
masseter	B-Entity
muscle	I-Entity
rigidity	I-Entity
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Masseter	B-Entity
muscle	I-Entity
rigidity	I-Entity
during	O
general	O
anesthesia	O
is	O
considered	O
an	O
early	O
warning	O
sign	O
of	O
a	O
possible	O
episode	O
of	O
malignant	B-Entity
hyperthermia	I-Entity
.	O

The	O
decision	O
whether	O
to	O
continue	O
or	O
discontinue	O
the	O
procedure	O
depends	O
on	O
the	O
urgency	O
of	O
the	O
surgery	O
and	O
severity	O
of	O
masseter	B-Entity
muscle	I-Entity
rigidity	I-Entity
.	O

Here	O
,	O
we	O
describe	O
a	O
case	O
of	O
severe	O
masseter	B-Entity
muscle	I-Entity
rigidity	I-Entity
(	O
jaw	B-Entity
of	I-Entity
steel	I-Entity
)	O
after	O
succinylcholine	I-Entity
(	O
Sch	I-Entity
)	O
administration	O
during	O
general	O
anesthetic	O
management	O
for	O
rigid	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Anesthesia	O
was	O
continued	O
uneventfully	O
with	O
propofol	I-Entity
infusion	O
while	O
all	O
facilities	O
were	O
available	O
to	O
detect	O
and	O
treat	O
malignant	B-Entity
hyperthermia	I-Entity
.	O



Minor	O
neurological	B-Entity
dysfunction	I-Entity
,	O
cognitive	O
development	O
,	O
and	O
somatic	O
development	O
at	O
the	O
age	O
of	O
3	O
to	O
7	O
years	O
after	O
dexamethasone	I-Entity
treatment	O
in	O
very	O
-	O
low	O
birth	O
-	O
weight	O
infants	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
minor	O
neurological	B-Entity
dysfunction	I-Entity
,	O
cognitive	O
development	O
,	O
and	O
somatic	O
development	O
after	O
dexamethasone	I-Entity
therapy	O
in	O
very	O
-	O
low	O
-	O
birthweight	O
infants	O
.	O

Thirty	O
-	O
three	O
children	O
after	O
dexamethasone	I-Entity
treatment	O
were	O
matched	O
to	O
33	O
children	O
without	O
dexamethasone	I-Entity
treatment	O
.	O

Dexamethasone	I-Entity
was	O
started	O
between	O
the	O
7th	O
and	O
the	O
28th	O
day	O
of	O
life	O
over	O
7	O
days	O
with	O
a	O
total	O
dose	O
of	O
2.35	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Exclusion	O
criteria	O
were	O
asphyxia	I-Entity
,	O
malformations	I-Entity
,	O
major	O
surgical	O
interventions	O
,	O
small	O
for	O
gestational	O
age	O
,	O
intraventricular	O
haemorrhage	I-Entity
grades	O
III	O
and	O
IV	O
,	O
periventricular	B-Entity
leukomalacia	I-Entity
,	O
and	O
severe	O
psychomotor	B-Entity
retardation	I-Entity
.	O

Each	O
child	O
was	O
examined	O
by	O
a	O
neuropediatrician	O
for	O
minor	O
neurological	B-Entity
dysfunctions	I-Entity
and	O
tested	O
by	O
a	O
psychologist	O
for	O
cognitive	O
development	O
with	O
a	O
Kaufman	O
Assessment	O
Battery	O
for	O
Children	O
and	O
a	O
Draw	O
-	O
a	O
-	O
Man	O
Test	O
.	O

After	O
dexamethasone	I-Entity
treatment	O
,	O
children	O
showed	O
a	O
higher	O
rate	O
of	O
minor	O
neurological	B-Entity
dysfunctions	I-Entity
.	O

Further	O
long	O
-	O
term	O
follow	O
-	O
up	O
studies	O
will	O
be	O
necessary	O
to	O
fully	O
evaluate	O
the	O
impact	O
of	O
dexamethasone	I-Entity
on	O
neurological	O
and	O
cognitive	O
development	O
.	O



Force	O
overflow	O
and	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

We	O
assessed	O
force	O
coordination	O
of	O
the	O
hand	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
and	O
its	O
relationship	O
to	O
motor	O
complications	O
of	O
levodopa	I-Entity
therapy	O
,	O
particularly	O
to	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
(	O
LID	I-Entity
)	O
.	O

We	O
studied	O
two	O
groups	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
patients	O
with	O
(	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
+	O
LID	I-Entity
,	O
n	O
=	O
23	O
)	O
and	O
without	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
(	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
-	O
LID	I-Entity
,	O
n	O
=	O
10	O
)	O
,	O
and	O
age	O
-	O
matched	O
healthy	O
controls	O
.	O

The	O
motor	O
score	O
of	O
the	O
Unified	O
Parkinson	B-Entity
's	I-Entity
Disease	I-Entity
Rating	O
Scale	O
,	O
a	O
dyskinesia	I-Entity
score	O
and	O
force	O
in	O
a	O
grip	O
-	O
lift	O
paradigm	O
were	O
assessed	O
ON	O
and	O
OFF	O
levodopa	I-Entity
.	O

A	O
pathological	O
increase	O
of	O
forces	O
was	O
seen	O
in	O
ON	O
-	O
state	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
+	O
LID	I-Entity
only	O
.	O

In	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
+	O
LID	I-Entity
,	O
the	O
force	O
involved	O
in	O
pressing	O
down	O
the	O
object	O
before	O
lifting	O
was	O
significantly	O
increased	O
by	O
levodopa	I-Entity
(	O
by	O
61%	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
contrast	O
,	O
no	O
excessive	O
force	O
was	O
found	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
-	O
LID	I-Entity
.	O

Peak	O
grip	O
force	O
in	O
ON	O
-	O
state	O
was	O
140%	O
(	O
P	O
<	O
0.05	O
)	O
higher	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
+	O
LID	I-Entity
than	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
-	O
LID	I-Entity
,	O
while	O
static	O
grip	O
force	O
was	O
increased	O
by	O
138%	O
(	O
P	O
<	O
0.01	O
)	O
between	O
groups	O
.	O

Severity	O
of	O
peak	O
-	O
dose	O
dyskinesias	I-Entity
was	O
strongly	O
correlated	O
with	O
grip	O
force	O
in	O
ON	O
-	O
state	O
(	O
r	O
=	O
0.79	O
with	O
peak	O
force	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Force	O
excess	O
was	O
only	O
observed	O
in	O
patients	O
with	O
LID	I-Entity
and	O
motor	O
fluctuations	O
.	O

A	O
close	O
relationship	O
was	O
seen	O
between	O
the	O
overshooting	O
of	O
forces	O
and	O
dyskinesias	I-Entity
in	O
the	O
ON	O
-	O
drug	O
condition	O
.	O

We	O
postulate	O
that	O
both	O
LID	I-Entity
and	O
grip	O
force	O
excess	O
share	O
common	O
pathophysiological	O
mechanisms	O
related	O
to	O
motor	O
fluctuations	O
.	O



Postinfarction	O
ventricular	B-Entity
septal	I-Entity
defect	I-Entity
associated	O
with	O
long	O
-	O
term	O
steroid	I-Entity
therapy	O
.	O

Two	O
cases	O
of	O
postinfarction	O
ventricular	B-Entity
septal	I-Entity
rupture	I-Entity
in	O
patients	O
on	O
long	O
-	O
term	O
steroid	I-Entity
therapy	O
are	O
presented	O
and	O
the	O
favourable	O
outcome	O
in	O
both	O
cases	O
described	O
.	O

A	O
possible	O
association	O
between	O
steroid	I-Entity
therapy	O
and	O
subsequent	O
postinfarction	O
septal	B-Entity
rupture	I-Entity
is	O
discussed	O
.	O



Angioedema	I-Entity
associated	O
with	O
droperidol	I-Entity
administration	O
.	O

Angioedema	I-Entity
,	O
also	O
known	O
as	O
angioneurotic	B-Entity
edema	I-Entity
or	O
Quincke	B-Entity
's	I-Entity
disease	I-Entity
,	O
is	O
a	O
well	O
-	O
demarcated	O
,	O
localized	O
edema	I-Entity
involving	O
the	O
subcutaneous	O
tissues	O
that	O
may	O
cause	O
upper	B-Entity
-	I-Entity
airway	I-Entity
obstruction	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
previously	O
healthy	O
19-year	O
-	O
old	O
man	O
with	O
no	O
known	O
drug	B-Entity
allergies	I-Entity
in	O
whom	O
angioedema	I-Entity
with	O
significant	O
tongue	B-Entity
swelling	I-Entity
and	O
protrusion	O
developed	O
within	O
10	O
minutes	O
of	O
the	O
administration	O
of	O
a	O
single	O
IV	O
dose	O
of	O
droperidol	I-Entity
.	O



Clarithromycin	I-Entity
-	O
associated	O
visual	B-Entity
hallucinations	I-Entity
in	O
a	O
patient	O
with	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
.	O

Visual	B-Entity
hallucinations	I-Entity
are	O
a	O
rare	O
event	O
in	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
and	O
not	O
related	O
to	O
uremia	I-Entity
per	O
se	O
.	O

Unreported	O
in	O
the	O
literature	O
is	O
visual	B-Entity
hallucinations	I-Entity
occurring	O
in	O
association	O
with	O
the	O
new	O
macrolide	I-Entity
antibiotic	O
,	O
clarithromycin	I-Entity
.	O

We	O
describe	O
such	O
a	O
case	O
in	O
a	O
patient	O
with	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
(	O
ESRD	I-Entity
)	O
maintained	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O

The	O
combination	O
of	O
a	O
relatively	O
high	O
dose	O
of	O
clarithromycin	I-Entity
in	O
face	O
of	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
in	O
a	O
functionally	O
anephric	O
patient	O
,	O
with	O
underlying	O
aluminum	I-Entity
intoxication	O
,	O
may	O
have	O
facilitated	O
the	O
appearance	O
of	O
this	O
neurotoxic	I-Entity
side	O
effect	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
pharmacokinetics	O
of	O
medications	O
in	O
face	O
of	O
chronic	B-Entity
renal	I-Entity
failure	I-Entity
,	O
the	O
possibility	O
of	O
drug	O
interactions	O
,	O
and	O
how	O
these	O
factors	O
should	O
help	O
guide	O
medication	O
therapy	O
in	O
the	O
ESRD	I-Entity
patient	O
.	O



Acute	O
renal	B-Entity
toxicity	I-Entity
of	O
doxorubicin	I-Entity
(	O
adriamycin)-loaded	I-Entity
cyanoacrylate	I-Entity
nanoparticles	O
.	O

Acute	O
doxorubicin	I-Entity
-	O
loaded	O
nanoparticle	O
(	O
DXNP	O
)	O
renal	B-Entity
toxicity	I-Entity
was	O
explored	O
in	O
both	O
normal	O
rats	O
and	O
rats	O
with	O
experimental	O
glomerulonephritis	I-Entity
.	O

In	O
normal	O
rats	O
,	O
2/6	O
rats	O
given	O
free	O
doxorubicin	I-Entity
(	O
DX	I-Entity
)	O
(	O
5	O
mg	O
/	O
kg	O
)	O
died	O
within	O
one	O
week	O
,	O
whereas	O
all	O
control	O
animals	O
and	O
all	O
rats	O
having	O
received	O
free	O
NP	O
or	O
DXNP	O
survived	O
.	O

A	O
3	O
times	O
higher	O
proteinuria	I-Entity
appeared	O
in	O
animals	O
treated	O
with	O
DXNP	O
than	O
in	O
those	O
treated	O
with	O
DX	I-Entity
.	O

Free	O
NP	O
did	O
not	O
provoke	O
any	O
proteinuria	I-Entity
.	O

Two	O
hr	O
post	O
-	O
injection	O
,	O
DXNP	O
was	O
2.7	O
times	O
more	O
concentrated	O
in	O
kidneys	O
than	O
free	O
DX	I-Entity
(	O
p	O
<	O
0.025	O
)	O
.	O

In	O
rats	O
with	O
immune	O
experimental	O
glomerulonephritis	I-Entity
,	O
5/6	O
rats	O
given	O
DX	I-Entity
died	O
within	O
7	O
days	O
,	O
in	O
contrast	O
to	O
animals	O
treated	O
by	O
DXNP	O
,	O
NP	O
,	O
or	O
untreated	O
,	O
which	O
all	O
survived	O
.	O

Proteinuria	I-Entity
appeared	O
in	O
all	O
series	O
,	O
but	O
was	O
2	O
-	O
5	O
times	O
more	O
intense	O
(	O
p	O
>	O
0.001	O
)	O
and	O
prolonged	O
after	O
doxorubicin	I-Entity
treatment	O
(	O
400	O
-	O
700	O
mg	O
/	O
day	O
)	O
,	O
without	O
significant	O
difference	O
between	O
DXNP	O
and	O
DX	I-Entity
.	O

These	O
results	O
demonstrate	O
that	O
,	O
in	O
these	O
experimental	O
conditions	O
,	O
DXNP	O
killed	O
less	O
animals	O
than	O
free	O
DX	I-Entity
,	O
despite	O
of	O
an	O
enhanced	O
renal	B-Entity
toxicity	I-Entity
of	O
the	O
former	O
.	O

Both	O
effects	O
(	O
better	O
survival	O
and	O
nephrosis	I-Entity
)	O
are	O
most	O
probably	O
related	O
to	O
an	O
enhanced	O
capture	O
of	O
DXNP	O
by	O
cells	O
of	O
the	O
mononuclear	O
phagocyte	O
system	O
,	O
including	O
mesangial	O
cells	O
.	O



Etoposide	I-Entity
-	O
related	O
myocardial	B-Entity
infarction	I-Entity
.	O

The	O
occurrence	O
of	O
a	O
myocardial	B-Entity
infarction	I-Entity
is	O
reported	O
after	O
chemotherapy	O
containing	O
etoposide	I-Entity
,	O
in	O
a	O
man	O
with	O
no	O
risk	O
factors	O
for	O
coronary	B-Entity
heart	I-Entity
disease	I-Entity
.	O



Subjective	O
assessment	O
of	O
sexual	B-Entity
dysfunction	I-Entity
of	O
patients	O
on	O
long	O
-	O
term	O
administration	O
of	O
digoxin	I-Entity
.	O

Various	O
data	O
suggest	O
that	O
male	O
patients	O
who	O
have	O
received	O
digoxin	I-Entity
on	O
a	O
longterm	O
basis	O
have	O
increased	O
levels	O
of	O
serum	O
estrogen	I-Entity
and	O
decreased	O
levels	O
of	O
plasma	O
testosterone	I-Entity
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
links	O
between	O
the	O
long	O
-	O
term	O
administration	O
of	O
digoxin	I-Entity
therapy	O
and	O
sexual	O
behavior	O
,	O
and	O
the	O
effect	O
of	O
digoxin	I-Entity
on	O
plasma	O
levels	O
of	O
estradiol	I-Entity
,	O
testosterone	I-Entity
,	O
and	O
LH	O
.	O

The	O
patients	O
of	O
the	O
study	O
and	O
control	O
group	O
(	O
without	O
digoxin	I-Entity
)	O
were	O
of	O
similar	O
cardiac	O
functional	O
capacity	O
and	O
age	O
(	O
25	O
-	O
40	O
years	O
)	O
and	O
were	O
randomly	O
selected	O
from	O
the	O
rheumatic	B-Entity
heart	I-Entity
disease	I-Entity
patients	O
.	O

The	O
findings	O
support	O
the	O
reports	O
concerning	O
digoxin	I-Entity
effect	O
on	O
plasma	O
estradiol	I-Entity
,	O
testosterone	I-Entity
,	O
and	O
LH	O
.	O

Tests	O
used	O
to	O
evaluate	O
the	O
changes	O
in	O
sexual	O
behavior	O
showed	O
a	O
significant	O
decrease	B-Entity
in	I-Entity
sexual	I-Entity
desire	I-Entity
,	O
sexual	O
excitement	O
phase	O
(	O
erection	O
)	O
,	O
and	O
frequency	O
of	O
sexual	O
relations	O
in	O
the	O
study	O
group	O
.	O



Fatal	O
aplastic	B-Entity
anemia	I-Entity
due	O
to	O
indomethacin	I-Entity
--	O
lymphocyte	O
transformation	O
tests	O
in	O
vitro	O
.	O

Although	O
indomethacin	I-Entity
has	O
been	O
implicated	O
as	O
a	O
possible	O
cause	O
of	O
aplastic	B-Entity
anemia	I-Entity
on	O
the	O
basis	O
of	O
a	O
few	O
clinical	O
observations	O
,	O
its	O
role	O
has	O
not	O
been	O
definitely	O
established	O
.	O

A	O
case	O
of	O
fatal	O
aplastic	B-Entity
anemia	I-Entity
is	O
described	O
in	O
which	O
no	O
drugs	O
other	O
than	O
allopurinol	I-Entity
and	O
indomethacin	I-Entity
were	O
given	O
.	O

Indomethacin	I-Entity
was	O
first	O
given	O
four	O
weeks	O
prior	O
to	O
the	O
onset	O
of	O
symptoms	O
.	O

A	O
positive	O
lymphocyte	O
transformation	O
test	O
with	O
indomethacin	I-Entity
in	O
vitro	O
further	O
substantiates	O
the	O
potential	O
role	O
of	O
this	O
drug	O
in	O
causing	O
aplastic	B-Entity
anemia	I-Entity
in	O
a	O
susceptible	O
patient	O
.	O



Plasma	O
and	O
urinary	O
lipids	O
and	O
lipoproteins	O
during	O
the	O
development	O
of	O
nephrotic	B-Entity
syndrome	I-Entity
induced	O
in	O
the	O
rat	O
by	O
puromycin	B-Entity
aminonucleoside	I-Entity
.	O

This	O
study	O
was	O
undertaken	O
to	O
ascertain	O
whether	O
the	O
alterations	O
of	O
plasma	O
lipoproteins	O
found	O
in	O
nephrotic	B-Entity
syndrome	I-Entity
induced	O
by	O
puromycin	B-Entity
aminonucleoside	I-Entity
were	O
due	O
to	O
nephrotic	B-Entity
syndrome	I-Entity
per	O
se	O
,	O
or	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
aminonucleoside	I-Entity
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
changes	O
in	O
plasma	O
and	O
urinary	O
lipoproteins	O
during	O
the	O
administration	O
of	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
20	O
mg	O
/	O
kg	O
for	O
7	O
days	O
)	O
and	O
the	O
subsequent	O
development	O
of	O
nephrotic	B-Entity
syndrome	I-Entity
.	O

Since	O
massive	O
albuminuria	I-Entity
occurred	O
after	O
6	O
days	O
of	O
treatment	O
,	O
the	O
time	O
-	O
course	O
study	O
was	O
divided	O
into	O
two	O
stages	O
:	O
pre	O
-	O
nephrotic	I-Entity
stage	O
(	O
day	O
1	O
-	O
5	O
)	O
and	O
nephrotic	I-Entity
stage	O
(	O
day	O
6	O
-	O
11	O
)	O
.	O

In	O
pre	O
-	O
nephrotic	I-Entity
stage	O
the	O
plasma	O
level	O
of	O
fatty	B-Entity
acids	I-Entity
,	O
triacylglycerol	I-Entity
and	O
VLDL	O
decreased	O
while	O
that	O
of	O
phospholipid	O
,	O
cholesteryl	B-Entity
esters	I-Entity
and	O
HDL	O
remained	O
constant	O
.	O

At	O
the	O
beginning	O
of	O
nephrotic	I-Entity
stage	O
(	O
day	O
6	O
)	O
the	O
concentration	O
of	O
plasma	O
albumin	O
dropped	O
to	O
a	O
very	O
low	O
level	O
,	O
while	O
that	O
of	O
apolipoprotein	O
A	O
-	O
I	O
increased	O
abruptly	O
(	O
4-fold	O
increase	O
)	O
and	O
continued	O
to	O
rise	O
,	O
although	O
less	O
steeply	O
,	O
in	O
the	O
following	O
days	O
.	O

In	O
the	O
pre	O
-	O
nephrotic	I-Entity
stage	O
lipoproteinuria	O
was	O
negligible	O
,	O
while	O
in	O
the	O
early	O
nephrotic	I-Entity
stage	O
the	O
urinary	O
loss	O
of	O
plasma	O
lipoproteins	O
consisted	O
mainly	O
of	O
HDL	O
.	O

These	O
observations	O
indicate	O
that	O
puromycin	B-Entity
aminonucleoside	I-Entity
alters	O
plasma	O
lipoproteins	O
by	O
lowering	O
VLDL	O
and	O
increasing	O
HDL	O
.	O

It	O
is	O
likely	O
that	O
the	O
early	O
and	O
striking	O
increase	O
of	O
plasma	O
HDL	O
found	O
in	O
nephrotic	I-Entity
rats	O
is	O
related	O
to	O
a	O
direct	O
effect	O
of	O
the	O
drug	O
on	O
HDL	O
metabolism	O
.	O



Circulating	O
lysosomal	O
enzymes	O
and	O
acute	B-Entity
hepatic	I-Entity
necrosis	I-Entity
.	O

The	O
activities	O
of	O
the	O
lysosomal	O
enzymes	O
acid	O
and	O
neutral	O
protease	O
,	O
N	O
-	O
acetylglucosaminidase	O
,	O
and	O
acid	O
phosphatase	O
were	O
measured	O
in	O
the	O
serum	O
of	O
patients	O
with	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
.	O

(	O
cathepsin	O
D	O
)	O
activity	O
was	O
increased	O
about	O
tenfold	O
in	O
patients	O
who	O
died	O
and	O
nearly	O
fourfold	O
in	O
those	O
who	O
survived	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
after	O
paracetamol	I-Entity
overdose	I-Entity
,	O
whereas	O
activities	O
were	O
increased	O
equally	O
in	O
patients	O
with	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
due	O
to	O
viral	B-Entity
hepatitis	I-Entity
whether	O
or	O
not	O
they	O
survived	O
.	O

A	O
correlation	O
was	O
found	O
between	O
serum	O
acid	O
protease	O
activity	O
and	O
prothrombin	O
time	O
,	O
and	O
the	O
increase	O
in	O
cathepsin	O
D	O
activity	O
was	O
sustained	O
over	O
several	O
days	O
compared	O
with	O
aspartate	I-Entity
aminotransferase	O
,	O
which	O
showed	O
a	O
sharp	O
early	O
peak	O
and	O
then	O
a	O
fall	O
.	O



Transketolase	O
abnormality	O
in	O
tolazamide	I-Entity
-	O
induced	O
Wernicke	B-Entity
's	I-Entity
encephalopathy	I-Entity
.	O

We	O
studied	O
a	O
thiamine	I-Entity
-	O
dependent	O
enzyme	O
,	O
transketolase	O
,	O
from	O
fibroblasts	O
of	O
a	O
diabetic	I-Entity
patient	O
who	O
developed	O
Wernicke	B-Entity
's	I-Entity
encephalopathy	I-Entity
when	O
treated	O
with	O
tolazamide	I-Entity
,	O
in	O
order	O
to	O
delineate	O
if	O
this	O
patient	O
also	O
had	O
transketolase	O
abnormality	O
[	O
high	O
Km	O
for	O
thiamine	B-Entity
pyrophosphate	I-Entity
(	O
TPP	I-Entity
)	O
]	O
,	O
as	O
previously	O
reported	O
in	O
postalcoholic	O
Wernicke	B-Entity
-	I-Entity
Korsakoff	I-Entity
syndrome	I-Entity
.	O

In	O
addition	O
to	O
this	O
patient	O
,	O
we	O
also	O
studied	O
this	O
enzyme	O
from	O
three	O
diabetic	I-Entity
kindreds	O
without	O
any	O
history	O
of	O
Wernicke	B-Entity
's	I-Entity
encephalopathy	I-Entity
and	O
from	O
four	O
normal	O
controls	O
.	O

We	O
found	O
that	O
the	O
above	O
-	O
mentioned	O
patient	O
and	O
one	O
of	O
the	O
diabetic	I-Entity
kindreds	O
with	O
no	O
history	O
of	O
Wernicke	B-Entity
's	I-Entity
encephalopathy	I-Entity
had	O
abnormal	O
transketolase	O
as	O
determined	O
by	O
its	O
Km	O
for	O
TPP	I-Entity
.	O

These	O
data	O
suggest	O
a	O
similarity	O
between	O
postalcoholic	O
Wernicke	B-Entity
-	I-Entity
Korsakoff	I-Entity
syndrome	I-Entity
and	O
the	O
patient	O
with	O
tolazamide	I-Entity
-	O
induced	O

Wernicke	B-Entity
's	I-Entity
encephalopathy	I-Entity
from	O
the	O
standpoint	O
of	O
transketolase	O
abnormality	O
.	O



Mechanisms	O
of	O
myocardial	B-Entity
ischemia	I-Entity
induced	O
by	O
epinephrine	I-Entity
:	O
comparison	O
with	O
exercise	O
-	O
induced	O
ischemia	I-Entity
.	O

The	O
role	O
of	O
epinephrine	I-Entity
in	O
eliciting	O
myocardial	B-Entity
ischemia	I-Entity
was	O
examined	O
in	O
patients	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
.	O

Objective	O
signs	O
of	O
ischemia	I-Entity
and	O
factors	O
increasing	O
myocardial	O
oxygen	I-Entity
consumption	O
were	O
compared	O
during	O
epinephrine	I-Entity
infusion	O
and	O
supine	O
bicycle	O
exercise	O
.	O

Both	O
epinephrine	I-Entity
and	O
exercise	O
produced	O
myocardial	B-Entity
ischemia	I-Entity
as	O
evidenced	O
by	O
ST	O
segment	O
depression	I-Entity
and	O
angina	I-Entity
.	O

However	O
,	O
the	O
mechanisms	O
of	O
myocardial	B-Entity
ischemia	I-Entity
induced	O
by	O
epinephrine	I-Entity
were	O
significantly	O
different	O
from	O
those	O
of	O
exercise	O
.	O

Exercise	O
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
was	O
marked	O
predominantly	O
by	O
increased	O
heart	O
rate	O
and	O
rate	O
-	O
pressure	O
product	O
with	O
a	O
minor	O
contribution	O
of	O
end	O
-	O
diastolic	O
volume	O
,	O
while	O
epinephrine	I-Entity
-	O
induced	O
ischemia	I-Entity
was	O
characterized	O
by	O
a	O
marked	O
increase	O
in	O
contractility	O
and	O
a	O
less	O
pronounced	O
increase	O
in	O
heart	O
rate	O
and	O
rate	O
-	O
pressure	O
product	O
.	O

These	O
findings	O
indicate	O
that	O
ischemia	I-Entity
produced	O
by	O
epinephrine	I-Entity
,	O
as	O
may	O
occur	O
during	O
states	O
of	O
emotional	O
distress	O
,	O
has	O
a	O
mechanism	O
distinct	O
from	O
that	O
due	O
to	O
physical	O
exertion	O
.	O



Transient	O
contralateral	B-Entity
rotation	I-Entity
following	O
unilateral	O
substantia	B-Entity
nigra	I-Entity
lesion	I-Entity
reflects	O
susceptibility	O
of	O
the	O
nigrostriatal	O
system	O
to	O
exhaustion	O
by	O
amphetamine	I-Entity
.	O

Following	O
unilateral	O
6-OHDA	I-Entity
induced	O
SN	B-Entity
lesion	I-Entity
,	O
a	O
transient	O
period	O
of	O
contralateral	B-Entity
rotation	I-Entity
has	O
been	O
reported	O
to	O
precede	O
the	O
predominant	O
ipsilateral	B-Entity
circling	I-Entity
.	O

In	O
order	O
to	O
clarify	O
the	O
nature	O
of	O
this	O
initial	O
contralateral	B-Entity
rotation	I-Entity
we	O
examined	O
the	O
effect	O
of	O
the	O
duration	O
of	O
recovery	O
period	O
after	O
the	O
lesion	O
,	O
on	O
amphetamine	I-Entity
-	O
induced	O
rotational	B-Entity
behavior	I-Entity
.	O

Such	O
contralateral	B-Entity
rotation	I-Entity
may	O
result	O
from	O
either	O
degeneration	O
-	O
induced	O
breakdown	O
of	O
the	O
DA	O
pool	O
,	O
or	O
lesion	O
-	O
induced	O
increase	O
of	O
DA	O
turnover	O
in	O
the	O
spared	O
neurons	O
.	O

A	O
substantial	O
degree	O
of	O
contralateral	O
preference	O
was	O
still	O
evident	O
when	O
amphetamine	I-Entity
was	O
administered	O
for	O
the	O
first	O
time	O
24	O
days	O
after	O
lesioning	O
,	O
indicating	O
involvement	O
of	O
spared	O
cells	O
in	O
the	O
contralateral	B-Entity
rotation	I-Entity
.	O

However	O
,	O
regardless	O
of	O
the	O
duration	O
of	O
recovery	O
(	O
and	O
irrespective	O
of	O
either	O
lesion	O
volume	O
,	O
amphetamine	I-Entity
dose	O
,	O
or	O
post	O
-	O
lesion	O
motor	O
exercise	O
)	O
,	O
amphetamine	I-Entity
-	O
induced	O
rotation	I-Entity
tended	O
to	O
become	O
gradually	O
more	O
ipsilateral	O
as	O
the	O
observation	O
session	O
progressed	O
,	O
and	O
all	O
rats	O
circled	O
ipsilaterally	O
to	O
the	O
lesion	O
in	O
response	O
to	O
further	O
amphetamine	I-Entity
injections	O
.	O

These	O
findings	O
suggest	O
that	O
amphetamine	I-Entity
has	O
an	O
irreversible	O
effect	O
on	O
the	O
post	O
-	O
lesion	O
DA	O
pool	O
contributing	O
to	O
contralateral	B-Entity
rotation	I-Entity
.	O



Thyroid	O
function	O
and	O
urine	O
-	O
concentrating	O
ability	O
during	O
lithium	I-Entity
treatment	O
.	O

It	O
has	O
been	O
suggested	O
that	O
adenylate	O
cyclase	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
development	O
of	O
both	O
nephrogenic	B-Entity
diabetes	I-Entity
insipidus	I-Entity
and	O
hypothyroidism	I-Entity
during	O
lithium	I-Entity
treatment	O
.	O

We	O
measured	O
serum	O
thyroxine	I-Entity
and	O
urine	O
-	O
concentrating	O
ability	O
(	O
Umax	O
)	O
in	O
response	O
to	O
desmopressin	O
(	O
DDAVP	O
)	O
in	O
85	O
patients	O
receiving	O
lithium	I-Entity
.	O

Hypothyroidism	I-Entity
developed	O
in	O
eight	O
patients	O
while	O
they	O
were	O
taking	O
lithium	I-Entity
.	O

Impaired	O
Umax	O
was	O
found	O
in	O
both	O
euthyroid	O
and	O
hypothyroid	I-Entity
patients	O
while	O
some	O
hypothyroid	I-Entity
patients	O
concentrated	O
their	O
urine	O
well	O
.	O

It	O
is	O
concluded	O
that	O
the	O
dominant	O
mechanisms	O
by	O
which	O
lithium	I-Entity
exerts	O
these	O
two	O
effects	O
are	O
different	O
.	O



Sensitivity	O
of	O
erythroid	O
progenitor	O
colonies	O
to	O
erythropoietin	O
in	O
azidothymidine	I-Entity
treated	O
immunodeficient	I-Entity
mice	O
.	O

The	O
anaemia	I-Entity
induced	O
by	O
3'-azido-3'dideoxythymidine	I-Entity
(	O
AZT	I-Entity
)	O
is	O
poorly	O
understood	O
.	O

We	O
have	O
used	O
a	O
murine	O
model	O
of	O
AIDS	I-Entity
,	O
infection	I-Entity
of	O
female	O
C57BL/6	O
mice	O
with	O
LP	O
-	O
BM5	O
murine	O
leukaemia	I-Entity
(	O
MuLV	O
)	O
virus	O
,	O
to	O
determine	O
if	O
AZT	I-Entity
-	O
induced	O
anaemia	I-Entity
is	O
due	O
,	O
in	O
part	O
,	O
to	O
decreased	O
responsiveness	O
of	O
erythropoietic	O
precursors	O
(	O
BFU	O
-	O
e	O
)	O
to	O
erythropoietin	O
(	O
EPO	O
)	O
.	O

Mice	O
in	O
the	O
early	O
stage	O
of	O
LP	O
-	O
BM5	O
MuLV	O
disease	O
were	O
given	O
AZT	I-Entity
in	O
their	O
drinking	O
water	O
at	O
1.0	O
and	O
2.5	O
mg	O
/	O
ml	O
.	O

AZT	I-Entity
produced	O
anaemia	I-Entity
in	O
both	O
groups	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

Despite	O
the	O
anaemia	I-Entity
,	O
the	O
number	O
of	O
splenic	O
and	O
bone	O
marrow	O
BFU	O
-	O
e	O
in	O
AZT	I-Entity
treated	O
mice	O
increased	O
up	O
to	O
five	O
-	O
fold	O
over	O
levels	O
observed	O
in	O
infected	O
untreated	O
animals	O
after	O
15	O
d	O
of	O
treatment	O
.	O

Colony	O
formation	O
by	O
splenic	O
and	O
bone	O
marrow	O
BFUe	O
was	O
stimulated	O
at	O
lower	O
concentrations	O
of	O
EPO	O
in	O
mice	O
receiving	O
AZT	I-Entity
for	O
15	O
d	O
than	O
for	O
infected	O
,	O
untreated	O
mice	O
.	O

The	O
mean	O
plasma	O
levels	O
of	O
EPO	O
observed	O
in	O
AZT	I-Entity
treated	O
mice	O
were	O
appropriate	O
for	O
the	O
degree	O
of	O
anaemia	I-Entity
observed	O
when	O
compared	O
with	O
phenylhydrazine	I-Entity
(	O
PHZ	I-Entity
)	O
treated	O
mice	O
.	O

The	O
numbers	O
of	O
BFU	O
-	O
e	O
and	O
the	O
percentage	O
of	O
bone	O
marrow	O
erythroblasts	O
observed	O
were	O
comparable	O
in	O
AZT	I-Entity
and	O
PHZ	I-Entity
treated	O
mice	O
with	O
similar	O
degrees	O
of	O
anaemia	I-Entity
.	O

However	O
,	O
reticulocytosis	I-Entity
was	O
inappropriate	O
for	O
the	O
degree	O
of	O
anaemia	I-Entity
observed	O
in	O
AZT	I-Entity
treated	O
infected	O
mice	O
.	O

AZT	I-Entity
-	O
induced	O
peripheral	O
anaemia	I-Entity
in	O
the	O
face	O
of	O
increased	O
numbers	O
of	O
BFU	O
-	O
e	O
and	O
increased	O
levels	O
of	O
plasma	O
EPO	O
suggest	O
a	O
lesion	O
in	O
terminal	O
differentiation	O
.	O



Detection	O
of	O
abnormal	O
cardiac	O
adrenergic	O
neuron	O
activity	O
in	O
adriamycin	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
with	O
iodine-125-metaiodobenzylguanidine	I-Entity
.	O

Radiolabeled	B-Entity
metaiodobenzylguanidine	I-Entity
(	O
MIBG	I-Entity
)	O
,	O
an	O
analog	O
of	O
norepinephrine	I-Entity
(	O
NE	I-Entity
)	O
,	O
serves	O
as	O
an	O
index	O
of	O
adrenergic	O
neuron	O
integrity	O
and	O
function	O
.	O

Using	O
a	O
rat	O
model	O
of	O
adriamycin	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
abnormal	O
cardiac	O
adrenergic	O
neuron	O
activity	O
may	O
appear	O
and	O
be	O
exacerbated	O
dose	O
-	O
dependently	O
in	O
adriamycin	I-Entity
cardiomyopathy	I-Entity
.	O

The	O
degree	O
of	O
vacuolar	B-Entity
degeneration	I-Entity
of	I-Entity
myocardial	I-Entity
cells	I-Entity
was	O
analyzed	O
in	O
relation	O
to	O
the	O
duration	O
of	O
adriamycin	I-Entity
treatment	O
(	O
2	O
mg	O
/	O
kg	O
,	O
once	O
a	O
week	O
)	O
.	O

Myocardial	O
accumulation	O
of	O
[	O
125I]MIBG	I-Entity
4	O
hr	O
after	O
intravenous	O
injection	O
did	O
not	O
differ	O
between	O
the	O
controls	O
and	O
the	O
groups	O
treated	O
3	O
wk	O
or	O
less	O
.	O

In	O
the	O
5-wk	O
group	O
,	O
MIBG	I-Entity
accumulation	O
in	O
the	O
right	O
and	O
left	O
ventricular	O
wall	O
was	O
35%	O
and	O
27%	O
of	O
that	O
in	O
controls	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

In	O
the	O
8-wk	O
group	O
,	O
MIBG	I-Entity
accumulation	O
in	O
the	O
right	O
and	O
left	O
ventricular	O
wall	O
was	O
18%	O
and	O
14%	O
of	O
that	O
in	O
controls	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Thus	O
,	O
MIBG	I-Entity
accumulation	O
in	O
the	O
myocardium	O
decreased	O
in	O
an	O
adriamycin	I-Entity
dose	O
-	O
dependent	O
manner	O
.	O

The	O
appearance	O
of	O
impaired	O
cardiac	O
adrenergic	O
neuron	O
activity	O
in	O
the	O
presence	O
of	O
slight	O
myocardial	B-Entity
impairment	I-Entity
(	O
scattered	O
or	O
focal	O
vacuolar	B-Entity
degeneration	I-Entity
)	O
indicates	O
that	O
MIBG	I-Entity
scintigraphy	O
may	O
be	O
a	O
useful	O
method	O
for	O
detection	O
of	O
adriamycin	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
.	O



Amnestic	B-Entity
syndrome	I-Entity
associated	O
with	O
propranolol	I-Entity
toxicity	I-Entity
:	O
a	O
case	O
report	O
.	O

An	O
elderly	O
woman	O
developed	O
an	O
Alzheimer	I-Entity
-	O
like	O
subacute	O
dementia	I-Entity
as	O
a	O
result	O
of	O
propranolol	I-Entity
toxicity	I-Entity
.	O

There	O
is	O
evidence	O
that	O
cerebral	O
reactions	O
to	O
drug	O
toxicity	I-Entity
can	O
exhibit	O
patterns	O
that	O
suggest	O
highly	O
selective	O
involvement	O
of	O
functional	O
subdivisions	O
of	O
the	O
brain	O
.	O



Biphasic	O
response	O
of	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
in	O
vivo	O
to	O
selective	O
administration	O
of	O
ketamine	I-Entity
.	O

Effect	O
of	O
ketamine	I-Entity
on	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
was	O
studied	O
in	O
vivo	O
using	O
a	O
selective	O
perfusion	O
technique	O
of	O
the	O
SA	O
node	O
artery	O
.	O

Injections	O
of	O
ketamine	I-Entity
in	O
doses	O
from	O
100	O
microgram	O
to	O
3	O
mg	O
into	O
the	O
artery	O
produced	O
a	O
depression	I-Entity
of	O
the	O
SA	O
nodal	O
activity	O
by	O
a	O
direct	O
action	O
.	O

This	O
depression	I-Entity
was	O
followed	O
by	O
the	O
sudden	O
appearance	O
of	O
a	O
stimulatory	O
phase	O
.	O

Bilateral	O
vagotomy	O
and	O
sympathectomy	O
or	O
prior	O
administration	O
of	O
a	O
ganglion	O
blocker	O
failed	O
to	O
inhibit	O
the	O
occurrence	O
of	O
the	O
ketamine	I-Entity
-	O
induced	O
tachycardia	I-Entity
,	O
while	O
it	O
was	O
completely	O
abolished	O
in	O
the	O
reserpinized	O
dogs	O
or	O
by	O
a	O
prior	O
injection	O
of	O
a	O
beta	O
-	O
blocking	O
agent	O
into	O
the	O
SA	O
node	O
artery	O
.	O

This	O
may	O
indicate	O
that	O
an	O
activation	O
of	O
the	O
peripheral	O
adrenergic	O
mechanism	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
the	O
excitatory	O
effect	O
of	O
ketamine	I-Entity
injected	O
in	O
the	O
SA	O
node	O
artery	O
.	O



The	O
use	O
of	O
serum	O
cholinesterase	O
in	O
succinylcholine	I-Entity
apnoea	I-Entity
.	O

Fifteen	O
patients	O
demonstrating	O
unexpected	O
prolonged	O
apnoea	I-Entity
lasting	O
several	O
hours	O
after	O
succinylcholine	I-Entity
have	O
been	O
treated	O
by	O
a	O
new	O
preparation	O
of	O
human	O
serum	O
cholinesterase	O
.	O

It	O
is	O
therefore	O
supposed	O
that	O
other	O
unknown	O
variants	O
of	O
serum	O
cholinesterase	O
exist	O
which	O
can	O
not	O
hydrolyze	O
succinylcholine	I-Entity
.	O

The	O
use	O
of	O
serum	O
cholinesterase	O
in	O
succinylcholine	I-Entity
apnoea	I-Entity
provided	O
considerable	O
relief	O
to	O
both	O
patient	O
and	O
anaesthetist	O
.	O



Orthostatic	B-Entity
hypotension	I-Entity
occurs	O
following	O
alpha	O
2-adrenoceptor	O
blockade	O
in	O
chronic	O
prazosin	I-Entity
-	O
pretreated	O
conscious	O
spontaneously	O
hypertensive	I-Entity
rats	O
.	O
1	O
.	O

Studies	O
were	O
performed	O
to	O
evaluate	O
whether	O
chronic	O
prazosin	I-Entity
treatment	O
alters	O
the	O
alpha	O
2-adrenoceptor	O
function	O
for	O
orthostatic	O
control	O
of	O
arterial	O
blood	O
pressure	O
in	O
conscious	O
spontaneously	O
hypertensive	I-Entity
rats	O
(	O
SHR	O
)	O
.	O

Conscious	O
SHR	O
(	O
male	O
300	O
-	O
350	O
g	O
)	O
were	O
subjected	O
to	O
90	O
degrees	O
head	O
-	O
up	O
tilts	O
for	O
60	O
s	O
following	O
acute	O
administration	O
of	O
prazosin	I-Entity
(	O
0.1	O
mg	O
kg-1	O
i.p	O
.	O
)	O
or	O
rauwolscine	I-Entity
(	O
3	O
mg	O
kg-1	O
i.v	O
.	O
)	O
.	O

Orthostatic	B-Entity
hypotension	I-Entity
was	O
determined	O
by	O
the	O
average	O
decrease	O
(	O
%	O
)	O
in	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
femoral	O
)	O
over	O
the	O
60-s	O
tilt	O
period	O
.	O

The	O
basal	O
MAP	O
of	O
conscious	O
SHR	O
was	O
reduced	O
to	O
a	O
similar	O
extent	O
by	O
prazosin	I-Entity
(	O
-23%(-)-26%	O
MAP	O
)	O
and	O
rauwolscine	I-Entity
(	O
-16%(-)-33%	O
MAP	O
)	O
.	O

However	O
,	O
the	O
head	O
-	O
up	O
tilt	O
induced	O
orthostatic	B-Entity
hypotension	I-Entity
in	O
the	O
SHR	O
treated	O
with	O
prazosin	I-Entity
(	O
-16%	O
MAP	O
,	O
n	O
=	O
6	O
)	O
,	O
but	O
not	O
in	O
the	O
SHR	O
treated	O
with	O
rauwolscine	I-Entity
(	O
less	O
than	O
+	O
2%	O
MAP	O
,	O
n	O
=	O
6	O
)	O
.	O

Conscious	O
SHR	O
were	O
treated	O
for	O
4	O
days	O
with	O
prazosin	I-Entity
at	O
2	O
mg	O
kg-1	O
day-1	O
i.p	O
.	O

MAP	O
in	O
conscious	O
SHR	O
after	O
chronic	O
prazosin	I-Entity
treatment	O
was	O
14%	O
lower	O
than	O
in	O
the	O
untreated	O
SHR	O
(	O
n	O
=	O
8)	O
.	O

Head	O
-	O
up	O
tilts	O
in	O
these	O
rats	O
did	O
not	O
produce	O
orthostatic	B-Entity
hypotension	I-Entity
when	O
performed	O
either	O
prior	O
to	O
or	O
after	O
acute	O
dosing	O
of	O
prazosin	I-Entity
(	O
0.1	O
mg	O
kg-1	O
i.p	O
.	O
)	O
.	O

Conversely	O
,	O
administration	O
of	O
rauwolscine	I-Entity
(	O
3	O
mg	O
kg-1	O
i.v	O
.	O
)	O
in	O
chronic	O
prazosin	I-Entity
treated	O
SHR	O
decreased	O
the	O
basal	O
MAP	O
by	O
12	O
-	O
31%	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
subsequent	O
tilts	O
induced	O
further	O
drops	O
of	O
MAP	O
by	O
19	O
-	O
23%	O
in	O
these	O
rats	O
.	O

The	O
pressor	O
responses	O
and	O
bradycardia	I-Entity
to	O
the	O
alpha	O
1-agonist	O
cirazoline	I-Entity
(	O
0.6	O
and	O
2	O
micrograms	O
kg-1	O
i.v	O
.	O
)	O
,	O
the	O
alpha	O
2-agonist	O
Abbott-53693	I-Entity
(	O
1	O
and	O
3	O
micrograms	O
kg-1	O
i.v	O
.	O
)	O
,	O
and	O
noradrenaline	I-Entity
(	O
0.1	O
and	O
1.0	O
micrograms	O
kg-1	O
i.v	O
.	O
)	O
were	O
determined	O
in	O
conscious	O
SHR	O
with	O
and	O
without	O
chronic	O
prazosin	I-Entity
pretreatment	O
.	O

Both	O
the	O
pressor	O
and	O
bradycardia	I-Entity
effects	O
of	O
cirazoline	I-Entity
were	O
abolished	O
in	O
chronic	O
prazosin	I-Entity
treated	O
SHR	O
(	O
n	O
=	O
4	O
)	O
as	O
compared	O
to	O
the	O
untreated	O
SHR	O
(	O
n	O
=	O
4	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
pressor	O
effects	O
of	O
Abbott-53693	I-Entity
were	O
similar	O
in	O
both	O
groups	O
of	O
SHR	O
,	O
but	O
the	O
accompanying	O
bradycardia	I-Entity
was	O
greater	O
in	O
SHR	O
with	O
chronic	O
prazosin	I-Entity
treatment	O
than	O
without	O
such	O
treatment	O
.	O

Furthermore	O
,	O
the	O
bradycardia	I-Entity
that	O
accompanied	O
the	O
noradrenaline	I-Entity
-	O
induced	O
pressor	O
effect	O
in	O
SHR	O
was	O
similar	O
with	O
and	O
without	O
chronic	O
prazosin	I-Entity
treatment	O
despite	O
a	O
47	O
-	O
71%	O
reduction	O
of	O
the	O
pressor	O
effect	O
in	O
chronic	O
alpha	O
1-receptor	O
blocked	O
SHR.(ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O



Coexistence	O
of	O
cerebral	B-Entity
venous	I-Entity
sinus	I-Entity
and	I-Entity
internal	I-Entity
carotid	I-Entity
artery	I-Entity
thrombosis	I-Entity
associated	O
with	O
exogenous	O
sex	O
hormones	O
.	O

A	O
forty	O
-	O
six	O
year	O
-	O
old	O
premenopausal	O
woman	O
developed	O
headache	I-Entity
,	O
nausea	I-Entity
and	O
vomiting	I-Entity
,	O
left	O
hemiparesis	I-Entity
and	O
seizure	I-Entity
two	O
days	O
after	O
parenteral	O
use	O
of	O
progesterone	I-Entity
and	O
estradiol	I-Entity
.	O

Diabetes	B-Entity
mellitus	I-Entity
(	O
DM	I-Entity
)	O
was	O
found	O
during	O
admission	O
.	O

Computed	O
tomography	O
showed	O
a	O
hemorrhagic	B-Entity
infarct	I-Entity
in	O
the	O
right	O
frontal	O
lobe	O
and	O
increased	O
density	O
in	O
the	O
superior	O
sagittal	O
sinus	O
(	O
SSS	O
)	O
.	O

Left	O
carotid	O
angiography	O
found	O
occlusion	B-Entity
of	I-Entity
the	I-Entity
left	I-Entity
internal	I-Entity
carotid	I-Entity
artery	I-Entity
(	O
ICA	O
)	O
.	O

Right	O
carotid	O
angiograms	O
failed	O
to	O
show	O
the	O
SSS	O
and	O
inferior	O
sagittal	O
sinus	O
,	O
suggestive	O
of	O
venous	B-Entity
sinus	I-Entity
thrombosis	I-Entity
.	O

Coexistence	O
of	O
the	O
cerebral	B-Entity
artery	I-Entity
and	I-Entity
the	I-Entity
venous	I-Entity
sinus	I-Entity
occlusion	I-Entity
has	O
been	O
described	O
infrequently	O
.	O

In	O
this	O
case	O
,	O
the	O
authors	O
postulate	O
that	O
the	O
use	O
of	O
estradiol	I-Entity
and	O
progesterone	I-Entity
and	O
the	O
underlying	O
DM	I-Entity
increased	O
vascular	O
thrombogenicity	O
,	O
which	O
provided	O
a	O
common	O
denominator	O
for	O
thrombosis	B-Entity
of	I-Entity
both	I-Entity
the	I-Entity
ICA	I-Entity
and	I-Entity
the	I-Entity
venous	I-Entity
sinus	I-Entity
.	O



Chloroquine	I-Entity
related	O
complete	O
heart	B-Entity
block	I-Entity
with	O
blindness	I-Entity
:	O
case	O
report	O
.	O

A	O
27-year	O
old	O
African	O
woman	O
with	O
history	O
of	O
regular	O
chloroquine	I-Entity
ingestion	O
presented	O
with	O
progressive	O
deterioration	B-Entity
of	I-Entity
vision	I-Entity
,	O
easy	O
fatiguability	I-Entity
,	O
dyspnoea	I-Entity
,	O
dizziness	I-Entity
progressing	O
to	O
syncopal	B-Entity
attacks	I-Entity
.	O

Ophthalmological	O
assessment	O
revealed	O
features	O
of	O
chloroquine	I-Entity
retinopathy	I-Entity
,	O
cardiac	O
assessment	O
revealed	O
features	O
of	O
heart	B-Entity
failure	I-Entity
and	O
a	O
complete	O
heart	B-Entity
block	I-Entity
with	O
right	B-Entity
bundle	I-Entity
branch	I-Entity
block	I-Entity
pattern	O
.	O

The	O
heart	B-Entity
block	I-Entity
was	O
treated	O
by	O
pacemaker	O
insertion	O
and	O
the	O
heart	B-Entity
failure	I-Entity
resolved	O
spontaneously	O
following	O
chloroquine	I-Entity
discontinuation	O
.	O

She	O
however	O
remains	O
blind	I-Entity
.	O



Systemic	O
toxicity	I-Entity
and	O
resuscitation	O
in	O
bupivacaine-	I-Entity
,	O
levobupivacaine-	I-Entity
,	O
or	O
ropivacaine	I-Entity
-	O
infused	O
rats	O
.	O

We	O
compared	O
the	O
systemic	O
toxicity	I-Entity
of	O
bupivacaine	I-Entity
,	O
levobupivacaine	I-Entity
,	O
and	O
ropivacaine	I-Entity
in	O
anesthetized	O
rats	O
.	O

Bupivacaine	I-Entity
,	O
levobupivacaine	I-Entity
,	O
or	O
ropivacaine	I-Entity
was	O
infused	O
at	O
a	O
rate	O
of	O
2	O
mg	O
.	O

When	O
asystole	I-Entity
was	O
recorded	O
,	O
drug	O
infusion	O
was	O
stopped	O
and	O
a	O
resuscitation	O
sequence	O
was	O
begun	O
.	O

Epinephrine	I-Entity
0.01	O
mg	O
/	O
kg	O
was	O
administered	O
at	O
1-min	O
intervals	O
while	O
external	O
cardiac	O
compressions	O
were	O
applied	O
.	O

The	O
cumulative	O
doses	O
of	O
levobupivacaine	I-Entity
and	O
ropivacaine	I-Entity
that	O
produced	O
seizures	I-Entity
were	O
similar	O
and	O
were	O
larger	O
than	O
those	O
of	O
bupivacaine	I-Entity
.	O

The	O
cumulative	O
doses	O
of	O
levobupivacaine	I-Entity
that	O
produced	O
dysrhythmias	I-Entity
and	O
asystole	I-Entity
were	O
smaller	O
than	O
the	O
corresponding	O
doses	O
of	O
ropivacaine	I-Entity
,	O
but	O
they	O
were	O
larger	O
than	O
those	O
of	O
bupivacaine	I-Entity
.	O

However	O
,	O
a	O
smaller	O
dose	O
of	O
epinephrine	I-Entity
was	O
required	O
in	O
the	O
Ropivacaine	I-Entity
group	O
than	O
in	O
the	O
other	O
groups	O
.	O

We	O
conclude	O
that	O
the	O
systemic	O
toxicity	I-Entity
of	O
levobupivacaine	I-Entity
is	O
intermediate	O
between	O
that	O
of	O
ropivacaine	I-Entity
and	O
bupivacaine	I-Entity
when	O
administered	O
at	O
the	O
same	O
rate	O
and	O
that	O
ropivacaine	I-Entity
-	O
induced	O
cardiac	B-Entity
arrest	I-Entity
appears	O
to	O
be	O
more	O
susceptible	O
to	O
treatment	O
than	O
that	O
induced	O
by	O
bupivacaine	I-Entity
or	O
levobupivacaine	I-Entity
.	O



22-oxacalcitriol	I-Entity
suppresses	O
secondary	B-Entity
hyperparathyroidism	I-Entity
without	O
inducing	O
low	B-Entity
bone	I-Entity
turnover	I-Entity
in	O
dogs	O
with	O
renal	B-Entity
failure	I-Entity
.	O

Calcitriol	I-Entity
therapy	O
suppresses	O
serum	O
levels	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
in	O
patients	O
with	O
renal	B-Entity
failure	I-Entity
but	O
has	O
several	O
drawbacks	O
,	O
including	O
hypercalcemia	I-Entity
and/or	O
marked	O
suppression	B-Entity
of	I-Entity
bone	I-Entity
turnover	I-Entity
,	O
which	O
may	O
lead	O
to	O
adynamic	B-Entity
bone	I-Entity
disease	I-Entity
.	O

A	O
new	O
vitamin	B-Entity
D	I-Entity
analogue	O
,	O
22-oxacalcitriol	I-Entity
(	O
OCT	I-Entity
)	O
,	O
has	O
been	O
shown	O
to	O
have	O
promising	O
characteristics	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effects	O
of	O
OCT	I-Entity
on	O
serum	O
PTH	O
levels	O
and	O
bone	O
turnover	O
in	O
states	O
of	O
normal	O
or	O
impaired	B-Entity
renal	I-Entity
function	I-Entity
.	O

The	O
animals	O
received	O
supplemental	O
phosphate	I-Entity
to	O
enhance	O
PTH	O
secretion	O
.	O

Fourteen	O
weeks	O
after	O
the	O
start	O
of	O
phosphate	I-Entity
supplementation	O
,	O
half	O
of	O
the	O
Nx	O
and	O
Sham	O
dogs	O
received	O
doses	O
of	O
OCT	I-Entity
(	O
three	O
times	O
per	O
week	O
)	O
;	O
the	O
other	O
half	O
were	O
given	O
vehicle	O
for	O
60	O
weeks	O
.	O

Biochemical	O
and	O
hormonal	O
indices	O
of	O
calcium	I-Entity
and	O
bone	O
metabolism	O
were	O
measured	O
throughout	O
the	O
study	O
,	O
and	O
bone	O
biopsies	O
were	O
done	O
at	O
baseline	O
,	O
60	O
weeks	O
after	O
OCT	I-Entity
or	O
vehicle	O
treatment	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
crossover	O
period	O
.	O

In	O
Nx	O
dogs	O
,	O
OCT	I-Entity
significantly	O
decreased	O
serum	O
PTH	O
levels	O
soon	O
after	O
the	O
induction	O
of	O
renal	B-Entity
insufficiency	I-Entity
.	O

In	O
long	O
-	O
standing	O
secondary	B-Entity
hyperparathyroidism	I-Entity
,	O
OCT	I-Entity
(	O
0.03	O
microg	O
/	O
kg	O
)	O
stabilized	O
serum	O
PTH	O
levels	O
during	O
the	O
first	O
months	O
.	O

These	O
effects	O
were	O
accompanied	O
by	O
episodes	O
of	O
hypercalcemia	I-Entity
and	O
hyperphosphatemia	I-Entity
.	O

In	O
animals	O
with	O
normal	O
renal	O
function	O
,	O
OCT	I-Entity
induced	O
a	O
transient	O
decrease	O
in	O
serum	O
PTH	O
levels	O
at	O
a	O
dose	O
of	O
0.1	O
microg	O
/	O
kg	O
,	O
which	O
was	O
not	O
sustained	O
with	O
lowering	O
of	O
the	O
doses	O
.	O

In	O
Nx	O
dogs	O
,	O
OCT	I-Entity
reversed	O
abnormal	O
bone	O
formation	O
,	O
such	O
as	O
woven	B-Entity
osteoid	I-Entity
and	O
fibrosis	I-Entity
,	O
but	O
did	O
not	O
significantly	O
alter	O
the	O
level	O
of	O
bone	O
turnover	O
.	O

In	O
addition	O
,	O
OCT	I-Entity
improved	O
mineralization	O
lag	O
time	O
,	O
(	O
that	O
is	O
,	O
the	O
rate	O
at	O
which	O
osteoid	O
mineralizes	O
)	O
in	O
both	O
Nx	O
and	O
Sham	O
dogs	O
.	O

These	O
results	O
indicate	O
that	O
even	O
though	O
OCT	I-Entity
does	O
not	O
completely	O
prevent	O
the	O
occurrence	O
of	O
hypercalcemia	I-Entity
in	O
experimental	O
dogs	O
with	O
renal	B-Entity
insufficiency	I-Entity
,	O
it	O
may	O
be	O
of	O
use	O
in	O
the	O
management	O
of	O
secondary	B-Entity
hyperparathyroidism	I-Entity
because	O
it	O
does	O
not	O
induce	O
low	B-Entity
bone	I-Entity
turnover	I-Entity
and	O
,	O
therefore	O
,	O
does	O
not	O
increase	O
the	O
risk	O
of	O
adynamic	B-Entity
bone	I-Entity
disease	I-Entity
.	O



Chemotherapy	O
of	O
advanced	O
inoperable	O
non	B-Entity
-	I-Entity
small	I-Entity
cell	I-Entity
lung	I-Entity
cancer	I-Entity
with	O
paclitaxel	I-Entity
:	O
a	O
phase	O
II	O
trial	O
.	O

Paclitaxel	I-Entity
(	O
Taxol	I-Entity
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
has	O
demonstrated	O
significant	O
antineoplastic	O
activity	O
against	O
different	O
tumor	I-Entity
types	O
,	O
notably	O
ovarian	B-Entity
and	I-Entity
breast	I-Entity
carcinoma	I-Entity
.	O

Two	O
phase	O
II	O
trials	O
of	O
24-hour	O
paclitaxel	I-Entity
infusions	O
in	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
stage	O

IIIB	O
or	O
IV	O
non	B-Entity
-	I-Entity
small	I-Entity
cell	I-Entity
lung	I-Entity
cancer	I-Entity
(	O
NSCLC	I-Entity
)	O
reported	O
response	O
rates	O
of	O
21%	O
and	O
24%	O
.	O

Leukopenia	I-Entity
was	O
dose	O
limiting	O
:	O
as	O
many	O
as	O
62.5%	O
of	O
patients	O
experienced	O
grade	O
4	O
leukopenia	I-Entity
.	O

We	O
investigated	O
the	O
efficacy	O
and	O
toxicity	I-Entity
of	O
a	O
3-hour	O
paclitaxel	I-Entity
infusion	O
in	O
a	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
inoperable	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	I-Entity
.	O

Most	O
patients	O
(	O
72.4%	O
)	O
had	O
stage	O
IV	O
NSCLC	I-Entity
.	O

Paclitaxel	I-Entity

Hematologic	O
toxicities	I-Entity
were	O
mild	O
:	O
only	O
one	O
patient	O
(	O
2%	O
)	O
developed	O
grade	O
3	O
or	O
4	O
neutropenia	I-Entity
,	O
while	O
29%	O
had	O
grade	O
1	O
or	O
2	O
.	O

Grade	O
1	O
or	O
2	O
polyneuropathy	I-Entity
affected	O
56%	O
of	O
patients	O
while	O
only	O
one	O
(	O
2%	O
)	O
experienced	O
severe	O
polyneuropathy	I-Entity
.	O

Similarly	O
,	O
grade	O
1	O
or	O
2	O
myalgia	I-Entity
/	O
arthralgia	I-Entity
was	O
observed	O
in	O
63.2%	O
of	O
patients	O
,	O
but	O
only	O
14.3%	O
experienced	O
grade	O
3	O
or	O
4	O
.	O

Nausea	I-Entity
and	O
vomiting	I-Entity
were	O
infrequent	O
,	O
with	O
14%	O
of	O
patients	O
experiencing	O
grade	O
1	O
or	O
2	O
and	O
only	O
2%	O
experiencing	O
grade	O
3	O
or	O
4	O
.	O

Paclitaxel	I-Entity
is	O
thus	O
an	O
active	O
single	O
agent	O
in	O
this	O
patient	O
population	O
,	O
with	O
a	O
3-hour	O
infusion	O
proving	O
comparably	O
effective	O
to	O
a	O
24-hour	O
infusion	O
and	O
superior	O
in	O
terms	O
of	O
the	O
incidence	O
of	O
hematologic	O
and	O
nonhematologic	O
toxicity	I-Entity
.	O

Further	O
phase	O
II	O
studies	O
with	O
paclitaxel	I-Entity
combined	O
with	O
other	O
drugs	O
active	O
against	O
NSCLC	I-Entity
are	O
indicated	O
,	O
and	O
phase	O
III	O
studies	O
comparing	O
paclitaxel	I-Entity
with	O
standard	O
chemotherapy	O
remain	O
to	O
be	O
completed	O
.	O



Cerebral	B-Entity
hemorrhage	I-Entity
associated	O
with	O
phenylpropanolamine	I-Entity
in	O
combination	O
with	O
caffeine	I-Entity
.	O

Phenylpropanolamine	I-Entity
(	O
PPA	I-Entity
)	O
is	O
a	O
drug	O
that	O
has	O
been	O
associated	O
with	O
serious	O
side	O
effects	O
including	O
stroke	I-Entity
.	O

It	O
is	O
often	O
combined	O
with	O
caffeine	I-Entity
in	O
diet	O
preparations	O
and	O
""""	O
look	O
-	O
alike	O
""""	O
pills	O
.	O

In	O
order	O
to	O
determine	O
if	O
PPA	I-Entity
/	O
caffeine	I-Entity
can	O
lead	O
to	O
stroke	I-Entity
in	O
normotensive	O
and/or	O
hypertensive	I-Entity
rats	O
,	O
we	O
administered	O
the	O
combination	O
in	O
six	O
times	O
the	O
allowed	O
human	O
dose	O
calculated	O
on	O
a	O
per	O
weight	O
basis	O
for	O
the	O
rats	O
two	O
times	O
per	O
day	O
for	O
five	O
days	O
.	O

Subarachnoid	B-Entity
and	I-Entity
cerebral	I-Entity
hemorrhage	I-Entity
was	O
noted	O
in	O
18%	O
of	O
the	O
hypertensive	I-Entity
rats	O
.	O

A	O
single	O
PPA	I-Entity
/	O
caffeine	I-Entity
administration	O
(	O
same	O
dose	O
)	O
lead	O
to	O
acute	O
hypertension	I-Entity
in	O
both	O
the	O
normotensive	O
and	O
hypertensive	I-Entity
animals	O
.	O

These	O
results	O
suggest	O
that	O
PPA	I-Entity
/	O
caffeine	I-Entity
can	O
lead	O
to	O
cerebral	B-Entity
hemorrhage	I-Entity
in	O
previously	O
hypertensive	I-Entity
animals	O
when	O
administered	O
in	O
greater	O
than	O
the	O
allowed	O
dosage	O
.	O



Long	O
-	O
term	O
efficacy	O
and	O
toxicity	I-Entity
of	O
high	O
-	O
dose	O
amiodarone	I-Entity
therapy	O
for	O
ventricular	B-Entity
tachycardia	I-Entity
or	O
ventricular	B-Entity
fibrillation	I-Entity
.	O

Amiodarone	I-Entity
was	O
administered	O
to	O
154	O
patients	O
who	O
had	O
sustained	O
,	O
symptomatic	O
ventricular	B-Entity
tachycardia	I-Entity
(	O
VT	I-Entity
)	O
(	O
n	O
=	O
118	O
)	O
or	O
a	O
cardiac	B-Entity
arrest	I-Entity
(	O
n	O
=	O
36	O
)	O
and	O
who	O
were	O
refractory	O
to	O
conventional	O
antiarrhythmic	O
drugs	O
.	O

Sixty	O
-	O
nine	O
percent	O
of	O
patients	O
continued	O
treatment	O
with	O
amiodarone	I-Entity
and	O
had	O
no	O
recurrence	O
of	O
symptomatic	O
VT	I-Entity
or	O
ventricular	B-Entity
fibrillation	I-Entity
(	O
VF	I-Entity
)	O
over	O
a	O
follow	O
-	O
up	O
of	O
6	O
to	O
52	O
months	O
(	O
mean	O
+	O
/-	O

Six	O
percent	O
of	O
the	O
patients	O
had	O
a	O
nonfatal	O
recurrence	O
of	O
VT	I-Entity
and	O
were	O
successfully	O
managed	O
by	O
continuing	O
amiodarone	I-Entity
at	O
a	O
higher	O
dose	O
or	O
by	O
the	O
addition	O
of	O
a	O
conventional	O
antiarrhythmic	O
drug	O
.	O

Adverse	O
effects	O
forced	O
a	O
reduction	O
in	O
the	O
dose	O
of	O
amiodarone	I-Entity
in	O
41%	O
and	O
discontinuation	O
of	O
amiodarone	I-Entity
in	O
10%	O
of	O
patients	O
.	O

The	O
most	O
common	O
symptomatic	O
adverse	O
reactions	O
were	O
tremor	I-Entity
or	O
ataxia	I-Entity
(	O
35%	O
)	O
,	O
nausea	I-Entity
and	O
anorexia	I-Entity
(	O
8%	O
)	O
,	O
visual	B-Entity
halos	I-Entity
or	I-Entity
blurring	I-Entity
(	O
6%	O
)	O
,	O
thyroid	B-Entity
function	I-Entity
abnormalities	I-Entity
(	O
6%	O
)	O
and	O
pulmonary	B-Entity
interstitial	I-Entity
infiltrates	I-Entity
(	O
5%	O
)	O
.	O

Although	O
large	O
-	O
dose	O
amiodarone	I-Entity
is	O
highly	O
effective	O
in	O
the	O
long	O
-	O
term	O
treatment	O
of	O
VT	I-Entity
or	O
VF	I-Entity
refractory	O
to	O
conventional	O
antiarrhythmic	O
drugs	O
,	O
it	O
causes	O
significant	O
toxicity	I-Entity
in	O
approximately	O
50%	O
of	O
patients	O
.	O

However	O
,	O
when	O
the	O
dose	O
is	O
adjusted	O
based	O
on	O
clinical	O
response	O
or	O
the	O
development	O
of	O
adverse	O
effects	O
,	O
75%	O
of	O
patients	O
with	O
VT	I-Entity
or	O
VF	I-Entity
can	O
be	O
successfully	O
managed	O
with	O
amiodarone	I-Entity
.	O



Effect	O
of	O
calcium	B-Entity
chloride	I-Entity
and	O
4-aminopyridine	I-Entity
therapy	O
on	O
desipramine	I-Entity
toxicity	I-Entity
in	O
rats	O
.	O

Hypotension	I-Entity
is	O
a	O
major	O
contributor	O
to	O
mortality	O
in	O
tricyclic	O
antidepressant	O
overdose	I-Entity
.	O

Recent	O
data	O
suggest	O
that	O
tricyclic	O
antidepressants	O
inhibit	O
calcium	I-Entity
influx	O
in	O
some	O
tissues	O
.	O

This	O
study	O
addressed	O
the	O
potential	O
role	O
of	O
calcium	I-Entity
channel	O
blockade	O
in	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	I-Entity
.	O

Two	O
interventions	O
were	O
studied	O
that	O
have	O
been	O
shown	O
previously	O
to	O
improve	O
blood	O
pressure	O
with	O
calcium	I-Entity
channel	O
blocker	O
overdose	I-Entity
.	O

CaCl2	I-Entity
and	O
4-aminopyridine	I-Entity
.	O

Anesthetized	O
rats	O
received	O
the	O
tricyclic	O
antidepressant	O
desipramine	I-Entity
IP	O
to	O
produce	O
hypotension	I-Entity
,	O
QRS	O
prolongation	O
,	O
and	O
bradycardia	I-Entity
.	O

min	O
later	O
,	O
animals	O
received	O
CaCl2	I-Entity
,	O
NaHCO3	I-Entity
,	O
or	O
saline	O
.	O

In	O
a	O
second	O
experiment	O
,	O
rats	O
received	O
tricyclic	O
antidepressant	O
desipramine	I-Entity
IP	O
followed	O
in	O
15	O
min	O
by	O
4-aminopyridine	I-Entity
or	O
saline	O
.	O

NaHCO3	I-Entity
briefly	O
(	O
5	O
min	O
)	O
reversed	O
hypotension	I-Entity
and	O
QRS	O
prolongation	O
.	O

CaCl2	I-Entity
and	O
4-aminopyridine	I-Entity
failed	O
to	O
improve	O
blood	O
pressure	O
.	O

The	O
incidence	O
of	O
ventricular	B-Entity
arrhythmias	I-Entity
(	O
p	O
=	O
0.004	O
)	O
and	O
seizures	I-Entity
(	O
p	O
=	O
0.03	O
)	O
in	O
the	O
CaCl2	I-Entity
group	O
was	O
higher	O
than	O
the	O
other	O
groups	O
.	O

CONCLUSION	O
:	O
The	O
administration	O
of	O
CaCl2	I-Entity
or	O
4-aminopyridine	I-Entity
did	O
not	O
reverse	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	I-Entity
in	O
rats	O
.	O

CaCl2	I-Entity
therapy	O
may	O
possibly	O
worsen	O
both	O
cardiovascular	B-Entity
and	I-Entity
central	I-Entity
nervous	I-Entity
system	I-Entity
toxicity	I-Entity
.	O

These	O
findings	O
do	O
not	O
support	O
a	O
role	O
for	O
calcium	I-Entity
channel	O
inhibition	O
in	O
the	O
pathogenesis	O
of	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	I-Entity
.	O



Phase	O
I	O
trial	O
of	O
13-cis	B-Entity
-	I-Entity
retinoic	I-Entity
acid	I-Entity
in	O
children	O
with	O
neuroblastoma	I-Entity
following	O
bone	O
marrow	O
transplantation	O
.	O

PURPOSE	O
:	O
Treatment	O
of	O
neuroblastoma	I-Entity
cell	O
lines	O
with	O
13-cis	B-Entity
-	I-Entity
retinoic	I-Entity
acid	I-Entity
(	O
cis	B-Entity
-	I-Entity
RA	I-Entity
)	O
can	O
cause	O
sustained	O
inhibition	O
of	O
proliferation	O
.	O

Since	O
cis	B-Entity
-	I-Entity
RA	I-Entity
has	O
demonstrated	O
clinical	O
responses	O
in	O
neuroblastoma	I-Entity
patients	O
,	O
it	O
may	O
be	O
effective	O
in	O
preventing	O
relapse	O
after	O
cytotoxic	O
therapy	O
.	O

This	O
phase	O
I	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
maximal	O
-	O
tolerated	O
dosage	O
(	O
MTD	O
)	O
,	O
toxicities	I-Entity
,	O
and	O
pharmacokinetics	O
of	O
cis	B-Entity
-	I-Entity
RA	I-Entity
administered	O
on	O
an	O
intermittent	O
schedule	O
in	O
children	O
with	O
neuroblastoma	I-Entity
following	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Fifty	O
-	O
one	O
assessable	O
patients	O
,	O
2	O
to	O
12	O
years	O
of	O
age	O
,	O
were	O
treated	O
with	O
oral	O
cis	B-Entity
-	I-Entity
RA	I-Entity
administered	O
in	O
two	O
equally	O
divided	O
doses	O
daily	O
for	O
2	O
weeks	O
,	O
followed	O
by	O
a	O
2-week	O
rest	O
period	O
,	O
for	O
up	O
to	O
12	O
courses	O
.	O

The	O
dose	O
was	O
escalated	O
from	O
100	O
to	O
200	O
mg	O
/	O
m2/d	O
until	O
dose	O
-	O
limiting	O
toxicity	I-Entity
(	O
DLT	O
)	O
was	O
observed	O
.	O

The	O
MTD	O
of	O
cis	B-Entity
-	I-Entity
RA	I-Entity
was	O
160	O
mg	O
/	O
m2/d	O
.	O

Dose	O
-	O
limiting	O
toxicities	I-Entity
in	O
six	O
of	O
nine	O
patients	O
at	O
200	O
mg	O
/	O
m2/d	O
included	O
hypercalcemia	I-Entity
(	O
n	O
=	O
3	O
)	O
,	O
rash	I-Entity
(	O
n	O
=	O
2	O
)	O
,	O
and	O
anemia	I-Entity
/	O
thrombocytopenia	I-Entity
/	O
emesis	I-Entity
/	O
rash	I-Entity
(	O
n	O
=	O
1	O
)	O
.	O

All	O
toxicities	I-Entity
resolved	O
after	O
cis	B-Entity
-	I-Entity
RA	I-Entity
was	O
discontinued	O
.	O

Three	O
complete	O
responses	O
were	O
observed	O
in	O
marrow	O
metastases	I-Entity
.	O

The	O
MTD	O
of	O
cis	B-Entity
-	I-Entity
RA	I-Entity
given	O
on	O
this	O
intermittent	O
schedule	O
was	O
160	O
mg	O
/	O
m2/d	O
.	O

Serum	O
levels	O
known	O
to	O
be	O
effective	O
against	O
neuroblastoma	I-Entity
in	O
vitro	O
were	O
achieved	O
at	O
this	O
dose	O
.	O

The	O
DLT	O
included	O
hypercalcemia	I-Entity
,	O
and	O
may	O
be	O
predicted	O
by	O
serum	O
cis	B-Entity
-	I-Entity
RA	I-Entity
levels	O
.	O

Monitoring	O
of	O
serum	O
calcium	I-Entity
and	O
cis	B-Entity
-	I-Entity
RA	I-Entity
levels	O
is	O
indicated	O
in	O
future	O
trials	O
.	O



Effect	O
of	O
calcium	B-Entity
chloride	I-Entity
on	O
gross	O
behavioural	O
changes	O
produced	O
by	O
carbachol	I-Entity
and	O
eserine	I-Entity
in	O
cats	O
.	O

The	O
effect	O
of	O
calcium	B-Entity
chloride	I-Entity
injected	O
into	O
the	O
cerebral	O
ventricles	O
of	O
group	O
-	O
housed	O
unanaesthetized	O
cats	O
upon	O
vocalization	O
(	O
rage	O
,	O
hissing	O
and	O
snarling	O
)	O
,	O
fighting	O
(	O
attack	O
with	O
paws	O
and	O
claws	O
,	O
defense	O
with	O
paws	O
and	O
claws	O
and	O
biting	O
)	O
,	O
mydriasis	I-Entity
,	O
tremor	I-Entity
and	O
clonic	B-Entity
-	I-Entity
tonic	I-Entity
convulsions	I-Entity
produced	O
by	O
carbachol	I-Entity
and	O
eserine	I-Entity
injected	O
similarly	O
was	O
investigated	O
.	O

Calcium	B-Entity
chloride	I-Entity
depressed	O
or	O
almost	O
completely	O
abolished	O
the	O
vocalization	O
and	O
fighting	O
due	O
to	O
carbachol	I-Entity
and	O
eserine	I-Entity
.	O

On	O
the	O
other	O
hand	O
,	O
mydriasis	I-Entity
,	O
tremor	I-Entity
and	O
clonic	B-Entity
-	I-Entity
tonic	I-Entity
convulsions	I-Entity
evoked	O
by	O
carbachol	I-Entity
and	O
eserine	I-Entity
were	O
not	O
significantly	O
changed	O
by	O
calcium	B-Entity
chloride	I-Entity
.	O

It	O
is	O
apparent	O
that	O
calcium	B-Entity
chloride	I-Entity
can	O
""""	O
dissociate	O
""""	O
vocalization	O
and	O
fighting	O
from	O
autonomic	O
and	O
motor	O
phenomena	O
such	O
as	O
mydriasis	I-Entity
,	O
tremor	I-Entity
and	O
clonic	B-Entity
-	I-Entity
tonic	I-Entity
convulsions	I-Entity
caused	O
by	O
carbachol	I-Entity
and	O
eserine	I-Entity
.	O

Calcium	B-Entity
chloride	I-Entity
inhibited	O
the	O
vocalization	O
and	O
fighting	O
produced	O
by	O
carbachol	I-Entity
and	O
eserine	I-Entity
most	O
probably	O
by	O
a	O
nonspecific	O
stabilizing	O
action	O
on	O
central	O
muscarinic	O
cholinoceptive	O
sites	O
.	O

These	O
results	O
further	O
support	O
the	O
view	O
that	O
calcium	I-Entity
ions	O
in	O
excess	O
have	O
an	O
atropine	I-Entity
-	O
like	O
action	O
also	O
in	O
the	O
central	O
nervous	O
system	O
.	O



Multiple	O
side	O
effects	O
of	O
penicillamine	I-Entity
therapy	O
in	O
one	O
patient	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
.	O

Skin	B-Entity
rashes	I-Entity
,	O
proteinuria	I-Entity
,	O
systemic	B-Entity
lupus	I-Entity
erythematosus	I-Entity
,	O
polymyositis	I-Entity
and	O
myasthenia	B-Entity
gravis	I-Entity
have	O
all	O
been	O
recorded	O
as	O
complications	O
of	O
penicillamine	I-Entity
therapy	O
in	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
.	O

The	O
skin	B-Entity
lesion	I-Entity
resembled	O
elastosis	B-Entity
perforans	I-Entity
serpiginosa	I-Entity
,	O
which	O
has	O
been	O
reported	O
as	O
a	O
rare	O
side	O
effect	O
in	O
patients	O
with	O
Wilson	B-Entity
's	I-Entity
disease	I-Entity
but	O
not	O
in	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
treated	O
with	O
penicillamine	I-Entity
.	O



Electrocardiographic	O
changes	O
and	O
cardiac	B-Entity
arrhythmias	I-Entity
in	O
patients	O
receiving	O
psychotropic	O
drugs	O
.	O

Eight	O
patients	O
had	O
cardiac	O
manifestations	O
that	O
were	O
life	O
-	O
threatening	O
in	O
five	O
while	O
taking	O
psychotropic	O
drugs	O
,	O
either	O
phenothiazines	I-Entity
or	O
tricyclic	O
antidepressants	O
.	O

Although	O
most	O
patients	O
were	O
receiving	O
several	O
drugs	O
,	O
Mellaril	I-Entity
(	O
thioridazine	I-Entity
)	O
appeared	O
to	O
be	O
responsible	O
for	O
five	O
cases	O
of	O
ventricular	B-Entity
tachycardia	I-Entity
,	O
one	O
of	O
which	O
was	O
fatal	O
in	O
a	O
35	O
year	O
old	O
woman	O
.	O

Supraventricular	B-Entity
tachycardia	I-Entity
developed	O
in	O
one	O
patient	O
receiving	O
Thorazine	I-Entity
(	O
chlorpromazine	I-Entity
)	O
.	O

Aventyl	I-Entity
(	O
nortriptyline	I-Entity
)	O
and	O
Elavil	I-Entity
(	O
amitriptyline	I-Entity
)	O
each	O
produced	O
left	B-Entity
bundle	I-Entity
branch	I-Entity
block	I-Entity
in	O
a	O
73	O
year	O
old	O
woman	O
.	O

The	O
ventricular	B-Entity
arrhythmias	I-Entity
responded	O
to	O
intravenous	O
administration	O
of	O
lidocaine	I-Entity
and	O
to	O
direct	O
current	O
electric	O
shock	O
;	O
ventricular	O
pacing	O
was	O
required	O
in	O
some	O
instances	O
and	O
intravenous	O
administration	O
of	O
propranolol	I-Entity
combined	O
with	O
ventricular	O
pacing	O
in	O
one	O
.	O

The	O
tachyarrhythmias	I-Entity
generally	O
subsided	O
within	O
48	O
hours	O
after	O
administration	O
of	O
the	O
drugs	O
was	O
stopped	O
.	O

Five	O
of	O
the	O
eight	O
patients	O
were	O
50	O
years	O
of	O
age	O
or	O
younger	O
;	O
only	O
one	O
clearly	O
had	O
antecedent	O
heart	B-Entity
disease	I-Entity
.	O

Major	O
cardiac	B-Entity
arrhythmias	I-Entity
are	O
a	O
potential	O
hazard	O
in	O
patients	O
without	O
heart	B-Entity
disease	I-Entity
who	O
are	O
receiving	O
customary	O
therapeutic	O
doses	O
of	O
psychotropic	O
drugs	O
.	O

A	O
prospective	O
clinical	O
trial	O
is	O
suggested	O
to	O
quantify	O
the	O
risk	O
of	O
cardiac	B-Entity
complications	I-Entity
to	O
patients	O
receiving	O
phenothiazines	I-Entity
or	O
tricyclic	O
antidepressant	O
drugs	O
.	O



Serotonergic	O
drugs	O
,	O
benzodiazepines	I-Entity
and	O
baclofen	I-Entity
block	O
muscimol	I-Entity
-	O
induced	O
myoclonic	B-Entity
jerks	I-Entity
in	O
a	O
strain	O
of	O
mice	O
.	O

In	O
male	O
Swiss	O
mice	O
,	O
muscimol	I-Entity
produced	O
myoclonic	B-Entity
jerks	I-Entity
.	O

Increasing	O
the	O
brain	O
serotonin	I-Entity
levels	O
by	O
the	O
administration	O
of	O
5-hydroxytryptophan	I-Entity
(	O
80	O
-	O
160	O
mg	O
/	O
kg	O
)	O
in	O
combination	O
with	O
a	O
peripheral	O
decarboxylase	O
inhibitor	O
resulted	O
in	O
an	O
inhibition	O
of	O
the	O
muscimol	I-Entity
effect	O
.	O

l	B-Entity
-	I-Entity
dopa	I-Entity
(	O
80	O
-	O
160	O
mg	O
/	O
kg	O
)	O
was	O
without	O
effect	O
.	O

In	O
doses	O
of	O
3	O
-	O
10	O
mg	O
/	O
kg	O
,	O
the	O
serotonin	I-Entity
receptor	O
agonist	O
MK-212	I-Entity
caused	O
a	O
dose	O
-	O
dependent	O
blockade	O
of	O
the	O
response	O
of	O
muscimol	I-Entity
.	O

Of	O
the	O
benzodiazepines	I-Entity
,	O
clonazepam	I-Entity
(	O
0.1	O
-	O
0.3	O
mg	O
/	O
kg	O
)	O
was	O
found	O
to	O
be	O
several	O
fold	O
more	O
potent	O
than	O
diazepam	I-Entity
(	O
0.3	O
-	O
3	O
mg	O
/	O
kg	O
)	O
in	O
blocking	O
the	O
myoclonic	B-Entity
jerks	I-Entity
.	O

While	O
(	O
-)-baclofen	I-Entity
(	O
1	O
-	O
3	O
mg	O
/	O
kg	O
)	O
proved	O
to	O
be	O
an	O
effective	O
antagonist	O
of	O
muscimol	I-Entity
,	O
its	O
(	O
+	O
)	O

Considering	O
the	O
fact	O
that	O
5-HTP	I-Entity
and	O
the	O
benzodiazepines	I-Entity
have	O
been	O
found	O
to	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
clinical	O
myoclonus	I-Entity
,	O
the	O
muscimol	I-Entity
-	O
induced	O
myoclonus	I-Entity
seems	O
to	O
be	O
a	O
satisfactory	O
animal	O
model	O
that	O
may	O
prove	O
useful	O
for	O
the	O
development	O
of	O
new	O
drug	O
treatments	O
for	O
this	O
condition	O
.	O

Our	O
present	O
study	O
indicated	O
the	O
possible	O
value	O
of	O
MK-212	I-Entity
and	O
(	O
-)-baclofen	I-Entity
in	O
the	O
management	O
of	O
clinical	O
myoclonus	I-Entity
.	O



Hyperglycemic	B-Entity
acidotic	I-Entity
coma	I-Entity
and	O
death	O
in	O
Kearns	B-Entity
-	I-Entity
Sayre	I-Entity
syndrome	I-Entity
.	O

This	O
paper	O
presents	O
the	O
clinical	O
and	O
metabolic	O
findings	O
in	O
two	O
young	O
boys	O
with	O
long	O
-	O
standing	O
Kearns	B-Entity
-	I-Entity
Sayre	I-Entity
syndrome	I-Entity
.	O

Following	O
short	O
exposure	O
to	O
oral	O
prednisone	I-Entity
,	O
both	O
boys	O
developed	O
lethargy	I-Entity
,	O
increasing	O
somnolence	I-Entity
,	O
polydipsia	I-Entity
,	O
polyphagia	I-Entity
,	O
and	O
polyuria	I-Entity
.	O

Both	O
presented	O
in	O
the	O
emergency	O
room	O
with	O
profound	O
coma	I-Entity
,	O
hypotension	I-Entity
,	O
severe	O
hyperglycemia	I-Entity
,	O
and	O
acidosis	I-Entity
.	O

Nonketotic	O
lactic	B-Entity
acidosis	I-Entity
was	O
present	O
in	O
one	O
and	O
ketosis	I-Entity
without	O
a	O
known	O
serum	O
lactate	I-Entity
level	O
was	O
present	O
in	O
the	O
other	O
.	O

Respiratory	B-Entity
failure	I-Entity
rapidly	O
ensued	O
and	O
both	O
patients	O
expired	O
in	O
spite	O
of	O
efforts	O
at	O
resuscitation	O
.	O

We	O
believe	O
these	O
two	O
cases	O
represent	O
a	O
newly	O
described	O
and	O
catastrophic	O
metabolic	B-Entity
-	I-Entity
endocrine	I-Entity
failure	I-Entity
in	O
the	O
Kearns	B-Entity
-	I-Entity
Sayre	I-Entity
syndrome	I-Entity
.	O



Effects	O
of	O
active	O
constituents	O
of	O
Crocus	O
sativus	O
L.	O
,	O
crocin	I-Entity
on	O
streptozocin	I-Entity
-	O
induced	O
model	O
of	O
sporadic	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
in	O
male	O
rats	O
.	O

BACKGROUND	O
:	O
The	O
involvement	O
of	O
water	O
-	O
soluble	O
carotenoids	I-Entity
,	O
crocins	I-Entity
,	O
as	O
the	O
main	O
and	O
active	O
components	O
of	O
Crocus	O
sativus	O
L.	O
extract	O
in	O
learning	O
and	O
memory	O
processes	O
has	O
been	O
proposed	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
crocins	I-Entity
on	O
sporadic	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
induced	O
by	O
intracerebroventricular	O
(	O
icv	O
)	O
streptozocin	I-Entity
(	O
STZ	I-Entity
)	O
in	O
male	O
rats	O
was	O
investigated	O
.	O

Male	O
adult	O
Wistar	O
rats	O
(	O
n	O
=	O
90	O
and	O
260	O
-	O
290	O
g	O
)	O
were	O
divided	O
into	O
1	O
,	O
control	O
;	O
2	O
and	O
3	O
,	O
crocins	I-Entity
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
)	O
;	O
4	O
,	O
STZ	I-Entity
;	O
5	O
and	O
6	O
,	O
STZ	I-Entity
+	O
crocins	I-Entity
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
)	O
groups	O
.	O

In	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
groups	O
,	O
rats	O
were	O
injected	O
with	O
STZ	I-Entity
-	O
icv	O
bilaterally	O
(	O
3	O
mg	O
/	O
kg	O
)	O
in	O
first	O
day	O
and	O
3	O
days	O
later	O
,	O
a	O
similar	O
STZ	I-Entity
-	O
icv	O
application	O
was	O
repeated	O
.	O

In	O
STZ	I-Entity
+	O
crocin	I-Entity
animal	O
groups	O
,	O
crocin	I-Entity
was	O
applied	O
in	O
doses	O
of	O
15	O
and	O
30	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O

Prescription	O
of	O
crocin	I-Entity
in	O
each	O
dose	O
was	O
repeated	O
once	O
for	O
two	O
days	O
.	O

It	O
was	O
found	O
out	O
that	O
crocin	I-Entity
(	O
30	O
mg	O

/	O
kg)-treated	O
STZ	I-Entity
-	O
injected	O
rats	O
show	O
higher	O
correct	O
choices	O
and	O
lower	O
errors	O
in	O
Y	O
-	O
maze	O
than	O
vehicle	O
-	O
treated	O
STZ	I-Entity
-	O
injected	O
rats	O
.	O

In	O
addition	O
,	O
crocin	I-Entity
in	O
the	O
mentioned	O
dose	O
could	O
significantly	O
attenuated	O
learning	B-Entity
and	I-Entity
memory	I-Entity
impairment	I-Entity
in	O
treated	O
STZ	I-Entity
-	O
injected	O
group	O
in	O
passive	O
avoidance	O
test	O
.	O

Therefore	O
,	O
these	O
results	O
demonstrate	O
the	O
effectiveness	O
of	O
crocin	I-Entity
(	O
30	O
mg	O
/	O
kg	O
)	O
in	O
antagonizing	O
the	O
cognitive	B-Entity
deficits	I-Entity
caused	O
by	O
STZ	I-Entity
-	O
icv	O
in	O
rats	O
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
neurodegenerative	B-Entity
diseases	I-Entity
such	O
as	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
.	O



Rosaceiform	O
dermatitis	I-Entity
associated	O
with	O
topical	O
tacrolimus	I-Entity
treatment	O
.	O

We	O
describe	O
herein	O
3	O
patients	O
who	O
developed	O
rosacea	I-Entity
-	O
like	O
dermatitis	I-Entity
eruptions	I-Entity
while	O
using	O
0.03%	O
or	O
0.1%	O
tacrolimus	I-Entity
ointment	O
for	O
facial	B-Entity
dermatitis	I-Entity
.	O

Skin	O
biopsy	O
specimens	O
showed	O
telangiectasia	I-Entity
and	O
noncaseating	O
epithelioid	O
granulomatous	O
tissue	O
formation	O
in	O
the	O
papillary	O
to	O
mid	O
dermis	O
.	O

Continuous	O
topical	O
use	O
of	O
immunomodulators	O
such	O
as	O
tacrolimus	I-Entity
or	O
pimecrolimus	I-Entity
should	O
be	O
regarded	O
as	O
a	O
potential	O
cause	O
of	O
rosaceiform	O
dermatitis	I-Entity
,	O
although	O
many	O
cases	O
have	O
not	O
been	O
reported	O
.	O



poly	B-Entity
-	I-Entity
L	I-Entity
-	I-Entity
lactid	I-Entity
acid	I-Entity
nanoparticles	O
was	O
used	O
as	O
a	O
model	O
of	O
colloidal	O
drug	O
delivery	O
system	O
,	O
able	O
to	O
trespass	O
the	O
BBB	O
.	O

Tacrine	I-Entity
,	O
administered	O
in	O
LiCl	I-Entity
pre	O
-	O
treated	O
rats	O
,	O
induces	O
electrocorticographic	O
seizures	I-Entity
and	O
delayed	O
hippocampal	B-Entity
damage	I-Entity
.	O

The	O
toxic	O
effects	O
of	O
tacrine	I-Entity
-	O
loaded	O
poly	B-Entity
-	I-Entity
L	I-Entity
-	I-Entity
lactid	I-Entity
acid	I-Entity
nanoparticles	O
(	O
5mg	O
/	O
kg	O
)	O
,	O
a	O
saline	O
solution	O
of	O
tacrine	I-Entity
(	O
5mg	O
/	O
kg	O
)	O
and	O
an	O
empty	O
colloidal	O
nanoparticle	O
suspension	O
were	O
compared	O
following	O
i.p	O
.	O

administration	O
in	O
LiCl	I-Entity
-	O
pre	O
-	O
treated	O
Wistar	O
rats	O
.	O

All	O
the	O
animals	O
treated	O
with	O
tacrine	I-Entity
-	O
loaded	O
nanoparticles	O
showed	O
an	O
earlier	O
outcome	O
of	O
CNS	O
adverse	O
symptoms	O
,	O
i.e.	O
epileptic	I-Entity
onset	O
,	O
with	O
respect	O
to	O
those	O
animals	O
treated	O
with	O
the	O
free	O
compound	O
(	O
10	O
min	O
vs.	O
22	O
min	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
tacrine	I-Entity
-	O
loaded	O
nanoparticles	O
administration	O
induced	O
damage	B-Entity
of	I-Entity
neuronal	I-Entity
cells	I-Entity
in	O
CA1	O
field	O
of	O
the	O
hippocampus	O
in	O
all	O
treated	O
animals	O
,	O
while	O
the	O
saline	O
solution	O
of	O
tacrine	I-Entity
only	O
in	O
60%	O
of	O
animals	O
.	O

In	O
conclusion	O
,	O
the	O
evaluation	O
of	O
time	O
-	O
to	O
-	O
onset	O
of	O
symptoms	O
and	O
the	O
severity	O
of	O
neurodegenerative	O
processes	O
induced	O
by	O
the	O
tacrine	I-Entity
-	O
lithium	I-Entity
model	O
of	O
epilepsy	I-Entity
in	O
the	O
rat	O
,	O
could	O
be	O
used	O
to	O
evaluate	O
preliminarily	O
the	O
capability	O
of	O
a	O
drug	O
delivery	O
system	O
to	O
trespass	O
(	O
or	O
not	O
)	O
the	O
BBB	O
in	O
vivo	O
.	O



The	O
antiarrhythmic	O
effect	O
and	O
possible	O
ionic	O
mechanisms	O
of	O
pilocarpine	I-Entity
on	O
animal	O
models	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
pilocarpine	I-Entity
and	O
explore	O
the	O
underlying	O
ionic	O
mechanism	O
,	O
using	O
both	O
aconitine	I-Entity
-	O
induced	O
rat	O
and	O
ouabain	I-Entity
-	O
induced	O
guinea	O
pig	O
arrhythmia	I-Entity
models	O
.	O

Confocal	O
microscopy	O
was	O
used	O
to	O
measure	O
intracellular	O
free	O
-	O
calcium	I-Entity
concentrations	O
(	O
[	O
Ca(2+)](i	I-Entity
)	O
)	O
in	O
isolated	O
myocytes	O
.	O

The	O
current	O
data	O
showed	O
that	O
pilocarpine	I-Entity
significantly	O
delayed	O
onset	O
of	O
arrhythmias	I-Entity
,	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	B-Entity
tachycardia	I-Entity
and	I-Entity
fibrillation	I-Entity
,	O
reduced	O
arrhythmia	I-Entity
score	O
,	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	I-Entity
rats	O
and	O
guinea	O
pigs	O
.	O

[	O
Ca(2+)](i	I-Entity
)	O
overload	O
induced	O
by	O
aconitine	I-Entity
or	O
ouabain	I-Entity
was	O
reduced	O
in	O
isolated	O
myocytes	O
pretreated	O
with	O
pilocarpine	I-Entity
.	O

Moreover	O
,	O
M(3)-muscarinic	O
acetylcholine	I-Entity
receptor	O
(	O
mAChR	O
)	O

antagonist	O
4-DAMP	I-Entity
(	O
4-diphenylacetoxy	B-Entity
-	I-Entity
N	I-Entity
-	I-Entity
methylpiperidine	I-Entity
-	I-Entity
methiodide	I-Entity
)	O
partially	O
abolished	O
the	O
beneficial	O
effects	O
of	O
pilocarpine	I-Entity
.	O

These	O
data	O
suggest	O
that	O
pilocarpine	I-Entity
produced	O
antiarrhythmic	O
actions	O
on	O
arrhythmic	I-Entity
rat	O
and	O
guinea	O
pig	O
models	O
induced	O
by	O
aconitine	I-Entity
or	O
ouabain	I-Entity
via	O
stimulating	O
the	O
cardiac	O
M(3)-mAChR.	O
The	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
improvement	O
of	O
Ca(2	I-Entity
+	O
)	O
handling	O
.	O



Disulfiram	I-Entity
-	O
induced	O
transient	O
optic	B-Entity
and	I-Entity
peripheral	I-Entity
neuropathy	I-Entity
:	O
a	O
case	O
report	O
.	O

AIM	O
:	O
To	O
report	O
a	O
case	O
of	O
optic	B-Entity
and	I-Entity
peripheral	I-Entity
neuropathy	I-Entity
after	O
chronic	O
use	O
of	O
disulfiram	I-Entity
for	O
alcohol	B-Entity
dependence	I-Entity
management	O
.	O

A	O
57-year	O
-	O
old	O
male	O
presented	O
with	O
gradual	O
loss	B-Entity
of	I-Entity
vision	I-Entity
in	O
both	O
eyes	O
with	O
intermittent	O
headaches	I-Entity
for	O
2	O
months	O
.	O

He	O
also	O
complained	O
of	O
paraesthesia	I-Entity
with	O
numbness	I-Entity
in	O
both	O
feet	O
.	O

Visual	O
field	O
testing	O
confirmed	O
bilateral	O
central	O
-	O
caecal	O
scotomata	I-Entity
.	O

He	O
had	O
been	O
taking	O
disulfiram	I-Entity
for	O
alcohol	B-Entity
dependence	I-Entity
for	O
the	O
preceding	O
3	O
years	O
.	O

Disulfiram	I-Entity
discontinuation	O
lead	O
to	O
an	O
immediate	O
symptomatic	O
improvement	O
.	O

Physicians	O
initiating	O
long	O
-	O
term	O
disulfiram	I-Entity
therapy	O
should	O
be	O
aware	O
of	O
these	O
adverse	O
effects	O
.	O



Sustained	O
clinical	O
improvement	O
of	O
a	O
patient	O
with	O
decompensated	O
hepatitis	B-Entity
B	I-Entity
virus	O
-	O
related	O
cirrhosis	I-Entity
after	O
treatment	O
with	O
lamivudine	I-Entity
monotherapy	O
.	O

Hepatitis	B-Entity
B	I-Entity
virus	I-Entity
(	I-Entity
HBV	I-Entity
)	I-Entity
infection	I-Entity
,	O
which	O
causes	O
liver	B-Entity
cirrhosis	I-Entity
and	O
hepatocellular	B-Entity
carcinoma	I-Entity
,	O
remains	O
a	O
major	O
health	O
problem	O
in	O
Asian	O
countries	O
.	O

In	O
this	O
report	O
,	O
we	O
encountered	O
a	O
patient	O
with	O
decompensated	O
HBV	O
-	O
related	O
cirrhosis	I-Entity
who	O
exhibited	O
the	O
dramatic	O
improvements	O
after	O
antiviral	O
therapy	O
.	O

However	O
,	O
the	O
administration	O
of	O
lamivudine	I-Entity
,	O
a	O
reverse	O
transcriptase	O
inhibitor	O
,	O
for	O
23	O
months	O
dramatically	O
improved	O
her	O
liver	O
severity	O
.	O

Moreover	O
,	O
both	O
hepatitis	B-Entity
B	I-Entity
surface	I-Entity
antigen	I-Entity
and	I-Entity
e	I-Entity
antigen	I-Entity
were	O
observed	O
to	O
have	O
disappeared	O
in	O
this	O
patient	O
.	O

The	O
administration	O
of	O
lamivudine	I-Entity
to	O
patients	O
with	O
HBV	O
-	O
related	O
cirrhosis	I-Entity
,	O
like	O
our	O
present	O
case	O
,	O
should	O
be	O
considered	O
as	O
an	O
initial	O
medical	O
therapeutic	O
option	O
,	O
especially	O
in	O
countries	O
where	O
liver	O
transplantation	O
is	O
not	O
reliably	O
available	O
.	O



Dual	O
effects	O
of	O
melatonin	I-Entity
on	O
barbiturate	I-Entity
-	O
induced	O
narcosis	I-Entity
in	O
rats	O
.	O

Melatonin	I-Entity
affects	O
the	O
circadian	O
sleep	O
/	O
wake	O
cycle	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
it	O
may	O
influence	O
drug	O
-	O
induced	O
narcosis	I-Entity
.	O

Sodium	B-Entity
thiopenthal	I-Entity
was	O
administered	O
intraperitoneally	O
into	O
male	O
rats	O
pre	O
-	O
treated	O
with	O
melatonin	I-Entity
(	O
0.05	O
,	O
0.5	O
,	O
5	O
and	O
50	O
mg	O
/	O
kg	O
)	O
.	O

Melatonin	I-Entity
pre	O
-	O
treatment	O
affected	O
in	O
a	O
dual	O
manner	O
barbiturate	I-Entity
narcosis	I-Entity
,	O
however	O
,	O
no	O
dose	O
-	O
effect	O
correlation	O
was	O
found	O
.	O

In	O
particular	O
,	O
low	O
doses	O
reduced	O
the	O
latency	O
to	O
and	O
prolonged	O
the	O
duration	O
of	O
barbiturate	I-Entity
narcosis	I-Entity
.	O

In	O
contrast	O
,	O
the	O
highest	O
dose	O
of	O
melatonin	I-Entity
(	O
50	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
paradoxical	O
increase	O
in	O
the	O
latency	O
and	O
produced	O
a	O
sustained	O
reduction	O
of	O
the	O
duration	O
of	O
narcosis	I-Entity
,	O
and	O
a	O
reduction	O
in	O
mortality	O
rate	O
.	O

Melatonin	I-Entity
0.5	O
and	O
5	O
mg	O
/	O
kg	O
influenced	O
the	O
duration	O
but	O
not	O
the	O
latency	O
of	O
ketamine-	I-Entity
or	O
diazepam	I-Entity
-	O
induced	O
narcosis	I-Entity
.	O

Thus	O
,	O
the	O
dual	O
action	O
of	O
melatonin	I-Entity
on	O
pharmacological	O
narcosis	I-Entity
seems	O
to	O
be	O
specific	O
for	O
the	O
barbiturate	I-Entity
mechanism	O
of	O
action	O
.	O



Effects	O
of	O
NIK-247	I-Entity
on	O
cholinesterase	O
and	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
.	O

The	O
effects	O
of	O
NIK-247	I-Entity
on	O
cholinesterase	O
,	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
and	O
spontaneous	O
movement	O
were	O
examined	O
and	O
compared	O
with	O
those	O
of	O
the	O
well	O
-	O
known	O
cholinesterase	O
inhibitors	O
tacrine	I-Entity
and	O
E-2020	I-Entity
.	O

NIK-247	I-Entity
,	O
tacrine	I-Entity
and	O
E-2020	I-Entity
all	O
strongly	O
inhibited	O
acetylcholinesterase	O
(	O
AChE	O
)	O
in	O
human	O
red	O
blood	O
cells	O
(	O
IC50s	O
=	O
1.0	O
x	O
10(-6	O
)	O
,	O
2.9	O
x	O
10(-7	O
)	O
and	O
3.7	O
x	O
10(-8	O
)	O

In	O
addition	O
,	O
NIK-247	I-Entity
and	O
tacrine	I-Entity
,	O
but	O
not	O
E-2020	I-Entity
,	O
strongly	O
inhibited	O
butyrylcholinestrase	O
(	O
BuChE	O
)	O

Moreover	O
,	O
the	O
inhibitory	O
effect	O
of	O
NIK-247	I-Entity
on	O
AChE	O
was	O
reversible	O
.	O

significantly	O
improved	O
the	O
amnesia	I-Entity
induced	O
by	O
scopolamine	I-Entity
(	O
0.5	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O

These	O
findings	O
suggest	O
that	O
NIK-247	I-Entity
at	O
a	O
low	O
dose	O
(	O
0.1	O
-	O
1	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O

improves	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
but	O
does	O
not	O
affect	O
spontaneous	O
movement	O
.	O

The	O
findings	O
suggest	O
that	O
NIK-247	I-Entity
may	O
be	O
a	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
.	O



Nightmares	O
and	O
hallucinations	I-Entity
after	O
long	O
-	O
term	O
intake	O
of	O
tramadol	I-Entity
combined	O
with	O
antidepressants	O
.	O

Tramadol	I-Entity
is	O
a	O
weak	O
opioid	O
with	O
effects	O
on	O
adrenergic	O
and	O
serotonergic	O
neurotransmission	O
that	O
is	O
used	O
to	O
treat	O
cancer	I-Entity
pain	I-Entity
and	O
chronic	O
non	O
malignant	O
pain	I-Entity
.	O

This	O
drug	O
was	O
initiated	O
in	O
association	O
with	O
paroxetine	I-Entity
and	O
dosulepine	B-Entity
hydrochloride	I-Entity
in	O
a	O
tetraparetic	I-Entity
patient	O
with	O
chronic	B-Entity
pain	I-Entity
.	O

Fifty	O
-	O
six	O
days	O
after	O
initiation	O
of	O
the	O
treatment	O
the	O
patient	O
presented	O
hallucinations	I-Entity
that	O
only	O
stopped	O
after	O
the	O
withdrawal	O
of	O
psycho	O
-	O
active	O
drugs	O
and	O
tramadol	I-Entity
.	O

The	O
case	O
report	O
questions	O
the	O
long	O
term	O
use	O
of	O
pain	I-Entity
killers	O
combined	O
with	O
psycho	O
-	O
active	O
drugs	O
in	O
chronic	O
non	O
malignant	O
pain	I-Entity
,	O
especially	O
if	O
pain	I-Entity
is	O
under	O
control	O
.	O



Apparent	O
cure	O
of	O
rheumatoid	B-Entity
arthritis	I-Entity
by	O
bone	O
marrow	O
transplantation	O
.	O

We	O
describe	O
the	O
induction	O
of	O
sustained	O
remissions	O
and	O
possible	O
cure	O
of	O
severe	O
erosive	O
rheumatoid	B-Entity
arthritis	I-Entity
(	O
RA	I-Entity
)	O
by	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
in	O
2	O
patients	O
.	O

BMT	O
was	O
used	O
to	O
treat	O
severe	O
aplastic	B-Entity
anemia	I-Entity
which	O
was	O
caused	O
by	O
gold	I-Entity
in	O
one	O
case	O
and	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
in	O
the	O
other	O
.	O

In	O
the	O
8	O
and	O
6	O
years	O
since	O
the	O
transplants	O
(	O
representing	O
8	O
and	O
4	O
years	O
since	O
cessation	O
of	O
all	O
immunosuppressive	O
therapy	O
,	O
respectively	O
)	O
,	O
the	O
RA	I-Entity
in	O
each	O
case	O
has	O
been	O
completely	O
quiescent	O
.	O

Although	O
short	O
term	O
remission	O
of	O
severe	O
RA	I-Entity
following	O
BMT	O
has	O
been	O
reported	O
,	O
these	O
are	O
the	O
first	O
cases	O
for	O
which	O
prolonged	O
followup	O
has	O
been	O
available	O
.	O

This	O
experience	O
raises	O
the	O
question	O
of	O
the	O
role	O
of	O
BMT	O
itself	O
as	O
a	O
therapeutic	O
option	O
for	O
patients	O
with	O
uncontrolled	O
destructive	O
synovitis	I-Entity
.	O



Urinary	O
enzymes	O
and	O
protein	O
patterns	O
as	O
indicators	O
of	O
injury	B-Entity
to	I-Entity
different	I-Entity
regions	I-Entity
of	I-Entity
the	I-Entity
kidney	I-Entity
.	O

Acute	B-Entity
experimental	I-Entity
models	I-Entity
of	I-Entity
renal	I-Entity
damage	I-Entity
to	O
the	O
proximal	O
tubular	O
,	O
glomerular	O
,	O
and	O
papillary	O
regions	O
of	O
the	O
rat	O
were	O
produced	O
by	O
administration	O
of	O
hexachloro-1:3-butadiene	I-Entity
(	O
HCBD	I-Entity
)	O
,	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN	I-Entity
)	O
,	O
and	O
2-bromoethylamine	I-Entity
(	O
BEA	I-Entity
)	O
,	O
respectively	O
.	O

Several	O
routine	O
indicators	O
of	O
nephrotoxicity	I-Entity
,	O
the	O
enzymes	O
alkaline	O
phosphatase	O
and	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
glucosaminidase	O
,	O
and	O
the	O
molecular	O
weight	O
of	O
protein	B-Entity
excretion	I-Entity
were	O
determined	O
on	O
urine	O
samples	O
.	O

Tubular	O
damage	O
produced	O
by	O
HCBD	I-Entity
or	O
BEA	I-Entity
was	O
discriminated	O
both	O
quantitatively	O
and	O
qualitatively	O
from	O
glomerular	B-Entity
damage	I-Entity
produced	O
by	O
PAN	I-Entity
.	O

The	O
latter	O
was	O
characterized	O
by	O
a	O
pronounced	O
increase	O
in	O
protein	B-Entity
excretion	I-Entity
,	O
especially	O
proteins	O
with	O
molecular	O
weight	O
greater	O
than	O
40,000	O
Da	O
.	O

In	O
contrast	O
,	O
protein	B-Entity
excretion	I-Entity
in	O
tubular	O
damage	O
was	O
raised	O
only	O
slightly	O
and	O
characterized	O
by	O
excretion	B-Entity
of	I-Entity
proteins	I-Entity
of	O
a	O
wide	O
range	O
of	O
molecular	O
weights	O
.	O

Proximal	O
tubular	O
damage	O
caused	O
by	O
HCBD	I-Entity
and	O
papillary	O
damage	O
caused	O
by	O
BEA	I-Entity
were	O
distinguished	O
both	O
by	O
conventional	O
urinalysis	O
(	O
volume	O
and	O
specific	O
gravity	O
)	O
and	O
by	O
measurement	O
of	O
the	O
two	O
urinary	O
enzymes	O
.	O

Alkaline	O
phosphatase	O
and	O
glucose	I-Entity
were	O
markedly	O
and	O
transiently	O
elevated	O
in	O
proximal	O
tubular	O
damage	O
and	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
glucosaminidase	O
showed	O
a	O
sustained	O
elevation	O
in	O
papillary	O
damage	O
.	O

It	O
is	O
concluded	O
that	O
both	O
selective	O
urinary	O
enzymes	O
and	O
the	O
molecular	O
weight	O
pattern	O
of	O
urinary	O
proteins	O
can	O
be	O
used	O
to	O
provide	O
diagnostic	O
information	O
about	O
the	O
possible	O
site	O
of	O
renal	B-Entity
damage	I-Entity
.	O



Neuromuscular	B-Entity
blockade	I-Entity
with	O
magnesium	B-Entity
sulfate	I-Entity
and	O
nifedipine	I-Entity
.	O

A	O
patient	O
who	O
received	O
tocolysis	O
with	O
nifedipine	I-Entity
developed	O
neuromuscular	B-Entity
blockade	I-Entity
after	O
500	O
mg	O
of	O
magnesium	B-Entity
sulfate	I-Entity
was	O
administered	O
.	O

This	O
reaction	O
demonstrates	O
that	O
nifedipine	I-Entity
can	O
seriously	O
potentiate	O
the	O
toxicity	I-Entity
of	O
magnesium	I-Entity
.	O



Ifosfamide	I-Entity
continuous	O
infusion	O
without	O
mesna	I-Entity
.	O

Twenty	O
patients	O
received	O
27	O
courses	O
of	O
ifosfamide	I-Entity
administered	O
as	O
a	O
24-hour	O
continuous	O
infusion	O
for	O
14	O
days	O
without	O
Mesna	I-Entity
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
deliver	O
a	O
dose	O
rate	O
and	O
total	O
cumulative	O
dose	O
of	O
ifosfamide	I-Entity
that	O
would	O
be	O
comparable	O
to	O
standard	O
bolus	O
or	O
short	O
-	O
term	O
infusions	O
administered	O
with	O
Mesna	I-Entity
.	O

Four	O
patients	O
developed	O
transient	O
microscopic	O
hematuria	I-Entity
at	O
400	O
,	O
450	O
,	O
and	O
500	O
mg	O
/	O
m2/d	O
.	O

There	O
were	O
no	O
instances	O
of	O
macroscopic	O
hematuria	I-Entity
.	O

At	O
550	O
mg	O
/	O
m2/d	O
,	O
three	O
patients	O
experienced	O
nonurologic	O
toxicity	I-Entity
;	O
confusion	I-Entity
(	O
1	O
)	O
,	O
nausea	I-Entity
(	O
1	O
)	O
,	O
and	O
Grade	O
2	O
leukopenia	I-Entity
(	O
1	O
)	O
.	O

The	O
frequency	O
and	O
predictability	O
of	O
hematuria	I-Entity
are	O
not	O
precise	O
,	O
and	O
at	O
least	O
daily	O
monitoring	O
by	O
urine	O

Hematest	O
is	O
essential	O
,	O
adding	O
Mesna	I-Entity
to	O
the	O
infusate	O
in	O
patients	O
with	O
persistent	O
hematuria	I-Entity
.	O

The	O
protracted	O
infusion	O
schedule	O
for	O
ifosfamide	I-Entity
permits	O
convenient	O
outpatient	O
administration	O
without	O
Mesna	I-Entity
and	O
reduces	O
the	O
drug	O
cost	O
of	O
clinical	O
usage	O
of	O
this	O
agent	O
by	O
up	O
to	O
890	O
per	O
cycle	O
.	O



Myocardial	B-Entity
infarction	I-Entity
in	O
pregnancy	O
associated	O
with	O
clomiphene	B-Entity
citrate	I-Entity
for	O
ovulation	O
induction	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Clomiphene	B-Entity
citrate	I-Entity
(	O
CC	I-Entity
)	O
is	O
commonly	O
prescribed	O
for	O
ovulation	O
induction	O
.	O

Thromboembolism	I-Entity
is	O
a	O
rare	O
but	O
life	O
-	O
threatening	O
complication	O
that	O
has	O
been	O
reported	O
after	O
ovulation	O
induction	O
with	O
CC	I-Entity
.	O

coronary	B-Entity
thrombosis	I-Entity
or	O
thromboembolism	I-Entity
with	O
subsequent	O
clot	O
lysis	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
myocardial	B-Entity
infarction	I-Entity
(	O
MI	I-Entity
)	O
during	O
pregnancy	O
,	O
with	O
a	O
subsequently	O
normal	O
coronary	O
angiogram	O
.	O

A	O
33-year	O
-	O
old	O
woman	O
with	O
a	O
5-week	O
gestation	O
had	O
recently	O
received	O
CC	I-Entity
for	O
ovulation	O
induction	O
and	O
presented	O
with	O
chest	B-Entity
pain	I-Entity
.	O

An	O
electrocardiogram	O
showed	O
a	O
lateral	O
and	O
anterior	O
wall	O
myocardial	B-Entity
infarction	I-Entity
.	O

At	O
the	O
time	O
of	O
admission	O
,	O
the	O
patient	O
was	O
at	O
high	O
risk	O
of	O
radiation	B-Entity
injury	I-Entity
to	O
the	O
fetus	O
,	O
so	O
a	O
coronary	O
angiogram	O
was	O
postponed	O
until	O
the	O
second	O
trimester	O
.	O

This	O
appears	O
to	O
be	O
the	O
first	O
reported	O
case	O
documenting	O
a	O
possible	O
association	O
between	O
CC	I-Entity
and	O
myocardial	B-Entity
infarction	I-Entity
.	O

Thrombosis	I-Entity
might	O
be	O
a	O
rare	O
but	O
hazardous	O
complication	O
of	O
CC	I-Entity
.	O



Hepatonecrosis	I-Entity
and	O
cholangitis	I-Entity
related	O
to	O
long	O
-	O
term	O
phenobarbital	I-Entity
therapy	O
:	O
an	O
autopsy	O
report	O
of	O
two	O
patients	O
.	O

Phenobarbital	I-Entity
(	O
PB	I-Entity
)	O
has	O
a	O
reputation	O
for	O
safety	O
,	O
and	O
it	O
is	O
commonly	O
believed	O
that	O
PB	I-Entity
-	O
related	O
increases	O
in	O
serum	O
aminotransferase	O
levels	O
do	O
not	O
indicate	O
or	O
predict	O
the	O
development	O
of	O
significant	O
chronic	O
liver	B-Entity
disease	I-Entity
.	O

Here	O
we	O
report	O
of	O
two	O
adult	O
patients	O
with	O
a	O
long	O
history	O
of	O
epilepsy	I-Entity
treated	O
with	O
PB	I-Entity
who	O
died	O
suddenly	O
:	O
one	O
as	O
consequence	O
of	O
cardiac	B-Entity
arrest	I-Entity
,	O
the	O
other	O
of	O
acute	O
bronchopneumonia	I-Entity
.	O

At	O
autopsy	O
,	O
analysis	O
of	O
liver	O
parenchyma	O
revealed	O
rich	O
portal	O
inflammatory	O
infiltrate	O
,	O
which	O
consisted	O
of	O
mixed	O
eosinophil	O
and	O
monocyte	O
cells	O
,	O
associated	O
with	O
several	O
foci	O
of	O
necrosis	I-Entity
surrounded	O
by	O
a	O
hard	O
ring	O
of	O
non	O
-	O
specific	O
granulomatous	O
tissue	O
.	O

Our	O
findings	O
illustrate	O
that	O
PB	I-Entity
may	O
be	O
associated	O
with	O
chronic	O
liver	B-Entity
damage	I-Entity
,	O
which	O
may	O
lead	O
to	O
more	O
serious	O
and	O
deleterious	O
consequences	O
.	O

For	O
this	O
reason	O
,	O
each	O
clinician	O
should	O
recognize	O
this	O
entity	O
in	O
the	O
differential	O
diagnosis	O
of	O
PB	I-Entity
-	O
related	O
asymptomatic	O
chronic	B-Entity
hepatic	I-Entity
enzyme	I-Entity
dysfunction	I-Entity
.	O



Ethambutol	I-Entity
-	O
associated	O
optic	B-Entity
neuropathy	I-Entity
.	O

Ethambutol	I-Entity
is	O
used	O
in	O
the	O
treatment	O
of	O
tuberculosis	I-Entity
,	O
which	O
is	O
still	O
prevalent	O
in	O
Southeast	O
Asia	O
,	O
and	O
can	O
be	O
associated	O
with	O
permanent	O
visual	B-Entity
loss	I-Entity
.	O

We	O
report	O
3	O
cases	O
which	O
presented	O
with	O
bitemporal	B-Entity
hemianopia	I-Entity
.	O

Three	O
patients	O
with	O
ethambutol	I-Entity
-	O
associated	O
toxic	O
optic	B-Entity
neuropathy	I-Entity
are	O
described	O
.	O

All	O
3	O
patients	O
had	O
loss	B-Entity
of	I-Entity
central	I-Entity
visual	I-Entity
acuity	I-Entity
,	I-Entity
colour	I-Entity
vision	I-Entity
(	I-Entity
Ishihara	I-Entity
)	I-Entity
and	I-Entity
visual	I-Entity
field	I-Entity
.	O

The	O
visual	B-Entity
field	I-Entity
loss	I-Entity
had	O
a	O
bitemporal	O
flavour	O
,	O
suggesting	O
involvement	O
of	O
the	O
optic	O
chiasm	O
.	O

Despite	O
stopping	O
ethambutol	I-Entity
on	O
diagnosis	O
,	O
visual	O
function	O
continued	O
to	O
deteriorate	O
for	O
a	O
few	O
months	O
.	O

All	O
3	O
patients	O
had	O
some	O
permanent	O
loss	B-Entity
of	I-Entity
visual	I-Entity
function	I-Entity
.	O

Ethambutol	I-Entity
usage	O
is	O
associated	O
with	O
permanent	O
visual	B-Entity
loss	I-Entity
and	O
should	O
be	O
avoided	O
if	O
possible	O
or	O
used	O
with	O
caution	O
and	O
proper	O
ophthalmological	O
follow	O
-	O
up	O
.	O

The	O
author	O
postulates	O
that	O
in	O
cases	O
of	O
ethambutol	I-Entity
associated	O
chiasmopathy	O
,	O
ethambutol	I-Entity
may	O
initially	O
affect	O
the	O
optic	O
nerves	O
and	O
subsequently	O
progress	O
to	O
involve	O
the	O
optic	O
chiasm	O
.	O



Tolerability	O
of	O
nimesulide	I-Entity
and	O
paracetamol	I-Entity
in	O
patients	O
with	O
NSAID	I-Entity
-	O
induced	O
urticaria	I-Entity
/	O
angioedema	I-Entity
.	O

Previous	O
studies	O
evaluated	O
the	O
tolerance	O
of	O
nimesulide	I-Entity
and	O
paracetamol	I-Entity
in	O
subjects	O
with	O
cutaneous	O
,	O
respiratory	O
and	O
anaphylactoid	O
reactions	O
induced	O
by	O
nonsteroidal	B-Entity
anti	I-Entity
-	I-Entity
inflammatory	I-Entity
drugs	I-Entity
(	O
NSAIDs	I-Entity
)	O
.	O

In	O
this	O
study	O
we	O
investigated	O
tolerability	O
and	O
reliability	O
of	O
nimesulide	I-Entity
and	O
paracetamol	I-Entity
in	O
a	O
very	O
large	O
number	O
of	O
patients	O
with	O
an	O
exclusive	O
well	O
-	O
documented	O
history	O
of	O
NSAID	I-Entity
-	O
induced	O
urticaria	I-Entity
/	O
angioedema	I-Entity
.	O

Furthermore	O
,	O
we	O
evaluated	O
whether	O
some	O
factors	O
have	O
the	O
potential	O
to	O
increase	O
the	O
risk	O
of	O
reaction	O
to	O
paracetamol	I-Entity
and	O
nimesulide	I-Entity
.	O

A	O
single	O
-	O
placebo	O
-	O
controlled	O
oral	O
challenge	O
procedure	O
with	O
nimesulide	I-Entity
or	O
paracetamol	I-Entity
was	O
applied	O
to	O
829	O
patients	O
with	O
a	O
history	O
of	O
NSAID	I-Entity
-	O
induced	O
urticaria	I-Entity
/	O
angioedema	I-Entity
.	O

patients	O
experienced	O
reactions	O
to	O
nimesulide	I-Entity
or	O
paracetamol	I-Entity
.	O

Of	O
the	O
715	O
patients	O
tested	O
with	O
nimesulide	I-Entity
62	O
(	O
8.6%	O
)	O
showed	O
a	O
positive	O
test	O
,	O
while	O
of	O
114	O
subjects	O
submitted	O
to	O
the	O
challenge	O
with	O
paracetamol	I-Entity
,	O
13	O
(	O
9.6%	O
)	O
did	O
not	O
tolerate	O
this	O
drug	O
.	O

Furthermore	O
,	O
18.28%	O
of	O
patients	O
with	O
a	O
history	O
of	O
chronic	O
urticaria	I-Entity
and	O
11.8%	O
of	O
subjects	O
with	O
an	O
history	O
of	O
NSAID	I-Entity
-	O
induced	O
urticaria	I-Entity
/	O
angioedema	I-Entity
or	O
angioedema	I-Entity
alone	O
(	O
with	O
or	O
without	O
chronic	O
urticaria	I-Entity
)	O
resulted	O
to	O
be	O
intolerant	O
to	O
alternative	O
drugs	O
.	O

Taken	O
together	O
,	O
our	O
results	O
confirm	O
the	O
good	O
tolerability	O
of	O
nimesulide	I-Entity
and	O
paracetamol	I-Entity
in	O
patients	O
who	O
experienced	O
urticaria	I-Entity
/	O
angioedema	I-Entity
caused	O
by	O
NSAIDs	I-Entity
.	O

However	O
,	O
the	O
risk	O
of	O
reaction	O
to	O
these	O
alternative	O
study	O
drugs	O
is	O
statistically	O
increased	O
by	O
a	O
history	O
of	O
chronic	O
urticaria	I-Entity
and	O
,	O
above	O
all	O
,	O
by	O
a	O
history	O
of	O
NSAID	I-Entity
-	O
induced	O
angioedema	I-Entity
.	O



Effects	O
of	O
verapamil	I-Entity
on	O
atrial	B-Entity
fibrillation	I-Entity
and	O
its	O
electrophysiological	O
determinants	O
in	O
dogs	O
.	O

Atrial	B-Entity
tachycardia	I-Entity
-	O
induced	O
remodeling	O
promotes	O
the	O
occurrence	O
and	O
maintenance	O
of	O
atrial	B-Entity
fibrillation	I-Entity
(	O
AF	I-Entity
)	O
and	O
decreases	O
L	O
-	O
type	O
Ca(2	I-Entity
+	O
)	O
current	O
.	O

There	O
is	O
also	O
a	O
clinical	O
suggestion	O
that	O
acute	O
L	O
-	O
type	O
Ca(2	I-Entity
)	O
channel	O
blockade	O
can	O
promote	O
AF	I-Entity
,	O
consistent	O
with	O
an	O
AF	I-Entity
promoting	O
effect	O
of	O
Ca(2	I-Entity
+	O
)	O
channel	O
inhibition	O
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
potential	O
mechanisms	O
of	O
AF	I-Entity
promotion	O
by	O
Ca(2	I-Entity
+	O
)	O
channel	O
blockers	O
,	O
we	O
administered	O
verapamil	I-Entity
to	O
morphine	I-Entity
-	O
chloralose	I-Entity
anesthetized	O
dogs	O
.	O

Diltiazem	I-Entity
was	O
used	O
as	O
a	O
comparison	O
drug	O
and	O
autonomic	O
blockade	O
with	O
atropine	I-Entity
and	O
nadolol	I-Entity
was	O
applied	O
in	O
some	O
experiments	O
.	O

Epicardial	O
mapping	O
with	O
240	O
epicardial	O
electrodes	O
was	O
used	O
to	O
evaluate	O
activation	O
during	O
AF	I-Entity
.	O

RESULTS	O
:	O
Verapamil	I-Entity
caused	O
AF	I-Entity
promotion	O
in	O
six	O
dogs	O
,	O
increasing	O
mean	O
duration	O
of	O
AF	I-Entity
induced	O
by	O
burst	O
pacing	O
,	O
from	O
8+/-4	O
s	O
(	O
mean+/-S.E.	O
)	O
to	O
95+/-39	O
s	O
(	O
P<0.01	O
vs.	O
control	O
)	O
at	O
a	O
loading	O
dose	O
of	O
0.1	O
mg	O
/	O
kg	O
and	O
228+/-101	O
s	O
(	O
P<0.0005	O
vs.	O
control	O
)	O
at	O
a	O
dose	O
of	O
0.2	O
mg	O
/	O
kg	O
.	O

Underlying	O
electrophysiological	O
mechanisms	O
were	O
studied	O
in	O
detail	O
in	O
five	O
additional	O
dogs	O
under	O
control	O
conditions	O
and	O
in	O
the	O
presence	O
of	O
the	O
higher	O
dose	O
of	O
verapamil	I-Entity
.	O

In	O
these	O
experiments	O
,	O
verapamil	I-Entity
shortened	O
mean	O
effective	O
refractory	O
period	O
(	O
ERP	O
)	O
from	O
122+/-5	O
to	O
114+/-4	O
ms	O
(	O
P<0.02	O
)	O
at	O
a	O
cycle	O
length	O
of	O
300	O
ms	O
,	O
decreased	O
ERP	O
heterogeneity	O
(	O
from	O
15+/-1	O
to	O
10+/-1%	O
,	O
P<0.05	O
)	O
,	O
heterogeneously	O
accelerated	O
atrial	O
conduction	O
and	O
decreased	O
the	O
cycle	O
length	O
of	O
AF	I-Entity
(	O
94+/-4	O
to	O
84+/-3	O
ms	O
,	O
P<0.005	O
)	O
.	O

Diltiazem	I-Entity
did	O
not	O
affect	O
ERP	O
,	O
AF	I-Entity
cycle	O
length	O
or	O
AF	I-Entity
duration	O
,	O
but	O
produced	O
conduction	O
acceleration	O
similar	O
to	O
that	O
caused	O
by	O
verapamil	I-Entity
(	O
n=5	O
)	O
.	O

In	O
the	O
presence	O
of	O
autonomic	O
blockade	O
,	O
verapamil	I-Entity
failed	O
to	O
promote	O
AF	I-Entity
and	O
increased	O
,	O
rather	O
than	O
decreasing	O
,	O
refractoriness	O
.	O

Neither	O
verapamil	I-Entity
nor	O
diltiazem	I-Entity
affected	O
atrial	O
conduction	O
in	O
the	O
presence	O
of	O
autonomic	O
blockade	O
.	O

Epicardial	O
mapping	O
suggested	O
that	O
verapamil	I-Entity
promoted	O
AF	I-Entity
by	O
increasing	O
the	O
number	O
of	O
simultaneous	O
wavefronts	O
reflected	O
by	O
separate	O
zones	O
of	O
reactivation	O
in	O
each	O
cycle	O
.	O

:	O
Verapamil	I-Entity
promotes	O
AF	I-Entity
in	O
normal	O
dogs	O
by	O
promoting	O
multiple	O
circuit	O
reentry	O
,	O
an	O
effect	O
dependent	O
on	O
intact	O
autonomic	O
tone	O
and	O
not	O
shared	O
by	O
diltiazem	I-Entity
.	O



Hypotension	I-Entity
,	O
bradycardia	I-Entity
,	O
and	O
asystole	I-Entity
after	O
high	O
-	O
dose	O
intravenous	O
methylprednisolone	I-Entity
in	O
a	O
monitored	O
patient	O
.	O

We	O
report	O
a	O
case	O
of	O
hypotension	I-Entity
,	O
bradycardia	I-Entity
,	O
and	O
asystole	I-Entity
after	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
methylprednisolone	I-Entity
in	O
a	O
73-year	O
-	O
old	O
patient	O
who	O
underwent	O
electrocardiographic	O
(	O
ECG	O
)	O
monitoring	O
throughout	O
the	O
episode	O
.	O

There	O
was	O
a	O
history	O
of	O
ischemic	I-Entity
cardiac	B-Entity
disease	I-Entity
9	O
years	O
earlier	O
.	O

The	O
patient	O
was	O
admitted	O
with	O
a	O
pulmonary	B-Entity
-	I-Entity
renal	I-Entity
syndrome	I-Entity
with	O
hemoptysis	I-Entity
,	O
rapidly	O
progressive	O
renal	B-Entity
failure	I-Entity
,	O
and	O
hypoxemia	I-Entity
that	O
required	O
mechanical	O
ventilation	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

The	O
ECG	O
showed	O
a	O
junctional	O
rhythm	O
without	O
ventricular	B-Entity
arrhythmia	I-Entity
.	O

This	O
study	O
reviews	O
the	O
current	O
proposed	O
mechanisms	O
of	O
sudden	B-Entity
death	I-Entity
after	O
a	O
high	O
dose	O
of	O
intravenous	O
methylprednisolone	I-Entity
(	O
IVMP	I-Entity
)	O
.	O

Rapid	O
infusion	O
and	O
underlying	O
cardiac	B-Entity
disease	I-Entity
were	O
important	O
risk	O
factors	O
in	O
the	O
case	O
reported	O
here	O
,	O
and	O
the	O
authors	O
discount	O
ventricular	B-Entity
arrhythmia	I-Entity
as	O
the	O
main	O
mechanism	O
.	O



Lifetime	O
treatment	O
of	O
mice	O
with	O
azidothymidine	I-Entity
(	O
AZT	I-Entity
)	O
produces	O
myelodysplasia	I-Entity
.	O

AZT	I-Entity
has	O
induced	O
a	O
macrocytic	B-Entity
anemia	I-Entity
in	O
AIDS	I-Entity
patients	O
on	O
long	O
term	O
AZT	I-Entity
therapy	O
.	O

It	O
is	O
generally	O
assumed	O
that	O
DNA	O
elongation	O
is	O
stopped	O
by	O
the	O
insertion	O
of	O
AZT	I-Entity
into	O
the	O
chain	O
in	O
place	O
of	O
thymidine	I-Entity
thus	O
preventing	O
the	O
phosphate	I-Entity
hydroxyl	O
linkages	O
and	O
therefore	O
suppresses	O
hemopoietic	O
progenitor	O
cell	O
proliferation	O
in	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O

CBA	O
/	O
Ca	O
male	O
mice	O
started	O
on	O
AZT	I-Entity
0.75	O
mg	O
/	O

ml	O
H2O	O
at	O
84	O
days	O
of	O
age	O
and	O
kept	O
on	O
it	O
for	O
687	O
days	O
when	O
dosage	O
reduced	O
to	O
0.5	O
mg	O
/	O
ml	O
H2O	O
for	O
a	O
group	O
,	O
another	O
group	O
removed	O
from	O
AZT	I-Entity
to	O
see	O
recovery	O
,	O
and	O
third	O
group	O
remained	O
on	O
0.75	O
mg	O
.	O

Histological	O
examination	O
on	O
9	O
of	O
10	O
mice	O
with	O
such	O
thrombocytopenia	I-Entity
showed	O
changes	O
compatible	O
with	O
myelodysplastic	B-Entity
syndrome	I-Entity
(	O
MDS	I-Entity
)	O
.	O

There	O
were	O
two	O
cases	O
of	O
hypocellular	O
myelodysplasia	I-Entity
,	O
two	O
cases	O
of	O
hypersegmented	O
myelodysplastic	I-Entity
granulocytosis	O
,	O
two	O
cases	O
of	O
hypercellular	O
marrow	O
with	O
abnormal	O
megakaryocytes	O
with	O
bizarre	O
nuclei	O
,	O
one	O
case	O
of	O
megakaryocytic	O
myelosis	O
associated	O
with	O
a	O
hyperplastic	B-Entity
marrow	I-Entity
,	O
dysmyelopoiesis	I-Entity
and	O
a	O
hypocellular	B-Entity
marrow	I-Entity
and	O
two	O
cases	O
of	O
myelodysplasia	I-Entity
with	O
dyserythropoiesis	I-Entity
,	O
hemosiderosis	I-Entity
and	O
a	O
hypocellular	B-Entity
marrow	I-Entity
.	O

Above	O
mentioned	O
AZT	I-Entity
incorporation	O
may	O
have	O
induced	O
an	O
ineffective	O
hemopoiesis	O
in	O
the	O
primitive	O
hemopoietic	O
progenitor	O
cells	O
,	O
which	O
is	O
known	O
to	O
be	O
seen	O
commonly	O
in	O
the	O
myelodysplastic	B-Entity
syndrome	I-Entity
.	O



Influence	O
of	O
diet	O
free	O
of	O
NAD	I-Entity
-	O
precursors	O
on	O
acetaminophen	I-Entity
hepatotoxicity	I-Entity
in	O
mice	O
.	O

Recently	O
,	O
we	O
demonstrated	O
the	O
hepatoprotective	O
effects	O
of	O
nicotinic	B-Entity
acid	I-Entity
amide	I-Entity
,	O
a	O
selective	O
inhibitor	O
of	O
poly(ADP	B-Entity
-	I-Entity
ribose	I-Entity
)	I-Entity
polymerase	O
(	O
PARP	O
;	O
EC	O
2.4.2.30	O
)	O
on	O
mice	O
suffering	O
from	O
acetaminophen	I-Entity
(	O
AAP)-hepatitis	I-Entity
,	O
suggesting	O
that	O
the	O
AAP	I-Entity
-	O
induced	O
liver	B-Entity
injury	I-Entity
involves	O
a	O
step	O
which	O
depends	O
on	O
adenoribosylation	O
.	O

The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
a	O
diet	O
free	O
of	O
precursors	O
of	O
NAD	I-Entity
,	O
the	O
substrate	O
on	O
which	O
PARP	O
acts	O
,	O
in	O
female	O
NMRI	O
mice	O
with	O
AAP	I-Entity
hepatitis	I-Entity
and	O
evaluates	O
the	O
influence	O
of	O
simultaneous	O
ethanol	I-Entity
consumption	O
in	O
these	O
animals	O
.	O

Liver	B-Entity
injuries	I-Entity
were	O
quantified	O
as	O
serum	O
activities	O
of	O
glutamate	I-Entity
-	O
oxaloacetate	I-Entity
transaminase	O
(	O
GOT	O
)	O
and	O
glutamate	I-Entity
-	O
pyruvate	I-Entity
transaminase	O
(	O
GPT	O
)	O
.	O

While	O
AAP	I-Entity
caused	O
a	O
117-fold	O
elevation	O
of	O
serum	O
transaminase	O
activities	O
in	O
mice	O
kept	O
on	O
a	O
standard	O
laboratory	O
diet	O
,	O
which	O
was	O
significantly	O
exacerbated	O
by	O
ethanol	I-Entity
and	O
inhibited	O
by	O
nicotinic	B-Entity
acid	I-Entity
amide	I-Entity
(	O
NAA	I-Entity
)	O
,	O
adverse	O
effects	O
were	O
noted	O
in	O
animals	O
fed	O
a	O
diet	O
free	O
of	O
precursors	O
of	O
NAD	I-Entity
.	O

In	O
these	O
animals	O
,	O
only	O
minor	O
increases	O
of	O
serum	O
transaminase	O
activities	O
were	O
measured	O
in	O
the	O
presence	O
of	O
AAP	I-Entity
,	O
and	O
unlike	O
the	O
exacerbation	O
caused	O
by	O
ethanol	I-Entity
in	O
mice	O
on	O
a	O
standard	O
diet	O
,	O
the	O
liver	B-Entity
damage	I-Entity
was	O
inhibited	O
by	O
50%	O
by	O
ethanol	I-Entity
.	O

A	O
further	O
64%	O
reduction	O
of	O
hepatitis	I-Entity
was	O
observed	O
,	O
when	O
NAA	I-Entity
was	O
given	O
to	O
ethanol	I-Entity
/	O
AAP	I-Entity
-	O
mice	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
AAP	I-Entity
-	O
induced	O
hepatitis	I-Entity
and	O
its	O
exacerbation	O
by	O
ethanol	I-Entity
can	O
either	O
be	O
reduced	O
by	O
end	O
-	O
product	O
inhibition	O
of	O
PARP	O
by	O
NAA	I-Entity
or	O
by	O
dietary	O
depletion	O
of	O
the	O
enzyme	O
's	O
substrate	O
NAD	I-Entity
.	O

We	O
see	O
the	O
main	O
application	O
of	O
NAA	I-Entity
as	O
for	O
the	O
combinational	O
use	O
in	O
pharmaceutical	O
preparations	O
of	O
acetaminophen	I-Entity
in	O
order	O
to	O
avoid	O
hepatic	B-Entity
damage	I-Entity
in	O
patients	O
treated	O
with	O
this	O
widely	O
used	O
analgesic	O
.	O



Antiarrhythmic	O
plasma	O
concentrations	O
of	O
cibenzoline	I-Entity
on	O
canine	O
ventricular	B-Entity
arrhythmias	I-Entity
.	O

Using	O
two	O
-	O
stage	O
coronary	O
ligation-	O
,	O
digitalis-	I-Entity
,	O
and	O
adrenaline	I-Entity
-	O
induced	O
canine	O
ventricular	B-Entity
arrhythmias	I-Entity
,	O
antiarrhythmic	O
effects	O
of	O
cibenzoline	I-Entity
were	O
examined	O
and	O
the	O
minimum	O
effective	O
plasma	O
concentration	O
for	O
each	O
arrhythmia	I-Entity
model	O
was	O
determined	O
.	O

Cibenzoline	I-Entity
suppressed	O
all	O
the	O
arrhythmias	I-Entity
,	O
and	O
the	O
minimum	O
effective	O
plasma	O
concentrations	O
for	O
arrhythmias	I-Entity
induced	O
by	O
24-h	O
coronary	O
ligation	O
,	O
48-h	O
coronary	O
ligation	O
,	O
digitalis	I-Entity
,	O
and	O
adrenaline	I-Entity
were	O
1.9	O
+	O
/-	O

The	O
concentration	O
for	O
adrenaline	I-Entity
-	O
induced	O
arrhythmia	I-Entity
was	O
significantly	O
higher	O
than	O
those	O
for	O
the	O
other	O
types	O
of	O
arrhythmias	I-Entity
.	O

This	O
pharmacological	O
profile	O
is	O
similar	O
to	O
those	O
of	O
mexiletine	I-Entity
and	O
tocainide	I-Entity
,	O
and	O
all	O
three	O
drugs	O
have	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
stimulant	O
action	O
.	O

Because	O
cibenzoline	I-Entity
had	O
only	O
weak	O
hypotensive	I-Entity
and	O
sinus	O
node	O
depressive	I-Entity
effects	O
and	O
was	O
found	O
to	O
be	O
orally	O
active	O
when	O
given	O
to	O
coronary	O
ligation	O
arrhythmia	I-Entity
dogs	O
,	O
its	O
clinical	O
usefulness	O
is	O
expected	O
.	O



Immunopathology	O
of	O
penicillamine	I-Entity
-	O
induced	O
glomerular	B-Entity
disease	I-Entity
.	O

Four	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
developed	O
heavy	O
proteinuria	I-Entity
after	O
five	O
to	O
12	O
months	O
of	O
treatment	O
with	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
.	O

The	O
findings	O
were	O
similar	O
to	O
those	O
in	O
early	O
membranous	B-Entity
glomerulonephritis	I-Entity
,	O
differences	O
being	O
observed	O
however	O
in	O
the	O
results	O
of	O
staining	O
for	O
the	O
early	O
-	O
acting	O
complement	O
components	O
C1q	O
and	O
C4	O
.	O



Ventricular	B-Entity
fibrillation	I-Entity
from	O
diatrizoate	I-Entity
with	O
and	O
without	O
chelating	O
agents	O
.	O

The	O
toxicity	I-Entity
of	O
Renografin	B-Entity
76%	I-Entity
was	O
compared	O
with	O
that	O
of	O
Hypaque	B-Entity
76%	I-Entity
by	O
selective	O
injection	O
of	O
each	O
into	O
the	O
right	O
coronary	O
artery	O
of	O
dogs	O
.	O

Renografin	I-Entity
contains	O
the	O
chelating	O
agents	O
sodium	B-Entity
citrate	I-Entity
and	O
disodium	B-Entity
edetate	I-Entity
,	O
while	O
Hypaque	I-Entity
contains	O
calcium	B-Entity
disodium	I-Entity
edetate	I-Entity
and	O
no	O
sodium	B-Entity
citrate	I-Entity
.	O

Ventricular	B-Entity
fibrillation	I-Entity
occurred	O
significantly	O
more	O
often	O
with	O
Renografin	I-Entity
,	O
suggesting	O
that	O
chelating	O
agents	O
contribute	O
to	O
toxicity	I-Entity
in	O
coronary	O
angiography	O
.	O



Rapid	O
reversal	O
of	O
anticoagulation	O
reduces	O
hemorrhage	I-Entity
volume	O
in	O
a	O
mouse	O
model	O
of	O
warfarin	I-Entity
-	O
associated	O
intracerebral	B-Entity
hemorrhage	I-Entity
.	O

Warfarin	I-Entity
-	O
associated	O
intracerebral	B-Entity
hemorrhage	I-Entity
(	O
W	O
-	O
ICH	I-Entity
)	O
is	O
a	O
severe	O
type	O
of	O
stroke	I-Entity
.	O

There	O
is	O
no	O
consensus	O
on	O
the	O
optimal	O
treatment	O
for	O
W	O
-	O
ICH	I-Entity
.	O

Using	O
a	O
mouse	O
model	O
,	O
we	O
tested	O
whether	O
the	O
rapid	O
reversal	O
of	O
anticoagulation	O
using	O
human	O
prothrombin	B-Entity
complex	I-Entity
concentrate	I-Entity
(	O
PCC	I-Entity
)	O
can	O
reduce	O
hemorrhagic	O
blood	O
volume	O
.	O

Male	O
CD-1	O
mice	O
were	O
treated	O
with	O
warfarin	I-Entity
(	O
2	O
mg	O
/	O
kg	O
over	O
24	O
h	O
)	O
,	O
resulting	O
in	O
a	O
mean	O
(	O
+	O
/-s.d	O
.	O
)	O

First	O
,	O
we	O
showed	O
that	O
an	O
intravenous	O
administration	O
of	O
human	O
PCC	I-Entity
rapidly	O
reversed	O
anticoagulation	O
in	O
mice	O
.	O

Second	O
,	O
a	O
stereotactic	O
injection	O
of	O
collagenase	O
was	O
administered	O
to	O
induce	O
hemorrhage	I-Entity
in	O
the	O
right	O
striatum	O
.	O

Forty	O
-	O
five	O
minutes	O
later	O
,	O
the	O
animals	O
were	O
randomly	O
treated	O
with	O
PCC	I-Entity
(	O
100	O
U	O
/	O
kg	O
)	O
or	O
saline	O
i.v	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
hemorrhage	I-Entity
induction	O
,	O
hemorrhagic	O
blood	O
volume	O
was	O
quantified	O
using	O
a	O
photometric	O
hemoglobin	O
assay	O
.	O

The	O
mean	O
hemorrhagic	O
blood	O
volume	O
was	O
reduced	O
in	O
PCC	I-Entity
-	O
treated	O
animals	O
(	O
6.5+/-3.1	O
microL	O
)	O
compared	O
with	O
saline	O
controls	O
(	O
15.3+/-11.2	O
microL	O
,	O
P=0.015	O
)	O
.	O

In	O
the	O
saline	O
group	O
,	O
45%	O
of	O
the	O
mice	O
developed	O
large	O
hematomas	I-Entity
(	O
i.e.	O
,	O
>	O
15	O
microL	O
)	O
.	O

In	O
contrast	O
,	O
such	O
extensive	O
lesions	O
were	O
never	O
found	O
in	O
the	O
PCC	I-Entity
group	O
.	O

We	O
provide	O
experimental	O
data	O
suggesting	O
PCC	I-Entity
to	O
be	O
an	O
effective	O
acute	O
treatment	O
for	O
W	O
-	O
ICH	I-Entity
in	O
terms	O
of	O
reducing	O
hemorrhagic	O
blood	O
volume	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
therapeutic	O
potential	O
emerging	O
from	O
our	O
finding	O
for	O
human	O
W	O
-	O
ICH	I-Entity
.	O



Impact	O
of	O
alcohol	I-Entity
exposure	O
after	O
pregnancy	O
recognition	O
on	O
ultrasonographic	O
fetal	O
growth	O
measures	O
.	O

BACKGROUND	O
:	O
More	O
than	O
3	O
decades	O
after	O
Jones	O
and	O
Smith	O
(	O
1973	O
)	O
reported	O
on	O
the	O
devastation	O
caused	O
by	O
alcohol	I-Entity
exposure	O
on	O
fetal	O
development	O
,	O
the	O
rates	O
of	O
heavy	O
drinking	O
during	O
pregnancy	O
remain	O
relatively	O
unchanged	O
.	O

Early	O
identification	O
of	O
fetal	O
alcohol	I-Entity
exposure	O
and	O
maternal	O
abstinence	O
led	O
to	O
better	O
infant	O
outcomes	O
.	O

This	O
study	O
examined	O
the	O
utility	O
of	O
biometry	O
for	O
detecting	O
alcohol	I-Entity
-	O
related	O
fetal	O
growth	B-Entity
impairment	I-Entity
.	O

METHODS	O
:	O
We	O
obtained	O
fetal	O
ultrasound	O
measures	O
from	O
routine	O
ultrasound	O
examinations	O
for	O
167	O
pregnant	O
hazardous	O
drinkers	O
who	O
were	O
enrolled	O
in	O
a	O
brief	O
alcohol	I-Entity
intervention	O
study	O
.	O

Because	O
intensity	O
of	O
alcohol	I-Entity
consumption	O
is	O
associated	O
with	O
poorer	O
fetal	O
outcomes	O
,	O
separate	O
analyses	O
were	O
conducted	O
for	O
the	O
heavy	O
(	O
average	O
of	O
>	O
or=5	O
drinks	O
per	O
drinking	O
day	O
)	O
alcohol	I-Entity
consumers	O
.	O

Analyses	O
of	O
covariance	O
were	O
used	O
to	O
determine	O
whether	O
there	O
were	O
differences	O
between	O
groups	O
after	O
controlling	O
for	O
influences	O
of	O
gestational	O
age	O
and	O
drug	B-Entity
abuse	I-Entity
.	O

When	O
women	O
reportedly	O
quit	O
drinking	O
early	O
in	O
their	O
pregnancies	O
,	O
fetal	O
growth	O
measures	O
were	O
not	O
significantly	O
different	O
from	O
a	O
non	O
-	O
alcohol	I-Entity
-	O
exposed	O
group	O
,	O
regardless	O
of	O
prior	O
drinking	O
patterns	O
.	O

Any	O
alcohol	I-Entity
consumption	O
postpregnancy	O
recognition	O
among	O
the	O
heavy	O
drinkers	O
resulted	O
in	O
reduced	B-Entity
cerebellar	I-Entity
growth	I-Entity
as	O
well	O
as	O
decreased	B-Entity
cranial	I-Entity
to	I-Entity
body	I-Entity
growth	I-Entity
in	O
comparison	O
with	O
women	O
who	O
either	O
quit	O
drinking	O
or	O
who	O
were	O
nondrinkers	O
.	O

Amphetamine	I-Entity
abuse	O
was	O
predictive	O
of	O
larger	O
cranial	O
to	O
body	O
growth	O
ratios	O
.	O

Although	O
the	O
reliance	O
on	O
self	O
-	O
reported	O
drinking	O
is	O
a	O
limitation	O
in	O
this	O
study	O
,	O
these	O
findings	O
support	O
the	O
benefits	O
of	O
early	O
abstinence	O
and	O
the	O
potential	O
for	O
ultrasound	O
examinations	O
in	O
the	O
detection	O
of	O
fetal	O
alcohol	I-Entity
effects	O
.	O



Urinary	O
symptoms	O
and	O
quality	O
of	O
life	O
changes	O
in	O
Thai	O
women	O
with	O
overactive	B-Entity
bladder	I-Entity
after	O
tolterodine	I-Entity
treatment	O
.	O

OBJECTIVES	O
:	O
To	O
study	O
the	O
urinary	O
symptoms	O
and	O
quality	O
of	O
life	O
changes	O
in	O
Thai	O
women	O
with	O
overactive	B-Entity
bladder	I-Entity
(	O
OAB	I-Entity
)	O
after	O
tolterodine	I-Entity
treatment	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
Thirty	O
women	O
(	O
aged	O
30	O
-	O
77	O
years	O
)	O
diagnosed	O
as	O
having	O
OAB	I-Entity
at	O
the	O
Gynecology	O
Clinic	O
,	O
King	O
Chulalongkorn	O
Memorial	O
Hospital	O
from	O
January	O
to	O
April	O
2004	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

Tolterodine	I-Entity
2	O
mg	O
,	O
twice	O
daily	O
was	O
given	O
.	O

The	O
number	O
of	O
nocturia	I-Entity
episodes	O
decreased	O
from	O
5.4	O
+	O
/-	O

The	O
most	O
common	O
side	O
effect	O
was	O
dry	B-Entity
month	I-Entity
in	O
5	O
cases	O
(	O
16.7%	O
)	O
with	O
2	O
cases	O
reporting	O
a	O
moderate	O
degree	O
and	O
1	O
case	O
with	O
severe	O
degree	O
.	O

Only	O
one	O
case	O
(	O
3.3%	O
)	O
withdrew	O
from	O
the	O
present	O
study	O
due	O
to	O
a	O
severe	O
dry	B-Entity
mouth	I-Entity
.	O

Tolterodine	I-Entity
was	O
well	O
tolerated	O
and	O
its	O
effects	O
improved	O
the	O
quality	O
of	O
life	O
in	O
Thai	O
women	O
with	O
OAB	I-Entity
.	O



Absence	O
of	O
acute	O
cerebral	O
vasoconstriction	O
after	O
cocaine	I-Entity
-	O
associated	O
subarachnoid	B-Entity
hemorrhage	I-Entity
.	O

Cocaine	I-Entity
use	O
has	O
been	O
associated	O
with	O
neurovascular	B-Entity
complications	I-Entity
,	O
including	O
arterial	O
vasoconstriction	O
and	O
vasculitis	I-Entity
.	O

However	O
,	O
there	O
are	O
few	O
studies	O
of	O
angiographic	O
effects	O
of	O
cocaine	I-Entity
on	O
human	O
cerebral	O
arteries	O
.	O

Information	O
on	O
these	O
effects	O
could	O
be	O
obtained	O
from	O
angiograms	O
of	O
patients	O
with	O
cocaine	I-Entity
-	O
associated	O
subarachnoid	B-Entity
hemorrhage	I-Entity
(	O
SAH	I-Entity
)	O
who	O
underwent	O
angiography	O
shortly	O
after	O
cocaine	I-Entity
use	O
.	O

METHODS	O
:	O
We	O
screened	O
patients	O
with	O
SAH	I-Entity
retrospectively	O
and	O
identified	O
those	O
with	O
positive	O
urine	O
toxicology	O
for	O
cocaine	I-Entity
or	O
its	O
metabolites	O
.	O

Quantitative	O
arterial	O
diameter	O
measurements	O
from	O
angiograms	O
of	O
these	O
patients	O
were	O
compared	O
to	O
measurements	O
from	O
control	O
patients	O
with	O
SAH	I-Entity
who	O
were	O
matched	O
for	O
factors	O
known	O
to	O
influence	O
arterial	O
diameter	O
.	O

RESULTS	O
:	O
Thirteen	O
patients	O
with	O
positive	O
cocaine	I-Entity
toxicology	O
were	O
compared	O
to	O
26	O
controls	O
.	O

No	O
quantitative	O
evidence	O
for	O
narrowing	O
of	O
large	O
cerebral	O
arteries	O
or	O
qualitative	O
angiographic	O
evidence	O
for	O
distal	O
narrowing	O
or	O
vasculitis	I-Entity
could	O
be	O
found	O
in	O
patients	O
who	O
underwent	O
angiography	O
after	O
aneurysmal	I-Entity
SAH	I-Entity
associated	O
with	O
cocaine	I-Entity
use	O
.	O



Atrial	B-Entity
fibrillation	I-Entity
following	O
chemotherapy	O
for	O
stage	O
IIIE	O
diffuse	O
large	O
B	O
-	O
cell	O
gastric	B-Entity
lymphoma	I-Entity
in	O
a	O
patient	O
with	O
myotonic	B-Entity
dystrophy	I-Entity
(	O
Steinert	B-Entity
's	I-Entity
disease	I-Entity
)	O
.	O

The	O
authors	O
describe	O
the	O
unusual	O
association	O
between	O
diffuse	O
B	O
-	O
cell	O
gastric	B-Entity
lymphoma	I-Entity
and	O
myotonic	B-Entity
dystrophy	I-Entity
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-Entity
dystrophy	I-Entity
,	O
and	O
sudden	O
atrial	B-Entity
fibrillation	I-Entity
following	O
one	O
cycle	O
of	O
doxorubicin	I-Entity
-	O
based	O
chemotherapy	O
in	O
the	O
same	O
patient	O
.	O

Atrial	B-Entity
fibrillation	I-Entity
or	O
other	O
cardiac	B-Entity
arrhythmias	I-Entity
are	O
unusual	O
complications	O
in	O
patients	O
treated	O
with	O
chemotherapy	O
.	O

The	O
cardiac	B-Entity
toxicity	I-Entity
intrinsically	O
associated	O
with	O
the	O
aggressive	O
chemotherapy	O
employed	O
could	O
function	O
as	O
a	O
triggering	O
factor	O
for	O
the	O
arrhythmia	I-Entity
in	O
the	O
predisposed	O
myocardium	O
of	O
this	O
patient	O
.	O



A	O
phase	O
II	O
study	O
of	O
thalidomide	I-Entity
in	O
advanced	O
metastatic	O
renal	B-Entity
cell	I-Entity
carcinoma	I-Entity
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
toxicity	I-Entity
and	O
activity	O
of	O
thalidomide	I-Entity
in	O
patients	O
with	O
advanced	O
metastatic	O
renal	B-Entity
cell	I-Entity
cancer	I-Entity
and	O
to	O
measure	O
changes	O
of	O
one	O
angiogenic	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF)165	O
,	O
with	O
therapy	O
.	O

29	O
patients	O
were	O
enrolled	O
on	O
a	O
study	O
of	O
thalidomide	I-Entity
using	O
an	O
intra	O
-	O
patient	O
dose	O
escalation	O
schedule	O
.	O

Patients	O
began	O
thalidomide	I-Entity
at	O
400	O
mg	O
/	O
d	O
and	O
escalated	O
as	O
tolerated	O
to	O
1200	O
mg	O
/	O
d	O
by	O
day	O
54	O
.	O

RESULTS	O
:	O
24	O
patients	O
were	O
evaluable	O
for	O
response	O
with	O
one	O
partial	O
response	O
of	O
11	O
months	O
duration	O
of	O
a	O
patient	O
with	O
hepatic	O
and	O
pulmonary	O
metastases	I-Entity
(	O
4%	O
)	O
,	O
one	O
minor	O
response	O
,	O
and	O
2	O
patients	O
stable	O
for	O
over	O
6	O
months	O
.	O

Somnolence	I-Entity
and	O
constipation	I-Entity
were	O
prominent	O
toxicities	I-Entity
and	O
most	O
patients	O
could	O
not	O
tolerate	O
the	O
1200	O
mg	O
/	O
day	O
dose	O
level	O
.	O

CONCLUSION	O
:	O
These	O
results	O
are	O
consistent	O
with	O
a	O
low	O
level	O
of	O
activity	O
of	O
thalidomide	I-Entity
in	O
renal	B-Entity
cell	I-Entity
carcinoma	I-Entity
.	O

The	O
dose	O
-	O
response	O
relationship	O
,	O
if	O
any	O
,	O
of	O
thalidomide	I-Entity
for	O
renal	B-Entity
cell	I-Entity
carcinoma	I-Entity
is	O
unclear	O
.	O



The	O
striatum	O
as	O
a	O
target	O
for	O
anti	O
-	O
rigor	O
effects	O
of	O
an	O
antagonist	O
of	O
mGluR1	O
,	O
but	O
not	O
an	O
agonist	O
of	O
group	O
II	O
metabotropic	O
glutamate	I-Entity
receptors	O
.	O

Haloperidol	I-Entity
(	O
1	O
mg	O
/	O
kg	O
ip	O
)	O
induced	O
parkinsonian	I-Entity
-	O
like	O
muscle	B-Entity
rigidity	I-Entity
,	O
measured	O
as	O
an	O
increased	O
resistance	O
of	O
a	O
rat	O
's	O
hind	O
foot	O
to	O
passive	O
flexion	O
and	O
extension	O
at	O
the	O
ankle	O
joint	O
.	O

(	B-Entity
RS)-1-aminoindan-1,5-dicarboxylic	I-Entity
acid	I-Entity
(	O
AIDA	I-Entity
;	O
0.5	O
-	O
15	O
microg/0.5	O
microl	O
)	O
,	O
a	O
potent	O
and	O
selective	O
mGluR1	O
antagonist	O
,	O
or	O
(	B-Entity
2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate	I-Entity
(	O
2R,4R	B-Entity
-	I-Entity
APDC	I-Entity
;	O
7.5	O
-	O
15	O
microg/0.5	O
microl	O
)	O
,	O
a	O
selective	O
group	O
II	O
agonist	O
,	O
was	O
injected	O
bilaterally	O
into	O
the	O
striatum	O
of	O
haloperidol	I-Entity
-	O
treated	O
animals	O
.	O

AIDA	I-Entity
in	O
doses	O
of	O
7.5	O
-	O
15	O
microg/0.5	O
microl	O
diminished	O
the	O
haloperidol	I-Entity
-	O
induced	O
muscle	B-Entity
rigidity	I-Entity
.	O

In	O
contrast	O
,	O
2R,4R	B-Entity
-	I-Entity
APDC	I-Entity
injections	O
were	O
ineffective	O
.	O

The	O
present	O
results	O
may	O
suggest	O
that	O
the	O
blockade	O
of	O
striatal	O
mGluR1	O
,	O
but	O
not	O
the	O
stimulation	O
of	O
group	O
II	O
mGluRs	O
,	O
may	O
ameliorate	O
parkinsonian	I-Entity
muscle	B-Entity
rigidity	I-Entity
.	O



Acute	O
cholestatic	B-Entity
hepatitis	I-Entity
after	O
exposure	O
to	O
isoflurane	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
acute	O
cholestatic	B-Entity
hepatitis	I-Entity
following	O
exposure	O
to	O
the	O
inhalational	O
anesthetic	O
isoflurane	I-Entity
.	O

A	O
70-year	O
-	O
old	O
healthy	O
woman	O
from	O
Iraq	O
developed	O
acute	O
cholestatic	B-Entity
hepatitis	I-Entity
3	O
weeks	O
following	O
repair	O
of	O
the	O
right	O
rotator	O
cuff	O
under	O
general	O
anesthesia	O
.	O

There	O
was	O
no	O
evidence	O
for	O
viral	O
,	O
autoimmune	O
,	O
or	O
metabolic	O
causes	O
of	O
hepatitis	I-Entity
.	O

No	O
other	O
medications	O
were	O
involved	O
except	O
for	O
dipyrone	I-Entity
for	O
analgesia	I-Entity
.	O

The	O
alanine	I-Entity
aminotransferase	O
was	O
elevated	O
to	O
a	O
peak	O
concentration	O
of	O
1533	O
U	O
/	O
L	O
and	O
the	O
serum	O
bilirubin	I-Entity
reached	O
a	O
peak	O
of	O
17.0	O
mg	O
/	O
dL.	O

Accidental	O
reexposure	O
by	O
the	O
patient	O
to	O
dipyrone	I-Entity
was	O
uneventful	O
.	O

The	O
clinical	O
and	O
histologic	O
picture	O
of	O
this	O
case	O
resembles	O
halothane	B-Entity
hepatitis	I-Entity
,	O
which	O
has	O
a	O
significant	O
mortality	O
rate	O
.	O

Isoflurane	I-Entity
,	O
a	O
common	O
anesthetic	O
agent	O
,	O
can	O
cause	O
severe	O
cholestatic	B-Entity
hepatitis	I-Entity
.	O



Calcitonin	O
gene	O
-	O
related	O
peptide	O
levels	O
during	O
nitric	B-Entity
oxide	I-Entity
-	O
induced	O
headache	I-Entity
in	O
patients	O
with	O
chronic	O
tension	B-Entity
-	I-Entity
type	I-Entity
headache	I-Entity
.	O

It	O
has	O
been	O
proposed	O
that	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
induced	O
headache	I-Entity
in	O
primary	B-Entity
headaches	I-Entity
may	O
be	O
associated	O
with	O
release	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
investigate	O
plasma	O
levels	O
of	O
CGRP	O
during	O
headache	I-Entity
induced	O
by	O
the	O
NO	I-Entity
donor	O
glyceryl	B-Entity
trinitrate	I-Entity
(	O
GTN	I-Entity
)	O
in	O
16	O
patients	O
with	O
chronic	O
tension	B-Entity
-	I-Entity
type	I-Entity
headache	I-Entity
and	O
16	O
healthy	O
controls	O
.	O

The	O
subjects	O
were	O
randomly	O
allocated	O
to	O
receive	O
0.5	O
microg	O
/	O
kg	O
/	O
min	O
GTN	I-Entity
or	O
placebo	O
over	O
20	O
min	O
on	O
two	O
headache	I-Entity
-	O
free	O
days	O
.	O

Both	O
patients	O
and	O
controls	O
developed	O
significantly	O
stronger	O
immediate	O
headache	I-Entity
on	O
the	O
GTN	I-Entity
day	O
than	O
on	O
the	O
placebo	O
day	O
and	O
the	O
headache	I-Entity
was	O
significantly	O
more	O
pronounced	O
in	O
patients	O
than	O
in	O
controls	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
area	O
under	O
the	O
CGRP	O
curve	O
(	O
AUCCGRP	O
)	O
on	O
GTN	I-Entity
vs.	O
placebo	O
day	O
in	O
either	O
patients	O
(	O
P=0.65	O
)	O
or	O
controls	O
(	O
P=0.48	O
)	O
.	O

The	O
AUCCGRP	O
recorded	O
on	O
the	O
GTN	I-Entity
day	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
(	O
P=0.36	O
)	O
.	O

Both	O
in	O
patients	O
and	O
controls	O
,	O
CGRP	O
levels	O
changed	O
significantly	O
over	O
time	O
,	O
on	O
both	O
the	O
GTN	I-Entity
and	O
placebo	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
present	O
study	O
indicates	O
that	O
NO	I-Entity
-	O
induced	O
immediate	O
headache	I-Entity
is	O
not	O
associated	O
with	O
release	O
of	O
CGRP	O
.	O



Myocardial	B-Entity
ischemia	I-Entity
due	O
to	O
coronary	B-Entity
artery	I-Entity
spasm	I-Entity
during	O
dobutamine	I-Entity
stress	O
echocardiography	O
.	O

Dobutamine	I-Entity
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
useful	O
and	O
safe	O
provocation	O
test	O
for	O
myocardial	B-Entity
ischemia	I-Entity
.	O

Until	O
now	O
,	O
the	O
test	O
has	O
been	O
focused	O
only	O
on	O
the	O
organic	O
lesion	O
in	O
the	O
coronary	O
artery	O
,	O
and	O
positive	O
DSE	O
has	O
indicated	O
the	O
presence	O
of	O
significant	O
fixed	O
coronary	B-Entity
artery	I-Entity
stenosis	I-Entity
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether	O
myocardial	B-Entity
ischemia	I-Entity
due	O
to	O
coronary	B-Entity
spasm	I-Entity
is	O
induced	O
by	O
dobutamine	I-Entity
.	O

We	O
performed	O
DSE	O
on	O
51	O
patients	O
with	O
coronary	B-Entity
spastic	I-Entity
angina	I-Entity
but	O
without	O
significant	O
fixed	O
coronary	B-Entity
artery	I-Entity
stenosis	I-Entity
.	O

All	O
patients	O
had	O
anginal	I-Entity
attacks	O
at	O
rest	O
with	O
ST	O
elevation	O
on	O
the	O
electrocardiogram	O
(	O
variant	B-Entity
angina	I-Entity
)	O
.	O

Coronary	O
spasm	O
was	O
induced	O
by	O
intracoronary	O
injection	O
of	O
acetylcholine	I-Entity
,	O
and	O
no	O
fixed	O
coronary	B-Entity
artery	I-Entity
stenosis	I-Entity
was	O
documented	O
on	O
angiograms	O
in	O
all	O
patients	O
.	O

DSE	O
was	O
performed	O
with	O
intravenous	O
dobutamine	I-Entity
infusion	O
with	O
an	O
incremental	O
doses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
30	O
,	O
and	O
40	O
microg	O
/	O
kg	O
/	O
min	O
every	O
5	O
minutes	O
.	O

All	O
7	O
patients	O
(	O
13.7%	O
)	O
had	O
chest	B-Entity
pain	I-Entity
during	O
asynergy	O
,	O
and	O
both	O
chest	B-Entity
pain	I-Entity
and	O
electrocardiographic	O
changes	O
were	O
preceded	O
by	O
asynergy	O
.	O

These	O
findings	O
indicate	O
that	O
dobutamine	I-Entity
can	O
provoke	O
coronary	B-Entity
spasm	I-Entity
in	O
some	O
patients	O
with	O
coronary	B-Entity
spastic	I-Entity
angina	I-Entity
.	O

When	O
DSE	O
is	O
performed	O
to	O
evaluate	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
,	O
not	O
only	O
fixed	O
coronary	B-Entity
stenosis	I-Entity
,	O
but	O
also	O
coronary	B-Entity
spasm	I-Entity
should	O
be	O
considered	O
as	O
a	O
genesis	O
of	O
asynergy	O
.	O



Nitric	B-Entity
oxide	I-Entity
synthase	O
expression	O
in	O
the	O
course	O
of	O
lead	I-Entity
-	O
induced	O
hypertension	I-Entity
.	O

We	O
recently	O
showed	O
elevated	O
reactive	O
oxygen	I-Entity
species	O
(	O
ROS	O
)	O
,	O
reduced	O
urinary	O
excretion	O
of	O
NO	I-Entity
metabolites	O
(	O
NOx	O
)	O
,	O
and	O
increased	O
NO	I-Entity
sequestration	O
as	O
nitrotyrosine	I-Entity
in	O
various	O
tissues	O
in	O
rats	O
with	O
lead	I-Entity
-	O
induced	O
hypertension	I-Entity
.	O

This	O
study	O
was	O
designed	O
to	O
discern	O
whether	O
the	O
reduction	O
in	O
urinary	O
NOx	O
in	O
lead	I-Entity
-	O
induced	O
hypertension	I-Entity
is	O
,	O
in	O
part	O
,	O
due	O
to	O
depressed	O
NO	I-Entity
synthase	O
(	O
NOS	O
)	O
expression	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
randomly	O
assigned	O
to	O
a	O
lead	I-Entity
-	O
treated	O
group	O
(	O
given	O
lead	B-Entity
acetate	I-Entity
,	O
100	O
ppm	O
,	O
in	O
drinking	O
water	O
and	O
regular	O
rat	O
chow	O
)	O
,	O
a	O
group	O
given	O
lead	I-Entity
and	O
vitamin	B-Entity
E	I-Entity
-	O
fortified	O
chow	O
,	O
or	O
a	O
normal	O
control	O
group	O
given	O
either	O
regular	O
food	O
and	O
water	O
or	O
vitamin	B-Entity
E	I-Entity
-	O
fortified	O
food	O
for	O
12	O
weeks	O
.	O

Tail	O
blood	O
pressure	O
,	O
urinary	O
NOx	O
excretion	O
,	O
plasma	O
malondialdehyde	I-Entity
(	O
MDA	I-Entity
)	O
,	O
and	O
endothelial	O
and	O
inducible	O
NOS	O
(	O
eNOS	O
and	O
iNOS	O
)	O
isotypes	O
in	O
the	O
aorta	O
and	O
kidney	O
were	O
measured	O
.	O

The	O
lead	I-Entity
-	O
treated	O
group	O
exhibited	O
a	O
rise	O
in	O
blood	O
pressure	O
and	O
plasma	O
MDA	I-Entity
concentration	O
,	O
a	O
fall	O
in	O
urinary	O
NOx	O
excretion	O
,	O
and	O
a	O
paradoxical	O
rise	O
in	O
vascular	O
and	O
renal	O
tissue	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

Vitamin	B-Entity
E	I-Entity
supplementation	O
ameliorated	O
hypertension	I-Entity
,	O
lowered	O
plasma	O
MDA	I-Entity
concentration	O
,	O
and	O
raised	O
urinary	O
NOx	O
excretion	O
while	O
significantly	O
lowering	O
vascular	O
,	O
but	O
not	O
renal	O
,	O
tissue	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

Vitamin	B-Entity
E	I-Entity
supplementation	O
had	O
no	O
effect	O
on	O
either	O
blood	O
pressure	O
,	O
plasma	O
MDA	I-Entity
,	O
or	O
NOS	O
expression	O
in	O
the	O
control	O
group	O
.	O

The	O
study	O
also	O
revealed	O
significant	O
inhibition	O
of	O
NOS	O
enzymatic	O
activity	O
by	O
lead	I-Entity
in	O
cell	O
-	O
free	O
preparations	O
.	O

In	O
conclusion	O
,	O
lead	I-Entity
-	O
induced	O
hypertension	I-Entity
in	O
this	O
model	O
was	O
associated	O
with	O
a	O
compensatory	O
upregulation	O
of	O
renal	O
and	O
vascular	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

NO	I-Entity
inactivation	O
,	O
lead	I-Entity
-	O
associated	O
inhibition	O
of	O
NOS	O
activity	O
,	O
and	O
perhaps	O
stimulatory	O
actions	O
of	O
increased	O
shear	O
stress	O
associated	O
with	O
hypertension	I-Entity
.	O



Risk	O
for	O
valvular	B-Entity
heart	I-Entity
disease	I-Entity
among	O
users	O
of	O
fenfluramine	I-Entity
and	O
dexfenfluramine	I-Entity
who	O
underwent	O
echocardiography	O
before	O
use	O
of	O
medication	O
.	O

Because	O
uncontrolled	O
echocardiographic	O
surveys	O
suggested	O
that	O
up	O
to	O
30%	O
to	O
38%	O
of	O
users	O
of	O
fenfluramine	I-Entity
and	O
dexfenfluramine	I-Entity
had	O
valvular	B-Entity
disease	I-Entity
,	O
these	O
drugs	O
were	O
withdrawn	O
from	O
the	O
market	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
risk	O
for	O
new	O
or	O
worsening	O
valvular	B-Entity
abnormalities	I-Entity
among	O
users	O
of	O
fenfluramine	I-Entity
or	O
dexfenfluramine	I-Entity
who	O
underwent	O
echocardiography	O
before	O
they	O
began	O
to	O
take	O
these	O
medications	O
.	O

PATIENTS	O
:	O
46	O
patients	O
who	O
used	O
fenfluramine	I-Entity
or	O
dexfenfluramine	I-Entity
for	O
14	O
days	O
or	O
more	O
and	O
had	O
echocardiograms	O
obtained	O
before	O
therapy	O
.	O

The	O
primary	O
outcome	O
was	O
new	O
or	O
worsening	O
valvulopathy	I-Entity
,	O
defined	O
as	O
progression	O
of	O
either	O
aortic	B-Entity
or	I-Entity
mitral	I-Entity
regurgitation	I-Entity
by	O
at	O
least	O
one	O
degree	O
of	O
severity	O
and	O
disease	O
that	O
met	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
criteria	O
(	O
at	O
least	O
mild	O
aortic	B-Entity
regurgitation	I-Entity
or	O
moderate	O
mitral	B-Entity
regurgitation	I-Entity
)	O
.	O

RESULTS	O
:	O
Two	O
patients	O
(	O
4.3%	O
[	O
95%	O
CI	O
,	O
0.6%	O
to	O
14.8%	O
]	O
)	O
receiving	O
fenfluramine	I-Entity
-	O
phentermine	I-Entity
developed	O
valvular	B-Entity
heart	I-Entity
disease	I-Entity
.	O

One	O
had	O
baseline	O
bicuspid	B-Entity
aortic	I-Entity
valve	I-Entity
and	O
mild	O
aortic	B-Entity
regurgitation	I-Entity
that	O
progressed	O
to	O
moderate	O
regurgitation	O
.	O

The	O
second	O
patient	O
developed	O
new	O
moderate	O
aortic	B-Entity
insufficiency	I-Entity
.	O

Users	O
of	O
diet	O
medications	O
are	O
at	O
risk	O
for	O
valvular	B-Entity
heart	I-Entity
disease	I-Entity
.	O



Carboplatin	I-Entity
toxic	O
effects	O
on	O
the	O
peripheral	O
nervous	O
system	O
of	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
The	O
most	O
striking	O
of	O
carboplatin	I-Entity
's	O
advantages	O
(	O
CBDCA	I-Entity
)	O
over	O
cisplatin	I-Entity
(	O
CDDP	I-Entity
)	O
is	O
its	O
markedly	O
reduced	O
rate	O
of	O
neurotoxic	I-Entity
effects	O
.	O

However	O
,	O
the	O
use	O
of	O
CBDCA	I-Entity
higher	O
-	O
intensity	O
schedules	O
and	O
the	O
association	O
with	O
other	O
neurotoxic	I-Entity
drugs	O
in	O
polychemotherapy	O
may	O
cause	O
some	O
concern	O
about	O
its	O
safety	O
with	O
respect	O
to	O
peripheral	B-Entity
nervous	I-Entity
system	I-Entity
damage	I-Entity
.	O

Two	O
different	O
schedules	O
of	O
CBDCA	I-Entity
administration	O
(	O
10	O
mg	O
/	O
kg	O
and	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O

Neurotoxicity	I-Entity
was	O
assessed	O
for	O
behavioral	O
(	O
tail	O
-	O
flick	O
test	O
)	O
,	O
neurophysiological	O
(	O
nerve	O
conduction	O
velocity	O
in	O
the	O
tail	O
nerve	O
)	O
,	O
morphological	O
,	O
morphometrical	O
and	O
analytical	O
effects	O
.	O

CBDCA	I-Entity
administration	O
induced	O
dose	O
-	O
dependent	O
peripheral	B-Entity
neurotoxicity	I-Entity
.	O

Pain	I-Entity
perception	O
and	O
nerve	O
conduction	O
velocity	O
in	O
the	O
tail	O
were	O
significantly	O
impaired	O
,	O
particularly	O
after	O
the	O
high	O
-	O
dose	O
treatment	O
.	O

The	O
dorsal	O
root	O
ganglia	O
sensory	O
neurons	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
satellite	O
cells	O
showed	O
the	O
same	O
changes	O
as	O
those	O
induced	O
by	O
CDDP	I-Entity
,	O
mainly	O
affecting	O
the	O
nucleus	O
and	O
nucleolus	O
of	O
ganglionic	O
sensory	O
neurons	O
.	O

Moreover	O
,	O
significant	O
amounts	O
of	O
platinum	I-Entity
were	O
detected	O
in	O
the	O
dorsal	O
root	O
ganglia	O
and	O
kidney	O
after	O
CBDCA	I-Entity
treatment	O
.	O

CBDCA	I-Entity
is	O
neurotoxic	I-Entity
in	O
our	O
model	O
,	O
and	O
the	O
type	O
of	O
pathological	O
changes	O
it	O
induces	O
are	O
so	O
closely	O
similar	O
to	O
those	O
caused	O
by	O
CDDP	I-Entity
that	O
it	O
is	O
probable	O
that	O
neurotoxicity	I-Entity
is	O
induced	O
in	O
the	O
two	O
drugs	O
by	O
the	O
same	O
mechanism	O
.	O

This	O
model	O
can	O
be	O
used	O
alone	O
or	O
in	O
combination	O
with	O
other	O
drugs	O
to	O
explore	O
the	O
effect	O
of	O
CBDCA	I-Entity
on	O
the	O
peripheral	O
nervous	O
system	O
.	O



Iatrogenic	O
risks	O
of	O
endometrial	B-Entity
carcinoma	I-Entity
after	O
treatment	O
for	O
breast	B-Entity
cancer	I-Entity
in	O
a	O
large	O
French	O
case	O
-	O
control	O
study	O
.	O

Since	O
tamoxifen	I-Entity
is	O
widely	O
used	O
in	O
breast	B-Entity
cancer	I-Entity
treatment	O
and	O
has	O
been	O
proposed	O
for	O
the	O
prevention	O
of	O
breast	B-Entity
cancer	I-Entity
,	O
its	O
endometrial	O
iatrogenic	O
effects	O
must	O
be	O
carefully	O
examined	O
.	O

We	O
have	O
investigated	O
the	O
association	O
between	O
endometrial	B-Entity
cancer	I-Entity
and	O
tamoxifen	I-Entity
use	O
or	O
other	O
treatments	O
in	O
women	O
treated	O
for	O
breast	B-Entity
cancer	I-Entity
in	O
a	O
case	O
-	O
control	O
study	O
.	O

Cases	O
of	O
endometrial	B-Entity
cancer	I-Entity
diagnosed	O
after	O
breast	B-Entity
cancer	I-Entity
(	O
n	O
=	O
135	O
)	O
and	O
467	O
controls	O
matched	O
for	O
age	O
,	O
year	O
of	O
diagnosis	O
of	O
breast	B-Entity
cancer	I-Entity
and	O
hospital	O
and	O
survival	O
time	O
with	O
an	O
intact	O
uterus	O
were	O
included	O
.	O

Women	O
who	O
had	O
received	O
tamoxifen	I-Entity
were	O
significantly	O
more	O
likely	O
to	O
have	O
endometrial	B-Entity
cancer	I-Entity
diagnosed	O
than	O
those	O
who	O
had	O
not	O
(	O
crude	O
relative	O
risk	O
=	O
4.9	O
,	O
p	O
=	O
0.0001	O
)	O
.	O

Univariate	O
and	O
adjusted	O
analyses	O
showed	O
that	O
the	O
risk	O
increased	O
with	O
the	O
length	O
of	O
treatment	O
(	O
p	O
=	O
0.0001	O
)	O
or	O
the	O
cumulative	O
dose	O
of	O
tamoxifen	I-Entity
received	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
irrespective	O
of	O
the	O
daily	O
dose	O
.	O

After	O
adjusting	O
for	O
confounding	O
factors	O
,	O
the	O
risk	O
was	O
higher	O
for	O
tamoxifen	I-Entity
users	O
(	O
p	O
=	O
0.0012	O
)	O
,	O

Women	O
who	O
had	O
endometrial	B-Entity
cancer	I-Entity
and	O
had	O
received	O
tamoxifen	I-Entity
had	O
more	O
advanced	B-Entity
disease	I-Entity
and	O
poorer	O
prognosis	O
than	O
those	O
with	O
endometrial	B-Entity
cancer	I-Entity
who	O
had	O
not	O
received	O
this	O
treatment	O
.	O

Our	O
results	O
suggest	O
a	O
causal	O
role	O
of	O
tamoxifen	I-Entity
in	O
endometrial	B-Entity
cancer	I-Entity
,	O
particularly	O
when	O
used	O
as	O
currently	O
proposed	O
for	O
breast	B-Entity
cancer	I-Entity
prevention	O
.	O

Pelvic	O
radiotherapy	O
may	O
be	O
an	O
additional	O
iatrogenic	O
factor	O
for	O
women	O
with	O
breast	B-Entity
cancer	I-Entity
.	O

Endometrial	B-Entity
cancers	I-Entity
diagnosed	O
in	O
women	O
treated	O
with	O
tamoxifen	I-Entity
have	O
poorer	O
prognosis	O
.	O

Women	O
who	O
receive	O
tamoxifen	I-Entity
for	O
breast	B-Entity
cancer	I-Entity
should	O
be	O
offered	O
gynaecological	O
surveillance	O
during	O
and	O
after	O
treatment	O
.	O

A	O
long	O
-	O
term	O
evaluation	O
of	O
the	O
risk	O
-	O
benefit	O
ratio	O
of	O
tamoxifen	I-Entity
as	O
a	O
preventive	O
treatment	O
for	O
breast	B-Entity
cancer	I-Entity
is	O
clearly	O
warranted	O
.	O



Granulosa	B-Entity
cell	I-Entity
tumor	I-Entity
of	I-Entity
the	I-Entity
ovary	I-Entity
associated	O
with	O
antecedent	O
tamoxifen	I-Entity
use	O
.	O

BACKGROUND	O
:	O
Increased	O
attention	O
has	O
been	O
focused	O
recently	O
on	O
the	O
estrogenic	O
effects	O
of	O
tamoxifen	I-Entity
.	O

Review	O
of	O
the	O
literature	O
reveals	O
an	O
association	O
between	O
tamoxifen	I-Entity
use	O
and	O
gynecologic	O
tumors	I-Entity
.	O

A	O
52-year	O
-	O
old	O
postmenopausal	O
woman	O
was	O
treated	O
with	O
tamoxifen	I-Entity
for	O
stage	O
II	O
estrogen	I-Entity
receptor	O
-	O
positive	O
breast	B-Entity
carcinoma	I-Entity
.	O

Her	O
aspartate	I-Entity
transaminase	O
and	O
alanine	I-Entity
transaminase	O
levels	O
increase	O
markedly	O
after	O
6	O
months	O
of	O
tamoxifen	I-Entity
use	O
.	O

After	O
an	O
additional	O
17	O
months	O
of	O
elevated	O
serum	O
transaminases	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
a	O
stage	O
Ic	O
granulosa	B-Entity
cell	I-Entity
tumor	I-Entity
of	I-Entity
the	I-Entity
ovary	I-Entity
.	O

Patients	O
with	O
tamoxifen	I-Entity
-	O
induced	O
liver	B-Entity
dysfunction	I-Entity
may	O
be	O
at	O
increased	O
risk	O
for	O
granulosa	B-Entity
cell	I-Entity
tumors	I-Entity
because	O
of	O
alterations	O
in	O
tamoxifen	I-Entity
metabolism	O
.	O



A	O
murine	O
model	O
of	O
adenomyosis	I-Entity
:	O
the	O
effects	O
of	O
hyperprolactinemia	I-Entity
induced	O
by	O
fluoxetine	B-Entity
hydrochloride	I-Entity
,	O
a	O
selective	O
serotonin	I-Entity
reuptake	O
inhibitor	O
,	O
on	O
adenomyosis	I-Entity
induction	O
in	O
Wistar	O
albino	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
fluoxetine	I-Entity
given	O
to	O
castrated	O
and	O
noncastrated	O
rats	O
caused	O
hyperprolactinemia	I-Entity
and	O
its	O
effects	O
with	O
respect	O
to	O
adenomyosis	I-Entity
.	O

Fluoxetine	I-Entity
,	O
a	O
serotonin	I-Entity
reuptake	O
inhibitor	O
,	O
was	O
given	O
to	O
Wistar	O
Albino	O
rats	O
for	O
98	O
days	O
to	O
produce	O
hyperprolactinemia	I-Entity
.	O

The	O
prolactin	O
levels	O
of	O
castrated	O
and	O
noncastrated	O
groups	O
treated	O
with	O
fluoxetine	I-Entity
were	O
statistically	O
significantly	O
higher	O
when	O
compared	O
to	O
their	O
respective	O
control	O
groups	O
.	O

Histological	O
studies	O
revealed	O
11	O
cases	O
of	O
adenomyosis	I-Entity
,	O
all	O
within	O
the	O
noncastrated	O
group	O
receiving	O
fluoxetine	I-Entity
.	O

It	O
was	O
suggested	O
that	O
high	O
serum	O
prolactin	O
levels	O
cause	O
degeneration	O
of	O
myometrial	O
cells	O
in	O
the	O
presence	O
of	O
ovarian	O
steroids	I-Entity
that	O
results	O
in	O
a	O
myometrial	O
invasion	O
by	O
endometrial	O
stroma	O
.	O

This	O
invasion	O
eventually	O
progresses	O
to	O
adenomyosis	I-Entity
.	O



Effects	O
of	O
deliberate	O
hypotension	I-Entity
induced	O
by	O
labetalol	I-Entity
with	O
isoflurane	I-Entity
on	O
neuropsychological	O
function	O
.	O

The	O
effect	O
of	O
deliberate	O
hypotension	I-Entity
on	O
brain	O
function	O
measured	O
by	O
neuropsychological	O
tests	O
was	O
studied	O
in	O
41	O
adult	O
patients	O
.	O

Twenty	O
-	O
four	O
patients	O
were	O
anaesthetized	O
for	O
middle	O
-	O
ear	O
surgery	O
with	O
deliberate	O
hypotension	I-Entity
induced	O
by	O
labetalol	I-Entity
with	O
isoflurane	I-Entity
(	O
hypotensive	I-Entity
group	O
)	O
.	O

Seventeen	O
patients	O
without	O
hypotension	I-Entity
served	O
as	O
a	O
control	O
group	O
.	O

0.3	O
kPa	O
)	O
before	O
hypotension	I-Entity
and	O
50	O
+	O
/-	O

0.0	O
kPa	O
)	O
during	O
hypotension	I-Entity
in	O
the	O
hypotensive	I-Entity
group	O
,	O
and	O
86	O
+	O
/-	O

The	O
following	O
psychological	O
tests	O
were	O
performed	O
:	O
four	O
subtests	O
of	O
the	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
(	O
similarities	O
,	O
digit	O
span	O
,	O
vocabulary	O
and	O
digit	O
symbol	O
)	O
,	O
Trail	O
-	O
Making	O
tests	O
A	O
and	O
B	O
,	O
Zung	O
tests	O
(	O
self	O
-	O
rating	O
anxiety	I-Entity
scale	O
and	O
self	O
-	O
rating	O
depression	I-Entity
scale	O
)	O
and	O
two	O
-	O
part	O
memory	O
test	O
battery	O
with	O
immediate	O
and	O
delayed	O
recall	O
.	O

The	O
results	O
indicate	O
that	O
hypotension	I-Entity
induced	O
by	O
labetalol	I-Entity
with	O
isoflurane	I-Entity
has	O
no	O
significant	O
harmful	O
effects	O
on	O
mental	O
functions	O
compared	O
to	O
normotensive	O
anaesthesia	O
.	O



Bupivacaine	I-Entity
0.75%	O
with	O
adrenaline	I-Entity
was	O
given	O
followed	O
by	O
a	O
24-hr	O
continuous	O
infusion	O
of	O
0.25%	O
bupivacaine	I-Entity
.	O

In	O
four	O
patients	O
hearing	B-Entity
impairment	I-Entity
on	O
the	O
side	O
of	O
the	O
block	O
was	O
demonstrated	O
after	O
operation	O
,	O
in	O
three	O
measurements	O
on	O
the	O
day	O
of	O
surgery	O
and	O
in	O
one	O
on	O
the	O
following	O
day	O
.	O

The	O
maximum	O
change	O
in	O
threshold	O
was	O
35	O
dB	O
at	O
6	O
kHz	O
measured	O
at	O
the	O
end	O
of	O
the	O
continuous	O
infusion	O
of	O
bupivacaine	I-Entity
.	O

IBPB	O
may	O
cause	O
transient	O
auditory	B-Entity
dysfunction	I-Entity
in	O
the	O
ipsilateral	O
ear	O
,	O
possibly	O
via	O
an	O
effect	O
on	O
sympathetic	O
innervation	O
.	O



Midazolam	I-Entity
compared	O
with	O
thiopentone	I-Entity
as	O
an	O
induction	O
agent	O
.	O

In	O
patients	O
premedicated	O
with	O
scopolamine	I-Entity
+	O
morphine	I-Entity
(	O
+	O
5	O
mg	O
nitrazepam	I-Entity
the	O
evening	O
before	O
surgery	O
)	O
,	O
the	O
sleep	O
-	O
inducing	O
effect	O
of	O
midazolam	I-Entity
0.15	O
mg	O
/	O
kg	O
i.v	O
.	O
was	O
clearly	O
slower	O
in	O
onset	O
than	O
that	O
of	O
thiopentone	I-Entity
4.67	O
mg	O
/	O
kg	O
i.v	O
.	O

Somewhat	O
fewer	O
cardiovascular	O
and	O
local	O
sequelae	O
were	O
found	O
in	O
the	O
midazolam	I-Entity
group	O
,	O
but	O
,	O
although	O
apnoea	I-Entity
occurred	O
less	O
often	O
in	O
the	O
midazolam	I-Entity
group	O
it	O
lasted	O
longer	O
.	O

On	O
the	O
whole	O
,	O
the	O
differences	O
between	O
midazolam	I-Entity
and	O
thiopentone	I-Entity
had	O
no	O
apparent	O
clinical	O
consequences	O
.	O

Midazolam	I-Entity
is	O
a	O
new	O
alternative	O
agent	O
for	O
induction	O
in	O
combination	O
anaesthesia	O
.	O



Cardiotoxic	I-Entity
and	O
possible	O
leukemogenic	O
effects	O
of	O
adriamycin	I-Entity
in	O
nonhuman	O
primates	O
.	O

10	O
monkeys	O
(	O
macaques	O
)	O
received	O
adriamycin	I-Entity
by	O
monthly	O
intravenous	O
injections	O
at	O
12	O
mg	O
/	O
m2	O
(	O
1	O
mg	O
/	O
kg	O
)	O
.	O

8	O
of	O
the	O
10	O
monkeys	O
developed	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
at	O
an	O
average	O
cumulative	O
adriamycin	I-Entity
dose	O
(	O
310	O
mg	O
/	O
m2	O
)	O
well	O
below	O
that	O
considered	O
the	O
safe	O
upper	O
limit	O
(	O
550	O
mg	O
/	O
m2	O
)	O
in	O
man	O
.	O

Histologically	O
,	O
the	O
myocardial	B-Entity
lesions	I-Entity
resembled	O
those	O
found	O
in	O
human	O
anthracycline	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
.	O

1	O
of	O
the	O
10	O
monkeys	O
developed	O
acute	B-Entity
myeloblastic	I-Entity
leukemia	I-Entity
after	O
receiving	O
324	O
mg	O
/	O
m2	O
of	O
adriamycin	I-Entity
;	O
the	O
10th	O
monkey	O
is	O
alive	O
and	O
well	O
26	O
months	O
after	O
the	O
last	O
dose	O
of	O
drug	O
.	O

Our	O
results	O
suggest	O
that	O
adriamycin	I-Entity
is	O
a	O
more	O
potent	O
cardiotoxin	O
in	O
monkeys	O
than	O
in	O
man	O
,	O
and	O
that	O
leukemia	I-Entity
may	O
be	O
a	O
consequence	O
of	O
prolonged	O
treatment	O
with	O
this	O
drug	O
.	O



Doxorubicin	I-Entity
cardiomyopathy	I-Entity
in	O
children	O
with	O
left	O
-	O
sided	O
Wilms	B-Entity
tumor	I-Entity
.	O

Two	O
children	O
with	O
Wilms	B-Entity
tumor	I-Entity
of	O
the	O
left	O
kidney	O
experienced	O
severe	O
anthracycline	I-Entity
cardiomyopathy	I-Entity
after	O
irradiation	O
to	O
the	O
tumor	I-Entity
bed	O
and	O
conventional	O
dosage	O
of	O
doxorubicin	I-Entity
.	O

The	O
cardiomyopathy	I-Entity
is	O
attributed	O
1	O
)	O
to	O
the	O
fact	O
that	O
radiation	O
fields	O
for	O
left	O
Wilms	B-Entity
tumor	I-Entity
include	O
the	O
lower	O
portion	O
of	O
the	O
heart	O
and	O
2	O
)	O
to	O
the	O
interaction	O
of	O
doxorubicin	I-Entity
and	O
irradiation	O
on	O
cardiac	O
muscle	O
.	O

It	O
is	O
recommended	O
that	O
doxorubicin	I-Entity
dosage	O
be	O
sharply	O
restricted	O
in	O
children	O
with	O
Wilms	B-Entity
tumor	I-Entity
of	O
the	O
left	O
kidney	O
who	O
receive	O
postoperative	O
irradiation	O
.	O



Promotional	O
effects	O
of	O
testosterone	I-Entity
and	O
dietary	O
fat	O
on	O
prostate	O
carcinogenesis	I-Entity
in	O
genetically	O
susceptible	O
rats	O
.	O

Wistar	O
(	O
LW	O
)	O
rats	O
,	O
fed	O
vegetable	O
diet	O
L-485	O
,	O
have	O
developed	O
prostate	B-Entity
adenocarcinomas	I-Entity
spontaneously	O
(	O
10%	O
incidence	O
)	O
at	O
average	O
age	O
34	O
months	O
.	O

Conventional	O
LW	O
rats	O
,	O
implanted	O
with	O
testosterone	I-Entity
at	O
age	O
4	O
months	O
,	O
developed	O
a	O
higher	O
incidence	O
of	O
prostate	B-Entity
cancer	I-Entity
after	O
an	O
average	O
interval	O
of	O
14	O
months	O
:	O
24%	O
had	O
developed	O
gross	O
tumors	I-Entity
,	O
and	O
40%	O
when	O
it	O
included	O
microscopic	O
tumors	I-Entity
.	O

Preliminary	O
results	O
indicate	O
that	O
testosterone	I-Entity
-	O
treated	O
LW	O
rats	O
that	O
were	O
fed	O
the	O
same	O
diet	O
,	O
which	O
was	O
supplemented	O
with	O
corn	O
oil	O
up	O
to	O
20%	O
fat	O
,	O
developed	O
prostate	B-Entity
cancer	I-Entity
after	O
intervals	O
of	O
6	O
-	O
12	O
months	O
.	O

rats	O
have	O
not	O
developed	O
prostate	B-Entity
cancer	I-Entity
spontaneously	O
.	O

Conventional	O
SD	O
rats	O
fed	O
diet	O
L-485	O
and	O
treated	O
with	O
testosterone	I-Entity
developed	O
only	O
prostatitis	I-Entity
.	O

Experimental	O
designs	O
should	O
consider	O
genetic	O
susceptibility	O
as	O
a	O
basic	O
prerequisite	O
for	O
studies	O
on	O
experimental	O
prostate	B-Entity
cancer	I-Entity
.	O



Mitomycin	B-Entity
C	I-Entity
associated	O
hemolytic	B-Entity
uremic	I-Entity
syndrome	I-Entity
.	O

Mitomycin	B-Entity
C	I-Entity
associated	O
Hemolytic	B-Entity
Uremic	I-Entity
Syndrome	I-Entity
(	O
HUS	I-Entity
)	O
is	O
a	O
potentially	O
fatal	O
but	O
uncommon	O
condition	O
that	O
is	O
not	O
yet	O
widely	O
recognised	O
.	O

It	O
consists	O
of	O
microangiopathic	O
hemolytic	B-Entity
anemia	I-Entity
,	O
thrombocytopenia	I-Entity
and	O
progressive	O
renal	B-Entity
failure	I-Entity
associated	O
with	O
mitomycin	B-Entity
C	I-Entity
treatment	O
and	O
affects	O
about	O
10%	O
of	O
patients	O
treated	O
with	O
this	O
agent	O
.	O

The	O
renal	B-Entity
failure	I-Entity
usually	O
develops	O
about	O
8	O
-	O
10	O
mth	O
after	O
start	O
of	O
mitomycin	B-Entity
C	I-Entity
treatment	O
and	O
the	O
mortality	O
is	O
approximately	O
60%	O
from	O
renal	B-Entity
failure	I-Entity
or	O
pulmonary	B-Entity
edema	I-Entity
.	O

Renal	B-Entity
lesions	I-Entity
are	O
similar	O
to	O
those	O
seen	O
in	O
idiopathic	O
HUS	I-Entity
and	O
include	O
arteriolar	O
fibrin	O
thrombi	I-Entity
,	O
expanded	O
subendothelial	O
zones	O
in	O
glomerular	O
capillary	O
walls	O
,	O
ischemic	I-Entity
wrinkling	O
of	O
glomerular	O
basement	O
membranes	O
and	O
mesangiolysis	O
.	O

The	O
mechanism	O
of	O
action	O
is	O
postulated	O
as	O
mitomycin	B-Entity
C	I-Entity
-	O
induced	O
endothelial	O
cell	O
damage	O
.	O

We	O
describe	O
the	O
clinical	O
course	O
and	O
pathological	O
findings	O
in	O
a	O
65	O
yr	O
-	O
old	O
man	O
with	O
gastric	B-Entity
adenocarcinoma	I-Entity
who	O
developed	O
renal	B-Entity
failure	I-Entity
and	O
thrombocytopenia	I-Entity
while	O
on	O
treatment	O
with	O
mitomycin	B-Entity
C	I-Entity
and	O
died	O
in	O
pulmonary	B-Entity
edema	I-Entity
.	O



Continuous	O
ambulatory	O
ECG	O
monitoring	O
during	O
fluorouracil	I-Entity
therapy	O
:	O
a	O
prospective	O
study	O
.	O

Although	O
there	O
have	O
been	O
anecdotal	O
reports	O
of	O
cardiac	B-Entity
toxicity	I-Entity
associated	O
with	O
fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
therapy	O
,	O
this	O
phenomenon	O
has	O
not	O
been	O
studied	O
in	O
a	O
systematic	O
fashion	O
.	O

We	O
prospectively	O
performed	O
continuous	O
ambulatory	O
ECG	O
monitoring	O
on	O
25	O
patients	O
undergoing	O
5-FU	I-Entity
infusion	O
for	O
treatment	O
of	O
solid	O
tumors	I-Entity
in	O
order	O
to	O
assess	O
the	O
incidence	O
of	O
ischemic	I-Entity
ST	O
changes	O
.	O

4	O
hours	O
before	O
5-FU	I-Entity
infusion	O
,	O
and	O
98	O
+	O
/-	O

9	O
hours	O
during	O
5-FU	I-Entity
infusion	O
.	O

Anginal	I-Entity
episodes	O
were	O
rare	O
:	O
only	O
one	O
patient	O
had	O
angina	I-Entity
(	O
during	O
5-FU	I-Entity
infusion	O
)	O
.	O

However	O
,	O
asymptomatic	O
ST	O
changes	O
(	O
greater	O
than	O
or	O
equal	O
to	O
1	O
mm	O
ST	O
deviation	O
)	O
were	O
common	O
:	O
six	O
of	O
25	O
patients	O
(	O
24%	O
)	O
had	O
ST	O
changes	O
before	O
5-FU	I-Entity
infusion	O
v	O
17	O
(	O
68%	O
)	O
during	O
5-FU	I-Entity
infusion	O
(	O
P	O
less	O
than	O
.002	O
)	O
.	O

The	O
incidence	O
of	O
ischemic	I-Entity
episodes	O
per	O
patient	O
per	O
hour	O
was	O
0.05	O
+	O
/-	O

0.02	O
prior	O
to	O
5-FU	I-Entity
infusion	O
v	O
0.13	O
+	O
/-	O

0.03	O
during	O
5-FU	I-Entity
infusion	O
(	O
P	O
less	O
than	O
.001	O
)	O
;	O
the	O
duration	O
of	O
ECG	O
changes	O
was	O
0.6	O
+	O
/-	O

0.3	O
minutes	O
per	O
patient	O
per	O
hour	O
before	O
5-FU	I-Entity
v	O
1.9	O
+	O
/-	O

0.5	O
minutes	O
per	O
patient	O
per	O
hour	O
during	O
5-FU	I-Entity
(	O
P	O
less	O
than	O
.01	O
)	O
.	O

ECG	O
changes	O
were	O
more	O
common	O
among	O
patients	O
with	O
known	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
.	O

There	O
were	O
two	O
cases	O
of	O
sudden	B-Entity
death	I-Entity
,	O
both	O
of	O
which	O
occurred	O
at	O
the	O
end	O
of	O
the	O
chemotherapy	O
course	O
.	O

We	O
conclude	O
that	O
5-FU	I-Entity
infusion	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
silent	O
ST	O
segment	O
deviation	O
suggestive	O
of	O
ischemia	I-Entity
,	O
particularly	O
among	O
patients	O
with	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
.	O



Lethal	O
anuria	I-Entity
complicating	O
high	O
dose	O
ifosfamide	I-Entity
chemotherapy	O
in	O
a	O
breast	B-Entity
cancer	I-Entity
patient	O
with	O
an	O
impaired	B-Entity
renal	I-Entity
function	I-Entity
.	O

A	O
sixty	O
-	O
year	O
-	O
old	O
woman	O
with	O
advanced	O
breast	B-Entity
cancer	I-Entity
,	O
previously	O
treated	O
with	O
cisplatin	I-Entity
,	O
developed	O
an	O
irreversible	O
lethal	O
renal	B-Entity
failure	I-Entity
with	O
anuria	I-Entity
,	O
the	O
day	O
after	O
5	O
g	O
/	O
m2	O
bolus	O
ifosfamide	I-Entity
.	O

Postrenal	B-Entity
failure	I-Entity
was	O
excluded	O
by	O
echography	O
.	O

A	O
prerenal	O
component	O
could	O
have	O
contributed	O
to	O
renal	B-Entity
failure	I-Entity
because	O
of	O
a	O
transient	O
hypotension	I-Entity
,	O
due	O
to	O
an	O
increasing	O
ascitis	O
,	O
occurring	O
just	O
before	O
anuria	I-Entity
.	O

Ifosfamide	I-Entity
is	O
a	O
known	O
nephrotoxic	I-Entity
drug	O
with	O
demonstrated	O
tubulopathies	I-Entity
.	O

We	O
strongly	O
suspect	O
that	O
this	O
lethal	O
anuria	I-Entity
was	O
mainly	O
due	O
to	O
ifosfamide	I-Entity
,	O
occurring	O
in	O
a	O
patient	O
having	O
received	O
previous	O
cisplatin	I-Entity
chemotherapy	O
and	O
with	O
poor	O
kidney	O
perfusion	O
due	O
to	O
transient	O
hypotension	I-Entity
.	O

We	O
recommend	O
careful	O
use	O
of	O
ifosfamide	I-Entity
in	O
patients	O
pretreated	O
with	O
nephrotoxic	I-Entity
chemotherapy	O
and	O
inadequate	O
renal	O
perfusion	O
.	O



Central	O
vein	B-Entity
thrombosis	I-Entity
and	O
topical	O
dipivalyl	B-Entity
epinephrine	I-Entity
.	O

A	O
report	O
is	O
given	O
on	O
an	O
83-year	O
-	O
old	O
female	O
who	O
acquired	O
central	O
vein	B-Entity
thrombosis	I-Entity
in	O
her	O
seeing	O
eye	O
one	O
day	O
after	O
having	O
started	O
topical	O
medication	O
with	O
dipivalyl	B-Entity
epinephrine	I-Entity
for	O
advanced	O
glaucoma	I-Entity
discovered	O
in	O
the	O
other	O
eye	O
.	O



Amelioration	O
of	O
bendrofluazide	I-Entity
-	O
induced	O
hypokalemia	I-Entity
by	O
timolol	I-Entity
.	O

The	O
beta	O
adrenergic	O
blocking	O
drug	O
,	O
timolol	I-Entity
,	O
tended	O
to	O
correct	O
the	O
hypokalemia	I-Entity
of	O
short	O
-	O
term	O
bendrofluazide	I-Entity
treatment	O
in	O
6	O
healthy	O
male	O
subjects	O
and	O
although	O
the	O
effect	O
was	O
small	O
it	O
was	O
significant	O
.	O

Timolol	I-Entity
also	O
reduced	O
the	O
rise	O
in	O
plasma	O
aldosterone	I-Entity
and	O
urine	O
potassium	I-Entity
excretion	O
following	O
bendrofluazide	I-Entity
and	O
increased	O
the	O
urine	O
sodium	I-Entity
/	O
potassium	I-Entity
ratio	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
shift	O
of	O
potassium	I-Entity
from	O
the	O
intracellular	O
to	O
the	O
extracellular	O
space	O
.	O



A	O
cross	O
-	O
sectional	O
evaluation	O
of	O
the	O
effect	O
of	O
risperidone	I-Entity
and	O
selective	O
serotonin	I-Entity
reuptake	O
inhibitors	O
on	O
bone	O
mineral	O
density	O
in	O
boys	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
risperidone	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
on	O
trabecular	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
children	O
and	O
adolescents	O
.	O

Medically	O
healthy	O
7-	O
to	O
17-year	O
-	O
old	O
males	O
chronically	O
treated	O
,	O
in	O
a	O
naturalistic	O
setting	O
,	O
with	O
risperidone	I-Entity
were	O
recruited	O
for	O
this	O
cross	O
-	O
sectional	O
study	O
through	O
child	O
psychiatry	O
outpatient	O
clinics	O
between	O
November	O
2005	O
and	O
June	O
2007	O
.	O

Hyperprolactinemia	I-Entity
was	O
present	O
in	O
49%	O
of	O
83	O
boys	O
(	O
n	O
=	O
41	O
)	O
treated	O
with	O
risperidone	I-Entity
for	O
a	O
mean	O
of	O
2.9	O
years	O
.	O

Serum	O
testosterone	I-Entity
concentration	O
increased	O
with	O
pubertal	O
status	O
but	O
was	O
not	O
affected	O
by	O
hyperprolactinemia	I-Entity
.	O

Controlling	O
for	O
relevant	O
covariates	O
,	O
we	O
also	O
found	O
treatment	O
with	O
selective	O
serotonin	I-Entity
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
to	O
be	O
associated	O
with	O
lower	O
trabecular	O
BMD	O
at	O
the	O
radius	O
(	O
P	O
=	O
.03	O
)	O
and	O
BMD	O
z	O
score	O
at	O
the	O
lumbar	O
spine	O
(	O
P	O
<	O
.05	O
)	O
.	O

Of	O
13	O
documented	O
fractures	I-Entity
,	O
3	O
occurred	O
after	O
risperidone	I-Entity
and	O
SSRIs	O
were	O
started	O
,	O
and	O
none	O
occurred	O
in	O
patients	O
with	O
hyperprolactinemia	I-Entity
.	O

This	O
is	O
the	O
first	O
study	O
to	O
link	O
risperidone	I-Entity
-	O
induced	O
hyperprolactinemia	I-Entity
and	O
SSRI	O
treatment	O
to	O
lower	O
BMD	O
in	O
children	O
and	O
adolescents	O
.	O



Seizures	I-Entity
associated	O
with	O
levofloxacin	I-Entity
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O

PURPOSE	O
:	O
We	O
present	O
a	O
case	O
of	O
a	O
patient	O
who	O
developed	O
seizures	I-Entity
shortly	O
after	O
initiating	O
treatment	O
with	O
levofloxacin	I-Entity
and	O
to	O
discuss	O
the	O
potential	O
drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
1A2	O
in	O
this	O
case	O
,	O
as	O
well	O
as	O
in	O
other	O
cases	O
,	O
of	O
levofloxacin	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

The	O
main	O
search	O
terms	O
utilized	O
were	O
case	O
report	O
and	O
levofloxacin	I-Entity
.	O

Six	O
cases	O
of	O
levofloxacin	I-Entity
-	O
induced	O
seizures	I-Entity
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

Drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
CYP1A2	O
by	O
levofloxacin	I-Entity
are	O
likely	O
involved	O
in	O
the	O
clinical	O
outcome	O
of	O
these	O
cases	O
.	O

Clinicians	O
are	O
exhorted	O
to	O
pay	O
close	O
attention	O
when	O
initiating	O
levofloxacin	I-Entity
therapy	O
in	O
patients	O
taking	O
medications	O
with	O
epileptogenic	O
properties	O
that	O
are	O
CYP1A2	O
substrates	O
.	O



Mice	O
lacking	O
mPGES-1	O
are	O
resistant	O
to	O
lithium	I-Entity
-	O
induced	O
polyuria	I-Entity
.	O

Cyclooxygenase-2	O
activity	O
is	O
required	O
for	O
the	O
development	O
of	O
lithium	I-Entity
-	O
induced	O
polyuria	I-Entity
.	O

However	O
,	O
the	O
involvement	O
of	O
a	O
specific	O
,	O
terminal	O
prostaglandin	I-Entity
(	O
PG	I-Entity
)	O
isomerase	O
has	O
not	O
been	O
evaluated	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
assess	O
lithium	I-Entity
-	O
induced	O
polyuria	I-Entity
in	O
mice	O
deficient	O
in	O
microsomal	O
prostaglandin	B-Entity
E	I-Entity
synthase-1	O
(	O
mPGES-1	O
)	O
.	O

A	O
2-wk	O
administration	O
of	O
LiCl	I-Entity
(	O
4	O
mmol.kg(-1).day(-1	O
)	O

ip	O
)	O
in	O
mPGES-1	O
+	O
/+	O
mice	O
led	O
to	O
a	O
marked	O
polyuria	I-Entity
with	O
hyposmotic	O
urine	O
.	O

This	O
was	O
associated	O
with	O
elevated	O
renal	O
mPGES-1	O
protein	O
expression	O
and	O
increased	O
urine	O
PGE(2	B-Entity
)	I-Entity

In	O
contrast	O
,	O
mPGES-1	O
-/-	O
mice	O
were	O
largely	O
resistant	O
to	O
lithium	I-Entity
-	O
induced	O
polyuria	I-Entity
and	O
a	O
urine	O
concentrating	O
defect	O
,	O
accompanied	O
by	O
nearly	O
complete	O
blockade	O
of	O
high	O
urine	O
PGE(2	B-Entity
)	I-Entity
and	O
cAMP	O
output	O
.	O

RT	O
-	O
PCR	O
consistently	O
detected	O
a	O
significant	O
decrease	O
in	O
aquaporin-2	O
(	O
AQP2	O
)	O
protein	O
expression	O
in	O
both	O
the	O
renal	O
cortex	O
and	O
medulla	O
of	O
lithium	I-Entity
-	O
treated	O
+	O
/+	O
mice	O
.	O

Similarly	O
,	O
the	O
total	O
protein	O
abundance	O
of	O
the	O
Na	I-Entity
-	O
K-2Cl	I-Entity
cotransporter	O
(	O
NKCC2	O
)	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
of	O
the	O
+	O
/+	O
mice	O
was	O
significantly	O
reduced	O
by	O
lithium	I-Entity
treatment	O
.	O

We	O
conclude	O
that	O
mPGES-1-derived	O
PGE(2	B-Entity
)	I-Entity
mediates	O
lithium	I-Entity
-	O
induced	O
polyuria	I-Entity
likely	O
via	O
inhibition	O
of	O
AQP2	O
and	O
NKCC2	O
expression	O
.	O



Identification	O
of	O
a	O
simple	O
and	O
sensitive	O
microplate	O
method	O
for	O
the	O
detection	O
of	O
oversulfated	O
chondroitin	B-Entity
sulfate	I-Entity
in	O
heparin	I-Entity
products	O
.	O

Heparin	I-Entity
is	O
a	O
commonly	O
implemented	O
anticoagulant	O
used	O
to	O
treat	O
critically	O
ill	O
patients	O
.	O

Recently	O
,	O
a	O
number	O
of	O
commercial	O
lots	O
of	O
heparin	I-Entity
products	O
were	O
found	O
to	O
be	O
contaminated	O
with	O
an	O
oversulfated	O
chondroitin	B-Entity
sulfate	I-Entity
(	O
OSCS	O
)	O
derivative	O
that	O
could	O
elicit	O
a	O
hypotensive	I-Entity
response	O
in	O
pigs	O
following	O
a	O
single	O
high	O
-	O
dose	O
infusion	O
.	O

Using	O
both	O
contaminated	O
heparin	I-Entity
products	O
and	O
the	O
synthetically	O
produced	O
derivative	O
,	O
we	O
showed	O
that	O
the	O
OSCS	O
produces	O
dose	O
-	O
dependent	O
hypotension	I-Entity
in	O
pigs	O
.	O

We	O
also	O
demonstrated	O
that	O
OSCS	O
can	O
be	O
identified	O
in	O
heparin	I-Entity
products	O
using	O
a	O
simple	O
,	O
inexpensive	O
,	O
commercially	O
available	O
heparin	I-Entity
enzyme	O
immunoassay	O
(	O
EIA	O
)	O
kit	O
that	O
has	O
a	O
limit	O
of	O
detection	O
of	O
approximately	O
0.1%	O
,	O
well	O
below	O
the	O
NOEL	O
.	O

This	O
kit	O
may	O
provide	O
a	O
useful	O
method	O
to	O
test	O
heparin	I-Entity
products	O
for	O
contamination	O
with	O
oversulfated	O
GAG	O
derivatives	O
.	O



Doxorubicin	I-Entity
cardiomyopathy	I-Entity
-	O
induced	O
inflammation	I-Entity
and	O
apoptosis	O
are	O
attenuated	O
by	O
gene	O
deletion	O
of	O
the	O
kinin	O
B1	O
receptor	O
.	O

Clinical	O
use	O
of	O
the	O
anthracycline	I-Entity
doxorubicin	I-Entity
(	O
DOX	I-Entity
)	O
is	O
limited	O
by	O
its	O
cardiotoxic	I-Entity
effects	O
,	O
which	O
are	O
attributed	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O

To	O
elucidate	O
the	O
possible	O
role	O
of	O
the	O
kinin	O
B1	O
receptor	O
(	O
B1R	O
)	O
during	O
the	O
development	O
of	O
DOX	I-Entity
cardiomyopathy	I-Entity
,	O
we	O
studied	O
B1R	O
knockout	O
mice	O
(	O
B1R(-/-	O
)	O
)	O
by	O
investigating	O
cardiac	O
inflammation	I-Entity
and	O
apoptosis	O
after	O
induction	O
of	O
DOX	I-Entity
-	O
induced	O
cardiomyopathy	I-Entity
.	O

DOX	I-Entity
control	O
mice	O
showed	O
cardiac	B-Entity
dysfunction	I-Entity
measured	O
by	O
pressure	O
-	O
volume	O
loops	O
in	O
vivo	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduced	O
activation	O
state	O
of	O
AKT	O
,	O
as	O
well	O
as	O
an	O
increased	O
bax	O
/	O
bcl2	O
ratio	O
in	O
Western	O
blots	O
,	O
indicating	O
cardiac	B-Entity
apoptosis	I-Entity
.	O

In	O
DOX	I-Entity
B1R(-/-	O
)	O
mice	O
,	O
cardiac	B-Entity
dysfunction	I-Entity
was	O
improved	O
compared	O
to	O
DOX	I-Entity
control	O
mice	O
,	O
which	O
was	O
associated	O
with	O
normalization	O
of	O
the	O
bax	O
/	O
bcl-2	O
ratio	O
and	O
interleukin	O
6	O
,	O
as	O
well	O
as	O
AKT	O
activation	O
state	O
.	O

These	O
findings	O
suggest	O
that	O
B1R	O
is	O
detrimental	O
in	O
DOX	I-Entity
cardiomyopathy	I-Entity
in	O
that	O
it	O
mediates	O
the	O
inflammatory	O
response	O
and	O
apoptosis	O
.	O

These	O
insights	O
might	O
have	O
useful	O
implications	O
for	O
future	O
studies	O
utilizing	O
B1R	O
antagonists	O
for	O
treatment	O
of	O
human	O
DOX	I-Entity
cardiomyopathy	I-Entity
.	O



Hepatotoxicity	I-Entity
associated	O
with	O
sulfasalazine	I-Entity
in	O
inflammatory	O
arthritis	I-Entity
:	O

We	O
report	O
an	O
investigation	O
from	O
a	O
local	O
surveillance	O
for	O
serious	O
adverse	O
drug	O
reactions	O
associated	O
with	O
disease	O
modifying	O
anti	O
-	O
rheumatic	O
drugs	O
that	O
was	O
triggered	O
by	O
the	O
occurrence	O
of	O
liver	B-Entity
failure	I-Entity
in	O
two	O
of	O
our	O
patients	O
.	O

Patients	O
'	O
,	O
who	O
had	O
hepatotoxicity	I-Entity
on	O
sulfasalazine	I-Entity
and	O
met	O
a	O
definition	O
of	O
a	O
serious	O
ADR	O
,	O
were	O
identified	O
.	O

The	O
likely	O
frequency	O
of	O
hepatotoxicity	I-Entity
with	O
sulfasalazine	I-Entity
was	O
estimated	O
by	O
making	O
a	O
series	O
of	O
conservative	O
assumptions	O
.	O

Eight	O
patients	O
were	O
hospitalised	O
,	O
two	O
in	O
hepatic	B-Entity
failure	I-Entity
-	O
one	O
died	O
after	O
a	O
liver	O
transplant	O
.	O

Seven	O
patients	O
had	O
a	O
skin	B-Entity
rash	I-Entity
,	O
three	O
eosinophilia	I-Entity
and	O
one	O
interstitial	B-Entity
nephritis	I-Entity
.	O

Drug	O
-	O
related	O
hepatotoxicity	I-Entity
was	O
judged	O
probable	O
or	O
highly	O
probable	O
in	O
8	O
patients	O
.	O

The	O
likely	O
frequency	O
of	O
serious	O
hepatotoxicity	I-Entity
with	O
sulfasalazine	I-Entity
was	O
estimated	O
at	O
0.4%	O
of	O
treated	O
patients	O
.	O

CONCLUSION	O
:	O
Serious	O
hepatotoxicity	I-Entity
associated	O
with	O
sulfasalazine	I-Entity
appears	O
to	O
be	O
under	O
-	O
appreciated	O
and	O
intensive	O
monitoring	O
and	O
vigilance	O
in	O
the	O
first	O
6	O
weeks	O
of	O
treatment	O
is	O
especially	O
important	O
.	O



An	O
evaluation	O
of	O
amikacin	I-Entity
nephrotoxicity	I-Entity
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O

Amikacin	I-Entity
is	O
an	O
aminoglycoside	I-Entity
commonly	O
used	O
to	O
provide	O
empirical	O
double	O
gram	O
-	O
negative	O
treatment	O
for	O
febrile	B-Entity
neutropenia	I-Entity
and	O
other	O
suspected	O
infections	I-Entity
.	O

To	O
evaluate	O
amikacin	I-Entity
-	O
associated	O
nephrotoxicity	I-Entity
in	O
an	O
adult	O
hematology	O
/	O
oncology	O
population	O
,	O
a	O
prospective	O
,	O
randomized	O
,	O
open	O
-	O
label	O
trial	O
was	O
conducted	O
at	O
a	O
university	O
-	O
affiliated	O
medical	O
center	O
.	O

Forty	O
patients	O
with	O
a	O
diagnosis	O
consistent	O
with	O
a	O
hematologic	B-Entity
/	I-Entity
oncologic	I-Entity
disorder	I-Entity
that	O
required	O
treatment	O
with	O
an	O
aminoglycoside	I-Entity
were	O
randomized	O
to	O
either	O
conventional	O
or	O
extended	O
-	O
interval	O
amikacin	I-Entity
.	O

The	O
occurrence	O
of	O
nephrotoxicity	I-Entity
by	O
means	O
of	O
an	O
increase	O
in	O
serum	O
creatinine	I-Entity
and	O
evaluation	O
of	O
efficacy	O
via	O
amikacin	I-Entity
serum	O
concentrations	O
with	O
respective	O
pathogens	O
were	O
assessed	O
.	O

The	O
occurrence	O
of	O
nephrotoxicity	I-Entity
was	O
similar	O
between	O
the	O
conventional	O
and	O
extended	O
-	O
interval	O
groups	O
,	O
at	O
10%	O
and	O
5%	O
,	O
respectively	O
(	O
P	O
=	O
1.00	O
)	O
.	O

The	O
occurrence	O
of	O
nephrotoxicity	I-Entity
was	O
similar	O
between	O
the	O
two	O
dosing	O
regimens	O
,	O
but	O
the	O
distribution	O
of	O
risk	O
factors	O
was	O
variable	O
between	O
the	O
two	O
groups	O
.	O



Memory	O
function	O
and	O
serotonin	I-Entity
transporter	O
promoter	O
gene	O
polymorphism	O
in	O
ecstasy	I-Entity
(	O
MDMA	I-Entity
)	O
users	O
.	O

Although	O
3,4-methylenedioxymethamphetamine	I-Entity
(	O
MDMA	I-Entity
or	O
ecstasy	I-Entity
)	O
has	O
been	O
shown	O
to	O
damage	O
brain	O
serotonin	I-Entity
(	O
5-HT	I-Entity
)	O
neurons	O
in	O
animals	O
and	O
possibly	O
humans	O
,	O
little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
consequences	O
of	O
MDMA	I-Entity
-	O
induced	O
5-HT	I-Entity
neurotoxic	B-Entity
lesions	I-Entity
on	O
functions	O
in	O
which	O
5-HT	I-Entity
is	O
involved	O
,	O
such	O
as	O
cognitive	O
function	O
.	O

Because	O
5-HT	I-Entity
transporters	O
play	O
a	O
key	O
element	O
in	O
the	O
regulation	O
of	O
synaptic	O
5-HT	I-Entity
transmission	O
it	O
may	O
be	O
important	O
to	O
control	O
for	O
the	O
potential	O
covariance	O
effect	O
of	O
a	O
polymorphism	O
in	O
the	O
5-HT	I-Entity
transporter	O
promoter	O
gene	O
region	O
(	O
5-HTTLPR	O
)	O
when	O
studying	O
the	O
effects	O
of	O
MDMA	I-Entity
as	O
well	O
as	O
cognitive	O
functioning	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moderate	O
and	O
heavy	O
MDMA	I-Entity
use	O
on	O
cognitive	O
function	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
long	O
-	O
term	O
abstention	O
from	O
MDMA	I-Entity
,	O
in	O
subjects	O
genotyped	O
for	O
5-HTTLPR	O
.	O

Fifteen	O
moderate	O
MDMA	I-Entity
users	O
(	O
<	O
55	O
lifetime	O
tablets	O
)	O
,	O
22	O
heavy	O
MDMA+	I-Entity
users	O
(	O
>	O
55	O
lifetime	O
tablets	O
)	O
,	O
16	O
ex	O
-	O
MDMA+	I-Entity
users	O
(	O
last	O
tablet	O
>	O
1	O
year	O
ago	O
)	O
and	O
13	O
controls	O
were	O
compared	O
on	O
a	O
battery	O
of	O
neuropsychological	O
tests	O
.	O

Heavy	O
and	O
ex	O
-	O
MDMA+	I-Entity
users	O
performed	O
significantly	O
poorer	O
on	O
memory	O
tasks	O
than	O
controls	O
.	O

In	O
contrast	O
,	O
no	O
evidence	O
of	O
memory	B-Entity
impairment	I-Entity
was	O
observed	O
in	O
moderate	O
MDMA	I-Entity
users	O
.	O

While	O
the	O
use	O
of	O
MDMA	I-Entity
in	O
quantities	O
that	O
may	O
be	O
considered	O
""""	O
moderate	O
""""	O
is	O
not	O
associated	O
with	O
impaired	B-Entity
memory	I-Entity
functioning	I-Entity
,	O
heavy	O
use	O
of	O
MDMA	I-Entity
use	O
may	O
lead	O
to	O
long	O
lasting	O
memory	B-Entity
impairments	I-Entity
.	O

No	O
effect	O
of	O
5-HTTLPR	O
or	O
gender	O
on	O
memory	O
function	O
or	O
MDMA	I-Entity
use	O
was	O
observed	O
.	O



Aging	O
process	O
of	O
epithelial	O
cells	O
of	O
the	O
rat	O
prostate	O
lateral	O
lobe	O
in	O
experimental	O
hyperprolactinemia	I-Entity
induced	O
by	O
haloperidol	I-Entity
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
influence	O
of	O
hyperprolactinemia	I-Entity
,	O
induced	O
by	O
haloperidol	I-Entity
(	O
HAL	I-Entity
)	O
on	O
age	O
related	O
morphology	O
and	O
function	O
changes	O
of	O
epithelial	O
cells	O
in	O
rat	O
prostate	O
lateral	O
lobe	O
.	O

Serum	O
concentrations	O
of	O
prolactin	O
(	O
PRL	I-Entity
)	O
and	O
testosterone	I-Entity
(	O
T	I-Entity
)	O
were	O
measured	O
.	O

In	O
rats	O
of	O
the	O
experimental	O
group	O
,	O
the	O
mean	O
concentration	O
of	O
:	O
PRL	I-Entity
was	O
more	O
than	O
twice	O
higher	O
,	O
whereas	O
T	I-Entity
concentration	O
was	O
almost	O
twice	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
.	O

Light	O
microscopy	O
visualized	O
the	O
following	O
:	O
hypertrophy	I-Entity
and	O
epithelium	O
hyperplasia	I-Entity
of	O
the	O
glandular	O
ducts	O
,	O
associated	O
with	O
increased	O
PCNA	O
expression	O
.	O



Does	O
supplemental	O
vitamin	B-Entity
C	I-Entity
increase	O
cardiovascular	B-Entity
disease	I-Entity
risk	O
in	O
women	O
with	O
diabetes	I-Entity
?	O

Vitamin	B-Entity
C	I-Entity
acts	O
as	O
a	O
potent	O
antioxidant	O
;	O
however	O
,	O
it	O
can	O
also	O
be	O
a	O
prooxidant	O
and	O
glycate	O
protein	O
under	O
certain	O
circumstances	O
in	O
vitro	O
.	O

These	O
observations	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
high	O
intake	O
of	O
vitamin	B-Entity
C	I-Entity
in	O
diabetic	I-Entity
persons	O
might	O
promote	O
atherosclerosis	I-Entity
.	O

The	O
objective	O
was	O
to	O
examine	O
the	O
relation	O
between	O
vitamin	B-Entity
C	I-Entity
intake	O
and	O
mortality	O
from	O
cardiovascular	B-Entity
disease	I-Entity
.	O

DESIGN	O
:	O
We	O
studied	O
the	O
relation	O
between	O
vitamin	B-Entity
C	I-Entity
intake	O
and	O
mortality	O
from	O
total	O
cardiovascular	B-Entity
disease	I-Entity
(	O
n	O
=	O
281	O
)	O
,	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
(	O
n	O
=	O
175	O
)	O
,	O
and	O
stroke	I-Entity
(	O
n	O
=	O
57	O
)	O
in	O
1923	O
postmenopausal	O
women	O
who	O
reported	O
being	O
diabetic	I-Entity
at	O
baseline	O
.	O

Diet	O
was	O
assessed	O
with	O
a	O
food	O
-	O
frequency	O
questionnaire	O
at	O
baseline	O
,	O
and	O
subjects	O
initially	O
free	O
of	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
were	O
prospectively	O
followed	O
for	O
15	O
y.	O
RESULTS	O
:	O

After	O
adjustment	O
for	O
cardiovascular	B-Entity
disease	I-Entity
risk	O
factors	O
,	O
type	O
of	O
diabetes	I-Entity
medication	O
used	O
,	O
duration	O
of	O
diabetes	I-Entity
,	O
and	O
intakes	O
of	O
folate	I-Entity
,	O
vitamin	B-Entity
E	I-Entity
,	O
and	O
beta	B-Entity
-	I-Entity
carotene	I-Entity
,	O
the	O
adjusted	O
relative	O
risks	O
of	O
total	O
cardiovascular	B-Entity
disease	I-Entity
mortality	O
were	O
1.0	O
,	O
0.97	O
,	O
1.11	O
,	O
1.47	O
,	O
and	O
1.84	O
(	O
P	O
for	O
trend	O
<	O
0.01	O
)	O
across	O
quintiles	O
of	O
total	O
vitamin	B-Entity
C	I-Entity
intake	O
from	O
food	O
and	O
supplements	O
.	O

Adjusted	O
relative	O
risks	O
of	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
were	O
1.0	O
,	O
0.81	O
,	O
0.99	O
,	O
1.26	O
,	O
and	O
1.91	O
(	O
P	O
for	O
trend	O
=	O
0.01	O
)	O
and	O
of	O
stroke	I-Entity
were	O
1.0	O
,	O
0.52	O
,	O
1.23	O
,	O
2.22	O
,	O
and	O
2.57	O
(	O
P	O
for	O
trend	O
<	O
0.01	O
)	O
.	O

When	O
dietary	O
and	O
supplemental	O
vitamin	B-Entity
C	I-Entity
were	O
analyzed	O
separately	O
,	O
only	O
supplemental	O
vitamin	B-Entity
C	I-Entity
showed	O
a	O
positive	O
association	O
with	O
mortality	O
endpoints	O
.	O

Vitamin	B-Entity
C	I-Entity
intake	O
was	O
unrelated	O
to	O
mortality	O
from	O
cardiovascular	B-Entity
disease	I-Entity
in	O
the	O
nondiabetic	O
subjects	O
at	O
baseline	O
.	O

CONCLUSION	O
:	O
A	O
high	O
vitamin	B-Entity
C	I-Entity
intake	O
from	O
supplements	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cardiovascular	B-Entity
disease	I-Entity
mortality	O
in	O
postmenopausal	O
women	O
with	O
diabetes	I-Entity
.	O



Absolute	O
and	O
attributable	O
risk	O
of	O
venous	B-Entity
thromboembolism	I-Entity
in	O
women	O
on	O
combined	O
cyproterone	B-Entity
acetate	I-Entity
and	O
ethinylestradiol	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
achieve	O
absolute	O
risk	O
estimates	O
of	O
venous	B-Entity
thromboembolism	I-Entity
(	O
VTE	I-Entity
)	O
among	O
women	O
on	O
cyproterone	B-Entity
acetate	I-Entity
plus	O
ethinylestradiol	I-Entity
(	O
CPA	I-Entity
/	O
EE	I-Entity
)	O
,	O
and	O
among	O
women	O
on	O
combined	B-Entity
oral	I-Entity
contraceptives	I-Entity
(	O
COCs	I-Entity
)	O
.	O

From	O
the	O
Danish	O
National	O
Register	O
of	O
Patients	O
(	O
NRP	O
)	O
,	O
1996	O
to	O
1998	O
,	O
the	O
records	O
of	O
1.1	O
million	O
Danish	O
women	O
,	O
ages	O
15	O
to	O
44	O
years	O
,	O
were	O
searched	O
for	O
evidence	O
of	O
VTE	I-Entity
.	O

COC	I-Entity
use	O
was	O
ascertained	O
through	O
mailed	O
questionnaires	O
.	O

Sales	O
statistics	O
of	O
COCs	I-Entity
and	O
CPA	I-Entity
/	O
EE	I-Entity
were	O
provided	O
through	O
Danish	O
Drug	O
Statistics	O
.	O

During	O
the	O
time	O
frame	O
of	O
the	O
study	O
,	O
330	O
women	O
were	O
found	O
to	O
have	O
had	O
VTE	I-Entity
while	O
on	O
COCs	I-Entity
.	O

Of	O
these	O
women	O
,	O
67	O
were	O
on	O
levonorgestrel	I-Entity
-	O
containing	O
COCs	I-Entity
.	O

Eleven	O
were	O
on	O
CPA	I-Entity
/	O
EE	I-Entity
.	O

The	O
corresponding	O
absolute	O
risk	O
of	O
VTE	I-Entity
was	O
3.4	O
(	O
range	O
,	O
3.1	O
-	O
3.8	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
the	O
women	O
on	O
COCs	I-Entity
,	O
4.2	O
(	O
range	O
,	O
3.2	O
-	O
5.2	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
women	O
on	O
levonorgestrel	I-Entity
-	O
containing	O
COCs	I-Entity
,	O
and	O
3.1	O
(	O
range	O
,	O
1.3	O
-	O
4.9	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
the	O
women	O
on	O
CPA	I-Entity
/	O
EE	I-Entity
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
the	O
absolute	O
risk	O
of	O
VTE	I-Entity
among	O
Danish	O
women	O
on	O
COCs	I-Entity
is	O
similar	O
to	O
that	O
among	O
women	O
taking	O
CPA	I-Entity
/	O
EE	I-Entity
.	O



Effect	O
of	O
lindane	I-Entity
on	O
hepatic	O
and	O
brain	O
cytochrome	O
P450s	O
and	O
influence	O
of	O
P450	O
modulation	O
in	O
lindane	I-Entity
induced	O
neurotoxicity	I-Entity
.	O

Oral	O
administration	O
of	O
lindane	I-Entity
(	O
2.5	O
,	O
5	O
,	O
10	O
and	O
15	O
mg	O
/	O
kg	O
,	O
body	O
weight	O
)	O
for	O
5	O
days	O
was	O
found	O
to	O
produce	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
activity	O
of	O
P450	O
dependent	O
7-ethoxyresorufin	O
-	O
O	O
-	O
deethylase	O
(	O
EROD	O
)	O
,	O
7-pentoxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
PROD	O
)	O
and	O
N	B-Entity
-	I-Entity
nitrosodimethylamine	I-Entity
demethylase	O
(	O
NDMA	I-Entity
-	O
d	O
)	O
in	O
rat	O
brain	O
and	O
liver	O
.	O

brain	O
P450	O
monooxygenases	O
was	O
also	O
observed	O
when	O
the	O
duration	O
of	O
exposure	O
of	O
low	O
dose	O
(	O
2.5	O
mg	O
/	O
kg	O
)	O
of	O
lindane	I-Entity
was	O
increased	O
from	O
5	O
days	O
to	O
15	O
or	O
21	O
days	O
.	O

In	O
vitro	O
studies	O
using	O
organic	O
inhibitors	O
specific	O
for	O
individual	O
P450	O
isoenzymes	O
and	O
antibody	O
inhibition	O
experiments	O
have	O
further	O
demonstrated	O
that	O
the	O
increase	O
in	O
the	O
activity	O
of	O
PROD	O
,	O
EROD	O
and	O
NDMA	I-Entity
-	O
d	O
are	O
due	O
to	O
the	O
increase	O
in	O
the	O
levels	O
of	O
P450	O
2B1/2B2	O
,	O
1A1/1A2	O
and	O
2E1	O
isoenzymes	O
,	O
respectively	O
.	O

Induction	O
studies	O
have	O
further	O
shown	O
that	O
while	O
pretreatment	O
of	O
3-methylcholanthrene	I-Entity
(	O
MC	I-Entity
)	O
,	O
an	O
inducer	O
of	O
P4501A1/1A2	O
,	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
incidence	O
of	O
lindane	I-Entity
induced	O
convulsions	I-Entity
,	O
pretreatment	O
with	O
phenobarbital	I-Entity
(	O
PB	O
)	O
,	O
an	O
inducer	O
of	O
P450	O
2B1/2B2	O
or	O
ethanol	I-Entity
,	O
an	O
inducer	O
of	O
P450	O
2E1	O

catalysed	O
reactions	O
,	O
significantly	O
increased	O
the	O
incidence	O
of	O
lindane	I-Entity
induced	O
convulsions	I-Entity
.	O

Similarly	O
,	O
when	O
the	O
P450-mediated	O
metabolism	O
of	O
lindane	I-Entity
was	O
blocked	O
by	O
cobalt	B-Entity
chloride	I-Entity
incidence	O
of	O
convulsions	I-Entity
was	O
increased	O
in	O
animals	O
treated	O
with	O
lindane	I-Entity
indicating	O
that	O
lindane	I-Entity
per	O
se	O
or	O
its	O
metabolites	O
formed	O
by	O
PB	O
or	O
ethanol	I-Entity
inducible	O

P450	O
isoenzymes	O
are	O
involved	O
in	O
its	O
neurobehavioral	O
toxicity	I-Entity
.	O



Seizure	I-Entity
associated	O
with	O
sleep	B-Entity
deprivation	I-Entity
and	O
sustained	O
-	O
release	O
bupropion	I-Entity
.	O

This	O
case	O
report	O
describes	O
a	O
generalized	O
seizure	I-Entity
associated	O
with	O
sustained	O
-	O
release	O
bupropion	I-Entity
use	O
and	O
sleep	B-Entity
deprivation	I-Entity
.	O

The	O
subject	O
,	O
a	O
31-year	O
-	O
old	O
female	O
smoker	O
,	O
was	O
participating	O
in	O
a	O
clinical	O
trial	O
evaluating	O
an	O
investigational	O
medication	O
for	O
smoking	O
cessation	O
that	O
used	O
sustained	O
-	O
release	O
bupropion	I-Entity
as	O
an	O
active	O
control	O
.	O

After	O
5	O
weeks	O
of	O
bupropion	I-Entity
use	O
,	O
the	O
subject	O
experienced	O
a	O
generalized	O
tonic	O
clonic	O
seizure	I-Entity
after	O
staying	O
up	O
nearly	O
all	O
night	O
packing	O
and	O
moving	O
to	O
a	O
new	O
residence	O
.	O

The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
seizures	I-Entity
.	O

We	O
suggest	O
that	O
sleep	B-Entity
deprivation	I-Entity
may	O
add	O
to	O
the	O
risk	O
of	O
bupropion	I-Entity
-	O
associated	O
seizures	I-Entity
.	O



Nephrotoxic	I-Entity
effects	O
in	O
high	O
-	O
risk	O
patients	O
undergoing	O
angiography	O
.	O

:	O
The	O
use	O
of	O
iodinated	O
contrast	O
medium	O
can	O
result	O
in	O
nephropathy	I-Entity
.	O

Whether	O
iso	O
-	O
osmolar	O
contrast	O
medium	O
is	O
less	O
nephrotoxic	I-Entity
than	O
low	O
-	O
osmolar	O
contrast	O
medium	O
in	O
high	O
-	O
risk	O
patients	O
is	O
uncertain	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
prospective	O
,	O
multicenter	O
study	O
comparing	O
the	O
nephrotoxic	I-Entity
effects	O
of	O
an	O
iso	O
-	O
osmolar	O
,	O
dimeric	O
,	O
nonionic	O
contrast	O
medium	O
,	O
iodixanol	I-Entity
,	O
with	O
those	O
of	O
a	O
low	O
-	O
osmolar	O
,	O
nonionic	O
,	O
monomeric	O
contrast	O
medium	O
,	O
iohexol	I-Entity
.	O

The	O
study	O
involved	O
129	O
patients	O
with	O
diabetes	I-Entity
with	O
serum	O
creatinine	I-Entity
concentrations	O
of	O
1.5	O
to	O
3.5	O
mg	O
per	O
deciliter	O
who	O
underwent	O
coronary	O
or	O
aortofemoral	O
angiography	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
peak	O
increase	O
from	O
base	O
line	O
in	O
the	O
creatinine	I-Entity
concentration	O
during	O
the	O
three	O
days	O
after	O
angiography	O
.	O

Other	O
end	O
points	O
were	O
an	O
increase	O
in	O
the	O
creatinine	I-Entity
concentration	O
of	O
0.5	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
an	O
increase	O
of	O
1.0	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
and	O
a	O
change	O
in	O
the	O
creatinine	I-Entity
concentration	O
from	O
day	O
0	O
to	O
day	O
7	O
.	O

The	O
creatinine	I-Entity
concentration	O
increased	O
significantly	O
less	O
in	O
patients	O
who	O
received	O
iodixanol	I-Entity
.	O

From	O
day	O
0	O
to	O
day	O
3	O
,	O
the	O
mean	O
peak	O
increase	O
in	O
creatinine	I-Entity
was	O
0.13	O
mg	O
per	O
deciliter	O
in	O
the	O
iodixanol	I-Entity
group	O
and	O
0.55	O
mg	O
per	O
deciliter	O
in	O
the	O
iohexol	I-Entity
group	O
(	O
P=0.001	O
;	O
the	O
increase	O
with	O
iodixanol	I-Entity
minus	O
the	O
increase	O
with	O
iohexol	I-Entity
,	O
-0.42	O
mg	O
per	O
deciliter	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
-0.73	O
to	O
-0.22	O
]	O
)	O
.	O

Two	O
of	O
the	O
64	O
patients	O
in	O
the	O
iodixanol	I-Entity
group	O
(	O
3	O
percent	O
)	O
had	O
an	O
increase	O
in	O
the	O
creatinine	I-Entity
concentration	O
of	O
0.5	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
as	O
compared	O
with	O
17	O
of	O
the	O
65	O
patients	O
in	O
the	O
iohexol	I-Entity
group	O
(	O
26	O
percent	O
)	O
(	O
P=0.002	O
;	O
odds	O
ratio	O
for	O
such	O
an	O
increase	O
in	O
the	O
iodixanol	I-Entity
group	O
,	O
0.09	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
0.02	O
to	O
0.41	O
]	O
)	O
.	O

No	O
patient	O
receiving	O
iodixanol	I-Entity
had	O
an	O
increase	O
of	O
1.0	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
but	O
10	O
patients	O
in	O
the	O
iohexol	I-Entity
group	O
(	O
15	O
percent	O
)	O
did	O
.	O

The	O
mean	O
change	O
in	O
the	O
creatinine	I-Entity
concentration	O
from	O
day	O
0	O
to	O
day	O
7	O
was	O
0.07	O
mg	O
per	O
deciliter	O
in	O
the	O
iodixanol	I-Entity
group	O
and	O
0.24	O
mg	O
per	O
deciliter	O
in	O
the	O
iohexol	I-Entity
group	O
(	O
P=0.003	O
;	O
value	O
in	O
the	O
iodixanol	I-Entity
group	O
minus	O
the	O
value	O
in	O
the	O
iohexol	I-Entity
group	O
,	O
-0.17	O
mg	O
per	O
deciliter	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
-0.34	O
to	O
-0.07	O
]	O
)	O
.	O

Nephropathy	I-Entity
induced	O
by	O
contrast	O
medium	O
may	O
be	O
less	O
likely	O
to	O
develop	O
in	O
high	O
-	O
risk	O
patients	O
when	O
iodixanol	I-Entity
is	O
used	O
rather	O
than	O
a	O
low	O
-	O
osmolar	O
,	O
nonionic	O
contrast	O
medium	O
.	O



Experimental	O
cranial	O
pain	I-Entity
elicited	O
by	O
capsaicin	I-Entity
:	O
a	O
PET	O
study	O
.	O

Using	O
a	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
it	O
was	O
shown	O
recently	O
that	O
in	O
migraine	I-Entity
without	O
aura	O
certain	O
areas	O
in	O
the	O
brain	O
stem	O
were	O
activated	O
during	O
the	O
headache	I-Entity
state	O
,	O
but	O
not	O
in	O
the	O
headache	I-Entity
free	O
interval	O
.	O

It	O
was	O
suggested	O
that	O
this	O
brain	O
stem	O
activation	O
is	O
inherent	O
to	O
the	O
migraine	I-Entity
attack	O
itself	O
and	O
represents	O
the	O
so	O
called	O
'	O
migraine	I-Entity
generator	O
'	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
performed	O
an	O
experimental	O
pain	I-Entity
study	O
in	O
seven	O
healthy	O
volunteers	O
,	O
using	O
the	O
same	O
positioning	O
in	O
the	O
PET	O
scanner	O
as	O
in	O
the	O
migraine	I-Entity
patients	O
.	O

A	O
small	O
amount	O
of	O
capsaicin	I-Entity
was	O
administered	O
subcutaneously	O
in	O
the	O
right	O
forehead	O
to	O
evoke	O
a	O
burning	O
painful	I-Entity
sensation	O
in	O
the	O
first	O
division	O
of	O
the	O
trigeminal	O
nerve	O
.	O

Using	O
the	O
same	O
stereotactic	O
space	O
limits	O
as	O
in	O
the	O
above	O
mentioned	O
migraine	I-Entity
study	O
no	O
brain	O
stem	O
activation	O
was	O
found	O
in	O
the	O
acute	O
pain	I-Entity
state	O
compared	O
to	O
the	O
pain	I-Entity
free	O
state	O
.	O

The	O
increase	O
of	O
activation	O
in	O
the	O
region	O
of	O
the	O
cavernous	O
sinus	O
however	O
,	O
suggests	O
that	O
this	O
structure	O
is	O
more	O
likely	O
to	O
be	O
involved	O
in	O
trigeminal	O
transmitted	O
pain	I-Entity
as	O
such	O
,	O
rather	O
than	O
in	O
a	O
specific	O
type	O
of	O
headache	I-Entity
as	O
was	O
suggested	O
for	O
cluster	B-Entity
headache	I-Entity
.	O



Neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
with	O
risperidone	I-Entity
.	O

Neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
is	O
thought	O
to	O
be	O
a	O
result	O
of	O
dopamine	I-Entity
D2	O
receptor	O
blockade	O
in	O
the	O
striatum	O
of	O
the	O
basal	O
ganglia	O
.	O

Risperidone	I-Entity
,	O
a	O
benzisoxazole	I-Entity
derivative	O
antipsychotic	O
,	O
has	O
high	O
serotonin	I-Entity
5-HT2	O
receptor	O
blockade	O
and	O
dose	O
-	O
related	O
D2	O
receptor	O
blockade	O
.	O

The	O
high	O
ratio	O
is	O
believed	O
to	O
impart	O
the	O
low	O
frequency	O
of	O
extrapyramidal	B-Entity
symptoms	I-Entity
with	O
risperidone	I-Entity
at	O
low	O
dosages	O
.	O

With	O
this	O
low	O
frequency	O
of	O
extrapyramidal	B-Entity
symptoms	I-Entity
,	O
it	O
was	O
thought	O
the	O
frequency	O
of	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
might	O
also	O
be	O
lowered	O
.	O

A	O
73-year	O
-	O
old	O
woman	O
developed	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
after	O
monotherapy	O
with	O
risperidone	I-Entity
.	O

The	O
syndrome	O
reversed	O
after	O
discontinuing	O
risperidone	I-Entity
and	O
starting	O
treatment	O
with	O
dantrolene	I-Entity
and	O
bromocriptine	I-Entity
.	O

It	O
appears	O
that	O
the	O
protection	O
from	O
extrapyramidal	O
side	O
effects	O
observed	O
with	O
risperidone	I-Entity
does	O
not	O
ensure	O
protection	O
from	O
neuroleptic	B-Entity
malignant	I-Entity
syndrome	I-Entity
.	O



Hepatic	O
and	O
extrahepatic	O
angiotensinogen	O
gene	O
expression	O
in	O
rats	O
with	O
acute	O
nephrotic	B-Entity
syndrome	I-Entity
.	O

Plasma	O
concentration	O
and	O
urine	O
excretion	O
of	O
the	O
renin	O
-	O
angiotensin	I-Entity
system	O
proteins	O
are	O
altered	O
in	O
rats	O
with	O
nephrotic	B-Entity
syndrome	I-Entity
(	O
NS	I-Entity
)	O
.	O

In	O
this	O
work	O
the	O
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
levels	O
of	O
angiotensinogen	O
(	O
Ao	O
)	O
were	O
analyzed	O
with	O
the	O
slot	O
-	O
blot	O
hybridization	O
technique	O
in	O
liver	O
and	O
other	O
extrahepatic	O
tissues	O
:	O
kidney	O
,	O
heart	O
,	O
brain	O
,	O
and	O
adrenal	O
gland	O
from	O
control	O
,	O
nephrotic	I-Entity
,	O
and	O
pair	O
-	O
fed	O
(	O
PF	O
)	O
rats	O
.	O

NS	I-Entity
was	O
induced	O
by	O
a	O
single	O
injection	O
of	O
puromycin	B-Entity
amino	I-Entity
-	I-Entity
nucleoside	I-Entity
(	O
PAN	I-Entity
)	O
.	O

Although	O
a	O
great	O
urinary	O
excretion	O
and	O
half	O
-	O
normal	O
plasma	O
levels	O
of	O
Ao	O
were	O
observed	O
on	O
day	O
6	O
after	O
PAN	I-Entity
injection	O
,	O
when	O
NS	I-Entity
was	O
clearly	O
established	O
,	O
hepatic	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
.	O

Furthermore	O
,	O
the	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
in	O
any	O
of	O
the	O
extrahepatic	O
tissues	O
studied	O
on	O
day	O
6	O
,	O
nor	O
did	O
its	O
hepatic	O
levels	O
at	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
or	O
7	O
after	O
PAN	I-Entity
injection	O
.	O

These	O
data	O
suggest	O
that	O
the	O
hepatic	O
and	O
extrahepatic	O
Ao	O
mRNA	O
levels	O
are	O
unaltered	O
during	O
the	O
development	O
of	O
the	O
acute	O
NS	I-Entity
induced	O
by	O
PAN	I-Entity
.	O



Cyclophosphamide	I-Entity
associated	O
bladder	B-Entity
cancer	I-Entity
--	O
a	O
highly	O
aggressive	O
disease	O
:	O
analysis	O
of	O
12	O
cases	O
.	O

We	O
gained	O
knowledge	O
of	O
the	O
etiology	O
,	O
treatment	O
and	O
prevention	O
of	O
cyclophosphamide	I-Entity
associated	O
urothelial	B-Entity
cancer	I-Entity
.	O

The	O
medical	O
records	O
of	O
6	O
men	O
and	O
6	O
women	O
(	O
mean	O
age	O
55	O
years	O
)	O
with	O
cyclophosphamide	I-Entity
associated	O
bladder	B-Entity
cancer	I-Entity
were	O
reviewed	O
.	O

RESULTS	O
:	O
All	O
tumors	I-Entity
were	O
grade	O
3	O
or	O
4	O
transitional	O
cell	O
carcinoma	I-Entity
.	O

The	O
remaining	O
patient	O
with	O
extensive	O
cancer	I-Entity
underwent	O
partial	O
cystectomy	O
for	O
palliation	O
and	O
died	O
3	O
months	O
later	O
.	O

Cyclophosphamide	I-Entity
associated	O
bladder	B-Entity
tumor	I-Entity
is	O
an	O
aggressive	O
disease	O
.	O

However	O
,	O
long	O
-	O
term	O
survival	O
is	O
possible	O
when	O
radical	O
cystectomy	O
is	O
performed	O
for	O
bladder	B-Entity
tumors	I-Entity
with	O
any	O
sign	O
of	O
invasion	O
and	O
for	O
recurrent	O
high	O
grade	O
disease	O
,	O
even	O
when	O
noninvasive	O
.	O



Leg	B-Entity
and	I-Entity
back	I-Entity
pain	I-Entity
after	O
spinal	O
anaesthesia	O
involving	O
hyperbaric	O
5%	O
lignocaine	I-Entity
.	O

Fifty	O
-	O
four	O
patients	O
,	O
aged	O
27	O
-	O
90	O
years	O
,	O
who	O
were	O
given	O
lignocaine	I-Entity
5%	O
in	O
6.8%	O
glucose	I-Entity
solution	O
for	O
spinal	O
anaesthesia	O
were	O
studied	O
.	O

Thirteen	O
of	O
these	O
patients	O
experienced	O
pain	B-Entity
in	I-Entity
the	I-Entity
legs	I-Entity
and/or	I-Entity
back	I-Entity
after	O
recovery	O
from	O
anaesthesia	O
.	O

The	O
patients	O
affected	O
were	O
younger	O
(	O
p	O
<	O
0.05	O
)	O
and	O
the	O
site	O
of	O
the	O
dural	O
puncture	O
was	O
higher	O
(	O
p	O
<	O
0.01	O
)	O
than	O
those	O
individuals	O
without	O
pain	I-Entity
.	O

Five	O
of	O
the	O
13	O
patients	O
(	O
38%	O
)	O
with	O
pain	I-Entity
and	O
seven	O
of	O
the	O
41	O
patients	O
(	O
17%	O
)	O
without	O
pain	I-Entity
admitted	O
to	O
a	O
high	O
alcohol	I-Entity
intake	O
,	O
which	O
might	O
be	O
a	O
contributing	O
factor	O
.	O

Leg	B-Entity
and/or	I-Entity
back	I-Entity
pain	I-Entity
is	O
associated	O
with	O
the	O
intrathecal	O
use	O
of	O
hyperbaric	O
5%	O
lignocaine	I-Entity
.	O



Acute	O
blood	O
pressure	O
elevations	O
with	O
caffeine	I-Entity
in	O
men	O
with	O
borderline	O
systemic	O
hypertension	I-Entity
.	O

Whether	O
the	O
vasoconstrictive	O
actions	O
of	O
caffeine	I-Entity
are	O
enhanced	O
in	O
hypertensive	I-Entity
persons	O
has	O
not	O
been	O
demonstrated	O
.	O

Thus	O
,	O
caffeine	I-Entity
(	O
3.3	O
mg	O
/	O
kg	O
)	O
versus	O
placebo	O
was	O
tested	O
in	O
48	O
healthy	O
men	O
(	O
aged	O
20	O
to	O
35	O
years	O
)	O
selected	O
after	O
screening	O
on	O
2	O
separate	O
occasions	O
.	O

Borderline	O
hypertensive	I-Entity
men	O
(	O
n	O
=	O
24	O
)	O
were	O
selected	O
with	O
screening	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
of	O
140	O
to	O
160	O
mm	O
Hg	O
and/or	O
diastolic	O
BP	O
90	O
to	O
99	O
mm	O
Hg	O
.	O

Low	O
-	O
risk	O
controls	O
(	O
n	O
=	O
24	O
)	O
reported	O
no	O
parental	O
history	O
of	O
hypertension	I-Entity
and	O
had	O
screening	O
BP	O
<	O
130/85	O
mm	O
Hg	O
.	O

Participants	O
were	O
then	O
tested	O
on	O
2	O
occasions	O
after	O
12-hour	O
abstinence	O
from	O
caffeine	I-Entity
in	O
each	O
of	O
2	O
protocols	O
;	O
this	O
required	O
a	O
total	O
of	O
4	O
laboratory	O
visits	O
.	O

Caffeine	I-Entity
-	O
induced	O
changes	O
in	O
diastolic	O
BP	O
were	O
2	O
to	O
3	O
times	O
larger	O
in	O
borderline	O
subjects	O
than	O
in	O
controls	O
(	O
+	O
8.4	O
vs	O
+	O
3.8	O
mm	O
Hg	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
were	O
attributable	O
to	O
larger	O
changes	O
in	O
impedance	O
-	O
derived	O
measures	O
of	O
systemic	O
vascular	O
resistance	O
(	O
+	O
135	O
vs	O
+	O
45	O
dynes.s.cm-5	O
,	O
p	O

Consequently	O
,	O
whereas	O
all	O
participants	O
exhibited	O
normotensive	O
levels	O
during	O
the	O
resting	O
predrug	O
baseline	O
,	O
33%	O
of	O
borderline	O
subjects	O
achieved	O
hypertensive	I-Entity
BP	O
levels	O
after	O
caffeine	I-Entity
ingestion	O
.	O

Thus	O
,	O
in	O
borderline	O
hypertensive	I-Entity
men	O
,	O
exaggerated	O
responses	O
to	O
caffeine	I-Entity
were	O
:	O
selective	O
for	O
diastolic	O
BP	O
,	O
consistent	O
with	O
greater	O
vasoconstriction	O
,	O
replicated	O
in	O
2	O
protocols	O
,	O
and	O
representative	O
of	O
nearly	O
all	O
borderline	O
hypertensives	I-Entity
.	O

We	O
suspect	O
that	O
the	O
potential	O
for	O
caffeine	I-Entity
to	O
stabilize	O
high	O
resistance	O
states	O
in	O
susceptible	O
persons	O
suggests	O
that	O
its	O
use	O
may	O
facilitate	O
their	O
disease	O
progression	O
,	O
as	O
well	O
as	O
hinder	O
accurate	O
diagnosis	O
and	O
treatment	O
.	O



Hallucinations	I-Entity
and	O
ifosfamide	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
.	O

Hallucinations	I-Entity
as	O
a	O
symptom	O
of	O
central	O
neurotoxicity	I-Entity
are	O
a	O
known	O
but	O
poorly	O
described	O
side	O
effect	O
of	O
ifosfamide	I-Entity
.	O

Most	O
cases	O
of	O
ifosfamide	I-Entity
-	O
induced	O
hallucinations	I-Entity
have	O
been	O
reported	O
with	O
other	O
mental	O
status	O
changes	O
.	O

:	O
The	O
authors	O
interviewed	O
six	O
persons	O
with	O
ifosfamide	I-Entity
-	O
induced	O
hallucinations	I-Entity
in	O
the	O
presence	O
of	O
a	O
clear	O
sensorium	O
.	O

All	O
patients	O
were	O
receiving	O
high	O
-	O
dose	O
ifosfamide	I-Entity
as	O
part	O
of	O
their	O
bone	O
marrow	O
transplant	O
procedure	O
.	O

Hallucinations	I-Entity
occurred	O
only	O
when	O
the	O
patient	O
's	O
eyes	O
were	O
closed	O
and	O
,	O
in	O
all	O
but	O
one	O
case	O
,	O
were	O
reported	O
as	O
disturbing	O
or	O
frightening	O
.	O

Underreporting	O
of	O
these	O
hallucinations	I-Entity
by	O
patients	O
is	O
likely	O
.	O

Hallucinations	I-Entity
may	O
be	O
the	O
sole	O
or	O
first	O
manifestation	O
of	O
neurotoxicity	I-Entity
.	O

The	O
clinician	O
should	O
be	O
alerted	O
for	O
possible	O
ifosfamide	I-Entity
-	O
induced	O
hallucinations	I-Entity
,	O
which	O
may	O
occur	O
without	O
other	O
signs	O
of	O
neurotoxicity	I-Entity
.	O

""""	O
Eyes	O
-	O
closed	O
""""	O
hallucinatory	I-Entity
experiences	O
appear	O
to	O
be	O
an	O
unusual	O
feature	O
of	O
this	O
presentation	O
.	O

If	O
agitation	I-Entity
becomes	O
marked	O
,	O
high	O
-	O
potency	O
neuroleptics	O
(	O
i.e.	O
,	O
haloperidol	I-Entity
)	O
may	O
be	O
effective	O
.	O



Chlorpropamide	I-Entity
-	O
induced	O
optic	B-Entity
neuropathy	I-Entity
.	O

A	O
65-year	O
-	O
old	O
woman	O
with	O
adult	B-Entity
-	I-Entity
onset	I-Entity
diabetes	I-Entity
treated	O
with	O
chlorpropamide	I-Entity
(	O
Diabenese	I-Entity
)	O
had	O
a	O
toxic	B-Entity
optic	I-Entity
neuropathy	I-Entity
that	O
resolved	O
with	O
discontinuation	O
of	O
chlorpropamide	I-Entity
therapy	O
.	O

Visual	B-Entity
loss	I-Entity
occurs	O
in	O
diabetics	I-Entity
for	O
a	O
variety	O
of	O
reasons	O
,	O
and	O
accurate	O
diagnosis	O
is	O
necessary	O
to	O
institute	O
appropriate	O
therapy	O
.	O

The	O
possibility	O
of	O
a	O
drug	O
-	O
induced	O
optic	B-Entity
neuropathy	I-Entity
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
visual	B-Entity
loss	I-Entity
in	O
diabetics	I-Entity
.	O



Levodopa	I-Entity
-	O
induced	O
dyskinesia	I-Entity
and	O
thalamotomy	O
.	O

Levodopa	I-Entity
-	O
induced	O
dyskinesia	I-Entity
of	O
the	O
limbs	O
in	O
thirteen	O
cases	O
of	O
Parkinsonism	I-Entity
,	O
which	O
was	O
choreic	O
,	O
ballistic	O
or	O
dystonic	I-Entity
in	O
type	O
,	O
was	O
alleviated	O
almost	O
completely	O
by	O
stereotaxic	O
surgery	O
using	O
a	O
microelectrode	O
technique	O
for	O
the	O
ventralis	O
oralis	O
anterior	O
and	O
posterior	O
nuclei	O
of	O
the	O
thalamus	O
,	O
but	O
much	O
less	O
by	O
the	O
ventralis	O
intermedius	O
nucleus	O
.	O

Control	O
of	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
by	O
thalamic	B-Entity
lesions	I-Entity
in	O
the	O
course	O
of	O
routine	O
treatment	O
of	O
Parkinsonism	I-Entity
is	O
discussed	O
.	O



Factors	O
associated	O
with	O
nephrotoxicity	I-Entity
and	O
clinical	O
outcome	O
in	O
patients	O
receiving	O
amikacin	I-Entity
.	O

Data	O
from	O
60	O
patients	O
treated	O
with	O
amikacin	I-Entity
were	O
analyzed	O
for	O
factors	O
associated	O
with	O
nephrotoxicity	I-Entity
.	O

Variables	O
evaluated	O
included	O
patient	O
weight	O
,	O
age	O
,	O
sex	O
,	O
serum	O
creatinine	I-Entity
level	O
,	O
creatinine	I-Entity
clearance	O
,	O
duration	O
of	O
therapy	O
,	O
total	O
dose	O
,	O
mean	O
daily	O
dose	O
,	O
organism	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
,	O
mean	O
peak	O
levels	O
,	O
mean	O
trough	O
levels	O
,	O

When	O
the	O
parameters	O
were	O
examined	O
individually	O
,	O
duration	O
of	O
therapy	O
and	O
total	O
AUC	O
correlated	O
significantly	O
(	O
P	O
less	O
than	O
.05	O
)	O
with	O
nephrotoxicity	I-Entity
.	O

Based	O
on	O
this	O
model	O
and	O
on	O
Bayes	O
'	O
theorem	O
,	O
the	O
predictive	O
accuracy	O
of	O
identifying	O
""""	O
nephrotoxic	I-Entity
""""	O
patients	O
increased	O
from	O
0.17	O
to	O
0.39	O
.	O



In	O
group	O
I	O
,	O
cyclosporine	I-Entity
was	O
given	O
before	O
the	O
procedure	O
at	O
a	O
loading	O
dose	O
of	O
17.5	O
mg	O
/	O
kg	O
and	O
then	O
continued	O
after	O
the	O
procedure	O
to	O
keep	O
a	O
whole	O
blood	O
level	O
about	O
1000	O
ng	O
/	O
ml	O
.	O

In	O
group	O
II	O
,	O
cyclosporine	I-Entity
was	O
started	O
only	O
after	O
the	O
procedure	O
at	O
a	O
lower	O
dosage	O
and	O
was	O
complemented	O
by	O
azathioprine	I-Entity
,	O
which	O
was	O
used	O
for	O
the	O
first	O
postoperative	O
week	O
.	O

Group	O
II	O
showed	O
a	O
better	O
perioperative	O
renal	O
function	O
as	O
determined	O
by	O
serum	O
blood	O
urea	B-Entity
nitrogen	I-Entity
and	O
serum	O
creatinine	I-Entity
levels	O
.	O

Group	O
II	O
also	O
showed	O
a	O
significant	O
decrease	O
of	O
chronic	O
nephrotoxicity	I-Entity
secondary	O
to	O
long	O
-	O
term	O
therapy	O
with	O
cyclosporine	I-Entity
.	O

Despite	O
this	O
improvement	O
in	O
late	O
renal	O
function	O
,	O
group	O
II	O
still	O
shows	O
a	O
slow	O
rise	O
in	O
serum	O
creatinine	I-Entity
.	O

We	O
think	O
that	O
even	O
these	O
lower	O
dosages	O
of	O
cyclosporine	I-Entity
can	O
cause	O
chronic	O
nephrotoxicity	I-Entity
and	O
that	O
further	O
modification	O
of	O
the	O
immunosuppressive	O
regimen	O
is	O
required	O
to	O
completely	O
abolish	O
this	O
toxic	O
side	O
effect	O
.	O



Reversible	O
cholestasis	I-Entity
with	O
bile	B-Entity
duct	I-Entity
injury	I-Entity
following	O
azathioprine	I-Entity
therapy	O
.	O

A	O
67-year	O
-	O
old	O
patient	O
,	O
with	O
primary	O
polymyositis	I-Entity
and	O
without	O
previous	O
evidence	O
of	O
liver	B-Entity
disease	I-Entity
,	O
developed	O
clinical	O
and	O
biochemical	O
features	O
of	O
severe	O
cholestasis	I-Entity
3	O
months	O
after	O
initiation	O
of	O
azathioprine	I-Entity
therapy	O
.	O

Liver	O
biopsy	O
showed	O
cholestasis	I-Entity
with	O
both	O
cytological	O
and	O
architectural	O
alterations	O
of	O
interlobular	O
bile	O
ducts	O
.	O

Azathioprine	I-Entity
withdrawal	O
resulted	O
after	O
7	O
weeks	O
in	O
the	O
resolution	O
of	O
clinical	O
and	O
biochemical	O
abnormalities	O
.	O

It	O
is	O
believed	O
that	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
reversible	O
azathioprine	I-Entity
-	O
induced	O
cholestasis	I-Entity
associated	O
with	O
histological	O
evidence	O
of	O
bile	B-Entity
duct	I-Entity
injury	I-Entity
.	O



Renal	O
function	O
and	O
hemodynamics	O
during	O
prolonged	O
isoflurane	I-Entity
-	O
induced	O
hypotension	I-Entity
in	O
humans	O
.	O

The	O
effect	O
of	O
isoflurane	I-Entity
-	O
induced	O
hypotension	I-Entity
on	O
glomerular	O
function	O
and	O
renal	O
blood	O
flow	O
was	O
investigated	O
in	O
20	O
human	O
subjects	O
.	O

Glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
effective	O
renal	O
plasma	O
flow	O
(	O
ERPF	O
)	O
were	O
measured	O
by	O
inulin	O
and	O
para	B-Entity
-	I-Entity
aminohippurate	I-Entity
(	O
PAH	I-Entity
)	O
clearance	O
,	O
respectively	O
.	O

Anesthesia	O
was	O
maintained	O
with	O
fentanyl	I-Entity
,	O
nitrous	B-Entity
oxide	I-Entity
,	O
oxygen	I-Entity
,	O
and	O
isoflurane	I-Entity
.	O

Hypotension	I-Entity
was	O
induced	O
for	O
236.9	O
+	O
/-	O

15.1	O
min	O
by	O
increasing	O
the	O
isoflurane	I-Entity
inspired	O
concentration	O
to	O
maintain	O
a	O
mean	O
arterial	O
pressure	O
of	O
59.8	O
+	O
/-	O

GFR	O
and	O
ERPF	O
decreased	O
with	O
the	O
induction	O
of	O
anesthesia	O
but	O
not	O
significantly	O
more	O
during	O
hypotension	I-Entity
.	O

Renal	O
vascular	O
resistance	O
increased	O
during	O
anesthesia	O
but	O
decreased	O
when	O
hypotension	I-Entity
was	O
induced	O
,	O
allowing	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
.	O

We	O
conclude	O
that	O
renal	O
compensatory	O
mechanisms	O
are	O
preserved	O
during	O
isoflurane	I-Entity
-	O
induced	O
hypotension	I-Entity
and	O
that	O
renal	O
function	O
and	O
hemodynamics	O
quickly	O
return	O
to	O
normal	O
when	O
normotension	O
is	O
resumed	O
.	O



Debrisoquine	I-Entity
phenotype	O
and	O
the	O
pharmacokinetics	O
and	O
beta-2	O
receptor	O
pharmacodynamics	O
of	O
metoprolol	I-Entity
and	O
its	O
enantiomers	O
.	O

The	O
metabolism	O
of	O
the	O
cardioselective	O
beta	O
-	O
blocker	O
metoprolol	I-Entity
is	O
under	O
genetic	O
control	O
of	O
the	O
debrisoquine	I-Entity
/	O
sparteine	I-Entity
type	O
.	O

The	O
two	O
metabolic	O
phenotypes	O
,	O
extensive	O
(	O
EM	O
)	O
and	O
poor	O
metabolizers	O
(	O
PM	O
)	O
,	O
show	O
different	O
stereoselective	O
metabolism	O
,	O
resulting	O
in	O
apparently	O
higher	O
beta-1	O
adrenoceptor	O
antagonistic	O
potency	O
of	O
racemic	O
metoprolol	I-Entity
in	O
EMs	O
.	O

We	O
investigated	O
if	O
the	O
latter	O
also	O
applies	O
to	O
the	O
beta-2	O
adrenoceptor	O
antagonism	O
by	O
metoprolol	I-Entity
.	O

The	O
drug	O
effect	O
studied	O
was	O
the	O
antagonism	O
by	O
metoprolol	I-Entity
of	O
terbutaline	I-Entity
-	O
induced	O
hypokalemia	I-Entity
.	O

By	O
using	O
pharmacokinetic	O
pharmacodynamic	O
modeling	O
the	O
pharmacodynamics	O
of	O
racemic	O
metoprolol	I-Entity
and	O
the	O
active	O
S	O
-	O
isomer	O

,	O
were	O
quantitated	O
in	O
EMs	O
and	O
PMs	O
in	O
terms	O
of	O
IC50	O
values	O
,	O
representing	O
metoprolol	I-Entity
plasma	O
concentrations	O
resulting	O
in	O
half	O
-	O
maximum	O
receptor	O
occupancy	O
.	O

Six	O
EMs	O
received	O
0.5	O
mg	O
of	O
terbutaline	I-Entity
s.c	O
.	O

on	O
two	O
different	O
occasions	O
:	O
1	O
)	O
1	O
hr	O
after	O
administration	O
of	O
a	O
placebo	O
and	O
2	O
)	O
1	O
hr	O
after	O
150	O
mg	O
of	O
metoprolol	I-Entity
p.o	O
.	O

Five	O
PMs	O
were	O
studied	O
according	O
to	O
the	O
same	O
protocol	O
,	O
except	O
for	O
a	O
higher	O
terbutaline	I-Entity
dose	O
(	O
0.75	O
mg	O
)	O
on	O
day	O
2	O
.	O

Blood	O
samples	O
for	O
the	O
analysis	O
of	O
plasma	O
potassium	I-Entity
,	O
terbutaline	I-Entity
,	O
metoprolol	I-Entity
(	O
racemic	O
,	O
R-	O
and	O
S	O
-	O
isomer	O
)	O
,	O
and	O

alpha	B-Entity
-	I-Entity
hydroxymetoprolol	I-Entity
concentrations	O
were	O
taken	O
at	O
regular	O
time	O
intervals	O
,	O
during	O
8	O
hr	O
after	O
metoprolol	I-Entity
.	O

In	O
PMs	O
,	O
metoprolol	I-Entity
increased	O
the	O
terbutaline	I-Entity
area	O
under	O
the	O
plasma	O
concentration	O
vs.	O
time	O
curve	O
(	O
+	O
67%	O
)	O
.	O

Higher	O
metoprolol	I-Entity
/	O
alpha	B-Entity
-	I-Entity
hydroxymetoprolol	I-Entity
ratios	O
in	O
PMs	O
were	O
predictive	O
for	O
higher	O
R-/S	O
-	O
isomer	O
ratios	O
of	O
unchanged	O
drug	O
.	O

There	O
was	O
a	O
difference	O
in	O
metoprolol	I-Entity
potency	O
with	O
higher	O
racemic	O
metoprolol	I-Entity
IC50	O
values	O
in	O
PMs	O
(	O
72	O
+	O
/-	O



Cefotetan	I-Entity
-	O
induced	O
immune	O
hemolytic	B-Entity
anemia	I-Entity
.	O

Immune	O
hemolytic	B-Entity
anemia	I-Entity
due	O
to	O
a	O
drug	O
-	O
adsorption	O
mechanism	O
has	O
been	O
described	O
primarily	O
in	O
patients	O
receiving	O
penicillins	I-Entity
and	O
first	O
-	O
generation	O
cephalosporins	I-Entity
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
anemia	I-Entity
while	O
receiving	O
intravenous	O
cefotetan	I-Entity
.	O

Cefotetan	I-Entity
-	O
dependent	O
antibodies	O
were	O
detected	O
in	O
the	O
patient	O
's	O
serum	O
and	O
in	O
an	O
eluate	O
prepared	O
from	O
his	O
red	O
blood	O
cells	O
.	O

The	O
eluate	O
also	O
reacted	O
weakly	O
with	O
red	O
blood	O
cells	O
in	O
the	O
absence	O
of	O
cefotetan	I-Entity
,	O
suggesting	O
the	O
concomitant	O
formation	O
of	O
warm	O
-	O
reactive	O
autoantibodies	O
.	O

These	O
observations	O
,	O
in	O
conjunction	O
with	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
extravascular	O
hemolysis	I-Entity
,	O
are	O
consistent	O
with	O
drug	O
-	O
induced	O
hemolytic	B-Entity
anemia	I-Entity
,	O
possibly	O
involving	O
both	O
drug	O
-	O
adsorption	O
and	O
autoantibody	O
formation	O
mechanisms	O
.	O

This	O
case	O
emphasizes	O
the	O
need	O
for	O
increased	O
awareness	O
of	O
hemolytic	O
reactions	O
to	O
all	O
cephalosporins	I-Entity
.	O



Acute	B-Entity
renal	I-Entity
failure	I-Entity
subsequent	O
to	O
the	O
administration	O
of	O
rifampicin	I-Entity
.	O

A	O
clinical	O
presentation	O
is	O
made	O
of	O
a	O
2	O
-	O
3	O
year	O
follow	O
-	O
up	O
of	O
six	O
cases	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
that	O
have	O
been	O
reported	O
earlier	O
.	O

The	O
patients	O
had	O
developed	O
transient	O
renal	B-Entity
failure	I-Entity
after	O
the	O
intermittent	O
administration	O
of	O
rifampicin	I-Entity
.	O

The	O
stage	O
of	O
olig	O
-	O
anuria	I-Entity
lasted	O
for	O
1	O
-	O
3	O
weeks	O
,	O
and	O
five	O
of	O
the	O
patients	O
were	O
treated	O
by	O
hemodialysis	O
.	O

Although	O
in	O
the	O
acute	O
stage	O
the	O
renal	B-Entity
lesions	I-Entity
histologically	O
appeared	O
toxic	O
,	O
evidence	O
suggestive	O
of	O
an	O
immunological	O
mechanism	O
can	O
not	O
be	O
excluded	O
.	O



Type	B-Entity
B	I-Entity
hepatitis	I-Entity
after	O
needle	O
-	O
stick	O
exposure	O
:	O

prevention	O
with	O
hepatitis	B-Entity
B	I-Entity
immune	O
globulin	O
.	O

Hepatitis	B-Entity
B	I-Entity
immune	O
globulin	O
(	O
HBIG	O
)	O
and	O
immune	O
serum	O
globulin	O
(	O
ISG	O
)	O
were	O
examined	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
to	O
assess	O
their	O
relative	O
efficacies	O
in	O
preventing	O
type	B-Entity
B	I-Entity
hepatitis	I-Entity
after	O
needle	O
-	O
stick	O
exposure	O
to	O
hepatitis	B-Entity
B	I-Entity
surface	I-Entity
antigen	I-Entity
(	O
HBsAG)-positive	I-Entity
donors	O
.	O

Clinical	O
hepatitis	I-Entity
developed	O
in	O
1.4%	O
of	O
HBIG	O
and	O
in	O
5.9%	O
of	O
ISG	O
recipients	O
(	O

Available	O
donor	O
sera	O
were	O
examined	O
for	O
DNA	O
polymerase	O
(	O
DNAP	O
)	O
and	O
e	O
antigen	O
and	O
antibody	O
(	O
HBeAg	I-Entity
;	O
anti	O
-	O
HBE	O
)	O
.	O

Both	O
DNAP	O
and	O
HBeAg	I-Entity
showed	O
a	O
highly	O
statistically	O
significant	O
correlation	O
with	O
the	O
infectivity	O
of	O
HBsAg	I-Entity
-	O
positive	O
donors	O
.	O

Hepatitis	B-Entity
B	I-Entity
immune	O
globulin	O
remained	O
significantly	O
superior	O
to	O
ISG	O
in	O
preventing	O
type	B-Entity
B	I-Entity
hepatitis	I-Entity
even	O
when	O
the	O
analysis	O
was	O
confined	O
to	O
these	O
two	O
high	O
-	O
risk	O
subgroups	O
.	O

The	O
efficacy	O
of	O
ISG	O
in	O
preventing	O
type	B-Entity
B	I-Entity
hepatitis	I-Entity
can	O
not	O
be	O
ascertained	O
because	O
a	O
true	O
placebo	O
group	O
was	O
not	O
included	O
.	O



Serotonin	B-Entity
syndrome	I-Entity
from	O
venlafaxine	I-Entity
-	O
tranylcypromine	I-Entity
interaction	O
.	O

Excessive	O
stimulation	O
of	O
serotonin	I-Entity
5HT1A	O
receptors	O
causes	O
a	O
syndrome	O
of	O
serotonin	I-Entity
excess	O
that	O
consists	O
of	O
shivering	O
,	O
muscle	B-Entity
rigidity	I-Entity
,	O
salivation	I-Entity
,	O
confusion	I-Entity
,	O
agitation	I-Entity
and	O
hyperthermia	I-Entity
.	O

The	O
most	O
common	O
cause	O
of	O
this	O
syndrome	O
is	O
an	O
interaction	O
between	O
a	O
monoamine	O
oxidase	O
inhibitor	O
(	O
MAOI	O
)	O
and	O
a	O
specific	O
serotonin	I-Entity
reuptake	O
inhibitor	O
.	O

Venlafaxine	I-Entity
is	O
a	O
new	O
antidepressant	O
agent	O
that	O
inhibits	O
the	O
reuptake	O
of	O
serotonin	I-Entity
and	O
norepinephrine	I-Entity
.	O

We	O
report	O
a	O
venlafaxine	I-Entity
-	O
MAOI	O
interaction	O
that	O
resulted	O
in	O
the	O
serotonin	B-Entity
syndrome	I-Entity
in	O
a	O
23-y	O
-	O
old	O
male	O
who	O
was	O
taking	O
tranylcypromine	I-Entity
for	O
depression	I-Entity
.	O

He	O
had	O
been	O
well	O
until	O
the	O
morning	O
of	O
presentation	O
when	O
he	O
took	O
1/2	O
tab	O
of	O
venlafaxine	I-Entity
.	O

Within	O
2	O
h	O
he	O
became	O
confused	O
with	O
jerking	O
movements	O
of	O
his	O
extremities	O
,	O
tremors	I-Entity
and	O
rigidity	I-Entity
.	O

He	O
was	O
brought	O
directly	O
to	O
a	O
hospital	O
where	O
he	O
was	O
found	O
to	O
be	O
agitated	O
and	O
confused	O
with	O
shivering	O
,	O
myoclonic	B-Entity
jerks	I-Entity
,	O
rigidity	I-Entity
,	O
salivation	I-Entity
and	O
diaphoresis	O
.	O

After	O
180	O
mg	O
of	O
diazepam	I-Entity
i.v	O
.	O

he	O
remained	O
tremulous	O
with	O
muscle	B-Entity
rigidity	I-Entity
and	O
clenched	O
jaws	O
.	O

He	O
was	O
intubated	O
for	O
airway	O
protection	O
and	O
because	O
of	O
hypoventilation	I-Entity
,	O
and	O
was	O
paralyzed	I-Entity
to	O
control	O
muscle	B-Entity
rigidity	I-Entity
.	O

His	O
subsequent	O
course	O
was	O
remarkable	O
for	O
non	O
-	O
immune	O
thrombocytopenia	I-Entity
which	O
resolved	O
.	O

The	O
patient	O
's	O
maximal	O
temperature	O
was	O
101.2	O
F	O
and	O
his	O
CPK	O
remained	O
<	O
500	O
units	O
/	O
L	O
with	O
no	O
other	O
evidence	O
of	O
rhabdomyolysis	I-Entity
.	O

This	O
patient	O
survived	O
without	O
sequelae	O
due	O
to	O
the	O
aggressive	O
sedation	O
and	O
neuromuscular	O
paralysis	I-Entity
.	O



Effect	O
of	O
nondopaminergic	O
drugs	O
on	O
L	B-Entity
-	I-Entity
dopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
in	O
MPTP	I-Entity
-	O
treated	O
monkeys	O
.	O

A	O
group	O
of	O
four	O
monkeys	O
was	O
rendered	O
parkinsonian	I-Entity
with	O
the	O
toxin	O
MPTP	I-Entity
.	O

They	O
were	O
then	O
treated	O
chronically	O
with	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
/	I-Entity
benserazide	I-Entity
50/12.5	O
mg	O
/	O
kg	O
given	O
orally	O
daily	O
for	O
2	O
months	O
.	O

This	O
dose	O
produced	O
a	O
striking	O
antiparkinsonian	O
effect	O
,	O
but	O
all	O
animals	O
manifested	O
dyskinesia	I-Entity
.	O

A	O
series	O
of	O
agents	O
acting	O
primarily	O
on	O
neurotransmitters	O
other	O
than	O
dopamine	I-Entity
were	O
then	O
tested	O
in	O
combination	O
with	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
to	O
see	O
if	O
the	O
dyskinetic	I-Entity
movements	O
would	O
be	O
modified	O
.	O

Several	O
drugs	O
,	O
including	O
clonidine	I-Entity
,	O
physostigmine	I-Entity
,	O
methysergide	I-Entity
,	O
5-MDOT	I-Entity
,	O
propranolol	I-Entity
,	O
and	O
MK-801	I-Entity
,	O
markedly	O
reduced	O
the	O
dyskinetic	I-Entity
movements	O
but	O
at	O
the	O
cost	O
of	O
a	O
return	O
of	O
parkinsonian	I-Entity
symptomatology	O
.	O

However	O
,	O
yohimbine	I-Entity
and	O
meperidine	I-Entity
reduced	O
predominantly	O
the	O
dyskinetic	I-Entity
movements	O
.	O

Baclofen	I-Entity
was	O
also	O
useful	O
in	O
one	O
monkey	O
against	O
a	O
more	O
dystonic	I-Entity
form	O
of	O
dyskinesia	I-Entity
.	O

Atropine	I-Entity
converted	O
the	O
dystonic	I-Entity
movements	O
into	O
chorea	I-Entity
.	O



CCNU	I-Entity
(	O
lomustine	I-Entity
)	O
toxicity	I-Entity
in	O
dogs	O
:	O
a	O
retrospective	O
study	O
(	O
2002	O
-	O
07	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
incidence	O
of	O
haematological	B-Entity
,	I-Entity
renal	I-Entity
,	I-Entity
hepatic	I-Entity
and	I-Entity
gastrointestinal	I-Entity
toxicities	I-Entity
in	O
tumour	O
-	O
bearing	O
dogs	O
receiving	O
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea	I-Entity
(	O
CCNU	I-Entity
)	O
.	O

The	O
medical	O
records	O
of	O
206	O
dogs	O
that	O
were	O
treated	O
with	O
CCNU	I-Entity
at	O
the	O
Melbourne	O
Veterinary	O
Specialist	O
Centre	O
between	O
February	O
2002	O
and	O
December	O
2007	O
were	O
retrospectively	O
evaluated	O
.	O

Of	O
the	O
206	O
dogs	O
treated	O
with	O
CCNU	I-Entity
,	O
185	O
met	O
the	O
inclusion	O
criteria	O
for	O
at	O
least	O
one	O
class	O
of	O
toxicity	I-Entity
.	O

CCNU	I-Entity
was	O
used	O
most	O
commonly	O
in	O
the	O
treatment	O
of	O
lymphoma	I-Entity
,	O
mast	B-Entity
cell	I-Entity
tumour	I-Entity
,	O
brain	B-Entity
tumour	I-Entity
,	O
histiocytic	B-Entity
tumours	I-Entity
and	O
epitheliotropic	B-Entity
lymphoma	I-Entity
.	O

experienced	O
neutropenia	I-Entity
,	O
34.2%	O
experienced	O
anaemia	I-Entity
and	O
14.2%	O
experienced	O
thrombocytopenia	I-Entity
.	O

Gastrointestinal	B-Entity
toxicosis	I-Entity
was	O
detected	O
in	O
37.8%	O
of	O
dogs	O
,	O
the	O
most	O
common	O
sign	O
of	O
which	O
was	O
vomiting	I-Entity
(	O
24.3%	O
)	O
.	O

Potential	O
renal	O
toxicity	I-Entity
and	O
elevated	O
alanine	I-Entity
transaminase	O
(	O
ALT	O
)	O

The	O
incidence	O
of	O
hepatic	B-Entity
failure	I-Entity
was	O
1.2%	O
.	O

CONCLUSIONS	O
:	O
CCNU	I-Entity
-	O
associated	O
toxicity	I-Entity
in	O
dogs	O
is	O
common	O
,	O
but	O
is	O
usually	O
not	O
life	O
threatening	O
.	O



Neuroactive	O
steroids	I-Entity
protect	O
against	O
pilocarpine-	I-Entity
and	O
kainic	B-Entity
acid	I-Entity
-	O
induced	O
limbic	O
seizures	I-Entity
and	O
status	B-Entity
epilepticus	I-Entity
in	O
mice	O
.	O

Several	O
structurally	O
related	O
metabolites	O
of	O
progesterone	I-Entity
(	O
3	B-Entity
alpha	I-Entity
-	I-Entity
hydroxy	I-Entity
pregnane-20-ones	I-Entity
)	O
and	O
deoxycorticosterone	I-Entity
(	O
3	B-Entity
alpha	I-Entity
-	I-Entity
hydroxy	I-Entity
pregnane-21-diol-20-ones	I-Entity
)	O
and	O
their	O
3	O
beta	O
-	O
epimers	O
were	O
evaluated	O
for	O
protective	O
activity	O
against	O
pilocarpine-	I-Entity
,	O
kainic	B-Entity
acid-	I-Entity
and	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA)-induced	I-Entity
seizures	I-Entity
in	O
mice	O
.	O

Steroids	I-Entity
with	O
the	O
3-hydroxy	O
group	O
in	O
the	O
alpha	O
-	O
position	O
and	O
5-H	O
in	O
the	O
alpha-	O
or	O
beta	O
-	O
configurations	O
were	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine	I-Entity
(	O
416	O
mg	O
/	O
kg	O
,	O
s.c.)-induced	O
limbic	O
motor	O
seizures	I-Entity
and	O
status	B-Entity
epilepticus	I-Entity
(	O
ED50	O
values	O
,	O
7.0	O
-	O
18.7	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

Although	O
the	O
neuroactive	O
steroids	I-Entity
were	O
considerably	O
less	O
potent	O
than	O
the	O
benzodiazepine	I-Entity
clonazepam	I-Entity
in	O
protecting	O
against	O
pilocarpine	I-Entity
seizures	I-Entity
,	O
steroids	I-Entity
with	O
the	O
5	O
alpha,3	O
alpha	O
-	O
configuration	O
had	O
comparable	O
or	O
higher	O
protective	O
index	O
values	O
(	O
TD50	O
for	O
motor	O
impairment	O
divided	O
by	O
ED50	O
for	O
seizure	I-Entity
protection	O
)	O
than	O
clonazepam	I-Entity
,	O
indicating	O
that	O
some	O
neuroactive	O
steroids	I-Entity
may	O
have	O
lower	O
relative	O
toxicity	I-Entity
.	O

Steroids	I-Entity
with	O
the	O
5	O
alpha,3	O
alpha-	O
or	O
5	O
beta,3	O
alpha	O
-	O
configurations	O
also	O
produced	O
a	O
dose	O
-	O
dependent	O
delay	O
in	O
the	O
onset	O
of	O
limbic	O
seizures	I-Entity
induced	O
by	O
kainic	B-Entity
acid	I-Entity
(	O
32	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
,	O
but	O
did	O
not	O
completely	O
protect	O
against	O
the	O
seizures	I-Entity
.	O

However	O
,	O
when	O
a	O
second	O
dose	O
of	O
the	O
steroid	I-Entity
was	O
administered	O
1	O
hr	O
after	O
the	O
first	O
dose	O
,	O
complete	O
protection	O
from	O
the	O
kainic	B-Entity
acid	I-Entity
-	O
induced	O
limbic	O
seizures	I-Entity
and	O
status	B-Entity
epilepticus	I-Entity
was	O
obtained	O
.	O

The	O
steroids	I-Entity
also	O
caused	O
a	O
dose	O
-	O
dependent	O
delay	O
in	O
NMDA	I-Entity
(	O
257	O
mg	O
/	O
kg	O
,	O
s.c.)-induced	O
lethality	O
,	O
but	O
did	O
not	O
completely	O
protect	O
against	O
NMDA	I-Entity
seizures	I-Entity
or	O
lethality	O
.	O

We	O
conclude	O
that	O
neuroactive	O
steroids	I-Entity
are	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine-	I-Entity
and	O
kainic	B-Entity
acid	I-Entity
-	O
induced	O
seizures	I-Entity
and	O
status	B-Entity
epilepticus	I-Entity
in	O
mice	O
,	O
and	O
may	O
be	O
of	O
utility	O
in	O
the	O
treatment	O
of	O
some	O
forms	O
of	O
status	B-Entity
epilepticus	I-Entity
in	O
humans	O
.	O



The	O
safety	O
and	O
efficacy	O
of	O
combination	O
N	B-Entity
-	I-Entity
butyl	I-Entity
-	I-Entity
deoxynojirimycin	I-Entity
(	O
SC-48334	I-Entity
)	O
and	O
zidovudine	I-Entity
in	O
patients	O
with	O
HIV-1	B-Entity
infection	I-Entity
and	O
200	O
-	O
500	O
CD4	O
cells	O
/	O
mm3	O
.	O

We	O
conducted	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
phase	O
II	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
activity	O
of	O
combination	O
therapy	O
with	O
N	B-Entity
-	I-Entity
butyl	I-Entity
-	I-Entity
deoxynojirimycin	I-Entity
(	O
SC-48334	I-Entity
)	O
(	O
an	O
alpha	O
-	O
glucosidase	O
I	O
inhibitor	O
)	O
and	O
zidovudine	I-Entity
versus	O
zidovudine	I-Entity
alone	O
.	O

mm3	O
who	O
tolerated	O
<	O
or	O
=	O
12	O
weeks	O
of	O
prior	O
zidovudine	I-Entity
therapy	O
received	O
SC-48334	I-Entity
(	O
1000	O
mg	O
every	O
8	O
h	O
)	O
and	O
zidovudine	I-Entity
(	O
100	O
mg	O
every	O
8	O
h	O
)	O
or	O
zidovudine	I-Entity
and	O
placebo	O
.	O

Sixty	O
patients	O
received	O
combination	O
therapy	O
and	O
58	O
,	O
zidovudine	I-Entity
and	O
placebo	O
.	O

Twenty	O
-	O
three	O
patients	O
(	O
38%	O
)	O
and	O
15	O
(	O
26%	O
)	O
,	O
in	O
the	O
combination	O
and	O
zidovudine	I-Entity
groups	O
,	O
respectively	O
,	O
discontinued	O
therapy	O
(	O
p	O
=	O
0.15	O
)	O
.	O

The	O
mean	O
SC-48334	I-Entity
steady	O
-	O
state	O
trough	O
level	O
(	O
4.04	O
+	O
/-	O

0.99	O
micrograms	O
/	O
ml	O
)	O
was	O
below	O
the	O
in	O
vitro	O
inhibitory	O
concentration	O
for	O
human	O
immunodeficiency	I-Entity
virus	O
(	O
HIV	O
)	O
.	O

/	O
mm3	O
for	O
the	O
combination	O
and	O
zidovudine	I-Entity
groups	O
,	O
respectively	O
(	O
p	O
>	O
0.36	O
)	O
.	O

For	O
patients	O
with	O
prior	O
zidovudine	I-Entity
therapy	O
,	O
the	O
mean	O
change	O
in	O
CD4	O
cells	O
in	O
the	O
combination	O
and	O
zidovudine	I-Entity
groups	O
was	O
63.7	O
cells	O
/	O
mm3	O
and	O
4.9	O
cells	O
/	O
mm3	O
at	O
week	O
8	O
and	O
6.8	O
cells	O
/	O
mm3	O
and	O
-45.1	O
cells	O
/	O
mm3	O
at	O
week	O
16	O
,	O
respectively	O
.	O

The	O
number	O
of	O
patients	O
with	O
suppression	O
of	O
HIV	O
p24	O
antigenemia	O
in	O
the	O
combination	O
and	O
zidovudine	I-Entity
groups	O
was	O
six	O
(	O
40%	O
)	O
and	O
two	O
(	O
11%	O
)	O
at	O
week	O
4	O
(	O
p	O
=	O
0.10	O
)	O
and	O
five	O
(	O
45%	O
)	O
and	O
two	O
(	O
14%	O
)	O
at	O
week	O
24	O
(	O
p	O
=	O
0.08	O
)	O
,	O
respectively	O
.	O

Diarrhea	I-Entity
,	O
flatulence	I-Entity
,	O
abdominal	B-Entity
pain	I-Entity
,	O
and	O
weight	B-Entity
loss	I-Entity
were	O
common	O
for	O
combination	O
recipients.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Recent	O
preclinical	O
and	O
clinical	O
studies	O
with	O
the	O
thymidylate	O
synthase	O
inhibitor	O
N10-propargyl-5,8-dideazafolic	B-Entity
acid	I-Entity
(	O
CB	B-Entity
3717	I-Entity
)	O
.	O

CB	B-Entity
3717	I-Entity
,	O
N10-propargyl-5,8-dideazafolic	B-Entity
acid	I-Entity
,	O
is	O
a	O
tight	O
-	O
binding	O
inhibitor	O
of	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
whose	O
cytotoxicity	I-Entity
is	O
mediated	O
solely	O
through	O
the	O
inhibition	O
of	O
this	O
enzyme	O
.	O

Recent	O
preclinical	O
studies	O
have	O
focused	O
on	O
the	O
intracellular	O
formation	O
of	O
CB	B-Entity
3717	I-Entity
polyglutamates	O
.	O

Following	O
a	O
12-hour	O
exposure	O
of	O
L1210	O
cells	O
to	O
50	O
microM	O
[	O
3H]CB	B-Entity
3717	I-Entity
,	O
30%	O
of	O
the	O
extractable	O
radioactivity	O
could	O
be	O
accounted	O
for	O
as	O
CB	B-Entity
3717	I-Entity
tetra-	O
and	O
pentaglutamate	O
,	O
as	O
determined	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analyses	O
.	O

As	O
inhibitors	O
of	O
isolated	O
L1210	O
TS	O
,	O
CB	O
3717	O
di-	O
,	O
tri-	O
,	O
tetra-	O
and	O
pentaglutamate	O
are	O
26-	O
,	O
87-	O
,	O
119-	O
and	O
114-fold	O
more	O
potent	O
than	O
CB	B-Entity
3717	I-Entity
,	O
respectively	O
,	O
and	O
their	O
formation	O
may	O
,	O
therefore	O
,	O
be	O
an	O
important	O
determinant	O
of	O
CB	B-Entity
3717	I-Entity
cytotoxicity	I-Entity
.	O

In	O
early	O
clinical	O
studies	O
with	O
CB	B-Entity
3717	I-Entity
,	O
activity	O
has	O
been	O
seen	O
in	O
breast	B-Entity
cancer	I-Entity
,	O
ovarian	B-Entity
cancer	I-Entity
,	O
hepatoma	I-Entity
,	O
and	O
mesothelioma	I-Entity
.	O

Toxicities	I-Entity
included	O
hepatotoxicity	I-Entity
,	O
malaise	I-Entity
,	O
and	O
dose	O
-	O
limiting	O
nephrotoxicity	I-Entity
.	O

This	O
latter	O
effect	O
is	O
thought	O
to	O
be	O
due	O
to	O
drug	O
precipitation	O
within	O
the	O
renal	O
tubule	O
as	O
a	O
result	O
of	O
the	O
poor	O
solubility	O
of	O
CB	B-Entity
3717	I-Entity
under	O
acidic	O
conditions	O
.	O

In	O
an	O
attempt	O
to	O
overcome	O
this	O
problem	O
,	O
a	O
clinical	O
trial	O
of	O
CB	B-Entity
3717	I-Entity
administered	O
with	O
alkaline	O
diuresis	O
is	O
under	O
way	O
.	O

Preliminary	O
results	O
at	O
400	O
and	O
500	O
mg	O
/	O
m2	O
suggest	O
that	O
a	O
reduction	O
in	O
nephrotoxicity	I-Entity
may	O
have	O
been	O
achieved	O
with	O
only	O
1	O
instance	O
of	O
renal	B-Entity
toxicity	I-Entity
in	O
10	O
patients	O
.	O

Hepatotoxicity	I-Entity
and	O
malaise	I-Entity
are	O
again	O
the	O
most	O
frequent	O
side	O
effects	O
.	O

Pharmacokinetic	O
investigations	O
have	O
shown	O
that	O
alkaline	O
diuresis	O
does	O
not	O
alter	O
CB	B-Entity
3717	I-Entity
plasma	O
levels	O
or	O
urinary	O
excretion	O
and	O
that	O
satisfactory	O
urinary	O
alkalinization	O
can	O
be	O
readily	O
achieved	O
.	O



Ethopropazine	I-Entity
and	O
benztropine	I-Entity
in	O
neuroleptic	O
-	O
induced	O
parkinsonism	I-Entity
.	O

In	O
a	O
12-week	O
controlled	O
study	O
ethopropazine	I-Entity
was	O
compared	O
to	O
benztropine	I-Entity
in	O
the	O
treatment	O
of	O
parkinsonism	I-Entity
induced	O
by	O
fluphenazine	B-Entity
enanthate	I-Entity
in	O
60	O
schizophrenic	I-Entity
outpatients	O
.	O

Ethopropazine	I-Entity
and	O
benztropine	I-Entity
were	O
found	O
to	O
be	O
equally	O
effective	O
in	O
controlling	O
parkinsonian	B-Entity
symptoms	I-Entity
and	O
were	O
as	O
efficacious	O
as	O
procyclidine	I-Entity
,	O
their	O
previous	O
antiparkinsonian	O
drug	O
.	O

However	O
,	O
benztropine	I-Entity
treated	O
patients	O
had	O
a	O
significant	O
increase	O
in	O
tardive	B-Entity
dyskinesia	I-Entity
compared	O
to	O
their	O
condition	O
during	O
procyclindine	I-Entity
treatment	O
,	O
and	O
significantly	O
more	O
anxiety	I-Entity
and	O
depression	I-Entity
than	O
ethopropazine	I-Entity
treated	O
patients	O
.	O

This	O
suggests	O
that	O
benztropine	I-Entity
is	O
not	O
the	O
anticholinergic	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
neuroleptic	O
-	O
induced	O
parkinsonian	B-Entity
symptoms	I-Entity
,	O
because	O
of	O
its	O
more	O
toxic	O
central	O
and	O
peripheral	O
atropinic	O
effect	O
.	O



Effect	O
of	O
alpha	B-Entity
-	I-Entity
tocopherol	I-Entity
and	O
deferoxamine	I-Entity
on	O
methamphetamine	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
.	O

Methamphetamine	I-Entity

(	O
MA)-induced	I-Entity
dopaminergic	O
neurotoxicity	I-Entity
is	O
believed	O
to	O
be	O
associated	O
with	O
the	O
increased	O
formation	O
of	O
free	O
radicals	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
alpha	B-Entity
-	I-Entity
tocopherol	I-Entity
(	O
alpha	B-Entity
-	I-Entity
TC	I-Entity
)	O
,	O
a	O
scavenger	O
of	O
reactive	O
oxygen	I-Entity
species	O
,	O
and	O
deferoxamine	I-Entity
(	O
DFO	I-Entity
)	O
,	O
an	O
iron	I-Entity
chelator	O
,	O
on	O
the	O
MA	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
.	O

Male	O
rats	O
were	O
treated	O
with	O
MA	I-Entity
(	O
10	O
mg	O
/	O
kg	O
,	O
every	O
2	O
h	O
for	O
four	O
injections	O
)	O
.	O

The	O
rat	O
received	O
either	O
alpha	B-Entity
-	I-Entity
TC	I-Entity
(	O
20	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
for	O
3	O
days	O
and	O
30	O
min	O
prior	O
to	O
MA	I-Entity
administration	O
or	O
DFO	I-Entity
(	O
50	O
mg	O
/	O
kg	O
)	O

min	O
before	O
MA	I-Entity
administration	O
.	O

The	O
concentrations	O
of	O
dopamine	I-Entity
(	O
DA	I-Entity
)	O
,	O
serotonin	I-Entity
and	O
their	O
metabolites	O
decreased	O
significantly	O
after	O
MA	I-Entity
administration	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
alpha	B-Entity
-	I-Entity
TC	I-Entity
and	O
DFO	I-Entity
pretreatment	O
.	O

alpha	B-Entity
-	I-Entity
TC	I-Entity
and	O
DFO	I-Entity
attenuated	O
the	O
MA	I-Entity
-	O
induced	O
hyperthermia	I-Entity
as	O
well	O
as	O
the	O
alterations	O
in	O
the	O
locomotor	O
activity	O
.	O

The	O
level	O
of	O
lipid	O
peroxidation	O
was	O
higher	O
and	O
the	O
reduced	O
glutathione	I-Entity
concentration	O
was	O
lower	O
in	O
the	O
MA	I-Entity
-	O
treated	O
rats	O
.	O

These	O
changes	O
were	O
significantly	O
attenuated	O
by	O
alpha	B-Entity
-	I-Entity
TC	I-Entity
and	O
DFO	I-Entity
.	O

This	O
suggests	O
that	O
alpha	B-Entity
-	I-Entity
TC	I-Entity
and	O
DFO	I-Entity
ameliorate	O
the	O
MA	I-Entity
-	O
induced	O
neuronal	B-Entity
damage	I-Entity
by	O
decreasing	O
the	O
level	O
of	O
oxidative	O
stress	O
.	O



Use	O
of	O
dexamethasone	I-Entity
with	O
mesna	I-Entity
for	O
the	O
prevention	O
of	O
ifosfamide	I-Entity
-	O
induced	O
hemorrhagic	B-Entity
cystitis	I-Entity
.	O

AIM	O
:	O
Hemorrhagic	B-Entity
cystitis	I-Entity
(	O
HC	I-Entity
)	O
is	O
a	O
limiting	O
side	O
-	O
effect	O
of	O
chemotherapy	O
with	O
ifosfamide	I-Entity
(	O
IFS	I-Entity
)	O
.	O

In	O
the	O
study	O
presented	O
here	O
,	O
we	O
investigated	O
the	O
use	O
of	O
dexamethasone	I-Entity
in	O
combination	O
with	O
mesna	I-Entity
for	O
the	O
prevention	O
of	O
IFS	I-Entity
-	O
induced	O
HC	I-Entity
.	O

Male	O
Wistar	O
rats	O
(	O
150	O
-	O
200	O
g	O
;	O
6	O
rats	O
per	O
group	O
)	O
were	O
treated	O
with	O
saline	O
or	O
mesna	I-Entity
5	O
min	O
(	O
i.p	O
.	O
)	O
before	O
and	O
2	O
and	O
6	O
h	O
after	O
(	O
v.o	O
.	O
)	O

administration	O
of	O
IFS	I-Entity
.	O

One	O
,	O
two	O
or	O
three	O
doses	O
of	O
mesna	I-Entity
were	O
replaced	O
with	O
dexamethasone	I-Entity
alone	O
or	O
with	O
dexamethasone	I-Entity
plus	O
mesna	I-Entity
.	O

Cystitis	I-Entity
was	O
evaluated	O
24	O
h	O
after	O
its	O
induction	O
by	O
the	O
changes	O
in	O
bladder	O
wet	O
weight	O
and	O
by	O
macroscopic	O
and	O
microscopic	O
analysis	O
.	O

The	O
replacement	O
of	O
the	O
last	O
dose	O
or	O
the	O
last	O
two	O
doses	O
of	O
mesna	I-Entity
with	O
dexamethasone	I-Entity
reduced	O
the	O
increase	O
in	O
bladder	O
wet	O
weight	O
induced	O
by	O
IFS	I-Entity
by	O
84.79%	O
and	O
89.13%	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
it	O
almost	O
abolished	O
the	O
macroscopic	O
and	O
microscopic	O
alterations	O
induced	O
by	O
IFS	I-Entity
.	O

Moreover	O
,	O
the	O
addition	O
of	O
dexamethasone	I-Entity
to	O
the	O
last	O
two	O
doses	O
of	O
mesna	I-Entity
was	O
more	O
efficient	O
than	O
three	O
doses	O
of	O
mesna	I-Entity
alone	O
when	O
evaluated	O
microscopically	O
.	O

CONCLUSION	O
:	O
Dexamethasone	I-Entity
in	O
combination	O
with	O
mesna	I-Entity
was	O
efficient	O
in	O
blocking	O
IFS	I-Entity
-	O
induced	O
HC	I-Entity
.	O

However	O
,	O
the	O
replacement	O
of	O
last	O
two	O
doses	O
of	O
mesna	I-Entity
with	O
saline	O
or	O
all	O
of	O
the	O
mesna	I-Entity
doses	O
with	O
dexamethasone	I-Entity
did	O
not	O
prevent	O
HC	I-Entity
.	O



Behavioral	O
effects	O
of	O
MK-801	I-Entity
on	O
reserpine	I-Entity
-	O
treated	O
mice	O
.	O

The	O
effects	O
of	O
dizocilpine	I-Entity
(	O
MK-801	I-Entity
)	O
,	O
a	O
noncompetitive	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O
receptor	O
antagonist	O
,	O
were	O
studied	O
on	O
dopamine	I-Entity
-	O
related	O
behaviors	O
induced	O
by	O
reserpine	I-Entity
treatments	O
.	O

This	O
study	O
focuses	O
on	O
behavioral	O
syndromes	O
that	O
may	O
used	O
as	O
models	O
for	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
,	O
or	O
tardive	B-Entity
dyskinesia	I-Entity
,	O
and	O
its	O
response	O
after	O
glutamatergic	O
blockage	O
.	O

Reserpine	I-Entity
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
administered	O
once	O
every	O
other	O
day	O
for	O
4	O
days	O
,	O
produced	O
increases	O
in	O
orofacial	B-Entity
dyskinesia	I-Entity
,	O
tongue	O
protrusion	O
and	O
vacuous	O
chewing	O
in	O
mice	O
,	O
which	O
are	O
signs	O
indicative	O
of	O
tardive	B-Entity
dyskinesia	I-Entity
.	O

Reserpine	I-Entity
also	O
produced	O
tremor	I-Entity
and	O
catalepsy	I-Entity
,	O
which	O
are	O
signs	O
suggestive	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

MK-801	I-Entity
(	O
0.1	O
mg	O
/	O
kg	O
)	O
,	O
administered	O
30	O
min	O
before	O
the	O
observation	O
test	O
,	O
prevented	O
the	O
vacuous	O
chewing	O
movements	O
,	O
tongue	O
protrusions	O
and	O
catalepsy	I-Entity
induced	O
by	O
reserpine	I-Entity
.	O

However	O
,	O
MK-801	I-Entity
injection	O
produced	O
a	O
significant	O
increase	O
of	O
tremor	I-Entity
in	O
reserpine	I-Entity
-	O
treated	O
mice	O
.	O

Reserpine	I-Entity
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
administered	O
90	O
min	O
before	O
the	O
test	O
and	O
followed	O
by	O
apomophine	I-Entity
injection	O
(	O
0.1	O
mg	O
/	O
kg	O
)	O

5	O
min	O
before	O
the	O
test	O
,	O
did	O
not	O
produce	O
oral	B-Entity
dyskinesia	I-Entity
in	O
mice	O
.	O

On	O
the	O
other	O
hand	O
,	O
reserpine	I-Entity
induced	O
increases	O
in	O
tremor	I-Entity
and	O
catalepsy	I-Entity
compared	O
to	O
control	O
mice	O
.	O

MK-801	I-Entity
(	O
0.1	O
mg	O
/	O
kg	O
)	O
administration	O
attenuated	O
the	O
catalepsy	I-Entity
and	O
tremor	I-Entity
induced	O
by	O
reserpine	I-Entity
.	O

Pretreatment	O
with	O
reserpine	I-Entity
(	O
1	O
mg	O
/	O
kg	O
)	O
24	O

h	O
before	O
the	O
observation	O
test	O
produced	O
increases	O
in	O
vacuous	O
chewing	O
movements	O
and	O
tongue	O
protrusion	O
,	O
as	O
well	O
as	O
increases	O
in	O
tremor	I-Entity
and	O
catalepsy	I-Entity
,	O
whereas	O
MK-801	I-Entity
(	O
0.1	O
mg	O
/	O
kg	O
)	O
injection	O
90	O
min	O
before	O
the	O
test	O
reversed	O
the	O
effects	O
of	O
reserpine	I-Entity
.	O

These	O
results	O
show	O
that	O
reserpine	I-Entity
produces	O
different	O
and	O
abnormal	B-Entity
movements	I-Entity
,	O
which	O
are	O
related	O
to	O
dose	O
and	O
schedule	O
employed	O
and	O
can	O
be	O
considered	O
as	O
parkinsonian	I-Entity
-	O
like	O
and	O
tardive	B-Entity
dsykinesia	I-Entity
signs	O
.	O

The	O
glutamatergic	O
blockage	O
produced	O
by	O
NMDA	I-Entity
can	O
restore	O
these	O
signs	O
,	O
such	O
as	O
vacuous	O
chewing	O
movements	O
,	O
tongue	O
protrusions	O
,	O
catalepsy	I-Entity
and	O
tremor	I-Entity
according	O
to	O
the	O
employed	O
model	O
.	O



Effect	O
of	O
glyceryl	B-Entity
trinitrate	I-Entity
on	O
the	O
sphincter	B-Entity
of	I-Entity
Oddi	I-Entity
spasm	I-Entity
evoked	O
by	O
prostigmine	I-Entity
-	O
morphine	I-Entity
administration	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
glyceryl	B-Entity
trinitrate	I-Entity
on	O
the	O
prostigmine	I-Entity
-	O
morphine	I-Entity
-	O
induced	O
sphincter	B-Entity
of	I-Entity
Oddi	I-Entity
spasm	I-Entity
was	O
evaluated	O
in	O
nine	O
female	O
patients	O
with	O
sphincter	B-Entity
of	I-Entity
Oddi	I-Entity
dyskinesia	I-Entity
.	O

METHOD	O
:	O
Sphincter	B-Entity
of	I-Entity
Oddi	I-Entity
spasm	I-Entity
was	O
induced	O
by	O
prostigmine	I-Entity
-	O
morphine	I-Entity
administration	O
(	O
0.5	O
mg	O
prostigmine	I-Entity
intramuscularly	O
and	O
10	O
mg	O
morphine	I-Entity
subcutaneously	O
)	O
and	O
visualized	O
by	O
quantitative	O
hepatobiliary	O
scintigraphy	O
.	O

The	O
entire	O
procedure	O
was	O
repeated	O
during	O
glyceryl	B-Entity
trinitrate	I-Entity
infusion	O
(	O
Nitrolingual	I-Entity
1	O

RESULTS	O
:	O
Prostigmine	I-Entity
-	O
morphine	I-Entity
provocation	O
caused	O
significant	O
increases	O
in	O
the	O
time	O
to	O
peak	O
activity	O
(	O
Tmax	O
)	O
over	O
the	O
hepatic	O
hilum	O
(	O
HH	O
:	O
34.33	O
+	O
/-	O

6.24	O
)	O
,	O
indicating	O
a	O
complete	O
spasm	I-Entity
at	O
the	O
level	O
of	O
the	O
sphincter	O
of	O
Oddi	O
.	O

Glyceryl	B-Entity
trinitrate	I-Entity
infusion	O
completely	O
normalized	O
the	O
prostigmine	I-Entity
-	O
morphine	I-Entity
-	O
induced	O
alterations	O
in	O
these	O
quantitative	O
parameters	O
(	O
TmaX	O
over	O
the	O
LP	O
:	O
11.33	O
+	O
/-	O

6.33	O
)	O
,	O
suggesting	O
an	O
effective	O
sphincter	O
-	O
relaxing	O
effect	O
of	O
glyceryl	B-Entity
trinitrate	I-Entity
.	O

CONCLUSION	O
:	O
These	O
results	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
effectiveness	O
of	O
glyceryl	B-Entity
trinitrate	I-Entity
on	O
the	O
morphine	I-Entity
-	O
induced	O
sphincter	B-Entity
of	I-Entity
Oddi	I-Entity
spasm	I-Entity
in	O
humans	O
.	O

Since	O
glyceryl	B-Entity
trinitrate	I-Entity
is	O
able	O
to	O
overcome	O
even	O
the	O
drastic	O
effect	O
of	O
morphine	I-Entity
,	O
it	O
might	O
be	O
of	O
relevance	O
in	O
the	O
treatment	O
of	O
sphincter	B-Entity
of	I-Entity
Oddi	I-Entity
dyskinesia	I-Entity
.	O



Effects	O
of	O
acute	O
steroid	I-Entity
administration	O
on	O
ventilatory	O
and	O
peripheral	O
muscles	O
in	O
rats	O
.	O

Occasional	O
case	O
reports	O
have	O
shown	O
that	O
acute	O
myopathy	I-Entity
may	O
occur	O
in	O
patients	O
treated	O
with	O
massive	O
doses	O
of	O
corticosteroids	I-Entity
.	O

The	O
mechanism	O
of	O
this	O
myopathy	I-Entity
is	O
poorly	O
understood	O
.	O

Therefore	O
,	O
60	O
male	O
rats	O
were	O
randomly	O
assigned	O
to	O
receive	O
daily	O
injection	O
of	O
saline	O
(	O
C	O
)	O
,	O
methylprednisolone	I-Entity
(	O
M	I-Entity
)	O
,	O
or	O
triamcinolone	I-Entity
(	O
T	I-Entity
)	O
80	O
mg	O
/	O
kg	O
/	O
d	O
for	O
5	O
d.	O
Nutritional	O
intake	O
,	O
measured	O
daily	O
in	O
15	O
animals	O
,	O
showed	O
a	O
significant	O
reduction	B-Entity
of	I-Entity
food	I-Entity
intake	I-Entity
in	O
the	O
steroid	I-Entity
-	O
treated	O
groups	O
(	O
-50	O
and	O
-79%	O
in	O
M	I-Entity
and	O
T	I-Entity
,	O
respectively	O
)	O
.	O

This	O
was	O
associated	O
with	O
a	O
similar	O
loss	B-Entity
in	I-Entity
body	I-Entity
weight	I-Entity
.	O

Weights	O
of	O
respiratory	O
and	O
peripheral	O
muscles	O
were	O
similarly	O
decreased	O
after	O
steroid	I-Entity
treatment	O
.	O

174	O
g	O
/	O
cm(2	O
)	O
)	O
than	O
in	O
the	O
M	I-Entity
group	O
(	O
837	O
+	O
/-	O

p	O
<	O
0.05	O
)	O
and	O
the	O
T	I-Entity
group	O
(	O
765	O
+	O
/-	O

Half	O
-	O
relaxation	O
time	O
was	O
prolonged	O
in	O
both	O
steroid	I-Entity
groups	O
,	O
and	O
time	O
to	O
peak	O
tension	O
was	O
longer	O
with	O
M	I-Entity
,	O
whereas	O
tetanic	I-Entity
tensions	O
were	O
similar	O
.	O

Steroid	I-Entity
treatment	O
also	O
induced	O
a	O
leftward	O
shift	O
of	O
the	O
force	O
-	O
frequency	O
curve	O
at	O
25	O
and	O
50	O
Hz	O
when	O
compared	O
with	O
saline	O
treatment	O
(	O
p	O
<	O
0.05	O
)	O
.	O

ATPase	O
staining	O
of	O
the	O
diaphragm	O
,	O
scalenus	O
medius	O
,	O
and	O
gastrocnemius	O
showed	O
type	O
IIb	O
fiber	O
atrophy	I-Entity
in	O
the	O
steroid	I-Entity
groups	O
and	O
also	O
diaphragmatic	O
type	O
IIa	O
atrophy	I-Entity
with	O
T	I-Entity
,	O
whereas	O
histologic	O
examinations	O
revealed	O
a	O
normal	O
muscular	O
pattern	O
with	O
absence	O
of	O
necrosis	I-Entity
.	O

Finally	O
,	O
a	O
pair	O
-	O
fed	O
(	O
PF	O
)	O
study	O
,	O
performed	O
in	O
18	O
rats	O
(	O
C	O
,	O
T	I-Entity
,	O
and	O
PF	O
)	O
,	O
showed	O
that	O
muscle	B-Entity
atrophy	I-Entity
was	O
considerably	O
less	O
pronounced	O
in	O
PF	O
animals	O
than	O
in	O
T	I-Entity
-	O
treated	O
animals	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
short	O
-	O
term	O
treatment	O
with	O
massive	O
doses	O
of	O
steroids	I-Entity
induced	O
severe	O
respiratory	O
and	O
limb	O
muscle	O
wasting	O
;	O
(	O
2	O
)	O
both	O
types	O
of	O
steroids	I-Entity
induced	O
predominantly	O
type	O
IIb	O
atrophy	I-Entity
,	O
resulting	O
in	O
the	O
expected	O
alterations	O
in	O
diaphragm	O
contractile	O
properties	O
;	O
(	O
3	O
)	O
neither	O
steroid	I-Entity
caused	O
muscle	O
necrosis	I-Entity
;	O
(	O
4	O
)	O
type	O
IIb	O
atrophy	I-Entity
was	O
not	O
caused	O
by	O
acute	O
nutritional	O
deprivation	O
alone	O
.	O



Refractory	O
cardiogenic	B-Entity
shock	I-Entity
and	O
complete	O
heart	B-Entity
block	I-Entity
after	O
verapamil	I-Entity
SR	O
and	O
metoprolol	I-Entity
treatment	O
.	O

A	O
seventy	O
-	O
eight	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
complete	O
heart	B-Entity
block	I-Entity
and	O
refractory	O
hypotension	I-Entity
two	O
days	O
after	O
a	O
therapeutic	O
dose	O
of	O
sustained	O
-	O
release	O
verapamil	I-Entity
with	O
concomitant	O
use	O
of	O
metoprolol	I-Entity
.	O

The	O
patient	O
continued	O
to	O
remain	O
hypotensive	I-Entity
with	O
complete	O
heart	B-Entity
block	I-Entity
,	O
even	O
with	O
multiple	O
uses	O
of	O
intravenous	O
atropine	I-Entity
as	O
well	O
as	O
high	O
doses	O
of	O
pressor	O
agents	O
such	O
as	O
dopamine	I-Entity
and	O
dobutamine	I-Entity
.	O

However	O
,	O
shortly	O
after	O
the	O
use	O
of	O
intravenous	O
calcium	B-Entity
chloride	I-Entity
,	O
the	O
refractory	O
hypotension	I-Entity
and	O
complete	O
heart	B-Entity
block	I-Entity
resolved	O
.	O



A	O
phase	O
I	O
clinical	O
study	O
of	O
the	O
antipurine	I-Entity
antifolate	O
lometrexol	I-Entity
(	O
DDATHF	I-Entity
)	O
given	O
with	O
oral	O
folic	B-Entity
acid	I-Entity
.	O

Lometrexol	I-Entity
is	O
an	O
antifolate	O
which	O
inhibits	O
glycinamide	B-Entity
ribonucleotide	I-Entity
formyltransferase	O
(	O
GARFT	O
)	O
,	O
an	O
enzyme	O
essential	O
for	O
de	O
novo	O
purine	I-Entity
synthesis	O
.	O

Extensive	O
experimental	O
and	O
limited	O
clinical	O
data	O
have	O
shown	O
that	O
lometrexol	I-Entity
has	O
activity	O
against	O
tumours	I-Entity
which	O
are	O
refractory	O
to	O
other	O
drugs	O
,	O
notably	O
methotrexate	I-Entity
.	O

However	O
,	O
the	O
initial	O
clinical	O
development	O
of	O
lometrexol	I-Entity
was	O
curtailed	O
because	O
of	O
severe	O
and	O
cumulative	O
antiproliferative	O
toxicities	I-Entity
.	O

Preclinical	O
murine	O
studies	O
demonstrated	O
that	O
the	O
toxicity	I-Entity
of	O
lometrexol	I-Entity
can	O
be	O
prevented	O
by	O
low	O
dose	O
folic	B-Entity
acid	I-Entity
administration	O
,	O
i.e.	O
for	O
7	O
days	O
prior	O
to	O
and	O
7	O
days	O
following	O
a	O
single	O
bolus	O
dose	O
.	O

This	O
observation	O
prompted	O
a	O
Phase	O
I	O
clinical	O
study	O
of	O
lometrexol	I-Entity
given	O
with	O
folic	B-Entity
acid	I-Entity
supplementation	O
which	O
has	O
confirmed	O
that	O
the	O
toxicity	I-Entity
of	O
lometrexol	I-Entity
can	O
be	O
markedly	O
reduced	O
by	O
folic	B-Entity
acid	I-Entity
supplementation	O
.	O

Thrombocytopenia	I-Entity
and	O
mucositis	I-Entity
were	O
the	O
major	O
toxicities	I-Entity
.	O

There	O
was	O
no	O
clear	O
relationship	O
between	O
clinical	O
toxicity	I-Entity
and	O
the	O
extent	O
of	O
plasma	O
folate	I-Entity
elevation	O
.	O

Associated	O
studies	O
demonstrated	O
that	O
lometrexol	I-Entity
plasma	O
pharmacokinetics	O
were	O
not	O
altered	O
by	O
folic	B-Entity
acid	I-Entity
administration	O
indicating	O
that	O
supplementation	O
is	O
unlikely	O
to	O
reduce	O
toxicity	I-Entity
by	O
enhancing	O
lometrexol	I-Entity
plasma	O
clearance	O
.	O

This	O
information	O
will	O
facilitate	O
the	O
future	O
evaluation	O
of	O
this	O
class	O
of	O
compounds	O
in	O
cancer	I-Entity
therapy	O
.	O



Involvement	O
of	O
the	O
mu	O
-	O
opiate	O
receptor	O
in	O
peripheral	O
analgesia	I-Entity
.	O

The	O
intradermal	O
injection	O
of	O
mu	O
(	O
morphine	I-Entity
,	O
Tyr	B-Entity
-	I-Entity
D	I-Entity
-	I-Entity
Ala	I-Entity
-	I-Entity
Gly	I-Entity
-	I-Entity
NMe	I-Entity
-	I-Entity
Phe	I-Entity
-	I-Entity
Gly	I-Entity
-	I-Entity
ol	I-Entity
and	O
morphiceptin	I-Entity
)	O
,	O
kappa	O
(	O
trans-3,4-dichloro	B-Entity
-	I-Entity
N	I-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
N[2-(1-pyrrolidinyl	I-Entity
)	I-Entity
cyclohexyl]benzeneactemide	I-Entity
)	O
and	O
delta	O
(	O
[	B-Entity
D	I-Entity
-	I-Entity
Pen2.5]-enkephalin	I-Entity
and	O
[	B-Entity
D	I-Entity
-	I-Entity
Ser2]-[Leu]enkephalin	I-Entity
-	I-Entity
Thr	I-Entity
)	O
selective	O
opioid	O
-	O
agonists	O
,	O
by	O
themselves	O
,	O
did	O
not	O
significantly	O
affect	O
the	O
mechanical	O
nociceptive	O
threshold	O
in	O
the	O
hindpaw	O
of	O
the	O
rat	O
.	O

,	O
however	O
,	O
produced	O
dose	O
-	O
dependent	O
inhibition	O
of	O
prostaglandin	B-Entity
E2-induced	I-Entity
hyperalgesia	I-Entity
.	O

The	O
analgesic	O
effect	O
of	O
the	O
mu	O
-	O
agonist	O
morphine	I-Entity
was	O
dose	O
-	O
dependently	O
antagonized	O
by	O
naloxone	I-Entity
and	O
prevented	O
by	O
co	O
-	O
injection	O
of	O
pertussis	O
toxin	O
.	O

Morphine	I-Entity
did	O
not	O
,	O
however	O
,	O
alter	O
the	O
hyperalgesia	I-Entity
induced	O
by	O
8-bromo	B-Entity
cyclic	I-Entity
adenosine	I-Entity
monophosphate	I-Entity
.	O

We	O
conclude	O
that	O
the	O
analgesic	O
action	O
of	O
opioids	O
on	O
the	O
peripheral	O
terminals	O
of	O
primary	O
afferents	O
is	O
via	O
a	O
binding	O
site	O
with	O
characteristics	O
of	O
the	O
mu	O
-	O
opioid	O
receptor	O
and	O
that	O
this	O
action	O
is	O
mediated	O
by	O
inhibition	O
of	O
the	O
cyclic	B-Entity
adenosine	I-Entity
monophosphate	I-Entity
second	O
messenger	O
system	O
.	O



Adequate	O
timing	O
of	O
ribavirin	I-Entity
reduction	O
in	O
patients	O
with	O
hemolysis	I-Entity
during	O
combination	O
therapy	O
of	O
interferon	I-Entity
and	O
ribavirin	I-Entity
for	O
chronic	B-Entity
hepatitis	I-Entity
C.	I-Entity
BACKGROUND	O
:	O

Hemolytic	B-Entity
anemia	I-Entity
is	O
one	O
of	O
the	O
major	O
adverse	O
events	O
of	O
the	O
combination	O
therapy	O
of	O
interferon	I-Entity
and	O
ribavirin	I-Entity
.	O

Because	O
of	O
ribavirin	I-Entity
-	O
related	O
hemolytic	B-Entity
anemia	I-Entity
,	O
dose	O
reduction	O
is	O
a	O
common	O
event	O
in	O
this	O
therapy	O
.	O

In	O
this	O
clinical	O
retrospective	O
cohort	O
study	O
we	O
have	O
examined	O
the	O
suitable	O
timing	O
of	O
ribavirin	I-Entity
reduction	O
in	O
patients	O
with	O
hemolysis	I-Entity
during	O
combination	O
therapy	O
.	O

METHODS	O
:	O
Thirty	O
-	O
seven	O
of	O
160	O
patients	O
who	O
had	O
HCV	O
-	O
genotype	O
1b	O
,	O
had	O
high	O
virus	O
load	O
,	O
and	O
received	O
24-week	O
combination	O
therapy	O
developed	O
anemia	I-Entity
with	O
hemoglobin	O
level	O
<	O
10	O
g	O
/	O
dl	O
or	O
anemia	I-Entity
-	O
related	O
signs	O
during	O
therapy	O
.	O

After	O
that	O
,	O
these	O
37	O
patients	O
were	O
reduced	O
one	O
tablet	O
of	O
ribavirin	I-Entity
(	O
200	O
mg	O
)	O
per	O
day	O
.	O

After	O
reduction	O
of	O
ribavirin	I-Entity
,	O
27	O
of	O
37	O
patients	O
could	O
continue	O
combination	O
therapy	O
for	O
a	O
total	O
of	O
24	O
weeks	O
(	O
group	O
A	O
)	O
.	O

However	O
,	O
10	O
of	O
37	O
patients	O
with	O
reduction	O
of	O
ribavirin	I-Entity
could	O
not	O
continue	O
combination	O
therapy	O
because	O

their	O
<	O
8.5	O
g	O
/	O
dl	O
hemoglobin	O
values	O
decreased	O
to	O
or	O
anemia	I-Entity
-	O
related	O
severe	O
side	O
effects	O
occurred	O
(	O
group	O
B	O
)	O
.	O

We	O
assessed	O
the	O
final	O
efficacy	O
and	O
safety	O
after	O
reduction	O
of	O
ribavirin	I-Entity
in	O
groups	O
A	O
and	O
B.	O
RESULTS	O
:	O

With	O
respect	O
to	O
hemoglobin	O
level	O
at	O
the	O
time	O
of	O
ribavirin	I-Entity
reduction	O
,	O
a	O
rate	O
of	O
continuation	O
of	O
therapy	O
in	O
patients	O
with	O
>	O
or	O
=	O
10	O
g	O
/	O
dl	O
hemoglobin	O
was	O
higher	O
than	O
that	O
in	O
patients	O
with	O
<	O
10	O
g	O
/	O
dl	O
(	O
P	O
=	O
0.036	O
)	O
.	O

Reduction	O
of	O
ribavirin	I-Entity
at	O
hemoglobin	O
level	O
>	O
or	O
=	O



Increased	O
expression	O
and	O
apical	O
targeting	O
of	O
renal	O
ENaC	O
subunits	O
in	O
puromycin	B-Entity
aminonucleoside	I-Entity
-	O
induced	O
nephrotic	B-Entity
syndrome	I-Entity
in	O
rats	O
.	O

Nephrotic	B-Entity
syndrome	I-Entity
is	O
often	O
accompanied	O
by	O
sodium	I-Entity
retention	O
and	O
generalized	O
edema	I-Entity
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
decreased	O
renal	O
sodium	I-Entity
excretion	O
remains	O
undefined	O
.	O

We	O
hypothesized	O
that	O
epithelial	O
Na	I-Entity
channel	O
(	O
ENaC	O
)	O
subunit	O
dysregulation	O
may	O
be	O
responsible	O
for	O
the	O
increased	O
sodium	I-Entity
retention	O
.	O

An	O
experimental	O
group	O
of	O
rats	O
was	O
treated	O
with	O
puromycin	B-Entity
aminonucleoside	I-Entity
(	O
PAN	I-Entity
;	O
180	O
mg	O
/	O
kg	O
iv	O
)	O
,	O
whereas	O
the	O
control	O
group	O
received	O
only	O
vehicle	O
.	O

After	O
7	O
days	O
,	O
PAN	I-Entity
treatment	O
induced	O
significant	O
proteinuria	I-Entity
,	O
hypoalbuminemia	I-Entity
,	O
decreased	O
urinary	O
sodium	I-Entity
excretion	O
,	O
and	O
extensive	O
ascites	I-Entity
.	O

Immunoelectron	O
microscopy	O
further	O
revealed	O
an	O
increased	O
labeling	O
of	O
alpha	O
-	O
ENaC	O
in	O
the	O
apical	O
plasma	O
membrane	O
of	O
cortical	O
collecting	O
duct	O
principal	O
cells	O
of	O
PAN	I-Entity
-	O
treated	O
rats	O
,	O
indicating	O
enhanced	O
apical	O
targeting	O
of	O
alpha	O
-	O
ENaC	O
subunits	O
.	O

In	O
contrast	O
,	O
the	O
protein	O
abundances	O
of	O
Na(+)/H(+	I-Entity
)	O
exchanger	O
type	O
3	O
(	O
NHE3	O
)	O
,	O
Na(+)-K(+)-2Cl(-	I-Entity
)	O

cotransporter	O
(	O
BSC-1	O
)	O
,	O
and	O
thiazide	I-Entity
-	O
sensitive	O
Na(+)-Cl(-	I-Entity
)	O

Moreover	O
,	O
the	O
abundance	O
of	O
the	O
alpha(1)-subunit	O
of	O
the	O
Na	I-Entity
-	O
K	I-Entity
-	O
ATPase	O
was	O
decreased	O
in	O
the	O
cortex	O
and	O
ISOM	O
,	O
but	O
it	O
remained	O
unchanged	O
in	O
the	O
IM	O
.	O

In	O
conclusion	O
,	O
the	O
increased	O
or	O
sustained	O
expression	O
of	O
ENaC	O
subunits	O
combined	O
with	O
increased	O
apical	O
targeting	O
in	O
the	O
DCT2	O
,	O
connecting	O
tubule	O
,	O
and	O
collecting	O
duct	O
are	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
sodium	I-Entity
retention	O
associated	O
with	O
PAN	I-Entity
-	O
induced	O
nephrotic	B-Entity
syndrome	I-Entity
.	O

The	O
decreased	O
abundance	O
of	O
NHE3	O
,	O
BSC-1	O
,	O
TSC	O
,	O
and	O
Na	I-Entity
-	O
K	I-Entity
-	O
ATPase	O
may	O
play	O
a	O
compensatory	O
role	O
to	O
promote	O
sodium	I-Entity
excretion	O
.	O



Does	O
hormone	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	B-Entity
cancer	I-Entity
have	O
a	O
detrimental	B-Entity
effect	I-Entity
on	I-Entity
memory	I-Entity
and	I-Entity
cognition	I-Entity
?	O

This	O
pilot	O
study	O
examines	O
whether	O
hormone	O
therapy	O
for	O
breast	B-Entity
cancer	I-Entity
affects	O
cognition	O
.	O

Patients	O
participating	O
in	O
a	O
randomised	O
trial	O
of	O
anastrozole	I-Entity
,	O
tamoxifen	I-Entity
alone	O
or	O
combined	O
(	O
ATAC	O
)	O
(	O
n=94	O
)	O
and	O
a	O
group	O
of	O
women	O
without	O
breast	B-Entity
cancer	I-Entity
(	O
n=35	O
)	O
completed	O
a	O
battery	O
of	O
neuropsychological	O
measures	O
.	O

The	O
results	O
showed	O
specific	O
impairments	O
in	O
processing	O
speed	O
and	O
verbal	O
memory	O
in	O
women	O
receiving	O
hormonal	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	B-Entity
cancer	I-Entity
.	O

Verbal	O
memory	O
may	O
be	O
especially	O
sensitive	O
to	O
changes	O
in	O
oestrogen	I-Entity
levels	O
,	O
a	O
finding	O
commonly	O
reported	O
in	O
studies	O
of	O
hormone	O
replacement	O
therapy	O
in	O
healthy	O
women	O
.	O



Association	O
of	O
nitric	B-Entity
oxide	I-Entity
production	O
and	O
apoptosis	O
in	O
a	O
model	O
of	O
experimental	O
nephropathy	I-Entity
.	O

In	O
recent	O
studies	O
increased	O
amounts	O
of	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O
and	O
apoptosis	O
have	O
been	O
implicated	O
in	O
various	O
pathological	O
conditions	O
in	O
the	O
kidney	O
.	O

We	O
have	O
studied	O
the	O
role	O
of	O
NO	I-Entity
and	O
its	O
association	O
with	O
apoptosis	O
in	O
an	O
experimental	O
model	O
of	O
nephrotic	B-Entity
syndrome	I-Entity
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	I-Entity
(	O
ADR	I-Entity
)	O
.	O

The	O
alteration	O
in	O
the	O
NO	I-Entity
pathway	O
was	O
assessed	O
by	O
measuring	O
nitrite	I-Entity
levels	O
in	O
serum	O
/	O
urine	O
and	O
by	O
evaluating	O
the	O
changes	O
in	O
vascular	O
reactivity	O
of	O
the	O
isolated	O
perfused	O
rat	O
kidney	O
(	O
IPRK	O
)	O
system	O
.	O

Rats	O
were	O
stratified	O
into	O
control	O
groups	O
and	O
ADR	I-Entity
-	O
induced	O
nephropathy	I-Entity
groups	O
.	O

These	O
two	O
groups	O
were	O
then	O
divided	O
into	O
:	O
group	O
1	O
,	O
animals	O
receiving	O
saline	O
;	O
and	O
group	O
2	O
,	O
animals	O
receiving	O
aminoguanidine	I-Entity
(	O
AG	I-Entity
)	O
which	O
is	O
a	O
specific	O
inhibitor	O
of	O
inducible	O
-	O
NO	I-Entity
synthase	O
.	O

RESULTS	O
:	O
Histopathological	O
examination	O
of	O
the	O
kidneys	O
of	O
rats	O
treated	O
with	O
ADR	I-Entity
revealed	O
focal	O
areas	O
of	O
mesangial	B-Entity
proliferation	I-Entity
and	O
mild	O
tubulointerstitial	B-Entity
inflammation	I-Entity
.	O

They	O
also	O
had	O
significantly	O
higher	O
levels	O
of	O
proteinuria	I-Entity
compared	O
with	O
control	O
and	O
treatment	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Urine	O
nitrite	I-Entity
levels	O
were	O
significantly	O
increased	O
in	O
the	O
ADR	I-Entity
-	O
nephropathy	I-Entity
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
the	O
IPRK	O
phenylephrine	I-Entity
and	O
acetylcholine	I-Entity
related	O
responses	O
were	O
significantly	O
impaired	O
in	O
the	O
ADR	I-Entity
-	O
nephropathy	I-Entity
group	O
.	O

However	O
,	O
in	O
the	O
ADR	I-Entity
-	O
nephropathy	I-Entity
group	O
,	O
numerous	O
apoptotic	O
cells	O
were	O
identified	O
in	O
the	O
tubulointerstitial	O
areas	O
.	O

Treatment	O
with	O
AG	I-Entity
prevented	O
the	O
impairment	O
of	O
renal	O
vascular	O
bed	O
responses	O
and	O
reduced	O
both	O
urine	O
nitrite	I-Entity
levels	O
and	O
apoptosis	O
to	O
control	O
levels	O
.	O

:	O
We	O
suggest	O
that	O
interactions	O
between	O
NO	I-Entity
and	O
apoptosis	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
the	O
ADR	I-Entity
-	O
induced	O
nephrosis	I-Entity
.	O



The	O
attenuating	O
effect	O
of	O
carteolol	B-Entity
hydrochloride	I-Entity
,	O
a	O
beta	O
-	O
adrenoceptor	O
antagonist	O
,	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	I-Entity
in	O
rats	O
.	O

It	O
is	O
known	O
that	O
beta	O
-	O
adrenoceptor	O
antagonists	O
are	O
effective	O
in	O
the	O
treatment	O
of	O
akathisia	I-Entity
,	O
one	O
of	O
the	O
extrapyramidal	O
side	O
effects	O
that	O
occur	O
during	O
neuroleptic	O
treatment	O
.	O

Neuroleptic	O
-	O
induced	O
catalepsy	I-Entity
,	O
a	O
model	O
of	O
neuroleptic	O
-	O
induced	O
extrapyramidal	O
side	O
effects	O
,	O
was	O
considered	O
suitable	O
as	O
a	O
model	O
for	O
predicting	O
neuroleptic	O
-	O
induced	O
akathisia	I-Entity
in	O
humans	O
,	O
although	O
neuroleptic	O
-	O
induced	O
catalepsy	I-Entity
was	O
not	O
considered	O
a	O
specific	O
test	O
for	O
neuroleptic	O
-	O
induced	O
akathisia	I-Entity
.	O

Therefore	O
,	O
the	O
effects	O
of	O
carteolol	I-Entity
,	O
a	O
beta	O
-	O
adrenoceptor	O
antagonist	O
,	O
on	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
in	O
rats	O
were	O
behaviorally	O
studied	O
and	O
compared	O
with	O
those	O
of	O
propranolol	I-Entity
and	O
biperiden	I-Entity
,	O
a	O
muscarinic	O
receptor	O
antagonist	O
.	O

Carteolol	I-Entity
,	O
as	O
well	O
as	O
propranolol	I-Entity
and	O
biperiden	I-Entity
,	O
inhibited	O
the	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
.	O

The	O
inhibitory	O
effect	O
of	O
carteolol	I-Entity
was	O
almost	O
comparable	O
to	O
that	O
of	O
propranolol	I-Entity
,	O
but	O
was	O
weaker	O
than	O
that	O
of	O
biperiden	I-Entity
.	O

Carteolol	I-Entity
did	O
not	O
evoke	O
postsynaptic	O

dopamine	I-Entity
receptor	O
-	O
stimulating	O
behavioral	O
signs	O
such	O
as	O
stereotypy	O
and	O
hyperlocomotion	I-Entity
in	O
rats	O
.	O

Carteolol	I-Entity
did	O
not	O
antagonize	O
the	O
inhibitory	O
effects	O
of	O
haloperidol	I-Entity
on	O
apomorphine	I-Entity
-	O
induced	O
stereotypy	O
and	O
locomotor	O
activity	O
in	O
rats	O
.	O

In	O
addition	O
,	O
carteolol	I-Entity
did	O
not	O
evoke	O
5-HT1A	O
receptor	O
-	O
stimulating	O
behavioral	O
signs	O
such	O
as	O
flat	O
body	O
posture	O
and	O
forepaw	O
treading	O
and	O
did	O
not	O
inhibit	O
5-hydroxytryptophan	I-Entity
-	O
induced	O
head	O
twitch	O
in	O
rats	O
.	O

Finally	O
,	O
carteolol	I-Entity
did	O
not	O
inhibit	O
physostigmine	I-Entity
-	O
induced	O
lethality	O
in	O
rats	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
carteolol	I-Entity
improves	O
haloperidol	I-Entity
-	O
induced	O
catalepsy	I-Entity
via	O
its	O
beta	O
-	O
adrenoceptor	O
antagonistic	O
activity	O
and	O
is	O
expected	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
akathisia	I-Entity
without	O
attenuating	O
neuroleptic	O
-	O
induced	O
antipsychotic	O
effects	O
due	O
to	O
its	O
postsynaptic	O
dopamine	I-Entity
receptor	O
antagonistic	O
activity	O
.	O



Penicillamine	I-Entity
-	O
induced	O
rapidly	O
progressive	O
glomerulonephritis	I-Entity
in	O
a	O
patient	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
.	O

A	O
67-year	O
-	O
old	O
woman	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
presented	O
rapidly	O
progressive	O
glomerulonephritis	I-Entity
(	O
RPGN	I-Entity
)	O
after	O
5	O
months	O
of	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
(	O
250	O
mg	O
/	O
day	O
)	O
treatment	O
.	O

Light	O
microscopy	O
study	O
showed	O
severe	O
glomerulonephritis	I-Entity
with	O
crescent	O
formation	O
in	O
60%	O
of	O
the	O
glomeruli	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
in	O
the	O
wall	O
of	O
an	O
arteriole	O
.	O

The	O
patient	O
was	O
treated	O
with	O
steroid	I-Entity
pulse	O
,	O
plasmapheresis	O
,	O
cyclophosphamide	I-Entity
and	O
antiplatelet	B-Entity
agents	I-Entity
.	O

This	O
new	O
case	O
of	O
RPGN	I-Entity
in	O
the	O
course	O
of	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
treatment	O
emphasizes	O
the	O
need	O
for	O
frequent	O
monitoring	O
of	O
renal	O
function	O
and	O
evaluation	O
of	O
urinary	O
sediment	O
and	O
proteinuria	I-Entity
in	O
these	O
patients	O
.	O

The	O
prompt	O
discontinuation	O
of	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
and	O
vigorous	O
treatment	O
measures	O
could	O
allow	O
for	O
a	O
good	O
prognosis	O
as	O
in	O
this	O
case	O
.	O



Nature	O
,	O
time	O
course	O
and	O
dose	O
dependence	O
of	O
zidovudine	I-Entity
-	O
related	O
side	O
effects	O
:	O
results	O
from	O
the	O
Multicenter	O
Canadian	O
Azidothymidine	I-Entity
Trial	O
.	O

To	O
characterize	O
the	O
nature	O
,	O
time	O
course	O
and	O
dose	O
dependency	O
of	O
zidovudine	I-Entity
-	O
related	O
side	O
effects	O
,	O
we	O
undertook	O
a	O
multicenter	O
,	O
prospective	O
,	O
dose	O
-	O
range	O
finding	O
study	O
.	O

Our	O
study	O
group	O
consisted	O
of	O
74	O
HIV	O
-	O
positive	O
homosexual	O
men	O
belonging	O
to	O
groups	O
II	O
B	O
,	O
III	O
and	O
IV	O
C2	O
from	O
the	O
Centers	O
for	O
Disease	O
Control	O
(	O
CDC	O
)	O
classification	O
of	O
HIV	B-Entity
disease	I-Entity
.	O

Following	O
a	O
3-week	O
observation	O
period	O
,	O
volunteers	O
were	O
treated	O
with	O
zidovudine	I-Entity
600	O
mg	O
/	O
day	O
for	O
18	O
weeks	O
,	O
900	O
mg	O
/	O
day	O
for	O
9	O
weeks	O
and	O
1200	O
mg	O

Symptomatic	O
adverse	O
effects	O
were	O
present	O
in	O
96%	O
of	O
subjects	O
,	O
most	O
commonly	O
nausea	I-Entity
(	O
64%	O
)	O
,	O
fatigue	I-Entity
(	O
55%	O
)	O
and	O
headache	I-Entity
(	O
49%	O
)	O
.	O

Bone	O
marrow	O
changes	O
occurred	O
rapidly	O
as	O
demonstrated	O
by	O
megaloblastosis	I-Entity
in	O
95%	O
of	O
65	O
specimens	O
at	O
week	O
18.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Bilateral	B-Entity
optic	I-Entity
neuropathy	I-Entity
due	O
to	O
combined	O
ethambutol	I-Entity
and	O
isoniazid	I-Entity
treatment	O
.	O

The	O
case	O
of	O
a	O
40-year	O
-	O
old	O
patient	O
who	O
underwent	O
an	O
unsuccessful	O
cadaver	O
kidney	O
transplantation	O
and	O
was	O
treated	O
with	O
ethambutol	I-Entity
and	O
isoniazid	I-Entity
is	O
reported	O
.	O

A	O
bilateral	B-Entity
retrobulbar	I-Entity
neuropathy	I-Entity
with	O
an	O
unusual	O
central	O
bitemporal	O
hemianopic	O
scotoma	I-Entity
was	O
found	O
.	O

Ethambutol	I-Entity
was	O
stopped	O
and	O
only	O
small	O
improvement	O
of	O
the	O
visual	O
acuity	O
followed	O
.	O

Isoniazid	I-Entity
was	O
discontinued	O
later	O
,	O
followed	O
by	O
a	O
dramatic	O
improvement	O
in	O
the	O
visual	O
acuity	O
.	O

The	O
hazards	O
of	O
optic	O
nerve	O
toxicity	I-Entity
due	O
to	O
ethambutol	I-Entity
are	O
known	O
.	O

We	O
emphasize	O
the	O
potential	O
danger	O
in	O
the	O
use	O
of	O
ethambutol	I-Entity
and	O
isoniazid	I-Entity
.	O



Progestational	O
agents	O
and	O
blood	B-Entity
coagulation	I-Entity
.	O

Thromboembolic	I-Entity
and	O
other	O
complications	O
of	O
oral	B-Entity
contraceptive	I-Entity
therapy	O
in	O
relationship	O
to	O
pretreatment	O
levels	O
of	O
blood	B-Entity
coagulation	I-Entity
factors	O
:	O
summary	O
report	O
of	O
a	O
ten	O
-	O
year	O
study	O
.	O

During	O
a	O
ten	O
-	O
year	O
period	O
,	O
348	O
women	O
were	O
studied	O
for	O
a	O
total	O
of	O
5,877	O
patient	O
months	O
in	O
four	O
separate	O
studies	O
relating	O
oral	B-Entity
contraceptives	I-Entity
to	O
changes	O
in	O
hematologic	O
parameters	O
.	O

Significant	O
increases	O
in	O
certain	O
factors	O
of	O
the	O
blood	B-Entity
coagulation	I-Entity
and	O
fibrinolysin	O
systems	O
(	O
factors	O
I	O
,	O
II	O
,	O
VII	O
,	O
VIII	O
,	O
IX	O
,	O
and	O
X	O
and	O
plasminogen	O
)	O
were	O
observed	O
in	O
the	O
treated	O
groups	O
.	O

All	O
four	O
had	O
an	O
abnormal	O
blood	B-Entity
coagulation	I-Entity
profile	O
,	O
suggesting	O
""""	O
hypercoagulability	I-Entity
""""	O
before	O
initiation	O
of	O
therapy	O
.	O

One	O
of	O
these	O
patients	O
developed	O
a	O
myocardial	B-Entity
infarction	I-Entity
before	O
receiving	O
any	O
medication	O
,	O
shortly	O
after	O
the	O
base	O
-	O
line	O
values	O
were	O
obtained	O
.	O

One	O
patient	O
developed	O
retinopathy	I-Entity
19	O
months	O
after	O
she	O
began	O
therapy	O
,	O
and	O
another	O
developed	O
thrombophlebitis	I-Entity
after	O
27	O
months	O
of	O
therapy	O
.	O

The	O
fourth	O
patient	O
developed	O
thrombophlebitis	I-Entity
14	O
days	O
after	O
initiation	O
of	O
contraceptive	O
therapy	O
.	O

Previous	O
studies	O
suggested	O
the	O
possiblility	O
of	O
increased	O
propensity	O
for	O
thromboembolic	B-Entity
episodes	I-Entity
in	O
patients	O
possessing	O
the	O
A	O
antigen	O
.	O

It	O
appears	O
from	O
these	O
data	O
that	O
hematologic	O
work	O
-	O
ups	O
may	O
be	O
useful	O
in	O
women	O
who	O
are	O
about	O
to	O
start	O
long	O
-	O
term	O
oral	B-Entity
contraceptive	I-Entity
therapy	O
.	O



Cardiac	B-Entity
arrest	I-Entity
in	O
a	O
child	O
with	O
cerebral	B-Entity
palsy	I-Entity
undergoing	O
sevoflurane	I-Entity
induction	O
of	O
anesthesia	O
after	O
preoperative	O
clonidine	I-Entity
.	O

Clonidine	I-Entity
is	O
a	O
frequently	O
administered	O
alpha2-adrenergic	O
agonist	O
which	O
can	O
decrease	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
5-year	O
-	O
old	O
child	O
with	O
cerebral	B-Entity
palsy	I-Entity
and	O
seizure	B-Entity
disorder	I-Entity
,	O
receiving	O
clonidine	I-Entity
for	O
restlessness	I-Entity
,	O
who	O
presented	O
for	O
placement	O
of	O
a	O
baclofen	I-Entity
pump	O
.	O

Without	O
the	O
knowledge	O
of	O
the	O
medical	O
personnel	O
,	O
the	O
patient	O
's	O
mother	O
administered	O
three	O
doses	O
of	O
clonidine	I-Entity
during	O
the	O
evening	O
before	O
and	O
morning	O
of	O
surgery	O
to	O
reduce	O
anxiety	I-Entity
.	O

During	O
induction	O
of	O
anesthesia	O
,	O
the	O
patient	O
developed	O
bradycardia	I-Entity
and	O
hypotension	I-Entity
requiring	O
cardiac	O
resuscitation	O
.	O

There	O
are	O
no	O
previous	O
reports	O
of	O
clonidine	I-Entity
-	O
associated	O
cardiac	B-Entity
arrest	I-Entity
in	O
a	O
child	O
undergoing	O
induction	O
of	O
anesthesia	O
.	O



Effects	O
of	O
UMB24	I-Entity
and	O
(	O
+	O
/-)-SM	B-Entity
21	I-Entity
,	O
putative	O
sigma2-preferring	O
antagonists	O
,	O
on	O
behavioral	O
toxic	O
and	O
stimulant	O
effects	O
of	O
cocaine	I-Entity
in	O
mice	O
.	O

Earlier	O
studies	O
have	O
demonstrated	O
that	O
antagonism	O
of	O
sigma1	O
receptors	O
attenuates	O
the	O
convulsive	I-Entity
,	O
lethal	O
,	O
locomotor	O
stimulatory	O
and	O
rewarding	O
actions	O
of	O
cocaine	I-Entity
in	O
mice	O
.	O

To	O
begin	O
addressing	O
this	O
need	O
,	O
we	O
characterized	O
UMB24	I-Entity
(	O
1-(2-phenethyl)-4-(2-pyridyl)-piperazine	I-Entity
)	O
and	O
(	O
+	O
/-)-SM	B-Entity
21	I-Entity
(	O
3alpha	B-Entity
-	I-Entity
tropanyl-2-(4-chorophenoxy)butyrate	I-Entity
)	O
in	O
receptor	O
binding	O
and	O
behavioral	O
studies	O
.	O

Receptor	O
binding	O
studies	O
confirmed	O
that	O
UMB24	I-Entity
and	O
(	O
+	O
/-)-SM	B-Entity
21	I-Entity
display	O
preferential	O
affinity	O
for	O
sigma2	O
over	O
sigma1	O
receptors	O
.	O

In	O
behavioral	O
studies	O
,	O
pretreatment	O
of	O
Swiss	O
Webster	O
mice	O
with	O
UMB24	I-Entity
or	O
(	O
+	O
/-)-SM	B-Entity
21	I-Entity
significantly	O
attenuated	O
cocaine	I-Entity
-	O
induced	O
convulsions	I-Entity
and	O
locomotor	O
activity	O
,	O
but	O
not	O
lethality	O
.	O

When	O
administered	O
alone	O
,	O
(	O
+	O
/-)-SM	B-Entity
21	I-Entity
produced	O
no	O
significant	O
effects	O
compared	O
to	O
control	O
injections	O
of	O
saline	O
,	O
but	O
UMB24	I-Entity
had	O
locomotor	O
depressant	O
actions	O
.	O

Together	O
,	O
the	O
data	O
suggest	O
that	O
sigma2	O
receptor	O
antagonists	O
have	O
the	O
potential	O
to	O
attenuate	O
some	O
of	O
the	O
behavioral	O
effects	O
of	O
cocaine	I-Entity
,	O
and	O
further	O
development	O
of	O
more	O
selective	O
,	O
high	O
affinity	O
ligands	O
are	O
warranted	O
.	O



Methimazole	I-Entity
-	O
induced	O
cholestatic	B-Entity
jaundice	I-Entity
.	O

Methimazole	I-Entity
is	O
a	O
widely	O
used	O
and	O
generally	O
well	O
-	O
tolerated	O
antithyroid	O
agent	O
.	O

A	O
43-year	O
-	O
old	O
woman	O
had	O
severe	O
jaundice	I-Entity
and	O
itching	I-Entity
1	O
month	O
after	O
receiving	O
methimazole	I-Entity
(	O
10	O
mg	O
tid	O
)	O
and	O
propranolol	I-Entity
(	O
20	O
mg	O
tid	O
)	O
for	O
treatment	O
of	O
hyperthyroidism	I-Entity
.	O

The	O
patient	O
continued	O
treatment	O
for	O
another	O
4	O
days	O
after	O
the	O
appearance	O
of	O
jaundice	I-Entity
until	O
she	O
finished	O
both	O
medications	O
.	O

When	O
seen	O
at	O
the	O
emergency	O
department	O
2	O
weeks	O
later	O
,	O
she	O
still	O
had	O
severe	O
icterus	I-Entity
,	O
pruritus	I-Entity
,	O
and	O
hyperbilirubinemia	I-Entity
,	O
formed	O
mainly	O
of	O
the	O
conjugated	O
fraction	O
.	O

Methimazole	I-Entity
-	O
induced	O
cholestasis	I-Entity
was	O
diagnosed	O
,	O
and	O
propranolol	I-Entity
therapy	O
was	O
resumed	O
.	O

Over	O
the	O
following	O
9	O
days	O
,	O
the	O
symptoms	O
improved	O
and	O
plasma	O
bilirubin	I-Entity
levels	O
were	O
normal	O
after	O
12	O
weeks	O
without	O
methimazole	I-Entity
.	O

In	O
rare	O
cases	O
within	O
the	O
first	O
few	O
weeks	O
of	O
therapy	O
,	O
this	O
drug	O
can	O
cause	O
severe	O
and	O
reversible	O
cholestatic	B-Entity
jaundice	I-Entity
.	O

Physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
this	O
adverse	O
effect	O
so	O
that	O
,	O
upon	O
occurrence	O
,	O
they	O
can	O
discontinue	O
methimazole	I-Entity
therapy	O
and	O
avoid	O
unnecessary	O
invasive	O
procedures	O
.	O



Ciprofloxacin	I-Entity
-	O
induced	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
and	O
autoimmune	B-Entity
hemolytic	I-Entity
anemia	I-Entity
.	O

Ciprofloxacin	I-Entity
has	O
been	O
associated	O
with	O
several	O
side	O
effects	O
including	O
interstitial	B-Entity
nephritis	I-Entity
and	O
hemolytic	B-Entity
anemia	I-Entity
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
case	O
of	O
ciprofloxacin	I-Entity
-	O
induced	O
interstitial	B-Entity
nephritis	I-Entity
and	O
autoimmune	B-Entity
hemolytic	I-Entity
anemia	I-Entity
.	O

Hemolytic	B-Entity
anemia	I-Entity
improved	O
after	O
stopping	O
the	O
drug	O
and	O
initiation	O
of	O
steroid	I-Entity
therapy	O
.	O

Unfortunately	O
,	O
acute	O
interstitial	B-Entity
nephritis	I-Entity
was	O
irreversible	O
and	O
the	O
patient	O
developed	O
end	B-Entity
-	I-Entity
stage	I-Entity
renal	I-Entity
disease	I-Entity
.	O



Contribution	O
of	O
sodium	B-Entity
valproate	I-Entity
to	O
the	O
syndrome	B-Entity
of	I-Entity
inappropriate	I-Entity
secretion	I-Entity
of	I-Entity
antidiuretic	I-Entity
hormone	I-Entity
.	O

We	O
report	O
the	O
case	O
of	O
a	O
62-year	O
-	O
old	O
man	O
who	O
was	O
administered	O
sodium	B-Entity
valproate	I-Entity
(	O
VPA	I-Entity
)	O
and	O
who	O
subsequently	O
developed	O
the	O
syndrome	B-Entity
of	I-Entity
inappropriate	I-Entity
secretion	I-Entity
of	I-Entity
antidiuretic	I-Entity
hormone	I-Entity
(	O
SIADH	I-Entity
)	O
.	O

He	O
had	O
been	O
taking	O
VPA	I-Entity
for	O
treatment	O
of	O
idiopathic	O
generalized	O
tonic	B-Entity
-	I-Entity
clonic	I-Entity
convulsions	I-Entity
since	O
he	O
was	O
56	O
years	O
old	O
.	O

After	O
substituting	O
VPA	I-Entity
with	O
zonisamide	I-Entity
,	O
the	O
serum	O
sodium	I-Entity
level	O
returned	O
to	O
normal	O
.	O

We	O
consider	O
this	O
episode	O
of	O
SIADH	I-Entity
to	O
be	O
the	O
result	O
of	O
a	O
combination	O
of	O
factors	O
including	O
a	O
weakness	B-Entity
of	I-Entity
the	I-Entity
central	I-Entity
nervous	I-Entity
system	I-Entity
and	O
the	O
long	O
-	O
term	O
administration	O
of	O
VPA	I-Entity
.	O



Vasopressin	I-Entity
in	O
the	O
treatment	O
of	O
milrinone	I-Entity
-	O
induced	O
hypotension	I-Entity
in	O
severe	O
heart	B-Entity
failure	I-Entity
.	O

The	O
use	O
of	O
phosphodiesterase	O
inhibitors	O
such	O
as	O
milrinone	I-Entity
in	O
the	O
treatment	O
of	O
severe	O
heart	B-Entity
failure	I-Entity
is	O
frequently	O
restricted	O
because	O
they	O
cause	O
vasodilation	O
and	O
hypotension	I-Entity
.	O

In	O
patients	O
with	O
decompensated	O
heart	B-Entity
failure	I-Entity
with	O
hypotension	I-Entity
after	O
treatment	O
with	O
milrinone	I-Entity
,	O
low	O
doses	O
of	O
vasopressin	I-Entity
restored	O
blood	O
pressure	O
without	O
inhibiting	O
the	O
inotropic	O
effect	O
of	O
milrinone	I-Entity
.	O



Halogenated	O
anesthetics	O
form	O
liver	O
adducts	O
and	O
antigens	O
that	O
cross	O
-	O
react	O
with	O
halothane	I-Entity
-	O
induced	O
antibodies	O
.	O

Two	O
halogenated	O
anesthetics	O
,	O
enflurane	I-Entity
and	O
isoflurane	I-Entity
,	O
have	O
been	O
associated	O
with	O
an	O
allergic	O
-	O
type	O
hepatic	B-Entity
injury	I-Entity
both	O
alone	O
and	O
following	O
previous	O
exposure	O
to	O
halothane	I-Entity
.	O

Halothane	I-Entity
hepatitis	I-Entity
appears	O
to	O
involve	O
an	O
aberrant	O
immune	O
response	O
.	O

An	O
antibody	O
response	O
to	O
a	O
protein	O
-	O
bound	O
biotransformation	O
product	O
(	O
trifluoroacetyl	I-Entity
adduct	O
)	O
has	O
been	O
detected	O
on	O
halothane	I-Entity
hepatitis	I-Entity
patients	O
.	O

This	O
study	O
was	O
performed	O
to	O
determine	O
cross	O
-	O
reactivity	O
between	O
enflurane	I-Entity
and	O
isoflurane	I-Entity
with	O
the	O
hypersensitivity	I-Entity
induced	O
by	O
halothane	I-Entity
.	O

The	O
subcellular	O
and	O
lobular	O
production	O
of	O
hepatic	O
neoantigens	O
recognized	O
by	O
halothane	I-Entity
-	O
induced	O
antibodies	O
following	O
enflurane	I-Entity
and	O
isoflurane	I-Entity
,	O
and	O
the	O
biochemical	O
nature	O
of	O
these	O
neoantigens	O
was	O
investigated	O
in	O
two	O
animal	O
models	O
.	O

Enflurane	I-Entity
administration	O
resulted	O
in	O
neoantigens	O
detected	O
in	O
both	O
the	O
microsomal	O
and	O
cytosolic	O
fraction	O
of	O
liver	O
homogenates	O
and	O
in	O
the	O
centrilobular	O
region	O
of	O
the	O
liver	O
.	O

This	O
supports	O
and	O
extends	O
previous	O
evidence	O
for	O
a	O
mechanism	O
by	O
which	O
enflurane	I-Entity
and/or	O
isoflurane	I-Entity
could	O
produce	O
a	O
hypersensitivity	I-Entity
condition	O
similar	O
to	O
that	O
of	O
halothane	I-Entity
hepatitis	I-Entity
either	O
alone	O
or	O
subsequent	O
to	O
halothane	I-Entity
administration	O
.	O



Induction	O
by	O
paracetamol	I-Entity
of	O
bladder	B-Entity
and	I-Entity
liver	I-Entity
tumours	I-Entity
in	O
the	O
rat	O
.	O

Groups	O
of	O
male	O
and	O
female	O
inbred	O
Leeds	O
strain	O
rats	O
were	O
fed	O
diets	O
containing	O
either	O
0.5%	O
or	O
1.0%	O
paracetamol	I-Entity
by	O
weight	O
for	O
up	O
to	O
18	O
months	O
.	O

Papillomas	I-Entity
of	O
the	O
transitional	O
epithelium	O
of	O
the	O
bladder	O
developed	O
in	O
all	O
paracetamol	I-Entity
-	O
treated	O
groups	O
,	O
and	O
three	O
rats	O
bore	O
bladder	B-Entity
carcinomas	I-Entity
.	O

However	O
,	O
significant	O
yields	O
of	O
bladder	B-Entity
tumours	I-Entity
were	O
only	O
obtained	O
from	O
low	O
dosage	O
females	O
and	O
high	O
dosage	O
males	O
.	O

Additionally	O
,	O
20	O
to	O
25%	O
of	O
paracetamol	I-Entity
-	O
treated	O
rats	O
developed	O
hyperplasia	I-Entity
of	O
the	O
bladder	O
epithelium	O
,	O
which	O
was	O
not	O
coincident	O
with	O
the	O
presence	O
of	O
bladder	B-Entity
calculi	I-Entity
.	O

A	O
low	O
yield	O
of	O
tumours	I-Entity
at	O
various	O
other	O
sites	O
also	O
arose	O
following	O
paracetamol	I-Entity
feeding	O
.	O

An	O
electron	O
microscope	O
study	O
of	O
the	O
livers	O
of	O
paracetamol	I-Entity
-	O
treated	O
rats	O
revealed	O
ultrastructural	O
changes	O
in	O
the	O
hepatocytes	O
that	O
resemble	O
those	O
that	O
result	O
from	O
exposure	O
to	O
a	O
variety	O
of	O
known	O
hepatocarcinogens	I-Entity
.	O



Local	O
anesthetics	O
that	O
are	O
commonly	O
used	O
in	O
ophthalmic	O
surgery	O
(	O
0.75%	O
bupivacaine	B-Entity
hydrochloride	I-Entity
,	O
2.0%	O
mepivacaine	B-Entity
hydrochloride	I-Entity
,	O
and	O
2.0%	O
lidocaine	B-Entity
hydrochloride	I-Entity
plus	O
1:100,000	O
epinephrine	I-Entity
)	O
were	O
injected	O
into	O
the	O
retrobulbar	O
area	O
of	O
rat	O
eyes	O
.	O

Muscle	B-Entity
degeneration	I-Entity
is	O
followed	O
by	O
regeneration	O
of	O
the	O
damaged	O
muscle	O
fibers	O
.	O

In	O
addition	O
to	O
muscle	B-Entity
damage	I-Entity
,	O
severe	O
damage	O
was	O
also	O
seen	O
in	O
harderian	O
glands	O
,	O
especially	O
after	O
exposure	O
to	O
mepivacaine	I-Entity
and	O
lidocaine	I-Entity
plus	O
epinephrine	I-Entity
.	O

With	O
these	O
findings	O
in	O
rats	O
,	O
it	O
is	O
hypothesized	O
that	O
the	O
temporary	O
diplopia	I-Entity
sometimes	O
seen	O
in	O
patients	O
after	O
ophthalmic	O
surgery	O
might	O
be	O
due	O
to	O
anesthetic	O
-	O
induced	O
damage	O
to	O
the	O
extraocular	O
muscles	O
.	O



Reversal	O
of	O
neuroleptic	O
-	O
induced	O
catalepsy	I-Entity
by	O
novel	O
aryl	B-Entity
-	I-Entity
piperazine	I-Entity
anxiolytic	O
drugs	O
.	O

The	O
novel	O
anxiolytic	O
drug	O
,	O
buspirone	I-Entity
,	O
reverses	O
catalepsy	I-Entity
induced	O
by	O
haloperidol	I-Entity
.	O

A	O
series	O
of	O
aryl	B-Entity
-	I-Entity
piperazine	I-Entity
analogues	O
of	O
buspirone	I-Entity
and	O
other	O
5-hydroxytryptaminergic	B-Entity
agonists	I-Entity
were	O
tested	O
for	O
their	O
ability	O
to	O
reverse	O
haloperidol	I-Entity
induced	O
catalepsy	I-Entity
.	O

Those	O
drugs	O
with	O
strong	O
affinity	O
for	O
5-hydroxytryptamine1a	I-Entity
receptors	O
were	O
able	O
to	O
reverse	O
catalepsy	I-Entity
.	O

Drugs	O
with	O
affinity	O
for	O
other	O
5-HT	I-Entity
receptors	O
or	O
weak	O
affinity	O
were	O
ineffective	O
.	O

However	O
,	O
inhibition	O
of	O
postsynaptic	O
5-HT	I-Entity
receptors	O
neither	O
inhibited	O
nor	O
potentiated	O
reversal	O
of	O
catalepsy	I-Entity
and	O
leaves	O
open	O
the	O
question	O
as	O
to	O
the	O
site	O
or	O
mechanism	O
for	O
this	O
effect	O
.	O



Diazepam	I-Entity
facilitates	O
reflex	O
bradycardia	I-Entity
in	O
conscious	O
rats	O
.	O

The	O
effects	O
of	O
diazepam	I-Entity
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
conscious	O
rats	O
.	O

Intravenous	O
administration	O
of	O
diazepam	I-Entity
(	O
1	O
-	O
30	O
mg	O
kg-1	O
)	O
produced	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
both	O
the	O
mean	O
arterial	O
pressure	O
and	O
the	O
heart	O
rate	O
.	O

Also	O
,	O
reflex	O
bradycardia	I-Entity
was	O
produced	O
in	O
rats	O
by	O
intravenous	O
infusion	O
of	O
adrenaline	I-Entity
(	O
1.25	O
-	O
2.5	O
micrograms	O
kg-1	O
)	O
.	O

Intravenous	O
pretreatment	O
of	O
the	O
rats	O
with	O
diazepam	I-Entity
,	O
although	O
causing	O
no	O
change	O
in	O
the	O
adrenaline	I-Entity
-	O
induced	O
pressor	O
effect	O
,	O
did	O
enhance	O
the	O
adrenaline	I-Entity
-	O
induced	O
reflex	O
bradycardia	I-Entity
.	O

However	O
,	O
the	O
diazepam	I-Entity
enhancement	O
of	O
adrenaline	I-Entity
-	O
induced	O
reflex	O
bradycardia	I-Entity
was	O
antagonized	O
by	O
pretreatment	O
of	O
rats	O
with	O
an	O
intravenous	O
dose	O
of	O
picrotoxin	I-Entity
(	O
an	O
agent	O
blocks	O
chloride	I-Entity
channels	O
by	O
binding	O
to	O
sites	O
associated	O
with	O
the	O
benzodiazepine	I-Entity
-	O
GABA	I-Entity
-	O
chloride	I-Entity
channel	O
macromolecular	O
complex	O
)	O
.	O

The	O
data	O
indicate	O
that	O
diazepam	I-Entity
acts	O
through	O
the	O
benzodiazepine	I-Entity
-	O
GABA	I-Entity
-	O
chloride	I-Entity
channel	O
macromolecular	O
complex	O
within	O
the	O
central	O
nervous	O
system	O
to	O
facilitate	O
reflex	O
bradycardia	I-Entity
mediated	O
through	O
baroreceptor	O
reflexes	O
in	O
response	O
to	O
an	O
acute	O
increase	O
in	O
arterial	O
pressure	O
.	O



Chronic	O
carbamazepine	I-Entity
inhibits	O
the	O
development	O
of	O
local	O
anesthetic	O
seizures	I-Entity
kindled	O
by	O
cocaine	I-Entity
and	O
lidocaine	I-Entity
.	O

The	O
effects	O
of	O
carbamazepine	I-Entity
(	O
CBZ	I-Entity
)	O
treatment	O
on	O
local	O
anesthetic	O
-	O
kindled	O
seizures	I-Entity
and	O
lethality	O
were	O
evaluated	O
in	O
different	O
stages	O
of	O
the	O
kindling	O
process	O
and	O
under	O
different	O
methods	O
of	O
CBZ	I-Entity
administration	O
.	O

Chronic	O
oral	O
CBZ	I-Entity
inhibited	O
the	O
development	O
of	O
both	O
lidocaine-	I-Entity
and	O
cocaine	I-Entity
-	O
induced	O
seizures	I-Entity
,	O
but	O
had	O
little	O
effect	O
on	O
the	O
fully	O
developed	O
local	O
anesthetic	O
seizures	I-Entity
.	O

Chronic	O
CBZ	I-Entity
also	O
decreased	O
the	O
incidence	O
of	O
seizure	I-Entity
-	O
related	O
mortality	O
in	O
the	O
cocaine	I-Entity
-	O
injected	O
rats	O
.	O

Acute	O
CBZ	I-Entity
over	O
a	O
range	O
of	O
doses	O
(	O
15	O
-	O
50	O
mg	O
/	O
kg	O
)	O
had	O
no	O
effect	O
on	O
completed	O
lidocaine	I-Entity
-	O
kindled	O
or	O
acute	O
cocaine	I-Entity
-	O
induced	O
seizures	I-Entity
.	O

injection	O
of	O
CBZ	I-Entity
(	O
15	O
mg	O
/	O
kg	O
)	O
also	O
was	O
without	O
effect	O
on	O
the	O
development	O
of	O
lidocaine-	I-Entity
or	O
cocaine	I-Entity
-	O
kindled	O
seizures	I-Entity
.	O

The	O
differential	O
effects	O
of	O
CBZ	I-Entity
depending	O
upon	O
stage	O
of	O
seizure	I-Entity
development	O
suggest	O
that	O
distinct	O
mechanisms	O
underlie	O
the	O
development	O
versus	O
maintenance	O
of	O
local	O
anesthetic	O
-	O
kindled	O
seizures	I-Entity
.	O

The	O
effectiveness	O
of	O
chronic	O
but	O
not	O
repeated	O
,	O
intermittent	O
injections	O
of	O
CBZ	I-Entity
suggests	O
that	O
different	O
biochemical	O
consequences	O
result	O
from	O
the	O
different	O
treatment	O
regimens	O
.	O

The	O
possible	O
utility	O
of	O
chronic	O
CBZ	I-Entity
in	O
preventing	O
the	O
development	O
of	O
toxic	O
side	O
effects	O
in	O
human	O
cocaine	I-Entity
users	O
is	O
suggested	O
by	O
these	O
data	O
,	O
but	O
remains	O
to	O
be	O
directly	O
evaluated	O
.	O



D	B-Entity
-	I-Entity
penicillamine	I-Entity
in	O
the	O
treatment	O
of	O
localized	B-Entity
scleroderma	I-Entity
.	O

Localized	B-Entity
scleroderma	I-Entity
has	O
no	O
recognized	O
internal	O
organ	O
involvement	O
but	O
may	O
be	O
disfiguring	O
and	O
disabling	O
when	O
the	O
cutaneous	O
lesions	O
are	O
extensive	O
or	O
affect	O
children	O
.	O

There	O
is	O
no	O
accepted	O
or	O
proven	O
treatment	O
for	O
localized	B-Entity
scleroderma	I-Entity
.	O

Case	O
reports	O
of	O
11	O
patients	O
with	O
severe	O
,	O
extensive	O
localized	B-Entity
scleroderma	I-Entity
who	O
were	O
treated	O
with	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
are	O
summarized	O
in	O
this	O
article	O
.	O

Joint	O
stiffness	O
and	O
contractures	I-Entity
also	O
improved	O
.	O

The	O
dose	O
of	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
associated	O
with	O
a	O
favorable	O
response	O
was	O
as	O
low	O
as	O
2	O
to	O
5	O
mg	O
/	O
kg	O
per	O
day	O
given	O
over	O
a	O
period	O
ranging	O
from	O
15	O
to	O
53	O
months	O
.	O

D	B-Entity
-	I-Entity
Penicillamine	I-Entity
caused	O
nephrotic	B-Entity
syndrome	I-Entity
in	O
1	O
patient	O
and	O
milder	O
reversible	O
proteinuria	I-Entity
in	O
3	O
other	O
patients	O
;	O
none	O
developed	O
renal	B-Entity
insufficiency	I-Entity
.	O

These	O
data	O
suggest	O
that	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
may	O
be	O
effective	O
in	O
severe	O
cases	O
of	O
localized	B-Entity
scleroderma	I-Entity
.	O



Preservation	O
of	O
renal	O
blood	O
flow	O
during	O
hypotension	I-Entity
induced	O
with	O
fenoldopam	I-Entity
in	O
dogs	O
.	O

The	O
introduction	O
of	O
drugs	O
that	O
could	O
induce	O
hypotension	I-Entity
with	O
different	O
pharmacological	O
actions	O
would	O
be	O
advantageous	O
because	O
side	O
effects	O
unique	O
to	O
a	O
specific	O
drug	O
could	O
be	O
minimized	O
by	O
selecting	O
appropriate	O
therapy	O
.	O

Specific	O
dopamine-1	I-Entity
,	O
(	O
DA1	I-Entity
)	O
and	O
dopamine-2	I-Entity
(	O
DA2	I-Entity
)	O

Fenoldopam	B-Entity
mesylate	I-Entity
is	O
a	O
specific	O
DA1	O
receptor	O
agonist	O
that	O
lowers	O
blood	O
pressure	O
by	O
vasodilatation	O
.	O

The	O
hypothesis	O
that	O
fenoldopam	I-Entity
could	O
be	O
used	O
to	O
induce	O
hypotension	I-Entity
and	O
preserve	O
blood	O
flow	O
to	O
the	O
kidney	O
was	O
tested	O
.	O

Systemic	O
aortic	O
blood	O
pressure	O
and	O
renal	O
blood	O
flow	O
were	O
measured	O
continuously	O
with	O
a	O
carotid	O
arterial	O
catheter	O
and	O
an	O
electromagnetic	O
flow	O
probe	O
respectively	O
,	O
in	O
order	O
to	O
compare	O
the	O
cardiovascular	O
and	O
renal	O
vascular	O
effects	O
of	O
fenoldopam	I-Entity
and	O
sodium	I-Entity
nitroprusside	I-Entity
in	O
ten	O
dogs	O
under	O
halothane	I-Entity
general	O
anaesthesia	O
.	O

8	O
per	O
cent	O
from	O
control	O
with	O
infusion	O
of	O
fenoldopam	I-Entity
(	O
3.4	O
+	O
/-	O

4	O
per	O
cent	O
with	O
infusion	O
of	O
sodium	I-Entity
nitroprusside	I-Entity
(	O
5.9	O
micrograms.kg-1.min-1	O
)	O
(	O
NS	O
)	O
.	O

Renal	O
blood	O
flow	O
(	O
RBF	O
)	O
increased	O
during	O
fenoldopam	I-Entity
-	O
induced	O
hypotension	I-Entity
11	O
+	O
/-	O

8	O
per	O
cent	O
during	O
sodium	I-Entity
nitroprusside	I-Entity
-	O
induced	O
hypotension	I-Entity
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Sodium	O
nitroprusside	I-Entity
is	O
a	O
non	O
-	O
selective	O
arteriolar	O
and	O
venous	O
vasodilator	O
that	O
can	O
produce	O
redistribution	O
of	O
blood	O
flow	O
away	O
from	O
the	O
kidney	O
during	O
induced	O
hypotension	I-Entity
.	O

Fenoldopam	O
is	O
a	O
selective	O
dopamine-1	I-Entity
(	O
DA1	O
)	O
receptor	O
agonist	O
that	O
causes	O
vasodilatation	O
to	O
the	O
kidney	O
and	O
other	O
organs	O
with	O
DA1	O
receptors	O
and	O
preserves	O
blood	O
flow	O
to	O
the	O
kidney	O
during	O
induced	O
hypotension	I-Entity
.	O



Antiarrhythmic	O
effects	O
of	O
optical	O
isomers	O
of	O
cibenzoline	I-Entity
on	O
canine	O
ventricular	B-Entity
arrhythmias	I-Entity
.	O

Antiarrhythmic	O
effects	O
of	O
(	O
+	O
)	O
-cibenzoline	I-Entity
and	O
(	O
-)-cibenzoline	I-Entity
were	O
examined	O
using	O
two	O
canine	O
ventricular	B-Entity
arrhythmia	I-Entity
models	O
.	O

Digitalis	I-Entity
arrhythmia	I-Entity
,	O
which	O
is	O
suppressed	O
by	O
Na	I-Entity
channel	O
blockers	O
,	O
was	O
induced	O
by	O
intermittent	O
intravenous	O
(	O
i.v	O
.	O
)	O

injection	O
of	O
ouabain	I-Entity
in	O
pentobarbital	I-Entity
-	O
anesthetized	O
dogs	O
.	O

Adrenaline	B-Entity
arrhythmia	I-Entity
,	O
which	O
is	O
suppressed	O
by	O
Ca	I-Entity
channel	O
blockers	O
,	O
was	O
induced	O
by	O
adrenaline	I-Entity
infusion	O
in	O
halothane	I-Entity
-	O
anesthetized	O
dogs	O
.	O

(	O
+	O
)	O
-cibenzoline	I-Entity
suppressed	O
digitalis-	I-Entity
and	O
adrenaline	I-Entity
-	O
induced	O
arrhythmias	I-Entity
,	O
respectively	O
.	O

The	O
minimum	O
effective	O
plasma	O
concentrations	O
of	O
(	O
+	O
)	O
-cibenzoline	I-Entity
for	O
digitalis-	I-Entity
and	O
adrenaline	I-Entity
-	O
induced	O
arrhythmias	I-Entity
were	O
1.4	O
+	O
/-	O

(	O
-)-cibenzoline	I-Entity
suppressed	O
the	O
digitalis	I-Entity
-	O
induced	O
arrhythmia	I-Entity
,	O
whereas	O
5	O
mg	O
/	O
kg	O
i.v	O
.	O

was	O
needed	O
to	O
suppress	O
adrenaline	I-Entity
-	O
induced	O
arrhythmias	I-Entity
.	O

The	O
minimum	O
effective	O
plasma	O
concentrations	O
of	O
(	O
-)-cibenzoline	I-Entity
for	O
digitalis-	I-Entity
and	O
adrenaline	I-Entity
-	O
induced	O
arrhythmia	I-Entity
were	O
0.06	O
+	O
/-	O

The	O
stronger	O
antiarrhythmic	O
effect	O
of	O
(	O
-)-cibenzoline	I-Entity
indicates	O
that	O
(	O
-)-isomer	O
may	O
have	O
an	O
effect	O
nearly	O
5	O
-	O
20	O
times	O
stronger	O
in	O
suppressing	O
Na	I-Entity
channels	O
,	O
but	O
effects	O
of	O
both	O
drugs	O
on	O
Ca	I-Entity
channels	O
may	O
be	O
almost	O
equipotent	O
.	O



Effect	O
of	O
Hibiscus	B-Entity
rosa	I-Entity
sinensis	I-Entity
on	O
reserpine	I-Entity
-	O
induced	O
neurobehavioral	O
and	O
biochemical	O
alterations	O
in	O
rats	O
.	O

Effect	O
of	O
methanolic	O
extract	O
of	O
Hibiscus	B-Entity
rosa	I-Entity
sinensis	I-Entity
(	O
100	O
-	O
300	O
mg	O
/	O
kg	O
)	O
was	O
studied	O
on	O
reserpine	I-Entity
-	O
induced	O
orofacial	O
dyskinesia	I-Entity
and	O
neurochemical	O
alterations	O
.	O

The	O
rats	O
were	O
treated	O
with	O
intraperitoneal	O
reserpine	I-Entity

Reserpine	I-Entity
treated	O
rats	O
significantly	O
developed	O
vacuous	O
chewing	O
movements	O
and	O
tongue	O
protrusions	O
however	O
,	O
coadministration	O
of	O
Hibiscus	B-Entity
rosa	I-Entity
sinensis	I-Entity
roots	O
extract	O
(	O
100	O
,	O
200	O
and	O
300	O
mg	O
/	O
kg	O
,	O
per	O
orally	O
)	O
attenuated	O
the	O
effects	O
.	O

Biochemical	O
analysis	O
of	O
brain	O
revealed	O
that	O
the	O
reserpine	I-Entity
treatment	O
significantly	O
increased	O
lipid	O
peroxidation	O
and	O
decreased	O
levels	O
of	O
superoxide	I-Entity
dismutase	O
(	O
SOD	O
)	O
,	O
catalase	O
(	O
CAT	O
)	O
and	O
glutathione	I-Entity
reductase	O
(	O
GSH	O
)	O
,	O
an	O
index	O
of	O
oxidative	O
stress	O
process	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
Hibiscus	B-Entity
rosa	I-Entity
sinensis	I-Entity
had	O
a	O
protective	O
role	O
against	O
reserpine	I-Entity
-	O
induced	O
orofacial	O
dyskinesia	I-Entity
and	O
oxidative	O
stress	O
.	O



Comparison	O
of	O
aqueous	O
and	O
gellan	O
ophthalmic	O
timolol	I-Entity
with	O
placebo	O
on	O
the	O
24-hour	O
heart	O
rate	O
response	O
in	O
patients	O
on	O
treatment	O
for	O
glaucoma	I-Entity
.	O

Topical	O
beta	O
-	O
blocker	O
treatment	O
is	O
routine	O
therapy	O
in	O
the	O
management	O
of	O
patients	O
with	O
glaucoma	I-Entity
.	O

This	O
trial	O
evaluated	O
the	O
effect	O
of	O
placebo	O
,	O
0.5%	O
aqueous	O
timolol	I-Entity
(	O
timolol	I-Entity
solution	O
)	O
and	O
a	O
0.5%	O
timolol	I-Entity
suspension	O
that	O
forms	O
a	O
gel	O
on	O
application	O
to	O
the	O
conjunctiva	O
(	O
timolol	I-Entity
gellan	O
)	O
on	O
the	O
24-hour	O
heart	O
rate	O
in	O
patients	O
currently	O
being	O
treated	O
for	O
glaucoma	I-Entity
to	O
quantify	O
the	O
reduction	O
in	O
mean	O
heart	O
rate	O
.	O

METHODS	O
:	O
Forty	O
-	O
three	O
Caucasian	O
patients	O
with	O
primary	O
open	B-Entity
-	I-Entity
angle	I-Entity
glaucoma	I-Entity
or	O
ocular	B-Entity
hypertension	I-Entity
with	O
a	O
mean	O
(	O
+	O
/-SD	O
)	O
age	O
of	O
63	O
(	O
+	O
/-8	O
)	O
years	O
were	O
randomized	O
and	O
crossed	O
over	O
in	O
a	O
double	O
-	O
masked	O
manner	O
to	O
14	O
days	O
of	O
treatment	O
with	O
placebo	O
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	O
)	O
,	O
timolol	I-Entity
solution	O
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	O
)	O
,	O
or	O
timolol	I-Entity
gellan	O
(	O
morning	O
in	O
both	O
eyes	O
with	O
placebo	O
in	O
the	O
evening	O
)	O
.	O

Both	O
timolol	I-Entity
solution	O
and	O
timolol	I-Entity
gellan	O
reduced	O
the	O
mean	O
24-hour	O
heart	O
rate	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
or	O
=	O
.001	O
)	O
,	O
and	O
this	O
reduction	O
was	O
most	O
pronounced	O
during	O
the	O
daytime	O
(	O
-7.5%	O
change	O
in	O
mean	O
heart	O
rate	O

Timolol	I-Entity
gellan	O
showed	O
a	O
numerically	O
but	O
not	O
significantly	O
smaller	O
reduction	O
in	O
24-hour	O
heart	O
rate	O
,	O
compared	O
with	O
timolol	I-Entity
solution	O
.	O

During	O
the	O
night	O
,	O
the	O
mean	O
12-hour	O
heart	O
rate	O
on	O
placebo	O
and	O
timolol	I-Entity
gellan	O
were	O
both	O
significantly	O
less	O
than	O
on	O
timolol	I-Entity
solution	O
;	O
the	O
difference	O
between	O
solution	O
and	O
gellan	O
treatments	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
.01	O
)	O
.	O

Both	O
timolol	I-Entity
solution	O
and	O
timolol	I-Entity
gellan	O
decrease	O
the	O
mean	O
24-hour	O
heart	O
rate	O
compared	O
with	O
placebo	O
.	O

These	O
data	O
quantify	O
the	O
modest	O
bradycardia	I-Entity
associated	O
with	O
ophthalmic	O
beta	O
-	O
blocker	O
therapy	O
in	O
a	O
typical	O
patient	O
population	O
on	O
therapy	O
for	O
glaucoma	I-Entity
.	O



5	B-Entity
flourouracil	I-Entity
-	O
induced	O
apical	B-Entity
ballooning	I-Entity
syndrome	I-Entity
:	O
a	O
case	O
report	O
.	O

The	O
apical	B-Entity
ballooning	I-Entity
syndrome	I-Entity
(	O
ABS	I-Entity
)	O
is	O
a	O
recently	O
described	O
stress	O
-	O
mediated	O
acute	B-Entity
cardiac	I-Entity
syndrome	I-Entity
characterized	O
by	O
transient	O
wall	O
-	O
motion	O
abnormalities	O
involving	O
the	O
apex	O
and	O
midventricle	O
with	O
hyperkinesis	I-Entity
of	O
the	O
basal	O
left	O
ventricular	O
(	O
LV	O
)	O
segments	O
without	O
obstructive	O
epicardial	B-Entity
coronary	I-Entity
disease	I-Entity
.	O

Cardiotoxicity	I-Entity
is	O
not	O
an	O
uncommon	O
adverse	O
effect	O
of	O
chemotherapeutic	O
agents	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
of	O
ABS	I-Entity
secondary	O
to	O
chemotherapeutic	O
agents	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
woman	O
who	O
developed	O
the	O
syndrome	O
after	O
chemotherapy	O
for	O
metastatic	O
cancer	I-Entity
.	O

A	O
79-year	O
-	O
old	O
woman	O
presented	O
with	O
typical	O
ischemic	I-Entity
chest	B-Entity
pain	I-Entity
,	O
elevated	O
cardiac	O
enzymes	O
with	O
significant	O
ST	O
-	O
segment	O
abnormalities	O
on	O
her	O
electrocardiogram	O
.	O

She	O
underwent	O
recent	O
chemotherapy	O
with	O
fluorouracil	I-Entity
for	O
metastatic	O
colorectal	B-Entity
cancer	I-Entity
.	O

Echocardiography	O
revealed	O
a	O
wall	O
-	O
motion	O
abnormality	O
involving	O
the	O
apical	O
and	O
periapical	O
segments	O
which	O
appeared	O
akinetic	I-Entity
.	O

Echocardiogram	O
revealed	O
a	O
normal	O
ejection	O
fraction	O
and	O
a	O
resolution	O
of	O
the	O
apical	O
akinesis	I-Entity
.	O

Pathogenetic	O
mechanisms	O
of	O
cardiac	B-Entity
complications	I-Entity
in	O
cancer	I-Entity
patients	O
undergoing	O
chemotherapy	O
include	O
coronary	B-Entity
vasospasm	I-Entity
,	O
endothelial	O
damage	O
and	O
consequent	O
thrombus	I-Entity
formation	O
.	O

In	O
our	O
patient	O
,	O
both	O
supraphysiologic	O
levels	O
of	O
plasma	O
catecholamines	I-Entity
and	O
stress	O
related	O
neuropeptides	O
caused	O
by	O
cancer	I-Entity
diagnosis	O
as	O
well	O
as	O
chemotherapy	O
may	O
have	O
contributed	O
the	O
development	O
of	O
ABS	I-Entity
.	O



Reduction	O
of	O
pain	I-Entity
during	O
induction	O
with	O
target	O
-	O
controlled	O
propofol	I-Entity
and	O
remifentanil	I-Entity
.	O

Pain	I-Entity
on	O
injection	O
of	O
propofol	I-Entity
is	O
unpleasant	O
.	O

We	O
hypothesized	O
that	O
propofol	I-Entity
infusion	O
pain	I-Entity
might	O
be	O
prevented	O
by	O
infusing	O
remifentanil	I-Entity
before	O
starting	O
the	O
propofol	I-Entity
infusion	O
in	O
a	O
clinical	O
setting	O
where	O
target	O
-	O
controlled	O
infusions	O
(	O
TCI	O
)	O
of	O
both	O
drugs	O
were	O
used	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
was	O
performed	O
to	O
determine	O
the	O
effect	O
-	O
site	O
concentration	O
(	O
Ce	O
)	O
of	O
remifentanil	I-Entity
to	O
prevent	O
the	O
pain	I-Entity
without	O
producing	O
complications	O
.	O

A	O
total	O
of	O
128	O
patients	O
undergoing	O
general	O
surgery	O
were	O
randomly	O
allocated	O
to	O
receive	O
normal	O
saline	O
(	O
control	O
)	O
or	O
remifentanil	I-Entity
to	O
a	O
target	O
Ce	O
of	O
2	O
ng	O
ml(-1	O
)	O
(	O
R2	O
)	O
,	O
4	O
ng	O
ml(-1	O
)	O
(	O
R4	O
)	O
,	O
or	O
6	O
ng	O
ml(-1	O
)	O
(	O
R6	O
)	O
administered	O
via	O
TCI	O
.	O

After	O
the	O
target	O
Ce	O
was	O
achieved	O
,	O
the	O
infusion	O
of	O
propofol	I-Entity
was	O
started	O
.	O

Remifentanil	I-Entity
-	O
related	O
complications	O
were	O
assessed	O
during	O
the	O
remifentanil	I-Entity
infusion	O
,	O
and	O
pain	I-Entity
caused	O
by	O
propofol	I-Entity
was	O
evaluated	O
using	O
a	O
four	O
-	O
point	O
scale	O
during	O
the	O
propofol	I-Entity
infusion	O
.	O

The	O
incidence	O
of	O
pain	I-Entity
was	O
significantly	O
lower	O
in	O
Groups	O
R4	O
and	O
R6	O
than	O
in	O
the	O
control	O
and	O
R2	O
groups	O
(	O
12/32	O
and	O
6/31	O
vs	O
26/31	O
and	O
25/32	O
,	O
respectively	O
,	O
P<0.001	O
)	O
.	O

Pain	I-Entity
was	O
less	O
severe	O
in	O
Groups	O
R4	O
and	O
R6	O
than	O
in	O
the	O
control	O
and	O
R2	O
groups	O
(	O
P<0.001	O
)	O
.	O

However	O
,	O
both	O
incidence	O
and	O
severity	O
of	O
pain	I-Entity
were	O
not	O
different	O
between	O
Groups	O
R4	O
and	O
R6	O
.	O

During	O
induction	O
of	O
anaesthesia	O
with	O
TCI	O
of	O
propofol	I-Entity
and	O
remifentanil	I-Entity
,	O
a	O
significant	O
reduction	O
in	O
propofol	I-Entity
infusion	O
pain	I-Entity
was	O
achieved	O
without	O
significant	O
complications	O
by	O
prior	O
administration	O
of	O
remifentanil	I-Entity
at	O
a	O
target	O
Ce	O
of	O
4	O
ng	O
ml(-1	O
)	O
.	O



Prenatal	O
exposure	O
to	O
fluoxetine	I-Entity
induces	O
fetal	B-Entity
pulmonary	I-Entity
hypertension	I-Entity
in	O
the	O
rat	O
.	O

Fluoxetine	I-Entity
is	O
a	O
selective	O
serotonin	I-Entity
reuptake	O
inhibitor	O
antidepressant	O
widely	O
used	O
by	O
pregnant	O
women	O
.	O

Epidemiological	O
data	O
suggest	O
that	O
fluoxetine	I-Entity
exposure	O
prenatally	O
increases	O
the	O
prevalence	O
of	O
persistent	O
pulmonary	B-Entity
hypertension	I-Entity
syndrome	I-Entity
of	O
the	O
newborn	O
.	O

The	O
mechanism	O
responsible	O
for	O
this	O
effect	O
is	O
unclear	O
and	O
paradoxical	O
,	O
considering	O
the	O
current	O
evidence	O
of	O
a	O
pulmonary	B-Entity
hypertension	I-Entity
protective	O
fluoxetine	I-Entity
effect	O
in	O
adult	O
rodents	O
.	O

To	O
evaluate	O
the	O
fluoxetine	I-Entity
effect	O
on	O
fetal	O
rat	O
pulmonary	O
vascular	O
smooth	O
muscle	O
mechanical	O
properties	O
and	O
cell	O
proliferation	O
rate	O
.	O

Pregnant	O
rats	O
were	O
treated	O
with	O
fluoxetine	I-Entity
(	O
10	O
mg	O
/	O
kg	O
)	O
from	O
Day	O
11	O
through	O
Day	O
21	O
of	O
gestation	O
.	O

As	O
compared	O
with	O
controls	O
,	O
fluoxetine	I-Entity
exposure	O
resulted	O
in	O
fetal	B-Entity
pulmonary	I-Entity
hypertension	I-Entity
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
weight	O
ratio	O
of	O
the	O
right	O
ventricle	O
to	O
the	O
left	O
ventricle	O
plus	O
septum	O
(	O
P	O
=	O
0.02	O
)	O
and	O
by	O
an	O
increase	O
in	O
pulmonary	O
arterial	O
medial	O
thickness	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Postnatal	O
mortality	O
was	O
increased	O
among	O
experimental	O
animals	O
,	O
and	O
arterial	O
oxygen	I-Entity
saturation	O
was	O
96	O
+	O
/-	O

1%	O
in	O
1-day	O
-	O
old	O
control	O
animals	O
and	O
significantly	O
lower	O
(	O
P	O
<	O
0.01	O
)	O
in	O
fluoxetine	I-Entity
-	O
exposed	O
pups	O
(	O
79	O
+	O
/-	O

In	O
vitro	O
,	O
fluoxetine	I-Entity
induced	O
pulmonary	O
arterial	O
muscle	O
contraction	O
in	O
fetal	O
,	O
but	O
not	O
adult	O
,	O
animals	O
(	O
P	O
<	O
0.01	O
)	O
and	O
reduced	O
serotonin	I-Entity
-	O
induced	O
contraction	O
at	O
both	O
ages	O
(	O
P	O
<	O
0.01	O
)	O
.	O

After	O
in	O
utero	O
exposure	O
to	O
a	O
low	O
fluoxetine	I-Entity
concentration	O
the	O
pulmonary	O
arterial	O
smooth	O
muscle	O
cell	O
proliferation	O
rate	O
was	O
significantly	O
increased	O
in	O
fetal	O
,	O
but	O
not	O
adult	O
,	O
cells	O
(	O
P	O
<	O
0.01	O
)	O
.	O

In	O
contrast	O
to	O
the	O
adult	O
,	O
fluoxetine	I-Entity
exposure	O
in	O
utero	O
induces	O
pulmonary	B-Entity
hypertension	I-Entity
in	O
the	O
fetal	O
rat	O
as	O
a	O
result	O
of	O
a	O
developmentally	O
regulated	O
increase	O
in	O
pulmonary	O
vascular	O
smooth	O
muscle	O
proliferation	O
.	O



Syncope	I-Entity
and	O
QT	B-Entity
prolongation	I-Entity
among	O
patients	O
treated	O
with	O
methadone	I-Entity
for	O
heroin	I-Entity
dependence	O
in	O
the	O
city	O
of	O
Copenhagen	O
.	O

Methadone	I-Entity
is	O
prescribed	O
to	O
heroin	I-Entity
addicts	O
to	O
decrease	O
illicit	O
opioid	O
use	O
.	O

Prolongation	O
of	O
the	O
QT	O
interval	O
in	O
the	O
ECG	O
of	O
patients	O
with	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
(	O
TdP	I-Entity
)	O
has	O
been	O
reported	O
in	O
methadone	I-Entity
users	O
.	O

As	O
heroin	I-Entity
addicts	O
sometimes	O
faint	O
while	O
using	O
illicit	O
drugs	O
,	O
doctors	O
might	O
attribute	O
too	O
many	O
episodes	O
of	O
syncope	I-Entity
to	O
illicit	O
drug	O
use	O
and	O
thereby	O
underestimate	O
the	O
incidence	O
of	O
TdP	I-Entity
in	O
this	O
special	O
population	O
,	O
and	O
the	O
high	O
mortality	O
in	O
this	O
population	O
may	O
,	O
in	O
part	O
,	O
be	O
caused	O
by	O
the	O
proarrhythmic	O
effect	O
of	O
methadone	I-Entity
.	O

In	O
this	O
cross	O
-	O
sectional	O
study	O
interview	O
,	O
ECGs	O
and	O
blood	O
samples	O
were	O
collected	O
in	O
a	O
population	O
of	O
adult	O
heroin	I-Entity
addicts	O
treated	O
with	O
methadone	I-Entity
or	O
buprenorphine	I-Entity
on	O
a	O
daily	O
basis	O
.	O

All	O
participants	O
were	O
interviewed	O
about	O
any	O
experience	O
of	O
syncope	I-Entity
.	O

The	O
association	O
between	O
opioid	O
dose	O
and	O
QT	O
,	O
and	O
methadone	I-Entity
dose	O
and	O
reporting	O
of	O
syncope	I-Entity
was	O
assessed	O
using	O
multivariate	O
linear	O
regression	O
and	O
logistic	O
regression	O
,	O
respectively	O
.	O

Methadone	I-Entity
dose	O
was	O
associated	O
with	O
longer	O
QT	O
interval	O
of	O
0.140	O
ms	O
/	O
mg	O
(	O
p	O
=	O
0.002	O
)	O
.	O

No	O
association	O
between	O
buprenorphine	I-Entity
and	O
QTc	O
was	O
found	O
.	O

Among	O
the	O
subjects	O
treated	O
with	O
methadone	I-Entity
,	O
28%	O
men	O
and	O
32%	O
women	O
had	O
prolonged	B-Entity
QTc	I-Entity
interval	I-Entity
.	O

None	O
of	O
the	O
subjects	O
treated	O
with	O
buprenorphine	I-Entity
had	O
QTc	O
interval	O
>	O
0.440	O
s((1/2	O
)	O
)	O
.	O

A	O
50	O
mg	O
higher	O
methadone	I-Entity
dose	O
was	O
associated	O
with	O
a	O
1.2	O
(	O
95%	O
CI	O
1.1	O
to	O
1.4	O
)	O
times	O
higher	O
odds	O
for	O
syncope	I-Entity
.	O

Methadone	I-Entity
is	O
associated	O
with	O
QT	B-Entity
prolongation	I-Entity
and	O
higher	O
reporting	O
of	O
syncope	I-Entity
in	O
a	O
population	O
of	O
heroin	I-Entity
addicts	O
.	O



Peripheral	B-Entity
neuropathy	I-Entity
caused	O
by	O
high	O
-	O
dose	O
cytosine	B-Entity
arabinoside	I-Entity
treatment	O
in	O
a	O
patient	O
with	O
acute	B-Entity
myeloid	I-Entity
leukemia	I-Entity
.	O

The	O
central	O
nervous	O
system	O
toxicity	I-Entity
of	O
high	O
-	O
dose	O
cytosine	B-Entity
arabinoside	I-Entity
is	O
well	O
recognized	O
,	O
but	O
the	O
toxicity	I-Entity
of	O
cytosine	B-Entity
arabinoside	I-Entity
in	O
the	O
peripheral	O
nervous	O
system	O
has	O
been	O
infrequently	O
reported	O
.	O

A	O
49-year	O
-	O
old	O
Japanese	O
man	O
was	O
diagnosed	O
with	O
acute	B-Entity
myeloid	I-Entity
leukemia	I-Entity
.	O

After	O
he	O
achieved	O
complete	O
remission	O
,	O
he	O
received	O
high	O
-	O
dose	O
cytosine	B-Entity
arabinoside	I-Entity
treatment	O
(	O
2	O
g	O
/	O
m2	O
twice	O
a	O
day	O
for	O
5	O
days	O
;	O
total	O
,	O
20	O
g	O
/	O
m2	O
)	O
as	O
consolidation	O
therapy	O
.	O

The	O
first	O
course	O
of	O
high	O
-	O
dose	O
cytosine	B-Entity
arabinoside	I-Entity
resulted	O
in	O
no	O
unusual	O
symptoms	O
,	O
but	O
on	O
day	O
21	O
of	O
the	O
second	O
course	O
of	O
treatment	O
,	O
the	O
patient	O
complained	O
of	O
numbness	I-Entity
in	O
his	O
right	O
foot	O
.	O

Electromyogram	O
and	O
nerve	O
-	O
conduction	O
studies	O
showed	O
peripheral	B-Entity
neuropathy	I-Entity
in	O
both	O
peroneal	O
nerves	O
.	O

This	O
neuropathy	I-Entity
was	O
gradually	O
resolving	O
;	O
however	O
,	O
after	O
the	O
patient	O
received	O
allogeneic	O
bone	O
marrow	O
transplantation	O
,	O
the	O
symptoms	O
worsened	O
,	O
with	O
the	O
development	O
of	O
graft	B-Entity
-	I-Entity
versus	I-Entity
-	I-Entity
host	I-Entity
disease	I-Entity
,	O
and	O
the	O
symptoms	O
subsequently	O
responded	O
to	O
methylprednisolone	I-Entity
.	O

Although	O
the	O
mechanisms	O
of	O
peripheral	B-Entity
neuropathy	I-Entity
are	O
still	O
unclear	O
,	O
high	O
-	O
dose	O
cytosine	B-Entity
arabinoside	I-Entity
is	O
a	O
therapy	O
that	O
is	O
potentially	O
toxic	O
to	O
the	O
peripheral	O
nervous	O
system	O
,	O
and	O
auto	O
/	O
alloimmunity	O
may	O
play	O
an	O
important	O
role	O
in	O
these	O
mechanisms	O
.	O



Atorvastatin	I-Entity
prevented	O
and	O
reversed	O
dexamethasone	I-Entity
-	O
induced	O
hypertension	I-Entity
in	O
the	O
rat	O
.	O

To	O
assess	O
the	O
antioxidant	O
effects	O
of	O
atorvastatin	I-Entity
(	O
atorva	I-Entity
)	O
on	O
dexamethasone	I-Entity
(	O
dex)-induced	I-Entity
hypertension	I-Entity
,	O
60	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
atorva	I-Entity
30	O
mg	O
/	O
kg	O
/	O
day	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dex	I-Entity
increased	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
from	O
109	O
+	O
/-	O

0.6	O
mmHg	O
and	O
plasma	O
superoxide	I-Entity
(	O
5711	O
+	O
/-	O

392.8	O
U	O
/	O
ml	O
dex	I-Entity
,	O
P	O
<	O
0.001	O
)	O
.	O

In	O
this	O
prevention	O
study	O
,	O
SBP	O
in	O
the	O
atorva	I-Entity
+	O
dex	I-Entity
group	O
was	O
increased	O
from	O
115	O
+	O
/-	O

1.5	O
mmHg	O
,	O
but	O
this	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
dex	I-Entity
-	O
only	O
group	O
(	O

Atorva	I-Entity
reversed	O
dex	I-Entity
-	O
induced	O
hypertension	I-Entity
(	O
129	O
+	O
/-	O

0.6	O
mmHg	O
P	O
'	O
<	O
0.05	O
)	O
and	O
decreased	O
plasma	O
superoxide	I-Entity
(	O
7931	O
+	O
/-	O

392.8	O
dex	I-Entity
,	O
1187	O

441.2	O
atorva	I-Entity
+	O
dex	I-Entity
,	O
P	O
<	O
0.0001	O
)	O
.	O

Plasma	O
nitrate	I-Entity
/	O
nitrite	I-Entity
(	O
NOx	O
)	O
was	O
decreased	O
in	O
dex	I-Entity
-	O
treated	O
rats	O
compared	O
to	O
saline	O
-	O
treated	O
rats	O
(	O
11.2	O
+	O
/-	O

Atorva	I-Entity
affected	O
neither	O
plasma	O
NOx	O
nor	O
thymus	O
weight	O
.	O

Thus	O
,	O
atorvastatin	I-Entity
prevented	O
and	O
reversed	O
dexamethasone	I-Entity
-	O
induced	O
hypertension	I-Entity
in	O
the	O
rat	O
.	O



Two	O
prodrugs	O
of	O
potent	O
and	O
selective	O
GluR5	O
kainate	I-Entity
receptor	O
antagonists	O
actives	O
in	O
three	O
animal	O
models	O
of	O
pain	I-Entity
.	O

Amino	O
acids	O
5	O
and	O
7	O
,	O
two	O
potent	O
and	O
selective	O
competitive	O
GluR5	O
KA	I-Entity
receptor	O
antagonists	O
,	O
exhibited	O
high	O
GluR5	O
receptor	O
affinity	O
over	O
other	O
glutamate	I-Entity
receptors	O
.	O

Their	O
ester	O
prodrugs	O
6	O
and	O
8	O
were	O
orally	O
active	O
in	O
three	O
models	O
of	O
pain	I-Entity
:	O
reversal	O
of	O
formalin	I-Entity
-	O
induced	O
paw	O
licking	O
,	O
carrageenan	I-Entity
-	O
induced	O
thermal	B-Entity
hyperalgesia	I-Entity
,	O
and	O
capsaicin	I-Entity
-	O
induced	O
mechanical	B-Entity
hyperalgesia	I-Entity
.	O



Sirolimus	I-Entity
and	O
mycophenolate	B-Entity
mofetil	I-Entity
for	O
calcineurin	O
-	O
free	O
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
.	O

Calcineurin	O
inhibitors	O
,	O
such	O
as	O
cyclosporine	I-Entity
and	O
tacrolimus	I-Entity
,	O
have	O
been	O
available	O
for	O
almost	O
20	O
years	O
.	O

Although	O
these	O
drugs	O
are	O
highly	O
effective	O
and	O
represent	O
the	O
mainstay	O
of	O
transplant	O
immunosuppression	O
,	O
they	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
nephrotoxicity	I-Entity
.	O

Acute	O
nephrotoxicity	I-Entity
,	O
which	O
occurs	O
in	O
the	O
early	O
period	O
after	O
transplantation	O
,	O
leads	O
to	O
a	O
higher	O
rate	O
of	O
dialysis	O
,	O
and	O
chronic	O
nephrotoxicity	I-Entity
may	O
eventually	O
result	O
in	O
graft	O
loss	O
.	O

Acute	O
and	O
chronic	O
nephrotoxicity	I-Entity
is	O
becoming	O
more	O
common	O
as	O
the	O
use	O
of	O
marginal	O
kidneys	O
for	O
transplantation	O
increases	O
.	O

Two	O
recently	O
available	O
immunosuppressive	O
agents	O
,	O
mycophenolate	B-Entity
mofetil	I-Entity
and	O
sirolimus	I-Entity
(	O
rapamycin	I-Entity
)	O
,	O
have	O
no	O
nephrotoxicity	I-Entity
.	O



Erythropoietin	O
restores	O
the	O
anemia	I-Entity
-	O
induced	O
reduction	O
in	O
cyclophosphamide	I-Entity
cytotoxicity	I-Entity
in	O
rat	O
tumors	I-Entity
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	O
of	O
anemia	I-Entity
prevention	O
by	O
recombinant	O
human	O
erythropoietin	O
(	O
rHuEPO	O
)	O
treatment	O
on	O
the	O
cytotoxicity	I-Entity
of	O
cyclophosphamide	I-Entity
in	O
solid	O
experimental	O
tumors	I-Entity
.	O

Anemia	I-Entity
was	O
induced	O
using	O
a	O
single	O
dose	O
of	O
carboplatin	I-Entity
(	O
50	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O

In	O
a	O
second	O
group	O
,	O
the	O
development	O
of	O
anemia	I-Entity
was	O
prevented	O
by	O
rHuEPO	O
(	O
1000	O
IU	O
/	O
kg	O
)	O
administered	O
s.c	O
.	O

three	O
times	O
/	O
week	O
starting	O
7	O
days	O
before	O
carboplatin	I-Entity
application	O
.	O

Four	O
days	O
after	O
carboplatin	I-Entity
treatment	O
,	O
tumors	I-Entity
(	O
DS	O
-	O
sarcoma	I-Entity
of	O
the	O
rat	O
)	O
were	O
implanted	O
s.c	O
.	O

Neither	O
carboplatin	I-Entity
nor	O
rHuEPO	O
treatment	O
influenced	O
tumor	I-Entity
growth	O
rate	O
per	O
se	O
.	O

When	O
tumors	I-Entity
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
cyclophosphamide	I-Entity
(	O
60	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
5	O
days	O
after	O
implantation	O
,	O
a	O
growth	O
delay	O
with	O
a	O
subsequent	O
regrowth	O
of	O
the	O
tumors	I-Entity
was	O
observed	O
.	O

In	O
the	O
anemia	I-Entity
group	O
,	O
the	O
growth	O
delay	O
was	O
significantly	O
shorter	O
compared	O
with	O
nonanemic	O
controls	O
(	O
13.3	O
days	O
versus	O
8.6	O
days	O
)	O
.	O

In	O
the	O
group	O
where	O
anemia	I-Entity
was	O
prevented	O
by	O
rHuEPO	O
treatment	O
,	O
growth	O
delay	O
was	O
comparable	O
with	O
that	O
of	O
nonanemic	O
controls	O
(	O
13.3	O
days	O
)	O
.	O

These	O
results	O
suggest	O
that	O
chemotherapy	O
-	O
induced	O
anemia	I-Entity
reduces	O
cytotoxicity	I-Entity
of	O
cyclophosphamide	I-Entity
in	O
tumors	I-Entity
,	O
whereas	O
correction	O
of	O
anemia	I-Entity
by	O
rHuEPO	O
treatment	O
(	O
epoetin	O
alpha	O
)	O
increases	O
the	O
sensitivity	O
,	O
probably	O
as	O
a	O
result	O
of	O
an	O
improved	O
oxygen	I-Entity
supply	O
to	O
tumor	I-Entity
tissue	O
.	O



The	O
role	O
of	O
nitrergic	O
system	O
in	O
lidocaine	I-Entity
-	O
induced	O
convulsion	I-Entity
in	O
the	O
mouse	O
.	O

The	O
effects	O
of	O
N	B-Entity
-	I-Entity
nitro	I-Entity
-	I-Entity
L	I-Entity
-	I-Entity
arginine	I-Entity
-	I-Entity
methyl	I-Entity
ester	I-Entity
(	O
L	B-Entity
-	I-Entity
NAME	I-Entity
)	O
a	O
nitric	B-Entity
oxide	I-Entity
(	O
NO	I-Entity
)	O

synthase	O
inhibitor	O
and	O
L	B-Entity
-	I-Entity
arginine	I-Entity
,	O
a	O
NO	I-Entity
precursor	O
,	O
were	O
investigated	O
on	O
lidocaine	I-Entity
-	O
induced	O
convulsions	I-Entity
.	O

In	O
the	O
first	O
experiment	O
,	O
four	O
groups	O
of	O
mice	O
received	O
physiological	O
saline	O
(	O
0.9%	O
)	O
,	O
L	B-Entity
-	I-Entity
arginine	I-Entity
(	O
300	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O

L	B-Entity
-	I-Entity
NAME	I-Entity
(	O
100	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
and	O

diazepam	I-Entity
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
respectively	O
.	O

Thirty	O
minutes	O
after	O
these	O
injections	O
,	O
all	O
mice	O
received	O
lidocaine	I-Entity
(	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

In	O
the	O
second	O
experiment	O
,	O
four	O
groups	O
of	O
mice	O
received	O
similar	O
treatment	O
in	O
the	O
first	O
experiment	O
,	O
and	O
30	O
min	O
after	O
these	O
injections	O
,	O
all	O
mice	O
received	O
a	O
higher	O
dose	O
of	O
lidocaine	I-Entity
(	O
80	O
mg	O
/	O
kg	O
)	O
.	O

L	B-Entity
-	I-Entity
NAME	I-Entity
(	O
100	O
mg	O
/	O

kg	O
,	O
i.p	O
.	O
)	O
and	O
diazepam	I-Entity
(	O
2	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
incidence	O
of	O
lidocaine	I-Entity
(	O
50	O
mg	O
/	O
kg)-induced	O
convulsions	I-Entity
.	O

In	O
contrast	O
,	O
the	O
L	B-Entity
-	I-Entity
arginine	I-Entity
treatment	O
increased	O
the	O
incidence	O
of	O
lidocaine	I-Entity
(	O
80	O
mg	O
/	O
kg	O
,	O
i.p.)-induced	O
convulsions	I-Entity
significantly	O
.	O

These	O
results	O
may	O
suggest	O
that	O
NO	I-Entity
is	O
a	O
proconvulsant	O
mediator	O
in	O
lidocaine	I-Entity
-	O
induced	O
convulsions	I-Entity
.	O



Effect	O
of	O
intravenous	O
metoprolol	I-Entity
or	O
intravenous	O
metoprolol	I-Entity
plus	O
glucagon	O
on	O
dobutamine	I-Entity
-	O
induced	O
myocardial	B-Entity
ischemia	I-Entity
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
effect	O
of	O
metoprolol	I-Entity
on	O
dobutamine	I-Entity
stress	O
testing	O
with	O
technetium-99	B-Entity
m	I-Entity
sestamibi	I-Entity
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
imaging	O
and	O
ST	O
-	O
segment	O
monitoring	O
,	O
and	O
to	O
assess	O
the	O
impact	O
of	O
intravenous	O
glucagon	O
on	O
metoprolol	I-Entity
's	O
effects	O
.	O

Patients	O
underwent	O
dobutamine	I-Entity
stress	O
tests	O
per	O
standard	O
protocol	O
.	O

Before	O
dobutamine	I-Entity
was	O
begun	O
,	O
no	O
therapy	O
was	O
given	O
during	O
the	O
first	O
visit	O
,	O
and	O
patients	O
were	O
randomized	O
on	O
subsequent	O
visits	O
to	O
receive	O
metoprolol	I-Entity
or	O
metoprolol	I-Entity
plus	O
glucagon	O
1	O
mg	O
.	O

Metoprolol	I-Entity
was	O
dosed	O
to	O
achieve	O
a	O
resting	O
predobutamine	I-Entity
heart	O
rate	O
below	O
65	O
beats	O
/	O
minute	O
or	O
a	O
total	O
intravenous	O
dose	O
of	O
20	O
mg	O
.	O

Metoprolol	I-Entity
reduced	O
maximum	O
heart	O
rate	O
31%	O
,	O
summed	O
stress	O
scores	O
29%	O
,	O
and	O
summed	O
difference	O
scores	O
43%	O
versus	O
control	O
.	O

Metoprolol	I-Entity
plus	O
glucagon	O
also	O
reduced	O
the	O
maximum	O
heart	O
rate	O
29%	O
versus	O
control	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
any	O
parameter	O
between	O
metoprolol	I-Entity
and	O
metoprolol	I-Entity
-	O
glucagon	O
.	O

During	O
dobutamine	I-Entity
stress	O
testing	O
,	O
metoprolol	I-Entity
attenuates	O
or	O
eliminates	O
evidence	O
of	O
myocardial	B-Entity
ischemia	I-Entity
.	O



Prednisolone	I-Entity
-	O
induced	O
muscle	B-Entity
dysfunction	I-Entity
is	O
caused	O
more	O
by	O
atrophy	I-Entity
than	O
by	O
altered	O
acetylcholine	I-Entity
receptor	O
expression	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
moderate	O
and	O
large	O
doses	O
of	O
prednisolone	I-Entity
on	O
muscle	O
function	O
and	O
pharmacology	O
,	O
and	O
their	O
relationship	O
to	O
changes	O
in	O
muscle	O
size	O
and	O
acetylcholine	I-Entity
receptor	O
(	O
AChR	O
)	O
expression	O
.	O

With	O
institutional	O
approval	O
,	O
35	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
randomly	O
allocated	O
to	O
receive	O
daily	O
subcutaneous	O
doses	O
of	O
10	O
mg	O
/	O
kg	O
prednisolone	I-Entity
(	O
P10	O
group	O
)	O
,	O
100	O
mg	O
/	O
kg	O
prednisolone	I-Entity
(	O
P100	O
group	O
)	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
(	O
S	O
group	O
)	O
for	O
7	O
days	O
.	O

On	O
Day	O
8	O
,	O
the	O
nerve	O
-	O
evoked	O
peak	O
twitch	O
tensions	O
,	O
tetanic	I-Entity
tensions	O
,	O
and	O
fatigability	O
,	O
and	O
the	O
dose	O
-	O
response	O
curves	O
of	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
in	O
the	O
tibialis	O
cranialis	O
muscle	O
were	O
measured	O
in	O
vivo	O
and	O
related	O
to	O
muscle	O
mass	O
or	O
expression	O
of	O
AChRs	O
.	O

The	O
evoked	O
peak	O
twitch	O
and	O
tetanic	I-Entity
tensions	O
were	O
less	O
in	O
the	O
P100	O
group	O
than	O
in	O
the	O
P10	O
or	O
S	O
groups	O
,	O
however	O
,	O
tension	O
per	O
milligram	O
of	O
muscle	O
mass	O
was	O
greater	O
in	O
the	O
P100	O
group	O
than	O
in	O
the	O
S	O
group	O
.	O

The	O
50%	O
effective	O
dose	O
of	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
(	O
microg	O
/	O
kg	O
)	O
in	O
the	O
tibialis	O
muscle	O
was	O
smaller	O
in	O
the	O
P10	O
(	O
33.6	O
+	O
/-	O

The	O
50%	O
effective	O
dose	O
of	O
d	B-Entity
-	I-Entity
tubocurarine	I-Entity
did	O
not	O
correlate	O
with	O
muscle	O
mass	O
or	O
AChR	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
neuromuscular	B-Entity
dysfunction	I-Entity
after	O
prednisolone	I-Entity
is	O
dose	O
-	O
dependent	O
,	O
and	O
derives	O
primarily	O
from	O
muscle	B-Entity
atrophy	I-Entity
and	O
derives	O
less	O
so	O
from	O
changes	O
in	O
AChR	O
expression	O
.	O

We	O
suggest	O
that	O
the	O
observed	O
effects	O
are	O
dose	O
-	O
dependent	O
and	O
derive	O
primarily	O
from	O
muscle	B-Entity
atrophy	I-Entity
and	O
derive	O
less	O
from	O
changes	O
in	O
acetylcholine	I-Entity
receptor	O
expression	O
.	O



Rapid	O
reversal	O
of	O
life	O
-	O
threatening	O
diltiazem	I-Entity
-	O
induced	O
tetany	I-Entity
with	O
calcium	B-Entity
chloride	I-Entity
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
tetany	I-Entity
with	O
sudden	O
respiratory	B-Entity
arrest	I-Entity
after	O
the	O
infusion	O
of	O
intravenous	O
diltiazem	I-Entity
.	O

The	O
administration	O
of	O
calcium	B-Entity
chloride	I-Entity
rapidly	O
resolved	O
the	O
patient	O
's	O
tetany	I-Entity
with	O
prompt	O
recovery	O
of	O
respiratory	O
function	O
,	O
averting	O
the	O
need	O
for	O
more	O
aggressive	O
airway	O
management	O
and	O
ventilatory	O
support	O
.	O

The	O
emergency	O
physician	O
should	O
be	O
aware	O
that	O
life	O
-	O
threatening	O
tetany	I-Entity
may	O
accompany	O
the	O
administration	O
of	O
intravenous	O
diltiazem	I-Entity
and	O
that	O
calcium	B-Entity
chloride	I-Entity
may	O
be	O
a	O
rapid	O
and	O
effective	O
remedy	O
.	O



Effects	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
on	O
hemostasis	O
in	O
patients	O
with	O
aneurysmal	B-Entity
subarachnoid	I-Entity
hemorrhage	I-Entity
.	O

Patients	O
with	O
aneurysmal	B-Entity
subarachnoid	I-Entity
hemorrhage	I-Entity
(	O
SAH	I-Entity
)	O
were	O
randomized	O
to	O
receive	O
either	O
ketoprofen	I-Entity
,	O
100	O
mg	O
,	O
three	O
times	O
a	O
day	O
(	O
ketoprofen	I-Entity
group	O
,	O

n	O
=	O
9	O
)	O
or	O
a	O
weak	O
NSAID	O
,	O
acetaminophen	I-Entity
,	O
1	O
g	O
,	O
three	O
times	O
a	O
day	O
(	O
acetaminophen	I-Entity
group	O
,	O

n	O
=	O
9	O
)	O
starting	O
immediately	O
after	O
the	O
diagnosis	O
of	O
aneurysmal	I-Entity
SAH	I-Entity
.	O

Maximal	O
platelet	B-Entity
aggregation	I-Entity
induced	O
by	O
6	O
microM	O
of	O
adenosine	B-Entity
diphosphate	I-Entity
decreased	O
after	O
administration	O
of	O
ketoprofen	I-Entity
.	O

Aggregation	O
was	O
lower	O
(	O
P	O
<	O
.05	O
)	O
in	O
the	O
ketoprofen	I-Entity
group	O
than	O
in	O
the	O
acetaminophen	I-Entity
group	O
just	O
before	O
surgery	O
and	O
on	O
the	O
third	O
postoperative	O
day	O
.	O

In	O
contrast	O
,	O
maximal	O
platelet	B-Entity
aggregation	I-Entity
increased	O
in	O
the	O
acetaminophen	I-Entity
group	O
on	O
the	O
third	O
postoperative	O
day	O
as	O
compared	O
with	O
the	O
pretreatment	O
platelet	B-Entity
aggregation	I-Entity
results	O
(	O
P	O
<	O
.05	O
)	O
.	O

One	O
patient	O
in	O
the	O
ketoprofen	I-Entity
group	O
developed	O
a	O
postoperative	O
intracranial	O
hematoma	I-Entity
.	O

Ketoprofen	I-Entity
but	O
not	O
acetaminophen	I-Entity
impaired	O
platelet	O
function	O
in	O
patients	O
with	O
SAH	I-Entity
.	O

If	O
ketoprofen	I-Entity
is	O
used	O
before	O
surgery	O
on	O
cerebral	O
artery	B-Entity
aneurysms	I-Entity
,	O
it	O
may	O
pose	O
an	O
additional	O
risk	O
factor	O
for	O
hemorrhage	I-Entity
.	O



Value	O
of	O
methylprednisolone	I-Entity
in	O
prevention	O
of	O
the	O
arthralgia	I-Entity
-	O
myalgia	I-Entity
syndrome	O
associated	O
with	O
the	O
total	O
dose	O
infusion	O
of	O
iron	B-Entity
dextran	I-Entity
:	O
a	O
double	O
blind	O
randomized	O
trial	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
total	O
dose	O
infusion	O
(	O
TDI	O
)	O
of	O
iron	B-Entity
dextran	I-Entity
has	O
been	O
well	O
documented	O
.	O

In	O
40%	O
of	O
treated	O
patients	O
,	O
an	O
arthralgia	I-Entity
-	O
myalgia	I-Entity
syndrome	O
develops	O
.	O

administration	O
of	O
methylprednisolone	I-Entity
(	O
MP	I-Entity
)	O
prevents	O
this	O
complication	O
.	O

MP	I-Entity
before	O
and	O
saline	O
after	O
TDI	O
(	O
group	O
2	O
)	O
,	O
or	O
125	O
mg	O
i.v	O
.	O

MP	I-Entity
before	O
and	O
after	O
TDI	O
(	O
group	O
3	O
)	O
.	O

These	O
data	O
demonstrate	O
that	O
administration	O
of	O
MP	I-Entity
before	O
and	O
after	O
TDI	O
reduces	O
the	O
frequency	O
and	O
severity	O
of	O
the	O
arthralgia	I-Entity
-	O
myalgia	I-Entity
syndrome	O
.	O

MP	I-Entity
should	O
be	O
given	O
routinely	O
before	O
and	O
after	O
TDI	O
of	O
iron	B-Entity
dextran	I-Entity
.	O



Long	O
-	O
term	O
effects	O
of	O
vincristine	I-Entity
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Forty	O
patients	O
with	O
Non	B-Entity
-	I-Entity
Hodgkin	I-Entity
's	I-Entity
Lymphoma	I-Entity
treated	O
with	O
vincristine	I-Entity
between	O
1984	O
and	O
1990	O
(	O
cumulative	O
dose	O
12	O
mg	O
in	O
18	O
-	O
24	O
weeks	O
)	O
were	O
investigated	O
in	O
order	O
to	O
evaluate	O
the	O
long	O
term	O
effects	O
of	O
vincristine	I-Entity
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

The	O
patients	O
were	O
interviewed	O
with	O
emphasis	O
on	O
neuropathic	B-Entity
symptoms	I-Entity
.	O

Physical	O
and	O
quantitative	O
sensory	O
examination	O
with	O
determination	O
of	O
vibratory	O
perception	O
and	O
thermal	O
discrimination	O
thresholds	O
were	O
performed	O
,	O
four	O
to	O
77	O
months	O
(	O
median	O
34	O
months	O
)	O
after	O
vincristine	I-Entity
treatment	O
.	O

Twenty	O
-	O
seven	O
patients	O
reported	O
neuropathic	B-Entity
symptoms	I-Entity
.	O

It	O
is	O
concluded	O
that	O
with	O
the	O
above	O
mentioned	O
vincristine	I-Entity
dose	O
schedule	O
signs	O
and	O
symptoms	O
of	O
vincristine	I-Entity
neuropathy	I-Entity
are	O
reversible	O
for	O
a	O
great	O
deal	O
and	O
prognosis	O
is	O
fairly	O
good	O
.	O



A	O
case	O
of	O
polymyositis	I-Entity
in	O
a	O
patient	O
with	O
primary	B-Entity
biliary	I-Entity
cirrhosis	I-Entity
treated	O
with	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
.	O

Although	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
has	O
been	O
used	O
for	O
many	O
rheumatologic	B-Entity
diseases	I-Entity
,	O
toxicity	I-Entity
limits	O
its	O
usefulness	O
in	O
many	O
patients	O
.	O

Polymyositis	I-Entity
/	O
dermatomyositis	I-Entity
can	O
develop	O
as	O
one	O
of	O
the	O
autoimmune	O
complications	O
of	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
treatment	O
,	O
but	O
its	O
exact	O
pathogenesis	O
remains	O
unclear	O
.	O

We	O
report	O
a	O
patient	O
with	O
primary	B-Entity
biliary	I-Entity
cirrhosis	I-Entity
,	O
who	O
developed	O
polymyositis	I-Entity
while	O
receiving	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
therapy	O
.	O

Patients	O
receiving	O
D	B-Entity
-	I-Entity
penicillamine	I-Entity
therapy	O
should	O
be	O
followed	O
carefully	O
for	O
the	O
development	O
of	O
autoimmune	O
complications	O
like	O
polymyositis	I-Entity
/	O
dermatomyositis	I-Entity
.	O



Photodistributed	O
nifedipine	I-Entity
-	O
induced	O
facial	O
telangiectasia	I-Entity
.	O

Five	O
months	O
after	O
starting	O
nifedipine	I-Entity
(	O
Adalat	I-Entity
)	O
,	O
two	O
patients	O
developed	O
photodistributed	O
facial	O
telangiectasia	I-Entity
,	O
which	O
became	O
more	O
noticeable	O
with	O
time	O
.	O

Neither	O
patient	O
complained	O
of	O
photosensitivity	O
or	O
flushing	I-Entity
.	O

One	O
commenced	O
the	O
closely	O
related	O
drug	O
amlodipine	I-Entity
3	O
years	O
later	O
,	O
with	O
recurrence	O
of	O
telangiectasia	I-Entity
.	O

The	O
photodistribution	O
of	O
the	O
telangiectasia	I-Entity
suggests	O
a	O
significant	O
drug	O
/	O
light	O
interaction	O
.	O



Nephrotoxicity	I-Entity
of	O
cyclosporin	B-Entity
A	I-Entity
and	O
FK506	I-Entity
:	O
inhibition	O
of	O
calcineurin	O
phosphatase	O
.	O

Cyclosporin	B-Entity
A	I-Entity
(	O
CsA	I-Entity
;	O
50	O
mg	O
/	O
kg	O
)	O
and	O
Fujimycine	I-Entity
(	O
FK506	I-Entity
;	O
5	O
mg	O
/	O
kg	O
)	O
,	O
but	O
not	O
the	O
related	O
macrolide	I-Entity
immunosuppressant	O
rapamycin	I-Entity
(	O
5	O
mg	O
/	O
kg	O
)	O
,	O
caused	O
a	O
reduction	O
of	O
glomerular	O
filtration	O
rate	O
,	O
degenerative	O
changes	O
of	O
proximal	O
tubular	O
epithelium	O
,	O
and	O
hypertrophy	I-Entity
of	O
the	O
juxtaglomerular	O
apparatus	O
in	O
male	O
Wistar	O
rats	O
when	O
given	O
for	O
10	O
days	O
.	O

The	O
molecular	O
mechanisms	O
of	O
CsA	I-Entity
and	O
FK506	I-Entity
toxicity	I-Entity
were	O
investigated	O
.	O

Cyclophilin	O
A	O
and	O
FK506-binding	I-Entity
protein	O
,	O
the	O
main	O
intracytoplasmic	O
receptors	O
for	O
CsA	I-Entity
and	O
FK506	I-Entity
,	O
respectively	O
,	O
were	O
each	O
detected	O
in	O
renal	O
tissue	O
extract	O
.	O

In	O
the	O
kidney	O
,	O
high	O
levels	O
of	O
immunoreactive	O
and	O
enzymatically	O
active	O
calcineurin	O
were	O
found	O
which	O
were	O
inhibited	O
by	O
the	O
immunosuppressants	O
CsA	I-Entity
and	O
FK506	I-Entity
,	O
but	O
not	O
by	O
rapamycin	I-Entity
.	O

Finally	O
,	O
specific	O
immunophilin	O
-	O
drug	O
-	O
calcineurin	O
complexes	O
formed	O
only	O
in	O
the	O
presence	O
of	O
CsA	I-Entity
and	O
FK506	I-Entity
,	O
but	O
not	O
rapamycin	I-Entity
.	O

These	O
results	O
suggest	O
that	O
the	O
nephrotoxic	I-Entity
effects	O
of	O
CsA	I-Entity
and	O
FK506	I-Entity
is	O
likely	O
mediated	O
through	O
binding	O
to	O
renal	O
immunophilin	O
and	O
inhibiting	O
calcineurin	O
phosphatase	O
.	O



Massive	O
cerebral	B-Entity
edema	I-Entity
associated	O
with	O
fulminant	O
hepatic	B-Entity
failure	I-Entity
in	O
acetaminophen	I-Entity
overdose	I-Entity
:	O
possible	O
role	O
of	O
cranial	O
decompression	O
.	O

Cerebral	B-Entity
edema	I-Entity
may	O
complicate	O
the	O
course	O
of	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
.	O

We	O
present	O
a	O
patient	O
with	O
fatal	O
acetaminophen	I-Entity
-	O
induced	O
fulminant	B-Entity
hepatic	I-Entity
failure	I-Entity
,	O
with	O
signs	O
and	O
symptoms	O
of	O
cerebral	B-Entity
edema	I-Entity
,	O
unresponsive	O
to	O
conventional	O
medical	O
therapy	O
.	O



Gentamicin	I-Entity
nephropathy	I-Entity
in	O
a	O
neonate	O
.	O

The	O
clinical	O
and	O
autopsy	O
findings	O
in	O
a	O
premature	O
baby	O
who	O
died	O
of	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
after	O
therapy	O
with	O
gentamicin	I-Entity
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
penicillin	I-Entity
are	O
presented	O
.	O

The	O
serum	O
gentamicin	I-Entity
concentration	O
had	O
reached	O
toxic	O
levels	O
when	O
anuria	I-Entity
developed	O
.	O

Numerous	O
periodic	B-Entity
acid	I-Entity
Schiff	O
(	O
PAS	O
)	O
positive	O
,	O
diastase	O
resistant	O
cytoplasmic	O
inclusion	O
bodies	O
which	O
appeared	O
as	O
myelin	O
figures	O
in	O
cytosegresomes	O
under	O
the	O
electron	O
microscope	O
were	O
identified	O
in	O
the	O
proximal	O
convoluted	O
tubules	O
.	O

The	O
pathological	O
changes	O
induced	O
by	O
gentamicin	I-Entity
in	O
the	O
human	O
neonatal	O
kidneys	O
have	O
not	O
been	O
previously	O
reported	O
.	O



Anti	O
-	O
carcinogenic	I-Entity
action	O
of	O
phenobarbital	I-Entity
given	O
simultaneously	O
with	O
diethylnitrosamine	I-Entity
in	O
the	O
rat	O
.	O

The	O
present	O
work	O
has	O
been	O
planned	O
in	O
order	O
to	O
elucidate	O
the	O
effect	O
of	O
phenobarbital	I-Entity
(	O
PB	I-Entity
:	O
15	O
mg	O
per	O
rat	O
of	O
ingested	O
dose	O
)	O
on	O
carcinogenesis	I-Entity
when	O
it	O
is	O
administered	O
simultaneously	O
with	O
diethylnitrosamine	I-Entity
(	O
DEN	I-Entity
:	O
10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

Wistar	O
rats	O
(	O
180	O
g	O
)	O
were	O
treated	O
by	O
DEN	I-Entity
alone	O
or	O
by	O
DEN	I-Entity
+	O
PB	I-Entity
during	O
2	O
,	O
4	O
and	O
6	O
weeks	O
according	O
to	O
our	O
schedule	O
for	O
hepatocarcinogenesis	I-Entity
.	O

After	O
the	O
end	O
of	O
the	O
treatment	O
,	O
the	O
number	O
and	O
the	O
size	O
of	O
induced	O
PAS	O
positive	O
preneoplastic	B-Entity
foci	I-Entity
was	O
significantly	O
reduced	O
when	O
PB	I-Entity
was	O
given	O
simultaneously	O
with	O
DEN	I-Entity
for	O
4	O
and	O
6	O
weeks	O
.	O

The	O
mitotic	O
inhibition	O
and	O
the	O
production	O
of	O
micronuclei	O
normally	O
observed	O
after	O
partial	O
hepatectomy	O
in	O
DEN	I-Entity
treated	O
rats	O
were	O
also	O
significantly	O
decreased	O
in	O
DEN	I-Entity
+	O
PB	I-Entity
treated	O
rats	O
.	O

When	O
the	O
treatment	O
last	O
only	O
2	O
weeks	O
,	O
the	O
presence	O
of	O
PB	I-Entity
did	O
not	O
change	O
significantly	O
the	O
last	O
parameters	O
.	O

In	O
DEN	I-Entity
+	O
PB	I-Entity
treated	O
rats	O
,	O
the	O
survival	O
was	O
prolonged	O
and	O
the	O
tumor	I-Entity
incidence	O
decreased	O
as	O
compared	O
with	O
the	O
results	O
obtained	O
by	O
DEN	I-Entity
alone	O
.	O

It	O
is	O
concluded	O
that	O
PB	I-Entity
,	O
which	O
promotes	O
carcinogenesis	I-Entity
when	O
administered	O
after	O
the	O
DEN	I-Entity
treatment	O
,	O
reduces	O
the	O
carcinogen	O
effect	O
when	O
given	O
simultaneously	O
with	O
DEN	I-Entity
.	O

This	O
'	O
anti	O
-	O
carcinogen	O
'	O
effect	O
acts	O
on	O
the	O
initiation	O
as	O
well	O
as	O
on	O
the	O
promotion	O
of	O
the	O
precancerous	B-Entity
lesions	I-Entity
.	O

Biochemical	O
investigations	O
are	O
in	O
progress	O
to	O
obtain	O
more	O
information	O
about	O
this	O
'	O
paradoxical	O
'	O
PB	I-Entity
effect	O
.	O



Post	O
-	O
operative	O
rigidity	I-Entity
after	O
fentanyl	I-Entity
administration	O
.	O

A	O
case	O
of	O
thoraco	O
-	O
abdominal	O
rigidity	I-Entity
leading	O
to	O
respiratory	B-Entity
failure	I-Entity
is	O
described	O
in	O
the	O
post	O
-	O
operative	O
period	O
in	O
an	O
elderly	O
patient	O
who	O
received	O
a	O
moderate	O
dose	O
of	O
fentanyl	I-Entity
.	O

This	O
was	O
successfully	O
reversed	O
by	O
naloxone	I-Entity
.	O



Postpartum	O
psychosis	I-Entity
induced	O
by	O
bromocriptine	I-Entity
.	O

Two	O
multigravida	O
patients	O
with	O
no	O
prior	O
psychiatric	I-Entity
history	O
were	O
seen	O
with	O
postpartum	O
psychosis	I-Entity
,	O
having	O
received	O
bromocriptine	I-Entity
for	O
inhibition	B-Entity
of	I-Entity
lactation	I-Entity
.	O

Bromocriptine	I-Entity
given	O
in	O
high	O
doses	O
has	O
been	O
associated	O
with	O
psychosis	I-Entity
in	O
patients	O
receiving	O
the	O
drug	O
for	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

These	O
cases	O
demonstrate	O
that	O
bromocriptine	I-Entity
may	O
cause	O
psychosis	I-Entity
even	O
when	O
given	O
in	O
low	O
doses	O
.	O



A	O
prospective	O
study	O
on	O
the	O
dose	O
dependency	O
of	O
cardiotoxicity	I-Entity
induced	O
by	O
mitomycin	B-Entity
C.	I-Entity

Since	O
1975	O
mitomycin	B-Entity
C	I-Entity
(	O
MMC	I-Entity
)	O
has	O
been	O
suggested	O
to	O
be	O
cardiotoxic	I-Entity
,	O
especially	O
when	O
combined	O
with	O
or	O
given	O
following	O
doxorubicin	I-Entity
.	O

Forty	O
-	O
four	O
MMC	I-Entity
-	O
treated	O
patients	O
were	O
studied	O
,	O
37	O
of	O
them	O
could	O
be	O
evaluated	O
.	O

One	O
of	O
the	O
patients	O
developed	O
cardiac	B-Entity
failure	I-Entity
after	O
30	O
mg	O
m-2	O
MMC	I-Entity
and	O
only	O
150	O
mg	O
m-2	O
doxorubicin	I-Entity
.	O

The	O
cardiac	B-Entity
failure	I-Entity
was	O
predicted	O
by	O
a	O
drop	O
in	O
EF	O
determined	O
during	O
a	O
cold	O
pressor	O
test	O
.	O

None	O
of	O
the	O
other	O
patients	O
developed	O
clinical	O
cardiotoxicity	I-Entity
,	O
nor	O
did	O
the	O
studied	O
parameters	O
change	O
.	O

Based	O
on	O
the	O
combined	O
data	O
from	O
the	O
present	O
study	O
and	O
the	O
literature	O
,	O
we	O
suggest	O
that	O
MMC	I-Entity
-	O
related	O
cardiotoxicity	I-Entity
is	O
dose	O
dependent	O
,	O
occurring	O
at	O
cumulative	O
dose	O
levels	O
of	O
30	O
mg	O
m-2	O
or	O
more	O
,	O
mainly	O
in	O
patients	O
also	O
(	O
previously	O
or	O
simultaneously	O
)	O
treated	O
with	O
doxorubicin	I-Entity
.	O



Phlorizin	I-Entity
-	O
induced	O
glycosuria	I-Entity
does	O
not	O
prevent	O
gentamicin	I-Entity
nephrotoxicity	I-Entity
in	O
rats	O
.	O

Because	O
rats	O
with	O
streptozotocin	I-Entity
-	O
induced	O
diabetes	B-Entity
mellitus	I-Entity
(	O
DM	I-Entity
)	O
have	O
a	O
high	O
solute	O
diuresis	O
(	O
glycosuria	I-Entity
of	O
10	O
to	O
12	O
g	O
/	O
day	O
)	O
,	O
we	O
have	O
suggested	O
that	O
this	O
may	O
in	O
part	O
be	O
responsible	O
for	O
their	O
resistance	O
to	O
gentamicin	I-Entity
-	O
induced	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
(	O
ARF	I-Entity
)	O
.	O

The	O
protection	O
from	O
gentamicin	I-Entity
nephrotoxicity	I-Entity
was	O
studied	O
in	O
non	O
-	O
diabetic	I-Entity
rats	O
with	O
chronic	O
solute	O
diuresis	O
induced	O
by	O
blockage	O
of	O
tubular	O
glucose	I-Entity
reabsorption	O
with	O
phlorizin	I-Entity
(	O
P	I-Entity
)	O
.	O

DM	I-Entity
rats	O
with	O
mild	O
glycosuria	I-Entity
(	O
similar	O
in	O
degree	O
to	O
that	O
of	O
the	O
P	I-Entity
treated	O
animals	O
)	O
were	O
also	O
studied	O
.	O

Group	O
1	O
(	O
P	I-Entity
alone	O
)	O
received	O
P	I-Entity
,	O
360	O
mg	O
/	O
day	O
,	O
for	O
15	O
days	O
;	O
Group	O
II	O
(	O
P	I-Entity
+	O
gentamicin	I-Entity
)	O
;	O
Group	O
III	O
(	O
gentamicin	I-Entity
alone	O
)	O
and	O
Group	O
IV	O
(	O
mild	O
DM	I-Entity
+	O
gentamicin	I-Entity
)	O
.	O

Nephrotoxic	I-Entity
doses	O
(	O
40	O
mg	O
/	O
kg	O
body	O
wt	O
/	O
day	O
)	O
of	O
gentamicin	I-Entity
were	O
injected	O
during	O
the	O
last	O
nine	O
days	O
of	O
study	O
to	O
the	O
animals	O
of	O
groups	O
II	O
to	O
IV	O
.	O

In	O
Group	O
I	O
,	O
P	I-Entity
induced	O
a	O
moderate	O
and	O
stable	O
glycosuria	I-Entity
(	O
3.9	O
+	O
/-	O

0.1	O
g	O
/	O
day	O
,	O
SE	O
)	O
,	O
and	O
no	O
functional	O
or	O
morphologic	O
evidence	O
of	O
renal	B-Entity
dysfunction	I-Entity
(	O
baseline	O
CCr	O
2.1	O
+	O
/-	O

ml	O
/	O
min	O
,	O
undetectable	O
lysozymuria	O
)	O
or	O
damage	O
(	O
tubular	B-Entity
necrosis	I-Entity
score	O
[	O
maximum	O
4	O
]	O
,	O
zero	O
)	O
.	O

In	O
Group	O
II	O
,	O
P	I-Entity
did	O
not	O
prevent	O
gentamicin	I-Entity
-	O
ARF	I-Entity
(	O
maximal	O
decrease	O
in	O
CCr	O
at	O
day	O
9.89%	O
,	O
P	I-Entity
less	O
than	O
0.001	O
;	O
peak	O
lysozymuria	O
,	O
1863	O
+	O
/-	O

321	O
micrograms	O
/	O
day	O
;	O
and	O
tubular	B-Entity
necrosis	I-Entity
score	O
,	O
3.9	O
+	O
/-	O

These	O
values	O
were	O
not	O
different	O
from	O
those	O
of	O
Group	O
III	O
:	O
maximal	O
decrease	O
in	O
CCr	O
73%	O
(	O
P	I-Entity
less	O
than	O
0.001	O
)	O
;	O
lysozymuria	O
,	O
2147	O
+	O
/-	O

701	O
micrograms	O
/	O
day	O
;	O
tubular	B-Entity
necrosis	I-Entity
score	O
,	O
3.8	O
+	O
/-	O



Tiapride	I-Entity
in	O
levodopa	I-Entity
-	O
induced	O
involuntary	B-Entity
movements	I-Entity
.	O

Tiapride	I-Entity
,	O
a	O
substituted	O
benzamide	I-Entity
derivative	O
closely	O
related	O
to	O
metoclopramide	I-Entity
,	O
reduced	O
levodopa	I-Entity
-	O
induced	O
peak	O
dose	O
involuntary	B-Entity
movements	I-Entity
in	O
16	O
patients	O
with	O
idiopathic	B-Entity
Parkinson	I-Entity
's	I-Entity
disease	I-Entity
.	O

However	O
,	O
an	O
unacceptable	O
increase	O
in	O
disability	O
from	O
Parkinsonism	I-Entity
with	O
aggravation	O
of	O
end	O
-	O
of	O
-	O
dose	O
akinesia	I-Entity
led	O
to	O
its	O
cessation	O
in	O
14	O
patients	O
.	O

Tiapride	I-Entity
had	O
no	O
effect	O
on	O
levodopa	I-Entity
-	O
induced	O
early	O
morning	O
of	O
""""	O
off	O
-	O
period	O
""""	O
segmental	O
dystonia	I-Entity
.	O

These	O
results	O
fail	O
to	O
support	O
the	O
notion	O
that	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
are	O
caused	O
by	O
overstimulation	O
of	O
a	O
separate	O
group	O
of	O
dopamine	I-Entity
receptors	O
.	O



Effects	O
of	O
the	O
hippocampal	O
deep	O
brain	O
stimulation	O
on	O
cortical	O
epileptic	I-Entity
discharges	O
in	O
penicillin	I-Entity
-	O
induced	O
epilepsy	I-Entity
model	O
in	O
rats	O
.	O

AIM	O
:	O
Experimental	O
and	O
clinical	O
studies	O
have	O
revealed	O
that	O
hippocampal	O
DBS	O
can	O
control	O
epileptic	I-Entity
activity	O
,	O
but	O
the	O
mechanism	O
of	O
action	O
is	O
obscure	O
and	O
optimal	O
stimulation	O
parameters	O
are	O
not	O
clearly	O
defined	O
.	O

The	O
aim	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
high	O
frequency	O
hippocampal	O
stimulation	O
on	O
cortical	O
epileptic	I-Entity
activity	O
in	O
penicillin	I-Entity
-	O
induced	O
epilepsy	I-Entity
model	O
.	O

In	O
group-1	O
(	O
n=10	O
)	O
hippocampal	O
DBS	O
was	O
off	O
and	O
in	O
the	O
group-2	O
(	O
n=10	O
)	O
hippocampal	O
DBS	O
was	O
on	O
(	O
185	O
Hz	O
,	O
0.5V	O
,	O
1V	O
,	O
2V	O
,	O
and	O
5V	O
for	O
60	O
sec	O
)	O
following	O
penicillin	B-Entity
G	I-Entity
injection	O
intracortically	O
.	O

EEG	O
recordings	O
were	O
obtained	O
before	O
and	O
15	O
minutes	O
following	O
penicillin	B-Entity
-	I-Entity
G	I-Entity
injection	O
,	O
and	O
at	O
10th	O
minutes	O
following	O
each	O
stimulus	O
for	O
analysis	O
in	O
terms	O
of	O
frequency	O
,	O
amplitude	O
,	O
and	O
power	O
spectrum	O
.	O

High	O
frequency	O
hippocampal	O
DBS	O
suppressed	O
the	O
acute	O
penicillin	I-Entity
-	O
induced	O
cortical	O
epileptic	I-Entity
activity	O
independent	O
from	O
stimulus	O
intensity	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
revealed	O
that	O
continuous	O
high	O
frequency	O
stimulation	O
of	O
the	O
hippocampus	O
suppressed	O
acute	O
cortical	O
epileptic	I-Entity
activity	O
effectively	O
without	O
causing	O
secondary	O
epileptic	I-Entity
discharges	O
.	O

These	O
results	O
are	O
important	O
in	O
terms	O
of	O
defining	O
the	O
optimal	O
parameters	O
of	O
hippocampal	O
DBS	O
in	O
patients	O
with	O
epilepsy	I-Entity
.	O



Neural	O
correlates	O
of	O
S	B-Entity
-	I-Entity
ketamine	I-Entity
induced	O
psychosis	I-Entity
during	O
overt	O
continuous	O
verbal	O
fluency	O
.	O

N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
D	I-Entity
-	I-Entity
aspartate	I-Entity
(	O
NMDA	I-Entity
)	O

receptor	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	I-Entity
.	O

Administered	O
to	O
healthy	O
volunteers	O
,	O
a	O
subanesthetic	O
dose	O
of	O
the	O
non	O
-	O
competitive	O
NMDA	I-Entity
receptor	O
antagonist	O
ketamine	I-Entity
leads	O
to	O
psychopathological	O
symptoms	O
similar	O
to	O
those	O
observed	O
in	O
schizophrenia	I-Entity
.	O

In	O
patients	O
with	O
schizophrenia	I-Entity
,	O
ketamine	I-Entity
exacerbates	O
the	O
core	O
symptoms	O
of	O
illness	O
,	O
supporting	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	B-Entity
dysfunction	I-Entity
.	O

In	O
a	O
counterbalanced	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
design	O
,	O
healthy	O
subjects	O
were	O
administered	O
a	O
continuous	O
subanesthetic	O
S	B-Entity
-	I-Entity
ketamine	I-Entity
infusion	O
while	O
differences	O
in	O
BOLD	O
responses	O
measured	O
with	O
fMRI	O
were	O
detected	O
.	O

Ketamine	I-Entity
-	O
induced	O
psychopathological	O
symptoms	O
were	O
assessed	O
with	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
.	O

Ketamine	I-Entity
elicited	O
psychosis	I-Entity
like	O
psychopathology	O
.	O

Post	O
-	O
hoc	O
t	O
-	O
tests	O
revealed	O
significant	O
differences	O
between	O
placebo	O
and	O
ketamine	I-Entity
for	O
the	O
amounts	O
of	O
words	O
generated	O
during	O
lexical	O
and	O
semantic	O
verbal	O
fluency	O
,	O
while	O
the	O
phonological	O
domain	O
remained	O
unaffected	O
.	O

Ketamine	I-Entity
led	O
to	O
enhanced	O
cortical	O
activations	O
in	O
supramarginal	O
and	O
frontal	O
brain	O
regions	O
for	O
phonological	O
and	O
lexical	O
verbal	O
fluency	O
,	O
but	O
not	O
for	O
semantic	O
verbal	O
fluency	O
.	O

Ketamine	I-Entity
induces	O
activation	O
changes	O
in	O
healthy	O
subjects	O
similar	O
to	O
those	O
observed	O
in	O
patients	O
with	O
schizophrenia	I-Entity
,	O
particularly	O
in	O
frontal	O
and	O
temporal	O
brain	O
regions	O
.	O

Our	O
results	O
provide	O
further	O
support	O
for	O
the	O
hypothesis	O
of	O
an	O
NMDA	I-Entity
receptor	O
dysfunction	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	I-Entity
.	O



Dopamine	I-Entity
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
methamphetamine	I-Entity
-	O
induced	O
neurotoxicity	I-Entity
.	O

It	O
is	O
widely	O
believed	O
that	O
dopamine	I-Entity
(	O
DA	I-Entity
)	O
mediates	O
methamphetamine	I-Entity
(	O
METH)-induced	I-Entity
toxicity	I-Entity
to	O
brain	O
dopaminergic	O
neurons	O
,	O
because	O
drugs	O
that	O
interfere	O
with	O
DA	I-Entity
neurotransmission	O
decrease	O
toxicity	I-Entity
,	O
whereas	O
drugs	O
that	O
increase	O
DA	I-Entity
neurotransmission	O
enhance	O
toxicity	I-Entity
.	O

However	O
,	O
temperature	O
effects	O
of	O
drugs	O
that	O
have	O
been	O
used	O
to	O
manipulate	O
brain	O
DA	I-Entity
neurotransmission	O
confound	O
interpretation	O
of	O
the	O
data	O
.	O

Here	O
we	O
show	O
that	O
the	O
recently	O
reported	O
ability	O
of	O
L	B-Entity
-	I-Entity
dihydroxyphenylalanine	I-Entity
to	O
reverse	O
the	O
protective	O
effect	O
of	O
alpha	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
para	I-Entity
-	I-Entity
tyrosine	I-Entity
on	O
METH	I-Entity
-	O
induced	O
DA	I-Entity
neurotoxicity	I-Entity
is	O
also	O
confounded	O
by	O
drug	O
effects	O
on	O
body	O
temperature	O
.	O

Further	O
,	O
we	O
show	O
that	O
mice	O
genetically	O
engineered	O
to	O
be	O
deficient	O
in	O
brain	O
DA	I-Entity
develop	O
METH	I-Entity
neurotoxicity	I-Entity
,	O
as	O
long	O
as	O
the	O
thermic	O
effects	O
of	O
METH	I-Entity
are	O
preserved	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
mice	O
genetically	O
engineered	O
to	O
have	O
unilateral	O
brain	O
DA	I-Entity
deficits	O
develop	O
METH	I-Entity
-	O
induced	O
dopaminergic	B-Entity
deficits	I-Entity
that	O
are	O
of	O
comparable	O
magnitude	O
on	O
both	O
sides	O
of	O
the	O
brain	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
demonstrate	O
that	O
DA	I-Entity
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
METH	I-Entity
-	O
induced	O
dopaminergic	O
neurotoxicity	I-Entity
and	O
suggest	O
that	O
mechanisms	O
independent	O
of	O
DA	I-Entity
warrant	O
more	O
intense	O
investigation	O
.	O



Brainstem	B-Entity
dysgenesis	I-Entity
in	O
an	O
infant	O
prenatally	O
exposed	O
to	O
cocaine	I-Entity
.	O

Many	O
authors	O
described	O
the	O
effects	O
on	O
the	O
fetus	O
of	O
maternal	O
cocaine	B-Entity
abuse	I-Entity
during	O
pregnancy	O
.	O

Vasoconstriction	O
appears	O
to	O
be	O
the	O
common	O
mechanism	O
of	O
action	O
leading	O
to	O
a	O
wide	O
range	O
of	O
fetal	B-Entity
anomalies	I-Entity
.	O

We	O
report	O
on	O
an	O
infant	O
with	O
multiple	B-Entity
cranial	I-Entity
-	I-Entity
nerve	I-Entity
involvement	I-Entity
attributable	O
to	O
brainstem	B-Entity
dysgenesis	I-Entity
,	O
born	O
to	O
a	O
cocaine	B-Entity
-	I-Entity
addicted	I-Entity
mother	O
.	O



The	O
protective	O
role	O
of	O
Nrf2	O
in	O
streptozotocin	I-Entity
-	O
induced	O
diabetic	B-Entity
nephropathy	I-Entity
.	O

Diabetic	B-Entity
nephropathy	I-Entity
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
renal	B-Entity
failure	I-Entity
,	O
which	O
is	O
accompanied	O
by	O
the	O
production	O
of	O
reactive	O
oxygen	I-Entity
species	O
(	O
ROS	O
)	O
.	O

Here	O
,	O
we	O
report	O
our	O
findings	O
demonstrating	O
a	O
protective	O
role	O
of	O
Nrf2	O
against	O
diabetic	B-Entity
nephropathy	I-Entity
.	O

We	O
explore	O
the	O
protective	O
role	O
of	O
Nrf2	O
against	O
diabetic	B-Entity
nephropathy	I-Entity
using	O
human	O
kidney	O
biopsy	O
tissues	O
from	O
diabetic	B-Entity
nephropathy	I-Entity
patients	O
,	O
a	O
streptozotocin	I-Entity
-	O
induced	O
diabetic	B-Entity
nephropathy	I-Entity
model	O
in	O
Nrf2(-/-	O
)	O
mice	O
,	O
and	O
cultured	O
human	O
mesangial	O
cells	O
.	O

The	O
glomeruli	O
of	O
human	O
diabetic	B-Entity
nephropathy	I-Entity
patients	O
were	O
under	O
oxidative	O
stress	O
and	O
had	O
elevated	O
Nrf2	O
levels	O
.	O

In	O
the	O
animal	O
study	O
,	O
Nrf2	O
was	O
demonstrated	O
to	O
be	O
crucial	O
in	O
ameliorating	O
streptozotocin	I-Entity
-	O
induced	O
renal	B-Entity
damage	I-Entity
.	O

This	O
is	O
evident	O
by	O
Nrf2(-/-	O
)	O
mice	O
having	O
higher	O
ROS	O
production	O
and	O
suffering	O
from	O
greater	O
oxidative	O
DNA	O
damage	O
and	O
renal	B-Entity
injury	I-Entity
compared	O
with	O
Nrf2(+/+	O
)	O
mice	O
.	O

Mechanistic	O
studies	O
in	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
systems	O
showed	O
that	O
the	O
Nrf2-mediated	O
protection	O
against	O
diabetic	B-Entity
nephropathy	I-Entity
is	O
,	O
at	O
least	O
,	O
partially	O
through	O
inhibition	O
of	O
transforming	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
and	O
reduction	O
of	O
extracellular	O
matrix	O
production	O
.	O

In	O
human	O
renal	O
mesangial	O
cells	O
,	O
high	O
glucose	I-Entity
induced	O
ROS	O
production	O
and	O
activated	O
expression	O
of	O
Nrf2	O
and	O
its	O
downstream	O
genes	O
.	O

This	O
work	O
clearly	O
indicates	O
a	O
protective	O
role	O
of	O
Nrf2	O
in	O
diabetic	B-Entity
nephropathy	I-Entity
,	O
suggesting	O
that	O
dietary	O
or	O
therapeutic	O
activation	O
of	O
Nrf2	O
could	O
be	O
used	O
as	O
a	O
strategy	O
to	O
prevent	O
or	O
slow	O
down	O
the	O
progression	O
of	O
diabetic	B-Entity
nephropathy	I-Entity
.	O



High	O
-	O
dose	O
tranexamic	B-Entity
Acid	I-Entity
is	O
associated	O
with	O
nonischemic	O
clinical	O
seizures	I-Entity
in	O
cardiac	O
surgical	O
patients	O
.	O

In	O
2	O
separate	O
centers	O
,	O
we	O
observed	O
a	O
notable	O
increase	O
in	O
the	O
incidence	O
of	O
postoperative	O
convulsive	I-Entity
seizures	I-Entity
from	O
1.3%	O
to	O
3.8%	O
in	O
patients	O
having	O
undergone	O
major	O
cardiac	O
surgical	O
procedures	O
.	O

These	O
events	O
were	O
temporally	O
coincident	O
with	O
the	O
initial	O
use	O
of	O
high	O
-	O
dose	O
tranexamic	B-Entity
acid	I-Entity
(	O
TXA	I-Entity
)	O
therapy	O
after	O
withdrawal	O
of	O
aprotinin	O
from	O
general	O
clinical	O
usage	O
.	O

The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
perform	O
a	O
retrospective	O
analysis	O
to	O
examine	O
whether	O
there	O
was	O
a	O
relation	O
between	O
TXA	I-Entity
usage	O
and	O
seizures	I-Entity
after	O
cardiac	O
surgery	O
.	O

An	O
in	O
-	O
depth	O
chart	O
review	O
was	O
undertaken	O
in	O
all	O
24	O
patients	O
who	O
developed	O
perioperative	O
seizures	I-Entity
.	O

Twenty	O
-	O
one	O
of	O
the	O
24	O
patients	O
did	O
not	O
have	O
evidence	O
of	O
new	O
cerebral	B-Entity
ischemic	I-Entity
injury	I-Entity
,	O
but	O
seizures	I-Entity
were	O
likely	O
due	O
to	O
ischemic	B-Entity
brain	I-Entity
injury	I-Entity
in	O
3	O
patients	O
.	O

All	O
patients	O
with	O
seizures	I-Entity
did	O
not	O
have	O
permanent	O
neurological	B-Entity
abnormalities	I-Entity
.	O

All	O
24	O
patients	O
with	O
seizures	I-Entity
received	O
high	O
doses	O
of	O
TXA	I-Entity
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg	O
/	O
kg	O
,	O
had	O
a	O
mean	O
age	O
of	O
69.9	O
years	O
,	O
and	O
21	O
of	O
24	O
had	O
undergone	O
open	O
chamber	O
rather	O
than	O
coronary	O
bypass	O
procedures	O
.	O

No	O
evidence	O
of	O
brain	B-Entity
ischemic	I-Entity
,	O
metabolic	O
,	O
or	O
hyperthermia	I-Entity
-	O
induced	O
causes	O
for	O
their	O
seizures	I-Entity
was	O
apparent	O
.	O

:	O
Our	O
results	O
suggest	O
that	O
use	O
of	O
high	O
-	O
dose	O
TXA	I-Entity
in	O
older	O
patients	O
in	O
conjunction	O
with	O
cardiopulmonary	O
bypass	O
and	O
open	O
-	O
chamber	O
cardiac	O
surgery	O
is	O
associated	O
with	O
clinical	O
seizures	I-Entity
in	O
susceptible	O
patients	O
.	O



Recurrent	O
dysosmia	I-Entity
induced	O
by	O
pyrazinamide	I-Entity
.	O

Pyrazinamide	I-Entity
can	O
have	O
adverse	O
effects	O
such	O
as	O
hepatic	B-Entity
toxicity	I-Entity
,	O
hyperuricemia	I-Entity
or	O
digestive	O
disorders	O
.	O

In	O
rare	O
cases	O
,	O
alterations	O
in	O
taste	O
and	O
smell	O
function	O
have	O
been	O
reported	O
for	O
pyrazinamide	I-Entity
when	O
combined	O
with	O
other	O
drugs	O
.	O

We	O
report	O
a	O
case	O
of	O
reversible	O
olfactory	B-Entity
disorder	I-Entity
related	O
to	O
pyrazinamide	I-Entity
in	O
a	O
woman	O
,	O
with	O
a	O
positive	O
rechallenge	O
.	O

Dysosmia	I-Entity
disappeared	O
completely	O
after	O
pyrazinamide	I-Entity
withdrawal	O
and	O
recurred	O
after	O
its	O
rechallenge	O
.	O



Longitudinal	O
assessment	O
of	O
air	O
conduction	O
audiograms	O
in	O
a	O
phase	O
III	O
clinical	O
trial	O
of	O
difluoromethylornithine	I-Entity
and	O
sulindac	I-Entity
for	O
prevention	O
of	O
sporadic	O
colorectal	B-Entity
adenomas	I-Entity
.	O

A	O
phase	O
III	O
clinical	O
trial	O
assessed	O
the	O
recurrence	O
of	O
adenomatous	B-Entity
polyps	I-Entity
after	O
treatment	O
for	O
36	O
months	O
with	O
difluoromethylornithine	I-Entity
(	O
DFMO	I-Entity
)	O
plus	O
sulindac	I-Entity
or	O
matched	O
placebos	O
.	O

Temporary	O
hearing	B-Entity
loss	I-Entity
is	O
a	O
known	O
toxicity	I-Entity
of	O
treatment	O
with	O
DFMO	I-Entity
,	O
thus	O
a	O
comprehensive	O
approach	O
was	O
developed	O
to	O
analyze	O
serial	O
air	O
conduction	O
audiograms	O
.	O

Based	O
on	O
290	O
subjects	O
,	O
there	O
was	O
an	O
average	O
difference	O
of	O
0.50	O
dB	O
between	O
subjects	O
treated	O
with	O
DFMO	I-Entity
plus	O
sulindac	I-Entity
compared	O
with	O
those	O
treated	O
with	O
placebo	O
(	O
95%	O
confidence	O
interval	O
,	O
-0.64	O
to	O
1.63	O
dB	O
;	O
P	O
=	O
0.39	O
)	O
,	O
adjusted	O
for	O
baseline	O
values	O
,	O
age	O
,	O
and	O
frequencies	O
.	O

There	O
were	O
14	O
of	O
151	O
(	O
9.3%	O
)	O
in	O
the	O
DFMO	I-Entity
plus	O
sulindac	I-Entity
group	O
and	O
4	O
of	O
139	O
(	O
2.9%	O
)	O
in	O
the	O
placebo	O
group	O
who	O
experienced	O
at	O
least	O
15	O
dB	O
hearing	O
reduction	O
from	O
baseline	O
in	O
2	O
or	O
more	O
consecutive	O
frequencies	O
across	O
the	O
entire	O
range	O
tested	O
(	O
P	O
=	O
0.02	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
proportion	O
of	O
subjects	O
in	O
the	O
DFMO	I-Entity
plus	O
sulindac	I-Entity
group	O
who	O
experienced	O
clinically	O
significant	O
hearing	B-Entity
loss	I-Entity
compared	O
with	O
the	O
placebo	O
group	O
.	O

The	O
estimated	O
attributable	O
risk	O
of	O
ototoxicity	I-Entity
from	O
exposure	O
to	O
the	O
drug	O
is	O
8.4%	O
(	O
95%	O
confidence	O
interval	O
,	O
-2.0%	O
to	O
18.8%	O
;	O
P	O
=	O
0.12	O
)	O
.	O

There	O
is	O
a	O
<	O
2	O
dB	O
difference	O
in	O
mean	O
threshold	O
for	O
patients	O
treated	O
with	O
DFMO	I-Entity
plus	O
sulindac	I-Entity
compared	O
with	O
those	O
treated	O
with	O
placebo	O
.	O



Increased	O
mental	B-Entity
slowing	I-Entity
associated	O
with	O
the	O
APOE	O
epsilon4	O
allele	O
after	O
trihexyphenidyl	I-Entity
oral	O
anticholinergic	O
challenge	O
in	O
healthy	O
elderly	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
examine	O
the	O
relationship	O
between	O
APOE	O
epsilon4	O
and	O
subjective	O
effects	O
of	O
trihexyphenidyl	I-Entity
on	O
measures	O
reflecting	O
sedation	O
and	O
confusion	I-Entity
and	O
to	O
investigate	O
the	O
relationship	O
between	O
trihexyphenidyl	I-Entity
-	O
induced	O
subjective	O
effects	O
and	O
objective	O
memory	O
performance	O
.	O

All	O
participants	O
received	O
1.0	O
mg	O
or	O
2.0	O
mg	O
trihexyphenidyl	I-Entity
or	O
placebo	O
administered	O
in	O
counterbalanced	O
sequences	O
over	O
a	O
period	O
of	O
three	O
consecutive	O
weeks	O
.	O

A	O
2.0-mg	O
oral	O
dose	O
of	O
trihexyphenidyl	I-Entity
resulted	O
in	O
increased	O
subjective	O
ratings	O
of	O
mental	B-Entity
slowness	I-Entity
in	O
carriers	O
of	O
the	O
APOE	O
epsilon4	O
allele	O
only	O
.	O

Drug	O
effects	O
as	O
determined	O
by	O
difference	O
scores	O
between	O
2.0	O
mg	O
trihexyphenidyl	I-Entity
and	O
placebo	O
on	O
ratings	O
of	O
mental	B-Entity
slowness	I-Entity
significantly	O
correlated	O
with	O
total	O
and	O
delayed	O
recall	O
on	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
in	O
carriers	O
of	O
the	O
APOE	O
epsilon4	O
allele	O
only	O
.	O

The	O
epsilon4	O
allele	O
in	O
healthy	O
elderly	O
was	O
associated	O
with	O
increased	O
subjective	O
mental	B-Entity
slowing	I-Entity
after	O
trihexyphenidyl	I-Entity
anticholinergic	O
challenge	O
.	O



Behavioral	O
effects	O
of	O
pubertal	O
anabolic	O
androgenic	O
steroid	I-Entity
exposure	O
in	O
male	O
rats	O
with	O
low	O
serotonin	I-Entity
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
interactive	O
effects	O
of	O
chronic	O
anabolic	O
androgenic	O
steroid	I-Entity
(	O
AAS	O
)	O
exposure	O
and	O
brain	O
serotonin	I-Entity
(	O
5-hydroxytryptamine	I-Entity
,	O
5-HT	I-Entity
)	O
depletion	O
on	O
behavior	O
of	O
pubertal	O
male	O
rats	O
.	O

Serotonin	I-Entity
was	O
depleted	O
beginning	O
on	O
postnatal	O
day	O
26	O
with	O
parachlorophenylalanine	I-Entity
(	O
PCPA	I-Entity
100	O
mg	O
/	O
kg	O
,	O
every	O
other	O
day	O
)	O
;	O
controls	O
received	O
saline	O
.	O

At	O
puberty	O
(	O
P40	O
)	O
,	O
half	O
the	O
PCPA	I-Entity
-	O
treated	O
rats	O
and	O
half	O
the	O
saline	O
-	O
treated	O
rats	O
began	O
treatment	O
with	O
testosterone	I-Entity
(	O
T	I-Entity
,	O
5	O
mg	O
/	O
kg	O
,	O
5	O
days	O
/	O
week	O
)	O
.	O

Behavioral	O
measures	O
included	O
locomotion	O
,	O
irritability	I-Entity
,	O
copulation	O
,	O
partner	O
preference	O
,	O
and	O
aggression	I-Entity
.	O

Animals	O
were	O
tested	O
for	O
aggression	I-Entity
in	O
their	O
home	O
cage	O
,	O
both	O
with	O
and	O
without	O
physical	O
provocation	O
(	O
mild	O
tail	O
pinch	O
)	O
.	O

Brain	O
levels	O
of	O
5-HT	I-Entity
and	O
its	O
metabolite	O
,	O
5-hydroxyindoleacetic	B-Entity
acid	I-Entity
(	O
5-HIAA	I-Entity
)	O
,	O
were	O
determined	O
using	O
HPLC	O
.	O

PCPA	I-Entity
significantly	O
and	O
substantially	O
depleted	O
5-HT	I-Entity
and	O
5-HIAA	I-Entity
in	O
all	O
brain	O
regions	O
examined	O
.	O

Chronic	O
T	I-Entity
treatment	O
significantly	O
decreased	O
5-HT	I-Entity
and	O
5-HIAA	I-Entity
in	O
certain	O
brain	O
areas	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
PCPA	I-Entity
.	O

Chronic	O
exposure	O
to	O
PCPA	I-Entity
alone	O
significantly	O
decreased	O
locomotor	O
activity	O
and	O
increased	O
irritability	I-Entity
but	O
had	O
no	O
effect	O
on	O
sexual	O
behavior	O
,	O
partner	O
preference	O
,	O
or	O
aggression	I-Entity
.	O

T	I-Entity
alone	O
had	O
no	O
effect	O
on	O
locomotion	O
,	O
irritability	I-Entity
,	O
or	O
sexual	O
behavior	O
but	O
increased	O
partner	O
preference	O
and	O
aggression	I-Entity
.	O

The	O
most	O
striking	O
effect	O
of	O
combining	O
T+PCPA	I-Entity
was	O
a	O
significant	O
increase	O
in	O
attack	O
frequency	O
as	O
well	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
latency	O
to	O
attack	O
,	O
particularly	O
following	O
physical	O
provocation	O
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
speculated	O
that	O
pubertal	O
AAS	O
users	O
with	O
low	O
central	O
5-HT	I-Entity
may	O
be	O
especially	O
prone	O
to	O
exhibit	O
aggressive	B-Entity
behavior	I-Entity
.	O



Intracavitary	O
chemotherapy	O
(	O
paclitaxel	I-Entity
/	O
carboplatin	I-Entity
liquid	O
crystalline	O
cubic	O
phases	O
)	O
for	O
recurrent	O
glioblastoma	I-Entity
--	O
clinical	O
observations	O
.	O

Human	O
malignant	O
brain	B-Entity
tumors	I-Entity
have	O
a	O
poor	O
prognosis	O
in	O
spite	O
of	O
surgery	O
and	O
radiation	O
therapy	O
.	O

For	O
human	O
glioblastoma	I-Entity
recurrences	O
,	O
the	O
feasibility	O
,	O
safety	O
,	O
and	O
short	O
-	O
term	O
effects	O
of	O
a	O
surgical	O
intracavitary	O
application	O
of	O
paclitaxel	I-Entity
and	O
carboplatin	I-Entity
encapsulated	O
by	O
liquid	O
crystalline	O
cubic	O
phases	O
are	O
examined	O
in	O
a	O
pilot	O
study	O
.	O

A	O
total	O
of	O
12	O
patients	O
with	O
a	O
recurrence	O
of	O
a	O
glioblastoma	I-Entity
multiforme	O
underwent	O
re	O
-	O
resection	O
and	O
received	O
an	O
intracavitary	O
application	O
of	O
paclitaxel	I-Entity
and	O
carboplatin	I-Entity
cubic	O
phases	O
in	O
different	O
dosages	O
.	O

Six	O
of	O
the	O
patients	O
received	O
more	O
than	O
15	O
mg	O
paclitaxel	I-Entity
and	O
suffered	O
from	O
moderate	O
to	O
severe	O
brain	B-Entity
edema	I-Entity
,	O
while	O
the	O
remaining	O
patients	O
received	O
only	O
a	O
total	O
of	O
15	O
mg	O
paclitaxel	I-Entity
.	O

In	O
the	O
latter	O
group	O
,	O
brain	B-Entity
edema	I-Entity
was	O
markedly	O
reduced	O
and	O
dealt	O
medically	O
.	O

Intracavitary	O
chemotherapy	O
in	O
recurrent	O
glioblastoma	I-Entity
using	O
cubic	O
phases	O
is	O
feasible	O
and	O
safe	O
,	O
yet	O
the	O
clinical	O
benefit	O
remains	O
to	O
be	O
examined	O
in	O
a	O
clinical	O
phase	O
II	O
study	O
.	O



Methylphenidate	I-Entity
-	O
induced	O
obsessive	B-Entity
-	I-Entity
compulsive	I-Entity
symptoms	I-Entity
in	O
an	O
elderly	O
man	O
.	O

An	O
82-year	O
-	O
old	O
man	O
with	O
treatment	B-Entity
-	I-Entity
resistant	I-Entity
depression	I-Entity
and	O
early	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
was	O
started	O
on	O
methylphenidate	I-Entity
.	O

Significant	O
obsessive	B-Entity
-	I-Entity
compulsive	I-Entity
behavior	I-Entity
ensued	O
but	O
diminished	O
over	O
several	O
weeks	O
when	O
methylphenidate	I-Entity
was	O
replaced	O
by	O
fluvoxamine	I-Entity
.	O

The	O
patient	O
had	O
no	O
prior	O
psychiatric	I-Entity
history	O
,	O
but	O
he	O
had	O
a	O
sister	O
with	O
obsessive	B-Entity
-	I-Entity
compulsive	I-Entity
disorder	I-Entity
.	O

It	O
appears	O
that	O
methylphenidate	I-Entity
precipitated	O
the	O
patient	O
's	O
pathological	O
behavior	O
.	O



Cardiac	B-Entity
arrest	I-Entity
after	O
intravenous	O
metoclopramide	I-Entity
-	O
a	O
case	O
of	O
five	O
repeated	O
injections	O
of	O
metoclopramide	I-Entity
causing	O
five	O
episodes	O
of	O
cardiac	B-Entity
arrest	I-Entity
.	O

We	O
describe	O
a	O
patient	O
where	O
intravenous	O
injection	O
of	O
metoclopramide	I-Entity
was	O
immediately	O
followed	O
by	O
asystole	I-Entity
repeatedly	O
.	O

The	O
patient	O
received	O
metoclopramide	I-Entity
10	O
mg	O
i.v	O
.	O

After	O
interviewing	O
the	O
attending	O
nurses	O
and	O
reviewing	O
the	O
written	O
documentation	O
,	O
it	O
is	O
clear	O
that	O
every	O
administration	O
of	O
metoclopramide	I-Entity
was	O
immediately	O
(	O
within	O
s	O
)	O
followed	O
by	O
asystole	I-Entity
.	O

The	O
asystole	I-Entity
lasted	O
15	O
-	O
30	O
s	O
on	O
four	O
occasions	O
,	O
on	O
one	O
occasion	O
it	O
lasted	O
2	O
min	O
.	O

The	O
patient	O
received	O
atropine	I-Entity
0.5	O
-	O
1	O
mg	O
and	O
chest	O
compressions	O
,	O
before	O
sinus	O
rhythm	O
again	O
took	O
over	O
.	O

We	O
interpret	O
this	O
as	O
episodes	O
of	O
cardiac	B-Entity
arrest	I-Entity
caused	O
by	O
metoclopramide	I-Entity
.	O

The	O
rapid	O
injection	O
via	O
the	O
central	O
venous	O
route	O
and	O
the	O
concomitant	O
tapering	O
of	O
dopamine	I-Entity
infusion	O
might	O
have	O
contributed	O
in	O
precipitating	O
the	O
adverse	O
drug	O
reaction	O
.	O



Severe	O
immune	O
hemolytic	B-Entity
anemia	I-Entity
associated	O
with	O
prophylactic	O
use	O
of	O
cefotetan	I-Entity
in	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Second-	O
and	O
third	O
-	O
generation	O
cephalosporins	I-Entity
,	O
especially	O
cefotetan	I-Entity
,	O
are	O
increasingly	O
associated	O
with	O
severe	O
,	O
sometimes	O
fatal	O
immune	O
hemolytic	B-Entity
anemia	I-Entity
.	O

We	O
noticed	O
that	O
10	O
of	O
our	O
35	O
cases	O
of	O
cefotetan	I-Entity
-	O
induced	O
hemolytic	B-Entity
anemias	I-Entity
were	O
in	O
patients	O
who	O
had	O
received	O
cefotetan	I-Entity
prophylactically	O
for	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Eight	O
of	O
these	O
cases	O
of	O
severe	O
immune	O
hemolytic	B-Entity
anemia	I-Entity
are	O
described	O
.	O



Cauda	B-Entity
equina	I-Entity
syndrome	I-Entity
after	O
spinal	O
anaesthesia	O
with	O
hyperbaric	O
5%	O

lignocaine	I-Entity
:	O
a	O
review	O
of	O
six	O
cases	O
of	O
cauda	B-Entity
equina	I-Entity
syndrome	I-Entity
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
1993	O
-	O
1997	O
.	O

Six	O
cases	O
of	O
cauda	B-Entity
equina	I-Entity
syndrome	I-Entity
with	O
varying	O
severity	O
were	O
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
during	O
the	O
period	O
1993	O
-	O
1997	O
.	O

All	O
were	O
associated	O
with	O
spinal	O
anaesthesia	O
using	O
hyperbaric	O
5%	O
lignocaine	I-Entity
.	O

The	O
dose	O
of	O
hyperbaric	O
5%	O
lignocaine	I-Entity
administered	O
ranged	O
from	O
60	O
to	O
120	O
mg	O
.	O

Three	O
of	O
the	O
cases	O
were	O
most	O
likely	O
caused	O
by	O
direct	O
neurotoxicity	I-Entity
of	O
hyperbaric	O
5%	O
lignocaine	I-Entity
.	O

In	O
the	O
other	O
3	O
cases	O
,	O
direct	O
neurotoxicity	I-Entity
was	O
also	O
probable	O
,	O
but	O
unfortunately	O
radiological	O
investigations	O
were	O
not	O
done	O
to	O
definitely	O
exclude	O
a	O
compressive	O
aetiology	O
.	O

All	O
cases	O
sustained	O
permanent	O
neurological	B-Entity
deficits	I-Entity
.	O

We	O
recommend	O
that	O
hyperbaric	O
lignocaine	I-Entity
should	O
be	O
administered	O
in	O
concentrations	O
not	O
greater	O
than	O
2%	O
and	O
at	O
a	O
total	O
dose	O
preferably	O
not	O
exceeding	O
60	O
mg	O
.	O



Cortical	O
motor	O
overactivation	O
in	O
parkinsonian	I-Entity
patients	O
with	O
L	B-Entity
-	I-Entity
dopa	I-Entity
-	O
induced	O
peak	O
-	O
dose	O
dyskinesia	I-Entity
.	O

We	O
have	O
studied	O
the	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
changes	O
induced	O
by	O
the	O
execution	O
of	O
a	O
finger	O
-	O
to	O
-	O
thumb	O
opposition	O
motor	O
task	O
in	O
the	O
supplementary	O
and	O
primary	O
motor	O
cortex	O
of	O
two	O
groups	O
of	O
parkinsonian	I-Entity
patients	O
on	O
L	B-Entity
-	I-Entity
dopa	I-Entity
medication	O
,	O
the	O
first	O
one	O
without	O
L	B-Entity
-	I-Entity
dopa	I-Entity
induced	O
dyskinesia	I-Entity
(	O
n	O
=	O
23	O
)	O
and	O
the	O
other	O
with	O
moderate	O
peak	O
-	O
dose	O
dyskinesia	I-Entity
(	O
n	O
=	O
15	O
)	O
,	O
and	O
of	O
a	O
group	O
of	O
14	O
normal	O
subjects	O
.	O

The	O
dyskinetic	I-Entity
parkinsonian	I-Entity
patients	O
exhibited	O
a	O
pattern	O
of	O
response	O
which	O
was	O
markedly	O
different	O
from	O
those	O
of	O
the	O
normal	O
subjects	O
and	O
non	O
-	O
dyskinetic	I-Entity
parkinsonian	I-Entity
patients	O
,	O
with	O
a	O
significant	O
overactivation	O
in	O
the	O
supplementary	O
motor	O
area	O
and	O
the	O
ipsi-	O
and	O
contralateral	O
primary	O
motor	O
areas	O
.	O

These	O
results	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
an	O
hyperkinetic	I-Entity
abnormal	B-Entity
involuntary	I-Entity
movement	I-Entity
,	O
like	O
L	B-Entity
-	I-Entity
dopa	I-Entity
-	O
induced	O
peak	O
dose	O
dyskinesia	I-Entity
,	O
is	O
due	O
to	O
a	O
disinhibition	O
of	O
the	O
primary	O
and	O
associated	O
motor	O
cortex	O
secondary	O
to	O
an	O
excessive	O
outflow	O
of	O
the	O
pallidothalamocortical	O
motor	O
loop	O
.	O



Dexamethasone	I-Entity
-	O
induced	O
ocular	B-Entity
hypertension	I-Entity
in	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

Glucocorticoid	O
administration	O
can	O
lead	O
to	O
the	O
development	O
of	O
ocular	B-Entity
hypertension	I-Entity
and	O
corticosteroid	B-Entity
glaucoma	I-Entity
in	O
a	O
subset	O
of	O
the	O
population	O
through	O
a	O
decrease	O
in	O
the	O
aqueous	O
humor	O
outflow	O
facility	O
.	O

M	O
dexamethasone	I-Entity
for	O
12	O
days	O
.	O

A	O
significant	O
increase	O
in	O
intraocular	O
pressure	O
developed	O
in	O
13	O
of	O
the	O
44	O
pairs	O
of	O
eyes	O
perfused	O
with	O
dexamethasone	I-Entity
with	O
an	O
average	O
pressure	O
rise	O
of	O
17.5	O
+	O
/-	O

3.8	O
mm	O
Hg	O
after	O
12	O
days	O
of	O
dexamethasone	I-Entity
exposure	O
.	O

The	O
contralateral	O
control	O
eyes	O
,	O
which	O
did	O
not	O
receive	O
dexamethasone	I-Entity
,	O
maintained	O
a	O
stable	O
intraocular	O
pressure	O
during	O
the	O
same	O
period	O
.	O

In	O
contrast	O
,	O
the	O
dexamethasone	I-Entity
-	O
treated	O
hypertensive	B-Entity
eyes	I-Entity
had	O
thickened	O
trabecular	O
beams	O
,	O
decreased	O
intertrabecular	O
spaces	O
,	O
thickened	O
juxtacanalicular	O
tissue	O
,	O
activated	O
trabecular	O
meshwork	O
cells	O
,	O
and	O
increased	O
amounts	O
of	O
amorphogranular	O
extracellular	O
material	O
,	O
especially	O
in	O
the	O
juxtacanalicular	O
tissue	O
and	O
beneath	O
the	O
endothelial	O
lining	O
of	O
the	O
canal	O
of	O
Schlemm	O
.	O

The	O
dexamethasone	I-Entity
-	O
treated	O
nonresponder	O
eyes	O
appeared	O
to	O
be	O
morphologically	O
similar	O
to	O
the	O
untreated	O
eyes	O
,	O
although	O
several	O
subtle	O
dexamethasone	I-Entity
-	O
induced	O
morphologic	O
changes	O
were	O
evident	O
.	O

Dexamethasone	I-Entity
treatment	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
led	O
to	O
the	O
generation	O
of	O
ocular	B-Entity
hypertension	I-Entity
in	O
approximately	O
30%	O
of	O
the	O
dexamethasone	I-Entity
-	O
treated	O
eyes	O
.	O

Steroid	I-Entity
treatment	O
resulted	O
in	O
morphologic	O
changes	O
in	O
the	O
trabecular	O
meshwork	O
similar	O
to	O
those	O
reported	O
for	O
corticosteroid	B-Entity
glaucoma	I-Entity
and	O
open	B-Entity
angle	I-Entity
glaucoma	I-Entity
.	O

This	O
system	O
may	O
provide	O
an	O
acute	O
model	O
in	O
which	O
to	O
study	O
the	O
pathogenic	O
mechanisms	O
involved	O
in	O
steroid	B-Entity
glaucoma	I-Entity
and	O
primary	B-Entity
open	I-Entity
angle	I-Entity
glaucoma	I-Entity
.	O



Cognitive	B-Entity
deterioration	I-Entity
from	O
long	O
-	O
term	O
abuse	O
of	O
dextromethorphan	I-Entity
:	O
a	O
case	O
report	O
.	O

Dextromethorphan	I-Entity
(	O
DM	I-Entity
)	O
,	O
the	O
dextrorotatory	O
isomer	O
of	O
3-hydroxy	B-Entity
-	I-Entity
N	I-Entity
-	I-Entity
methylmorphinan	I-Entity
,	O
is	O
the	O
main	O
ingredient	O
in	O
a	O
number	O
of	O
widely	O
available	O
,	O
over	O
-	O
the	O
-	O
counter	O
antitussives	O
.	O

The	O
drug	O
is	O
known	O
to	O
cause	O
a	O
variety	O
of	O
acute	O
toxic	O
effects	O
,	O
ranging	O
from	O
nausea	I-Entity
,	O
restlessness	I-Entity
,	O
insomnia	I-Entity
,	O
ataxia	I-Entity
,	O
slurred	O
speech	O
and	O
nystagmus	I-Entity
to	O
mood	O
changes	O
,	O
perceptual	O
alterations	O
,	O
inattention	O
,	O
disorientation	O
and	O
aggressive	B-Entity
behavior	I-Entity
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O

There	O
have	O
also	O
been	O
two	O
reported	O
fatalities	O
from	O
DM	I-Entity
overdoses	O
(	O
Fleming	O
1986	O
)	O
.	O

This	O
report	O
describes	O
a	O
case	O
of	O
cognitive	B-Entity
deterioration	I-Entity
resulting	O
from	O
prolonged	O
use	O
of	O
DM	I-Entity
.	O



Long	O
-	O
term	O
lithium	I-Entity
treatment	O
and	O
the	O
kidney	O
.	O

This	O
is	O
a	O
report	O
on	O
the	O
first	O
part	O
of	O
our	O
study	O
of	O
the	O
effects	O
of	O
long	O
-	O
term	O
lithium	I-Entity
treatment	O
on	O
the	O
kidney	O
.	O

Creatinine	I-Entity
clearance	O
,	O
maximum	O
urinary	O
osmolality	O
and	O
24	O
hour	O
urine	O
volume	O
have	O
been	O
tested	O
in	O
50	O
affectively	O
ill	O
patients	O
who	O
have	O
been	O
on	O
long	O
-	O
term	O
lithium	I-Entity
for	O
more	O
than	O
one	O
year	O
.	O

These	O
findings	O
have	O
been	O
compared	O
with	O
norms	O
and	O
with	O
values	O
of	O
the	O
same	O
tests	O
from	O
screening	O
prior	O
to	O
lithium	I-Entity
,	O
available	O
for	O
most	O
of	O
our	O
patients	O
.	O

No	O
evidence	O
was	O
found	O
for	O
any	O
reduction	O
of	O
glomerular	O
filtration	O
during	O
lithium	I-Entity
treatment	O
.	O

Low	O
clearance	O
values	O
found	O
in	O
several	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
their	O
age	O
and	O
their	O
pre	O
-	O
lithium	I-Entity
values	O
.	O

Polyuria	I-Entity
above	O
3	O
litres/24	O
hours	O
was	O
found	O
in	O
10%	O
of	O
patients	O
.	O



Complete	O
heart	B-Entity
block	I-Entity
following	O
a	O
single	O
dose	O
of	O
trazodone	I-Entity
.	O

Forty	O
minutes	O
after	O
receiving	O
a	O
single	O
starting	O
dose	O
of	O
trazodone	I-Entity
,	O
a	O
patient	O
developed	O
complete	O
heart	B-Entity
block	I-Entity
.	O

The	O
case	O
illustrates	O
that	O
,	O
despite	O
the	O
results	O
of	O
earlier	O
studies	O
,	O
trazodone	I-Entity
's	O
effect	O
on	O
cardiac	O
conduction	O
may	O
be	O
severe	O
in	O
individuals	O
at	O
risk	O
for	O
conduction	O
delay	O
.	O



Quinidine	B-Entity
phenylethylbarbiturate	I-Entity
-	O
induced	O
fulminant	O
hepatitis	I-Entity
in	O
a	O
pregnant	O
woman	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
19-year	O
-	O
old	O
Laotian	O
patient	O
affected	O
by	O
fulminant	O
hepatitis	I-Entity
during	O
the	O
third	O
trimester	O
of	O
her	O
pregnancy	O
after	O
a	O
1-month	O
administration	O
of	O
quinidine	B-Entity
phenylethylbarbiturate	I-Entity
.	O

Quinidine	I-Entity
itself	O
or	O
phenylethylbarbiturate	I-Entity
may	O
be	O
responsible	O
for	O
fulminant	O
hepatitis	I-Entity
in	O
this	O
patient	O
.	O



The	O
epidemiology	O
of	O
the	O
acute	O
flank	B-Entity
pain	I-Entity
syndrome	O
from	O
suprofen	I-Entity
.	O

Suprofen	I-Entity
,	O
a	O
new	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
was	O
marketed	O
in	O
early	O
1986	O
as	O
an	O
analgesic	O
agent	O
.	O

Until	O
physicians	O
began	O
reporting	O
an	O
unusual	O
acute	O
flank	B-Entity
pain	I-Entity
syndrome	O
to	O
the	O
spontaneous	O
reporting	O
system	O
,	O
700,000	O
persons	O
used	O
the	O
drug	O
in	O
the	O
United	O
States	O
.	O

To	O
elucidate	O
the	O
epidemiology	O
of	O
the	O
syndrome	O
,	O
a	O
case	O
-	O
control	O
study	O
was	O
performed	O
,	O
comparing	O
62	O
of	O
the	O
case	O
patients	O
who	O
had	O
been	O
reported	O
to	O
the	O
spontaneous	O
reporting	O
system	O
to	O
185	O
suprofen	I-Entity
-	O
exposed	O
control	O
subjects	O
who	O
did	O
not	O
have	O
the	O
syndrome	O
.	O

Case	O
patients	O
were	O
more	O
likely	O
to	O
be	O
men	O
(	O
odds	O
ratio	O
,	O
3.8	O
;	O
95%	O
confidence	O
interval	O
,	O
1.2	O
-	O
12.1	O
)	O
,	O
suffer	O
from	O
hay	B-Entity
fever	I-Entity
and	O
asthma	I-Entity
(	O
odds	O
ratio	O
,	O
3.4	O
;	O
95%	O
confidence	O
interval	O
,	O
1.0	O
-	O
11.9	O
)	O
;	O
to	O
participate	O
in	O
regular	O
exercise	O
(	O
odds	O
ratio	O
,	O
5.9	O
;	O
95%	O
confidence	O
interval	O
,	O
1.1	O
-	O
30.7	O
)	O
,	O
especially	O
in	O
the	O
use	O
of	O
Nautilus	O
equipment	O
(	O
p	O
=	O
0.02	O
)	O
;	O
and	O
to	O
use	O
alcohol	I-Entity
(	O
odds	O
ratio	O
,	O
4.4	O
;	O
95%	O
confidence	O
interval	O
,	O
1.1	O
-	O
17.5	O
)	O
.	O

Possible	O
risk	O
factors	O
included	O
young	O
age	O
,	O
concurrent	O
use	O
of	O
other	O
analgesic	O
agents	O
(	O
especially	O
ibuprofen	I-Entity
)	O
,	O
preexisting	O
renal	B-Entity
disease	I-Entity
,	O
a	O
history	O
of	O
kidney	B-Entity
stones	I-Entity
,	O
a	O
history	O
of	O
gout	I-Entity
,	O
a	O
recent	O
increase	O
in	O
activity	O
,	O
a	O
recent	O
increase	O
in	O
sun	O
exposure	O
,	O
and	O
residence	O
in	O
the	O
Sunbelt	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
mechanism	O
for	O
this	O
unusual	O
syndrome	O
:	O
acute	O
diffuse	O
crystallization	O
of	O
uric	B-Entity
acid	I-Entity
in	O
renal	O
tubules	O
.	O



Hemolytic	B-Entity
-	I-Entity
uremic	I-Entity
syndrome	I-Entity
associated	O
with	O
ingestion	O
of	O
quinine	I-Entity
.	O

Hemolytic	B-Entity
-	I-Entity
uremic	I-Entity
syndrome	I-Entity
following	O
quinine	I-Entity
ingestion	O
is	O
a	O
newly	O
described	O
phenomenon	O
,	O
with	O
just	O
two	O
previous	O
descriptions	O
of	O
4	O
cases	O
in	O
the	O
literature	O
.	O

The	O
reaction	O
may	O
be	O
mediated	O
by	O
the	O
presence	O
of	O
antibodies	O
reactive	O
against	O
platelets	O
in	O
the	O
presence	O
of	O
quinine	I-Entity
.	O

Treatment	O
has	O
included	O
use	O
of	O
plasma	O
exchange	O
,	O
prednisone	I-Entity
,	O
aspirin	I-Entity
,	O
and	O
dipyridamole	I-Entity
.	O

Quinine	I-Entity
-	O
associated	O
hemolytic	B-Entity
-	I-Entity
uremic	I-Entity
syndrome	I-Entity
probably	O
occurs	O
more	O
often	O
than	O
is	O
recognized	O
.	O

It	O
is	O
important	O
to	O
recognize	O
this	O
reaction	O
when	O
it	O
occurs	O
and	O
to	O
avoid	O
further	O
quinine	I-Entity
exposure	O
,	O
since	O
the	O
reaction	O
seems	O
to	O
be	O
recurrent	O
.	O



The	O
etiology	O
of	O
pyeloureteritis	B-Entity
cystica	I-Entity
has	O
long	O
been	O
attributed	O
to	O
chronic	O
infection	I-Entity
and	O
inflammation	I-Entity
.	O

There	O
is	O
no	O
evidence	O
of	O
antecedent	O
or	O
concurrent	O
infection	I-Entity
in	O
this	O
patient	O
.	O

The	O
disease	O
occurred	O
subsequent	O
to	O
the	O
initiation	O
of	O
heparin	I-Entity
therapy	O
for	O
suspected	O
pelvic	O
thrombophlebitis	I-Entity
and	O
cleared	O
rapidly	O
subsequent	O
to	O
its	O
discontinuation	O
.	O

The	O
rate	O
of	O
resolution	O
of	O
the	O
radiographic	O
findings	O
may	O
be	O
helpful	O
in	O
distinguishing	O
between	O
true	O
pyeloureteritis	B-Entity
cystica	I-Entity
and	O
submucosal	B-Entity
hemorrhage	I-Entity
.	O



Changes	O
in	O
peroxisomes	O
in	O
preneoplastic	O
liver	O
and	O
hepatoma	I-Entity
of	O
mice	O
induced	O
by	O
alpha	B-Entity
-	I-Entity
benzene	I-Entity
hexachloride	I-Entity
.	O

Peroxisomes	O
in	O
hepatomas	I-Entity
and	O
hyperplastic	O
preneoplastic	O
liver	B-Entity
lesions	I-Entity
induced	O
in	O
mice	O
by	O
500	O
ppm	O
alpha	B-Entity
-	I-Entity
benzene	I-Entity
hexachloride	I-Entity
were	O
examined	O
histochemically	O
and	O
electron	O
microscopically	O
.	O

Although	O
most	O
of	O
the	O
hepatomas	I-Entity
were	O
well	O
-	O
differentiated	O
tumors	I-Entity
and	O
contained	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
,	O
the	O
tumor	I-Entity
cells	O
did	O
not	O
respond	O
to	O
ethyl	B-Entity
-	I-Entity
alpha	I-Entity
-	I-Entity
p	I-Entity
-	I-Entity
chlorophenoxyisobutyrate	I-Entity
with	O
proliferation	O
of	O
peroxisomes	O
.	O

These	O
cells	O
proliferated	O
further	O
,	O
replacing	O
the	O
most	O
part	O
of	O
the	O
nodules	O
,	O
and	O
with	O
this	O
process	O
hepatomas	I-Entity
appeared	O
to	O
have	O
been	O
formed	O
.	O

No	O
abnormal	O
matrical	O
inclusions	O
of	O
peroxisomes	O
were	O
formed	O
in	O
the	O
cells	O
of	O
hyperplastic	O
nodules	O
by	O
ethyl	B-Entity
-	I-Entity
alpha	I-Entity
-	I-Entity
p	I-Entity
-	I-Entity
chlorophenoxyisobutyrate	I-Entity
unlike	O
in	O
the	O
case	O
of	O
rats	O
.	O



Quinidine	I-Entity
hepatitis	I-Entity
.	O

Long	O
-	O
term	O
administration	O
of	O
quinidine	I-Entity
was	O
associated	O
with	O
persistent	O
elevation	O
of	O
serum	O
concentrations	O
of	O
SGOT	O
,	O
lactic	B-Entity
acid	I-Entity
dehydrogenase	O
,	O
and	O
alkaline	O
phosphatase	O
.	O

Liver	O
biopsy	O
showed	O
active	O
hepatitis	I-Entity
.	O

Discontinuance	O
of	O
quinidine	I-Entity
therapy	O
led	O
to	O
normalization	O
of	O
liver	O
function	O
tests	O
.	O

A	O
challenge	O
dose	O
of	O
quinidine	I-Entity
caused	O
clinical	O
symptoms	O
and	O
abrupt	O
elevation	O
of	O
SGOT	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
lactic	B-Entity
acid	I-Entity
dehydrogenase	O
values	O
.	O

We	O
concluded	O
that	O
this	O
patient	O
had	O
quinidine	I-Entity
hepatotoxicity	I-Entity
and	O
believe	O
that	O
this	O
is	O
the	O
first	O
case	O
reported	O
with	O
liver	O
biopsy	O
documentation	O
.	O

This	O
report	O
also	O
suggests	O
that	O
,	O
even	O
after	O
long	O
-	O
term	O
administration	O
,	O
the	O
hepatic	B-Entity
toxicity	I-Entity
is	O
reversible	O
.	O



Cholesteryl	B-Entity
hemisuccinate	I-Entity
treatment	O
protects	O
rodents	O
from	O
the	O
toxic	O
effects	O
of	O
acetaminophen	I-Entity
,	O
adriamycin	I-Entity
,	O
carbon	B-Entity
tetrachloride	I-Entity
,	O
chloroform	I-Entity
and	O
galactosamine	I-Entity
.	O

In	O
addition	O
to	O
its	O
use	O
as	O
a	O
stabilizer	O
/	O
rigidifier	O
of	O
membranes	O
,	O
cholesteryl	B-Entity
hemisuccinate	I-Entity
,	O
tris	B-Entity
salt	I-Entity
(	O
CS	I-Entity
)	O
administration	O
has	O
also	O
been	O
shown	O
to	O
protect	O
rats	O
from	O
the	O
hepatotoxic	I-Entity
effects	O
of	O
carbon	B-Entity
tetrachloride	I-Entity
(	O
CCl4	I-Entity
)	O
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
mechanism	O
of	O
CS	I-Entity
cytoprotection	O
,	O
we	O
examined	O
in	O
rats	O
and	O
mice	O
the	O
protective	O
abilities	O
of	O
CS	I-Entity
and	O
the	O
non	O
-	O
hydrolyzable	O
ether	O
form	O
of	O
CS	I-Entity
,	O
gamma	B-Entity
-	I-Entity
cholesteryloxybutyric	I-Entity
acid	I-Entity
,	O
tris	B-Entity
salt	I-Entity
(	O
CSE	I-Entity
)	O
against	O
acetaminophen-	I-Entity
,	O
adriamycin-	I-Entity
,	O
carbon	B-Entity
tetrachloride-	I-Entity
,	O
chloroform-	I-Entity
and	O
galactosamine	I-Entity
-	O
induced	O
toxicity	I-Entity
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrated	O
that	O
CS	I-Entity
-	O
mediated	O
protection	O
is	O
not	O
selective	O
for	O
a	O
particular	O
species	O
,	O
organ	O
system	O
or	O
toxic	O
chemical	O
.	O

A	O
24-h	O
pretreatment	O
of	O
both	O
rats	O
and	O
mice	O
with	O
a	O
single	O
dose	O
of	O
CS	I-Entity
(	O
100mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
resulted	O
in	O
significant	O
protection	O
against	O
the	O
hepatotoxic	I-Entity
effects	O
of	O
CCl4	I-Entity
,	O
CHCl3	I-Entity
,	O
acetaminophen	I-Entity
and	O
galactosamine	I-Entity
and	O
against	O
the	O
lethal	O
(	O
and	O
presumably	O
cardiotoxic	I-Entity
)	O
effect	O
of	O
adriamycin	I-Entity
administration	O
.	O

Maximal	O
CS	I-Entity
-	O
mediated	O
protection	O
was	O
observed	O
in	O
experimental	O
animals	O
pretreated	O
24	O
h	O
prior	O
to	O
the	O
toxic	O
insult	O
.	O

These	O
data	O
suggest	O
that	O
CS	I-Entity
intervenes	O
in	O
a	O
critical	O
cellular	O
event	O
that	O
is	O
an	O
important	O
common	O
pathway	O
to	O
toxic	O
cell	O
death	O
.	O

The	O
mechanism	O
of	O
CS	I-Entity
protection	O
does	O
not	O
appear	O
to	O
be	O
dependent	O
on	O
the	O
inhibition	O
of	O
chemical	O
bioactivation	O
to	O
a	O
toxic	O
reactive	O
intermediate	O
(	O
in	O
light	O
of	O
the	O
protection	O
observed	O
against	O
galactosamine	I-Entity
hepatotoxicity	I-Entity
)	O
.	O

However	O
,	O
based	O
on	O
the	O
data	O
presented	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
CS	I-Entity
administration	O
inhibits	O
chemical	O
bioactivation	O
.	O

Our	O
findings	O
do	O
suggest	O
that	O
CS	I-Entity
-	O
mediated	O
protection	O
is	O
dependent	O
on	O
the	O
action	O
of	O
the	O
intact	O
anionic	O
CS	I-Entity
molecule	O
(	O
non	O
-	O
hydrolyzable	O
CSE	I-Entity
was	O
as	O
protective	O
as	O
CS	I-Entity
)	O
,	O
whose	O
mechanism	O
has	O
yet	O
to	O
be	O
defined	O
.	O



DSMM	O
XI	O
study	O
:	O
dose	O
definition	O
for	O
intravenous	O
cyclophosphamide	I-Entity
in	O
combination	O
with	O
bortezomib	I-Entity
/	O
dexamethasone	I-Entity
for	O
remission	O
induction	O
in	O
patients	O
with	O
newly	O
diagnosed	O
myeloma	I-Entity
.	O

A	O
clinical	O
trial	O
was	O
initiated	O
to	O
evaluate	O
the	O
recommended	O
dose	O
of	O
cyclophosphamide	I-Entity
in	O
combination	O
with	O
bortezomib	I-Entity
and	O
dexamethasone	I-Entity
as	O
induction	O
treatment	O
before	O
stem	O
cell	O
transplantation	O
for	O
younger	O
patients	O
with	O
newly	O
diagnosed	O
multiple	B-Entity
myeloma	I-Entity
(	O
MM	I-Entity
)	O
.	O

Thirty	O
patients	O
were	O
treated	O
with	O
three	O
21-day	O
cycles	O
of	O
bortezomib	I-Entity
1.3	O
mg	O
/	O
m(2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
plus	O
dexamethasone	I-Entity
40	O
mg	O
on	O
the	O
day	O
of	O
bortezomib	I-Entity
injection	O
and	O
the	O
day	O
after	O
plus	O
cyclophosphamide	I-Entity
at	O
900	O
,	O
1,200	O
,	O
or	O
1,500	O
mg	O
/	O
m(2	O
)	O
on	O
day	O
1	O
.	O

The	O
maximum	O
tolerated	O
dose	O
of	O
cyclophosphamide	I-Entity
was	O
defined	O
as	O
900	O
mg	O
/	O
m(2	O
)	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
were	O
hematological	B-Entity
and	I-Entity
gastrointestinal	I-Entity
toxicities	I-Entity
as	O
well	O
as	O
neuropathy	I-Entity
.	O

The	O
results	O
suggest	O
that	O
bortezomib	I-Entity
in	O
combination	O
with	O
cyclophosphamide	I-Entity
at	O
900	O
mg	O
/	O
m(2	O
)	O
and	O
dexamethasone	I-Entity
is	O
an	O
effective	O
induction	O
treatment	O
for	O
patients	O
with	O
newly	O
diagnosed	O
MM	I-Entity
that	O
warrants	O
further	O
investigation	O
.	O



Results	O
of	O
a	O
comparative	O
,	O
phase	O
III	O
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
assessment	O
of	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
fixed	O
-	O
dose	O
combination	O
of	O
telmisartan	I-Entity
and	O
amlodipine	I-Entity
versus	O
amlodipine	I-Entity
monotherapy	O
in	O
Indian	O
adults	O
with	O
stage	O
II	O
hypertension	I-Entity
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
new	O
fixed	O
-	O
dose	O
combination	O
(	O
FDC	O
)	O
of	O
telmisartan	I-Entity
40	O
mg	O
+	O
amlodipine	I-Entity
5	O
mg	O
(	O
T+A	O
)	O
compared	O
with	O
amlodipine	I-Entity
5-mg	O
monotherapy	O
(	O
A	O
)	O
in	O
adult	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	I-Entity
.	O

This	O
comparative	O
,	O
Phase	O
III	O
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
was	O
conducted	O
in	O
Indian	O
patients	O
aged	O
18	O
to	O
65	O
years	O
with	O
established	O
stage	O
II	O
hypertension	I-Entity
.	O

Peripheral	O
edema	I-Entity
was	O
reported	O
in	O
8.5%	O
patients	O
(	O
9/106	O
)	O
in	O
the	O
T+A	O
group	O
compared	O
with	O
13.5%	O
(	O
14/104	O
)	O
in	O
the	O
A	O
group	O
,	O
and	O
cough	I-Entity
was	O
reported	O
in	O
3.8%	O
patients	O
(	O
4/106	O
)	O
in	O
the	O
T+A	O
group	O
and	O
1.0%	O
(	O
1/104	O
)	O
patients	O
in	O
the	O
A	O
group	O
;	O
these	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
incidences	O
of	O
headache	I-Entity
,	O
dizziness	I-Entity
,	O
and	O
diarrhea	I-Entity
were	O
similar	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
:	O
Among	O
these	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	I-Entity
,	O
the	O
FDC	O
of	O
T+A	O
was	O
found	O
to	O
be	O
significantly	O
more	O
effective	O
,	O
with	O
regard	O
to	O
BP	O
reductions	O
,	O
than	O
A	O
,	O
and	O
both	O
treatments	O
were	O
well	O
tolerated	O
.	O



Cutaneous	B-Entity
leucocytoclastic	I-Entity
vasculitis	I-Entity
associated	O
with	O
oxacillin	I-Entity
.	O

A	O
67-year	O
-	O
old	O
man	O
who	O
was	O
treated	O
with	O
oxacillin	I-Entity
for	O
one	O
week	O
because	O
of	O
Staphylococcus	B-Entity
aureus	I-Entity
bacteremia	I-Entity
,	O
developed	O
renal	B-Entity
failure	I-Entity
and	O
diffuse	O
,	O
symmetric	O
,	O
palpable	O
purpuric	B-Entity
lesions	I-Entity
on	O
his	O
feet	O
.	O

Necrotic	B-Entity
blisters	I-Entity
were	O
noted	O
on	O
his	O
fingers	O
.	O

Skin	O
biopsies	O
showed	O
findings	O
diagnostic	O
of	O
leucocytoclastic	B-Entity
vasculitis	I-Entity
.	O

Oxacillin	I-Entity
was	O
discontinued	O
and	O
patient	O
was	O
treated	O
with	O
corticosteroids	I-Entity
.	O

The	O
rash	I-Entity
disappeared	O
after	O
three	O
weeks	O
and	O
renal	O
function	O
returned	O
to	O
normal	O
.	O

Leucocytoclastic	B-Entity
vasculitis	I-Entity
presents	O
as	O
palpable	O
purpura	I-Entity
of	O
the	O
lower	O
extremities	O
often	O
accompanied	O
by	O
abdominal	B-Entity
pain	I-Entity
,	O
arthralgia	I-Entity
,	O
and	O
renal	B-Entity
involvement	I-Entity
.	O

Etiologic	O
factors	O
or	O
associated	O
disorders	O
include	O
infections	I-Entity
,	O
medications	O
,	O
collagen	B-Entity
vascular	I-Entity
disease	I-Entity
and	O
neoplasia	I-Entity
.	O

Usually	O
it	O
is	O
a	O
self	O
-	O
limited	O
disorder	O
,	O
but	O
corticosteroid	I-Entity
therapy	O
may	O
be	O
needed	O
in	O
life	O
-	O
threatening	O
cases	O
since	O
early	O
treatment	O
with	O
corticosteroids	I-Entity
in	O
severe	O
cases	O
can	O
prevent	O
complications	O
.	O

Oxacillin	I-Entity
should	O
be	O
included	O
among	O
the	O
drugs	O
that	O
can	O
cause	O
leucocytoclastic	B-Entity
vasculitis	I-Entity
.	O



Naloxazone	I-Entity
pretreatment	O
modifies	O
cardiorespiratory	O
,	O
temperature	O
,	O
and	O
behavioral	O
effects	O
of	O
morphine	I-Entity
.	O

Behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
a	O
lethal	O
dose	O
of	O
morphine	I-Entity
were	O
evaluated	O
in	O
rats	O
pretreated	O
with	O
saline	O
or	O
naloxazone	I-Entity
,	O
an	O
antagonist	O
of	O
high	O
-	O
affinity	O
mu	O
1	O
opioid	O
receptors	O
.	O

Pretreatment	O
with	O
naloxazone	I-Entity
significantly	O
blocked	O
morphine	I-Entity
analgesia	I-Entity
,	O
catalepsy	I-Entity
and	O
hypothermia	I-Entity
at	O
a	O
dose	O
which	O
completely	O
eliminated	O
high	O
-	O
affinity	O
binding	O
in	O
brain	O
membranes	O
.	O

Moreover	O
,	O
naloxazone	I-Entity
significantly	O
attenuated	O
the	O
morphine	I-Entity
-	O
induced	O
hypotension	I-Entity
and	O
respiratory	B-Entity
depression	I-Entity
,	O
whereas	O
morphine	I-Entity
-	O
induced	O
bradycardia	I-Entity
was	O
less	O
affected	O
.	O

Results	O
indicate	O
that	O
subpopulations	O
of	O
mu	O
receptors	O
may	O
mediate	O
selective	O
behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
morphine	I-Entity
.	O



Dexrazoxane	I-Entity
protects	O
against	O
myelosuppression	I-Entity
from	O
the	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
etoposide	I-Entity
and	O
daunorubicin	I-Entity
but	O
not	O
doxorubicin	I-Entity
.	O

The	O
anthracyclines	I-Entity
daunorubicin	I-Entity
and	O
doxorubicin	I-Entity
and	O
the	O
epipodophyllotoxin	I-Entity
etoposide	I-Entity
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	I-Entity
and	O
cardiac	B-Entity
toxicity	I-Entity
limit	O
their	O
use	O
.	O

Dexrazoxane	I-Entity
(	O
ICRF-187	I-Entity
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	B-Entity
toxicity	I-Entity
following	O
coadministration	O
of	O
dexrazoxane	I-Entity
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O

Sensitivity	O
of	O
human	O
and	O
murine	O
blood	O
progenitor	O
cells	O
to	O
etoposide	I-Entity
,	O
daunorubicin	I-Entity
,	O
and	O
doxorubicin	I-Entity
+	O
/-	O

dexrazoxane	I-Entity
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O

Likewise	O
,	O
in	O
vivo	O
,	O
B6D2F1	O
mice	O
were	O
treated	O
with	O
etoposide	I-Entity
,	O
daunorubicin	I-Entity
,	O
and	O
doxorubicin	I-Entity
,	O
with	O
or	O
without	O
dexrazoxane	I-Entity
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O

RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	I-Entity
reduced	O
myelosuppression	I-Entity
and	O
weight	B-Entity
loss	I-Entity
from	O
daunorubicin	I-Entity
and	O
etoposide	I-Entity
in	O
mice	O
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	I-Entity
neither	O
reduced	O
myelosuppression	I-Entity
,	O
weight	B-Entity
loss	I-Entity
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	I-Entity
from	O
doxorubicin	I-Entity
.	O

CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	I-Entity
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	I-Entity
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	I-Entity
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	I-Entity
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	I-Entity
.	O

Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	I-Entity
combining	O
dexrazoxane	I-Entity
and	O
high	O
doses	O
of	O
etoposide	I-Entity
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	B-Entity
toxicity	I-Entity
.	O



Effects	O
of	O
the	O
novel	O
compound	O
aniracetam	I-Entity
(	O
Ro	B-Entity
13	I-Entity
-	I-Entity
5057	I-Entity
)	O
upon	O
impaired	B-Entity
learning	I-Entity
and	I-Entity
memory	I-Entity
in	O
rodents	O
.	O

The	O
effect	O
of	O
aniracetam	I-Entity
(	O
Ro	B-Entity
13	I-Entity
-	I-Entity
5057	I-Entity
,	O
1-anisoyl-2-pyrrolidinone	I-Entity
)	O
was	O
studied	O
on	O
various	O
forms	O
of	O
experimentally	O
impaired	B-Entity
cognitive	I-Entity
functions	I-Entity
(	O
learning	O
and	O
memory	O
)	O
in	O
rodents	O
and	O
produced	O
the	O
following	O
effects	O
:	O
(	O
1	O
)	O
almost	O
complete	O
prevention	O
of	O
the	O
incapacity	O
to	O
learn	O
a	O
discrete	O
escape	O
response	O
in	O
rats	O
exposed	O
to	O
sublethal	O
hypercapnia	I-Entity
immediately	O
before	O
the	O
acquisition	O
session	O
;	O
(	O
2	O
)	O
partial	O
(	O
rats	O
)	O
or	O
complete	O
(	O
mice	O
)	O
prevention	O
of	O
the	O
scopolamine	I-Entity
-	O
induced	O
short	O
-	O
term	O
amnesia	I-Entity
for	O
a	O
passive	O
avoidance	O
task	O
;	O

(	O
3	O
)	O
complete	O
protection	O
against	O
amnesia	I-Entity
for	O
a	O
passive	O
avoidance	O
task	O
in	O
rats	O
submitted	O
to	O
electroconvulsive	O
shock	O
immediately	O
after	O
avoidance	O
acquisition	O
;	O
(	O
4	O
)	O
prevention	O
of	O
the	O
long	O
-	O
term	O
retention-	O
or	O
retrieval	O
-	O
deficit	O
for	O
a	O
passive	O
avoidance	O
task	O
induced	O
in	O
rats	O
and	O
mice	O
by	O
chloramphenicol	I-Entity
or	O
cycloheximide	I-Entity
administered	O
immediately	O
after	O
acquisition	O
;	O
(	O
5	O
)	O
reversal	O
,	O

when	O
administered	O
as	O
late	O
as	O
1	O
h	O
before	O
the	O
retention	O
test	O
,	O
of	O
the	O
deficit	O
in	O
retention	O
or	O
retrieval	O
of	O
a	O
passive	O
avoidance	O
task	O
induced	O
by	O
cycloheximide	I-Entity
injected	O
2	O
days	O
previously	O
;	O
(	O
6	O
)	O
prevention	O
of	O
the	O
deficit	O
in	O
the	O
retrieval	O
of	O
an	O
active	O
avoidance	O
task	O
induced	O
in	O
mice	O
by	O
subconvulsant	O
electroshock	O
or	O
hypercapnia	I-Entity
applied	O
immediately	O
before	O
retrieval	O
testing	O
(	O
24	O
h	O
after	O
acquisition	O
)	O
.	O

These	O
improvements	O
or	O
normalizations	O
of	O
impaired	B-Entity
cognitive	I-Entity
functions	I-Entity
were	O
seen	O
at	O
oral	O
aniracetam	I-Entity
doses	O
of	O
10	O
-	O
100	O
mg	O
/	O
kg	O
.	O

The	O
mechanisms	O
underlying	O
the	O
activity	O
of	O
aniracetam	I-Entity
and	O
its	O
'	O
therapeutic	O
window	O
'	O
are	O
unknown	O
.	O

Piracetam	I-Entity
,	O
another	O
pyrrolidinone	I-Entity
derivative	O
was	O
used	O
for	O
comparison	O
.	O

It	O
was	O
active	O
only	O
in	O
six	O
of	O
nine	O
tests	O
and	O
had	O
about	O
one	O
-	O
tenth	O
the	O
potency	O
of	O
aniracetam	I-Entity
.	O

The	O
results	O
indicate	O
that	O
aniracetam	I-Entity
improves	O
cognitive	O
functions	O
which	O
are	O
impaired	O
by	O
different	O
procedure	O
and	O
in	O
different	O
phases	O
of	O
the	O
learning	O
and	O
memory	O
process	O
.	O



Nicotine	I-Entity
potentiation	O
of	O
morphine	I-Entity
-	O
induced	O
catalepsy	I-Entity
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
effects	O
of	O
nicotine	I-Entity
on	O
catalepsy	I-Entity
induced	O
by	O
morphine	I-Entity
in	O
mice	O
have	O
been	O
investigated	O
.	O

Morphine	I-Entity
but	O
not	O
nicotine	I-Entity
induced	O
a	O
dose	O
-	O
dependent	O
catalepsy	I-Entity
.	O

The	O
response	O
of	O
morphine	I-Entity
was	O
potentiated	O
by	O
nicotine	I-Entity
.	O

Intraperitoneal	O
administration	O
of	O
atropine	I-Entity
,	O
naloxone	I-Entity
,	O
mecamylamine	I-Entity
,	O
and	O
hexamethonium	I-Entity
to	O
mice	O
reduced	O

catalepsy	I-Entity
induced	O
by	O
a	O
combination	O
of	O
morphine	I-Entity
with	O
nicotine	I-Entity
.	O

Intracerebroventricular	O
injection	O
of	O
atropine	I-Entity
,	O
hexamethonium	I-Entity
,	O
and	O
naloxone	I-Entity
also	O
decreased	O
catalepsy	I-Entity
induced	O
by	O
morphine	I-Entity
plus	O
nicotine	I-Entity
.	O

Intraperitoneal	O
administration	O
of	O
atropine	I-Entity
,	O
but	O
not	O
intraperitoneal	O
or	O
intracerebroventricular	O
injection	O
of	O
hexamethonium	I-Entity
,	O
decreased	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
morphine	I-Entity
.	O

It	O
was	O
concluded	O
that	O
morphine	I-Entity
catalepsy	I-Entity
can	O
be	O
elicited	O
by	O
opioid	O
and	O
cholinergic	O
receptors	O
,	O
and	O
the	O
potentiation	O
of	O
morphine	I-Entity
induced	O
by	O
nicotine	I-Entity
may	O
also	O
be	O
mediated	O
through	O
cholinergic	O
receptor	O
mechanisms	O
.	O



Reduced	O
cardiotoxicity	I-Entity
and	O
preserved	O
antitumor	O
efficacy	O
of	O
liposome	O
-	O
encapsulated	O
doxorubicin	I-Entity
and	O
cyclophosphamide	I-Entity
compared	O
with	O
conventional	O
doxorubicin	I-Entity
and	O
cyclophosphamide	I-Entity
in	O
a	O
randomized	O
,	O
multicenter	O
trial	O
of	O
metastatic	O
breast	B-Entity
cancer	I-Entity
.	O

To	O
determine	O
whether	O
Myocet	I-Entity
(	O
liposome	O
-	O
encapsulated	O
doxorubicin	I-Entity
;	O
The	O
Liposome	O
Company	O
,	O
Elan	O
Corporation	O
,	O
Princeton	O
,	O
NJ	O
)	O
in	O
combination	O
with	O
cyclophosphamide	I-Entity
significantly	O
reduces	O
doxorubicin	I-Entity
cardiotoxicity	I-Entity
while	O
providing	O
comparable	O
antitumor	O
efficacy	O
in	O
first	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B-Entity
cancer	I-Entity
(	O
MBC	I-Entity
)	O
.	O

Two	O
hundred	O
ninety	O
-	O
seven	O
patients	O
with	O
MBC	I-Entity
and	O
no	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
were	O
randomized	O
to	O
receive	O
either	O
60	O
mg	O
/	O
m(2	O
)	O
of	O
Myocet	I-Entity
(	O
M	O
)	O
or	O
conventional	O
doxorubicin	I-Entity
(	O
A	O
)	O
,	O
in	O
combination	O
with	O
600	O
mg	O
/	O
m(2	O
)	O
of	O
cyclophosphamide	I-Entity
(	O
C	O
)	O
,	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	I-Entity
.	O

Cardiotoxicity	I-Entity
was	O
defined	O
by	O
reductions	O
in	O
left	O
-	O
ventricular	O
ejection	O
fraction	O
,	O
assessed	O
by	O
serial	O
multigated	O
radionuclide	O
angiography	O
scans	O
,	O
or	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
(	O
CHF	I-Entity
)	O
.	O

Antitumor	O
efficacy	O
was	O
assessed	O
by	O
objective	O
tumor	I-Entity
response	O
rates	O
(	O
World	O
Health	O
Organization	O
criteria	O
)	O
,	O
time	O
to	O
progression	O
,	O
and	O
survival	O
.	O

Six	O
percent	O
of	O
MC	O
patients	O
versus	O
21%	O
(	O
including	O
five	O
cases	O
of	O
CHF	I-Entity
)	O
of	O
AC	O
patients	O
developed	O
cardiotoxicity	I-Entity
(	O
P	O
=	O
.0002	O
)	O
.	O

Median	O
cumulative	O
doxorubicin	I-Entity
dose	O
at	O
onset	O
was	O
more	O
than	O
2,220	O
mg	O
/	O
m(2	O
)	O
for	O
MC	O
versus	O
480	O
mg	O
/	O
m(2	O
)	O
for	O
AC	O
(	O
P	O
=	O
.0001	O
,	O
hazard	O
ratio	O
,	O
5.04	O
)	O
.	O

MC	O
patients	O
also	O
experienced	O
less	O
grade	O
4	O
neutropenia	I-Entity
.	O

CONCLUSION	O
:	O
Myocet	I-Entity
improves	O
the	O
therapeutic	O
index	O
of	O
doxorubicin	I-Entity
by	O
significantly	O
reducing	O
cardiotoxicity	I-Entity
and	O
grade	O
4	O
neutropenia	I-Entity
and	O
provides	O
comparable	O
antitumor	O
efficacy	O
,	O
when	O
used	O
in	O
combination	O
with	O
cyclophosphamide	I-Entity
as	O
first	O
-	O
line	O
therapy	O
for	O
MBC	I-Entity
.	O



Protective	O
effect	O
of	O
a	O
specific	O
platelet	O
-	O
activating	O
factor	O
antagonist	O
,	O
BN	B-Entity
52021	I-Entity
,	O
on	O
bupivacaine	I-Entity
-	O
induced	O
cardiovascular	B-Entity
impairments	I-Entity
in	O
rats	O
.	O

Administration	O
of	O
the	O
local	O
anaesthetic	O
bupivacaine	I-Entity
(	O
1.5	O
or	O
2	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O

to	O
rats	O
elicited	O
a	O
marked	O
decrease	B-Entity
of	I-Entity
mean	I-Entity
arterial	I-Entity
blood	I-Entity
pressure	I-Entity
(	I-Entity
MBP	I-Entity
)	I-Entity
and	I-Entity
heart	I-Entity
rate	I-Entity
(	I-Entity
HR	I-Entity
)	I-Entity
leading	O
to	O
death	O
(	O
in	O
67%	O
or	O
90%	O
of	O
animals	O
respectively	O
)	O
.	O

Intravenous	O
injection	O
of	O
the	O
specific	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
antagonist	O
BN	B-Entity
52021	I-Entity
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
30	O
min	O
before	O
bupivacaine	I-Entity
administration	O
(	O
2	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
suppressed	O
both	O
the	O
decrease	B-Entity
of	I-Entity
MBP	I-Entity
and	I-Entity
HR	I-Entity
.	O

In	O
contrast	O
,	O
doses	O
of	O
1	O
mg	O
/	O
kg	O
BN	B-Entity
52021	I-Entity
given	O
30	O
min	O
before	O
or	O
10	O
mg	O
/	O
kg	O
administered	O
5	O
min	O
before	O
i.v	O
.	O

injection	O
of	O
bupivacaine	I-Entity
were	O
ineffective	O
.	O

When	O
BN	B-Entity
52021	I-Entity
(	O
20	O
mg	O

was	O
injected	O
immediately	O
after	O
bupivacaine	I-Entity
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
a	O
partial	O
reversion	O
of	O
the	O
decrease	B-Entity
of	I-Entity
MBP	I-Entity
and	I-Entity
HR	I-Entity
was	O
observed	O
,	O
whereas	O
the	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
was	O
ineffective	O
.	O

A	O
partial	O
recovery	O
of	O
bupivacaine	I-Entity
-	O
induced	O
ECG	O
alterations	O
was	O
observed	O
after	O
pretreatment	O
of	O
the	O
rats	O
with	O
BN	B-Entity
52021	I-Entity
.	O

Since	O
the	O
administration	O
of	O
BN	B-Entity
52021	I-Entity
,	O
at	O
all	O
doses	O
studied	O
,	O
did	O
not	O
alter	O
MBP	O
and	O
HR	O
at	O
the	O
doses	O
used	O
,	O
the	O
bulk	O
of	O
these	O
results	O
clearly	O
demonstrate	O
a	O
protective	O
action	O
of	O
BN	B-Entity
52021	I-Entity
,	O
a	O
specific	O
antagonist	O
of	O
PAF	O
,	O
against	O
bupivacaine	I-Entity
-	O
induced	O
cardiovascular	B-Entity
toxicity	I-Entity
.	O

Thus	O
,	O
consistent	O
with	O
its	O
direct	O
effect	O
on	O
heart	O
,	O
PAF	O
appears	O
to	O
be	O
implicated	O
in	O
bupivacaine	I-Entity
-	O
induced	O
cardiovascular	B-Entity
alterations	I-Entity
.	O



Benzylacyclouridine	I-Entity
reverses	O
azidothymidine	I-Entity
-	O
induced	O
marrow	B-Entity
suppression	I-Entity
without	O
impairment	O
of	O
anti	O
-	O
human	O
immunodeficiency	I-Entity
virus	O
activity	O
.	O

Increased	O
extracellular	O
concentrations	O
of	O
uridine	I-Entity
(	O
Urd	I-Entity
)	O
have	O
been	O
reported	O
to	O
reduce	O
,	O
in	O
vitro	O
,	O
azidothymidine	I-Entity
(	O
AZT)-induced	I-Entity
inhibition	O
of	O
human	O
granulocyte	O
-	O
macrophage	O
progenitor	O
cells	O
without	O
impairment	O
of	O
its	O
antihuman	O
immunodeficiency	I-Entity
virus	O
(	O
HIV	O
)	O
activity	O
.	O

Because	O
of	O
the	O
clinical	O
toxicities	I-Entity
associated	O
with	O
chronic	O
Urd	I-Entity
administration	O
,	O
the	O
ability	O
of	O
benzylacyclouridine	I-Entity
(	O
BAU	I-Entity
)	O
to	O
effect	O
,	O
in	O
vivo	O
,	O
AZT	I-Entity
-	O
induced	O
anemia	I-Entity
and	O
leukopenia	I-Entity
was	O
assessed	O
.	O

This	O
agent	O
inhibits	O
Urd	I-Entity
catabolism	O
and	O
,	O
in	O
vivo	O
,	O
increases	O
the	O
plasma	O
concentration	O
of	O
Urd	I-Entity
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
without	O
Urd	I-Entity
-	O
related	O
toxicity	I-Entity
.	O

In	O
mice	O
rendered	O
anemic	I-Entity
and	O
leukopenic	I-Entity
by	O
the	O
administration	O
of	O
AZT	I-Entity
for	O
28	O
days	O
in	O
drinking	O
water	O
(	O
1.5	O
mg	O
/	O
mL	O
)	O
,	O
the	O
continued	O
administration	O
of	O
AZT	I-Entity
plus	O
daily	O
BAU	I-Entity
(	O
300	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
partially	O
reversed	O
AZT	I-Entity
-	O
induced	O
anemia	I-Entity
and	O
leukopenia	I-Entity
(	O
P	O
less	O
than	O
.05	O
)	O
,	O
increased	O
peripheral	O
reticulocytes	O
(	O
to	O
4.9%	O
,	O
P	O
less	O
than	O
.01	O
)	O
,	O
increased	O
cellularity	O
in	O
the	O
marrow	O
,	O
and	O
improved	O
megaloblastosis	I-Entity
.	O

When	O
coadministered	O
with	O
AZT	I-Entity
from	O
the	O
onset	O
of	O
drug	O
administration	O
,	O
BAU	I-Entity
reduced	O
AZT	I-Entity
-	O
induced	O
marrow	B-Entity
toxicity	I-Entity
.	O

In	O
vitro	O
,	O
at	O
a	O
concentration	O
of	O
100	O
mumol	O
/	O
L	O
,	O
BAU	I-Entity
possesses	O
minimal	O
anti	O
-	O
HIV	O
activity	O
and	O
has	O
no	O
effect	O
on	O
the	O
ability	O
of	O
AZT	I-Entity
to	O
reverse	O
the	O
HIV	O
-	O
induced	O
cytopathic	O
effect	O
in	O
MT4	O
cells	O
.	O



Cyclophosphamide	I-Entity
-	O
induced	O
cystitis	I-Entity
in	O
freely	O
-	O
moving	O
conscious	O
rats	O
:	O
behavioral	O
approach	O
to	O
a	O
new	O
model	O
of	O
visceral	B-Entity
pain	I-Entity
.	O

PURPOSE	O
:	O
To	O
develop	O
a	O
model	O
of	O
visceral	B-Entity
pain	I-Entity
in	O
rats	O
using	O
a	O
behavioral	O
approach	O
.	O

Cyclophosphamide	I-Entity
(	O
CP	I-Entity
)	O
,	O
an	O
antitumoral	O
agent	O
known	O
to	O
produce	O
toxic	O
effects	O
on	O
the	O
bladder	O
wall	O
through	O
its	O
main	O
toxic	O
metabolite	O
acrolein	I-Entity
,	O
was	O
used	O
to	O
induce	O
cystitis	I-Entity
.	O

CP	I-Entity
was	O
administered	O
at	O
doses	O
of	O
50	O
,	O
100	O
and	O
200	O
mg./kg	O
.	O

The	O
effects	O
of	O
morphine	I-Entity
(	O
0.5	O
to	O
4	O
mg./kg	O
.	O

i.v	O
.	O
)	O
on	O
CP	I-Entity
-	O
induced	O
behavioral	O
modifications	O
were	O
tested	O
administered	O
alone	O
and	O
after	O
naloxone	I-Entity
(	O
1	O
mg./kg	O
.	O

In	O
addition	O
,	O
90	O
minutes	O
after	O
CP	I-Entity
injection	O
,	O
that	O
is	O
,	O
at	O
the	O
time	O
of	O
administration	O
of	O
morphine	I-Entity
,	O
the	O
bladder	O
was	O
removed	O
in	O
some	O
rats	O
for	O
histological	O
examination	O
.	O

Finally	O
,	O
to	O
show	O
that	O
the	O
bladder	O
is	O
essential	O
for	O
the	O
CP	I-Entity
-	O
induced	O
behavioral	O
modifications	O
,	O
female	O
rats	O
also	O
received	O
CP	I-Entity
at	O
doses	O
of	O
200	O
mg./kg	O
.	O

by	O
the	O
intravesical	O
route	O
,	O
and	O
acrolein	I-Entity
at	O
doses	O
of	O
0.5	O
mg	O
.	O

CP	I-Entity
dose	O
-	O
relatedly	O
induced	O
marked	O
behavioral	O
modifications	O
in	O
male	O
rats	O
:	O
breathing	O
rate	O
decrease	O
,	O
closing	O
of	O
the	O
eyes	O
and	O
occurrence	O
of	O
specific	O
postures	O
.	O

Morphine	I-Entity
dose	O
-	O
dependently	O
reversed	O
these	O
behavioral	B-Entity
disorders	I-Entity
.	O

produced	O
a	O
reduction	O
of	O
almost	O
50%	O
of	O
the	O
behavioral	O
score	O
induced	O
by	O
CP	I-Entity
200	O
mg./kg	O
.	O

This	O
effect	O
was	O
completely	O
prevented	O
by	O
pretreatment	O
with	O
naloxone	I-Entity
.	O

At	O
the	O
time	O
of	O
administration	O
of	O
morphine	I-Entity
,	O
histological	O
modifications	O
of	O
the	O
bladder	O
wall	O
,	O
such	O
as	O
chorionic	O
and	O
muscle	O
layer	O
edema	I-Entity
,	O
were	O
observed	O
.	O

In	O
female	O
rats	O
,	O
CP	I-Entity
200	O
mg./kg	O
.	O

intravesically	O
,	O
CP	I-Entity
did	O
not	O
produce	O
any	O
behavioral	O
effects	O
,	O
whereas	O
acrolein	I-Entity
at	O
0.5	O
mg	O
.	O

intravesically	O
induced	O
behavioral	O
modifications	O
identical	O
to	O
those	O
under	O
CP	I-Entity
200	O
mg./kg	O
.	O

Conversely	O
,	O
acrolein	I-Entity
5	O
mg./kg	O
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
this	O
experimental	O
model	O
of	O
CP	I-Entity
-	O
induced	O
cystitis	I-Entity
may	O
be	O
an	O
interesting	O
new	O
behavioral	O
model	O
of	O
inflammatory	O
visceral	B-Entity
pain	I-Entity
,	O
allowing	O
a	O
better	O
understanding	O
of	O
these	O
painful	B-Entity
syndromes	I-Entity
and	O
thus	O
a	O
better	O
therapeutic	O
approach	O
to	O
them	O
.	O



Hyperalgesia	I-Entity
and	O
myoclonus	I-Entity
in	O
terminal	O
cancer	I-Entity
patients	O
treated	O
with	O
continuous	O
intravenous	O
morphine	I-Entity
.	O

Eight	O
cancer	I-Entity
patients	O
in	O
the	O
terminal	O
stages	O
of	O
the	O
disease	O
treated	O
with	O
high	O
doses	O
of	O
intravenous	O
morphine	I-Entity
developed	O
hyperalgesia	I-Entity
.	O

Five	O
patients	O
developed	O
universal	O
hyperalgesia	I-Entity
and	O
hyperesthesia	I-Entity
which	O
in	O
2	O
cases	O
were	O
accompanied	O
by	O
myoclonus	I-Entity
.	O

In	O
3	O
patients	O
a	O
pre	O
-	O
existing	O
neuralgia	I-Entity
increased	O
to	O
excruciating	O
intensity	O
and	O
in	O
2	O
of	O
these	O
cases	O
myoclonus	I-Entity
occurred	O
simultaneously	O
.	O

Although	O
only	O
few	O
clinical	O
descriptions	O
of	O
the	O
relationship	O
between	O
hyperalgesia	I-Entity
/	O
myoclonus	I-Entity
and	O
high	O
doses	O
of	O
morphine	I-Entity
are	O
available	O
,	O
experimental	O
support	O
from	O
animal	O
studies	O
indicates	O
that	O
morphine	I-Entity
,	O
or	O
its	O
metabolites	O
,	O
plays	O
a	O
causative	O
role	O
for	O
the	O
observed	O
behavioural	O
syndrome	O
.	O



A	O
prospective	O
study	O
of	O
adverse	O
reactions	O
associated	O
with	O
vancomycin	I-Entity
therapy	O
.	O

A	O
prospective	O
evaluation	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
vancomycin	I-Entity
was	O
conducted	O
in	O
54	O
consecutive	O
patients	O
over	O
a	O
16-month	O
period	O
.	O

Vancomycin	I-Entity
was	O
curative	O
in	O
95%	O
of	O
43	O
patients	O
with	O
proven	O
infection	I-Entity
.	O

Drugs	O
were	O
ceased	O
in	O
six	O
patients	O
because	O
of	O
adverse	O
reactions	O
;	O
in	O
three	O
of	O
these	O
vancomycin	I-Entity
was	O
considered	O
the	O
likely	O
cause	O
.	O

Reactions	O
included	O
thrombophlebitis	I-Entity
(	O
20	O
of	O
54	O
patients	O
)	O
,	O
rash	I-Entity
(	O
4	O
of	O
54	O
)	O
,	O
nephrotoxicity	I-Entity
(	O
4	O
of	O
50	O
)	O
,	O
proteinuria	I-Entity
(	O
1	O
of	O
50	O
)	O
and	O
ototoxicity	I-Entity
(	O
1	O
of	O
11	O
patients	O
tested	O
by	O
audiometry	O
)	O
.	O

Thrombophlebitis	I-Entity
occurred	O
only	O
with	O
infusion	O
through	O
peripheral	O
cannulae	O
;	O
nephrotoxicity	I-Entity
and	O
ototoxicity	I-Entity
were	O
confined	O
to	O
patients	O
receiving	O
an	O
aminoglycoside	I-Entity
plus	O
vancomycin	I-Entity
.	O

We	O
conclude	O
that	O
vancomycin	I-Entity
,	O
administered	O
appropriately	O
,	O
constitutes	O
safe	O
,	O
effective	O
therapy	O
for	O
infections	I-Entity
caused	O
by	O
susceptible	O
bacteria	O
.	O



Blockade	O
of	O
both	O
D-1	O
and	O
D-2	O
dopamine	I-Entity
receptors	O
may	O
induce	O
catalepsy	I-Entity
in	O
mice	O
.	O

The	O
catalepsy	I-Entity
induced	O
by	O
dopamine	I-Entity
antagonists	O
has	O
been	O
tested	O
and	O
the	O
possible	O
dopamine	I-Entity
subtypes	O
involved	O
in	O
catalepsy	I-Entity
was	O
determined	O
.	O

Dopamine	I-Entity
antagonist	O
fluphenazine	I-Entity
,	O
D-1	O
antagonist	O
SCH	B-Entity
23390	I-Entity
or	O

D-2	O
antagonist	O
sulpiride	I-Entity
induced	O
catalepsy	I-Entity
.	O

The	O
effect	O
of	O
fluphenazine	I-Entity
and	O
sulpiride	I-Entity
was	O
dose	O
-	O
dependent	O
.	O

Combination	O
of	O
SCH	B-Entity
23390	I-Entity
with	O
sulpiride	I-Entity
did	O
not	O
induce	O
catalepsy	I-Entity
potentiation	O
.	O

SKF	B-Entity
38393	I-Entity
or	O
D-2	O
agonist	O
quinpirole	I-Entity
decreased	O
the	O
catalepsy	I-Entity
induced	O
by	O
fluphenazine	I-Entity
,	O
SCH	B-Entity
23390	I-Entity
or	O
sulpiride	I-Entity
.	O

4	O
.	O
Combination	O
of	O
SKF	B-Entity
38393	I-Entity
with	O
quinpirole	I-Entity
did	O
not	O
cause	O
potentiated	O
inhibitory	O
effect	O
on	O
catalepsy	I-Entity
induced	O
by	O
dopamine	I-Entity
antagonists	O
.	O

The	O
data	O
may	O
indicate	O
that	O
although	O
D-2	O
receptor	O
blockade	O
is	O
involved	O
in	O
catalepsy	I-Entity
,	O
the	O
D-1	O
receptor	O
may	O
plan	O
a	O
role	O
.	O



Dextran	I-Entity
-	O
etodolac	I-Entity
conjugates	O
:	O
synthesis	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
.	O

Etodolac	I-Entity
(	O
E	I-Entity
)	O
,	O
is	O
a	O
non	O
-	O
narcotic	O
analgesic	O
and	O
antiinflammatory	O
drug	O
.	O

A	O
biodegradable	O
polymer	O
dextran	I-Entity
has	O
been	O
utilized	O
as	O
a	O
carrier	O
for	O
synthesis	O
of	O
etodolac	I-Entity
-	O
dextran	I-Entity
conjugates	O
(	O
ED	O
)	O
to	O
improve	O
its	O
aqueous	O
solubility	O
and	O
reduce	O
gastrointestinal	O
side	O
effects	O
.	O

An	O
activated	O
moiety	O
,	O
i.e.	O
N	B-Entity
-	I-Entity
acylimidazole	I-Entity
derivative	O
of	O
etodolac	I-Entity
(	O
EAI	I-Entity
)	O
,	O
was	O
condensed	O
with	O
the	O
polysaccharide	O
polymer	O
dextran	I-Entity
of	O
different	O
molecular	O
weights	O
(	O
40000	O
,	O
60000	O
,	O
110000	O
and	O
200000	O
)	O
.	O

Etodolac	I-Entity
contents	O
were	O
evaluated	O
by	O
UV	O
-	O
spectrophotometric	O
analysis	O
.	O

At	O
pH	O
9	O
,	O
a	O
higher	O
rate	O
of	O
etodolac	I-Entity
release	O
from	O
ED	O
was	O
observed	O
as	O
compared	O
to	O
aqueous	O
buffer	O
of	O
pH	O
7.4	O
and	O
80%	O
human	O
plasma	O
(	O
pH	O
7.4	O
)	O
,	O
following	O
first	O
-	O
order	O
kinetics	O
.	O

Acute	O
analgesic	O
and	O
antiinflammatory	O
activities	O
were	O
ascertained	O
using	O
acetic	B-Entity
acid	I-Entity
induced	O
writhing	I-Entity
model	O
(	O
mice	O
)	O
and	O
carrageenan	I-Entity
-	O
induced	O
rat	O
paw	O
edema	I-Entity
model	O
,	O
respectively	O
.	O

In	O
comparison	O
to	O
control	O
,	O
E	I-Entity
and	O
ED1-ED4	O
showed	O
highly	O
significant	O
analgesic	O
and	O
antiinflammatory	O
activities	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Biological	O
evaluation	O
suggested	O
that	O
conjugates	O
(	O
ED1-ED4	O
)	O
retained	O
comparable	O
analgesic	O
and	O
antiinflammatory	O
activities	O
with	O
remarkably	O
reduced	O
ulcerogenicity	O
as	O
compared	O
to	O
their	O
parent	O
drug	O
--	O
etodolac	I-Entity
.	O



Hypersensitivity	I-Entity
myocarditis	I-Entity
complicating	O
hypertrophic	B-Entity
cardiomyopathy	I-Entity
heart	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
eosinophilic	B-Entity
myocarditis	I-Entity
complicating	O
hypertrophic	B-Entity
cardiomyopathy	I-Entity
.	O

The	O
47-year	O
-	O
old	O
female	O
patient	O
,	O
known	O
to	O
have	O
hypertrophic	B-Entity
cardiomyopathy	I-Entity
,	O
was	O
admitted	O
with	O
biventricular	B-Entity
failure	I-Entity
and	O
managed	O
aggressively	O
with	O
dobutamine	I-Entity
infusion	O
and	O
other	O
drugs	O
while	O
being	O
assessed	O
for	O
heart	O
transplantation	O
.	O

On	O
transthoracic	O
echocardiogram	O
,	O
she	O
had	O
moderate	O
left	B-Entity
ventricular	I-Entity
dysfunction	I-Entity
with	O
regional	O
variability	O
and	O
moderate	O
mitral	B-Entity
regurgitation	I-Entity
.	O

The	O
recipient	O
's	O
heart	O
showed	O
the	O
features	O
of	O
apical	O
hypertrophic	B-Entity
cardiomyopathy	I-Entity
and	O
myocarditis	I-Entity
with	O
abundant	O
eosinophils	O
.	O

Myocarditis	I-Entity
is	O
rare	O
and	O
eosinophilic	B-Entity
myocarditis	I-Entity
is	O
rarer	O
.	O

It	O
is	O
likely	O
that	O
the	O
hypersensitivity	I-Entity
(	O
eosinophilic	I-Entity
)	O

myocarditis	I-Entity
was	O
related	O
to	O
dobutamine	I-Entity
infusion	O
therapy	O
.	O

Eosinophilic	B-Entity
myocarditis	I-Entity
has	O
been	O
reported	O
with	O
an	O
incidence	O
of	O
2.4%	O
to	O
7.2%	O
in	O
explanted	O
hearts	O
and	O
may	O
be	O
related	O
to	O
multidrug	O
therapy	O
.	O



All-	B-Entity
trans	I-Entity
-	I-Entity
retinoic	I-Entity
acid	I-Entity
-	O
induced	O
erythema	B-Entity
nodosum	I-Entity
in	O
patients	O
with	O
acute	B-Entity
promyelocytic	I-Entity
leukemia	I-Entity
.	O

Erythema	B-Entity
nodosum	I-Entity
associated	O
with	O
all-	B-Entity
trans	I-Entity
-	I-Entity
retinoic	I-Entity
acid	I-Entity
(	O
ATRA	I-Entity
)	O
for	O
acute	B-Entity
promyelocytic	I-Entity
leukemia	I-Entity
(	O
APL	I-Entity
)	O
is	O
very	O
rare	O
.	O

We	O
describe	O
four	O
patients	O
with	O
classic	O
APL	I-Entity
who	O
developed	O
erythema	B-Entity
nodosum	I-Entity
during	O
ATRA	I-Entity
therapy	O
.	O

Fever	I-Entity
and	O
subsequent	O
multiple	O
painful	I-Entity
erythematous	B-Entity
nodules	I-Entity
over	O
extremities	O
developed	O
on	O
D11	O
,	O
D16	O
,	O
D17	O
,	O
and	O
D19	O
,	O
respectively	O
,	O
after	O
ATRA	I-Entity
therapy	O
.	O

The	O
skin	O
biopsy	O
taken	O
from	O
each	O
patient	O
was	O
consistent	O
with	O
erythema	B-Entity
nodosum	I-Entity
.	O

All	O
patients	O
received	O
short	O
course	O
of	O
steroids	I-Entity
.	O

Fever	I-Entity
subsided	O
rapidly	O
and	O
the	O
skin	O
lesions	O
regressed	O
completely	O
.	O

All	O
patients	O
achieved	O
complete	O
remission	O
without	O
withdrawal	O
of	O
ATRA	I-Entity
.	O

ATRA	I-Entity
seemed	O
to	O
be	O
the	O
most	O
possible	O
etiology	O
of	O
erythema	B-Entity
nodosum	I-Entity
in	O
our	O
patients	O
.	O

Short	O
-	O
term	O
use	O
of	O
steroid	I-Entity
is	O
very	O
effective	O
in	O
ATRA	I-Entity
-	O
induced	O
erythema	B-Entity
nodosum	I-Entity
.	O



Delayed	O
-	O
onset	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
.	O

Heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
presents	O
5	O
to	O
12	O
days	O
after	O
heparin	I-Entity
exposure	O
,	O
with	O
or	O
without	O
arterial	B-Entity
or	I-Entity
venous	I-Entity
thromboemboli	I-Entity
.	O

Delayed	O
recognition	O
and	O
treatment	O
of	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
contribute	O
to	O
poor	O
patient	O
outcomes	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
and	O
increase	O
awareness	O
of	O
a	O
clinical	O
scenario	O
in	O
which	O
the	O
onset	O
or	O
manifestations	O
of	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
are	O
delayed	O
.	O

PATIENTS	O
:	O
14	O
patients	O
seen	O
over	O
a	O
3-year	O
period	O
in	O
whom	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
became	O
apparent	O
on	O
delayed	O
presentation	O
with	O
thromboembolic	I-Entity
complications	O
.	O

MEASUREMENTS	O
:	O
Platelet	O
counts	O
,	O
onset	O
of	O
objectively	O
determined	O
thromboembolism	I-Entity
,	O
results	O
of	O
heparin	I-Entity
-	O
induced	O
platelet	O
factor	O
4	O
antibody	O
tests	O
,	O
and	O
outcomes	O
.	O

Patients	O
went	O
home	O
after	O
hospitalizations	O
that	O
had	O
included	O
heparin	I-Entity
exposure	O
--	O
in	O
most	O
cases	O
,	O
with	O
no	O
thrombocytopenia	I-Entity
recognized	O
--	O
only	O
to	O
return	O
to	O
the	O
hospital	O
(	O
median	O
,	O
day	O
14	O
)	O
with	O
thromboembolic	I-Entity
complications	O
.	O

Thromboemboli	I-Entity
were	O
venous	O
(	O
12	O
patients	O
,	O
7	O
with	O
pulmonary	B-Entity
emboli	I-Entity
)	O
or	O
arterial	O
(	O
4	O
patients	O
)	O
or	O
both	O
.	O

On	O
readmission	O
,	O
11	O
patients	O
received	O
therapeutic	O
heparin	I-Entity
,	O
which	O
worsened	O
the	O
patients	O
'	O
clinical	O
condition	O
and	O
,	O
in	O
all	O
11	O
cases	O
,	O
decreased	O
the	O
platelet	O
count	O
(	O
mean	O
at	O
readmission	O
,	O
143	O
x	O
10(9	O
)	O
cells	O
/	O
L	O
;	O
mean	O
nadir	O
after	O
heparin	I-Entity
re	O
-	O
exposure	O
,	O
39	O
x	O
10(9	O
)	O
cells	O
/	O
L	O
)	O
.	O

Results	O
of	O
serologic	O
tests	O
for	O
heparin	I-Entity
-	O
induced	O
antibodies	O
were	O
positive	O
in	O
all	O
patients	O
.	O

Subsequent	O
treatments	O
included	O
alternative	O
anticoagulants	O
(	O
11	O
patients	O
)	O
,	O
thrombolytic	O
drugs	O
(	O
3	O
patients	O
)	O
,	O
inferior	O
vena	O
cava	O
filters	O
(	O
3	O
patients	O
)	O
and	O
,	O
eventually	O
,	O
warfarin	I-Entity
(	O
11	O
patients	O
)	O
.	O

heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
is	O
increasingly	O
being	O
recognized	O
.	O

To	O
avoid	O
disastrous	O
outcomes	O
,	O
physicians	O
must	O
consider	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
whenever	O
a	O
recently	O
hospitalized	O
patient	O
returns	O
with	O
thromboembolism	I-Entity
;	O
therapy	O
with	O
alternative	O
anticoagulants	O
,	O
not	O
heparin	I-Entity
,	O
should	O
be	O
initiated	O
.	O



Valsartan	I-Entity
,	O
a	O
new	O
angiotensin	B-Entity
II	I-Entity
antagonist	O
for	O
the	O
treatment	O
of	O
essential	O
hypertension	I-Entity
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
against	O
amlodipine	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
antihypertensive	O
efficacy	O
of	O
a	O
new	O
angiotensin	B-Entity
II	I-Entity
antagonist	O
,	O
valsartan	I-Entity
,	O
with	O
a	O
reference	O
therapy	O
,	O
amlodipine	I-Entity
.	O

One	O
hundred	O
sixty	O
-	O
eight	O
adult	O
outpatients	O
with	O
mild	O
to	O
moderate	O
hypertension	I-Entity
were	O
randomly	O
allocated	O
in	O
double	O
-	O
blind	O
fashion	O
and	O
equal	O
number	O
to	O
receive	O
80	O
mg	O
valsartan	I-Entity
or	O
5	O
mg	O
amlodipine	I-Entity
for	O
12	O
weeks	O
.	O

After	O
8	O
weeks	O
of	O
therapy	O
,	O
in	O
patients	O
whose	O
blood	O
pressure	O
remained	O
uncontrolled	O
,	O
5	O
mg	O
amlodipine	I-Entity
was	O
added	O
to	O
the	O
initial	O
therapy	O
.	O

Both	O
valsartan	I-Entity
and	O
amlodipine	I-Entity
were	O
effective	O
at	O
lowering	O
blood	O
pressure	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

For	O
the	O
primary	O
variable	O
the	O
difference	O
was	O
0.5	O
mm	O
Hg	O
in	O
favor	O
of	O
valsartan	I-Entity
(	O
p	O
=	O
0.68	O
;	O
95%	O
confidence	O
interval	O
,	O
-2.7	O
to	O
1.7	O
)	O
.	O

Responder	O
rates	O
at	O
8	O
weeks	O
were	O
66.7%	O
for	O
valsartan	I-Entity
and	O
60.2%	O
for	O
amlodipine	I-Entity

The	O
incidence	O
of	O
drug	O
-	O
related	O
dependent	O
edema	I-Entity
was	O
somewhat	O
higher	O
in	O
the	O
amlodipine	I-Entity
group	O
,	O
particularly	O
at	O
a	O
dose	O
of	O
10	O
mg	O
per	O
day	O
(	O
2.4%	O
for	O
80	O
mg	O
valsartan	I-Entity
;	O
3.6%	O
for	O
5	O
mg	O
amlodipine	I-Entity
;	O
0%	O
for	O
valsartan	I-Entity
plus	O
5	O
mg	O
amlodipine	I-Entity
;	O
14.3%	O
for	O
10	O
mg	O
amlodipine	I-Entity
)	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
show	O
that	O
valsartan	I-Entity
is	O
at	O
least	O
as	O
effective	O
as	O
amlodipine	I-Entity
in	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
hypertension	I-Entity
.	O

The	O
results	O
also	O
show	O
valsartan	I-Entity
to	O
be	O
well	O
tolerated	O
and	O
suggest	O
that	O
it	O
is	O
not	O
associated	O
with	O
side	O
effects	O
characteristic	O
of	O
this	O
comparator	O
class	O
,	O
dihydropyridine	I-Entity
calcium	I-Entity
antagonists	O
.	O



KF17837	I-Entity
:	O
a	O
novel	O
selective	O
adenosine	I-Entity
A2A	O
receptor	O
antagonist	O
with	O
anticataleptic	O
activity	O
.	O

KF17837	I-Entity
is	O
a	O
novel	O
selective	O
adenosine	I-Entity
A2A	O
receptor	O
antagonist	O
.	O

Oral	O
administration	O
of	O
KF17837	I-Entity
(	O
2.5	O
,	O
10.0	O
and	O
30.0	O
mg	O
/	O
kg	O
)	O
significantly	O
ameliorated	O
the	O
cataleptic	I-Entity
responses	O
induced	O
by	O
intracerebroventricular	O
administration	O
of	O
an	O
adenosine	I-Entity
A2A	O
receptor	O
agonist	O
,	O
CGS	B-Entity
21680	I-Entity
(	O
10	O
micrograms	O
)	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

KF17837	I-Entity
also	O
reduced	O
the	O
catalepsy	I-Entity
induced	O
by	O
haloperidol	I-Entity
(	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
and	O
by	O
reserpine	I-Entity
(	O
5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

Moreover	O
,	O
KF17837	I-Entity
(	O
0.625	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O

potentiated	O
the	O
anticataleptic	O
effects	O
of	O
a	O
subthreshold	O
dose	O
of	O
L-3,4-dihydroxyphenylalanine	I-Entity
(	O
L	B-Entity
-	I-Entity
DOPA	I-Entity
;	O
25	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O

plus	O
benserazide	I-Entity
(	O
6.25	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

These	O
results	O
suggested	O
that	O
KF17837	I-Entity
is	O
a	O
centrally	O
active	O
adenosine	I-Entity
A2A	O
receptor	O
antagonist	O
and	O
that	O
the	O
dopaminergic	O
function	O
of	O
the	O
nigrostriatal	O
pathway	O
is	O
potentiated	O
by	O
adenosine	I-Entity
A2A	O
receptor	O
antagonists	O
.	O

Furthermore	O
,	O
KF17837	I-Entity
may	O
be	O
a	O
useful	O
drug	O
in	O
the	O
treatment	O
of	O
parkinsonism	I-Entity
.	O



Some	O
central	O
effects	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	I-Entity
.	O

We	O
investigated	O
the	O
effect	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	I-Entity
,	O
a	O
selective	O
serotonin	I-Entity
uptake	O
inhibitor	O
,	O
on	O
behavioral	O
effects	O
of	O
dopaminomimetics	O
and	O
methoxamine	I-Entity
and	O
on	O
the	O
animal	O
behavior	O
in	O
the	O
""""	O
behavioral	O
despair	O
""""	O
test	O
.	O

A	O
repeated	O
treatment	O
with	O
fluvoxamine	I-Entity
(	O
twice	O
daily	O
for	O
14	O
days	O
)	O
potentiated	O
in	O
mice	O
and	O
in	O
rats	O
(	O
weaker	O
)	O
the	O
amphetamine	I-Entity
-	O
induced	O
hyperactivity	I-Entity
.	O

The	O
hyperactivity	I-Entity
induced	O
by	O
nomifensine	I-Entity
in	O
mice	O
remained	O
unaffected	O
by	O
fluvoxamine	I-Entity
.	O

The	O
stimulation	O
of	O
locomotor	O
activity	O
by	O
intracerebroventricularly	O
administered	O
methoxamine	I-Entity
was	O
not	O
affected	O
by	O
repeated	O
treatment	O
with	O
fluvoxamine	I-Entity
.	O

Given	O
three	O
times	O
fluvoxamine	I-Entity
had	O
no	O
effect	O
on	O
the	O
immobilization	O
time	O
in	O
the	O
""""	O
behavioral	O
despair	O
""""	O
test	O
in	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
fluvoxamine	I-Entity
given	O
repeatedly	O
acts	O
differently	O
than	O
citalopram	I-Entity
,	O
another	O
selective	O
serotonin	I-Entity
uptake	O
inhibitor	O
,	O
and	O
differs	O
also	O
from	O
other	O
antidepressant	O
drugs	O
.	O



Severe	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
patient	O
on	O
amiodarone	I-Entity
presenting	O
with	O
myxedemic	B-Entity
coma	I-Entity
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
myxedema	B-Entity
coma	I-Entity
secondary	O
to	O
amiodarone	I-Entity
-	O
induced	O
hypothyroidism	I-Entity
in	O
a	O
patient	O
with	O
severe	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
(	O
CHF	I-Entity
)	O
.	O

To	O
our	O
knowledge	O
and	O
after	O
reviewing	O
the	O
literature	O
there	O
is	O
one	O
case	O
report	O
of	O
myxedema	B-Entity
coma	I-Entity
during	O
long	O
term	O
amiodarone	I-Entity
therapy	O
.	O

Myxedema	B-Entity
coma	I-Entity
is	O
a	O
life	O
threatening	O
condition	O
that	O
carries	O
a	O
mortality	O
reaching	O
as	O
high	O
as	O
20%	O
with	O
treatment	O
.	O

The	O
condition	O
is	O
treated	O
with	O
intravenous	O
thyroxine	I-Entity
(	O
T4	I-Entity
)	O
or	O
intravenous	O
tri	B-Entity
-	I-Entity
iodo	I-Entity
-	I-Entity
thyronine	I-Entity
(	O
T3	I-Entity
)	O
.	O

Patients	O
with	O
CHF	I-Entity
on	O
amiodarone	I-Entity
may	O
suffer	O
serious	O
morbidity	O
and	O
mortality	O
from	O
hypothyroidism	I-Entity
,	O
and	O
thus	O
may	O
deserve	O
closer	O
follow	O
up	O
for	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
.	O

This	O
case	O
report	O
carries	O
an	O
important	O
clinical	O
application	O
given	O
the	O
frequent	O
usage	O
of	O
amiodarone	I-Entity
among	O
CHF	I-Entity
patients	O
.	O

The	O
myriad	O
clinical	O
presentation	O
of	O
myxedema	B-Entity
coma	I-Entity
and	O
its	O
serious	O
morbidity	O
and	O
mortality	O
stresses	O
the	O
need	O
to	O
suspect	O
this	O
clinical	O
syndrome	O
among	O
CHF	I-Entity
patients	O
presenting	O
with	O
hypotension	I-Entity
,	O
weakness	I-Entity
or	O
other	O
unexplained	O
symptoms	O
.	O



Fear	O
-	O
potentiated	O
startle	I-Entity
,	O
but	O
not	O
light	O
-	O
enhanced	O
startle	I-Entity
,	O
is	O
enhanced	O
by	O
anxiogenic	O
drugs	O
.	O

The	O
light	O
-	O
enhanced	O
startle	I-Entity
paradigm	O
(	O
LES	O
)	O
is	O
suggested	O
to	O
model	O
anxiety	I-Entity
,	O
because	O
of	O
the	O
non	O
-	O
specific	O
cue	O
and	O
the	O
long	O
-	O
term	O
effect	O
.	O

In	O
contrast	O
,	O
the	O
fear	O
-	O
potentiated	O
startle	I-Entity
(	O
FPS	O
)	O
is	O
suggested	O
to	O
model	O
conditioned	O
fear	O
.	O

Male	O
Wistar	O
rats	O
received	O
each	O
dose	O
of	O
the	O
alpha(2)-adrenoceptor	O
antagonist	O
yohimbine	I-Entity
(	O
0.25	O
-	O
1.0mg	O
/	O
kg	O
)	O
,	O
the	O
5-HT(2C	I-Entity
)	O
receptor	O
agonist	O
m	B-Entity
-	I-Entity
chlorophenylpiperazine	I-Entity
(	O
mCPP	I-Entity
,	O
0.5	O
-	O
2.0mg	O

/	O
kg	O
)	O
or	O
the	O
GABA(A	I-Entity
)	O
inverse	O
receptor	O
agonist	O
pentylenetetrazole	I-Entity
(	O
PTZ	I-Entity
,	O
3	O
-	O
30mg	O
/	O
kg	O
)	O
and	O
were	O
subsequently	O
tested	O
in	O
either	O
LES	O
or	O
FPS	O
.	O

None	O
of	O
the	O
drugs	O
enhanced	O
LES	O
,	O
whereas	O
mCPP	I-Entity
increased	O
percentage	O
FPS	O
and	O
yohimbine	I-Entity
increased	O
absolute	O
FPS	O
values	O
.	O

Furthermore	O
,	O
yohimbine	I-Entity
increased	O
baseline	O
startle	I-Entity
amplitude	O
in	O
the	O
LES	O
,	O
while	O
mCPP	I-Entity
suppressed	O
baseline	O
startle	I-Entity
in	O
both	O
the	O
LES	O
and	O
FPS	O
and	O
PTZ	I-Entity
suppressed	O
baseline	O
startle	I-Entity
in	O
the	O
FPS	O
.	O



Proteinase	O
3-antineutrophil	O
cytoplasmic	O
antibody-(PR3-ANCA	O
)	O
positive	O
necrotizing	O
glomerulonephritis	I-Entity
after	O
restarting	O
sulphasalazine	I-Entity
treatment	O
.	O

A	O
59-year	O
-	O
old	O
woman	O
with	O
ulcerative	B-Entity
colitis	I-Entity
developed	O
red	B-Entity
eyes	I-Entity
,	O
pleural	B-Entity
effusion	I-Entity
,	O
eosinophilia	I-Entity
and	O
urinary	B-Entity
abnormalities	I-Entity
after	O
restarting	O
of	O
sulphasalazine	I-Entity
treatment	O
.	O

Light	O
microscopy	O
of	O
a	O
kidney	O
biopsy	O
revealed	O
segmental	B-Entity
necrotizing	I-Entity
glomerulonephritis	I-Entity
without	O
deposition	O
of	O
immunoglobulin	O
or	O
complement	O
.	O

PR3-ANCA	O
titer	O
was	O
250	O
and	O
1,070	O
EU	O
in	O
pleural	B-Entity
effusions	I-Entity
on	O
right	O
and	O
left	O
side	O
,	O
respectively	O
.	O

Although	O
cessation	O
of	O
sulphasalazine	I-Entity
treatment	O
resulted	O
in	O
improvements	O
in	O
fever	I-Entity
,	O
red	B-Entity
eyes	I-Entity
,	O
chest	B-Entity
pain	I-Entity
,	O
titer	O
of	O
C	O
-	O
reactive	O
protein	O
and	O
volume	O
of	O
the	O
pleural	B-Entity
effusions	I-Entity
,	O
we	O
initiated	O
steroid	I-Entity
therapy	O
,	O
because	O
PR3-ANCA	O
titer	O
rose	O
to	O
320	O
EU	O
,	O
eosinophil	O
count	O
increased	O
to	O
1,100	O
cells	O
/	O
microl	O
,	O
and	O
the	O
pleural	B-Entity
effusion	I-Entity
remained	O
.	O

One	O
month	O
after	O
steroid	I-Entity
therapy	O
,	O
the	O
pleural	B-Entity
effusion	I-Entity
disappeared	O
,	O
and	O
PR3-ANCA	O
titer	O
normalized	O
3	O
months	O
later	O
.	O

This	O
case	O
suggests	O
that	O
sulphasalazine	I-Entity
can	O
induce	O
PR3-ANCA	O
-	O
positive	O
necrotizing	O
glomerulonephritis	I-Entity
.	O



Is	O
phenytoin	I-Entity
administration	O
safe	O
in	O
a	O
hypothermic	I-Entity
child	O
?	O

A	O
male	O
neonate	O
with	O
a	O
Chiari	B-Entity
malformation	I-Entity
and	O
a	O
leaking	O
myelomeningocoele	O
underwent	O
ventriculoperitoneal	O
shunt	O
insertion	O
followed	O
by	O
repair	O
of	O
myelomeningocoele	O
.	O

During	O
anaesthesia	O
and	O
surgery	O
,	O
he	O
inadvertently	O
became	O
moderately	O
hypothermic	I-Entity
.	O

Intravenous	O
phenytoin	I-Entity
was	O
administered	O
during	O
the	O
later	O
part	O
of	O
the	O
surgery	O
for	O
seizure	I-Entity
prophylaxis	O
.	O

Following	O
phenytoin	I-Entity
administration	O
,	O
the	O
patient	O
developed	O
acute	O
severe	O
bradycardia	I-Entity
,	O
refractory	O
to	O
atropine	I-Entity
and	O
adrenaline	I-Entity
.	O

The	O
cardiac	O
depressant	O
actions	O
of	O
phenytoin	I-Entity
and	O
hypothermia	I-Entity
can	O
be	O
additive	O
.	O

Administration	O
of	O
phenytoin	I-Entity
in	O
the	O
presence	O
of	O
hypothermia	I-Entity
may	O
lead	O
to	O
an	O
adverse	O
cardiac	O
event	O
in	O
children	O
.	O

As	O
phenytoin	I-Entity
is	O
a	O
commonly	O
used	O
drug	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
interaction	O
.	O



Amisulpride	I-Entity
related	O
tic	B-Entity
-	I-Entity
like	I-Entity
symptoms	I-Entity
in	O
an	O
adolescent	O
schizophrenic	I-Entity
.	O

Tic	B-Entity
disorders	I-Entity
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	O
such	O
as	O
risperidone	I-Entity
,	O
olanzapine	I-Entity
and	O
ziprasidone	I-Entity
.	O

However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	B-Entity
-	I-Entity
like	I-Entity
symptoms	I-Entity
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	I-Entity
or	O
clozapine	I-Entity
.	O

We	O
present	O
a	O
15-year	O
-	O
old	O
girl	O
schizophrenic	I-Entity
who	O
developed	O
frequent	O
involuntary	B-Entity
eye	I-Entity
-	I-Entity
blinking	I-Entity
movements	I-Entity
after	O
5	O
months	O
of	O
amisulpride	I-Entity
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O

The	O
tic	B-Entity
-	I-Entity
like	I-Entity
symptoms	I-Entity
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	I-Entity
down	O
to	O
800	O
mg	O
per	O
day	O
.	O

However	O
,	O
her	O
psychosis	I-Entity
recurred	O
after	O
the	O
dose	O
reduction	O
.	O

We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	I-Entity
.	O

No	O
more	O
tic	B-Entity
-	I-Entity
like	I-Entity
symptoms	I-Entity
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O

Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	O
suggests	O
that	O
tic	B-Entity
-	I-Entity
like	I-Entity
symptoms	I-Entity
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
such	O
as	O
quetiapine	I-Entity
,	O
clozapine	I-Entity
,	O
or	O
amisulpride	I-Entity
.	O



Comparison	O
of	O
developmental	O
toxicology	O
of	O
aspirin	I-Entity
(	O
acetylsalicylic	B-Entity
acid	I-Entity
)	O
in	O
rats	O
using	O
selected	O
dosing	O
paradigms	O
.	O

Analysis	O
of	O
the	O
literature	O
for	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
suggests	O
that	O
a	O
low	O
incidence	O
of	O
developmental	B-Entity
anomalies	I-Entity
occurs	O
in	O
rats	O
given	O
NSAIDs	O
on	O
specific	O
days	O
during	O
organogenesis	O
.	O

Aspirin	I-Entity
(	O
acetylsalicylic	B-Entity
acid	I-Entity
[	O
ASA	I-Entity
]	O
)	O
,	O
an	O
irreversible	O
cyclooxygenase	O
1	O
and	O
2	O
inhibitor	O
,	O
induces	O
developmental	B-Entity
anomalies	I-Entity
when	O
administered	O
to	O
Wistar	O
rats	O
on	O
gestational	O
day	O
(	O
GD	O
)	O
9	O
,	O
10	O
,	O
or	O
11	O

There	O
are	O
no	O
published	O
ASA	I-Entity
studies	O
using	O
the	O
multiple	O
dosing	O
paradigm	O
of	O
GDs	O
6	O
to	O
17	O
.	O

Objectives	O
of	O
the	O
current	O
study	O
were	O
to	O
compare	O
results	O
between	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
strains	O
when	O
ASA	I-Entity
is	O
administered	O
on	O
GD	O
9	O
,	O
10	O
,	O
or	O
11	O
;	O
to	O
compare	O
the	O
malformation	O
patterns	O
following	O
single	O
and	O
multiple	O
dosings	O
during	O
organogenesis	O
in	O
SD	O
rats	O
;	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
maternal	O
gastrointestinal	B-Entity
toxicity	I-Entity
confounds	O
the	O
detection	O
of	O
low	O
incidence	O
malformations	I-Entity
with	O
ASA	I-Entity
when	O
a	O
multiple	O
dosing	O
paradigm	O
is	O
used	O
.	O

ASA	I-Entity
was	O
administered	O
as	O
a	O
single	O
dose	O
on	O
GD	O
9	O
(	O
0	O
,	O
250	O
,	O
500	O
,	O
or	O
625	O
mg	O
/	O
kg	O
)	O
,	O
10	O
(	O
0	O
,	O
500	O
,	O
625	O
,	O
or	O
750	O
mg	O
/	O
kg	O
)	O
,	O
or	O
11	O
(	O
0	O
,	O
500	O
,	O
750	O
,	O
or	O
1000	O
mg	O
/	O
kg	O
)	O
and	O
from	O
GD	O
6	O
to	O
GD	O
17	O
(	O
0	O
,	O
50	O
,	O
125	O
,	O
or	O
250	O
mg	O
/	O
kg	O
a	O
day	O
)	O
in	O
the	O
multiple	O
dose	O
study	O
to	O
SD	O
rats	O
.	O

The	O
literature	O
evaluation	O
suggested	O
that	O
NSAIDs	O
induce	O
ventricular	B-Entity
septal	I-Entity
defects	I-Entity
(	O
VSDs	I-Entity
)	O
and	O
midline	B-Entity
defects	I-Entity
(	O
MDs	I-Entity
)	O
in	O
rats	O
and	O
diaphragmatic	B-Entity
hernia	I-Entity
(	O
DH	I-Entity
)	O
,	O
MDs	I-Entity
,	O
and	O
VSDs	I-Entity
in	O
rabbits	O

;	O
hence	O
,	O
the	O
present	O
study	O
focused	O
on	O
these	O
malformations	I-Entity
,	O
even	O
though	O
ASA	I-Entity
induces	O
several	O
other	O
low	O
-	O
incidence	O
malformations	I-Entity
.	O

In	O
single	O
dose	O
studies	O
,	O
DH	I-Entity
,	O
MD	I-Entity
,	O
and	O
VSD	I-Entity
were	O
induced	O
on	O
GDs	O
9	O
and	O
10	O
.	O

VSD	I-Entity
also	O
was	O
noted	O
following	O
treatment	O
on	O
GD	O
11	O
.	O

In	O
contrast	O
,	O
DH	I-Entity
and	O
MD	I-Entity
were	O
noted	O
in	O
the	O
multiple	O
dose	O
study	O
design	O
only	O
in	O
the	O
high	O
-	O
dose	O
group	O
,	O
and	O
VSD	I-Entity
was	O
noted	O
across	O
all	O
dose	O
groups	O
.	O

CONCLUSIONS	O
:	O
High	O
concordance	O
in	O
major	O
developmental	B-Entity
anomalies	I-Entity
between	O
Wistar	O
and	O
SD	O
rats	O
were	O
noted	O
with	O
the	O
exception	O
of	O
VSD	I-Entity
in	O
the	O
SD	O
rats	O
and	O
hydrocephalus	I-Entity
in	O
the	O
Wistar	O
rats	O
.	O

Variations	O
and	O
malformations	I-Entity
were	O
similar	O
when	O
ASA	I-Entity
was	O
administered	O
as	O
a	O
single	O
dose	O
or	O
during	O
the	O
period	O
of	O
organogenesis	O
(	O
GDs	O
6	O
to	O
17	O
)	O
.	O

It	O
was	O
also	O
evident	O
that	O
,	O
by	O
titrating	O
the	O
dose	O
to	O
achieve	O
a	O
maximum	O
tolerated	O
dose	O
,	O
malformations	I-Entity
that	O
normally	O
occur	O
at	O
low	O
incidence	O
,	O
as	O
reported	O
from	O
previous	O
single	O
dose	O
studies	O
,	O
could	O
also	O
be	O
induced	O
with	O
ASA	I-Entity
given	O
at	O
multiple	O
doses	O
.	O



Torsade	B-Entity
de	I-Entity
pointes	I-Entity
induced	O
by	O
metoclopramide	I-Entity
in	O
an	O
elderly	O
woman	O
with	O
preexisting	O
complete	O
left	B-Entity
bundle	I-Entity
branch	I-Entity
block	I-Entity
.	O

There	O
is	O
a	O
growing	O
list	O
of	O
drugs	O
implicated	O
in	O
acquired	O
long	B-Entity
QT	I-Entity
syndrome	I-Entity
and	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
.	O

However	O
,	O
the	O
torsadogenic	O
potential	O
of	O
metoclopramide	I-Entity
,	O
a	O
commonly	O
used	O
antiemetic	O
and	O
prokinetic	O
drug	O
,	O
has	O
not	O
been	O
reported	O
in	O
the	O
literature	O
,	O
despite	O
its	O
chemical	O
similarity	O
to	O
procainamide	I-Entity
.	O

We	O
report	O
on	O
a	O
92-year	O
-	O
old	O
woman	O
with	O
preexisting	O
complete	O
left	B-Entity
bundle	I-Entity
branch	I-Entity
block	I-Entity
who	O
developed	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
after	O
intravenous	O
and	O
oral	O
administration	O
of	O
metoclopramide	I-Entity
.	O

This	O
patient	O
also	O
developed	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
when	O
cisapride	I-Entity
and	O
erythromycin	I-Entity
were	O
given	O
simultaneously	O
.	O

This	O
is	O
the	O
first	O
documentation	O
that	O
metoclopramide	I-Entity
provokes	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
clinically	O
.	O

Metoclopramide	I-Entity
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
risk	O
of	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
.	O



Apomorphine	I-Entity
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

Apomorphine	I-Entity
was	O
the	O
first	O
dopaminergic	O
drug	O
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
.	O

While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
by	O
subcutaneous	O
administration	O
of	O
apomorphine	I-Entity
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O

A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	I-Entity
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	I-Entity
and	O
that	O
apomorphine	I-Entity
rescue	O
injections	O
can	O
reliably	O
revert	O
off	O
-	O
periods	O
even	O
in	O
patients	O
with	O
complex	O
on	O
-	O
off	O
motor	O
swings	O
.	O

Continuous	O
subcutaneous	O
apomorphine	I-Entity
infusions	O
can	O
reduce	O
daily	O
off	O
-	O
time	O
by	O
more	O
than	O
50%	O
in	O
this	O
group	O
of	O
patients	O
,	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add	O
-	O
on	O
therapy	O
with	O
oral	O
dopamine	I-Entity
agonists	O
or	O
COMT	O
inhibitors	O
.	O

Extended	O
follow	O
-	O
up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long	O
-	O
term	O
persistence	O
of	O
apomorphine	I-Entity
efficacy	O
.	O

In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	I-Entity
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
.	O

The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	I-Entity
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	I-Entity
complications	O
play	O
a	O
lesser	O
role	O
.	O

Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	I-Entity
treatment	O
in	O
fluctuating	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O



Fatal	O
excited	O
delirium	I-Entity
following	O
cocaine	I-Entity
use	O
:	O
epidemiologic	O
findings	O
provide	O
new	O
evidence	O
for	O
mechanisms	O
of	O
cocaine	I-Entity
toxicity	I-Entity
.	O

We	O
describe	O
an	O
outbreak	O
of	O
deaths	O
from	O
cocaine	I-Entity
-	O
induced	O
excited	O
delirium	I-Entity
(	O
EDDs	I-Entity
)	O
in	O
Dade	O
County	O
,	O
Florida	O
between	O
1979	O
and	O
1990	O
.	O

From	O
a	O
registry	O
of	O
all	O
cocaine	I-Entity
-	O
related	O
deaths	O
in	O
Dade	O
County	O
,	O
Florida	O
,	O
from	O
1969	O
-	O
1990	O
,	O
58	O
EDDs	I-Entity
were	O
compared	O
with	O
125	O
victims	O
of	O
accidental	O
cocaine	I-Entity
overdose	I-Entity
without	O
excited	O
delirium	I-Entity
.	O

Compared	O
with	O
controls	O
,	O
EDDs	I-Entity
were	O
more	O
frequently	O
black	O
,	O
male	O
,	O
and	O
younger	O
.	O

They	O
were	O
less	O
likely	O
to	O
have	O
a	O
low	O
body	O
mass	O
index	O
,	O
and	O
more	O
likely	O
to	O
have	O
died	O
in	O
police	O
custody	O
,	O
to	O
have	O
received	O
medical	O
treatment	O
immediately	O
before	O
death	O
,	O
to	O
have	O
survived	O
for	O
a	O
longer	O
period	O
,	O
to	O
have	O
developed	O
hyperthermia	I-Entity
,	O
and	O
to	O
have	O
died	O
in	O
summer	O
months	O
.	O

EDDs	I-Entity
had	O
concentrations	O
of	O
cocaine	I-Entity
and	O
benzoylecgonine	I-Entity
in	O
autopsy	O
blood	O
that	O
were	O
similar	O
to	O
those	O
for	O
controls	O
.	O

The	O
epidemiologic	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
hypothesis	O
that	O
chronic	O
cocaine	I-Entity
use	O
disrupts	O
dopaminergic	O
function	O
and	O
,	O
when	O
coupled	O
with	O
recent	O
cocaine	I-Entity
use	O
,	O
may	O
precipitate	O
agitation	I-Entity
,	O
delirium	I-Entity
,	O
aberrant	O
thermoregulation	O
,	O
rhabdomyolysis	I-Entity
,	O
and	O
sudden	B-Entity
death	I-Entity
.	O



Heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
,	O
thrombosis	I-Entity
,	O
and	O
hemorrhage	I-Entity
.	O

Sixty	O
-	O
two	O
patients	O
with	O
a	O
heparin	I-Entity
-	O
induced	O
thrombocytopenia	I-Entity
are	O
reported	O
.	O

Clinical	O
manifestations	O
of	O
this	O
disorder	O
include	O
hemorrhage	I-Entity
or	O
,	O
more	O
frequently	O
,	O
thromboembolic	I-Entity
events	O
in	O
patients	O
receiving	O
heparin	I-Entity
.	O

Laboratory	O
testing	O
has	O
revealed	O
a	B-Entity
falling	I-Entity
platelet	I-Entity
count	I-Entity
,	O
increased	O
resistance	O
to	O
heparin	I-Entity
,	O
and	O
aggregation	O
of	O
platelets	O
by	O
the	O
patient	O
's	O
plasma	O
when	O
heparin	I-Entity
is	O
added	O
.	O

Immunologic	O
testing	O
has	O
demonstrated	O
the	O
presence	O
of	O
a	O
heparin	I-Entity
-	O
dependent	O
platelet	O
membrane	O
antibody	O
.	O

The	O
20	O
deaths	O
,	O
52	O
hemorrhagic	B-Entity
and	I-Entity
thromboembolic	I-Entity
complications	I-Entity
,	O
and	O
21	O
surgical	O
procedures	O
to	O
manage	O
the	O
complications	O
confirm	O
the	O
seriousness	O
of	O
the	O
disorder	O
.	O

Specific	O
risk	O
factors	O
have	O
not	O
been	O
identified	O
;	O
therefore	O
,	O
all	O
patients	O
receiving	O
heparin	I-Entity
should	O
be	O
monitored	O
.	O

If	O
the	O
platelet	O
count	O
falls	O
to	O
less	O
than	O
100,000/mm3	O
,	O
while	O
the	O
patient	O
is	O
receiving	O
heparin	I-Entity
,	O
platelet	B-Entity
aggregation	I-Entity
testing	O
,	O
using	O
the	O
patient	O
's	O
plasma	O
,	O
is	O
indicated	O
.	O

Management	O
consists	O
of	O
cessation	O
of	O
heparin	I-Entity
,	O
platelet	O
anti	O
-	O
aggregating	O
agents	O
,	O
and	O
alternate	O
forms	O
of	O
anticoagulation	O
when	O
indicated	O
.	O



Cardiac	B-Entity
toxicity	I-Entity
of	O
5-fluorouracil	I-Entity
.	O

Report	O
of	O
a	O
case	O
of	O
spontaneous	O
angina	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
colon	B-Entity
carcinoma	I-Entity
and	O
liver	O
metastasis	I-Entity
who	O
presented	O
chest	B-Entity
pain	I-Entity
after	O
5-fluorouracil	I-Entity
(	O
5-FU	I-Entity
)	O
administration	O
.	O

Clinical	O
electrocardiographic	O
evolution	O
was	O
similar	O
to	O
that	O
observed	O
in	O
Prinzmetal	B-Entity
's	I-Entity
angina	I-Entity
,	O
and	O
chest	B-Entity
pain	I-Entity
promptly	O
resolved	O
with	O
nifedipine	I-Entity
.	O

These	O
data	O
suggest	O
that	O
coronary	B-Entity
spasm	I-Entity
may	O
be	O
the	O
cause	O
of	O
cardiotoxicity	I-Entity
due	O
to	O
5-FU	I-Entity
,	O
and	O
that	O
calcium	I-Entity
antagonists	O
may	O
probably	O
be	O
used	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
5-FU	I-Entity
cardiotoxicity	I-Entity
.	O



Toxicity	I-Entity
due	O
to	O
remission	O
inducing	O
drugs	O
in	O
rheumatoid	B-Entity
arthritis	I-Entity
.	O

Twenty	O
-	O
five	O
patients	O
with	O
rheumatoid	B-Entity
arthritis	I-Entity
(	O
RA	I-Entity
)	O
who	O
developed	O
toxicity	I-Entity
while	O
taking	O
remission	O
inducing	O
drugs	O
and	O
30	O
without	O
toxicity	I-Entity
were	O
studied	O
for	O
possible	O
associations	O
with	O
class	O
I	O
and	O
II	O
HLA	O
antigens	O
.	O

A	O
strong	O
association	O
has	O
been	O
found	O
between	O
nephritis	I-Entity
and	O
dermatitis	I-Entity
due	O
to	O
Tiopronin	I-Entity
(	O
a	O
D	B-Entity
-	I-Entity
Penicillamine	I-Entity
like	O
compound	O
)	O
and	O
class	O
I	O
antigens	O
B35-Cw4	O
,	O
and	O
between	O
dermatitis	I-Entity
due	O
to	O
gold	I-Entity
thiosulphate	I-Entity
and	O
B35	O
.	O

Compared	O
to	O
healthy	O
controls	O
a	O
lower	O
DR5	O
frequency	O
was	O
observed	O
in	O
patients	O
with	O
RA	I-Entity
except	O
for	O
the	O
Tiopronin	I-Entity
related	O
nephritis	I-Entity
group	O
.	O



Transient	O
hemiparesis	I-Entity
:	O
a	O
rare	O
manifestation	O
of	O
diphenylhydantoin	I-Entity
toxicity	I-Entity
.	O

Among	O
the	O
common	O
side	O
effects	O
of	O
diphenylhydantoin	I-Entity
(	O
DPH	I-Entity
)	O
overdose	I-Entity
,	O
the	O
most	O
frequently	O
encountered	O
neurological	O
signs	O
are	O
those	O
of	O
cerebellar	B-Entity
dysfunction	I-Entity
.	O

Two	O
patients	O
are	O
presented	O
who	O
suffered	O
progressive	O
hemiparesis	I-Entity
due	O
to	O
DPH	I-Entity
overdose	I-Entity
.	O

Both	O
had	O
brain	O
surgery	O
before	O
DPH	I-Entity
treatment	O
.	O

It	O
is	O
assumed	O
that	O
patients	O
with	O
some	O
cerebral	B-Entity
damage	I-Entity
are	O
liable	O
to	O
manifest	O
DPH	I-Entity
toxicity	I-Entity
as	O
focal	O
neurological	O
signs	O
.	O



Nerve	O
growth	O
factor	O
and	O
prostaglandins	I-Entity
in	O
the	O
urine	O
of	O
female	O
patients	O
with	O
overactive	B-Entity
bladder	I-Entity
.	O

NGF	O
and	O
PGs	I-Entity
in	O
the	O
bladder	O
can	O
be	O
affected	O
by	O
pathological	O
changes	O
in	O
the	O
bladder	O
and	O
these	O
changes	O
can	O
be	O
detected	O
in	O
urine	O
.	O

We	O
investigated	O
changes	O
in	O
urinary	O
NGF	O
and	O
PGs	I-Entity
in	O
women	O
with	O
OAB	I-Entity
.	O

The	O
study	O
groups	O
included	O
65	O
women	O
with	O
OAB	I-Entity
and	O
20	O
without	O
bladder	O
symptoms	O
who	O
served	O
as	O
controls	O
.	O

NGF	O
,	O
PGE2	I-Entity
,	O
PGF2alpha	I-Entity
and	O
PGI2	I-Entity
were	O
measured	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
correlations	O
between	O
urinary	O
NGF	O
and	O
PG	I-Entity
,	O
and	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	I-Entity
were	O
examined	O
.	O

Urinary	O
NGF	O
,	O
PGE2	I-Entity
and	O
PGF2alpha	I-Entity
were	O
significantly	O
increased	O
in	O
patients	O
with	O
OAB	I-Entity
compared	O
with	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
.	O

However	O
,	O
urinary	O
PGI2	I-Entity
was	O
not	O
different	O
between	O
controls	O
and	O
patients	O
with	O
OAB	I-Entity
.	O

In	O
patients	O
with	O
OAB	I-Entity
urinary	O
PGE2	I-Entity
positively	O
correlated	O
with	O
volume	O
at	O
first	O
desire	O
to	O
void	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Urinary	O
NGF	O
,	O
PGF2alpha	I-Entity
and	O
PGI2	I-Entity
did	O
not	O
correlate	O
with	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	I-Entity
.	O

NGF	O
and	O
PGs	I-Entity
have	O
important	O
roles	O
in	O
the	O
development	O
of	O
OAB	I-Entity
symptoms	O
in	O
female	O
patients	O
.	O

Urinary	O
levels	O
of	O
these	O
factors	O
may	O
be	O
used	O
as	O
markers	O
to	O
evaluate	O
OAB	I-Entity
symptoms	O
.	O



Acute	O
low	B-Entity
back	I-Entity
pain	I-Entity
during	O
intravenous	O
administration	O
of	O
amiodarone	I-Entity
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Amiodarone	I-Entity
represents	O
an	O
effective	O
antiarrhythmic	O
drug	O
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	B-Entity
fibrillation	I-Entity
(	O
AF	I-Entity
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O

We	O
briefly	O
describe	O
two	O
patients	O
suffering	O
from	O
recent	O
-	O
onset	O
atrial	B-Entity
fibrillation	I-Entity
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	B-Entity
back	I-Entity
pain	I-Entity
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	I-Entity
loading	O
.	O



Postoperative	B-Entity
myalgia	I-Entity
after	O
succinylcholine	I-Entity
:	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
.	O

A	O
common	O
side	O
effect	O
associated	O
with	O
succinylcholine	I-Entity
is	O
postoperative	B-Entity
myalgia	I-Entity
.	O

The	O
pathogenesis	O
of	O
this	O
myalgia	I-Entity
is	O
still	O
unclear	O
;	O
inflammation	I-Entity
has	O
been	O
suggested	O
but	O
without	O
convincing	O
evidence	O
.	O

We	O
designed	O
the	O
present	O
study	O
to	O
investigate	O
whether	O
an	O
inflammatory	O
reaction	O
contributes	O
to	O
this	O
myalgia	I-Entity
.	O

The	O
incidence	O
and	O
severity	O
of	O
succinylcholine	I-Entity
-	O
associated	O
myalgia	I-Entity
was	O
determined	O
in	O
64	O
patients	O
pretreated	O
with	O
saline	O
or	O
dexamethasone	I-Entity
before	O
succinylcholine	I-Entity
(	O
n	O
=	O
32	O
for	O
each	O
)	O
.	O

Incidence	O
and	O
severity	O
of	O
myalgia	I-Entity
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
15	O
patients	O
in	O
the	O
dexamethasone	I-Entity
group	O
complained	O
of	O
myalgia	I-Entity
compared	O
with	O
18	O
patients	O
in	O
the	O
saline	O
group	O
,	O
and	O
severe	O
myalgia	I-Entity
was	O
reported	O
by	O
five	O
patients	O
and	O
three	O
patients	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
.	O

At	O
48	O
h	O
after	O
surgery	O
,	O
12	O
patients	O
in	O
both	O
groups	O
still	O
suffered	O
from	O
myalgia	I-Entity
(	O
not	O
significant	O
)	O
.	O

In	O
addition	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
as	O
an	O
early	O
marker	O
of	O
inflammation	I-Entity
was	O
assessed	O
in	O
a	O
subgroup	O
of	O
10	O
patients	O
pretreated	O
with	O
saline	O
.	O

We	O
found	O
an	O
increase	O
of	O
IL-6	O
for	O
only	O
three	O
patients	O
,	O
but	O
only	O
one	O
patient	O
reported	O
myalgia	I-Entity
;	O
no	O
relationship	O
between	O
myalgia	I-Entity
and	O
the	O
increase	O
of	O
IL-6	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
of	O
succinylcholine	I-Entity
-	O
associated	O
myalgia	I-Entity
.	O

Administration	O
of	O
dexamethasone	I-Entity
before	O
succinylcholine	I-Entity
was	O
not	O
effective	O
in	O
decreasing	O
the	O
incidence	O
or	O
the	O
severity	O
of	O
succinylcholine	I-Entity
-	O
induced	O
postoperative	B-Entity
myalgia	I-Entity
.	O

Furthermore	O
,	O
there	O
was	O
no	O
significant	O
relationship	O
between	O
postoperative	B-Entity
myalgia	I-Entity
and	O
time	O
course	O
of	O
interleukin-6	O
concentrations	O
,	O
a	O
marker	O
of	O
inflammation	I-Entity
.	O

Pretreatment	O
with	O
dexamethasone	I-Entity
is	O
not	O
justified	O
to	O
prevent	O
postoperative	B-Entity
myalgia	I-Entity
after	O
succinylcholine	I-Entity
.	O



Levodopa	I-Entity
-	O
induced	O
oromandibular	O
dystonia	I-Entity
in	O
progressive	B-Entity
supranuclear	I-Entity
palsy	I-Entity
.	O

Levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
have	O
been	O
reported	O
in	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
and	O
multiple	B-Entity
system	I-Entity
atrophy	I-Entity
.	O

Cranial	O
dystonias	I-Entity
are	O
rare	O
in	O
patients	O
with	O
progressive	B-Entity
supranuclear	I-Entity
palsy	I-Entity
(	O
PSP	I-Entity
)	O
.	O

In	O
this	O
report	O
we	O
describe	O
an	O
unusual	O
case	O
of	O
reversible	O
levodopa	I-Entity
-	O
induced	O
Oromandibular	B-Entity
dystonia	I-Entity
(	O
OMD	I-Entity
)	O
in	O
a	O
PSP	I-Entity
patient	O
to	O
highlight	O
the	O
importance	O
of	O
recognizing	O
this	O
drug	O
related	O
complication	O
in	O
the	O
management	O
of	O
PSP	I-Entity
,	O
and	O
discuss	O
the	O
possible	O
underlying	O
pathophysiology	O
.	O



Protective	O
effect	O
of	O
edaravone	I-Entity
against	O
streptomycin	I-Entity
-	O
induced	O
vestibulotoxicity	I-Entity
in	O
the	O
guinea	O
pig	O
.	O

This	O
study	O
investigated	O
alleviation	O
of	O
streptomycin	I-Entity
-	O
induced	O
vestibulotoxicity	I-Entity
by	O
edaravone	I-Entity
in	O
guinea	O
pigs	O
.	O

Edaravone	I-Entity
,	O
a	O
free	O
radical	O
scavenger	O
,	O
has	O
potent	O
free	O
radical	O
quenching	O
action	O
and	O
is	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
cerebral	B-Entity
infarction	I-Entity
.	O

Streptomycin	I-Entity
was	O
administered	O
to	O
the	O
inner	O
ear	O
by	O
osmotic	O
pump	O
for	O
24	O
h	O
,	O
and	O
edaravone	I-Entity
(	O
n=8	O
)	O
or	O
saline	O
(	O
n=6	O
)	O
was	O
intraperitoneally	O
injected	O
once	O
a	O
day	O
for	O
7	O
days	O
.	O

Animals	O
injected	O
with	O
saline	O
showed	O
statistically	O
smaller	O
gains	O
than	O
those	O
injected	O
with	O
edaravone	I-Entity
.	O

These	O
results	O
suggest	O
that	O
edaravone	I-Entity
suppresses	O
streptomycin	I-Entity
-	O
induced	O
vestibulotoxicity	I-Entity
.	O



Ketamine	I-Entity
in	O
war	O
/	O
tropical	O
surgery	O
(	O
a	O
final	O
tribute	O
to	O
the	O
racemic	O
mixture	O
)	O
.	O

A	O
technique	O
of	O
continuous	O
intravenous	O
anaesthesia	O
with	O
ketamine	I-Entity
was	O
used	O
successfully	O
during	O
the	O
Somalia	O
civil	O
war	O
in	O
1994	O
and	O
in	O
north	O
Uganda	O
in	O
1999	O
for	O
64	O
operations	O
in	O
62	O
patients	O
,	O
aged	O
from	O
6	O
weeks	O
to	O
70	O
years	O
,	O
undergoing	O
limb	O
and	O
abdominal	O
surgery	O
including	O
caesarian	O
sections	O
and	O
interventions	O
in	O
neonates	O
.	O

Operations	O
lasting	O
up	O
to	O
2h	O
could	O
be	O
performed	O
in	O
the	O
absence	O
of	O
sophisticated	O
equipment	O
such	O
as	O
pulse	O
oximeters	O
or	O
ventilators	O
in	O
patients	O
on	O
spontaneous	O
ventilation	O
breathing	O
air	O
/	O
oxygen	I-Entity
only	O
.	O

After	O
premedication	O
with	O
diazepam	I-Entity
,	O
glycopyrrolate	I-Entity
and	O
local	O
anaesthesia	O
,	O
and	O
induction	O
with	O
standard	O
doses	O
of	O
ketamine	I-Entity
,	O
a	O
maintenance	O
dose	O
of	O
10	O
-	O
20	O
microg	O
/	O
kg	O

/	O
min	O
of	O
ketamine	I-Entity
proved	O
safe	O
and	O
effective	O
.	O

Diazepam	I-Entity
,	O
unless	O
contraindicated	O
or	O
risky	O
,	O
remains	O
the	O
only	O
necessary	O
complementary	O
drug	O
to	O
ketamine	I-Entity
as	O
it	O
buffers	O
its	O
cardiovascular	O
response	O
and	O
decreases	O
the	O
duration	O
and	O
intensity	O
of	O
operative	O
and	O
postoperative	O
hallucinations	I-Entity
.	O

Local	O
anaesthetic	O
blocks	O
were	O
useful	O
in	O
decreasing	O
the	O
requirement	O
for	O
postoperative	O
analgesia	I-Entity
.	O

An	O
antisialogue	O
was	O
usually	O
unnecessary	O
in	O
operations	O
lasting	O
up	O
to	O
2	O
h	O
,	O
glycopyrrolate	I-Entity
being	O
the	O
best	O
choice	O
for	O
its	O
lowest	O
psychotropic	O
and	O
chronotropic	O
effects	O
,	O
especially	O
in	O
a	O
hot	O
climate	O
.	O



Steroid	I-Entity
structure	O
and	O
pharmacological	O
properties	O
determine	O
the	O
anti	O
-	O
amnesic	I-Entity
effects	O
of	O
pregnenolone	B-Entity
sulphate	I-Entity
in	O
the	O
passive	O
avoidance	O
task	O
in	O
rats	O
.	O

Pregnenolone	B-Entity
sulphate	I-Entity
(	O
PREGS	I-Entity
)	O
has	O
generated	O
interest	O
as	O
one	O
of	O
the	O
most	O
potent	O
memory	O
-	O
enhancing	O
neurosteroids	O
to	O
be	O
examined	O
in	O
rodent	O
learning	O
studies	O
,	O
with	O
particular	O
importance	O
in	O
the	O
ageing	O
process	O
.	O

The	O
mechanism	O
by	O
which	O
this	O
endogenous	O
steroid	I-Entity
enhances	O
memory	O
formation	O
is	O
hypothesized	O
to	O
involve	O
actions	O
on	O
glutamatergic	O
and	O
GABAergic	O
systems	O
.	O

This	O
hypothesis	O
stems	O
from	O
findings	O
that	O
PREGS	I-Entity
is	O
a	O
potent	O
positive	O
modulator	O
of	O
N	B-Entity
-	I-Entity
methyl	I-Entity
-	I-Entity
d	I-Entity
-	I-Entity
aspartate	I-Entity
receptors	O
(	O
NMDARs	O
)	O
and	O
a	O
negative	O
modulator	O
of	O
gamma	B-Entity
-	I-Entity
aminobutyric	I-Entity
acid(A	I-Entity
)	O
receptors	O
(	O
GABA(A)Rs	I-Entity
)	O
.	O

Moreover	O
,	O
PREGS	I-Entity
is	O
able	O
to	O
reverse	O
the	O
amnesic	I-Entity
-	O
like	O
effects	O
of	O
NMDAR	O
and	O
GABA(A)R	I-Entity
ligands	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
the	O
present	O
study	O
in	O
rats	O
examined	O
the	O
memory	O
-	O
altering	O
abilities	O
of	O
structural	O
analogs	O
of	O
PREGS	I-Entity
,	O
which	O
differ	O
in	O
their	O
modulation	O
of	O
NMDAR	O
and/or	O
GABA(A)R	I-Entity
function	O
.	O

The	O
analogs	O
tested	O
were	O
:	O
11-ketopregnenolone	B-Entity
sulphate	I-Entity
(	O
an	O
agent	O
that	O
is	O
inactive	O
at	O
GABA(A)Rs	I-Entity
and	O
NMDARs	O
)	O
,	O
epipregnanolone	B-Entity
(	I-Entity
[	I-Entity
3beta	I-Entity
-	I-Entity
hydroxy-5beta	I-Entity
-	I-Entity
pregnan-20-one	I-Entity
]	I-Entity
sulphate	I-Entity
,	O
an	O
inhibitor	O
of	O
both	O
GABA(A)Rs	I-Entity
and	O
NMDARs	O
)	O
,	O
and	O
a	O
newly	O
synthesized	O
(	O
-	O
)	O

PREGS	I-Entity
enantiomer	O
(	O
which	O
is	O
identical	O
to	O
PREGS	I-Entity
in	O
effects	O
on	O
GABA(A)Rs	I-Entity
and	O
NMDARs	O
)	O
.	O

The	O
memory	O
-	O
enhancing	O
effects	O
of	O
PREGS	I-Entity
and	O
its	O
analogs	O
were	O
tested	O
in	O
the	O
passive	O
avoidance	O
task	O
using	O
the	O
model	O
of	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
.	O

Both	O
PREGS	I-Entity
and	O
its	O
(	O
-	O
)	O
enantiomer	O
blocked	O
the	O
effects	O
of	O
scopolamine	I-Entity
.	O

The	O
results	O
show	O
that	O
,	O
unlike	O
PREGS	I-Entity
,	O
11-ketopregnenolone	B-Entity
sulphate	I-Entity
and	O
epipregnanolone	B-Entity
sulphate	I-Entity
failed	O
to	O
block	O
the	O
effect	O
of	O
scopolamine	I-Entity
,	O
suggesting	O
that	O
altering	O
the	O
modulation	O
of	O
NMDA	I-Entity
receptors	O
diminishes	O
the	O
memory	O
-	O
enhancing	O
effects	O
of	O
PREGS	I-Entity
.	O

Moreover	O
,	O
enantioselectivity	O
was	O
demonstrated	O
by	O
the	O
ability	O
of	O
natural	O
PREGS	I-Entity
to	O
be	O
an	O
order	O
of	O
magnitude	O
more	O
effective	O
than	O
its	O
synthetic	O
enantiomer	O
in	O
reversing	O
scopolamine	I-Entity
-	O
induced	O
amnesia	I-Entity
.	O

These	O
results	O
identify	O
a	O
novel	O
neuropharmacological	O
site	O
for	O
the	O
modulation	O
of	O
memory	O
processes	O
by	O
neuroactive	O
steroids	I-Entity
.	O



Preliminary	O
efficacy	O
assessment	O
of	O
intrathecal	O
injection	O
of	O
an	O
American	O
formulation	O
of	O
adenosine	I-Entity
in	O
humans	O
.	O

Preclinical	O
studies	O
of	O
intrathecal	O
adenosine	I-Entity
suggest	O
it	O
may	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
acute	B-Entity
and	I-Entity
chronic	I-Entity
pain	I-Entity
in	O
humans	O
,	O
and	O
preliminary	O
studies	O
in	O
volunteers	O
and	O
patients	O
with	O
a	O
Swedish	O
formulation	O
of	O
adenosine	I-Entity
suggests	O
it	O
may	O
be	O
effective	O
in	O
hypersensitivity	I-Entity
states	O
but	O
not	O
with	O
acute	O
noxious	O
stimulation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
screen	O
for	O
efficacy	O
of	O
a	O
different	O
formulation	O
of	O
adenosine	I-Entity
marketed	O
in	O
the	O
US	O
,	O
using	O
both	O
acute	O
noxious	O
stimulation	O
and	O
capsaicin	I-Entity
-	O
evoked	O
mechanical	O
hypersensitivity	I-Entity
.	O

Following	O
Food	O
and	O
Drug	O
Administration	O
and	O
institutional	O
review	O
board	O
approval	O
and	O
written	O
informed	O
consent	O
,	O
65	O
volunteers	O
were	O
studied	O
in	O
two	O
trials	O
:	O
an	O
open	O
-	O
label	O
,	O
dose	O
-	O
escalating	O
trial	O
with	O
intrathecal	O
adenosine	I-Entity
doses	O
of	O
0.25	O
-	O
2.0	O
mg	O
and	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
adenosine	I-Entity
,	O
2	O
mg	O
.	O

Cerebrospinal	O
fluid	O
was	O
obtained	O
for	O
pharmacokinetic	O
analysis	O
,	O
and	O
pain	I-Entity
ratings	O
in	O
response	O
to	O
acute	O
heat	O
stimuli	O
and	O
areas	O
of	O
mechanical	B-Entity
hyperalgesia	I-Entity
and	O
allodynia	I-Entity
after	O
intradermal	O
capsaicin	I-Entity
injection	O
were	O
determined	O
.	O

Adenosine	I-Entity
produced	O
no	O
effect	O
on	O
pain	I-Entity
report	O
to	O
acute	O
noxious	O
thermal	O
or	O
chemical	O
stimulation	O
but	O
reduced	O
mechanical	B-Entity
hyperalgesia	I-Entity
and	O
allodynia	I-Entity
from	O
intradermal	O
capsaicin	I-Entity
injection	O
for	O
at	O
least	O
24	O
h.	O

In	O
contrast	O
,	O
residence	O
time	O
of	O
adenosine	I-Entity
in	O
cerebrospinal	O
fluid	O
was	O
short	O
(	O
<	O
4	O
h	O
)	O
.	O

These	O
results	O
show	O
selective	O
inhibition	O
by	O
intrathecal	O
adenosine	I-Entity
of	O
hypersensitivity	I-Entity
,	O
presumed	O
to	O
reflect	O
central	O
sensitization	O
in	O
humans	O
after	O
peripheral	O
capsaicin	I-Entity
injection	O
.	O

The	O
long	O
-	O
lasting	O
effect	O
is	O
consistent	O
with	O
that	O
observed	O
in	O
preliminary	O
reports	O
of	O
patients	O
with	O
chronic	O
neuropathic	B-Entity
pain	I-Entity
and	O
is	O
not	O
due	O
to	O
prolonged	O
residence	O
of	O
adenosine	I-Entity
in	O
cerebrospinal	O
fluid	O
.	O



Effect	O
of	O
lithium	I-Entity
maintenance	O
therapy	O
on	O
thyroid	O
and	O
parathyroid	O
function	O
.	O

To	O
assess	O
changes	O
induced	O
by	O
lithium	I-Entity
maintenance	O
therapy	O
on	O
the	O
incidence	O
of	O
thyroid	O
,	O
parathyroid	O
and	O
ion	O
alterations	O
.	O

These	O
were	O
evaluated	O
with	O
respect	O
to	O
the	O
duration	O
of	O
lithium	I-Entity
therapy	O
,	O
age	O
,	O
sex	O
,	O
and	O
family	O
history	O
(	O
whether	O
or	O
not	O
the	O
patient	O
had	O
a	O
first	O
-	O
degree	O
relative	O
with	O
thyroid	B-Entity
disease	I-Entity
)	O
.	O

One	O
hundred	O
and	O
one	O
patients	O
(	O
28	O
men	O
and	O
73	O
women	O
)	O
with	O
bipolar	B-Entity
disorder	I-Entity
receiving	O
lithium	I-Entity
maintenance	O
therapy	O
ranging	O
from	O
1	O
year	O
's	O
to	O
32	O
years	O
'	O
duration	O
.	O

The	O
control	O
group	O
consisted	O
of	O
82	O
patients	O
with	O
no	O
psychiatric	I-Entity
or	O
endocrinological	O
diagnoses	O
from	O
the	O
hospital	O
's	O
out	O
-	O
patient	O
clinics	O
.	O

Laboratory	O
analyses	O
of	O
calcium	I-Entity
,	O
magnesium	I-Entity
and	O
thyroid	O
-	O
stimulating	O
hormone	O
levels	O
performed	O
before	O
beginning	O
lithium	I-Entity
therapy	O
and	O
at	O
biannual	O
follow	O
-	O
up	O
.	O

Hypothyroidism	I-Entity
developed	O
in	O
40	O
patients	O
,	O
excluding	O
8	O
patients	O
who	O
were	O
hypothyroid	I-Entity
at	O
baseline	O
.	O

All	O
patients	O
having	O
first	O
-	O
degree	O
relatives	O
affected	O
by	O
thyroid	B-Entity
illness	I-Entity
had	O
accelerated	O
onset	O
of	O
hypothyroidism	I-Entity
(	O
3.7	O
years	O
after	O
onset	O
of	O
lithium	I-Entity
therapy	O
)	O
compared	O
with	O
patients	O
without	O
a	O
family	O
history	O
(	O
8.6	O
years	O
after	O
onset	O
of	O
lithium	I-Entity
therapy	O
)	O
.	O

Women	O
over	O
60	O
years	O
of	O
age	O
were	O
more	O
often	O
affected	O
by	O
hypothyroidism	I-Entity
than	O
women	O
under	O
60	O
years	O
of	O
age	O
(	O
34.6%	O
versus	O
31.9%	O
)	O
.	O

Magnesium	I-Entity
levels	O
in	O
patients	O
on	O
lithium	I-Entity
treatment	O
were	O
unchanged	O
from	O
baseline	O
levels	O
.	O

After	O
lithium	I-Entity
treatment	O
,	O
calcium	I-Entity
levels	O
were	O
higher	O
than	O
either	O
baseline	O
levels	O
or	O
control	O
levels	O
.	O

Thus	O
,	O
lithium	I-Entity
treatment	O
counteracted	O
the	O
decrease	O
in	O
plasma	O
calcium	I-Entity
levels	O
associated	O
with	O
aging	O
.	O

CONCLUSIONS	O
:	O
Familial	O
thyroid	B-Entity
illness	I-Entity
is	O
a	O
risk	O
factor	O
for	O
hypothyroidism	I-Entity
and	O
hypercalcemia	I-Entity
during	O
lithium	I-Entity
therapy	O
.	O



Systemic	O
toxicity	I-Entity
following	O
administration	O
of	O
sirolimus	I-Entity
(	O
formerly	O
rapamycin	I-Entity
)	O
for	O
psoriasis	I-Entity
:	O
association	O
of	O
capillary	B-Entity
leak	I-Entity
syndrome	I-Entity
with	O
apoptosis	O
of	O
lesional	O
lymphocytes	O
.	O

BACKGROUND	O
:	O
Sirolimus	I-Entity
(	O
formerly	O
rapamycin	I-Entity
)	O
is	O
an	O
immunosuppressive	O
agent	O
that	O
interferes	O
with	O
T	O
-	O
cell	O
activation	O
.	O

After	O
2	O
individuals	O
with	O
psoriasis	I-Entity
developed	O
a	O
capillary	B-Entity
leak	I-Entity
syndrome	I-Entity
following	O
treatment	O
with	O
oral	O
sirolimus	I-Entity
lesional	O
skin	O
cells	O
and	O
activated	O
peripheral	O
blood	O
cells	O
were	O
analyzed	O
for	O
induction	O
of	O
apoptosis	O
.	O

A	O
keratome	O
skin	O
specimen	O
from	O
1	O
patient	O
with	O
sirolimus	I-Entity
-	O
induced	O
capillary	B-Entity
leak	I-Entity
syndrome	I-Entity
had	O
a	O
2.3-fold	O
increase	O
in	O
percentage	O
of	O
apoptotic	O
cells	O
(	O
to	O
48%	O
)	O
compared	O
with	O
an	O
unaffected	O
sirolimus	I-Entity
-	O
treated	O
patient	O
with	O
psoriasis	I-Entity
(	O
21%	O
)	O
.	O

Activated	O
peripheral	O
blood	O
T	O
cells	O
from	O
patients	O
with	O
psoriasis	I-Entity
tended	O
to	O
exhibit	O
greater	O
spontaneous	O
or	O
dexamethasone	I-Entity
-	O
induced	O
apoptosis	O
than	O
did	O
normal	O
T	O
cells	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
sirolimus	I-Entity
.	O

Severe	O
adverse	O
effects	O
of	O
sirolimus	I-Entity
include	O
fever	I-Entity
,	O
anemia	I-Entity
,	O
and	O
capillary	B-Entity
leak	I-Entity
syndrome	I-Entity
.	O

Because	O
patients	O
with	O
severe	O
psoriasis	I-Entity
may	O
develop	O
capillary	B-Entity
leak	I-Entity
from	O
various	O
systemic	O
therapies	O
,	O
clinical	O
monitoring	O
is	O
advisable	O
for	O
patients	O
with	O
inflammatory	B-Entity
diseases	I-Entity
who	O
are	O
treated	O
with	O
immune	O
modulators	O
.	O



Contribution	O
of	O
the	O
glycine	I-Entity
site	O
of	O
NMDA	I-Entity
receptors	O
in	O
rostral	O
and	O
intermediate	O
-	O
caudal	O
parts	O
of	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
in	O
rats	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
contribution	O
of	O
the	O
glycine	I-Entity
site	O
of	O
NMDA	I-Entity
receptors	O
in	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
.	O

Muscle	B-Entity
rigidity	I-Entity
was	O
induced	O
by	O
haloperidol	I-Entity
(	O
2.5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

5,7-dichlorokynurenic	B-Entity
acid	I-Entity
(	O
5,7-DCKA	I-Entity
)	O
,	O
a	O
selective	O
glycine	I-Entity
site	O
antagonist	O
,	O
injected	O
in	O
doses	O
of	O
2.5	O
and	O
4.5	O
microg/0.5	O
microl	O
bilaterally	O
,	O
into	O
the	O
rostral	O
region	O
of	O
the	O
striatum	O
,	O
decreased	O
both	O
the	O
haloperidol	I-Entity
-	O
induced	O
muscle	B-Entity
rigidity	I-Entity
(	O
MMG	O
)	O
and	O
the	O
enhanced	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
.	O

5,7-DCKA	I-Entity
injected	O
bilaterally	O
in	O
a	O
dose	O
of	O
4.5	O
microg/0.5	O
microl	O
into	O
the	O
intermediate	O
-	O
caudal	O
region	O
of	O
the	O
striatum	O
of	O
rats	O
not	O
pretreated	O
with	O
haloperidol	I-Entity
had	O
no	O
effect	O
on	O
the	O
muscle	O
tone	O
.	O

The	O
present	O
results	O
suggest	O
that	O
blockade	O
of	O
the	O
glycine	I-Entity
site	O
of	O
NMDA	I-Entity
receptors	O
in	O
the	O
rostral	O
part	O
of	O
the	O
striatum	O
may	O
be	O
mainly	O
responsible	O
for	O
the	O
antiparkinsonian	O
action	O
of	O
this	O
drug	O
.	O



Efficacy	O
and	O
tolerability	O
of	O
lovastatin	I-Entity
in	O
3390	O
women	O
with	O
moderate	O
hypercholesterolemia	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
lovastatin	I-Entity
in	O
women	O
with	O
moderate	O
hypercholesterolemia	I-Entity
.	O

The	O
Expanded	O
Clinical	O
Evaluation	O
of	O
Lovastatin	I-Entity
(	O
EXCEL	O
)	O
Study	O
,	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
diet-	O
and	O
placebo	O
-	O
controlled	O
trial	O
,	O
in	O
which	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
lovastatin	I-Entity
at	O
doses	O
of	O
20	O
or	O
40	O
mg	O
once	O
daily	O
,	O
or	O
20	O
or	O
40	O
mg	O
twice	O
daily	O
for	O
48	O
weeks	O
.	O

MEASUREMENTS	O
:	O
Plasma	O
total	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	I-Entity
,	O
and	O
triglycerides	I-Entity
;	O
and	O
laboratory	O
and	O
clinical	O
evidence	O
of	O
adverse	O
events	O
monitored	O
periodically	O
throughout	O
the	O
study	O
.	O

Among	O
women	O
,	O
lovastatin	I-Entity
(	O
20	O
to	O
80	O
mg	O
/	O
d	O
)	O
produced	O
sustained	O
(	O
12-	O
to	O
48-week	O
)	O
,	O
dose	O
-	O
related	O
changes	O
(	O
P	O
<	O
0.001	O
)	O
:	O
decreases	O
in	O
LDL	O
cholesterol	I-Entity
(	O
24%	O
to	O
40%	O
)	O
and	O
triglycerides	I-Entity
(	O
9%	O
to	O
18%	O
)	O
,	O
and	O
increases	O
in	O
HDL	O
cholesterol	I-Entity
(	O
6.7%	O
to	O
8.6%	O
)	O
.	O

Depending	O
on	O
the	O
dose	O
,	O
from	O
82%	O
to	O
95%	O
of	O
lovastatin	I-Entity
-	O
treated	O
women	O
achieved	O
the	O
National	O
Cholesterol	I-Entity
Education	O
Program	O
goal	O
of	O
LDL	O
cholesterol	I-Entity
levels	O
less	O
than	O
4.14	O
mmol	O
/	O
L	O
(	O
160	O
mg	O
/	O
dL	O
)	O
,	O
and	O
40%	O
to	O
87%	O
achieved	O
the	O
goal	O
of	O
3.36	O
mmol	O
/	O
L	O
(	O
130	O
mg	O
/	O
dL	O
)	O
.	O

Myopathy	I-Entity
,	O
defined	O
as	O
muscle	O
symptoms	O
with	O
creatine	I-Entity
kinase	O
elevations	O
greater	O
than	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
was	O
rare	O
and	O
associated	O
with	O
the	O
highest	O
recommended	O
daily	O
dose	O
of	O
lovastatin	I-Entity
(	O
80	O
mg	O
)	O
.	O

Estrogen	O
-	O
replacement	O
therapy	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
either	O
the	O
efficacy	O
or	O
safety	O
profile	O
of	O
lovastatin	I-Entity
.	O

CONCLUSION	O
:	O
Lovastatin	I-Entity
is	O
highly	O
effective	O
and	O
generally	O
well	O
tolerated	O
as	O
therapy	O
for	O
primary	O
hypercholesterolemia	I-Entity
in	O
women	O
.	O



REM	B-Entity
sleep	I-Entity
deprivation	I-Entity
changes	O
behavioral	O
response	O
to	O
catecholaminergic	O
and	O
serotonergic	O
receptor	O
activation	O
in	O
rats	O
.	O

The	O
effects	O
of	O
REM	B-Entity
sleep	I-Entity
deprivation	I-Entity
(	O
REMD	I-Entity
)	O
on	O
apomorphine	I-Entity
-	O
induced	O
aggressiveness	I-Entity
and	O
quipazine	I-Entity
-	O
induced	O
head	B-Entity
twitches	I-Entity
in	O
rats	O
were	O
determined	O
.	O

hr	O
of	O
REMD	I-Entity
increased	O
apomorphine	I-Entity
-	O
induced	O
aggressiveness	I-Entity
,	O
and	O
reduced	O
(	O
immediately	O
after	O
completing	O
of	O
REMD	I-Entity
)	O
or	O
increased	O
(	O
96	O
hr	O
after	O
completing	O
of	O
REMD	I-Entity
)	O

quipazine	I-Entity
-	O
induced	O
head	B-Entity
twitches	I-Entity
.	O



Extrapyramidal	O
side	O
effects	O
and	O
oral	O
haloperidol	I-Entity
:	O
an	O
analysis	O
of	O
explanatory	O
patient	O
and	O
treatment	O
characteristics	O
.	O

The	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
(	O
EPS	O
)	O
was	O
evaluated	O
in	O
98	O
patients	O
treated	O
with	O
haloperidol	I-Entity
.	O

The	O
incidence	O
of	O
parkinsonism	I-Entity
was	O
higher	O
at	O
higher	O
doses	O
of	O
haloperidol	I-Entity
and	O
in	O
younger	O
patients	O
.	O

However	O
,	O
these	O
medications	O
were	O
more	O
effective	O
in	O
both	O
young	O
and	O
old	O
patients	O
when	O
given	O
after	O
parkinsonism	I-Entity
developed	O
.	O

Akathisia	I-Entity
was	O
controlled	O
by	O
the	O
benzodiazepine	I-Entity
lorazepam	I-Entity
in	O
14	O
out	O
of	O
16	O
patients	O
,	O
while	O
prophylactic	O
antiparkinsonians	O
were	O
ineffective	O
.	O

The	O
present	O
study	O
points	O
to	O
patient	O
characteristics	O
that	O
may	O
be	O
of	O
significance	O
in	O
the	O
development	O
of	O
EPS	O
due	O
to	O
haloperidol	I-Entity
.	O



Hepatic	B-Entity
veno	I-Entity
-	I-Entity
occlusive	I-Entity
disease	I-Entity
caused	O
by	O
6-thioguanine	I-Entity
.	O

Clinically	O
reversible	O
veno	B-Entity
-	I-Entity
occlusive	I-Entity
disease	I-Entity
of	I-Entity
the	I-Entity
liver	I-Entity
developed	O
in	O
a	O
23-year	O
-	O
old	O
man	O
with	O
acute	B-Entity
lymphocytic	I-Entity
leukemia	I-Entity
after	O
10	O
months	O
of	O
maintenance	O
therapy	O
with	O
6-thioguanine	I-Entity
.	O

Although	O
this	O
disease	O
was	O
clinically	O
reversible	O
,	O
some	O
subintimal	O
fibrosis	I-Entity
about	O
the	O
terminal	O
hepatic	O
veins	O
persisted	O
.	O

This	O
case	O
presented	O
a	O
unique	O
opportunity	O
to	O
observe	O
the	O
histologic	O
features	O
of	O
clinically	O
reversible	O
hepatic	B-Entity
veno	I-Entity
-	I-Entity
occlusive	I-Entity
disease	I-Entity
over	O
time	O
,	O
and	O
may	O
be	O
the	O
first	O
case	O
of	O
veno	O
-	O
occlusive	O
related	O
solely	O
to	O
6-thioguanine	I-Entity
.	O



Treatment	O
of	O
ifosfamide	I-Entity
-	O
induced	O
urothelial	B-Entity
toxicity	I-Entity
by	O
oral	O
administration	O
of	O
sodium	B-Entity
2-mercaptoethane	I-Entity
sulphonate	I-Entity
(	O
MESNA	I-Entity
)	O
to	O
patients	O
with	O
inoperable	O
lung	B-Entity
cancer	I-Entity
.	O

The	O
protective	O
effect	O
of	O
oral	O
administration	O
of	O
the	O
thiol	I-Entity
compound	O
sodium	B-Entity
2-mercaptoethane	I-Entity
sulphonate	I-Entity
(	O
MESNA	I-Entity
)	O
against	O
urothelial	B-Entity
toxicity	I-Entity
induced	O
by	O
ifosfamide	I-Entity
(	O
IF	I-Entity
)	O
was	O
tested	O
in	O
a	O
group	O
of	O
45	O
patients	O
with	O
inoperable	O
lung	B-Entity
cancer	I-Entity
under	O
treatment	O
with	O
IF	I-Entity
(	O
2250	O
mg	O
/	O
m2	O
on	O
days	O
2	O
-	O
5	O
)	O
as	O
part	O
of	O
a	O
polychemotherapy	O
regimen	O
repeated	O
in	O
a	O
4-week	O
cycle	O
.	O

MESNA	I-Entity
was	O
given	O
orally	O
on	O
the	O
days	O
of	O
treatment	O
with	O
IF	I-Entity
in	O
3	O
doses	O
of	O
840	O
mg	O
/	O
m2	O
,	O
each	O
administered	O
at	O
0	O
hr	O
(=	O
injection	O
of	O
IF	I-Entity
)	O
,	O
4	O
hr	O
and	O
8	O
hr	O
p.i	O
.	O

Out	O
of	O
a	O
total	O
of	O
88	O
courses	O
of	O
this	O
treatment	O
we	O
observed	O
10	O
episodes	O
of	O
asymptomatic	O
microscopic	O
haematuria	I-Entity
and	O
no	O
episodes	O
of	O
gross	O
haematuria	I-Entity
.	O

In	O
this	O
group	O
of	O
45	O
patients	O
under	O
protection	O
with	O
MESNA	I-Entity
there	O
were	O
5	O
complete	O
remissions	O
and	O
9	O
partial	O
remissions	O
(	O
total	O
31%	O
)	O
.	O

A	O
further	O
group	O
of	O
25	O
patients	O
under	O
polychemotherapy	O
with	O
IF	I-Entity
were	O
treated	O
by	O
conventional	O
prophylactic	O
measures	O
(	O
raised	O
fluid	O
intake	O
and	O
forced	O
diuresis	O
)	O
.	O

In	O
this	O
group	O
there	O
were	O
1	O
complete	O
and	O
5	O
partial	O
remissions	O
(	O
total	O
24%	O
)	O
,	O
but	O
nearly	O
all	O
patients	O
developed	O
either	O
gross	O
haematuria	I-Entity
and/or	O
symptoms	O
of	O
bladder	B-Entity
irritation	I-Entity
(	O
cystitis	I-Entity
and	O
pollakisuria	I-Entity
)	O
.	O

There	O
were	O
no	O
appreciable	O
differences	O
between	O
the	O
MESNA	I-Entity
series	O
and	O
the	O
conventional	O
prophylaxis	O
series	O
with	O
respect	O
to	O
either	O
haematological	O
or	O
systemic	O
toxicity	I-Entity
of	O
the	O
cytostatic	O
treatment	O
.	O

Our	O
results	O
support	O
the	O
view	O
that	O
MESNA	I-Entity
,	O
given	O
orally	O
in	O
conjunction	O
with	O
combined	O
cytostatic	O
regimens	O
which	O
include	O
IF	I-Entity
,	O
simplifies	O
the	O
treatment	O
and	O
provides	O
optimum	O
protection	O
for	O
the	O
urinary	O
epithelium	O
.	O

Protection	O
with	O
oral	O
MESNA	I-Entity
is	O
particularly	O
suitable	O
for	O
outpatients	O
.	O



Time	O
course	O
alterations	O
of	O
QTC	O
interval	O
due	O
to	O
hypaque	B-Entity
76	I-Entity
.	O

Sequential	O
measurement	O
of	O
QT	O
interval	O
during	O
left	O
ventricular	O
angiography	O
was	O
made	O
30	O
seconds	O
and	O
one	O
,	O
three	O
,	O
five	O
and	O
ten	O
minutes	O
after	O
injection	O
of	O
hypaque	B-Entity
76	I-Entity
.	O

Significant	O
QTC	B-Entity
prolongation	I-Entity
occurred	O
in	O
30	O
seconds	O
to	O
one	O
minute	O
in	O
association	O
with	O
marked	O
hypotension	I-Entity
and	O
elevation	O
of	O
cardiac	O
output	O
.	O



Production	O
of	O
autochthonous	O
prostate	B-Entity
cancer	I-Entity
in	O
Lobund	O
-	O
Wistar	O
rats	O
by	O
treatments	O
with	O
N	B-Entity
-	I-Entity
nitroso	I-Entity
-	I-Entity
N	I-Entity
-	I-Entity
methylurea	I-Entity
and	O
testosterone	I-Entity
.	O

strain	O
rats	O
developed	O
large	O
,	O
palpable	O
prostate	B-Entity
adenocarcinomas	I-Entity
(	O
PAs	I-Entity
)	O
following	O
treatments	O
with	O
N	B-Entity
-	I-Entity
nitroso	I-Entity
-	I-Entity
N	I-Entity
-	I-Entity
methylurea	I-Entity

(	O
CAS	O
:	O
684	O
-	O
93	O
-	O
5	O
)	O
and	O
testosterone	B-Entity
propionate	I-Entity
[	O
(	O
TP	I-Entity
)	O
CAS	O
:	O
57	O
-	O
85	O
-	O
2	O
]	O
,	O
and	O
most	O
of	O
the	O
tumor	I-Entity
-	O
bearing	O
rats	O
manifested	O
metastatic	O
lesions	O
.	O

Within	O
the	O
same	O
timeframe	O
,	O
no	O
L	O
-	O
W	O
rat	O
developed	O
a	O
similar	O
palpable	O
PA	I-Entity
when	O
treated	O
only	O
with	O
TP	I-Entity
.	O

In	O
L	O
-	O
W	O
rats	O
,	O
TP	I-Entity
acted	O
as	O
a	O
tumor	I-Entity
enhancement	O
agent	O
,	O
with	O
primary	O
emphasis	O
on	O
the	O
development	O
of	O
prostate	B-Entity
cancer	I-Entity
.	O



A	O
dystonia	I-Entity
-	O
like	O
syndrome	O
after	O
neuropeptide	O
(	O
MSH	I-Entity
/	O
ACTH	I-Entity
)	O
stimulation	O
of	O
the	O
rat	O
locus	O
ceruleus	O
.	O

The	O
movement	B-Entity
disorder	I-Entity
investigated	O
in	O
these	O
studies	O
has	O
some	O
features	O
in	O
common	O
with	O
human	O
idiopathic	O
dystonia	I-Entity
,	O
and	O
information	O
obtained	O
in	O
these	O
studies	O
may	O
be	O
of	O
potential	O
clinical	O
benefit	O
.	O

However	O
,	O
it	O
is	O
not	O
certain	O
as	O
to	O
the	O
following	O
:	O
(	O
a	O
)	O
what	O
receptors	O
were	O
stimulated	O
by	O
the	O
ACTH	I-Entity
N	O
-	O
terminal	O
fragments	O
at	O
the	O
LC	O
that	O
resulted	O
in	O
this	O
disorder	O
;	O
(	O
b	O
)	O
whether	O
NE	O
,	O
released	O
onto	O
Purkinje	O
cell	O
synapses	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	O
pathway	O
,	O
did	O
indeed	O
cause	O
the	O
long	O
-	O
term	O
depression	I-Entity
at	O
Purkinje	O
cell	O
synapses	O
(	O
previously	O
described	O
by	O
others	O
)	O
that	O
resulted	O
in	O
the	O
long	O
duration	O
of	O
the	O
movement	B-Entity
disorder	I-Entity
;	O
(	O
c	O
)	O
whether	O
the	O
inhibition	O
of	O
inhibitory	O
Purkinje	O
cells	O
resulted	O
in	O
disinhibition	O
or	O
increased	O
excitability	O
of	O
the	O
unilateral	O
cerebellar	O



Dexmedetomidine	I-Entity
,	O
acting	O
through	O
central	O
alpha-2	O
adrenoceptors	O
,	O
prevents	O
opiate	O
-	O
induced	O
muscle	B-Entity
rigidity	I-Entity
in	O
the	O
rat	O
.	O

The	O
highly	O
-	O
selective	O
alpha-2	O
adrenergic	O
agonist	O
dexmedetomidine	I-Entity
(	O
D	B-Entity
-	I-Entity
MED	I-Entity
)	O
is	O
capable	O
of	O
inducing	O
muscle	B-Entity
flaccidity	I-Entity
and	O
anesthesia	O
in	O
rats	O
and	O
dogs	O
.	O

Intense	O
generalized	O
muscle	B-Entity
rigidity	I-Entity
is	O
an	O
undesirable	O
side	O
effect	O
of	O
potent	O
opiate	O
agonists	O
.	O

Although	O
the	O
neurochemistry	O
of	O
opiate	O
-	O
induced	O
rigidity	I-Entity
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
,	O
recent	O
work	O
suggests	O
a	O
role	O
for	O
a	O
central	O
adrenergic	O
mechanism	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
determined	O
if	O
treatment	O
with	O
D	B-Entity
-	I-Entity
MED	I-Entity
prevents	O
the	O
muscle	B-Entity
rigidity	I-Entity
caused	O
by	O
high	O
-	O
dose	O
alfentanil	I-Entity
anesthesia	O
in	O
the	O
rat	O
.	O

Animals	O
(	O
n	O
=	O
42	O
)	O
were	O
treated	O
intraperitoneally	O
with	O
one	O
of	O
the	O
following	O
six	O
regimens	O
:	O
1	O
)	O
L	O
-	O
MED	O
(	O
the	O
inactive	O
L	O
-	O
isomer	O
of	O
medetomidine	I-Entity
)	O
,	O
30	O
micrograms	O
/	O
kg	O
;	O
2	O
)	O
D	B-Entity
-	I-Entity
MED	I-Entity
,	O
10	O
micrograms	O
/	O
kg	O
;	O

3	O
)	O
D	B-Entity
-	I-Entity
MED	I-Entity
,	O
30	O
micrograms	O
/	O
kg	O
;	O
4	O
)	O
D	B-Entity
-	I-Entity
MED	I-Entity
[	O
30	O
micrograms	O
/	O
kg	O
]	O
and	O
the	O
central	O
-	O
acting	O
alpha-2	O
antagonist	O
,	O
idazoxan	I-Entity
[	O
10	O
mg	O
/	O
kg	O
]	O
;	O
5	O
)	O
D	B-Entity
-	I-Entity
MED	I-Entity
[	O
30	O
micrograms	O
/	O
kg	O
]	O
and	O
the	O
peripheral	O
-	O
acting	O
alpha-2	O
antagonist	O
DG-5128	I-Entity
[	O
10	O
mg	O
/	O
kg	O
]	O
,	O
or	O
;	O
6	O
)	O

Each	O
rat	O
was	O
then	O
injected	O
with	O
alfentanil	I-Entity
(	O
ALF	I-Entity
,	O
0.5	O
mg	O
/	O
kg	O
sc	O
)	O
.	O

ALF	I-Entity
injection	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
hindlimb	O
EMG	O
activity	O
in	O
the	O
L	O
-	O
MED	O
treatment	O
group	O
which	O
was	O
indistinguishable	O
from	O
that	O
seen	O
in	O
animals	O
treated	O
with	O
saline	O
.	O

In	O
contrast	O
,	O
D	B-Entity
-	I-Entity
MED	I-Entity
prevented	O
alfentanil	I-Entity
-	O
induced	O
muscle	B-Entity
rigidity	I-Entity
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

The	O
small	O
EMG	O
values	O
obtained	O
in	O
the	O
high	O
-	O
dose	O
D	B-Entity
-	I-Entity
MED	I-Entity
group	O
were	O
comparable	O
with	O
those	O
recorded	O
in	O
earlier	O
studies	O
from	O
control	O
animals	O
not	O
given	O
any	O
opiate	O
.	O

The	O
high	O
-	O
dose	O
D	B-Entity
-	I-Entity
MED	I-Entity
animals	O
were	O
flaccid	O
,	O
akinetic	I-Entity
,	O
and	O
lacked	O
a	O
startle	I-Entity
response	O
during	O
the	O
entire	O
experimental	O
period.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Seizure	I-Entity
activity	O
with	O
imipenem	I-Entity
therapy	O
:	O
incidence	O
and	O
risk	O
factors	O
.	O

Two	O
elderly	O
patients	O
with	O
a	O
history	O
of	O
either	O
cerebral	B-Entity
vascular	I-Entity
accident	I-Entity
(	O
CVA	I-Entity
)	O
or	O
head	B-Entity
trauma	I-Entity
and	O
no	O
evidence	O
of	O
renal	B-Entity
disease	I-Entity
developed	O
seizures	I-Entity
while	O
receiving	O
maximum	O
doses	O
of	O
imipenem	B-Entity
/	I-Entity
cilastatin	I-Entity
.	O

Neither	O
patient	O
had	O
reported	O
previous	O
seizures	I-Entity
or	O
seizure	I-Entity
-	O
like	O
activity	O
nor	O
was	O
receiving	O
anticonvulsant	O
agents	O
.	O

All	O
seizures	I-Entity
were	O
controlled	O
with	O
therapeutic	O
doses	O
of	O
phenytoin	I-Entity
.	O

Both	O
patients	O
had	O
received	O
maximum	O
doses	O
of	O
other	O
beta	B-Entity
-	I-Entity
lactam	I-Entity
antibiotics	O
without	O
evidence	O
of	O
seizure	I-Entity
activity	O
.	O



The	O
ability	O
of	O
insulin	O
treatment	O
to	O
reverse	O
or	O
prevent	O
the	O
changes	O
in	O
urinary	O
bladder	O
function	O
caused	O
by	O
streptozotocin	I-Entity
-	O
induced	O
diabetes	B-Entity
mellitus	I-Entity
.	O
1	O
.	O

The	O
effects	O
of	O
insulin	O
treatment	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
urinary	O
bladder	O
function	O
in	O
streptozotocin	I-Entity
-	O
diabetic	I-Entity
rats	O
were	O
investigated	O
.	O

Diabetes	I-Entity
of	O
2	O
months	O
duration	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
;	O
effects	O
which	O
were	O
prevented	O
by	O
insulin	O
treatment	O
.	O

3	O
.	O
Insulin	O
treatment	O
also	O
prevented	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	I-Entity
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	I-Entity
,	O
and	O
bethanechol	I-Entity
.	O

Diabetes	I-Entity
of	O
4	O
months	O
duration	O
also	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
,	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
,	O
effects	O
which	O
were	O
reversed	O
by	O
insulin	O
treatment	O
for	O
the	O
final	O
2	O
months	O
of	O
the	O
study	O
.	O

Insulin	O
treatment	O
reversed	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	I-Entity
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	I-Entity
,	O
and	O
bethanechol	I-Entity
.	O

The	O
data	O
indicate	O
that	O
the	O
effects	O
of	O
streptozotocin	I-Entity
-	O
induced	O
diabetes	I-Entity
on	O
urinary	O
bladder	O
function	O
are	O
both	O
prevented	O
and	O
reversed	O
by	O
insulin	O
treatment	O
.	O



Delayed	O
institution	O
of	O
hypertension	I-Entity
during	O
focal	O
cerebral	B-Entity
ischemia	I-Entity
:	O
effect	O
on	O
brain	B-Entity
edema	I-Entity
.	O

The	O
effect	O
of	O
induced	O
hypertension	I-Entity
instituted	O
after	O
a	O
2-h	O
delay	O
following	O
middle	B-Entity
cerebral	I-Entity
artery	I-Entity
occlusion	I-Entity
(	O
MCAO	I-Entity
)	O
on	O
brain	B-Entity
edema	I-Entity
formation	O
and	O
histochemical	O
injury	O
was	O
studied	O
.	O

Under	O
isoflurane	I-Entity
anesthesia	O
,	O
the	O
MCA	O
of	O
14	O
spontaneously	O
hypertensive	I-Entity
rats	O
was	O
occluded	O
.	O

In	O
the	O
hypertensive	I-Entity
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
MAP	O
was	O
elevated	O
by	O
25	O
-	O
30	O
mm	O
Hg	O
beginning	O
2	O
h	O
after	O
MCAO	I-Entity
.	O

Four	O
hours	O
after	O
MCAO	I-Entity
,	O
the	O
rats	O
were	O
killed	O
and	O
the	O
brains	O
harvested	O
.	O

The	O
brains	O
were	O
sectioned	O
along	O
coronal	O
planes	O
spanning	O
the	O
distribution	O
of	O
ischemia	I-Entity
produced	O
by	O
MCAO	I-Entity
.	O

Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	I-Entity
territory	O
)	O
.	O

The	O
extent	O
of	O
neuronal	B-Entity
injury	I-Entity
was	O
determined	O
by	O
2,3,5-triphenyltetrazolium	I-Entity
staining	O
.	O

In	O
the	O
ischemic	I-Entity
core	O
,	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O

In	O
the	O
periphery	O
of	O
the	O
ischemic	I-Entity
territory	O
,	O
SG	O
in	O
the	O
cortex	O
was	O
greater	O
(	O
less	O
edema	I-Entity
accumulation	O
)	O
in	O
the	O
hypertensive	I-Entity
group	O
(	O
1.041	O
+	O
/-	O

The	O
area	O
of	O
histochemical	O
injury	O
(	O
as	O
a	O
percent	O
of	O
the	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
hemisphere	O
)	O
was	O
less	O
in	O
the	O
hypertensive	I-Entity
group	O
(	O
33	O
+	O
/-	O

The	O
data	O
indicate	O
that	O
phenylephrine	I-Entity
-	O
induced	O
hypertension	I-Entity
instituted	O
2	O
h	O
after	O
MCAO	I-Entity
does	O
not	O
aggravate	O
edema	I-Entity
in	O
the	O
ischemic	I-Entity
core	O
,	O
that	O
it	O
improves	O
edema	I-Entity
in	O
the	O
periphery	O
of	O
the	O
ischemic	I-Entity
territory	O
,	O
and	O
that	O
it	O
reduces	O
the	O
area	O
of	O
histochemical	O
neuronal	B-Entity
dysfunction	I-Entity
.	O



Amiodarone	I-Entity
pulmonary	B-Entity
toxicity	I-Entity
.	O

Amiodarone	I-Entity
is	O
an	O
effective	O
antiarrhythmic	O
agent	O
whose	O
utility	O
is	O
limited	O
by	O
many	O
side	O
-	O
effects	O
,	O
the	O
most	O
problematic	O
being	O
pneumonitis	I-Entity
.	O

The	O
pulmonary	B-Entity
toxicity	I-Entity
of	O
amiodarone	I-Entity
is	O
thought	O
to	O
result	O
from	O
direct	O
injury	O
related	O
to	O
the	O
intracellular	O
accumulation	O
of	O
phospholipid	O
and	O
T	O
cell	O
-	O
mediated	O
hypersensitivity	B-Entity
pneumonitis	I-Entity
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
amiodarone	I-Entity
-	O
induced	O
pulmonary	B-Entity
toxicity	I-Entity
are	O
characteristic	O
but	O
nonspecific	O
.	O

The	O
diagnosis	O
depends	O
on	O
exclusion	O
of	O
other	O
entities	O
,	O
such	O
as	O
heart	B-Entity
failure	I-Entity
,	O
infection	I-Entity
,	O
and	O
malignancy	I-Entity
.	O

While	O
withdrawal	O
of	O
amiodarone	I-Entity
leads	O
to	O
clinical	O
improvement	O
in	O
majority	O
of	O
cases	O
,	O
this	O
is	O
not	O
always	O
possible	O
or	O
advisable	O
.	O

Dose	O
reduction	O
or	O
concomitant	O
steroid	I-Entity
therapy	O
may	O
have	O
a	O
role	O
in	O
selected	O
patients	O
.	O



Light	O
chain	O
proteinuria	I-Entity
and	O
cellular	O
mediated	O
immunity	O
in	O
rifampin	I-Entity
treated	O
patients	O
with	O
tuberculosis	I-Entity
.	O

Light	O
chain	O
proteinuria	I-Entity
was	O
found	O
in	O
9	O
of	O
17	O
tuberculosis	I-Entity
patients	O
treated	O
with	O
rifampin	I-Entity
.	O

Response	O
to	O
Varidase	O
skin	O
test	O
antigen	O
was	O
negative	O
for	O
all	O
eight	O
tuberculosis	I-Entity
patients	O
tested	O
,	O
but	O
there	O
occurred	O
a	O
hyper	O
-	O
responsiveness	O
of	O
the	O
lymphocytes	O
of	O
these	O
eight	O
patients	O
to	O
phytomitogen	O
(	O
PHA	O
-	O
P	O
)	O
.	O

as	O
well	O
as	O
of	O
those	O
of	O
seven	O
other	O
tuberculous	I-Entity
patients	O
.	O

This	O
last	O
finding	O
may	O
be	O
related	O
to	O
time	O
of	O
testing	O
and/or	O
endogenous	O
serum	O
binding	O
of	O
rifampin	I-Entity
which	O
could	O
have	O
inhibited	O
mitogen	O
activity	O
for	O
the	O
lymphocyte	O
.	O



Initial	O
potassium	I-Entity
loss	O
and	O
hypokalaemia	I-Entity
during	O
chlorthalidone	I-Entity
administration	O
in	O
patients	O
with	O
essential	O
hypertension	I-Entity
:	O
the	O
influence	O
of	O
dietary	O
sodium	I-Entity
restriction	O
.	O

To	O
investigate	O
the	O
initial	O
potassium	I-Entity
loss	O
and	O
development	O
of	O
hypokalaemia	I-Entity
during	O
the	O
administration	O
of	O
an	O
oral	O
diuretic	O
,	O
metabolic	O
balance	O
studies	O
were	O
performed	O
in	O
ten	O
patients	O
with	O
essential	O
hypertension	I-Entity
who	O
had	O
shown	O
hypokalaemia	I-Entity
under	O
prior	O
oral	O
diuretic	O
treatment	O
.	O

Chlorthalidone	I-Entity
(	O
50	O
mg	O
daily	O
)	O
was	O
given	O
for	O
14	O
days	O
.	O

Six	O
patients	O
received	O
a	O
normal	O
-	O
sodium	I-Entity
diet	O
and	O
four	O
a	O
low	O
-	O
sodium	I-Entity
(	O
17	O
mmol	O
/	O
day	O
)	O
diet	O
.	O

All	O
patients	O
had	O
a	O
normal	O
initial	O
total	O
body	O
potassium	I-Entity
(	O
40	O
K	O
)	O
.	O

The	O
electrolyte	O
balances	O
,	O
weight	O
,	O
bromide	O
space	O
,	O
plasma	O
renin	O
activity	O
,	O
and	O
aldosterone	I-Entity
secretion	O
rate	O
were	O
measured	O
.	O

In	O
both	O
groups	O
a	O
potassium	I-Entity
deficit	O
developed	O
,	O
with	O
proportionally	O
larger	O
losses	O
from	O
the	O
extracellular	O
than	O
from	O
the	O
intracellular	O
compartment	O
.	O

In	O
the	O
normal	O
-	O
sodium	I-Entity
group	O
the	O
highest	O
mean	O
potassium	I-Entity
deficit	O
was	O
176	O
mmol	O
on	O
day	O
9	O
,	O
after	O
which	O
some	O
potassium	I-Entity
was	O
regained	O
;	O
in	O
the	O
low	O
-	O
sodium	I-Entity
group	O
the	O
highest	O
deficit	O
was	O
276	O
mmol	O
on	O
day	O
13	O
.	O

The	O
normal	O
-	O
sodium	I-Entity
group	O
showed	O
an	O
immediate	O
but	O
temporary	O
rise	O
of	O
the	O
renin	O
and	O
aldosterone	I-Entity
levels	O
;	O
in	O
the	O
low	O
-	O
sodium	I-Entity
group	O
renin	O
and	O
aldosterone	I-Entity
increased	O
more	O
slowly	O
but	O
remained	O
elevated	O
.	O

It	O
is	O
concluded	O
that	O
dietary	O
sodium	I-Entity
restriction	O
increases	O
diuretic	O
-	O
induced	O
potassium	I-Entity
loss	O
,	O
presumably	O
by	O
an	O
increased	O
activity	O
of	O
the	O
renin	O
-	O
angiotensin	I-Entity
-	O
aldosterone	I-Entity
system	O
,	O
while	O
sodium	I-Entity
delivery	O
to	O
the	O
distal	O
renal	O
tubules	O
remains	O
sufficiently	O
high	O
to	O
allow	O
increased	O
potassium	I-Entity
secretion	O
.	O



Dynamic	O
response	O
of	O
blood	O
vessel	O
in	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O

In	O
this	O
study	O
we	O
postulated	O
that	O
during	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
induced	O
by	O
gentamicin	I-Entity
the	O
transient	O
or	O
dynamic	O
response	O
of	O
blood	O
vessels	O
could	O
be	O
affected	O
,	O
and	O
that	O
antioxidants	O
can	O
prevent	O
the	O
changes	O
in	O
dynamic	O
responses	O
of	O
blood	O
vessels	O
.	O

Our	O
results	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin	I-Entity
-	O
treated	O
animals	O
.	O

The	O
beneficial	O
effects	O
of	O
vitamin	B-Entity
C	I-Entity
administration	O
to	O
gentamicin	I-Entity
-	O
treated	O
animals	O
are	O
also	O
confirmed	O
through	O
:	O
lower	O
level	O
of	O
blood	O
urea	I-Entity
and	O
creatinine	I-Entity
and	O
higher	O
level	O
of	O
potassium	I-Entity
.	O

The	O
pressure	O
dynamic	O
responses	O
of	O
isolated	O
blood	O
vessels	O
show	O
a	O
faster	O
pressure	O
change	O
in	O
gentamicin	I-Entity
-	O
treated	O
animals	O
(	O
8.07	O
+	O
/-	O

Vitamin	B-Entity
C	I-Entity
administration	O
induced	O
slowdown	O
of	O
pressure	O
change	O
back	O
to	O
the	O
control	O
values	O
.	O

The	O
pressure	O
dynamic	O
properties	O
,	O
quantitatively	O
defined	O
by	O
comparative	O
pressure	O
dynamic	O
and	O
total	O
pressure	O
dynamic	O
,	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin	I-Entity
-	O
treated	O
animals	O
and	O
beneficial	O
effects	O
of	O
vitamin	B-Entity
C	I-Entity
administration	O
.	O



The	O
hemodynamics	O
of	O
oxytocin	I-Entity
and	O
other	O
vasoactive	O
agents	O
during	O
neuraxial	O
anesthesia	O
for	O
cesarean	O
delivery	O
:	O
findings	O
in	O
six	O
cases	O
.	O

Oxytocin	I-Entity
is	O
a	O
commonly	O
used	O
uterotonic	O
that	O
can	O
cause	O
significant	O
and	O
even	O
fatal	O
hypotension	I-Entity
,	O
particularly	O
when	O
given	O
as	O
a	O
bolus	O
.	O

The	O
resulting	O
hypotension	I-Entity
can	O
be	O
produced	O
by	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
or	O
cardiac	O
output	O
through	O
a	O
decrease	O
in	O
venous	O
return	O
.	O

Parturients	O
with	O
normal	O
volume	O
status	O
,	O
heart	O
valves	O
and	O
pulmonary	O
vasculature	O
most	O
often	O
respond	O
to	O
this	O
hypotension	I-Entity
with	O
a	O
compensatory	O
increase	O
in	O
heart	O
rate	O
and	O
stroke	I-Entity
volume	O
.	O

Oxytocin	I-Entity
-	O
induced	O
hypotension	I-Entity
at	O
cesarean	O
delivery	O
may	O
be	O
incorrectly	O
attributed	O
to	O
blood	B-Entity
loss	I-Entity
.	O

Hypotension	I-Entity
in	O
response	O
to	O
oxytocin	I-Entity
was	O
associated	O
with	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
and	O
a	O
compensatory	O
increase	O
in	O
stroke	I-Entity
volume	O
,	O
heart	O
rate	O
and	O
cardiac	O
output	O
.	O

Pulse	O
power	O
analysis	O
may	O
be	O
helpful	O
in	O
determining	O
the	O
etiology	O
of	O
and	O
treating	O
hypotension	I-Entity
during	O
cesarean	O
delivery	O
under	O
neuraxial	O
anesthesia	O
.	O



Exaggerated	O
expression	O
of	O
inflammatory	O
mediators	O
in	O
vasoactive	O
intestinal	O
polypeptide	O
knockout	O
(	O
VIP-/-	O
)	O
mice	O
with	O
cyclophosphamide	I-Entity
(	O
CYP)-induced	I-Entity
cystitis	I-Entity
.	O

VIP(-/-	O
)	O
mice	O
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	I-Entity
(	O
CYP)-induced	I-Entity
cystitis	I-Entity
.	O

Given	O
VIP	O
's	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	O
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP(-/-	O
)	O
mice	O
would	O
exhibit	O
enhanced	O
inflammatory	O
mediator	O
expression	O
after	O
cystitis	I-Entity
.	O

A	O
mouse	O
inflammatory	O
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP(-/-	O
)	O
mice	O
with	O
or	O
without	O
CYP	I-Entity
-	O
induced	O
cystitis	I-Entity
(	O
150	O
mg	O
/	O
kg	O
;	O
i.p	O
.	O
;	O
48	O
h	O
)	O
.	O

Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	I-Entity
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP(-/-	O
)	O

control	O
versus	O
CYP	I-Entity
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP(-/-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	I-Entity
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP(-/-	O
)	O
with	O
CYP	I-Entity
treatment	O
(	O
48	O
h	O
)	O
.	O

CYP	I-Entity
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
increased	O
expression	O
of	O
CXCL1	O
and	O
IL-1beta	O
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP(-/-	O
)	O
mice	O
,	O
but	O
expression	O
in	O
VIP(-/-	O
)	O
mice	O
with	O
CYP	I-Entity
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
greater	O
(	O
4.2-	O
to	O
13-fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	O
(	O
3.6-	O
to	O
5-fold	O
increase	O
)	O
.	O

The	O
data	O
suggest	O
that	O
in	O
VIP(-/-	O
)	O
mice	O
with	O
bladder	B-Entity
inflammation	I-Entity
,	O
inflammatory	O
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	I-Entity
.	O

This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	B-Entity
dysfunction	I-Entity
in	O
VIP(-/-	O
)	O
mice	O
with	O
bladder	B-Entity
inflammation	I-Entity
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O



Intraocular	O
pressure	O
in	O
patients	O
with	O
uveitis	I-Entity
treated	O
with	O
fluocinolone	B-Entity
acetonide	I-Entity
implants	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
the	O
incidence	O
and	O
management	O
of	O
elevated	B-Entity
intraocular	I-Entity
pressure	I-Entity
(	O
IOP	O
)	O
in	O
patients	O
with	O
uveitis	I-Entity
treated	O
with	O
the	O
fluocinolone	B-Entity
acetonide	I-Entity
(	O
FA	I-Entity
)	O

DESIGN	O
:	O
Pooled	O
data	O
from	O
3	O
multicenter	O
,	O
double	O
-	O
masked	O
,	O
randomized	O
,	O
controlled	O
,	O
phase	O
2b/3	O
clinical	O
trials	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
0.59-mg	O
or	O
2.1-mg	O
FA	I-Entity
intravitreal	O
implant	O
or	O
standard	O
therapy	O
were	O
analyzed	O
.	O

The	O
rate	O
of	O
hypotony	I-Entity
(	O
IOP	O
<	O
/=	O
5	O
mm	O
Hg	O
)	O
following	O
IOP	O
-	O
lowering	O
surgery	O
(	O
42.5%	O
)	O
was	O
not	O
different	O
from	O
that	O
of	O
implanted	O
eyes	O
not	O
subjected	O
to	O
surgery	O
(	O
35.4%	O
)	O



A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	O
treatment	O
of	O
Parkinson	B-Entity
's	I-Entity
disease	I-Entity
(	O
PD	I-Entity
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	O
by	O
Laitinen	O
in	O
1985	O
.	O

Laitinen	O
's	O
procedure	O
improved	O
most	O
symptoms	O
in	O
drug	O
-	O
resistant	O
PD	I-Entity
,	O
which	O
engendered	O
wide	O
interest	O
in	O
the	O
neurosurgical	O
community	O
.	O

According	O
to	O
the	O
literature	O
pallidotomy	O
improves	O
the	O
""""	O
on	O
""""	O
symptoms	O
of	O
PD	I-Entity
,	O
such	O
as	O
dyskinesias	I-Entity
,	O
as	O
well	O
as	O
the	O
""""	O
off	O
""""	O
symptoms	O
,	O
such	O
as	O
rigidity	I-Entity
,	O
bradykinesia	I-Entity
,	O
and	O
on	O
-	O
off	O
fluctuations	O
.	O

Pallidal	O
stimulation	O
improves	O
bradykinesia	I-Entity
and	O
rigidity	I-Entity
to	O
a	O
minor	O
extent	O
;	O
however	O
,	O
its	O
strength	O
seems	O
to	O
be	O
in	O
improving	O
levodopa	I-Entity
-	O
induced	O
dyskinesias	I-Entity
.	O

Stimulation	O
often	O
produces	O
an	O
improvement	O
in	O
the	O
hyper-	B-Entity
or	I-Entity
dyskinetic	I-Entity
upper	O
limbs	O
,	O
but	O
increases	O
the	O
""""	O
freezing	O
""""	O
phenomenon	O
in	O
the	O
lower	O
limbs	O
at	O
the	O
same	O
time	O
.	O



Case	O
report	O
:	O
Dexatrim	I-Entity
(	O
Phenylpropanolamine	I-Entity
)	O
as	O
a	O
cause	O
of	O
myocardial	B-Entity
infarction	I-Entity
.	O

Phenylpropanolamine	I-Entity
(	O
PPA	I-Entity
)	O
is	O
a	O
sympathetic	O
amine	I-Entity
used	O
in	O
over	O
-	O
the	O
-	O
counter	O
cold	O
remedies	O
and	O
weight	O
-	O
control	O
preparations	O
worldwide	O
.	O

Its	O
use	O
has	O
been	O
associated	O
with	O
hypertensive	I-Entity
episodes	O
and	O
hemorrhagic	B-Entity
strokes	I-Entity
in	O
younger	O
women	O
.	O

Several	O
reports	O
have	O
linked	O
the	O
abuse	O
of	O
PPA	I-Entity
with	O
myocardial	B-Entity
injury	I-Entity
,	O
especially	O
when	O
overdose	I-Entity
is	O
involved	O
.	O

We	O
report	O
here	O
the	O
first	O
case	O
of	O
Dexatrim	I-Entity
(	O
PPA)-induced	I-Entity
myocardial	B-Entity
injury	I-Entity
in	O
a	O
young	O
woman	O
who	O
was	O
using	O
it	O
at	O
recommended	O
doses	O
for	O
weight	O
control	O
.	O

In	O
addition	O
,	O
we	O
review	O
the	O
7	O
other	O
cases	O
of	O
PPA	I-Entity
related	O
myocardial	B-Entity
injury	I-Entity
that	O
have	O
been	O
reported	O
so	O
far	O
.	O

Physicians	O
and	O
patients	O
should	O
be	O
alert	O
to	O
the	O
potential	O
cardiac	O
risk	O
associated	O
with	O
the	O
use	O
of	O
PPA	I-Entity
,	O
even	O
at	O
doses	O
generally	O
considered	O
to	O
be	O
safe	O
.	O



Risperidone	I-Entity
-	O
associated	O
,	O
benign	O
transient	O
visual	B-Entity
disturbances	I-Entity
in	O
schizophrenic	I-Entity
patients	O
with	O
a	O
past	O
history	O
of	O
LSD	I-Entity
abuse	O
.	O

Two	O
schizophrenic	I-Entity
patients	O
,	O
who	O
had	O
a	O
prior	O
history	O
of	O
LSD	I-Entity
abuse	O
and	O
who	O
had	O
previously	O
developed	O
EPS	I-Entity
with	O
classic	O
antipsychotics	O
,	O
were	O
successfully	O
treated	O
with	O
risperidone	I-Entity
.	O

They	O
both	O
reported	O
short	O
episodes	O
of	O
transient	O
visual	B-Entity
disturbances	I-Entity
,	O
which	O
appeared	O
immediately	O
after	O
starting	O
treatment	O
with	O
risperidone	I-Entity
.	O

This	O
imagery	O
resembled	O
visual	B-Entity
disturbances	I-Entity
previously	O
experienced	O
as	O
""""	O
flashbacks	O
""""	O
related	O
to	O
prior	O
LSD	I-Entity
consumption	O
.	O

Risperidone	I-Entity
administration	O
was	O
continued	O
and	O
the	O
visual	B-Entity
disturbances	I-Entity
gradually	O
wore	O
off	O
.	O

During	O
a	O
six	O
-	O
month	O
follow	O
-	O
up	O
period	O
,	O
there	O
was	O
no	O
recurrence	O
of	O
visual	B-Entity
disturbances	I-Entity
.	O

This	O
phenomenon	O
may	O
be	O
interpreted	O
as	O
a	O
benign	O
,	O
short	O
-	O
term	O
and	O
self	O
-	O
limiting	O
side	O
effect	O
which	O
does	O
not	O
contraindicate	O
the	O
use	O
of	O
risperidone	I-Entity
or	O
interfere	O
with	O
treatment	O
.	O



Activation	O
of	O
poly(ADP	B-Entity
-	I-Entity
ribose	I-Entity
)	I-Entity
polymerase	O
contributes	O
to	O
development	O
of	O
doxorubicin	I-Entity
-	O
induced	O
heart	B-Entity
failure	I-Entity
.	O

Activation	O
of	O
the	O
nuclear	O
enzyme	O
poly(ADP	B-Entity
-	I-Entity
ribose	I-Entity
)	I-Entity
polymerase	O
(	O
PARP	O
)	O
by	O
oxidant	O
-	O
mediated	O
DNA	O
damage	O
is	O
an	O
important	O
pathway	O
of	O
cell	O
dysfunction	O
and	O
tissue	O
injury	O
in	O
conditions	O
associated	O
with	O
oxidative	O
stress	O
.	O

Increased	O
oxidative	O
stress	O
is	O
a	O
major	O
factor	O
implicated	O
in	O
the	O
cardiotoxicity	I-Entity
of	O
doxorubicin	I-Entity
(	O
DOX	I-Entity
)	O
,	O
a	O
widely	O
used	O
antitumor	O
anthracycline	I-Entity
antibiotic	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
the	O
activation	O
of	O
PARP	O
may	O
contribute	O
to	O
the	O
DOX	I-Entity
-	O
induced	O
cardiotoxicity	I-Entity
.	O

Using	O
a	O
dual	O
approach	O
of	O
PARP-1	O
suppression	O
,	O
by	O
genetic	O
deletion	O
or	O
pharmacological	O
inhibition	O
with	O
the	O
phenanthridinone	O
PARP	O
inhibitor	O
PJ34	I-Entity
,	O
we	O
now	O
demonstrate	O
the	O
role	O
of	O
PARP	O
in	O
the	O
development	O
of	O
cardiac	B-Entity
dysfunction	I-Entity
induced	O
by	O
DOX	I-Entity
.	O

PARP-1+/+	O
and	O
PARP-1-/-	O
mice	O
received	O
a	O
single	O
injection	O
of	O
DOX	I-Entity
(	O
25	O
mg	O
/	O
kg	O
i.p	O
)	O
.	O

Five	O
days	O
after	O
DOX	I-Entity
administration	O
,	O
left	O
ventricular	O
performance	O
was	O
significantly	O
depressed	O
in	O
PARP-1+/+	O
mice	O
,	O
but	O
only	O
to	O
a	O
smaller	O
extent	O
in	O
PARP-1-/-	O
ones	O
.	O

Similar	O
experiments	O
were	O
conducted	O
in	O
BALB	O
/	O
c	O
mice	O
treated	O
with	O
PJ34	I-Entity
or	O
vehicle	O
.	O

Treatment	O
with	O
a	O
PJ34	I-Entity
significantly	O
improved	O
cardiac	B-Entity
dysfunction	I-Entity
and	O
increased	O
the	O
survival	O
of	O
the	O
animals	O
.	O

In	O
addition	O
PJ34	I-Entity
significantly	O
reduced	O
the	O
DOX	I-Entity
-	O
induced	O
increase	O
in	O
the	O
serum	O
lactate	I-Entity
dehydrogenase	O
and	O
creatine	I-Entity
kinase	O
activities	O
but	O
not	O
metalloproteinase	O
activation	O
in	O
the	O
heart	O
.	O

Thus	O
,	O
PARP	O
activation	O
contributes	O
to	O
the	O
cardiotoxicity	I-Entity
of	O
DOX	I-Entity
.	O

PARP	O
inhibitors	O
may	O
exert	O
protective	O
effects	O
against	O
the	O
development	O
of	O
severe	O
cardiac	B-Entity
complications	I-Entity
associated	O
with	O
the	O
DOX	I-Entity
treatment	O
.	O



Fluconazole	I-Entity
-	O
induced	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
.	O

OBJECTIVE	O
:	O
To	O
present	O
a	O
case	O
of	O
fluconazole	I-Entity
-	O
associated	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
(	O
TDP	I-Entity
)	O
and	O
discuss	O
fluconazole	I-Entity
's	O
role	O
in	O
causing	O
TDP	I-Entity
.	O

A	O
68-year	O
-	O
old	O
white	O
woman	O
with	O
Candida	O
glabrata	O
isolated	O
from	O
a	O
presacral	O
abscess	O
developed	O
TDP	I-Entity
eight	O
days	O
after	O
commencing	O
oral	O
fluconazole	I-Entity

The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
TDP	I-Entity
,	O
including	O
coronary	B-Entity
artery	I-Entity
disease	I-Entity
,	O
cardiomyopathy	I-Entity
,	O
congestive	B-Entity
heart	I-Entity
failure	I-Entity
,	O
and	O
electrolyte	O
abnormalities	O
There	O
was	O
a	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
fluconazole	I-Entity
and	O
TDP	I-Entity
.	O

The	O
TDP	I-Entity
resolved	O
when	O
fluconazole	I-Entity
was	O
discontinued	O
;	O
however	O
,	O
the	O
patient	O
continued	O
to	O
have	O
premature	B-Entity
ventricular	I-Entity
contractions	I-Entity
and	O
nonsustained	O
ventricular	B-Entity
tachycardia	I-Entity
(	O
NSVT	I-Entity
)	O
until	O
six	O
days	O
after	O
drug	O
cessation	O
DISCUSSION	O
:	O

Use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
use	O
of	O
fluconazole	I-Entity
and	O
the	O
development	O
of	O
TDP	I-Entity
.	O

The	O
possible	O
mechanism	O
is	O
depression	I-Entity
of	O
rapidly	O
activating	O
delayed	O
rectifier	O
potassium	I-Entity
currents	O
.	O

In	O
our	O
patient	O
,	O
there	O
was	O
no	O
other	O
etiology	O
identified	O
that	O
could	O
explain	O
QT	B-Entity
prolongation	I-Entity
or	O
TDP	I-Entity

The	O
complete	O
disappearance	O
of	O
NSVT	I-Entity
and	O
premature	B-Entity
ventricular	I-Entity
contractions	I-Entity
followed	O
by	O
normalization	O
of	O
QT	O
interval	O
after	O
the	O
drug	O
was	O
stopped	O
strongly	O
suggests	O
fluconazole	I-Entity
as	O
the	O
etiology	O
.	O

Clinicians	O
should	O
be	O
aware	O
that	O
fluconazole	I-Entity
,	O
even	O
at	O
low	O
doses	O
,	O
may	O
cause	O
prolongation	B-Entity
of	I-Entity
the	I-Entity
QT	I-Entity
interval	I-Entity
,	O
leading	O
to	O
TDP	I-Entity
.	O

Serial	O
electrocardiographic	O
monitoring	O
may	O
be	O
considered	O
when	O
fluconazole	I-Entity
is	O
administered	O
in	O
patients	O
who	O
are	O
at	O
risk	O
for	O
ventricular	B-Entity
arrhythmias	I-Entity
.	O



High	O
-	O
dose	O
methylprednisolone	I-Entity
may	O
do	O
more	O
harm	O
for	O
spinal	B-Entity
cord	I-Entity
injury	I-Entity
.	O

Because	O
of	O
the	O
National	O
Acute	O
Spinal	B-Entity
Cord	I-Entity
Injury	I-Entity
Studies	O
(	O
NASCIS	O
)	O
,	O
high	O
-	O
dose	O
methylprednisolone	I-Entity
became	O
the	O
standard	O
of	O
care	O
for	O
the	O
acute	O
spinal	B-Entity
cord	I-Entity
injury	I-Entity
.	O

In	O
the	O
NASCIS	O
,	O
there	O
was	O
no	O
mention	O
regarding	O
the	O
possibility	O
of	O
acute	O
corticosteroid	I-Entity
myopathy	I-Entity
that	O
high	O
-	O
dose	O
methylprednisolone	I-Entity
may	O
cause	O
.	O

The	O
dosage	O
of	O
methylprednisolone	I-Entity
recommended	O
by	O
the	O
NASCIS	O
3	O
is	O
the	O
highest	O
dose	O
of	O
steroids	I-Entity
ever	O
being	O
used	O
during	O
a	O
2-day	O
period	O
for	O
any	O
clinical	O
condition	O
.	O

We	O
hypothesize	O
that	O
it	O
may	O
cause	O
some	O
damage	B-Entity
to	I-Entity
the	I-Entity
muscle	I-Entity
of	O
spinal	B-Entity
cord	I-Entity
injury	I-Entity
patients	O
.	O

Further	O
,	O
steroid	I-Entity
myopathy	I-Entity
recovers	O
naturally	O
and	O
the	O
neurological	O
improvement	O
shown	O
in	O
the	O
NASCIS	O
may	O
be	O
just	O
a	O
recording	O
of	O
this	O
natural	O
motor	O
recovery	O
from	O
the	O
steroid	I-Entity
myopathy	I-Entity
,	O
instead	O
of	O
any	O
protection	O
that	O
methylprednisolone	I-Entity
offers	O
to	O
the	O
spinal	B-Entity
cord	I-Entity
injury	I-Entity
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
discussion	O
considering	O
the	O
possibility	O
that	O
the	O
methylprednisolone	I-Entity
recommended	O
by	O
NASCIS	O
may	O
cause	O
acute	O
corticosteroid	I-Entity
myopathy	I-Entity
.	O



The	O
pharmacological	O
response	O
to	O
drugs	O
that	O
act	O
on	O
the	O
cholinergic	O
system	O
of	O
the	O
iris	O
has	O
been	O
used	O
to	O
predict	O
deficits	O
in	O
central	O
cholinergic	O
functioning	O
due	O
to	O
diseases	O
such	O
as	O
Alzheimer	B-Entity
's	I-Entity
disease	I-Entity
,	O
yet	O
correlations	O
between	O
central	O
and	O
peripheral	O
responses	O
have	O
not	O
been	O
properly	O
studied	O
.	O

This	O
study	O
assessed	O
the	O
effect	O
of	O
normal	O
aging	O
on	O
(	O
1	O
)	O
the	O
tropicamide	I-Entity
-	O
induced	O
increase	O
in	O
pupil	O
diameter	O
,	O
and	O
(	O
2	O
)	O
the	O
reversal	O
of	O
this	O
effect	O
with	O
pilocarpine	I-Entity
.	O

Scopolamine	I-Entity
was	O
used	O
as	O
a	O
positive	O
control	O
to	O
detect	O
age	O
-	O
dependent	O
changes	O
in	O
central	O
cholinergic	O
functioning	O
in	O
the	O
elderly	O
.	O

In	O
1	O
session	O
,	O
tropicamide	I-Entity
(	O
20	O
microL	O
,	O
0.01%	O
)	O
was	O
administered	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

In	O
another	O
session	O
,	O
tropicamide	I-Entity
(	O
20	O
microL	O
,	O
0.01%	O
)	O
was	O
administered	O
to	O
both	O
eyes	O
,	O
followed	O
23	O
minutes	O
later	O
by	O
the	O
application	O
of	O
pilocarpine	I-Entity
(	O
20	O
microL	O
,	O
0.1%	O
)	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

In	O
2	O
separate	O
sessions	O
,	O
a	O
single	O
dose	O
of	O
scopolamine	I-Entity
(	O
0.5	O
mg	O
,	O
intravenously	O
)	O
or	O
placebo	O
was	O
administered	O
,	O
and	O
the	O
effects	O
on	O
word	O
recall	O
were	O
measured	O
using	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
over	O
2	O
hours	O
.	O

Pupil	O
size	O
at	O
time	O
points	O
after	O
administration	O
of	O
tropicamide	I-Entity
and	O
pilocarpine	I-Entity
;	O
scopolamine	I-Entity
-	O
induced	O
impairment	B-Entity
in	I-Entity
word	I-Entity
recall	I-Entity
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
elderly	O
and	O
young	O
volunteers	O
in	O
pupillary	O
response	O
to	O
tropicamide	I-Entity
at	O
any	O
time	O
point	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
elderly	O
group	O
had	O
a	O
significantly	O
greater	O
pilocarpine	I-Entity
-	O
induced	O
net	O
decrease	O
in	O
pupil	O
size	O
85	O
,	O
125	O
,	O
165	O
and	O
215	O
minutes	O
after	O
administration	O
,	O
compared	O
with	O
the	O
young	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Compared	O
with	O
the	O
young	O
group	O
,	O
the	O
elderly	O
group	O
had	O
greater	O
scopolamine	I-Entity
-	O
induced	O
impairment	B-Entity
in	I-Entity
word	I-Entity
recall	I-Entity
60	O
,	O
90	O
and	O
120	O
minutes	O
after	O
administration	O
(	O

CONCLUSION	O
:	O
There	O
is	O
an	O
age	O
-	O
related	O
pupillary	O
response	O
to	O
pilocarpine	I-Entity
that	O
is	O
not	O
found	O
with	O
tropicamide	I-Entity
.	O

Thus	O
,	O
pilocarpine	I-Entity
may	O
be	O
useful	O
to	O
assess	O
variations	O
in	O
central	O
cholinergic	O
function	O
in	O
elderly	O
patients	O
.	O



Acetazolamide	I-Entity
-	O
induced	O
Gerstmann	B-Entity
syndrome	I-Entity
.	O

Acute	O
confusion	I-Entity
induced	O
by	O
acetazolamide	I-Entity
is	O
a	O
well	O
known	O
adverse	O
drug	O
reaction	O
in	O
patients	O
with	O
renal	B-Entity
impairment	I-Entity
.	O

We	O
report	O
a	O
case	O
of	O
acetazolamide	I-Entity
-	O
induced	O
Gerstmann	B-Entity
syndrome	I-Entity
in	O
a	O
patient	O
with	O
normal	O
renal	O
function	O
,	O
to	O
highlight	O
predisposing	O
factors	O
that	O
are	O
frequently	O
overlooked	O
.	O



Hypomania	I-Entity
-	O
like	O
syndrome	O
induced	O
by	O
olanzapine	I-Entity
.	O

We	O
report	O
a	O
female	O
patient	O
with	O
a	O
diagnosis	O
of	O
a	O
not	O
otherwise	O
specified	O
psychotic	B-Entity
disorder	I-Entity
(	O
DSM	O
-	O
IV	O
)	O
who	O
developed	O
hypomania	I-Entity
shortly	O
after	O
the	O
introduction	O
of	O
olanzapine	I-Entity
treatment	O
.	O



Neutrophil	O
superoxide	I-Entity
and	O
hydrogen	B-Entity
peroxide	I-Entity
production	O
in	O
patients	O
with	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
.	O

Defects	O
in	O
superoxide	I-Entity
and	O
hydrogen	B-Entity
peroxide	I-Entity
production	O
may	O
be	O
implicated	O
in	O
the	O
high	O
incidence	O
of	O
bacterial	B-Entity
infections	I-Entity
in	O
patients	O
with	O
acute	B-Entity
liver	I-Entity
failure	I-Entity
(	O
ALF	I-Entity
)	O
.	O

In	O
the	O
present	O
study	O
,	O
oxygen	I-Entity
radical	O
production	O
in	O
patients	O
with	O
ALF	I-Entity
due	O
to	O
paracetamol	I-Entity
overdose	I-Entity
was	O
compared	O
with	O
that	O
of	O
healthy	O
volunteers	O
.	O

Neutrophils	O
from	O
14	O
ALF	I-Entity
patients	O
were	O
stimulated	O
via	O
the	O
complement	O
receptors	O
using	O
zymosan	O
opsonized	O
with	O
ALF	I-Entity
or	O
control	O
serum	O
.	O

Superoxide	I-Entity
and	O
hydrogen	B-Entity
peroxide	I-Entity
production	O
by	O
ALF	I-Entity
neutrophils	O
stimulated	O
with	O
zymosan	O
opsonized	O
with	O
ALF	I-Entity
serum	O
was	O
significantly	O
reduced	O
compared	O
with	O
the	O
control	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Superoxide	I-Entity
and	O
hydrogen	B-Entity
peroxide	I-Entity
production	O
in	O
neutrophils	O
stimulated	O
with	O
formyl	B-Entity
-	I-Entity
methionyl	I-Entity
-	I-Entity
leucyl	I-Entity
-	I-Entity
phenylalanine	I-Entity
(	O
fMLP	I-Entity
)	O
from	O
a	O
further	O
18	O
ALF	I-Entity
patients	O
was	O
unaffected	O
compared	O
with	O
control	O
neutrophils	O
.	O

Serum	O
C3	O
complement	O
levels	O
were	O
significantly	O
reduced	O
in	O
ALF	I-Entity
patients	O
compared	O
with	O
control	O
subjects	O
(	O
P	O
<	O
0.0005	O
)	O
.	O

These	O
results	O
demonstrate	O
a	O
neutrophil	O
defect	O
in	O
ALF	I-Entity
due	O
to	O
paracetamol	I-Entity
overdose	I-Entity
,	O
that	O
is	O
complement	O
dependent	O
but	O
independent	O
of	O
serum	O
complement	O
,	O
possibly	O
connected	O
to	O
the	O
complement	O
receptor	O
.	O



Absence	O
of	O
effect	O
of	O
sertraline	I-Entity
on	O
time	O
-	O
based	O
sensitization	O
of	O
cognitive	B-Entity
impairment	I-Entity
with	O
haloperidol	I-Entity
.	O

This	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
evaluated	O
the	O
effects	O
of	O
haloperidol	I-Entity
alone	O
and	O
haloperidol	I-Entity
plus	O
sertraline	I-Entity
on	O
cognitive	O
and	O
psychomotor	O
function	O
in	O
24	O
healthy	O
male	O
subjects	O
.	O

All	O
subjects	O
received	O
placebo	O
on	O
Day	O
1	O
and	O
haloperidol	I-Entity
2	O
mg	O
on	O
Days	O
2	O
and	O
25	O
.	O

From	O
Days	O
9	O
to	O
25	O
,	O
subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
sertraline	I-Entity
(	O
12	O
subjects	O
)	O
or	O
placebo	O
(	O
12	O
subjects	O
)	O
;	O
the	O
sertraline	I-Entity
dose	O
was	O
titrated	O
from	O
50	O
to	O
200	O
mg	O
/	O
day	O
from	O
Days	O
9	O
to	O
16	O
,	O
and	O
remained	O
at	O
200	O
mg	O
/	O
day	O
for	O
the	O
final	O
10	O
days	O
of	O
the	O
drug	O
administration	O
period	O
.	O

RESULTS	O
:	O
Impairment	B-Entity
of	I-Entity
cognitive	I-Entity
function	I-Entity
was	O
observed	O
6	O
to	O
8	O
hours	O
after	O
administration	O
of	O
haloperidol	I-Entity
on	O
Day	O
2	O
but	O
was	O
not	O
evident	O
23	O
hours	O
after	O
dosing	O
.	O

When	O
single	O
-	O
dose	O
haloperidol	I-Entity
was	O
given	O
again	O
25	O
days	O
later	O
,	O
greater	O
impairment	O
with	O
earlier	O
onset	O
was	O
noted	O
in	O
several	O
tests	O
in	O
both	O
treatment	O
groups	O
,	O
suggesting	O
enhancement	O
of	O
this	O
effect	O
.	O

There	O
was	O
no	O
indication	O
that	O
sertraline	I-Entity
exacerbated	O
the	O
impairment	O
produced	O
by	O
haloperidol	I-Entity
since	O
an	O
equivalent	O
effect	O
also	O
occurred	O
in	O
the	O
placebo	O
group	O
.	O

Three	O
subjects	O
(	O
2	O
on	O
sertraline	I-Entity
and	O
1	O
on	O
placebo	O
)	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
sertraline	I-Entity
and	O
of	O
placebo	O
were	O
similar	O
.	O

Haloperidol	I-Entity
produced	O
a	O
clear	O
profile	O
of	O
cognitive	B-Entity
impairment	I-Entity
that	O
was	O
not	O
worsened	O
by	O
concomitant	O
sertraline	I-Entity
administration	O
.	O



Ciprofloxacin	I-Entity
-	O
induced	O
nephrotoxicity	I-Entity
in	O
patients	O
with	O
cancer	I-Entity
.	O

Nephrotoxicity	I-Entity
associated	O
with	O
ciprofloxacin	I-Entity
is	O
uncommon	O
.	O

Five	O
patients	O
with	O
cancer	I-Entity
who	O
developed	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
that	O
followed	O
treatment	O
with	O
ciprofloxacin	I-Entity
are	O
described	O
and	O
an	O
additional	O
15	O
cases	O
reported	O
in	O
the	O
literature	O
are	O
reviewed	O
.	O

Other	O
than	O
elevation	O
of	O
serum	O
creatinine	I-Entity
levels	O
,	O
characteristic	O
clinical	O
manifestations	O
and	O
abnormal	O
laboratory	O
findings	O
are	O
not	O
frequently	O
present	O
.	O

Allergic	O
interstitial	B-Entity
nephritis	I-Entity
is	O
believed	O
to	O
be	O
the	O
underlying	O
pathological	O
-	O
process	O
.	O

An	O
improvement	O
in	O
renal	O
function	O
that	O
followed	O
the	O
discontinuation	O
of	O
the	O
offending	O
antibiotic	O
supports	O
the	O
presumptive	O
diagnosis	O
of	O
ciprofloxacin	I-Entity
-	O
induced	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
.	O



Case	O
report	O
:	O
pentamidine	I-Entity
and	O
polymorphic	O
ventricular	B-Entity
tachycardia	I-Entity
revisited	O
.	O

Pentamidine	B-Entity
isethionate	I-Entity
has	O
been	O
associated	O
with	O
ventricular	B-Entity
tachyarrhythmias	I-Entity
,	O
including	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
.	O

Pentamidine	I-Entity
-	O
induced	O
torsade	B-Entity
de	I-Entity
pointes	I-Entity
may	O
be	O
related	O
to	O
serum	O
magnesium	I-Entity
levels	O
and	O
hypomagnesemia	I-Entity
may	O
synergistically	O
induce	O
torsade	O
.	O

Torsade	B-Entity
de	I-Entity
pointes	I-Entity
occurred	O
after	O
an	O
average	O
of	O
10	O
days	O
of	O
treatment	O
with	O
pentamidine	I-Entity
.	O

In	O
these	O
patients	O
,	O
no	O
other	O
acute	O
side	O
effects	O
of	O
pentamidine	I-Entity
were	O
observed	O
.	O

Torsade	B-Entity
de	I-Entity
pointes	I-Entity
can	O
be	O
treated	O
when	O
recognized	O
early	O
,	O
possibly	O
without	O
discontinuation	O
of	O
pentamidine	I-Entity
.	O

When	O
QTc	B-Entity
interval	I-Entity
prolongation	I-Entity
is	O
observed	O
,	O
early	O
magnesium	I-Entity
supplementation	O
is	O
advocated	O
.	O



Time	O
dependence	O
of	O
plasma	O
malondialdehyde	I-Entity
,	O
oxypurines	I-Entity
,	O
and	O
nucleosides	I-Entity
during	O
incomplete	O
cerebral	B-Entity
ischemia	I-Entity
in	O
the	O
rat	O
.	O

Incomplete	O
cerebral	B-Entity
ischemia	I-Entity
(	O
30	O
min	O
)	O
was	O
induced	O
in	O
the	O
rat	O
by	O
bilaterally	O
clamping	O
the	O
common	O
carotid	O
arteries	O
.	O

Peripheral	O
venous	O
blood	O
samples	O
were	O
withdrawn	O
from	O
the	O
femoral	O
vein	O
four	O
times	O
(	O
once	O
every	O
5	O
min	O
)	O
before	O
ischemia	I-Entity
(	O
0	O
time	O
)	O
and	O
5	O
,	O
15	O
,	O
and	O
30	O
min	O
after	O
ischemia	I-Entity
.	O

Plasma	O
extracts	O
were	O
analyzed	O
by	O
a	O
highly	O
sensitive	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
method	O
for	O
the	O
direct	O
determination	O
of	O
malondialdehyde	I-Entity
,	O
oxypurines	I-Entity
,	O
and	O
nucleosides	I-Entity
.	O

During	O
ischemia	I-Entity
,	O
a	O
time	O
-	O
dependent	O
increase	O
of	O
plasma	O
oxypurines	I-Entity
and	O
nucleosides	I-Entity
was	O
observed	O
.	O

Plasma	O
malondialdehyde	I-Entity
,	O
which	O
was	O
present	O
in	O
minimal	O
amount	O
at	O
zero	O
time	O
(	O
0.058	O
mumol	O
/	O
liter	O
plasma	O
;	O

SD	O
0.015	O
)	O
,	O
increased	O
after	O
5	O
min	O
of	O
ischemia	I-Entity
,	O
resulting	O
in	O
a	O
fivefold	O
increase	O
after	O
30	O
min	O
of	O
carotid	O
occlusion	O
(	O
0.298	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0.078	O
)	O
.	O

Increased	O
plasma	O
malondialdehyde	I-Entity
was	O
also	O
recorded	O
in	O
two	O
other	O
groups	O
of	O
animals	O
subjected	O
to	O
the	O
same	O
experimental	O
model	O
,	O
one	O
receiving	O
20	O
mg	O
/	O
kg	O
b.w	O
.	O
of	O
the	O
cyclooxygenase	O

inhibitor	O
acetylsalicylate	I-Entity
intravenously	O
immediately	O
before	O
ischemia	I-Entity
,	O
the	O
other	O
receiving	O
650	O
micrograms	O
/	O
kg	O
b.w	O
.	O

of	O
the	O
hypotensive	I-Entity
drug	O
nitroprusside	I-Entity
at	O
a	O
flow	O
rate	O
of	O
103	O
microliters	O
/	O

min	O
intravenously	O
during	O
ischemia	I-Entity
,	O
although	O
in	O
this	O
latter	O
group	O
malondialdehyde	I-Entity
was	O
significantly	O
higher	O
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
determination	O
of	O
malondialdehyde	I-Entity
,	O
oxypurines	I-Entity
,	O
and	O
nucleosides	I-Entity
in	O
peripheral	O
blood	O
,	O
may	O
be	O
used	O
to	O
monitor	O
the	O
metabolic	O
alterations	O
of	O
tissues	O
occurring	O
during	O
ischemic	I-Entity
phenomena.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O



Cholinergic	O
toxicity	I-Entity
resulting	O
from	O
ocular	O
instillation	O
of	O
echothiophate	B-Entity
iodide	I-Entity
eye	O
drops	O
.	O

A	O
patient	O
developed	O
a	O
severe	O
cholinergic	O
syndrome	O
from	O
the	O
use	O
of	O
echothiophate	B-Entity
iodide	I-Entity
ophthalmic	O
drops	O
,	O
presented	O
with	O
profound	O
muscle	B-Entity
weakness	I-Entity
and	O
was	O
initially	O
given	O
the	O
diagnosis	O
of	O
myasthenia	B-Entity
gravis	I-Entity
.	O



Acute	B-Entity
renal	I-Entity
failure	I-Entity
in	O
high	O
dose	O
carboplatin	I-Entity
chemotherapy	O
.	O

Carboplatin	I-Entity
has	O
been	O
reported	O
to	O
cause	O
acute	B-Entity
renal	I-Entity
failure	I-Entity
when	O
administered	O
in	O
high	O
doses	O
to	O
adult	O
patients	O
.	O

We	O
report	O
a	O
4	O
1/2-year	O
-	O
old	O
girl	O
who	O
was	O
treated	O
with	O
high	O
-	O
dose	O
carboplatin	I-Entity
for	O
metastatic	O
parameningeal	O
embryonal	B-Entity
rhabdomyosarcoma	I-Entity
.	O

Acute	B-Entity
renal	I-Entity
failure	I-Entity
developed	O
followed	O
by	O
a	O
slow	O
partial	O
recovery	O
of	O
renal	O
function	O
.	O



Endometrial	B-Entity
carcinoma	I-Entity
after	O
Hodgkin	B-Entity
disease	I-Entity
in	O
childhood	O
.	O

A	O
34-year	O
-	O
old	O
patient	O
developed	O
metastic	O
endometrial	B-Entity
carcinoma	I-Entity
after	O
Hodgkin	B-Entity
disease	I-Entity
in	O
childhood	O
.	O

She	O
had	O
ovarian	B-Entity
failure	I-Entity
after	O
abdominal	O
irradiation	O
and	O
chemotherapy	O
for	O
Hodgkin	B-Entity
disease	I-Entity
,	O
and	O
received	O
exogenous	O
estrogens	I-Entity
,	O
a	O
treatment	O
implicated	O
in	O
the	O
development	O
of	O
endometrial	B-Entity
cancer	I-Entity
in	O
menopausal	O
women	O
.	O

Young	O
women	O
on	O
replacement	O
estrogens	I-Entity
for	O
ovarian	B-Entity
failure	I-Entity
after	O
cancer	I-Entity
therapy	O
may	O
also	O
have	O
increased	O
risk	O
of	O
endometrial	B-Entity
carcinoma	I-Entity
and	O
should	O
be	O
examined	O
periodically	O
.	O



Induction	O
of	O
the	O
obstructive	B-Entity
sleep	I-Entity
apnea	I-Entity
syndrome	I-Entity
in	O
a	O
woman	O
by	O
exogenous	O
androgen	I-Entity
administration	O
.	O

We	O
documented	O
airway	O
occlusion	O
during	O
sleep	O
and	O
an	O
abnormally	O
high	O
supraglottic	O
resistance	O
while	O
awake	O
in	O
a	O
54-yr	O
-	O
old	O
woman	O
who	O
had	O
developed	O
physical	O
changes	O
and	O
the	O
syndrome	B-Entity
of	I-Entity
obstructive	I-Entity
sleep	I-Entity
apnea	I-Entity
while	O
being	O
administered	O
exogenous	O
androgens	I-Entity
.	O

When	O
the	O
androgens	I-Entity
were	O
withdrawn	O
,	O
the	O
patient	O
's	O
physical	O
changes	O
,	O
symptoms	O
,	O
sleep	O
study	O
,	O
and	O
supraglottic	O
resistance	O
all	O
returned	O
to	O
normal	O
.	O

A	O
rechallenge	O
with	O
androgen	I-Entity
produced	O
symptoms	O
of	O
obstructive	B-Entity
sleep	I-Entity
apnea	I-Entity
that	O
abated	O
upon	O
withdrawal	O
of	O
the	O
hormone	O
.	O

Previous	O
reports	O
have	O
favored	O
a	O
role	O
of	O
androgens	I-Entity
in	O
the	O
pathogenesis	O
of	O
sleep	B-Entity
apnea	I-Entity
.	O

Structural	O
and	O
functional	O
measurements	O
indicate	O
that	O
androgens	I-Entity
exert	O
a	O
permissive	O
or	O
necessary	O
action	O
on	O
the	O
structural	O
configuration	O
of	O
the	O
oropharynx	O
that	O
predisposes	O
to	O
obstruction	O
during	O
sleep	O
.	O

Development	O
of	O
the	O
obstructive	B-Entity
sleep	I-Entity
apnea	I-Entity
syndrome	I-Entity
must	O
be	O
considered	O
a	O
possible	O
side	O
effect	O
of	O
androgen	I-Entity
therapy	O
.	O



Effect	O
of	O
captopril	I-Entity
on	O
pre	O
-	O
existing	O
and	O
aminonucleoside	I-Entity
-	O
induced	O
proteinuria	I-Entity
in	O
spontaneously	O
hypertensive	I-Entity
rats	O
.	O

Proteinuria	I-Entity
is	O
a	O
side	O
effect	O
of	O
captopril	I-Entity
treatment	O
in	O
hypertensive	I-Entity
patients	O
.	O

The	O
possibility	O
of	O
reproducing	O
the	O
same	O
renal	B-Entity
abnormality	I-Entity
with	O
captopril	I-Entity
was	O
examined	O
in	O
SHR	O
.	O

Oral	O
administration	O
of	O
captopril	I-Entity
at	O
100	O
mg	O
/	O
kg	O
for	O
14	O
days	O
failed	O
to	O
aggravate	O
proteinuria	I-Entity
pre	O
-	O
existing	O
in	O
SHR	O
.	O

Also	O
,	O
captopril	I-Entity
treatment	O
failed	O
to	O
potentiate	O
or	O
facilitate	O
development	O
of	O
massive	O
proteinuria	I-Entity
invoked	O
by	O
puromycin	B-Entity
aminonucleoside	I-Entity
in	O
SHR	O
.	O

Captopril	I-Entity
had	O
little	O
or	O
no	O
demonstrable	O
effects	O
on	O
serum	O
electrolyte	O
concentrations	O
,	O
excretion	O
of	O
urine	O
,	O
sodium	I-Entity
and	O
potassium	I-Entity
,	O
endogenous	O
creatinine	I-Entity
clearance	O
,	O
body	O
weight	O
,	O
and	O
food	O
and	O
water	O
consumption	O
.	O

However	O
,	O
ketone	I-Entity
bodies	O
were	O
consistently	O
present	O
in	O
urine	O
and	O
several	O
lethalities	O
occurred	O
during	O
multiple	O
dosing	O
of	O
captopril	I-Entity
in	O
SHR	O
.	O



Epileptogenic	O
properties	O
of	O
enflurane	I-Entity
and	O
their	O
clinical	O
interpretation	O
.	O

Three	O
cases	O
of	O
EEG	O
changes	O
induced	O
by	O
single	O
exposure	O
to	O
enflurane	I-Entity
anesthesia	O
are	O
reported	O
.	O

In	O
one	O
patient	O
,	O
enflurane	I-Entity
administered	O
during	O
a	O
donor	O
nephrectomy	O
resulted	O
in	O
unexpected	O
partial	O
motor	O
seizures	I-Entity
.	O

Until	O
the	O
cause	O
of	O
the	O
seizures	I-Entity
was	O
correctly	O
identified	O
,	O
the	O
patient	O
was	O
inappropriately	O
treated	O
with	O
anticonvulsants	O
.	O

Two	O
other	O
patients	O
suffered	O
from	O
partial	O
,	O
complex	O
and	O
generalized	O
seizures	I-Entity
uncontrolled	O
by	O
medication	O
.	O

Epileptic	I-Entity
foci	O
delineated	O
and	O
activated	O
by	O
enflurane	I-Entity
were	O
surgically	O
ablated	O
and	O
the	O
patients	O
are	O
now	O
seizure	I-Entity
-	O
free	O
.	O

Previous	O
exposures	O
to	O
enflurane	I-Entity
have	O
to	O
be	O
disclosed	O
to	O
avoid	O
mistakes	O
in	O
clinical	O
interpretation	O
of	O
the	O
EEG	O
.	O

On	O
the	O
other	O
hand	O
,	O
enflurane	I-Entity
may	O
prove	O
to	O
be	O
a	O
safe	O
fast	O
acting	O
activator	O
of	O
epileptic	I-Entity
foci	O
during	O
corticography	O
or	O
depth	O
electrode	O
intraoperative	O
recordings	O
.	O



Reversible	O
cerebral	B-Entity
lesions	I-Entity
associated	O
with	O
tiazofurin	I-Entity
usage	O
:	O
MR	O
demonstration	O
.	O

Tiazofurin	I-Entity
is	O
an	O
experimental	O
chemotherapeutic	O
agent	O
currently	O
undergoing	O
clinical	O
evaluation	O
.	O

We	O
report	O
our	O
results	O
with	O
magnetic	O
resonance	O
(	O
MR	O
)	O
in	O
demonstrating	O
reversible	O
cerebral	B-Entity
abnormalities	I-Entity
concurrent	O
with	O
the	O
use	O
of	O
this	O
drug	O
.	O



Antagonism	O
of	O
diazepam	I-Entity
-	O
induced	O
sedative	O
effects	O
by	O
Ro15	B-Entity
-	I-Entity
1788	I-Entity
in	O
patients	O
after	O
surgery	O
under	O
lumbar	O
epidural	O
block	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
Ro15	B-Entity
-	I-Entity
1788	I-Entity
and	O
a	O
placebo	O
in	O
reversing	O
diazepam	I-Entity
-	O
induced	O
effects	O
after	O
surgery	O
under	O
epidural	O
block	O
,	O
and	O
to	O
evaluate	O
the	O
local	O
tolerance	O
and	O
general	O
safety	O
of	O
Ro15	B-Entity
-	I-Entity
1788	I-Entity
.	O

Fifty	O
-	O
seven	O
patients	O
were	O
sedated	O
with	O
diazepam	I-Entity
for	O
surgery	O
under	O
epidural	O
anaesthesia	O
.	O

Antagonism	O
of	O
diazepam	I-Entity
-	O
induced	O
effects	O
by	O
Ro15	B-Entity
-	I-Entity
1788	I-Entity
was	O
investigated	O
postoperatively	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
.	O

The	O
patient	O
's	O
subjective	O
assessment	O
of	O
mood	O
rating	O
,	O
an	O
objective	O
test	O
of	O
performance	O
,	O
a	O
test	O
for	O
amnesia	I-Entity
,	O
and	O
vital	O
signs	O
were	O
recorded	O
for	O
up	O
to	O
300	O
min	O
after	O
administration	O
of	O
the	O
trial	O
drug	O
.	O

No	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
observed	O
for	O
mood	O
rating	O
,	O
amnesia	I-Entity
,	O
or	O
vital	O
signs	O
.	O

The	O
Ro15	B-Entity
-	I-Entity
1788	I-Entity
group	O
showed	O
a	O
significant	O
improvement	O
in	O
the	O
performance	O
test	O
up	O
to	O
120	O
min	O
after	O
administration	O
of	O
the	O
drug	O
.	O



Enhanced	O
stimulus	O
-	O
induced	O
neurotransmitter	O
overflow	O
in	O
epinephrine	I-Entity
-	O
induced	O
hypertensive	I-Entity
rats	O
is	O
not	O
mediated	O
by	O
prejunctional	O
beta	O
-	O
adrenoceptor	O
activation	O
.	O

The	O
present	O
study	O
examines	O
the	O
effect	O
of	O
6-day	O
epinephrine	I-Entity
treatment	O
(	O
100	O
micrograms	O
/	O
kg	O
per	O
h	O
,	O
s.c	O
.	O
)	O

endogenous	O
neurotransmitter	O
overflow	O
from	O
the	O
isolated	O
perfused	O
kidney	O
of	O
vehicle-	O
and	O
epinephrine	I-Entity
-	O
treated	O
rats	O
.	O

Renal	O
catecholamine	I-Entity
stores	O
and	O
stimulus	O
-	O
induced	O
overflow	O
in	O
the	O
vehicle	O
-	O
treated	O
group	O
consisted	O
of	O
norepinephrine	I-Entity
only	O
.	O

However	O
,	O
epinephrine	I-Entity
treatment	O
resulted	O
in	O
the	O
incorporation	O
of	O
epinephrine	I-Entity
into	O
renal	O
catecholamine	I-Entity
stores	O
such	O
that	O
approximately	O
40%	O
of	O
the	O
catecholamine	I-Entity
present	O
was	O
epinephrine	I-Entity
while	O
the	O
norepinephrine	I-Entity
content	O
was	O
reduced	O
by	O
a	O
similar	O
degree	O
.	O

Total	O
tissue	O
catecholamine	I-Entity
content	O
of	O
the	O
kidney	O
on	O
a	O
molar	O
basis	O
was	O
unchanged	O
.	O

Stimulus	O
-	O
induced	O
fractional	O
overflow	O
of	O
neurotransmitter	O
from	O
the	O
epinephrine	I-Entity
-	O
treated	O
kidneys	O
was	O
approximately	O
twice	O
normal	O
and	O
consisted	O
of	O
both	O
norepinephrine	I-Entity
and	O
epinephrine	I-Entity
in	O
proportions	O
similar	O
to	O
those	O
found	O
in	O
the	O
kidney	O
.	O

Propranolol	I-Entity
had	O
no	O
effect	O
on	O
stimulus	O
-	O
induced	O
overflow	O
in	O
either	O
group	O
.	O

Phentolamine	I-Entity
increased	O
stimulus	O
-	O
induced	O
overflow	O
in	O
both	O
groups	O
although	O
the	O
increment	O
in	O
overflow	O
was	O
greater	O
in	O
the	O
epinephrine	I-Entity
-	O
treated	O
group	O
.	O

In	O
conclusion	O
,	O
chronic	O
epinephrine	I-Entity
treatment	O
results	O
in	O
enhanced	O
fractional	O
neurotransmitter	O
overflow	O
.	O

Furthermore	O
,	O
data	O
obtained	O
with	O
phentolamine	I-Entity
alone	O
do	O
not	O
suggest	O
alpha	O
-	O
adrenoceptor	O
desensitization	O
as	O
the	O
cause	O
of	O
the	O
enhanced	O
neurotransmitter	O
overflow	O
after	O
epinephrine	I-Entity
treatment	O
.	O



Ocular	O
manifestations	O
of	O
juvenile	B-Entity
rheumatoid	I-Entity
arthritis	I-Entity
.	O

We	O
followed	O
210	O
cases	O
of	O
juvenile	B-Entity
rheumatoid	I-Entity
arthritis	I-Entity
closely	O
for	O
eleven	O
years	O
.	O

Thirty	O
-	O
six	O
of	O
the	O
210	O
patients	O
(	O
17.2%	O
)	O
developed	O
iridocyclitis	I-Entity
.	O

Iridocyclitis	I-Entity
was	O
seen	O
most	O
frequently	O
in	O
young	O
female	O
patients	O
(	O
0	O
to	O
4	O
years	O
)	O
with	O
the	O
monoarticular	O
or	O
pauciatricular	O
form	O
of	O
the	O
arthritis	I-Entity
.	O

However	O
,	O
30%	O
of	O
the	O
patients	O
developed	O
uveitis	I-Entity
after	O
16	O
years	O
of	O
age	O
.	O

Although	O
61%	O
of	O
patients	O
had	O
a	O
noncontributory	O
ocular	O
history	O
on	O
entry	O
,	O
42%	O
had	O
active	O
uveitis	I-Entity
on	O
entry	O
.	O

Our	O
approach	O
was	O
effective	O
in	O
detecting	O
uveitis	I-Entity
in	O
new	O
cases	O
and	O
exacerbations	O
of	O
uveitis	I-Entity
in	O
established	O
cases	O
.	O

Forty	O
-	O
four	O
percent	O
of	O
patients	O
with	O
uveitis	I-Entity
had	O
one	O
or	O
more	O
identifiable	O
signs	O
or	O
symptoms	O
,	O
such	O
as	O
red	O
eye	O
,	O
ocular	B-Entity
pain	I-Entity
,	O
decreased	B-Entity
visual	I-Entity
acuity	I-Entity
,	O
or	O
photophobia	I-Entity
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
.	O

Even	O
after	O
early	O
detection	O
and	O
prompt	O
treatment	O
,	O
41%	O
of	O
cases	O
of	O
uveitis	I-Entity
did	O
not	O
respond	O
to	O
more	O
than	O
six	O
months	O
of	O
intensive	O
topical	O
treatment	O
with	O
corticosteroids	I-Entity
and	O
mydriatics	O
.	O

Despite	O
this	O
,	O
there	O
was	O
a	O
dramatic	O
decrease	O
in	O
the	O
50%	O
incidence	O
of	O
blinding	O
complications	O
of	O
uveitis	I-Entity
cited	O
in	O
earlier	O
studies	O
.	O

Cataract	I-Entity
and	O
band	B-Entity
keratopathy	I-Entity
occurred	O
in	O
only	O
22	O
and	O
13%	O
of	O
our	O
group	O
,	O
respectively	O
.	O

We	O
used	O
chloroquine	I-Entity
or	O
hydroxychloroquine	I-Entity
in	O
173	O
of	O
210	O
cases	O
and	O
found	O
only	O
one	O
case	O
of	O
chorioretinopathy	I-Entity
attributable	O
to	O
these	O
drugs	O
.	O

Systemically	O
administered	O
corticosteroids	I-Entity
were	O
used	O
in	O
75	O
of	O
210	O
cases	O
;	O
a	O
significant	O
number	O
of	O
posterior	O
subcapsular	O
cataracts	I-Entity
was	O
found	O
.	O

Typical	O
keratoconjunctivitis	I-Entity
sicca	O
developed	O
in	O
three	O
of	O
the	O
uveitis	I-Entity
cases	O
.	O

This	O
association	O
with	O
uveitis	I-Entity
and	O
JRA	O
was	O
not	O
noted	O
previously	O
.	O

Surgical	O
treatment	O
of	O
cataracts	I-Entity
,	O
band	B-Entity
keratopathy	I-Entity
,	O
and	O
glaucoma	I-Entity
achieved	O
uniformly	O
discouraging	O
results	O
.	O



Water	B-Entity
intoxication	I-Entity
associated	O
with	O
oxytocin	I-Entity
administration	O
during	O
saline	O
-	O
induced	O
abortion	I-Entity
.	O

Four	O
cases	O
of	O
water	B-Entity
intoxication	I-Entity
in	O
connection	O
with	O
oxytocin	I-Entity
administration	O
during	O
saline	O
-	O
induced	O
abortions	I-Entity
are	O
described	O
.	O

The	O
mechanism	O
of	O
water	B-Entity
intoxication	I-Entity
is	O
discussed	O
in	O
regard	O
to	O
these	O
cases	O
.	O

Oxytocin	I-Entity
administration	O
during	O
midtrimester	O
-	O
induced	O
abortions	I-Entity
is	O
advocated	O
only	O
if	O
it	O
can	O
be	O
carried	O
out	O
under	O
careful	O
observations	O
of	O
an	O
alert	O
nursing	O
staff	O
,	O
aware	O
of	O
the	O
symptoms	O
of	O
water	B-Entity
intoxication	I-Entity
and	O
instructed	O
to	O
watch	O
the	O
diuresis	O
and	O
report	O
such	O
early	O
signs	O
of	O
the	O
syndrome	O
as	O
asthenia	I-Entity
,	O
muscular	O
irritability	I-Entity
,	O
or	O
headaches	I-Entity
.	O

The	O
oxytocin	I-Entity
should	O
be	O
given	O
only	O
in	O
Ringers	O
lactate	I-Entity
or	O
,	O
alternately	O
,	O
in	O
Ringers	O
lactate	I-Entity
and	O
a	O
5	O
per	O
cent	O
dextrose	I-Entity
and	O
water	O
solutions	O
.	O

The	O
urinary	O
output	O
should	O
be	O
monitored	O
and	O
the	O
oxytocin	I-Entity
administration	O
discontinued	O
and	O
the	O
serum	O
electrolytes	O
checked	O
if	O
the	O
urinary	O
output	O
decreases	O
.	O

The	O
oxytocin	I-Entity
should	O
not	O
be	O
administered	O
in	O
excess	O
of	O
36	O
hours	O
.	O

If	O
the	O
patient	O
has	O
not	O
aborted	O
by	O
then	O
the	O
oxytocin	I-Entity
should	O
be	O
discontinued	O
for	O
10	O
to	O
12	O
hours	O
in	O
order	O
to	O
perform	O
electrolyte	O
determinations	O
and	O
correct	O
any	O
electrolyte	O
imbalance	O
.	O


